# FILE HISTORY US 6,713,464

PATENT:	6,713,464
INVENTORS:	Meese, Claus
	Sparf, Bengt
TITLE:	Derivatives of 3,3-diphenylpropylamines
APPLICATION NO:	US2000700094A
FILED:	02 JAN 2001
ISSUED:	30 MAR 2004
COMPILED:	17 SEP 2013



(FACE)

# 6,713,464

. . .

;

# NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES

# **Transaction History**

Date	Transaction Description
11/8/2000	Receipt of 371 Request
11/17/2000	371 Application Preexamination Docketing
11/17/2000	Correspondence Address Change
12/4/2000	371 Application Preexamination Docketing
12/5/2000	Notice of DO/EO Missing Requirements Mailed
1/2/2001	Preliminary Amendment
1/2/2001	Affidavit(s) (Rule 131 or 132) or Exhibit(s) Received
1/2/2001	Applicant 371 Filing Paper Received
1/2/2001	Applicant 371 Filing Paper Received
1/2/2001	Initial Exam Team nn
1/16/2001	Released to OIPE
1/16/2001	Notice of DO/EO Acceptance Mailed
1/30/2001	IFW Scan & PACR Auto Security Review
2/15/2001	Application Dispatched from OIPE
5/2/2001	Case Docketed to Examiner in GAU
6/27/2001	Change in Power of Attorney (May Include Associate POA)
6/27/2001	Correspondence Address Change
6/27/2001	Change in Power of Attorney (May Include Associate POA)
8/15/2001	Information Disclosure Statement (IDS) Filed
8/15/2001	Information Disclosure Statement (IDS) Filed
9/7/2001	Mail Restriction Requirement
9/7/2001	Restriction/Election Requirement
4/9/2002	Case Docketed to Examiner in GAU
4/10/2002	Mail Abandonment for Failure to Respond to Office Action
4/10/2002	Aband. for Failure to Respond to O. A.
5/31/2002	Petition Entered
1/17/2003	Response to Election / Restriction Filed
1/17/2003	Request for Extension of Time - Granted
1/17/2003	Mail-Petition to Revive Application - Granted
1/24/2003	Mail Notice of Rescinded Abandonment
1/24/2003	Notice of Rescinded Abandonment in TCs
2/6/2003	Mail Non-Final Rejection
2/6/2003	Non-Final Rejection

2/6/2003	Date Forwarded to Examiner
2/6/2003	Correspondence Address Change
4/14/2003	Response after Non-Final Action
4/24/2003	Date Forwarded to Examiner
4/28/2003	Workflow - Drawings Finished
4/28/2003	Workflow - Drawings Matched with File at Contractor
4/28/2003	Supplemental Response
5/8/2003	Date Forwarded to Examiner
5/15/2003	Notice of Allowance Data Verification Completed
5/15/2003	Case Docketed to Examiner in GAU
5/16/2003	Mail Notice of Allowance
5/19/2003	Dispatch to Publications
5/22/2003	Workflow - File Sent to Contractor
5/22/2003	Receipt into Pubs
7/11/2003	Receipt into Pubs
8/18/2003	Information Disclosure Statement (IDS) Filed
8/18/2003	Information Disclosure Statement (IDS) Filed
8/18/2003	Request for Continued Examination (RCE)
8/18/2003	Workflow - Request for RCE - Finish
8/18/2003	Workflow - Request for RCE - Begin
10/28/2003	Date Forwarded to Examiner
10/28/2003	Disposal for a RCE / CPA / R129
11/3/2003	Formal Drawings Required
11/3/2003	Notice of Allowance Data Verification Completed
11/4/2003	Mail Notice of Allowance
11/4/2003	Mail Formal Drawings Required
12/10/2003	Receipt into Pubs
1/28/2004	Issue Fee Payment Verified
1/28/2004	Issue Fee Payment Received
2/18/2004	Correspondence Address Change
2/20/2004	Application Is Considered Ready for Issue
2/25/2004	Receipt into Pubs
3/11/2004	Issue Notification Mailed
3/30/2004	Patent Issue Date Used in PTA Calculation
4/6/2004	Recordation of Patent Grant Mailed
4/20/2004	Correspondence Address Change
2/28/2005	Post Issue Communication - Certificate of Correction
3/7/2006	Correspondence Address Change
3/8/2006	Change in Power of Attorney (May Include Associate POA)

,

. . . ÷

487

.

			•	
n9/700094			EP99/0	232/2-
				$\gamma \sim 10^{-10}$
	U9/U00	94.	INITIA	LS
	CÔNTI	ÉNTS		A contraction of the second se
	Date received			Date received
	(Incl. C. of <sub>.</sub> M.) or Data Mailed	States to H		(incl. C. of M.) or 。
1. Application	s	42.	Divicion	
2	0 8 DEC 2800	43		ð ,
3 _ allon2	-22n0	44		·
X	-16 JAN 2001	<b>45.</b>		
B. C. Grude a		46		
F. BILD. PLAIN	4-24-01	48		
. Not ication I H Accep	ted) 6-27-0	49		
P T T T	<u>- 3-15-01</u>	7 <sup>50.</sup>		
10710000000000000000000000000000000000		51		
12 Petiter Devine	4/10/00	52`		
13. Pet Granded	1-17-03	53		
14. Change & faddres	5 1/28/03	55		
13 Rey Binos	<u>Q. 6. 63</u>	56		·
10. + m. d+ 0	<u> </u>	57		·
17. Supp Hmdt D	ZT 5 1 16 03	58	,	· ·
allour no	SIGTOS	60.		
20 RCE	8/18/03	61.	······	
21. Suppl INS	8/18/03	62		
363 Cellouxlility	- H-4-3	63	······	
23. allowance.	<u> </u>	64		
25 h 1 ()	136	65		
26.		67		· · · · · ·
27.		68		<u> </u>
28		<b>69.</b>		%
29		70		
30		71	,	· · ·
32.		72		<u> </u>
33		74		
34		75		· · ·
35	· · · · · · · · · · · · · · · · · · ·	76		
36		77.		
38		79	······································	
39		80	······································	
the comments of the comments o		81		
		82	<u> </u>	·
	(I FFT O	UTSIDF)		

rnat 7C

> (erni tern

rior >rior Prio

App 17 SI

) Inv ;) Inv /

ERN

1		
		•

(54)

ኇ፟፝ዸ

۶۵۲

140, 255

316

	- <u></u>					
Class	Sub.	Date	Exmr.			
560	110,108 121,123, 124,138, 140,142	<pre>[]</pre> [][]	03 <del>21</del>			
514	530,531, 532,53 534 544/54 548, 548, 551	B, ) P )				
VEDATE :			·}			
549	269	17				
ઝાપ	175, 529 530, 547, 548	\$ 28/03	21			
560	140,255					
564	316 (40.12475)	)				
544	269					
514	175,529, 530,547, 548	> 10/2%/0	37-			
560	140,255		1			
504	316	)				
INTERFERENCE SEARCHED						
Class	Sub.	Date	Exmr.			
549 514	269 175,529 538,547 548	Suf 12/03	21			
		1				

ļ

¥

SEARCHED

SEARCH	NOTE	ES TEGY
	Date	Exmr.
STN REGESTRY CAPLUS STRUCTURE - ESTERS X W/ CAPUS	1/28/03	21-
EAST USPAT WERWENT EPO JPO USTE PUB "TOLTERODINE" "METAB #"	,/28/03	21
("AI M TNVENTOR SEARCH -	( 28/03	-21-
UPDATE : ELST - USPAF - X W/ SVBCLASSES EPO, 5PO, DERWENT 'YPLITERODITIE"	¥/28/03	25

TH.

1

;;

1.

.:

• • • • •

\_

RIGHT OUTSIDE



## (12) United States Patent Meese et al.

#### (54) DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES

- Inventors: Claus Meese, Monheim (DE); Bengt (75) Sparf, Trangsund (SE)
- (73) Assignee: Schwarz Pharma AG, Monheim (DE)
- Subject to any disclaimer, the term of this (\*) Notice: patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- 09/700,094 (21) Appl. No.:
- (22) PCT Filed: May 11, 1999
- (86) PCT No.: PCT/EP99/03212 § 371 (c)(1),

(2), (4) Date: Jan. 2, 2001

(87) PCT Pub. No.: WO99/58478 PCT Pub. Date: Nov. 18, 1999

#### (30) **Foreign Application Priority Data**

- May 12, 1998 (EP) ..... 98108608
- (51) Int. Cl.<sup>7</sup> ..... A61K 31/215; A61K 31/22;
- A61K 31/225; A01N 37/08; A01N 37/02 U.S. Cl. ..... 514/175; 514/529; 514/530; (52)514/546; 514/547; 514/548; 549/269; 560/140;
- 560/255; 564/316
- ..... 560/110, 108, (58) Field of Search ..... 560/121, 123, 124, 138, 140, 142, 255; 514/530, 531, 532, 533, 534, 544, 547, 548, 551, 175, 529; 549/269; 564/316

#### (56) **References Cited**

#### **U.S. PATENT DOCUMENTS**

6.313.132 B1 11/2001 Johansson et al. ..... 514/277 FOREIGN PATENT DOCUMENTS

wo	WO 89/06644		7/1989
wo	WO 94/11337	*	5/1994

#### OTHER PUBLICATIONS

Nilvebrant et al, "Antimuscarinic Potency and Bladder Selectivity of PNU-200577, a Major Metabolite of Tolterodine" Pharmacology and Toxicology, vol. 81, pp. 169-172 (1997).\*

US 6,713,464 B1 (10) Patent No.: Mar. 30, 2004 (45) Date of Patent:

Nilvebrant et al, "Tolterodine-A New Bladder Selective Muscarinic Receptor Antagonist: Preclinical Pharmacological and Clinical Data" Life Sciences, vol. 60(13/14), pp. 1129-1136 (1997).\*

Postlind et al, "Tolterodine, A New Muscarinic Receptor Antagonist, is Metabolized by Cytochromes P450 and 3A in Human Liver Microsomes" Drug Metabolism and Disposition, vol. 26(4), pp. 289-293 (1998).\*

Andersson et al, "Biotransformation of Tolterodine, A New Muscarinic Receptor Antagonist, in Mice, Rats, and Dogs" Drug Metabolism and Disposition, vol. 26(6), pp. 528-535 (1998).\*

Brynne et al, "Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity" J. Clin. Pharm. Ther. vol. 35(7), pp. 287-295 (1997).\*

Nilvebrant et al., European Journal of Pharmacology, 327(1997) pp. 195-207.

\* cited by examiner

Primary Examiner-John M. Ford

Assistant Examiner—Zachary C. Tucker (74) Attorney, Agent, or Firm—Edwards & Angell, LLP; Peter F. Corless; Christine C. O'Day

#### ABSTRACT (57)

The invention concerns novel derivatives of 3,3diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

#### 26 Claims, 1 Drawing Sheet

FORMATION OF THE ACTIVE METABOLITE FROM DIFFERENT PRODRUGS BY HUMAN LIVER S 9 (%) IN 1h





15

#### DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES

1

#### BACKGROUND OF THE INVENTION

The present invention relates to novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs.

In man, normal urinary bladder contractions are mediated mainly through cholinergic muscarinic receptor stimulation. There is reason to believe that muscarinic receptors mediate not only normal bladder contractions, but also the main part of the contractions in the overactive bladder resulting in symptoms such as urinary frequency, Urgency and urge incontinence. For this reason, antimuscarinic drugs have been proposed for the treatment of bladder overactivity.

Among the antimuscarinic drugs available on the market, oxybutynin is currently regarded as the gold standard for pharmacological treatment of urge incontinence and other symptoms related to bladder overactivity. The effectiveness of oxybutynin has been demonstrated in several clinical studies, but the clinical usefulness of oxybutynin is limited due to antimuscarinic side effects. Dryness of the mouth is the most common experienced side effect which may be severe enough to result in poor compliance or discontinuation of Treatment (Andersson, K.-E., 1988, Current concepts in the treatment of disorders of micturition, Drugs 35, 477–494; Kelleher et al. 1994).

Tolterodine is a new, potent and competitive, muscarinic receptor antagonist intended for the treatment of urinary urge incontinence and detrusor hyperactivity. Preclinical pharmacological data show that tolterodine exhibits a 35 favourable tissue selectivity in vivo for the urinary bladder over the effect on the salivation (Nilvebrant et al., 1997, Tolterodine-a new bladder-selective antimuscarinic agent, Eur. J. Pharmacol. 327 (1997), 195-207), whereas oxybutynin exhibits the reversed selectivity. Tolterodine is equipotent to oxybutynin at urinary bladder muscarinic receptors and the favourable tissue selectivity of tolterodine demonstrated in the preclinical studies has been confirmed in clinical studies. Thus a good clinical efficacy has been combined with a very low number of incidences of dry  $_{45}$ mouth and antimuscarinic side effects.

A major metabolite of tolterodine, the 5-hydroxymethyl derivative is also a potent muscarinic receptor antagonist and the pharmacological in vitro and in vivo profiles of this metabolite are almost identical to those of tolterodine <sub>50</sub> (Nilvebrant et al., 1997, Eur. J. Pharmacol. 327 (1997), 195–207). Combined pharmacological and pharmacokinetic data indicate that it is most likely that the metabolite gives a major contribution to the clinical effect in most patients.

WO 94/11337 proposes the active metabolite of toltero-55 dine as a new drug for urge incontinence. Administration of the active metabolite directly to patients has the advantage compared to tolterodine that only one active principle (compound) has to be handled by the patient which normally should result in a lower variation in efficacy and side effects 60 between patients and lower risk of interaction with other drugs.

However, the introduction of an additional hydroxy group in the tolterodine results in an increased hydrophilic property of the new compounds (3,3-diphenylpropylamines) 65 compared to the parent compounds which normally results in a lower absorption/bioavailability, leading to pre-systemic

side effects or interactions due to non-absorbed antimuscarinic drug. In a method to circumvent this disadvantage, different prodrugs of the metabolite have been synthesized and tested for their antimuscarinic activity, potential absorption through biological membranes and enzymatic cleavage.

#### SUMMARY OF THE INVENTION

It is an object of the present invention to provide novel derivatives of 3,3-diphenylpropylamines. It is a further object of the present invention to provide new derivatives of 3,3-diphenylpropylamines which will be more useful as prodrugs for treatment of urinary incontinence and other spasmogenic conditions that are caused by muscarinic mechanisms while avoiding the disadvantage of a too low absorption through biological membranes of the drugs or an unfavourable metabolism.

A further object of the invention is to provide novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to present drugs as oxybutynin and tolterodine, methods for preparing thereof, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the formation of the active metabolite from different prodrugs by human liver S 9(%) in 1 hour.

#### DETAILED DESCRIPTION OF THE INVENTION

According to the present invention, novel 3,3diphenylpropyl amines are provided, which are represented by the general formulae I and VII'

Formula I



10

15

50



- wherein R and R' are independently selected from a) hydrogen,  $C_1-C_6$  alkyl,  $C_3-C_{10}$  cycloalkyl, substi-tuted or unsubstituted benzyl, allyl or carbohydrate; 30 or
  - b) formyl,  $C_1-C_6$  alkylcarbonyl, cycloalkylcarbonyl, substituted or unsubstituted arylcarbonyl, preferably benzoyl; or
  - c)  $C_1 C_6$  alkoxycarbonyl, substituted or unsubstituted aryloxycarbonyl, benzoylacyl, benzoylglycyl, a substituted or unsubstituted amino acid residue; or



d)

wherein  $\mathbb{R}^4$  and  $\mathbb{R}^5$  independently represent  $_{45}$  include the following groups a) to h): hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, substituted or unsubstituted aryl, preferably substituted or unsubstituted phenyl, benzyl or phenoxyalkyl wherein the alkyl residue has 1 to 4 carbon atoms and wherein  $R^4$  and  $R^5$  may form a ring together with the amine nitrogen; or e)

55

wherein  $R^6$  and  $R^7$  independently represent  $C_1-C_6$ alkyl, substituted or unstubstituted aryl, preferably substituted or unsubstituted phenyl, benzyl or phenoxyalkyl wherein the alkyl residue has 1 to 6 carbon atoms; or

f) an ester moiety of inorganic acids,

 $-SiR_aR_bR_c$ , wherein  $R_a$ ,  $R_b$ ,  $R_c$  are independently g) selected from  $C_1 - C_4$  alkyl or aryl, preferably phenyl, 65 with the proviso that R' is not hydrogen, methyl or benzyl if R is hydrogen.

Δ

X represents a tertiary amino group of formula Ia

Formula Ia

- wherein R<sup>8</sup> and R<sup>9</sup> represent non-aromatic hydrocaryl groups, which may be the same or different and which together contain at least three carbon atoms, and wherein R<sup>8</sup> and R<sup>9</sup> may form a ring together with the amine nitrogen.
- Y and Z independently represent a single bond between the  $(CH_2)_n$ , group and the carbonyl group, O, S or NH,
  - A represents hydrogen (<sup>1</sup>H) or deuterium (<sup>2</sup>H),

n is 0 to 12 and

- <sup>20</sup> their salts with physiologically acceptable acids, their free bases and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers.
- 25 The aforementioned compounds can form salts with physiologically acceptable organic and inorganic acids. Furthermore, the aforementioned compounds comprise the free bases as well as the salts thereof. Examples of such acid addition salts include the hydrochloride, hydrobromide and the like.

When the novel compounds are in the form of optical isomers, the invention comprises the racemic mixture as well as the individual isomers as such.

Preferably each of  $R^8$  and  $R^9$  independently signifies a saturated hydrocarbyl group, especially saturated aliphatic hydrocarbyl groups such as  $C_{1-8}$ -alkyl, especially  $C_{1-5}$ -alkyl, or adamantyl, R<sup>8</sup> and R<sup>9</sup> together comprising at least three, 40 preferably at least four carbon atoms.

According to another embodiment of the invention, at least one of  $\mathbb{R}^{8}$  and  $\mathbb{R}^{9}$  comprises a branched carbon chain.

Presently preferred tertiary amino groups X in formula I



a)

b)

c)

d)

e)

f)

g)

h)

20

25

40

5



Group a) is particularly preferred.

The aforementioned tertiary amino groups X are described in WO 94/11337 and the compounds according to the present invention can be obtained by using the corresponding starting compounds.

In the compounds according to the present invention, the term "alkyl" preferably represents a straight-chain or branched-chain hydrocarbon group having 1 to 6 carbon 35 atoms. Such hydrocarbon groups may be selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl and hexyl. The term "cycloalkyl" denotes a cyclic hydrocarbon group having 3 to 10 carbon atoms which may be substituted conveniently.

The term "substituted or unsubstituted benzyl" denotes a benyl group — $CH_2$ — $C_6H_5$  which is optionally substituted by one or more substituents on the phenyl ring. Suitable substituents are selected from alkyl, alkoxy, halogen, nitro and iodine atoms. Preferred substituted benzyl groups are 4-methylbenzyl, 2-methylbenzyl, 4-methoxybenzyl, 2-methoxybenzyl, 4-nitrobenzyl, 2-nitrobenzyl, 4-chlorobenzyl and 2-chlorobenzyl.

In the compounds according to the present invention the 50 term " $C_1$ - $C_6$  alkylcarbonyl" denotes a group R—C(=0)wherein R is an alkyl group as defined hereinbefore. Preferred C<sub>1</sub>-C<sub>6</sub> alkylcarbonyl groups are selected from acetyl, propionyl, isobutyryl, butyryl, valeroyl and pivaloyl. The term "cycloalkylcarbonyl" denotes a group R-C(=0)-55 wherein R is a cyclic hydrocarbon group as defined hereinbefore. The same counts to the selected carbonyl groups.

The term "aryl" denotes an aromatic hydrocarbon group such as phenyl-( $C_6H_5$ —), naphthyl-( $C_{10}H_7$ —), anthryl-( $C_{14}H_9$ —), etc. Preferred aryl groups according to the 60 present invention are phenyl and naphthyl with phenyl being particularly preferred.

The term "benzoyl" denotes an acyl group of the formula -CO-C<sub>6</sub>H<sub>5</sub> wherein the phenyl ring may have one or more substituents. 65

Preferred substituents of the aryl group and in particular of the phenyl group are selected from alkyl, alkoxy, halogen

and nitro. As substituted benzoyl groups 4-methylbenzoyl, 2-methylbenzoyl, 4-methoxybenzoyl, 2-methoxybenzoyl, 4-chlorobenzoyl, 2-chlorobenzoyl, 4-nitrobenzoyl and 2-nitrobenzoyl may be mentioned.

The term " $C_1$ - $C_6$  alkoxycarbonyl" refers to a group ROC(=O)- wherein R is an alkyl group as defined hereinbefore. Preferred  $C_1-C_6$  alkoxycarbonyl groups are 10 selected from  $CH_3OC(=0)$ -,  $C_2H_5-OC(=0)$ -, C<sub>3</sub>H<sub>7</sub>OC(=O)- and (CH<sub>3</sub>)<sub>3</sub>COC(=O)- and alicyclic alkyloxycarbonyl.

The term "amino acid residue" denotes the residue of a 15 naturally occurring or synthetic amino acid. Particularly preferred amino acid residues are selected from the group consisting of glycyl, valyl, leucyl, isoleucyl, phenylalanyl, prolyl, seryl, threonyl, methionyl, hydroxyprolyl.

The amino acid residue may be substituted by a suitable group and as substituted amino acid residues, benzoylglycyl and N-acetylglycyl may be mentioned.

The term "carbohydrate" denotes the residue of a polyhydroxy aldehyde or polyhydroxy ketone of the formula  $C_n H_{2n} O_n$ , or  $C_n (H_2 O)_n$  and corresponding carbohydrate groups are, for example, described in Aspinal, The Polysaccharides, New York: Academic Press 1982, 1983. A 30 preferred carbohydrate group in the compounds according to the present invention is a glucuronosyl group, in particular a 1 $\beta$ -D-glucuronosyl group.

The term "LG" as used herein denotes a leaving group selected from halogenides, carboxylates, imidazolides and the like.

The term "Bn" as used herein denotes a benzyl group.

Suitable ester moieties of inorganic acids may be derived and the like. Suitable halogen atoms are fluorine, chlorine 45 from inorganic acids such as sulfuric acid and phosphoric acid.

> Preferred compounds according to the present invention are:

> A) Phenolic monoesters represented by the genera formulae II and II'

> > Formula II



#### US 6,713,464 B1



wherein  $R^1$  represents hydrogen,  $C_1-C_6$  alkyl or phenyl. Particularly preferred phenolic monoesters are listed below:

- (±)-formic acid 2-(3-diisopropylamino-1-phenylpropyl)- 30 4-hydroxymethylphenyl ester,
- (±)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester,
- (±)-propionic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-n-butyric acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-isobutyric acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- R-(+)-isobutyric acid 2-(3-diisopropylamino-1-<sup>40</sup> phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-2,2-dimethylpropionic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-2-acetamidoacetic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-cyclopentanecarboxylic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-cyclohexanecarboxylic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, 50
- (±)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
- R-(+)-benzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-4-methylbenzoic acid 2-(3-diisopropylamino-1-<sup>55</sup> phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-2-methylbenzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-2-acetoxybenzoic acid 2-(3-diisopropylamino-1- 60 phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-1-naphthoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-2-naphthoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-4-chlorobenzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,

- (±)-4-methoxybenzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-2-methoxybenzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-4-nitrobenzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-2-nitrobenzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-malonic acid bis-[2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethyl-phenyl]ester,
- (±)-succinic acid bis-[2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethyl-phenyl]ester,
- (±)-pentanedioic acid bis-[2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethyl-phenyl]ester,
- (±)-hexanedioic acid bis-[2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethyl-phenyl]ester.
- B) Identical diesters represented by the general formula

Formula III



wherein  $R^1$  is as defined above.

35

65

Particularly preferred identical diesters are listed below: (±)-formic acid 2-(3-diisopropylamino-1-phenylpropyl)-

- 4-formyloxymethylphenyl ester,
- (±)-acetic acid 4-acetoxy-3-(3-diisopropylamino-1phenylpropyl)-benzyl ester,
- (±)-propionic acid 2-(3-diisopropylamino-1phenylpropyl)-4-propionyloxymethylphenyl ester,
- (±)-n-butyric acid 4-n-butyryloxymethyl-2-(3diisopropylamino-1-phenylpropyl)-phenyl ester,
- (±)-isobutyric acid 2-(3-diisopropylamino-1phenylpropyl)-4-isobutyryloxymethylphenyl ester,
- (±)-2,2-dimethylpropionic acid 3-(3-diisopropylamino-1phenylpropyl)-4-(2,2-dimethyl-propionyloxy)-benzyl ester,
- (±)-benzoic acid 4-benzoyloxymethyl-2-(3disopropylamino-1-phenylpropyl)-phenyl ester,
- R-(+)-benzoic acid 4-benzoyloxymethyl-2-(3diisopropylamino-1-phenylpropyl)-phenyl ester,
- (±)-pent-4-enoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-(pent-4-enoyloxymethyl)-phenyl ester,
- cyclic oct-4-ene-1,8-dioate of Intermediate B,

cyclic octane-1,8-dioate of Intermediate B,

poly-co-DL-lactides of Intermediate B.



9



wherein R<sup>1</sup> is as defined above and

R represents hydrogen,  $C_1$ - $C_6$  alkyl or phenyl with the proviso that  $R^1$  and  $R^2$  are not identical.

- Particularly preferred mixed diesters are listed below: 20 (±)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4formyloxymethylphenyl ester,
- (±)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-formyloxymethylphenyl ester,
- (±)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-<sup>25</sup> 4-acetoxymethylphenyl ester,
- R-(+)-benzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-acetoxymethylphenyl ester,
- (±)-isobutyric acid 4-acetoxymethyl-2-(3diisopropylamino-1-phenylpropyl)-phenyl ester,
- R-(+)-isobutyric acid 4-acetoxymethyl-2-(3diisopropylamino-1-phenylpropyl)-phenyl ester,
- (±)-2,2-dimethylpropionic acid 4-acetoxy-3-(3diisopropylamino-1-phenylpropyl)-benzyl ester,
- (±)-2,2-dimethylpropionic acid 4-acetoxymethyl-2-(3diisopropylamino-1-phenylpropyl)-phenyl ester,
- (±)-benzoic acid 4-benzyloxy-3-(3-diisopropylamino-1phenylpropyl)-benzyl ester.
- D) Benzylic monoesters represented by the general formula 40 v



wherein  $R^1$  is as defined above.

Particularly preferred benzylic monoesters, are listed below:

- (±)-formic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester,
- (±)-acetic acid 3-(3-diisopropylamino-1-phenylpropyl)-4- 60 hydroxybenzyl ester,
- (±)-propionic acid 3-(3-diisopropylamino-1phenylpropyl)-4-hydroxybenzyl ester,
- (±)-butyric acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester,
- (±)-isobutyric acid 3-(3-diisopropylamino-1phenylpropyl)-4-hydroxybenzyl ester,

- (±)-2,2-dimethylpropionic acid 3-(3-diisopropylamino-1phenylpropyl)-4-hydroxybenzyl ester,
- (±)-benzoic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester.

E) Ethers and silyl ethers represented by the general formula 5 VI





- wherein at least one of  $R^{10}$  and  $R^{11}$  is selected from  $C_1-C_6$ alkyl, benzyl or  $-SiR_aR_bR_c$  as defined above and the other one of  $R^{10}$  and  $R^{11}$  may additionally represent hydrogen,  $C_1-C_6$  alkylcarbonyl or benzoyl. Particularly preferred ethers and silyl ethers are listed
- below:
  - (±)-2-(3-diisopropylamino-1-phenylpropyl)-4methoxymethylphenol,
  - (±)-2-(3-diisopropylamino-1-phenylpropyl)-4ethoxymethylphenol,
  - (±)-2-(3-diisopropylamino-1-phenylpropyl)-4propoxymethylphenol,
  - (±)-2-(3-diisopropylamino-1-phenylpropyl)-4isopropoxymethylphenol,
  - (±)-2-(3-diisopropylamino-1-phenylpropyl)-4butoxymethylphenol,
  - (±)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4methoxymethylphenyl ester,
  - (±)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4ethoxymethylphenyl ester,
  - (±)-2-(3-diisopropylamino-1-phenylpropyl)-4trimethylsilanyloxymethylphenol,
  - (±)-diisopropyl-[3-phenyl-3-(2-trimethylsilanyloxy-5trimethylsilanyloxymethylphenyl)-propyl]-amine,
  - (±)-[3-(3-diisopropylamino-1-phenylpropyl)-4trimethylsilanyloxyphenyl]-methanol,
  - (±)-diisopropyl-[3-(5-methoxymethyl-2trimehylsilanyloxyphenyl)-3-phenylpropylamine,
  - (±)-diisopropyl-[3-(5-ethoxymethyl-2trimethylsilanyloxyphenyl)-3-phenylpropylamine,
  - (±)-[4-(tert.-butyl-dimethylsilanyloxy)-3-(3diisopropylamino-1-phenylpropyl)-phenyl]-methanol,
  - (±)-acetic acid 4-(tert.-butyl-dimethylsilanyloxy)-3-(3diisopropylamino-1-phenylpropyl)-benzyl ester,
  - (±)-4-(tert.-butyl-dimethylsilanyloxy)-3-(3diisopropylamino-1-phenylpropyl)-phenol,
  - (±)-acetic acid 4-(tert.-butyl-dimethylsilanyloxy)-2-(3diisopropylamino-1-phenylpropyl)-phenyl ester,
  - (±)-{3-[2-(tert.-butyl-dimethylsilanyloxy)-5-(tert.-butyldimethylsilanyloxymethyl)-phenyl]-3-phenylpropyl}diisopropylamine,
  - (±)-[4-(tert.-butyl-diphenylsilanyloxy)-3-(3diisopropylamino-1-phenylpropyl)-phenyl]-methanol,
  - (±)-acetic acid 4-(tert.-butyl-diphenylsilanyloxymethyl)-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester,

- (±)-4-(tert.-butyl-diphenylsilanyloxymethyl)-2-(3diisopropylamino-1-phenylpropyl)-phenol,
- (±)-{3-[2-(tert.-butyl-diphenylsilanyloxy)-5-(tert.-butyldiphenylsilanyloxymethyl)-phenyl]-2-phenylpropyl}diisopropylamine,
- (±)-acetic acid 4-benzyloxy-3-(3-diisopropylamino-1phenylpropyl)-benzyl ester,
- (±)-benzoic acid 4-benzyloxy-3-(3-d4isopropylamino-1phenylpropyl)-benzyl ester,
- (±)-isobutyric acid 4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester,
- (±)-2-(3-diisopropylamino-1-phenylpropyl)-4-(1β-Dglucuronosyloxymethyl)-phenol.
- F) Carbonates and carbamates represented by the general 15 formulae VII and VIII



Formula VIII

35

50



wherein Y, Z and n are as defined above and wherein  $R^{12}$ and  $R^{13}$  represent a  $C_1-C_6$  alkoxycarbonyl group or



wherein  $\mathbb{R}^4$  and  $\mathbb{R}^5$  are as defined above.

#### 12

Particularly preferred carbonates and carbamates are listed below:

- (±)-N-ethylcarbamic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-N,N-dimethylcarbamic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-N,N-diethylcarbamic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-N-phenylcarbamic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-[2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethyl-phenoxycarbonylamino]acetic acid ethyl ester hydrochloride,
- (±)-N-ethylcarbamic acid 3-(3-diisopropylamino-1phenylpropyl)-4-N-ethylcarbamoyloxybenzyl ester,
- (±)-N,N-dimethylcarbamic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-N,N-dimethylcarbamoyloxybenzyl ester,
- (±)-N,N-diethylcarbamic acid 3-(3-diisopropylamino-1phenylpropyl)-4-N,N-diethylcarbamoyloxybenzyl ester,
- (±)-N-phenylcarbamic acid 3-(3-diisopropylamino-1phenylpropyl)-4-N-phenylcarbamoyloxybenzyl ester,
- (±)-{4-[2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenoxycarbonylamino]-butyl}-
- carbamic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-carbonic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester ethyl ester,
- (±)-carbonic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester phenyl ester,
- (±)-carbonic acid 2-(3-diisopropylamino-1phenylpropyl)-4-ethoxycarbonyloxymethylphenyl ester ethyl ester,
- (±)-carbonic acid 2-(3-diisopropylamino-1phenylpropyl)-4-phenoxycarbonyloxymethylphenyl ester phenyl ester.
- G) 3,3-Diphenylpropylamines selected from(i) compounds of the formulae IX and IX'

Formula IX



#### ' US 6,713,464 B1

10

15

40





- wherein 0 and p are the same or different and represent the number of methylene units  $-(CH_2)$  and may <sup>20</sup> range from 0 to 6,
- (ii) (±)-Benzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-sulphooxymethyl-phenyl ester
- (iii) Poly-co-DL-lactides of 2-(3disopropylaminophenylpropyl)-4-hydroxymethyl-<sup>25</sup> phenol
- (iv) (±)-2-(3-Diisopropylamino-1-phenylpropyl)-4-(1β-D-glucuronosyloxymethyl)-phenol having the formula



#### and

their salts with physiologically acceptable acids, their free bases and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers.

The present invention, moreover, relates to processes for the preparation of the aforementioned compounds. In particular, according to the present invention, he following processes are provided:

A process for the production of phenolic monoesters represented by the general formula II



as defined above, which comprises treatment of a compound of the formula



with an equivalent of an acylating agent selected from



wherein LG represents a leaving group selected from halogenide, carboxylate and imidazolide and R<sup>1</sup> is as defined above, in an inert solvent in the presence of a condensating agent.

Preferably, the acylating agent is selected from



wherein Hal represents a halogen atom, preferably a chlorine atom, and  $R^1$  is a defined above.

A process for the production of phenolic monoesters represented by the general formula  $I^{\prime}$ 

Formula II'



as defined above, which comprises treatment of two equivalents of a compound of the formula

14

#### , US 6,713,464 B1

10

15

25

30



15

with an acylating agent selected from



wherein Hal represents a halogen atom, preferably a chlorine atom.

Hence, in these processes, an Intermediate B having the formula



is treated with an equivalent of an acylating agent (e.g. an acyl halogenite or acyl anhydride) in an inert solvent and in the presence of a condensating agent (e.g.  $_{40}$ amine) to provide phenolic monoesters of formula II or formula II' (wherein n is 0-12), respectively, if polyfunctional acylating agents (e.g. acid halides, preferably acid chlorides of dicarboxylic acids) are used.

The Intermediate B as used in the processes for the 45 production of the 3,3-diphenylpropylamines according to the present invention can be in the form of a racemic mixture or of optically active compounds in accordance with the formulae shown below: 50





16 -continued

Intermediate R-(+)

Intermediate S-(-)

Alternatively, structures of formula II or II' may be obtained by regioselective deprotection of a protected ben-zylic hydroxy group (chemically or enzymatically: T. W. Greene, P. G. M. Wuts, "Protective Groups in Organic 35 Chemistry", 2nd Ed., J. Wily & Sons, New York 1991).

Ш



as defined above can be prepared by a process which comprises treatment of a compound of the formula



with at least two equivalents of the acylating agent  $R^1$ —C(==O)—LG as defined above.

The identical diesters represented by the general formula



25

Thus, the aforementioned di-acyl compounds are readily accessible if an at least two-molar excess of an acylating agent is used in the above-mentioned conversion of Intermediate B or, more general, on treatment of compounds of 5 formula I with acylating agents in the presence of suitable catalysts. In the above process, the following Intermediate A

17



wherein R' denotes a benzyl group can be used instead of 20 Intermediate B. The Intermediate A can be used in the form of a racemic mixture or of optically active compounds (similar to Intermediate B).

Benzylic monoestes represented by the general formula V



wherein  $R^1$  is as defined above can be prepared by a process which comprises treatment of a compound of the formula



at room temperature and under anhydrous conditions 55 with activated esters in the presence of enzymes selected from lipases or esterases.

Hence, this process relates to the preparation of phenols with para acyloxymethyl substituents (cf. formula V). These compounds can be prepared in several chemical steps from 60 intermediates such as formula I, where R represents hydrogen and R' is hydrogen or any suitable protective group which can, be removed by known methods (T. W. Greene, P. G. M. Wuts, "Protective Groups in Organic Chemistry", 2nd Ed., J. Wily & Sons, New York 1991) in the presence of the 65 newly introduced substituent R<sup>1</sup>CO. It was found, however, that the benzylic substituent R<sup>1</sup>CO can be introduced more

conveniently and in only one step if Intermediate B is treated at room temperature and under anhydrous conditions with activated esters (e.g. vinyl acylates, isopropenyl acylates) in the presence of enzymes such as lipases or esterases.

The mixed diesters represented by the general formula IV





wherein  $R^1$  and  $R^2$  are as defined above can be precared by a process which comprises acylation of the abovementioned benzylic monoester represented by the general formula V



wherein  $R^1$  is as defined above or of a phenolic monoester benzylic represented by the general formula II



as defined hereinbefore.

In general, mixed diesters of formula IV can be obtained by acylation of compounds of the general formula I wherein R and R' are different substituents selected from the group consisting of hydrogen, acyl residues or protecting groups that are cleavable under the acylation reaction conditions.

Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0017

## US 6,713,464 B1

Ethers represented by the general formula VI

19



as defined hereinbefore wherein R<sup>11</sup> is hydrogen can be prepared by a process which comprises reacting a compound of the formula 20



with an alcohol R<sup>10</sup>—OH in the presence of an esterification catalyst. 35

A further process for the preparation of ethers represented by the general formula VI



wherein R<sup>10</sup> and R<sup>11</sup> are as defined hereinbefore, comprises acid or base treatment of free benzylic alcohols selected from 55





20

-continued

 $HO \xrightarrow{R^{1}} O \xrightarrow{N} \downarrow$ 





R<sup>12</sup>O

wherein  $\mathbb{R}^{12}$  is hydrogen and  $\mathbb{R}^{13}$  represents a  $\mathbb{C}_1 - \mathbb{C}_6$  alkoxycarbonyl group or



wherein  $R^4$  and  $R^5$  are as defined above

Formula VI

Formula II



Formula VII



Formula IV

50

55



wherein  $R^1$  and  $R^2$  are as defined hereinbefore in the presence of suitable hydroxy reagents. Finally, ethers of formula VI can be prepared by a process

which comprises treating a compound of the formula



wherein R<sup>10</sup> is as defined above with an alkylating agent selected from alkyl halogenides, alkyl sulphates and 60 alkyl triflates, said alkyl group having 1 to 6 carbon atoms.

In summary, regioselective modification of the benzylic hydroxy groups is achieved either by acid or base treatment of benzylic acylates in the presence of suitable hydroxy 65 reagents (e.g. alcohols) or by catalytic ether formation as described in the literature for other benzylic substrates (J. M.

Saa, A. Llobera, A. Garcia-Raso, A. Costa, P. M. Deya; J. Org. Chem. 53: 4263-4273 [1988]). Both free benzylic alcohols such as Intermediates A and B or compounds of formulas II or VI (in which  $R^{10}$  is hydrogen) or formula VII (in which  $R^{12}$  is hydrogen) as well as benzylic acylates such as formulae III, IV, V may serve as starting materials for the preparation of benzylic ethers (B. Loubinoux, J. Miazimbakana, P. Gerardin; Tetrahedron Lett. 30: 10 1939–1942 [1989]).

Likewise the phenolic hydroxy groups are readily transformed into phenyl ethers (R<sup>11</sup>=alkyl) using alkylating agents such as e.g. alkyl halogenides, alkyl sulphates, alkyl triflates or employing Mitsunobu type reaction conditions <sup>15</sup> (Synthesis 1981, 1–28). Similarly, both phenolic and alcoholic monosilyl ethers are obtained by regioselective silylation or by desilylation of bis-silyl ethers of Intermediate B as described for other compounds in the literature (J. 20 Paladino, C. Guyard, C. Thurieau, J.-L. Fauchere, Helv. Chim. Acta 76: 2465-2472 [1993]; Y. Kawazoe, M. Nomura, Y. Kondo, K. Kohda, Tetrahedron Lett. 26: 4307-4310 [1987]).

Carbonates and carbamates represented by the general 25 formulae VII and VIII

Formula VII





as defined hereinbefore can be prepared by a process which comprises reacting a compound selected from the group consisting of



wherein R<sup>1</sup> is defined as above, n is 0 to 12, Bn is benzyl, R<sup>10</sup> or R<sup>11</sup> is hydrogen with activated carbonyl compounds or carbonyl precursor reagents selected from haloformates, ketenes, activated esters, mixed anhydrides of organic or inorganic acids, isocyanates and isothiocyanates.

The coupling reactions can be carried out in inert solvents  $^{65}$  over periods of several hours at temperatures from  $-10^{\circ}$  C. to the refluxing temperature of the solvent or reagent used to

provide compounds of the general formula VII where  $R^{12}$  represents hydrogen, alkyl, aliphatic or aromatic acyl, or carbamoyl, and  $R^{13}$  represents —C(=O)—Y— $R^3$ , wherein Y and  $R^3$  represent O, S, NH and alkyl or aryl, respectively. Polyfunctional reagents give the corresponding derivatives. For example, diisocyanates or di-carbonylchlorides provide compounds of formula VIII where X, Y have the meaning of O, S, or NH and n is zero to twelve.

The invention, moreover, relates to pharmaceutical compositions comprising one or more of the aforementioned 3,3-diphenylpropylamines. In other words, the compounds according to the present invention can be used as pharmaceutically active substances, especially as antimuscarinic agents.

They can be used for preparing pharmaceutical formulations containing at least one of said compounds.

The compounds according to the present invention in the form of free bases or salts with physiologically acceptable acids, can be brought into suitable galenic forms, such as compositions for oral use, for injection, for nasal spray administration or the like, in accordance with accepted pharmaceutical procedures. Such pharmaceutical compositions according to the invention comprise an effective amount of the compounds of claims 1 to 15 in association with compatible pharmaceutically acceptable carrier materials, or diluents, as is well known in the art. The carriers may be any inert material, organic or inorganic, suitable for enteral, percutaneous or parenteral administration, such as water, gelatine, gum arabicum, lactose, microcrystalline cellulose starch, sodium starch glycolate, calcium hydrogen phosphae, magnesium stearate, talcum, colloidal silicon dioxide, and the like. Such compositions may also contain other pharmaceutically active agents, and conventional additives, such as stabilizers, wetting agents, emulsifiers, flavouring agents, buffers, and the like.

The composition according to the invention can e.g. be made up in solid or liquid form for oral administration, such as tablets, capsules, powders, syrups, elixirs and the like, in the form of sterile solutions, suspensions or emulsions for parenteral administration, and the like.

The compounds according to the invention may be used in a patch formulation. The compounds can be administered transdermally with a reduced incidence of side effects and improved individual compliance.

The compounds and compositions can, as mentioned above, be used for the treatment of urinary incontinence and other spasmogenic conditions that are caused by muscarinic mechanisms. The dosage of the specific compound will vary depending on its potency, the mode of administration, the age and weight of the patient and the severity of the condition to be treated. The daily dosage may, for example, range from about 0.01 mg to about 5 mg, administered singly or multiply in doses e.g. from about 0.05 mg to about 50 g each.

The invention will be further illustrated by the following non-limiting examples and pharmacological tests.

#### I. Experimental

1. General

All compounds were fully characterized by <sup>1</sup>H and <sup>13</sup>C NMR spectroscopy (Bruker DPX 200). The chemical shifts reported for <sup>13</sup>C NMR spectra (50 MHz, ppm values given) refer to the solvents CDCl<sub>3</sub> (77.10 ppm), dideuterio dichloromethane (CD<sub>2</sub>Cl<sub>2</sub>, 53.8 ppm), CD<sub>3</sub>OD (49.00 ppm) or hexadeuterio dimethylsulphoxide (DMSO-d<sub>6</sub>, 39.70 ppm), respectively. <sup>1</sup>H NMR data (200 MHz, ppm) refer to internal tetramethylsilane). Thin-layer chromatography (tlc,  $R_f$  val-

.

ues reported) was conducted on precoated  $5 \times 10$  cm E. Merck silica gel plates (60F254), spots were visualized by fluorescence quenching or spaying with alkaline potassium permanganate solution.

Solvent systems: (1), ethyl acetate/n-hexane (30/70, v/v- 5 %); (2), toluene/acetone/methanol/acetic acid (70/5/20/5, v/v-%); (3), n-hexane/acetone/diethylamine (70/20/10, v/v-%); (4), n-hexane/acetone/triethylamine (70/20/10, v/v-%); (5), ethyl acetate/n-hexane/2-propanol/triethylamine (60/40/20/1, v/v-%); (6), ethyl acetate/triethylamine (90/10, v/v-%); 10 (7), cyclohexane/acetone/acetic acid (80/20/0.5, v/v-%).

Optical rotations were measured at 589.3 nm and room temperature on a Perkin Elmer Polarimeter Type 241.

Melting points (mp) reported are uncorrected and were determined on a Mettler FP 1 instrument.

IR spectra were taken from a Perkin-Elmer FTIR spectrometer Series 1610, resolution 4 cm<sup>-1</sup>.

Gas chromatography-mass spectrometry (GC-MS): spectra (m/z values and relative abundance (%) reported) were recorded on a Finnigan TSQ 700 triple mass spectrometer in 20 the positive (P-CI) or negative (N-CI) chemical ionization mode using methane or ammonia as reactant gas. Hydroxylic compounds were analyzed as their trimethylsilyl ether derivatives. Combined liquid chromatography-mass spectrometry (LC-MS): Waters Integrety System, Thermabeam 25 Mass Detector (EI, 70 eV), m/z values and relative abundance reported.

2. Synthesis of Intermediates A and B

3-Phenylacrylic Acid 4-Bromophenyl Ester

An ice-cooled solution of 4-bromophenol (69.2 g) and 30 cinnamoyl chloride (66.8 g) in dichloromethane (150 ml) was treated with triethylamine (40.6 g). After stirring for 18 hrs at room temperature the mixture was washed with water (250 ml), 1 M aqueous HCl, and dried over anhydrous sodium sulphate. Evaporation in vacuum left solid 35 3-phenylacrylic acid 4-bromophenyl ester (121.0 g, 99.8% yield), m.p. 113.3° C., tlc: (1) 0.83. NMR (CDCl<sub>3</sub>): 116.85, 118.87, 123.49, 128.38, 129.06, 130.90, 132.49, 134.02, 147.07, 149.84, 165.06.

(±)-6-Bromo-4-phenylchroman-2-one

A portion of the ester (60.0 g) was dissolved in a mixture of acetic acid (60 ml) and concentrated sulphuric acid (18 ml) and refluxed for 2 hrs. After cooling, the reaction mixture was poured into ice water and the product was isolated by extraction with ethylacetate. Evaporation of the 45 solvent and recrystallization of the residue from boiling ethanol (150 ml) yielded 26.3 g (43.8% yield) of pure, crystalline ( $\pm$ )-6-bromo-4-phenylchroman-2-one, m.p. 117.8° C., tlc: (1) 0.67. NMR (CDCl<sub>3</sub>): 36.56, 40.51, 117.29, 118.87, 127.47, 127.89, 128.33, 129.32, 131.07, 131.79, 50 139.42, 150.76, 166.84.

(±)-3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropionic Acid Methyl Ester

A suspension consisting of  $(\pm)$ -6-bromo-4phenylchroman-2-one (85.0 g), anhydrous potassium car-55 bonate (46.7 g), sodium iodide (20.5 g) and benzyl chloride (40.6 g) in methanol (350 ml) and acetone (350 ml) was refluxed for 3 hrs. After evaporation of the solvents the residue was extracted with diethyl ether (2×300 ml) and the extract was washed with water (2×200 ml) and aqueous 60 sodium carbonate. Drying (Na<sub>2</sub>SO<sub>4</sub>) and rotoevaporation left 121.8 g (102.1% crude yield) of ( $\pm$ )-3-(2-benzyloxy-5bromophenyl)-3-phenylpropionic acid methyl ester as a light yellow oil, tlc: (1) 0.77; NMR (CDCl<sub>3</sub>): 39.22, 40.53, 51.63, 70.16, 113.10, 113.77, 126.46, 126.92, 127.88, 65 128.08, 128.34, 128.45, 130.31, 130.55, 134.41, 136.44, 142.37, 154.94, 172.08. 26

(±)-3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropionic Acid

A solution of (±)-3-(2-benzyloxy-5-bromophenyl)-3phenylpropionic acid methyl ester (0,391 g, 0,92 mmol) in ethanol (5 ml) was treated at 50° C. with excess aqueous sodium hydroxide solution until the milky emulsion became clear. The reaction mixture was then acidified (pH 3), evaporated and extracted with dichloromethane. The organic extract was evaporated and the remaining oil was redissolved in a minimum of boiling ethanol. The precipitation formed after 18 hrs at 4° C. was filtered off and dried in vacuo to yield 0.27 g (71.4%) of (±)-3-(2-Benzyloxy)-5bromophenyl)-3-phenylpropionic acid, colourless crystals, m.p. 124.9° C.; tlc: (1) 0.15 starting material methyl ester 0.75); NMR (CDCl<sub>3</sub>): 39.15, 40.26, 70.25, 113.21, 113.90, 126.62, 127.27, 127.98, 128.17, 128.47, 128.54, 130.46, 15 130.68, 134.34, 136.45, 142.16, 154.95, 177.65. LC-MS: 412/410 (14/11%, M<sup>+</sup>), 394/392 (15/13%), 321/319 (17/ 22%), 304/302 (17/21%), 259 (24%), 194 (22%), 178 (21%), 167 (65%), 152 (49%), 92 (100%). IR (KBr): 3434, 3030, 1708, 1485, 1452, 1403, 1289, 1243, 1126, 1018, 804, 735, 698, 649. Calculated for  $C_{22}H_{19}BrO_3$  (mol-wgt. 411.30): C, 64.25%, H, 4.66%, Br, 19.43%, O, 11.67%; found: C, 63.72%, H, 4.70%, Br, 19.75%, O, 11.80%.

Alternatively, the crude reaction mixture from the above described synthesis of  $(\pm)$ -3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid methyl ester was evaporated, redissolved in warm ethanol, and treated with excess aqueous potassium hydroxide solution. Acidification to pH 3 (conc. hydrochloric acid) and cooling to 4° C. resulted in the formation of a solid, which was filtered off after 18 hrs, washed repeatedly with water and dried to yield  $(\pm)$ -3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid in 82% yield.

a) Resolution of 3-(2-Benzyloxy-5-bromophenyl)-3phenylpropionic Acid

 $R \cdot (-) - 3 \cdot (2 - B e n z y l o x y - 5 - b r o m o p h e n y l) - 3 - phenylpropionic Acid$ 

Warm solutions of (±)-3-(2-benzyloxy-5-bromophenyl)3-phenylpropionic acid (815.6 g, 1.85 mol) and 1S,2R-(+)-ephedrine hemihydrate (232.1 g, 1.85 mol) in 2000 ml and 700 ml, respectively, of absolute ethanol were combined and then allowed to cool to 0° C. The precipitate formed was collected, washed with cold ethanol and dried in vacuum to 45 give 553.2 g or the ephedrinium salt of the title compound (m.p. 153° C., e.e. 65% as determined by NMR and HPLC). The salt was recrystallized twice from boiling ethanol to give R-(-)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid 7S,2R-(+)-ephedrinium salt in 75% yield, colourless crystalls, m.p. 158.6° C., e.e. 97.6% (HPLC). NMR (CDCl<sub>3</sub>): 9.53, 30.90, 41.54, 42.83, 61.45, 70.15, 70.42, 113.05, 113.68, 125.89, 126.03, 127.33, 127.85, 128.19, 128.28, 128.45, 129.86, 130.70, 135.91, 136.65, 140.40, 144.09, 155.20, 178.94.

1.2 g (2.0 mmol) of the ephedrinium salt were dissolved in a mixture of acetone (5 ml) and ethanol (10 ml). After treatment with water (0.4 ml) and conc. (37%) aqueous hydrochloric acid (0.34 ml), the solution was evaporated in vacuum, and the residue was redissolved in 1M aqueous hydrochloric acid (2 ml) and dichloromethane (10 ml). The organic phase was separated, washed twice with water (2 ml), and evaporated to dryness to give R-(-)-3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropionic acid as a colourless oil which slowly solidified (0.4 g, 98% yield), m.p. 105.6° C. (from ethyl acetate/n-heptane); tlc: (7) 0.21;  $[\alpha]_D^{20} = -21.1$  (c=1.0, ethanol), e.e. 99.9% (HPLC). NMR: identical with the racemtic acid.

S-(+)-3-(2-Benzyloxy-5-bromophenyl)-3phenylpropionic Acid

The combined mother liquids from the above resolution and recrystallizations were treated under stirring and cooling (18° C.) with excess conc. aqueous hydrochloric acid. The precipitate (ephedrinium hydrochloride) was filtered off, and the filtrate was evaporated to dryness. The residue was redissolved in dichloromethane (1.5 liter) and then washed with several portions of 1 M aqueous hydrochloric acid followed by water. After drying (Na<sub>2</sub>SO<sub>4</sub>), filtration, and 10 evaporation 479 g of crude S-(+)-3-(2-benzyloxy-5bromophenyl)-3-phenylpropionic acid were obtained as a yellow viscous oil. The pure S-(+)enantiomeric acid was converted into the 1R,2S-(-)-ephedrine salt as described above for the R-(-) acid. Two recrystallizations from boiling 15 ethanol provided colourless crystals of S-(+)-3-(2benzyloxy-5-bromophenyl)-3-phenylpropionic acid 1R,2S-(-)-ephedrinium salt in 83% yield, m.p. 158.7° C., e.e. 97.8% (HPLC). NMR (CDCl<sub>3</sub>): 9.47, 30.85, 41.54, 42.92, 61.48, 70.13, 70.30, 113.04, 113.66, 125.89, 126.01, 127.32, 20 127.84, 128.18, 128.44, 129.83, 130.68, 135.94, 136.63, 140.44, 144.13, 155.19, 178.94.

S-(+)-3-(2-Benzyloxy-5-bromophenyl)-3phenylpropionic acid was obtained in quantitative yield from this ephedrinium salt by the method described above 25 for the R-(-) acid, tlc: (7) 0.20, e.e. (NMR) >99%, mp 105.5° C.;  $[\alpha]_D^{20} =+22.6$  (c=1.0, ethanol); NMR: identical with the racemic acid.

b) Enantioselective Synthesis of R-(-)- and S-(+)-3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropionic Acid

28

was collected by suction and recrystallized from a minimum of boiling methanol.

3-[3-(2-Benzyloxy-5-bromophenyl)-acryloyl]-(4R)-4phenyloxazolidin-2-one

Pivaloylchloride (7 g) was added dropwise at -30° C. to a stirred solution of 3-(2-benzyloxy-5-bromophenyl)-acrylic acid (50.0 mmol) and triethylamine (15.0 ml) in 200 ml of tetrahydrofuran. After an additional hour the temperature was lowered to  $-50^{\circ}$  C. and (R)-2-phenyloxazolidin-2-one (9.0 g) and lithium chloride (2.5 g) were added in one portion. The cooling bath was then removed and stirring was continued over 18 hrs. The reaction was diluted with water and 3-[3-(2-benzyloxy-5-bromophenyl)-acryloyl]-(4R)-4phenyloxazolidin-2-one was isolated by extraction with ethyl acetate.

3-[3-(2-Benzyloxy-5-bromophenyl)-(38)-3-

phenylpropionyl]-(4R)-4-phenyloxazolidin-2-one To a precooled (-30° C.) mixture of copper-(I) chloride (21.0 g) and dimethylsulfide (45 ml) in dry tetrahydrofuran (150 ml) was added dropwise an ethereal solution of phe-nylmagnesiumbromide (0.3 mol). The mixture was stirred 20 min at the same temperature and then cooled to  $-40^{\circ}$  C. A solution of 3-[3-(2-Benzyloxy-5-bromophenyl)-acryloyl]-(4R)-4-phenyloxazolidin-2-one (50.0 mmol) in dry tetrahydrofuran (150 ml) was added during 10 min. The cooling bath was removed and stirring was continued for 18 hrs. The mixture was quenched with half-saturated aqueous ammonium chloride solution and the product was isolated by extraction with ethyl acetate.

S-(+)-3-(2-Benzyloxy-5-bromophenyl)-3phenylpropionic Acid



2-Benzyloxy-5-bromobenzaldehyde

To a solution of 0.1 mol of 5-bromo-2-benzaldehyde in THF (150 ml) was added 0.1 mol of K<sub>2</sub>CO<sub>3</sub> and 0.11 mol of benzyl bromide. The mixture was refluxed for 2 hrs and water (500 ml) was added. After addition of ethyl acetate (400 ml) and stirring the organic layer was washed with water, dried (sodium sulphate) and evaporated to dryness. The resulting slightly yellow solid of pure (tlc) 2-benzyloxy-5-bromo-benzaldehyde was used as such in the next step. 3-(2-Benzyloxy-5-bromophenyl)-acrylic Acid

A mixture of 2-benzyloxy-5-bromobenzaldehyde (0.10 mol), malonic acid (15.0 g), and piperidine (2.0 ml) in 150 ml of pyridine was first heated at 90° C. for 90 min and subsequently refluxed for 0.5 hrs. After cooling to room 65 temperature, the reaction was poured on a mixture of ice (1 kg) and concentrated aqueous hydrochloric acid (250 ml). The solid material that precipitated after stirring for 2 hrs.

A solution of the above described 3-[3-(2-benzyloxy-5bromophenyl)-(3S)-3-phenylpropionyl]-(4R)-4-phenyloxazolidin-2-one in tetrahydrofuran (300 ml) and water (100 ml) was cooled to 0° C. and then treated with 30% aqueous hydrogen peroxide (20 ml) followed by solid lithium hydroxide (4.3 g). Water was added after 2 hrs and the chiral auxiliary was removed by extraction with ethyl acetate. The aqueous phase was acidified with aqueous hydrochloric acid (10%) and crude S-(+)-3-(2-benzyloxy-5bromophenyl)-3-phenylpropionic acid was extracted with tert.-butyl-methylether.

HPLC analysis (Chiralpak AD, mobile phase hexane/2 propanol/trifluoro acetic acid [92:8:0.1, vol/vol-%); flow 1.0 ml/min, detection 285 nm) indicated an enantiomeric ratio 93:7 (retention times 14.8 min and 11.5 min, respectively). The e.e. of 86% of the S-(+)enantiomer can be improved to >98.5% by recrystallization of the diastereomeric salts using

"nitromix" (Angew. Chem. Int. Ed. Engl. 1998, Vol. 37, p. 2349) or (1R,2S)-(-)-ephedrine hemihydrate as described above. The S-(+)-3-(2-benzyloxy-5-bromophenyl)-3phenylpropionic acid was isolated after acidification of aqueous solutions of the diastereometric salts. It forms 5 colourless crystals which gave an optical rotation of  $[\alpha]_D^{-1}$ =+21.6 (c=0.5, MeOH).

R-(-)-3-(2-Benzyloxy-5-bromophenyl)-3phenylpropionic Acid

Conjugate organocuprate addition of phenylmagnesium- 10 bromide to 3-[3-(2-benzyloxy-5-bromophenyl)-acryloyl]-(4S)-4-phenoyloxazolidin-2-one as described above for the S-(+)enantiomer gave crystalline R-(-)-3-(2-benzyloxy-5bromophenyl)-3-phenylpropionic acid in an e.e. of 99.6% after two recrystallizations,  $[\alpha]_D^{22} = -21.7$  (c=0.5, MeOH). 15 c) Synthesis of the R- and S-Enantiomers of Intermediate B

(i) Phenylpropanol Route



(±)-3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropan-1ol

A solution of the methyl(±)-propionate (121.0 g) in 350 ml of dry tetrahydrofuran was slowly added under an atmosphere of nitrogen to a suspension of lithium alu- 60 minium hydride (7.9 g) in tetrahydrofuran (350 ml). After stirring at room temperature for 18 hrs, 20% aqueous HCl was added dropwise and the product was isolated by repeated extraction with diethyl ether. The combined extracts were gradually washed with hydrochloric acid, 65 sodium hydroxide solution, distilled water, and then dried  $(Na_2SO_4)$  to give a light yellow viscous oil (108.8 g, 96.3%)

yield) after evaporation which gradually crystallized, m.p. 73.8° C., tlc: (1) 0.47, (±)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropan-1-ol. NMR (CDCl<sub>3</sub>): 37.52, 39.52, 60.84, 70.54, 113.54, 113.83, 126.29, 127.30, 127.51, 129.99, 128.24, 128.38, 129.99, 130.88, 135.69, 136.40, 143.53, 155.12.

The same product was obtained after reduction of (±)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid with lithium aluminium hydride in tetrahydrofuran (30 min, 25° C.), 31% yield.

(±)-Toluene-4-sulphonic Acid 3-(2-Benzyloxy-5bromophenyl)-3-phenylpropyl Ester A cooled (5° C.) solution of (±)-3-(2-benzyloxy-5-

bromophenyl)-3-phenylpropan-1-ol (108.0 g) in dichloromethane (300 ml) was treated with pyridine (79.4 ml) and then p-toluenesulphonyl chloride (60.6 g) in dichloromethane (200 ml). After 18 hrs. at room temperature the solvent was removed in vacuum and the residue was extracted with diethyl ether. The extract was washed with 20 hydrochloric acid, water, and dried over anhydrous sodium sulphate to give (±)-toluene-4-sulphonic acid 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl ester as a light yellow oil after concentration under reduced pressure (140.3 g, 93.6% yield), tlc: (1) 0.66. NMR (CDCl<sub>3</sub>): 21.67, 33.67, 25 39.69, 68.58, 70.28, 113.21, 113.76, 126.47, 127.84, 128.10,

128.25, 128.41, 128.51, 129.81, 130.26, 130.42, 132.91, 134.39, 136.41, 142.16, 155.07.

(±)-[3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropyl]diisopropylamine

A solution of the (±)-toluenesulphonate ((±)-toluene-4-sulphonic acid 3-(2-benzyloxy-5-bromophenyl)-3-30 phenylpropyl ester, 139.3 g) in acetonitrile (230 ml) and N,N-diisopropylamine (256 g) was refluxed for 97 hrs. The reaction mixture was then evaporated to dryness and the 35 residue thus formed was partitioned between diethyl ether (500 ml) and aqueous sodium hydroxide (2 M, 240 ml). The organic phase was washed twice with water (250 ml) and then extracted with 1 M sulphuric acid. The aqueous phase was adjusted to about pH 12-13 and reextracted with ether (500 ml). The organic phase was washed with water, dried  $(Na_2SO_4)$  and evaporated to provide  $(\pm)$ -[3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl]-diisopropylamine as a brown and viscous syrup (94.5 g, 77.9% yield), tlc: (2) 0.49. NMR (CDCl<sub>3</sub>): 20.65, 20.70, 36.70, 41.58, 43.78, 48.77, 70.24, 113.52, 126.02, 127.96, 128.20, 128.36, 129.82, 130.69, 136.34, 136.76, 144.20, 155.15.

(ii) Phenylpropionamide Route





S-(+)-3-(2-Benzyloxy-5-bromophenyl)-3phenylpropionyl Chloride

Thionylchloride (4.5 g, 2.8 ml, 37.8 mmol) and some drops of dimethylformamide were added to a solution of S-(+)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic 30 acid (10.3 g, 25 mmol) in ethyl acetate (60 ml). The mixture was refluxed until tlc control indicated complete consumption of the starting material (2 hrs). Evaporation in vacuum gave the acid chloride as a light yellow liquid in almost quantitative yield (10.7 g). Conversion of an aliquot to the methyl ester showed a single spot in tlc ( $R_f 0.54$ , solvent <sup>35</sup> system (7))

S-(+)-N,N-Diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionamide

A solution of S-(+)-3-(2-benzyloxy-5-bromophenyl)-3phenylpropionyl chloride (9.6 g, 22.3 mmol) in ethyl acetate 40 (40 ml) was added dropwise to a stirred and cooled (3° C.) solution of diisopropylamine (6.4 g, 49.0 mmol) in 60 ml of ethyl acetate. The reaction was stirred for 18 hrs at room temperature and then washed with water, aqueous hydrochloric acid (1 M) and half saturated brine. The organic 45 phase was dried (sodium sulphate) and evaporated to dryness. The colourless oily residue (10.7 g, 97% yield) of S-(+)-N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3phenylpropionamide showed a single spot on tlc: (R, 0.70)  $(\pm)-[4-Benzyloxy-3-(3-(4))]$  NMR (CDCl<sub>3</sub>): 18.42, 20.46, 20.63, 20.98, 39.51, 50 phenylpropyl)-phenyl]-methanol 41.44, 45.76, 48.63, 70.00, 112.84, 113.64, 126.10, 126.45 127.34, 127.78, 128.20, 128.36. 129.93, 130.59, 135.18, 136.52, 143.52, 155.17, 69.61.

(±)-N,N-Diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3phenylpropionamide

The amide was prepared from duisopropylamine and the racemic acid chloride as described above for the S-(+) enantiomer. The viscous colourless oil was dissolved in ethanol and the solution stored at -30° C. From this solution colourless crystals were obtained, m.p. 101.8° C.

(±)-[3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropyl]diisopropylamine

To a stirred solution of (±)-N,N-diisopropyl-3-(2benzyloxy-5-bromophenyl)-3-phenylpropionamide (11.8 g) in 40 ml of dry tetrahydrofuran was added 1 M lithium 65 aluminium hydride/tetrahydrofuran (36 ml). The reaction was refluxed for 4 hrs and then quenched with the dropwise

addition of water. After removal of the precipitate the solvent was evaporated and the oily residue dissolved in diluted sulphuric acid. The aqueous phase was washed several times with diethyl ether, adjusted to pH 10-12 (aqueous NaOH), and extracted with diethyl ether. The extract was dried (sodium sulphate), filtered and evaporated to dryness in vacuum to leave 8.1 g (76.7%) of the title compound as a viscous colourless oil, tlc: (4) 0.86. The NMR spectrum corresponds to the product, obtained from 10 the tosylate precursor (see above).

S-(+)-13-(2-Benzyloxy-5-bromophenyl)-3phenylpropyl]-diisopropylamine

Repetition of the reaction sequence by using S-(+)-3-(2-

benzyloxy-5-bromophenyl)-3-phenylpropionic acid as the starting material gave S-(+)-[3-(2-Benzyloxy-5bromophenyl)-3-phenylpropyl]-diisopropylamine as a viscous colourless oil,  $[\alpha]_D^{22}$  =+18.5 (c=10.0, ethanol), e.e. of a representative batch 99.4%.

R-(-)-[3-(2-Benzyloxy-5-bromophenyl)-3phenylpropyl]-diisopropylamine

Repetition of the reaction sequence by using R-(-)-3-(2benzyloxy-5-bromophenyl)-3-phenylpropionic acid as the starting material gave R-(-)-[3-(2-Benzyloxy-5bromophenyl)-3-phenylpropyl]-diisopropylamine as a viscous colourless oil,  $[\alpha]_D^{22} = -17.3$  (c=10.0, ethanol), e.e. of a representative batch 98.3%.

The optical purities were determined by chiral HPLC using Chiralpak OD columns.

(±)-4-Benzyloxy-3-(3-diisopropylamino-1phenylpropyl)-benzoic Acid Hydrochloride

An ethereal Grignard solution, prepared from the above (±)-amine (22.8 g), ethyl bromide (17.4 g) and magnesium (6.1 g) under an atmosphere of nitrogen was diluted with dry tetrahydrofuran (200 ml) and then cooled to -60° C. Powdered solid carbon dioxide (ca. 50 g) was then added in small portions and the green reaction mixture was warmed to room temperature. After the addition of an aqueous solution of ammonium chloride (200 ml, 10%) and adjustment of the aqueous phase to pH 0.95, a white solid was recovered by filtration to provide (±)-4-benzyloxy-3-(3diisopropylamino-1-phenylpropyl)-benzoic acid hydrochloride (14.7 g, 64.3% yield), m.p. 140° C. (dec.), tlc: (2) 0.33. NMR (CD<sub>3</sub>OD): 17.07, 18.77, 33.55, 43.27, 56.50, 71.50, 112.89, 124.10, 127.94, 129.07, 129.25, 129.34, 129.59, 129.66, 130.18, 131.60, 132.78, 137.60, 143.30, 161.11, 169.70

(±)-[4-Benzyloxy-3-(3-diisopropylamino-1-

Intermediate A (n=1)

The  $(\pm)$ -hydrochloride was converted into its methyl ester (MeOH, trace sulphuric acid, 6 h reflux) and the free oily base thus obtained (28 g; tlc (2):  $R_f 0.46$ ) was dissolved in dry diethyl ether (230 ml). This solution was slowly (2 h) 55 dropped under a nitrogen atmosphere to a suspension of lithium aluminium hydride (1.8 g) in ether (140 ml). After stirring for 18 hrs, the reaction was quenched by the addition of water (4.7 ml). The organic phase was dried over anhydrous sodium sulphate, filtered and evaporated to dryness to 60 provide (±)-[4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-methanol (26 g, 98.9% yield), as an oil which gradually crystallized, m.p.  $86.4^{\circ}$  C., tlc: (2) 0.32. NMR (CDCl<sub>3</sub>): 20.53, 20.61, 36.87, 41.65, 44.14, 48.82, 65.12, 70.09, 111.80, 125.77, 125.97, 126.94, 127.55, 128.08, 128.37, 128.44, 133.27, 134.05, 134.27, 137.21, 144.84.



33

(±)-[4-Benzyloxy-3-(3-diisopropylamino-1phenylpropyl)-phenyl]-[C<sup>2</sup>H]methanol

Intermediate  $d_{2}$ -A (n=2)

Repetition of the above described reduction of the methylester of (±)-4-benzyloxy-3-(3-diisopropylamino-1phenylpropyl)-benzoic acid by the use of lithium aluminium deuteride gave (±)-[4-benzyloxy-3-(3-diisopropylamino-1- 20 phenylpropyl)-phenyl]-[C<sup>2</sup>H]methanol, colourless amorphous solid in 77% yield; tlc: (2) 0.33. NMR (CDCl<sub>3</sub>): 20.46, 20.55, 36.77, 41.62, 44.09, 48.77, multiplett centered at 64.96, 70.05, 111.76, 125.72, 127.34, 128.03, 128.32, 128.38, 133.15, 133.99, 137.17, 144.80, 155.52/

(±)-2-(3-Diisopropylamino-1-phenylpropyl)-4hydroxymethylphenol

Intermediate B (n=1)

A solution of Intermediate A (9.1 g) in methanol (100 ml) 30 was hydrogenated over Raneynickel (4.5 g) under ambient conditions. After 5 hrs thin layer chromatography indicated complete hydrogenolysis. The catalyst was filtered off and the solution evaporated to dryness to leave an oil (6.95 g, 35 96.5% yield) which gradually solidified,  $(\pm)$ -2-(3diisopropylamino-1-phenylpropyl)-4hydroxymethylphenol, m.p. 50° C., tlc: (2) 0.15. NMR

(CDCl<sub>3</sub>): 19.42, 19.83, 33.22, 39.62, 42.27, 48.27, 65.19, 118.32, 126.23, 126.55, 127.47, 128.33, 132.50, 144.47, 155.38. Hydrochloride: colourless crystalls, m.p. 187-190° C. (with decomposition).



S-(-)-2-(3-Diisopropylamino-1-phenylpropyl)-4hydroxymethylphenol

Hydrogenolysis of S-(-)-[4-benzyloxy-3-(3diisopropylamino-1-phenylpropyl)-phenyl]-methanol (prepared from S-(+)-3-(2-benzyloxy-5-bromophenyl)-3phenylpropionic acid as described for the racemic series) gave the title compound in 85% yield, colourless solid; m.p. >50° C.,  $[\alpha]_D^{22}$  =-19.8 (c=1.0, ethanol); NMR (CDCl<sub>3</sub>): 19.58, 19.96, 33.30, 39.52, 42.10, 48.00, 65.40, 118.58, 126.31, 126.57, 127.16, 127.54, 128.57, 132.63, 132.83,

34

144.55, 155.52. S-(+)hydrochloride: colourless, nonhygroscopic solid, m.p. 186.4° C. (dec.);  $[\alpha]_D^{22} = +6.6$ (c=0.5, water). NMR (DMSO-d<sub>6</sub>): 16.58, 18.17, 31.62, 41.37, 45.90, 54.02, 63.07, 115.18, 126.05, 126.37, 128.03, 128.45, 129.04, 133.12, 143.88, 153.77.

R-(+)-2-(3-Diisopropylamino-1-phenylpropyl)-4hydroxymethylphenol

Hydrogenolysis of R-(+)-[4-benzyloxy-3-(3-10 diisopropylamino-1-phenylpropyl)-phenyl]-methanol (prepared from R-(-)-3-(2-benzyloxy-5-bromophenyl)-3phenylpropionic acid as described for the racemic series) gave the title compound in 87% yield, colourless solid; m.p.

 $\geq 50^{\circ}$  C.,  $[\alpha]_D^{22} = +21.3$  (c=1.0, ethanol). R-(-) hydrochloride: colourless, non-hygroscopic solid, m.p. 179.8° C. (dec.);  $[\alpha]_D^{22}$  =-7.2 (c=0.5, water); NMR (DMSO-d<sub>6</sub>): 16.59, 18.19, 31.64, 41.38, 45.92, 54.07, 63.08, 115.19, 126.07, 126.39, 128.04, 128.46, 129.05, 133.13, 143.89, 153.79. R-(+)-mandelate: m.p. 139.7° C.,  $[\alpha]_D^{21}$ 

(±)-2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxy-25 [<sup>2</sup>H<sub>2</sub>]methyl-phenol

Intermediate  $d_2$ -B (n=2)

A stirred suspension of lithium aluminium deuteride (0.1 g, 2.38 mmol) in 5 ml of dry diethyl ether was treated during 30 min at room temperature under an atmosphere of dry nitrogen with a solution of  $(\pm)$ -4-benzyloxy-3-(3diisopropylamino-1-phenylpropyl)-benzoic acid methyl ester (1.0 g, 2.17 mmol) in dry diethyl ether (5 ml). After an additional stirring at room temperature for 18 hrs the reaction was quenched by the dropwise addition of 0.17 ml of <sup>2</sup>H<sub>2</sub>O. The resultant precipitation was filtered off, washed with small portions of ether, and the combined organic phases were evaporated to dryness in vacuum to leave (±)-[4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)phenyl]-[<sup>2</sup>H<sub>2</sub>]methanol as slightly yellow, viscous oil which gradually crystallized, m.p. 84.1° C.; tlc: (2) 0.33 (starting material 0.46), 0.725 g, 77.2% yield. NMR (CDCl<sub>3</sub>): 20.46, 45 20.55, 36.77, 41.62, 44.09, 48.77, multiplett centered at 64.30, 70.05, 111.76, 125.72, 125.94, 126.92, 127.34, 127.71, 128.03, 128.32, 128.38, 133.15, 133.99, 137.17, 144.80, 155.52.

50 A solution of the above  $(\pm)$ -[4-benzyloxy-3-(3diisopropylamino-1-phenylpropyl)-phenyl]-[<sup>2</sup>H<sub>2</sub>]methanol (0.129 g, 0.29 mmol) in a suspension of methanol (5 ml) and wet Raney-Nickel (0.1-0.2 g) was stirred at room tempera-55 ture under an atmosphere of deuterium gas ( $^{2}$  H<sub>2</sub>). After 1 hr tlc indicated complete disappearance of the starting material. The mixture was filtered, evaporated and the residue was redissolved in diethyl ether (5 ml). The solution was washed with water (2×5 ml), dried over sodium sulphate, filtered and 60 evaporated to dryness to leave a pale yellow oil, 76.3 mg, in 74.6% yield, which gradually solidified to give a colourless solid of a m.p. range of 46-49° C. Tlc: (4) 0.57 (starting material 0.77). NMR (CDCl<sub>3</sub>): 19.57, 19,94, 33.33, 39.56, 65 42.18, 48.07, 48.43, multiplett centred at 64.61, 118.47, 126.29, 126.58, 127.55, 127.94, 128.38, 132.53, 144.53,

# 15

=+38.3 (c=1.0, ethanol).

Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0025

155.37. GC-MS (P-CI, ammonia, TMS derivative): 488.43 (100%), 489.56 (70%), 490.56 (31%), 491.57 (8%).

35



20 (±)-2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxy-[<sup>2</sup>H<sub>2</sub>]methyl-phenol

Intermediate d<sub>2</sub>-B

(iii) Heck-Cuprate-Route to Intermediate B

(benzonitrile)-palladium-II chloride (1.5 mol %), and 20 ml of N-methyl-2-pyrrolidinone was heated at 130° C. until no starting material could be detected by tlc (starting material methyl 3-bromo-4-methoxybenzoate:  $R_f \ 0.73$ ; N,Ndiisopropylacrylamide:  $R_f 0.46$ ; solvent system (1)). After cooling to room temperature 50 ml of an aqueous 2N HCl solution was added. The reaction was diluted with dichloromethane (50 ml) and the precipitated grey palladium metal was filtered off. The organic phase was washed with five portions (50 ml each) of 2N aqueous hydrochloric acid, 10 dried (MgSO<sub>4</sub>) and evaporated to dryness. The remaining off-white solid was recrystallized from ethyl acetate/nnexane to give 4.4U g (E)-N,N-diisopropyl-3-(2-methoxy-5-methoxycarbonylphenyl)-acrylamide in 69% yield, m.p. 139–140° C., tlc: (1) R<sub>f</sub> 0.40. NMR (CD<sub>2</sub>Cl<sub>2</sub>): 21.22, 22.10, 46.39, 48.87, 52.59, 56.61, 111.42, 123.39, 123.78, 125.54, 130.32, 132.53, 135.07. MS (EI, DI, 105° C.): 319 (M<sup>+</sup>, 22), 304 (6%), 276 (8%), 219 (100%), 187 (18%), 160 (7%). ( $\pm$ )-N,N-D i is o p r o p yl-3 - (2 - m et ho x y - 5 -methoxycarbonylphenyl)-3-phenylpropionamide (( $\pm$ )-3-(2-Diisopropylcarbamoyl-1-phenylethyl)-4 hexane to give 4.40 g (E)-N,N-diisopropyl-3-(2-methoxy-

((±)-3-(2-Diisopropylcarbamoyl-1-phenylethyl)-4-

methoxybenzoic Acid Methyl Ester) The reaction was carried out under an atmosphere of dry

and oxygen-free nitrogen gas. All solvents and reagents were dried before use.



N,N-Diisopropyl-acrylamide

A solution of acroyl chloride (42.2 g, 40.6 ml, 0.467 mol) in 125 ml of dichloromethane was slowly added to a cooled (0-5° C.) solution of N,N-diisopropylamine in dichloromethane (500 ml). After 2 hrs the precipitated ammonium 50 salt was filtered off and the filtrate was washed with 1M hydrochloric acid (3×100 ml), dried (sodium sulphate), and evaporated to dryness. N,N-diisopropyl-acrylamide was obtained as a slight yellow liquid in 48% yield and ca. 99% purity. NMR (CDCl<sub>3</sub>): 20.54, 21.25, 45.66, 48.10, 125.62, 55 130.70, 166.17

(E)-N,N-Diisopropyl-3-(2-methoxy-5methoxycarbonylphenyl)-acrylamide

((E)-3-(2-Diisopropylcarbamoyl-vinyl)-4methoxybenzoic Acid Methyl Ester)

The reaction was carried out under an atmosphere of dry and oxygen-free nitrogen gas. All solvents and reagents were dried before use.

A stirred suspension consisting of N,N-dimethylglycine (6.0 mmol), anhydrous sodium acetate (40 mmol), methyl 65 3-bromo-4-methoxybenzoate (20 mmol, 4.90 g), N,Ndiisopropylacrylamide (24 mmol, 3.72 g), bis-

A dark green solution of lithium diphenylcuprate was prepared by addition of phenyllithium solution (12 ml, 24 mmol, cyclohexane/diethyl ether) to a cooled (0° C.) and stirred suspension of copper-I bromide dimethylsulphide adduct (2.71 g, 13 mmol) in diethyl ether (40 ml). This solution was cooled to  $-78^{\circ}$  C. and then subsequently solutions were added of trimethylchlorosilane (1.5 ml, 12 mmol) in diethyl ether (5 ml) followed by the above cinnamide (3.19 g, 10.0 mmol, (E)-N,N-diisopropyl-3-(2methoxy-5-methoxycarbonylphenyl)-acrylamide) in 10 ml of tetrahydrofuran. The reaction was stirred for one hour at -78° C., warmed to room temperature and then quenched by the addition of 150 ml of a saturated aqueous solution of ammonium chloride. After 90 min the organic phase was washed with two portions (100 ml) of half saturated aqueous sodium chloride, dried (MgSO<sub>4</sub>) and evaporated to dryness. The yellow oily residue was dissolved in a minimum of ethyl acetate and purified by column chromatography on silica gel (mobile phase (1)). Evaporation of the combined fractions of the title compound gave (±)-N,N-diisopropyl-3-(2-methoxy-5-methoxycarbonylphenyl)-3-phenylpropionamide as a viscous slightly yellow syrup (1.8 g, 44% yield). NMR

Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0026

(CD<sub>2</sub>Cl<sub>2</sub>): 19.45, 19.56, 19.74, 38.86, 44.87, 47.92, 50.80, 54.76, 109.41, 121.32, 125.53, 128.10, 128.43, 128.78, 132.03, 143.20, 159.95, 165.95, 168.87. MS (EI, DI, 105° C.): 397 (M<sup>+</sup>, 41%), 366 (5%), 322 (2%), 269 (3%), 255 (14%), 237 (7%), 165 (5%), 128 (12%), 91 (43%), 58  $^{5}$  (100%).

(±)-2-(3-Diisopropylamino-1-phenylpropyl)-4hydroxymethylphenol

A solution of (±)-N,N-diisopropyl-3-(2-methoxy-5-10 methoxycarbonylphenyl)-3-phenylpropionamide (0.79 g, 2.0 mmol) in 20 ml of tetrahydrofuran was cooled to 5° C. and then treated with 2.5 ml of 1M LiAlH<sub>4</sub>/THF. After stirring at room temperature for 18 hrs. finely powdered aluminium chloride (0.3 g) was added and stirring was continued for additional 4 hrs. The reaction was quenched at 5° C. by the dropwise addition of water followed by aqueous sodium hydroxide solution. The mixture was diluted with diethyl ether (150 ml) and the organic phase was washed with half saturated brine, dried (sodium sulphate), and evaporated to dryness to give the title compound as a solid 20off-white foam. Tlc (2) 0.16, m.p. 48-51° C. A portion of the material was converted into the hydrochloride (ethereal hydrochloric acid), m.p. 186–189° C. (dec.).

Hydrogenolytic Deoxygenation of S-(-)-2-(3-Diisopropylamino-1-phenylpropyl)-4hydroxymethylphenol

A mixture of S-(-)-2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol (683 mg, 2.0 mmol, <sup>2</sup> =+19.8 (c=1.0, ethanol)), platinium-on-carbon cata-[α]<sub>0</sub> 30 lyst (120 mg) and acetic acid (1.0 ml) was diluted with ethyl acetate (50 ml) and then hydrogenated at room temperature under a pressure of 4 bar hydrogen gas for 5 hrs. The catalyst was filtered off and the filtrate was evaporated to leave an oil. The residue was redissolved in dichloromethane (25 ml) and the solution was washed with aqueous sodium hydrogencarbonate solution. The organic phase was concentrated to dryness and the oily residue taken up in ethanol (7 ml). Addition of D-(-)-tartaric acid (300 mg) and storage of the clear solution at -25° C. gave colourless crystals (310 mg) of S-(-)-2-(3-diisopropylamino-1-phenylpropyl)-4methylphenol D-(-)hydrogentartrate in 33% yield, tlc: (4): 0.66 (starting material 0.31),  $[\alpha]_D^{22} = -26.7$  (c=1.0, methanol). NMR (CD<sub>3</sub>OD): 17.98, 18.37, 20.69, 33.68, 43.12, 56.33, 74.17, 116.31, 127.51, 129.11, 129.50, 129.70, 129.89, 130.41, 144.57, 153.67, 176.88.

A portion of the tartrate was treated with aqueous sodium hydrogenearbonate solution and the free base was isolated in quantitative yield as a colourless oil by extraction with ethyl acetate and evaporation of the extract.  $[\alpha]_D^{22} = -26.3$  (c=1.0, 50 methanol).

Preferred intermediates in the processes for the preparation of the 3,3-diphenylpropylamines according to the present invention are:

- (±)-3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropanoic 55 acid and its salts,
- R-(-)-(2-Benzyloxy-5-bromophenyl)-3-phenylpropanoic acid and its salts,
- S-(+)-(2-Benzyloxy-5-bromophenyl)-3-phenylpropanoic acid and its salts, 60
- (±)-2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxy-[C<sup>2</sup>H<sub>2</sub>]methyl-phenol,
- S-(-)-2-(3-Diisopropylamino-1-phenylpropyl)-4hydroxy-[C<sup>2</sup>H<sub>2</sub>]methyl-phenol, 65
- R-(+)-2-(3-Diisopropylamino-1-phenylpropyl)-4hydroxy-[C<sup>2</sup>H<sub>2</sub>]methyl-phenol and their salts.

3. Example

a) Phenolic Monoesters

aa) General Procedure Eaters of Carboxylic Acids

A stirred solution of  $(\pm)$ -2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol (Intermediate B, 1.71 g, 5.01 mmol) and acid chloride (5.00 mmol carboxylic acid monochloride for compounds of formula II, 2.50 mmol for compounds of formula II') in 60 ml of dichloromethane was cooled to 0° C. and then triethylamine (0.502 g, 4.96 mmol for compounds of formula II, 1.05 g, 9.92 mmol for compounds of formula II'), dissolved in 10 ml of dichloromethane, was added dropwise during 5–10 min. Stirring was continued for 18 hrs at room temperature, and then the mixture was washed successively with water (25 ml), aqueous sodium hydrogen carbonate (5%, 25 ml), and water (25 ml). The organic phase was then dried (sodium sulphate) and evaporated under reduced pressure and at low temperature. The oily residues thus formed were finally exposed to high vacuum (2–4 hrs.) to remove traces of residual solvents.

The esters of formula II or II' were obtained as colourless to light yellow solids or viscous syrups in puritees between 90% and 99% (tlc, HPLC, NMR).

Esters of N-Acylamino Acids

Phenolic Monoesters

To a solution of the respective amino acid (2.0 mmol) in 0.7 ml to 5 ml of N,N-dimethylformamide and 0.5 ml of triethylamine was added at 5° C. in one portion methyl chloroformate (2.0 mmol, 288 mg). After stirring for 2 hrs. at the same temperature the cooling bath was removed and a solution of Intermediate B (2.0 mmol, 682 mg) in 5 ml of dichloromethane and triethylamine (0.5 ml) was added. The reaction was allowed to stir for 2–8 hrs and then diluted with diethyl ether (70 ml). Solid precipitates were filtered off and the mixture was washed with aqueous sodium hydrogen sulphate solution (5%) and water. After drying (sodium sulphate), filtration and evaporation in vacuum the residue was purified by flash chromatography on silica gel (eluent: solvent system (4)). N-acylamino acid esters were obtained as viscous oils or waxy solids in yields between 24% and 73%.

bb) Salt Formation (Example hydrochloride)

A cooled (0° C.) solution of 4.94 mmol amino base in 30 ml of dry diethyl ether was treated under an atmosphere of nitrogen with 4.70 mmol (monoamines of formula II) or 9.4 mmol (diamines of formula II') ethereal (1 M) hydrochloric acid. The oily precipitation was washed repeatedly with dry ether and then evaporated in high vacuum. The residual product solidificated in most cases as an amorphous foam. The highly hygroscopic solids show a wide melting range above 100° C. (with decomposition).

The following compounds were prepared according to the method described above and their analytical data are listed below:

(±)-Acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, tlc:  $R_f$  0.47 (4), NMR (CDCl<sub>3</sub>): 20.36, 20.68, 20.97, 36.59, 42.35, 43.83, 48.76, 64.58, 122.69, 125.61, 126.22, 126.71, 127.96, 128.34, 136.82, 138.97, 143.73, 147.77, 169.24; GC-MS/P-CI (ammonia, trimethylsilyl derivative): 456.8 (100%), 398.4 (4%).

(±)-Propionic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester, tlc:  $R_f$  0.52 (4); NMR (CDCl<sub>3</sub>): 20.44, 20.64, 27.67, 36.67, 42.21, 43.87, 48.78, 64.70, 122.71, 125.62, 126.52, 126.78, 127.97, 128.53, 136.86, 138.82, 143.82, 147.86, 172.68; GC-MS/P-Cl (ammonia, trimethylsilyl derivative): 470.38 (100%), 398.4 (4%).

(±)-n-Butyric acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester, tlc:  $R_f$  0.43 (4); NMR (CDCl<sub>3</sub>): 13.77, 18.40, 20.43, 20.51, 20.59, 36.15, 36.82, 42.16, 43.90, 48.83, 49.20, 64.58, 122.66, 125.98, 50.82, 42.10, 43.90, 48.83, 49.20, 64.38, 122.00, 123.98, 126.17, 126.74, 127.33, 127.94, 128.33, 136.79, 138.91, 143.82, 171.88; GC-MS/N-CI (methane, trimethylsilyl derivative): 482.3 (20%), 412.3 (100%), 340.1 (33%), 298.1 (89%), 234.7 (15%); GC-MS/P-CI (methane, trimethylsilyl derivative): 484.5 (100%), 468.4 (62%), 394.3 (22%); 62.048, 2000 (1000), 468.4 (62%), 394.3 (22%); 62.048, 2000 (1000), 468.4 (62%), 394.3 (22%); 62.048, 2000 (1000), 468.4 (62%), 394.3 (22%); 62.048, 2000 (1000), 468.4 (62%), 394.3 (22%); 62.048, 2000 (1000), 468.4 (62%), 394.3 (22%); 62.048, 2000 (1000), 468.4 (62%), 394.3 (22%); 62.048, 2000 (1000), 468.4 (62%), 394.3 (22%); 62.048, 2000 (1000), 468.4 (62%), 394.3 (22%); 62.048, 2000 (1000), 468.4 (62\%), 394.3 (22%); 62.048, 2000 (1000), 468.4 (62\%), 394.3 (22%); 62.048, 2000 (1000), 468.4 (62\%), 394.3 (22\%); 62.048, 2000 (1000), 468.4 (62\%), 394.3 (22\%); 62.048, 2000 (1000), 468.4 (62\%), 394.3 (22\%); 62.048, 2000 (1000), 468.4 (62\%), 4600 (1000), 468.4 (62\%), 4600 (1000), 468.4 (62\%), 394.3 (22\%); 62.048, 2000 (1000), 468.4 (62\%), 4600 (1000), 468.4 (62\%), 4600 (1000), 468.4 (62\%), 4600 (1000), 468.4 (62\%), 4600 (1000), 468.4 (62\%), 4600 (10000), 4600 (10000), 4600 (10000), 4600 (1000), 4600 (1000), 460 GC-MS/P-CI (ammonia, trimethylsilyl derivative): 484.4 10 (100%), 398.4 (3%).

(±)-Isobutyric acid 2-(3-diisopropylamino-1phenýlpropyl)-4-hydroxymethylphenyl ester, tlc:  $R_f$  0.43 (4); NMR (CDCl<sub>3</sub>): 18.99, 19.11, 20.54, 34.21, 36.88, 41.84, 43.91, 48.78, 64.61, 122.54, 125.57, 126.14, 126.81, 127.94, 15 128.34, 136.84, 138.84, 143.89, 147.85, 175.36.

R-(+)-Isobutyric Acid 2-(3-Diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl Ester

Tlc:  $R_f 0.38$  (4), starting material: 0.26; colourless oil 20 (yield 95%); NMR (CDCl<sub>3</sub>): 19.02, 19.14, 19.96, 20.61, 34.26, 36.92, 41.87, 43.90, 48.80, 64.84, 122.63, 122.63, 125.64, 126.19, 126.92, 127.98, 128.39, 136.96, 138,76, 143.93, 147.97, 175.39. Hydrochloride: colourless hygroscopic solid;  $[\alpha]_D^{\ 20} =+5.5$  (c=1.0, chloroform); NMR (CDCl<sub>3</sub>): 17.03, 17.53, 18.30, 18.52, 18.95, 19.12, 31.23, 25 34.10, 41.69, 45.40, 54.22, 54.47, 64.00, 122.32, 126.62, 126.81, 127.40, 128.06, 128.70, 133.88, 140.64, 142.25, 147.81, 175.89.

(±)-2,2-Dimethylpropionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, tlc:  $R_f 0.49$ (1); NMR (CDCl<sub>3</sub>): 20.46, 20.66, 26.53, 27.34, 37.12, 39.21, 41.46, 43.98, 48.81, 64.65, 122.42, 125.58, 126.16, 126.92, 128.37, 134.27, 136.92, 138.82, 143.97, 148.02, 176.97; GC-MS/P-CI (ammonia, trimethylsilyl derivative): 498.8 (100%), 482.5 (10%), 398.4 (4%).

(±)-2-Acetamidoacetic Acid 2-(3-Diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl Ester

((±)-2-[Diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-(acetylamino)acetate)

NMR (CD<sub>3</sub>OD): 20.33, 20.61, 22.17, 30.54, 42.39, 48.62, 51.04, 64.88, 117.99, 124.73, 125.51, 127.01, 127.75, 129.31, 131.63, 137.33, 146.67, 147.43, 171.47, 173,82.

(±)-Cyclopentanecarboxylic Acid 2-(3-Diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl Ester

Tlc: R<sub>c</sub> 0.66 (4), starting material Intermediate B 3 (0.50), colourless oil, yield: 82%. NMR (CDCl<sub>3</sub>): 20.42, 25.87, 30.25, 36.57, 41.89, 43.97, 47.15, 49.02, 64.63, 122.56, 50 125.60, 126.16, 126.81, 127.60, 127.94, 128.35, 128.77, 136.74, 138.88, 143.85, 147.92, 175.05.

(±)-Cyclohexanecarboxylic Acid 2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl Ester

Tlc:  $R_f 0.67$  (4), starting material Intermediate B 3 (0.50) 55 colourless oil, yield: 93%. NMR (CDCl<sub>3</sub>): 20.27, 25.40, 25.74, 29.03, 29.16, 36.29, 41.82, 43.31, 44.08, 49.36, 64.62, 122.56, 125.68, 126.22, 126.92, 127.92, 128.38, 136.65, 139.00, 143.72, 147.86, 174.40.

(±)-Benzoic Acid 2-(3-Diisopropylamino-1- 60 phenylpropyl)-4-hydroxymethylphenyl Ester

Tlc: R<sub>6</sub> 0.31 (4); colourless syrup (99% yield, purity >95%); gradually crystallized upon refrigeration; NMR (CDCl<sub>3</sub>): 20.41, 20.51, 36.65, 42.42, 43.85, 48.79, 64.70, 122.79, 125.74, 126.17, 126.83, 128.13, 128.28, 128.58, 65 129.48, 130.25, 133.62, 137.21, 139.10, 143.67, 148.00, 164.99

R-(+)-Benzoic Acid 2-(3-Diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl Ester

phenypropyl)-4-hydroxymentylpientyl Ester tlc R<sub>f</sub> 0.30 (4); colourless syrup; Hydrochloride: colour-less amorphous solid;  $[\alpha]_D^{20} =+14.9$  (c=1.0, chloroform); NMR (CDCl<sub>3</sub>): 17.06, 17.53, 18.25, 18.61, 31.23, 42.19, 45.49, 54.26, 54.53, 64.09, 122.55, 126.77, 127.13, 127.8, 128.10, 128.50, 128.72, 128.78, 129.02, 130.17, 133.96, 34.27, 140.81, 142.13, 147.91, 165.40. (1) 4 Mathubergraphic Acid 2 (3 Diigenropulaming 1

(±)-4-Methylbenzoic Acid 2-(3-Diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl Ester

Tlc: R<sub>f</sub> 0.30 (4), starting material Intermediate B: 0.24; yield: quantitative, viscous light yellow oil; NMR (CDCl<sub>3</sub>): 20.32, 20.50, 21.78, 36.13, 42.35, 43.98, 49.29, 64.66, 122.79, 125.81, 126.19, 126.70, 127.04, 128.30, 129.32, 129.76, 130.29, 136.94, 139.20, 143.61, 144.46, 148.04, 165.07. LC-MS: 459 (M<sup>+</sup>, 3.5%), 444 (17%), 223 (2.5%), 195 (2%), 119 (48%), 114 (100%).

(±)-2-Methylbenzoic Acid 2-(3-Diisopropylamino-1-

(±)-2-Methylbenzoic Acid 2-(3-Disopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl Ester viscous colourless oil, tlc: (4) 0.64 (starting material R, 0.51), yield 84%. NMR (CDCl<sub>3</sub>): 20.44, 20.53, 21.86, 22.01, 36.74, 42.36, 43.87, 48.81, 64.76, 122.93, 123.11, 125.71, 126.12, 126.88, 128.10, 128.48, 130.76, 131.26, 131.70, 132.03, 132.79, 137.28, 139.00, 141.73, 143.72, 148.04, 165.25. LC-MS: 459 (M<sup>+</sup>, 21%), 444 (100%), 326 (1%), 223 (10%), 213 (6%), 195 (9%), 165 (14%), 115 (94%), 91 (90%) (99%)

(±)-2-Acetoxybenzoic Acid 2-(3-Diisopropylamino-1-

(±)-2-Actoxybenzole Acid 2-(3-Disopiopylainino-1-phenylpropyl)-4-hydroxymethylphenyl Ester colourless syrup, tlc: (4) 0.47 (starting material R<sub>f</sub> 0.51), yield 82%. NMR (CDCl<sub>3</sub>): 20.39, 20.57, 20.96, 36.92, 42.29, 43.88, 48.87, 64.64, 122.39, 122.64, 124.05, 125.80, 126.11, 126.75, 128.09, 128.32, 132.23, 134.66, 137.27, 139.32, 143.64, 147.63, 151.37, 162.72, 169.73. LC-MS: 503 (M<sup>+</sup> 7%) 488 (50%) 446 (6%) 326 (22%) 023 (0%) 503 (M<sup>+</sup>, 7%), 488 (59%), 446 (6%), 326 (22%), 223 (9%), 213 (9%), 195 (9%), 163 (14%), 121 (100%), 114 (88%). (±)-1-Naphthoic Acid 2-(3-Diisopropylamino-1-

phenylpropyl)-4-hydroxymethylphenyl Ester

colourless viscous oil, tlc: (4) 0.57 (starting material R, 0.51), yield 82%. NMR (CDCl<sub>3</sub>): 20.46, 20.58, 36.82, 42.46, 43.89, 48.76, 64.81, 122.98, 124.51, 125.64, 125.79, 125.98, 126.15, 126.44, 126.94, 128.12, 128.36, 128.65, 131.37, 131.82, 133.98, 134.45, 137.44, 139.08, 143.73, 148.13, 165.49. LC-MS: 495 (M<sup>+</sup>, 8%), 480 (100%), 213 (7%), 165 (8%), 155 (95%), 127 (100%), 114 (90%)

(±)-2-Naphthoic Acid 2-(3-Diisopropylamino-1-45 phenylpropyl)-4-hydroxymethylphenyl Ester

colourless slightly yellow viscous oil, tlc: (4) 0.57 (starting material R, 0.51), yield 71%. NMR (CDCl<sub>3</sub>): 20.47, 20.59, 36.71, 42.59, 43.85, 48.81, 64.82, 122.89, 126.89, 127.89, 128.19, 128.41, 128.68, 129.50, 132.03, 132.55, 135.87, 137.22, 139.08, 143.83, 148.20, 165.14. LC-MS: 495 (M<sup>+</sup>, 7%), 480 (98%), 223 (8%), 213 (6%), 195 (6%), 165 (8%), 155 (96%), 127 (100%), 114 (81%).

(±)-4-Chlorobenzoic Acid 2-(3-Diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl Ester

Tlc:  $R_f 0.54$  (4), starting material Intermediate B: 0.44; yield: quantitative, viscous light yellow oil; NMR (CDCl<sub>3</sub>): 20.34, 20.50, 36.41, 42.51, 43.84, 48.93, 64.66, 122.72, 125.82, 126.88, 127.27, 128.06, 128.56, 128.96, 131.60, 133.80, 136.95, 139.30, 140.16, 143.60, 147.87, 164.10. LC-MS: 479 (M<sup>+</sup>, 1.5%), 464 (10%), 223 (2%), 195 (2%), 165 (1.5%), 139 (25%), 114 (100%).

(±)-4-Methoxybenzoic Acid 2-(3-Diisopropylamino-7phenylpropyl)-4-hydroxymethylphenyl Ester

Tlc: R<sub>f</sub> 0.47 (4), starting material Intermediate B: 0.42; yield: 89%, viscous light yellow oil; NMR (CDCl<sub>3</sub>): 20.31, 20.47, 36.43, 42.39, 43.90, 48.97, 55.53, 64.71, 121.79, 122.86, 125.72, 126.14, 126.79, 128.11, 128.27, 131.27,

131.77, 132.36, 132.84, 137.15, 139.01, 143.74, 148.08, 163.92, 164.71. LC-MS: 475 (M<sup>+</sup>, 3.5%), 460 (20%), 223 (2%), 195 (2%), 135 (48%), 114 (100%).

(±)-2-Methoxybenzoic Acid 2-(3-Diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl Ester

Tlc:  $R_f 0.40$  (4), starting material Intermediate B: 0.42; yield: 98%, viscous light yellow oil; NMR (CDCl<sub>3</sub>): 20.29, 20.42, 36.50, 41.92, 44.02, 49.09, 55.95, 64.72, 119.10, 120.20, 122.86, 125.64, 126.10, 126.82, 128.06, 128.30, 132.38, 134.32, 137.11, 139.01, 143.87, 148.00, 159.82, 164.40. LC-MS: 475 (M<sup>+</sup>, 3.5%), 460 (18%), 223 (1%), 195 10 (1%), 135 (49%), 114 (100%). (±)-4-Nitrobenzoic Acid 2-(3-Diisopropylamino-1-

phenylpropyl)-4-hydroxymethylphenyl Ester

The: R<sub>f</sub> 0.44 (4), starting material Intermediate B: 0.42; 15 yield: 78%, viscous yellow oil which slowly solidified; m.p. 123.6° C.; NMR (CDCl<sub>3</sub>): 20.47, 20.62, 36.52, 42.66, 43.70, (15%), 327 (0.8%), 223 (3%), 195 (3%), 150 (15%), 114 (100%)

(±)-2-Nitrobenzoic Acid 2-(3-Diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl Ester

Tlc: R<sub>f</sub> 0.32 (4), starting material Intermediate B: 0.42; 25 yield: 92%, viscous yellow oil which slowly solidified; NMR (CDCl<sub>3</sub>): 20.39, 20.50, 36.74, 42.14, 43.89, 48.71, 48.92, 64.59, 122.15, 123.95, 124.18, 125.89, 126.25, 127.23, 127.99, 128.39, 129.95, 132.95, 133.08, 136.72, 139.62, 143.64, 147.63, 148.15, 163.90. LC-MS: 490 (M+, 1%), 475 (11%), 327 (2.5%), 223 (2.5%), 195 (3%), 165 (3%), 150 (7%), 114 (100%)

(±)-N-Acetylglycine 2-(3-Diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl Ester/(±)-2-Acetamidoacetic Acid 2-(3-diisopropylamino-1- 35 phenylpropyl)-4-hydroxymethylphenyl Ester

((±)-2-[Diisopropylamino-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-(Acetylamino)acetate)

NMR (CD<sub>3</sub>OD): 20.33, 20.61, 22.17, 30.54, 42.39, 48.62, 51.04, 64.88, 117.99, 124.73, 125.51, 127.01, 127.75, 40 129.31, 131.63, 137.33, 146.67, 147.43, 171,47, 173.82.

(±)-Malonic Acid bis-[2-(3-Diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl]ester, tlc:  $R_f 0.38$ (4); NMR (CDCl<sub>3</sub>): 20.52, 20.62, 20.69, 36.95, 41.84, 42.82, 43.89, 48.23, 64.83, 123.37, 127.36, 127.97, 128.42, 128.38, 129.06, 131.55, 137.50, 138.90, 148.23, 148.32, 160.54.

(±)-Succinic acid bis-[2-(3-diisopropylamino-1 phenylpropyl)-4-hydroxymethylphenyl]ester, tlc:  $R_f$  0.40 (4); NMR (CDCl<sub>3</sub>): 20.54, 20.63, 20.73, 30.69, 36.91, 41.80, 43.92, 48.20, 64.81, 122.60, 127.41, 127.93, 128.39, 129.31, 50 131.80, 136.73, 138.92, 143.82, 148.17, 168.01

(±)-Pentanedioic acid bis-[2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl]ester, tlc: R, 0.43; NMR (CDCl<sub>3</sub>): 20.47, 20.60, 32.87, 36.93, 41.82, 43.90, 48.22, 64.81, 64.83, 122.85, 127.39, 127.99, 128.35, 129.31, 55 131.84, 136.98, 138.94, 143.80, 147.40, 169.05.

(±)-Hexanedioic acid bis-[2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl]ester, tlc:  $R_f$  0.43; NMR (CDCl<sub>3</sub>): 20.64, 23.40, 34.37, 36.95, 41.84, 43.88, 48.25, 64.87, 122.88, 127.34, 127.97, 128.39, 129.33, 60 121.80, 136.99, 138.94, 143.82, 147.65, 168.72.

b) Identical Diesters

(±)-Identical diesters (formula III) were prepared and worked up as described above with the exception that 2.4 mmol of both triethylamine and acyl chloride ( $R^1$ -COCl) 65 were used. The physical properties were similar to the bases and salts described above.

Diesters of N-acylaminoacids were prepared as described for phenolic monoesters with the exception that an additional molar equivalent of acylating agent (mixed acid anhydride) was used.

In particular, the following compounds were prepared and their analytical data are given below:

(±)-Formic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-formyloxymethylphenyl ester, tlc:  $R_f 0.65$  (4). This diester was prepared from mixed formic acetic anhydride and Intermediate B as described for other substrates previously (F. Reber, A. Lardon, T. Reichstein, Helv. Chim. Acta 37: 45-58 [1954]).

(±)-Acetic acid 4-acetoxy-3-(3-diisopropylamino-1phenylpropyl)-benzyl ester, tlc: R, 0.76 (4); GC-MS/P-CI (ammonia): 426.3 (100%), 368.3 (22%); GC-MS/P-CI (methane, trimethylsilyl derivative): 426.4 (64%), 410.3 (16%), 366.3 (100%); hydrochloride, NMR (DMSOd<sub>6</sub>): 16.50, 16.76, 18.05, 20.94, 21.04, 27.02, 31.39, 41.28, 45.26, 53.80, 65.21, 123.39, 126.84, 127.61, 127.85, 128.70,

(±)-Propionic acid 2-(3-diisopropylamino-1phenylpropyl)-4-propionyloxymethylphenyl ester, tlc: R<sub>f</sub> 0.82 (4); NMR (CDCl<sub>3</sub>): 20.53, 20.73, 21.14, 27.66, 36.73, 42.10, 43.68, 48.65, 65.75, 122.65, 126.10, 127.01, 127.70, 128.34, 128.78, 133.73, 136.81, 143.76, 148.45, 172.45, 174.21; GC-MS/P-CI (ammonia): 454.8 (100%), 438.5 (9%), 382.4 (27%).

(±)-n-Butyric acid 4-n-butyryloxymethyl-2-(3diisopropylamino-1-phenylpropyl)-phenyl ester, tlc: Rf 0.86 (4); NMR (CDCl<sub>3</sub>): 13.70, 13.76, 18.44, 20.53, 20.69, 21.13, 36.14, 36.76, 37.09, 42.08, 43.73, 48.71, 65.64, 122.81, 125.97, 126.97, 127.92, 128.35, 128.77, 133.78, 136.99, 143.76, 148.41, 171.68, 173.40; GC-MS/P-CI (ammonia): 482.8 (100%), 396.4 (67%).

(±)-Isobutyric acid 2-(3-diisopropylamino-1phenylpropyl)-4-isobutyryloxymethylphenyl ester, tlc: R<sub>f</sub> 0.83 (4), NMR (CDCl<sub>3</sub>): 18.97, 19.10, 20.64, 20.67, 34.01, 34.23, 36.98, 41.72, 43.70, 48.65, 65.61, 122.50, 126.18, 126.73, 127.92, 128.13, 128.36, 133.90, 137.01, 143.85, 148.41, 175.17, 176.81; GC-MS/N-CI (methane): 480.3 (15%); GC-MS/P-CI (methane): 482.5 (63%), 466.4 (18%), 394.3 (100%).

(±)-2,2-Dimethylpropionic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-(2,2-dimethylpropionyloxy)-benzyl ester, Tlc: R<sub>f</sub> 0.96 (4); NMR (CDCl<sub>3</sub>): 20.44, 20.75, 27.09, 27.24, 37.18, 38.68, 39.15, 41.25, 43.66, 48.20, 65.50, 122.36, 126.32, 127.22, 127.48, 127.83, 128.29, 133.99, 136.98, 143.87, 148.37, 176.70, 178.10; GC-MS/P-CI (methane): 510.5 (76%), 494.5 (21%), 408.4 (100%). (±)-Benzoic acid 4-benzoyloxymethyl-2-(3-

diisopropylamino-1-phenylpropyl)-phenyl ester, tlc:  $R_f 0.80$  (4); NMR (CDCl<sub>3</sub>): 20.62, 36.95, 41.72, 43.89, 48.23, 66.76, 122.22, 125.33, 127.36, 127.62, 127.89, 127.89, 127.97, 128.38, 129.49, 130.52, 130.64, 131.15, 131.22, 131.98, 136.38, 137.66, 143.82, 148.95, 164.77, 166.60.

(±)-Benzoic Acid 4-Benzoyloxymethyl-2-(3diisopropylamino-1-phenylpropyl)-phenyl Ester

Hydrochloride: colourless solid; tlc: (4) 0.70,  $[\alpha]_D^{20}$ +24.2 (c=1.0, chloroform). NMR (DMSO-d<sub>6</sub>): 16.52, 17.99,

18.06, 26.99, 31.32, 53.94, 65.98, 123.58, 127.65, 127.98, 128.62, 128.90, 129.02, 129.45, 129.71, 130.10, 133.64, 134.32, 134.55, 135.60, 142.52, 148.37, 164.53, 165.76.

c) Mixed Diesters

Mixed diesters (formula IV) were prepared by acylation of the respective benzylic or phenolic monoesters. Working up and physical properties corresponded to the bases and salts described above.

<u>,</u>\*

а**т** 

In particular, the following compounds were prepared and their analytical data are given below:

(±)-Acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-formyloxymethylphenyl ester, tlc:  $R_f$  0.76 (4); NMR (CDCl<sub>3</sub>): 20.62, 20.91, 33.25, 42.20, 42.28, 48.23, 70.70, 122.96, 127.36, 127.97, 128.38, 128.73, 132.02, 135.41, 137.11, 143.81, 149.35, 161.34, 168.95.

(±)-Benzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-formyloxymethylphenyl ester, tlc:  $R_f$  0.74 (4); NMR (CDCl<sub>3</sub>): 20.60, 36.93, 41.72, 43.89, 48.23, 70.71, 10 122.50, 125.33, 127.30, 127.89, 127.97, 128.36, 129.57, 130.65, 131.13, 132.05, 135.41, 136.66, 143.80, 149.15, 161.35, 164.78.

(±)-Benzoic Acid 2-(3-Diisopropylamino-1phenylpropyl)-4-acetoxymethylphenyl Ester

Viscous colourless oil, tlc:  $R_f 0.70$  (4); NMR (CDCl<sub>3</sub>): identical with R-(+)enantiomer, see below.

R-(+)-Benzoic Acid 2-(3-Diisopropylamino-1phenylpropyl)-4-acetoxymethylphenyl Ester

tlc:  $R_f 0.70$  (4); Hydrochloride: colourless non- 20 hygroscopic solid  $[\alpha]_D^{20} =+27.1$  (c=1.0, chloroform). NMR (CDCl<sub>3</sub>): 17.14, 18.53, 21.04, 31.51, 42.25, 46.27, 54.74, 65.58, 123.18, 127.07, 127.55, 127.61, 127.99, 128.80, 130.22, 134.14, 134.81, 135.27, 141.44, 148.54, 165.19, 170.81.

(±)-Isobutyric acid 4-acetoxymethyl-2-(3disopropylamino-1-phenylpropyl)-phenyl ester, tlc:  $R_f 0.77$ (4); NMR (CDCl<sub>3</sub>): 18.99, 19.12, 20.65, 21.05, 34.24, 37.02, 41.79, 43.79, 48.72, 65.98, 122.75, 126.76, 127.14, 127.94, 128.39, 128.84, 133.55, 137.04, 143.84, 148.56, 170.84, 30 175.18.

(±)-Isobutyric acid 4-acetoxymethyl-2-(3diisopropylamino-1-phenylpropyl)-phenyl Ester

colourless oil; Hydrochloride: colourless hygroscopic solid;  $[\alpha]_D^{20} =+14.6$  (c=1.0, chloroform); NMR (CDCl<sub>3</sub>): 35 16.89, 17.04, 18.31, 18.54, 18.92, 19.06, 20.95, 31.49, 34.07, 41.64, 46.17, 54.55, 65.49, 122.91, 126.93, 127.48, 127.83, 128.74, 134.50, 134.88, 141.61, 148.44, 170.67, 175.63.

(±)-2,2-Dimethylpropionic acid 4-acetoxy-3-(3-40 diisopropylamino-1-phenylpropyl)-benzyl ester, tlc:  $R_f 0.80$  (4); NMR (CDCl<sub>3</sub>): 20.63, 20.93, 27.19, 33.25, 37.49, 42.21, 42.25, 48.22, 67.37, 123.18, 127.36, 127.84, 128.39, 131.16, 137.34, 143.84, 148.29, 168.93, 178.40.

(±)-2,2-Dimethylpropionic acid 4-acetoxymethyl-2-(3- 45 diisopropylamino-1-phenylpropyl)-phenyl ester, tlc:  $R_f 0.81$  (4); NMR (CDCl<sub>3</sub>): 20.60, 20.79, 27.09, 36.93, 37.35, 41.85, 42.29, 48.25, 65.91, 122.36, 127.37, 127.99, 128.39, 129.38, 132.69, 136.00, 136.85, 143.80, 170.45, 176.60.

d) Benzylic Monoesters

A mixture consisting of Intermediate B (80 mg, 0.23 mmol), vinyl ester (0.4 ml), tert.-butyl methylether (18 ml), and lipase enzyme (1.0 9) was gently shaken at room temperature. Benzylic formate, acetate, and n-butyrate were prepared from the corresponding vinyl ester donors using 55 SAM I lipase (Amano Pharmaceutical Co.). Benzoylation was achieved with vinyl benzoate in the presence of Lipozym IM 20 (Novo Nordisk), whereas pivalates and isobutyrates were obtained from the corresponding vinyl esters under catalysis of Novozym SP 435 (Novo Nordisk). 60 Tlc analysis indicated after 2–24 hrs complete disappearence of the starting material ( $R_f$ =0.45 (3)). The mixture was filtered and then evaporated under high vacuum (<40° C.) to give the carboxylic acid ( $R^1$ —CO<sub>2</sub>H) salts of the respective benzylic monoesters as colourless to light yellow oils. 65

In particular, the following compounds were prepared and their analytical data are given below:

(±)-Formic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester, tlc: R<sub>f</sub> 0.25 (2); NMR (CDCl<sub>3</sub>): 19.43, 33.24, 39.61, 42.25, 48.21, 68.44, 118.09, 127.34, 127.66, 128.31, 128.39, 133.97, 144.47, 156.63, 161.32.

(±)-Acetic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester, tlc: R<sub>f</sub> 0.26 (2); NMR (CDCl<sub>3</sub>): 19.45, 20.96, 33.26, 39.63, 42.27, 48.23, 63.59, 118.00, 127.36, 128.33, 128.48, 128.53, 129.13, 131.59, 133.88, 144.49, 155.74, 170.44.

(±)-Propionic acid 3-(3-diisopropylamino-1phenylpropyl)-4-hydroxybenzyl ester, tlc:  $R_f 0.45$  (2); NMR (CDCl<sub>3</sub>): 19.02, 19.43, 27.58, 33.20, 39.61, 42.25, 48.21, 64.08, 118.30, 125.30, 127.03, 127.39, 128.31, 130.12, 134.22, 144.51, 155.64, 173.22.

(±)-Butyric acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester, tlc:  $R_f$  0.54 (2); NMR (CDCl<sub>3</sub>): 13.58, 18.40, 19.45, 33.29, 35.88, 39.65, 42.23, 48.25, 63.96, 118.32, 124.55, 126.20, 127.35, 128.32, 129.91, 134.22, 144.50, 155.60, 169.05.

(±)-Isobutyric acid 3-(3-diisopropylamino-1phenylpropyl)-4-hydroxybenzyl ester, tlc:  $R_f 0.56$  (4); NMR (CD)CO<sub>3</sub>): 19.09, 19.45, 33.28, 33.59, 39.65, 42.29, 48.25, 64.63, 118.35, 125.35, 127.03, 127.38, 128.35, 128.49, 129.79, 134.22, 144.52, 155.65, 175.48.

(±)-2,2-Dimethylpropionic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester, tlc: R, 0.61 (4); NMR (CDCl<sub>3</sub>): 19.41, 27.15, 33.24, 37.46, 39.61, 42.25, 48.21, 65.10, 118.30, 125.32, 127.00, 127.34, 128.31, 129.42, 134.18, 144.47, 155.61, 178.39.

(±)-Benzoic acid 3-(3-diisopropylamino-1phenylpropyl)-4-hydroxybenzyl ester, tlc:  $R_f 0.77$  (4); NMR (CDCl<sub>3</sub>): 18.01, 19.40, 33.24, 39.60, 42.40, 48.20, 66.93, 117.13, 127.18, 127.81, 128.33, 129.98, 130.17, 132.96, 133.58, 142.33, 156.95, 166.60.

e) Ethers and Silyl Ethers

A mixture of Intermediate B (3.4 g, 10 mmol), methanesulphonic acid (2 ml, 31 mmol)/ and alcohol  $R^{10}$ —OH (50–150 ml) was stirred at room temperature until no starting material was detectable (2–24 hrs). After evaporation to dryness (<35° C.) the residue was redissolved in aqueous sodium hydrogen carbonate solution (100–200 ml, 5%, w/v) and the solution was extracted with ethyl acetate (75 ml). The organic phase was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and evaporated to give bases of formula VI ( $R^{11}$ =H) as colourless to light yellow oils.

Mixed ester ether derivatives, e.g. of Intermediate A, were prepared by benzylic acylation of phenolic ethers, such as Intermediate A, according to the procedure described for examples of the structure of formula IV.

Hydrochlorides:

50

Molar equivalents of bases of formula VI ( $R^{11}$ =H), dissolved in tert.-butyl methylether, and ethereal hydrochloric acid were combined at room temperature oily precipitates were separated and dried in vacuum, crystalline hydrochlorides were isolated and recrystallized from acetonitrile or acetone to give colourless crystalline material.

In particular, the following compounds were prepared and their analytical data are given below:

(±)-2-(3-Diisopropylamino-1-phenylpropyl)-4methoxymethylphenol, tlc: R<sub>f</sub> 0.61 (4); GC-MS/P-CI
(methane, trimethylsilyl derivative): 428.4 (100%), 412.3 (49%), 396.3 (52%); hydrochloride: amorphous hygroscopic colourless solid; m.p. 161° C.; NMR (CD<sub>3</sub>OD): 17.39/18.75 (broad signals), 33.79, 43.13, 56.47, 58.00, 75.59, 116.19, 120.79, 127.62, 129.04, 129.14, 129.42, 129.55, 130.43, 65 144.32, 155.85.

(±)-2-(3-Diisopropylamino-1-phenylpropyl)-4ethoxymethylphenol, tlc:  $R_f$  0.72 (4); GC-MS/P-CI (ammonia, triethylsilyl derivative): 444.8 (100%), 398.4 (6%); hydrochloride: colourless non-hygroscopic crystals, m.p. 158–161° C., NMR (CD<sub>3</sub>OD) 15.43, 17.12, 18.82, 33.80, 56.49, 66.49, 73.62, 116.19, 127.63, 128.99, 129.13, 129.36, 129.55, 130.58, 130.75, 144.32, 155.77.

(±)-2-(3-Diisopropylamino-1-phenylpropyl)-4propoxymethylphenol, NMR (CDCl<sub>3</sub>): 18.62, 19.44, 23.10, 33.24, 39.61, 42.26, 48.22, 71.87, 73.94, 117.78, 124.95, 127.35, 127.57, 128.32, 128.47, 133.66, 134.23, 144.48, 155.25.

(±)-2-(3-Diisopropylamino-1-phenylpropyl)-4isopronoxymethylphenol, NMR (CDCl<sub>3</sub>): 19.44, 22.32, 33.27, 39.65, 42.29, 48.25, 69.28, 72.10, 117.90, 127.38, 128.03, 128.41, 131.10, 133.76, 134.37, 144.51, 154.65. Hydrochloride: colourless crystals, m.p. 140.400, tlc (4) 0.61. LC-MS: 383 (6%, [M-HCl]<sup>+</sup>), 368 (11%), 324 (1%), 223 (6%), 195 (3%), 165 (2%), 155 (5%), 114 (100%). NMR (DMSO-d<sub>6</sub>): 16.57, 18.09, 18.19, 22.29, 31.58, 41.25, 45.87, 53.97, 69.26, 69.92, 115.28, 126.34, 127.08, 127.25, 127.96, 128.45, 129.07, 129.70, 132.31, 143.88, 154.22.

(±)-2-(3-Diisopropylamino-1-phenylpropyl)-4- 20 butoxymethylphenol, NMR (CDCl<sub>3</sub>): 13.75, 19.44, 19.75, 32.24, 33.28, 39.60, 42.20, 48.20, 72.45, 117.87, 125.50, 127.29, 128.39, 133.70, 134.30, 144.47, 155.36.

(±)-Acetic acid 2-(3-Diisopropylamino-1-phenylpropyl)-4-methoxymethylphenyl ester, NMR (CDCl<sub>3</sub>): 19.99, 20.62, 25 20.90, 33.33, 42.30, 48.21, 58.41, 75.94, 122.92, 127.37, 127.95, 128.35 131.85, 136.99, 138.81, 143.88, 147.88, 168.95.

(±)-Acetic acid 2-(3-Diisopropylamino-1-phenylpropyl)-4-ethoxymethylphenyl ester, NMR (CDCl<sub>3</sub>): 15.49, 19.94, 30 20.95, 33.23, 42.25, 48.25, 65.70, 73.73, 122.63, 127.46, 127.95, 128.36, 131.65, 136.79, 139.71, 143.80, 147.66, 168.99.

(±)-2-(3-Diisopropylamino-1-phenylpropyl)-4trimethylsilanyloxymethylphenol, NMR (CDCl<sub>3</sub>): 0.10, 35 19.40, 19.43, 33.25, 39.65, 42.25, 48.20, 64.93, 117.90, 124.90, 126.60, 127.35, 128.35, 128.48, 133.80, 137.15, 144.49, 155.28.

(±)-Diisopropyl-[3-phenyl-3-(2-trimethylsilanyloxy-5trimethylsilanyloxymethylphenyl)-propyl]amine, NMR 40 (CDCl<sub>3</sub>): 0.10, 0.29, 19.40, 19.53, 33.28, 41.19, 42.27, 48.25, 66.40, 121.37, 127.36, 128.25, 128.50, 136.42, 144.10, 154.98.

(±)-[3-(3-Diisopropylamino-1-phenylpropyl)-4trimethylsilanyloxyphenyl]methanol, NMR (CDCl<sub>3</sub>): 0.29, 45 0.33, 19.40, 19.53, 33.27, 41.16, 42.27, 48.23, 65.22, 118.04, 124.99, 126.52, 127.30, 128.25, 134.16, 136.80, 144.14, 155.06.

(±)-Diisopropyl-[3-(5-methoxymethyl-2trimethylsilanyloxyphenyl)-3-phenylpropyl]amine, NMR 50 (CDCl<sub>3</sub>): 0.28, 0.32, 19.39, 19.43, 33.28, 41.22, 42.33, 48.19, 58.40, 75.95, 117.68, 124.92, 126.60, 127.35, 128.25, 128.55, 134.00, 136.47, 144.16, 155.09.

(±)-Diisopropyl-[3-(5-ethoxymethyl-2trimethylsilanyloxyphenyl)-3-phenylpropyl]amine, NMR 55 (CDCl<sub>3</sub>): 0.28, 0.31, 15.50, 19.42, 19.58, 33.29, 41.17, 42.25, 48.20, 65.70, 72.48, 117.50, 124.75, 126.39, 127.39, 128.25, 128.50, 134.99, 136.28, 144.19, 154.28.

(±)-[4-(tert.-Butyl-dimethylsilanyloxy)-3-(3diisopropylamino-1-phenylpropyl)-phenyl]methanol,  $R_f = 60$ 0.65 (3).

(±)-Acetic acid 4-(tert.-butyl-dimethylsilanyloxy)-3-(3diisopropylamino-1-phenylpropyl)-benzyl ester, NMR (CDCl<sub>3</sub>): -4.92, -5.00, 19.40, 19.49, 20.40, 20.83, 23.49, 33.25, 41.22, 42.25, 48.25, 72.55, 81.55, 121.24, 124.88, 65 127.40, 128.26, 128.44, 128.48, 133.37, 135.74, 144.11, 155.20.

(±)-4-(tert.-Butyl-dimethylsilanyloxymethyl)-2-(3diisopropylamino-1-phenylpropyl)-phenol, tlc:  $R_f$  0.70 (3); GC-MS/N-CI (methane, trimethylsilyl derivative): 526.5 (59%), 454.3 (100%), 412.2 (14%), 340.1 (42%); GC-MS/ P-CI (methane, trimethylsilyl derivative): 528.6 (100%), 512.5 (85%), 470.43 (10%), 396.3 (31%).

512.5 (85%), 470.43 (10%), 396.3 (31%). (±)-Acetic acid 4-(tert.-butyl-dimethylsilanyloxy)-2-(3diisopropylamino-1-phenylpropyl)-phenyl ester, NMR (CDCl<sub>3</sub>): -4.77, -4.88, 19.15, 20.65, 20.93, 24.77, 33.25, 42.20, 48.20, 67.90, 122.79, 125.15, 127.44, 127.90, 128.41, 136.99, 140.55, 143.85, 147.86, 168.95.

(±)-{3-[2-(tert.-Butyl-dimethylsilanyloxy)-5-(tert.-butyldimethylsilanyloxymethyl)-phenyl]-3-phenylpropyl}diisopropylamine, tlc: R<sub>1</sub>0.94 (3); GC-MS/N-CI (methane): 568.6 (62%), 454.3 (100%), 438.2 (10%), 340.2 (58%), 324.8 (16%), 234.7 (78%); GC-MS/P-CI (methane): 570.6 (70%), 554.5 (52%), 512.5 (18%), 438.4 (24%). (±)-Acetic acid 4-benzyloxy-3-(3-diisopropylamino-1-

( $\pm$ )-Acetic acid 4-benzyloxy-3-(3-diisopropylamino-1phenylpropyl)-benzyl ester, tlc: R<sub>f</sub> 0.56 (5); GC-MS/P-CI (ammonia): 474.4 (100%), 416.4 (54%); NMR (CDCl<sub>3</sub>): 20.44, 20.56, 21.07, 36.73, 41.53, 44.01, 48.79, 66.43, 70.00, 111.61, 125.75, 127.34, 127.55, 127.76, 127.90, 128.03, 128.27, 128.39, 133.98, 136.98, 144.63, 156.05, 170.94.

(±)-Benzoic acid 4-benzyloxy-3-(3-diisopropylamino-1phenylpropyl)-benzyl ester, tlc:  $R_f 0.87$  (4); NMR (CDCl<sub>3</sub>): 20.54, 20.60, 36.80, 41.51, 43.95, 48.67, 66.83, 70.04, 111.66, 125.76, 127.35, 127.45, 127.78, 128.06, 128.27, 128.30, 128.42, 128.85, 129.66, 130.55, 132.86, 134.05, 137.03, 144.75, 156.08, 166.46; GC-MS/P-CI (ammonia): 536.5 (100%), 416.4 (42%).

(±)-Isobutyric acid 4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester, tlc: R<sub>f</sub> 0.77 (4); NMR (CDCl<sub>3</sub>): 19.01, 20.62, 20.65, 34.04, 36.85, 41.54, 43.97, 48.71, 66.15, 70.06, 111.62, 125.79, 125.96, 126.97, 127.24, 127.55, 127.81, 128.08, 128.34, 128.45, 134.05, 137.10, 144.79, 156.00, 177.01; GC-MS/P-CI (ammonia): 502.4 (100%), 416.4 (49%).

f) Carbamates and Carbonates

Mono N-substituted Carbamates

A solution of 4.0 mmol of Intermediate B, benzylic ether (formula VI,  $R^{11}$ =H) or monoester of formula II in dichloromethane (20 ml) was treated at room temperature for 16 hrs with isocyanate (4.8 mmol) or diisocyanaze (2.2 mmol). After washing with 10 ml aqueous sodium hydrogen carbonate (5%, w/v), drying (Na<sub>2</sub>SO<sub>4</sub>) and evaporation oily residues or colourless solids of the free bases were obtained.

N-disubstituted carbamates N,N-dialkyl-carbamoylchloride (4.4 mmol) was dissolved in dichloromethane and dropped into a cooled (0° C.)

and stirred mixture consisting of Intermediate B (4.0 mmol), dichloromethane (30 ml) and triethylamine (7.0 mmol, 0.71 mg, 1 ml). Stirring was continued for 6 hrs. The mixture was then washed with 5 portions (10 ml) of aqueous sodium hydrogen carbonate, dried (sodium sulphate), filtered and evaporated to give the carbamates as colourless oils or solids.

Bis-carbamates were prepared in like manner using intermediate B and excess isocyanate (4.8 mmol) and toluene as solvent at 65° C. over 18 hrs.

Carbonates were prepared and worked-up according to the methods described for the preparation of compounds of formulae II to IV. Alkyl chloroformates were used as acylation reagents.

Hydrochlorides:

The oils or solids were redissolved in tetrahydrofuran (10 ml). Addition of ethereal hydrochloric acid and evaporation

to dryness in high vacuum gave crystalline or amorphous carbamate hydrochlorides.

In particular, the following compounds were prepared and their analytical data are given below:

(±)-N-Ethylcarbamic acid 2-(3-diisopropylamino-1- <sup>5</sup> phenylpropyl)-4-hydroxymethylphenyl ester, tlc:  $R_f$  0.38 (4); GC-MS/P-CI (ammonia, trimethylsilyl derivative): 486.8 (100%), 413.4 (5%), 398.4 (6%); hydrochloride: m.p. 64° C. (with decomposition); NMR (DMSO-d<sub>6</sub>): 15.16, 16.68, 18.05, 18.13, 25.33, 31.26, 35.46, 53.94, 62.65, <sup>10</sup> 67.22, 123.04, 125.70, 126.72, 127.86, 128.67, 135.42, 136.02, 140.07, 142.98, 147.53, 154.52.

(±)-N,N-Dimethylcarbamic Acid 2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl Ester

NMR (CDCl<sub>3</sub>): 20.34, 20.66, 30.51, 36.33, 36.77, 42.00, <sup>15</sup> 48.28, 50.21, 65.65, 119.83, 123.44, 125.19, 126.60, 127.38, 127.54, 129.31, 136.62, 143.33, 150.99, 155.67.

(±)-N,N-Diethylcarbamic Acid 2-(3-Diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl Ester

NMR (CDCl<sub>3</sub>): 20.54, 20.66, 30.49, 35.61, 42.42, 48.31, <sup>2</sup> 50.20, 65.56, 119.43, 123.40, 125.33, 126.66, 126.99, 127.05, 136.30, 143.27, 149.13, 154.97.

(±)-N-Phenylcarbamic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester; NMR 25 (CDCl<sub>3</sub>): 20.52, 20.61, 36.91, 39.44, 42.25, 48.22, 62.66, 118.36, 119.46, 123.50, 125.32, 127.11, 127.99, 130.15, 132.63, 139.65, 141.33, 145.16, 152.21, 156.00.

(±)-[2-(3-Diisopropylamino-1-phenylpropyl)-4hydroxymethylphenoxycarbonylamino)acetic Acid Ethyl <sub>30</sub> Ester Hydrochloride

Tlc:  $R_f$  0.14 (4); m.p. colourless crystals (from acetone, 21% yield); NMR (CDCl<sub>3</sub>): 16.76, 16.86, 18.45, 20.96, 31.37, 42.20, 46.13, 54.56, 65.50, 123.10, 126.98, 127.66, 128.72, 130.14, 134.05, 134.72, 135.22, 141.37, 148.47, 35 165.12, 170.71.

(±)-N-Ethylcarbamic acid 3-(3-diisopropylamino-1phenyl-propyl)-4-N-ethylcarbamoyloxybenzyl ester, tlc:  $R_f$  0.36 (3); NMR (CDCl<sub>3</sub>): 15.00, 19.23, 19.40, 33.26, 36.00, 39.62, 42.35, 48.12, 65.95, 118.30, 125.45, 127.08, 128.33, 40 130.37, 134.24, 144.44, 155.44, 157.74.

(±)-N,N-Dimethylcarbamic Acid 3-(3-diisopropylamino-1-phenylpropyl)-4-N,N-dimethylcarbamoyloxybenzyl Ester

NMR (CDCl<sub>3</sub>): 20.59, 20.66, 30.59, 35.96, 36.40, 36.74, 36.98, 42.03, 48.26, 50.09, 67.09, 119.04, 123.23, 123.49, 125.01, 126.67, 127.72, 129.33, 133.65, 143.43, 150.99, 155.63.

(±)-N,N-Diethylcarbamic Acid 3-(3-Diisopropylamino-1phenylpropyl)-4-N,N-diethylcarbamoyloxybenzyl Ester

NMR (CDCl<sub>3</sub>): 13.31, 13.64, 13.89, 20.33, 20.71, 31.57, <sup>50</sup> 37.97, 41.55, 42.37, 48.46, 51.00, 67.23, 120.00, 123.39, 124.82, 126.31, 126.95, 127.33, 150.36, 157.18, 158.97.

(±)-{4-C2-(3-Diisopropylamino-1-phenylpropyl)-4hydroxymethyl-phenoxycarbonylamino]-butyl}-carbamic Acid 2-(3-Diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl Ester

(formula VII', X=Y=NH, n=4) tlc:  $R_f 0.60$  (6); dihydrochloride m.p. 142.5–145.6° C.

(±)-Carbonic acid 2-(3-diisopropylamino-1- $_{60}$  phenylpropyl)-4-hydroxymethylphenyl ester ethyl ester, R<sub>f</sub> 0.67 (4).

(±)-Carbonic acid 2-(3-diisopropylamino-1phenylpropyl)-4-ethoxycarbonyloxymethylphenyl ester ethyl ester,  $R_f 0.87$  (4). 65

g) Intramolecular Cyclic Diesters Via Ring Closing Metathesis (RCM)



Example:

(±)-Pent-4-enoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-(pent-4-enoyloxymethyl)-phenyl Ester (x=y=2)

A cooled (4° C.) mixture of pent-4-enoic acid, isobutyl chloroformate, and triethylamine (each 5.84 mmol) in 10 ml of dichloromethane was stirred 5 hrs under an atmosphere of dry nitrogen gas. The cooling bath was then removed and both triethylamine (1.46 mmol) and 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol (1.46 mmol) were added in one portion. After 18 hrs the mixture was diluted with dichloromethane 30 ml), washed several times with water and finally aqueous 5% sodium hydrogen carbonate solution. After drying (sodium sulphate), filtration and evaporation the oily residue was re-dissolved in a small volume of a solvent mixture consisting of ethyl acetate/ heptane/triethylamine (65/30/5, vol.-%) and applied on a silica gel flash chromatography column. Elution of the column with the same solvent mixture, collection of the appropriate fractions, and evaporation of the combined fractions gave (±)-pent-4-enoic acid 2-(3-diisopropyl amino-1-phenylpropyl)-4-(pent-4-enoyloxymethyl)-phenyl ester as a pale yellow syrupy oil (50% yield), tlc: (4) 0.75. NMR (CDCl<sub>3</sub>): 18.95, 20.77, 27.75, 28.87, 33.58, 36.83, 42.13, 43.72, 48.71, 65.85, 70.55, 115.47, 115.99, 122.45, 126.26, 127.08, 127.96, 128.11, 128.83, 133.73, 136.38, 136.79, 137.04, 143.77, 148.46, 171.11, 172.78.



Intramolecular Cyclic Diesters of 1, ω-Dioic Acids and Intermediate B Example:

Intramolecular cyclic diester of octane-1,8-dioic acid and 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-5 phenol Grubbs catalyst (benzylidene-bis-(tricyclohexylphosphine)dichlororuthenium, 16 mg, 0.002 mmol, 2 mol-%) was added to a solution of (±)-pent-4-enoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-(pent-4enoyloxymethyl)-phenyl ester (483 mg, 0.96 mmol) in 10 dichloromethane (150 ml) and the mixture was refluxed for 96 hrs. under an atmosphere of nitrogen gas, after which all of the starting material was consumed as indicated by tlc. The mixture was filtered through a short pad of basic alumina, and the solvent was removed an vacuum. Flash 15 chromatography (solvent system (4)) afforded the intermediate intramolecular cyclic diester of oct-4-ene-1,8-dioic acid and 2-(3-diisopropylamino)-1-(phenylpropyl)-4hydroxymethyl-phenol (324 mg) as a colourless syrup (tlc: isomers. NMR (CDCl<sub>3</sub>, major isomer): 19.24, 20.61, 23.11, 25.62, 30.55, 33.53, 35.02, 42.41, 48.29, 50.20, 65.30, 114.46, 124.33, 125.58, 127.15, 128.70, 129.29, 131.10, 132.46, 139.54, 146.76, 147.98, 173.76, 174.39.

A portion of this material (140 mg) was dissolved in ethyl 25 acetate (10 ml) and hydrogenated at room temperature in the presence of palladium-on carbon catalyst to afford the intramolecular cyclic diester of octane-1,8-dioic acid and 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol in essentially quantitative yield, 139 mg, colourless 30 oil, tlc: (4) 0.71.

NMR (CDCl<sub>3</sub>): 19.36, 20.73, 24.84, 25.28, 28.90, 29.70, 30.57, 33.72, 34.37, 42.39, 48.26, 50.20, 65.26, 114.45, 124.37, 127.11, 128.67, 129.29, 131.18, 132.45, 139.52, 146.77, 147.69, 173.90, 174.15.

Poly-co-DL-Lactides of Intermediate B

All reagents were dried over  $P_2O_5$  in vacuum (>1 mbar) and at room temperature. The reactions were carried out at room temperature in an atmosphere of dry, oxygen-free nitrogen.

Low Molecular Weight Copolymer

A 15% solution of n-butyllithium (0.36 ml) was injected through a rubber septum into a stirred solution of 2-(3diisopropylamino-phenylpropyl)-4-hydroxymethyl-phenol (100 mg, Intermediate B) and DL-dilactide (1.5 g) in 15 ml 45 of dry toluene. The polymerization was allowed to proceed for 4 days at room temperature. Distilled water (10 ml), was then added in order to terminate the polymerization. The organic phase was separated and slowly dropped into 200 ml of methanol. The precipitated colourless oil was treated with 50 water (100 ml) and then dried in high vacuum for 48 hrs.

The copolymer was obtained in 72.7% yield. NMR analysis (see below) indicated an average molecular weight range of M<sub>n</sub> 2000-4000 and a weight content of Intermediate B of about 8.4% (NMR). Tlc analysis showed the absence of 55 monomeric Intermediate B. Gel permeation chromatography (GPC) analysis showed a Mw of 1108 and a Mn of 702. High Molecular Weight Copolymer

The high molecular weight copolymer was prepared as described above with the exception that 3.0 g of 60 DL-dilactide was used. Precipitation by methanol gave a fluffy white solid which was carefully washed with water and then dried as described to give the copolymer in 81%yield. NMR analysis (see below) indicated an average molecular weight range of M<sub>n</sub> 4000-8000 and a weight 65 content of Intermediate B of about 2.0%. Tlc analysis showed the absence of monomeric Intermediate B. Gel

permeation chromatography (GPC) showed a Mw of 9347 and a Mn or 6981. Differential scanning calorimetry (DSC) provided a Tg of 42.5° C, NMR Analysis

The <sup>1</sup>H NMR resonance signals of the poly-lactyl chain were clearly separated from the copolymeric part of Intermediate B (solvent  $CDCl_3$ ):

CH<sub>3</sub> resonances of the poly-lactyl chain: 1.30-1.60 ppm

CH resonances of the poly-lactyl chain: 5.10-5.30 ppm CH resonances of the connecting lactyl units with the two hydroxy groups of Intermediate B: 4.8-5.0 ppm and 5.5-5.7 ppm.

Polymer bound Intermediate B: 1.06-1.11 (CH<sub>3</sub>), 2.20-2.30 (CH<sub>2</sub>CH<sub>2</sub>), 2.40-2.80 (NCH<sub>2</sub>), 3.30-3.50 (NCH), 4.45–4.55 ( $\underline{CH}CH_2$ ), 4.70–4.80 ( $\underline{CH}_2$ –OCO-lactyl), 6.70-7.30 (aryl CH).

h) Inorganic Ester Example:

(±)-Benzoic acid 2-(3-diisopropylamino-1-(4) R<sub>f</sub> 0.68) in 71% yield, mixture of two geometrical 20 phenylpropyl)-4-sulphooxymethyl-phenyl Ester Hydrochloride

> To a stirred solution of chlorosulphonic acid (116 mg, 1.0 mmol) in 5 ml of dry diethyl ether was slowly added at 0° C. a solution of (±)-benzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester (445.6 mg, 1.0 mmol) in 3 ml of dry diethyl ether. The gel formed Immediately during the addition was stirred at room temperature until it became a crystalline consistency (ca. 1 hr). The precipitate was washed several times with diethyl ether and then dried in vacuum to give 0.52 g (46% yield) colourless crystals, m.p. 63–65° C. NMR (CDCl<sub>3</sub>): 16.85, 17.03, 18.32, 18.49, 32.01, 42.29, 46.23, 55.23, 55.50, 69.24, 122.52, 126.94, 127.15, 129.04, 129.76, 130.25, 133.89, 134.93, 136.85, 141.87, 147.80, 165.19.

> i) Benzylic 1-O- $\beta$ -D-glucuronide of 2-(3diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol  $((\pm)-2-(3-Diisopropylamino-1-phenylpropyl)-4-(1\beta-D-$





A solution of methyl 2,3,4-triacetyl-1- $\alpha$ -D-glucuronosylbromide (2.07 g, 4.64 mmol) in 24 ml of dry toluene was cooled to  $-25^{\circ}$  C, under an atmosphere of nitrogen and then treated with a solution of  $(\pm)$ -benzoic acid 2-(3diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester in 7 ml of toluene. To this mixture was added dropwise with stirring and under protection from light a solution of silver triflate in 14 ml of toluene (immediate formation of a white precipitate). The cooling bath was removed after 15 min and pyridine (0.38 ml) was added. The mixture was diluted with ethyl acetate (200 ml), filtered and the clear yellow filtrae was washed sequentially with aqueous solutions of sodium thiosulphate (5%), sodium hydrogen car-bonate (5%), and sodium chloride (20%). The solution was dried with solid sodium sulphate, treated with charcoal, filtered and evaporated to dryness. The waxy residue was re-dissolved in a small volume of a solvent mixture consisting of ethyl acetate/heptane/triethylamine (65/30/5, vol.-

Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0033

## US 6,713,464 B1

%) and applied on a silica gel flash chromatography column. Elution of the column with the same solvent mixture, collection of the appropriate fractions, and evaporation of the combined fractions cave (±)-benzoic acid 2-(3diisopropylamino-1-phenylpropyl)-4-(2,3,4-triacetyl-1\beta-Dglucuronosyloxymethyl)-phenyl ester, colourless syrup, tlc (4) 0.70 (starting amine: 0.31, bromo glycoside: 0.23), yield 14%

NMR (CDCl<sub>3</sub>, mixture of diastereomers): 20.41, 20.51, 10 20.60, 20.65, 20.84, 36.49, 42.44, 43.65, 48.73, 52.91, 69.46, 70.43, 71.12, 72.11, 72.60, 73.99, 99.19, 122.91, 126.23, 126.38, 126.54, 127.60, 127.92, 128.06, 128.09, 128.31, 128.59, 129.38, 130.22, 133.67, 134.31, 137.41, 143.52, 148.46, 164.82, 167.26, 169.21, 169.39, 170.07.

A portion (350 mg) of the above described material was dissolved and hydrolyzed in a solvent mixture consisting of tetrahydrofuran/methanol/aqueous potassium hydroxide (excess, 12 hrs, 22° C.). The mixture was evaporated, 2 re-dissolved in 5 ml of water and the pH was adjusted to 8.3. This solution was applied to a chromatography column charged with prewashed XAD 2 resin (50 g). The column was washed with water (ca. 250 ml) and then eluted with methanol. Collection of the appropriate methanol fractions, <sup>2</sup> and evaporation of the combined fractions in vacuum gave 111 mg of (±)-2-(3-diisopropylamino-1-phenylpropyl)-4-(1\beta-D-glucuronosyloxymethyl)-phenol, sodium salt, amorphous colourless solid, m.p. ≈110-124° C. (dec.), tlc (4) 30 0.12. NMR (CD<sub>3</sub>OD, major isomer): 19.43, 19.67, 33.26, 39.63, 42.27, 48.23, 69.76, 73.55, 74.70, 75.95, 78.03, 107.64, 117.95, 125.51, 127.36, 128.33, 133.83, 134.77, 144.49, 155.36, 176.76.

#### II. Incubations of Different Compounds of the Invention With Human Liver S 9-Fraction

#### a) Incubation of Unlabelled Substrates

A pooled human liver S 9-preparation was used to show the in-vitro metabolism of different compounds of the invention and to prove the generation of the active metabolite by enzymatic process.

The pooled human liver S 9-preparation was delivered by 45 Gentest, Woburn, Mass., USA

In a routine assay, 25  $\mu$ L of pooled human liver S 9 (20 mg protein/mL, H961, Gentest, Woburn, Mass., USA) was M potassium phosphate buffer in the presence of NADPH (1 mM). The reaction was quenched by the addition of concentrated perchioric acid and precipitating protein was removed by centrifugation. The supernatant was adjusted to pH 3 with concentrated potassium phosphate solution, 55 centrifuged, and injected into the HPLC for analysis of the respective products.

The analysis of the non-deuterated compounds was performed by a routine High Pressure Liquid Chromatography 60 (HPLC) method with UV-detection.

The incubation results expressed in (%) of theoretical turnover are presented in FIG. 1.

They ranged from 96 to 63.2%. The formation of the 65 active metabolite is dependent on the substituents both at the benzylic and phenolic side of the respective compounds.

#### Explanation:

The prodrugs introduced in the assay show the following chemical structure:

52



5	chemical structure 2	X-/-Y	
-	AcO-/-OAc	means	acetate
	HO-/-OBut	means	hydroxy and <u>n</u> -butyrate
	HO-/-OiBut	means	hydroxy and iso-butyrate
	iButO-/-OiBut	means	iso-butyrate
0	ButO-/-OBut	means	n-butyrate
	Propo-/-OProp	means	proprionate
	HO-/-OProp	means	hydroxy and proprionate
	HO-/-OAc	means	hydroxy and acetate
	BzO-/-OBz	means	benzoate and benzoate
	AcO-/-OiBut	means	acetate and isobutyrate
5	AcO-/-OBz	means	acetate and benzoate

#### b) Incubation of Labelled Substrates

The metabolic degradation of the unlabelled hydroxy metabolite (i.e. Intermediate B) and the deuteriated hydroxymetabolite (Intermediate d<sub>2</sub>B) were compared in vitro. Used were the respective enantiomers and the racemates

The hydroxy metabolite and the deuteriated hydroxy-35 metabolite expressed significant differences in the rate to produce the corresponding carboxylic acid.

The measurement was performed with an incubation time of 3 hrs at 37.0° C. in a concentration of 40  $\mu$ M. The formation of the carboxylic acid from the deuteriated hydroxy-metabolite showed a significantly decreased velocity of 10%.

These in-vitro experiments indicate a reduced metabolic turnover of the deuteriated compound in vitro, which may result in higher plasma levels.

c) Receptor Binding Study

WO 94/11337 discloses that the active metabolite has incubated for 2 hrs at 37° C. with 40  $\mu$ M substrate in a 0.01 50 high affinity to muscarinic receptors in the guinea-pig bladder. Different compounds of the present invention were tested in a well established standardized assay, measuring the binding of [<sup>3</sup>H]-methylscopolamine to recombinant human M3 receptors BSR-M3H cells transfected with a plasmid encoding the human muscarinic M3 receptor were used to prepare membranes in modified Tris-HCl pH 7.4 buffer using standard techniques. An aliquot of the membrane preparation was incubated with [<sup>3</sup>H]methylscopolamine in the presence or absence of different concentrations of several compounds of the invention for 60 minutes a 25° C. Nonspecific binding was estimated in the presence of 1  $\mu$ M atropine. Membranes were filtered and washed three times and the filters were counted to determine the amount of [<sup>3</sup>H]-methylscopolamine specifically bound. The following table shows the  $IC_{50}$  values of several compounds of the invention in the M3 receptor binding assay.

### US 6,713,464 BI

54

Interaction with hun	an M3 receptors in vitro			Penetration through human skin	
Prodrug	IC <sub>50</sub> [nM]	5	·	Prodrug	Flux rate
(+)HO-/-OH	8.7			Tiodiug	
(-)HO-/-OH	1300			HO-/-OH	3
(+)HO-/-OiBut	159	· · · · ·		HO-/-OiBut	150
(+)HO-/-OBz	, 172			iButO-/-OiBut	60
BzO-/-OBz	2400	. 10		PropO-/-OProp	70
AcO-/-OiBut	3600		·		
AcO-/-OBz	5400		· · · ·		

55

nolic hydroxyl moiety results in an about 20 times less potent binding. If both functionalities are derivatized, the binding is even more dramatically reduced. Furthermore, it is demonstrated that the enantiomers of the active metabolite exhibit a marked difference in the binding characteristics to human M3 receptors.

The compounds were tested for their anticholineruic activity in a standard tissue assay, the guinea-pig ileum. A 25 segment of ileum was obtained from Duncan Hartley guinea-pigs which were sacrified by cervical dislocation. The tissue was placed under 1 g tension in a 10 ml bath containing Krebs, solution (pH 7.4, 32° C.) and the concentration-dependent ability of different compounds to 30 reduce the methacholine-induced (0.6  $\mu$ M) contractile response was recorded. The IC<sub>50</sub> values for the different substances were calculated and examples are presented in the following table. 35

Antichonneigie activity in g	unca-pig neum in vitio	
Prodrug	IC <sub>so</sub> [nM]	4
(+)HO-/-OH	20	
(-)HO-/-OH	680	
(+)HO-/-OiBut	·57	
(+)HO-/-OBz	180	
(+)BzO-/-OBz	220	
(+)AcO-/-OiBut	240	4

These data confirm the results obtained in the receptor binding assays and demonstrate that the anticholinergic 50 activity of the compounds decreases with increased derivatization.

#### d) Biological Membranes

Different compounds of the invention were tested or their ability to penetrate the human skin (200  $\mu$ m thick) in the "Flow through cell" at 32° C. according to Tiemessen et al. (Acta Pharm. Technol. 1998; 34:99–101). Phosphate buffer <sub>60</sub> (pH 6.2) was used as the acceptor medium. Samples were drawn at different time points and analysed by RP-HPLC with UV detection 220 nm). Permeation profiles were plotted and mean flux rates of different substances were calculated by linear regression analysis. The data obtained for 65 different compounds oft the invention are summarized in the following table.

Disubstitution of the hydroxy group of HO--/--OH leads to a  $\geq$ 20-fold increase in skin permeation in relation to the These data clearly showed that derivatization at the phe-<sup>15</sup> parent HO—/—OH. Suprisingly monosubstitution of the penolic hydroxy group resulted in even higher 50-fold penetration rate through human skin.

> Taken together, these biological data clearly demonstrate that the compounds of the invention have a reduced affinity to bind to human muscarinic M3 receptors. They exhibit an increased penetration through biological membranes, e.g. the human skin, and they are rapidly transformed to the active metabolite, once they have entered the systemic circulation as shown by the in vitro metabolism by the

> Thus, the antimuscarinic prodrugs according to this invention showed a profile that defines excellent prodrugs. What is claimed is:

1. A 3,3-Diphenylpropylamine of the general formula I:



wherein R and R' are independently a) hydrogen; or

- b) formyl, C<sub>1</sub>-C<sub>6</sub> alkylcarbonyl, cycloalkylcarbonyl, substituted or unsubstitited arylcarbonyl;
- with the proviso that R' is not hydrogen, methyl or benzyl when R is hydrogen, and R is not ethyl when R' is hydrogen,
- X represents a tertiary amino group of formula Ia

Formula Ia

Formula I

wherein  $R^8$  and  $R^9$  represent  $C_1 - C_6$  alkyl groups, which may be the same or different and which together contain at least three carbon atoms, or R<sup>8</sup> and R<sup>9</sup> ' may form a ring together with the amine nitrogen,

A represents hydrogen (<sup>1</sup>H) or deuterium (<sup>2</sup>H), and

their salts with physiologically acceptable acids, their free bases and, when the compounds are in the form of optical isomers, the racemic mixture and the individual enantiomers.

20

human liver S 9 preparation.

Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0035

53

55 2. The 3,3-Diphenylpropylamine as claimed in claim 1, wherein X is



3. The 3,3-Diphenylpropylamine as claimed in claim 2 selected from phenolic monoesters represented by the gen- 10 eral formula II





wherein  $R^1$  represents hydrogen,  $C_1-C_6$  alkyl or phenyl. 50 4. The 3,3-Diphenylpropylamine as claimed in claim 2 selected from:

- (±)-formic acid 2-(3diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester,
- (±)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4- 55 hydroxymethylphenyl ester,
- (±)-propionic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-n-butyric acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-isobutyric acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- R-(+)-isobutyric acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester, 65
- (±)-2,2methylpropionic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,

56

- (±)-cyclopentanecarboxylic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-cyclohexanecarboxylic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
- R-(+)-benzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-4-methylbenzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-2-methylbenzoic acid 2-(3-diisopropylamino-1phenylpropyl)hydroxymethylphenyl ester,
- (±)-2-acetoxybenzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-1-naphthoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-2-naphthoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-4-chlorobenzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-4-methoxybenzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-2-methoxybenzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,
- (±)-4-nitrobenzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester, and
- (±)-2-nitrobenzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester.

5. The 3,3-Diphenylpropylamine as claimed in claim 2 represented by the general formula III

Formula III



wherein  $R^1$  is hydrogen,  $C_1 - C_6$  alkyl or phenyl.

6. The 3,3-Diphenylpropylamine as claimed in claim 5 selected from:

- (±)-formic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-formyloxymethylphenyl ester,
- (±)-acetic acid 4-acetoxy-3-(3-diisopropylamino-1phenylpropyl)-benzyl ester,
- (±)-propionic acid 2-(3-diisopropylamino-1phenylpropyl)-4-propionyloxymethylphenyl ester,
- (±)-n-butyric acid 4-n-butyryloxymethyl-2-(3diisopropylamino-1-phenylpropyl)-phenyl ester,
- (±)-isobutyric acid 2-(3-diisopropylamino-1phenylpropyl)-4-isobutyryloxymethylphenyl ester,
- (±)-2,2-dimethylpropionic acid 3-(3-diisopropylamino-1phenylpropyl)-4-(2,2-dimethylpropionyloxy)-benzyl ester,
5

- (±)-benzoic acid 4-benzoyloxymethyl-2-(3diisopropylamino-1-phenylpropyl)-phenyl ester,
- R-(+)-benzoic acid 4-benzoyloxymethyl-2-(3diisopropylamino-1-phenylpropyl)-phenyl ester,
- (±)-pent-4-enoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-(pent-4-enoyloxymethyl)-phenyl ester,
- cyclic oct-4-ene-1,8-dioate of Intermediate B,
- cyclic octane-1,8-dioate of Intermediate B, and
- poly-co-DL-lactides of Intermediate B, said Intermediate B having the formula



7. The 3,3-Diphenylpropylamine as claimed in claim 2  $^{25}$ selected from mixed diesters represented by the general formula IV



wherein  $R^1$  is hydrogen,  $C_1$ - $C_6$  alkyl or phenyl, and 45  $R^2$  represents hydrogen,  $C_1$ - $C_6$  alkyl or phenyl with the proviso that  $R^1$  and  $R^2$  are not identical.

- 8. The 3,3-Diphenylpropylamine as claimed in claim 7 selected from:
  - (±)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4- 50 formyloxymethylphenyl ester,
  - (±)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-formyloxymethylphenyl ester,
  - (±)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-55 4-acetoxymethylphenyl ester, R-(+)-benzoic acid 2-(3diisopropylamino-1-phenylpropyl)-4acetoxymethylphenyl ester,
  - (±)-isobutyric acid 4-acetoxymethyl-2-(3diisopropylamino-1-phenylpropyl)-phenyl ester, 60
  - R-(+)-isobutyric acid 4-acetoxymethyl-2-(3diisopropylamino-1-phenylpropyl)-phenyl ester,
  - (±)-2,2-dimethylpropionic acid 4-acetoxy-3-(3diisopropylamino-1-phenylpropyl)-benzyl ester,
  - (±)-2,2-dimethylpropionic acid 4-acetoxymethyl-2-(3diisopropylamino-1-phenylpropyl)-phenyl ester, and

58

(±)-benzoic acid 4-benzyloxy-3-(3-diisopropylamino-1phenylpropyl)-benzyl ester.

9. The 3,3-Diphenylpropylamine as claimed in claim 2 selected from benzylic monoesters represented by the general formula V



wherein  $R^1$  is hydrogen,  $C_1$ - $C_6$  alkyl or phenyl.

10. The 3,3-Diphenylpropylamine as claimed in claim 9 selected from:

- (±)-formic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester,
- (±)-acetic acid 3-(3-diisopropylamino-1-phenylpropyl)-4hydroxybenzyl ester,
- (±)-propionic acid 3-(3-diisopropylamino-1phenylpropyl)-4-hydroxybenzyl ester,
- (±)-butyric acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester,
- (±)-isobutyric acid 3-(3-diisopropylamino-1phenylpropyl)-4-hydroxybenzyl ester,
- (±)-2,2-dimethylpropionic acid 3-(3-diisopropylamino-1phenylpropyl)-4-hydroxybenzyl ester, and
- (±)-benzoic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester.

Formula IX

- 11. A 3,3-Diphenylpropylamine selected from
- (i) compounds of the formulae IX and IX'

CH<sub>3</sub> HaC CH

### US 6,713,464 B1

5

10

15

35

Formula IX





wherein 0 and p are the same or different and range  $^{20}$  from 0 to 6,

(ii) Poly-co-DL-lactides of 2-(3-diisopropylaminophenylpropyl)-4-hydroxymethylphenol and

their salts with physiologically acceptable acids, their free bases and, when the compounds are in the form of optical <sup>25</sup> isomers, the racemic mixture and the individual enantiomers.

12. A process for the production of phenolic monoesters according to claim 3, which comprises treatment of a compound of the formula  $^{30}$ 



with an equivalent of an acylating agent of formula

wherein LG represents a leaving group selected from halide, carboxylate and imidazolide in an inert solvent in the presence of a condensing agent.

13. A process for the production of identical diesters according to claim 5, which comprises treatment of a compound of the formula



with at least two equivalents of the acylating agent of formula



 $R^1 - LG$ 

wherein LG represents a leaving group selected from halide, carboxylate and imidazolide in an inert solyent in the presence of a condensing agent.

14. A process for the preparation of benzylic monoesters according to claim 9, which comprises treatment of a compound of the formula



at room temperature and under anhydrous conditions with activated esters in the presence of enzymes selected from lipases or esterases.

15. A process for the preparation of mixed diesters according to claim 7, which comprises acylation of a benzylic monoester represented by the general formula V



or of a phenolic monoester represented by the formula II

Formula II





40

50

60

wherein R<sup>8</sup> and R<sup>9</sup> represent non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and wherein  $\mathbb{R}^8$  and  $\mathbb{R}^9$  may form a ring together with <sup>45</sup> the amine nitrogen.

- Y and Z independently represent a single bond between the  $(CH_2)_n$  group and the carbonyl group, O, S or NH,
- A represents hydrogen (<sup>1</sup>H) or deuterium (<sup>2</sup>H),

n is 0 to 12, and

their salts with physiologically acceptable acids, their free bases and, when the compounds are in the form of optical isomers, the racemic mixture and the individual enanti-55 omers

17. The 3,3-Diphenylpropylamines as claimed in claim 16, wherein X is



18. The 3,3-Diphenylpropylamine as claimed in claim 17, 65 selected from phenolic monoesters represented by the general formula II





wherein Hal represents a halogen atom.

20. A pharmaceutical composition comprising a 3,3diphenylpropylamine according to any one of claims 1-10, 11 and 16-18 and a pharmaceutically acceptable carrier.

21. A method of antagonizing a muscarinic receptor, the method comprising contacting the receptor with a compound according to any one of claims 1-10, 11 and 16-18.

22. A method of treating a disease in a mammal that is amenable to treatment by antagonizing muscarinic receptors in the mammal, the method comprising administering an amount of a composition according to claim 20 effective to diminish or eliminate symptoms of the disease.

23. The method according to claim 22 wherein the disease is urinary incontinence.

24. The method according to claim 23 wherein the mammal is a human.

25. A 3,3-Diphenylpropylamine selected from:

(±)-malonic acid bis-[2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl]ester,

19. A process for the production of phenolic monoesters according to claim 18, which comprises treatment of two

# US 6,713,464 B1

Formula II'

H3

H

CH

CH-

US 6,713,464 B1

5

(±)-succinic acid bis-[2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethyl-phenyl]ester,

(±)-pentanedioic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenyl]ester, and
(±)-hexanedioic acid bis-[2-(3-diisopropylamino-1-

phenylpropyl)-4-hydroxymethylphenyl]ester.

26. The 3,3-Diphenylpropylamine of claim 2, wherein the 3,3-Diphenylpropylamine is R-(+)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester or a pharmaceutically acceptable salt thereof.

## UNITED STATES PATENT AND TRADEMARK OFFICE **CERTIFICATE OF CORRECTION**

PATENT NO. DATED

: 6,713,464 B1 : March 30, 2004 INVENTOR(S) : Claus Meese and Bengt Sparf

Page 1 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 4,

Line 9, delete "hydrocaryl" and insert therefor -- hydrocarbyl --. Line 43, delete " $\mathbb{R}^{8 \text{ and } R9}$ " and insert therefore --  $\mathbb{R}^{8}$  and  $\mathbb{R}^{9}$  --.

Column 8, Line 21, after "formula" add -- III --.

Column 9, Line 18, delete "R" and insert therefor -- R<sup>2</sup> --.

<u>Column 10,</u> Line 49, delete "2-trimehylsilanyl" and insert therefor -- 2-trimethylsilanyl --.

Column 11, Line 9, delete "3-d4isopropyl" and insert therefor -- 3-diisopropyl --.

Column 13, Line 47, delete "he" and insert therefor -- the --.

Column 14, Line 38, after "formula" delete "I" and insert therefor -- II' --.

Column 17, Line 64, delete "can, be" and insert therefor -- can be --.

Column 18, Line 23, delete "precared" and insert therefor -- prepared --.

Column 24, Line 31, delete "phosphae" and insert therefor -- phosphate --.

Column 26, Line 49, delete "7S,2R" and insert therefor -- 1S,2R --.

Column 31, Line 53, delete "69.61" and insert therefore -- 169.61 --. Line 56, delete "duisopropylamine" and insert therefor -- diisopropylamine --.

Column 32. Line 11, delete "13-(2" insert -- [3-(2 --.

## UNITED STATES PATENT AND TRADEMARK OFFICE **CERTIFICATE OF CORRECTION** PATENT NO. : 6,713,464 B1 Page 2 of 3 : March 30, 2004 DATED INVENTOR(S) : Claus Meese and Bengt Sparf It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below: Column 34, Line 21, delete "R-(+)" and insert therefor -- S-(+) --. Column 38, Line 4, delete "Eaters" and insert therefor -- Esters --. <u>Column 39,</u> Lines 47 and 55, delete "Intermediate B.3 (0.50)" and insert therefor -- Intermediate B (0.50) --. <u>Column 40,</u> Line 6, delete "127.8" and insert therefor -- 127.58 --. Line 8, delete "34.27" and insert therefor -- 134.27 --. Line 62, delete "Diisopropylamino-7-phenyl" and insert therefor -- Diisopropylamino-l-phenyl --. Column 41, Line 61, delete "121.80" and insert therefor -- 131.80 --. Column 45, Line 11, delete "isopronoxymethylphenol" and insert therefor -- isopropoxymethylphenol --. Line 14, delete "140.400" and insert therefor -- 140.4 °C --. Line 44, delete "diisocyanaze" and insert therefor -- diisocyanate --. Column 47, Line 30, delete "amino)acetic" and insert therefor -- amino]acetic --. Line 53, delete "4-C2-" and insert therefor -- 4-[2- --. <u>Column 51,</u> Line 4, delete "cave" and insert therefor -- gave --. Line 53, delete "perchioric" and insert therefor -- perchloric --. <u>Column 52,</u> Line 21, delete "Propo-/" and insert therefor -- PropO-/ --Line 54, delete "receptors" and insert therefor -- receptors. --Column 53, Line 56, delete "tested or" and insert therefor -- tested for --. Line 66, delete "oft he" and insert therefor -- of the --. !

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,713,464 B1 DATED : March 30, 2004 INVENTOR(S) : Claus Meese and Bengt Sparf Page 3 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<u>Column 55,</u>

Lines 25-48, delete formula II. Line 53, delete "3diisopropyl" and insert therefor -- 3-diisopropyl --. Line 66, delete "2,2-methylpropionic" and insert therefor -- 2,2-dimethylpropionic --.

<u>Column 56,</u>

Line 13, delete "propyl)hydroxyl" and insert therefor -- propyl)-4-hydroxy --.

<u>Column 57,</u> Lines 54-58, insert a line break before the compound "R-(+)- benzoic acid 2-(3diisopropylamino-1-phenylpropyl)-4-acetoxymethylphenyl ester".

### Signed and Sealed this



JON W. DUDAS Director of the United States Patent and Trademark Office



### UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR FO UNITED STATES PATENT AND TRADEMARK ( WASHINGTON, D C

# Bib Data Sheet

	SERIAL NUMBE 09/700,094	R FILING DATE 01/02/2001 RULE _	CLASS 514	GROUP AR 1614		ATTORNEY DOCKET NO. MBHB00-1121
	APPLICANTS Claus Meese Bengt Sparf,	e, Monheim, GERMANY; Trangsund, SWEDEN;				
	** CONTINUING D THIS APPLI	ATA ***********************************	** T/EP99/03212 05/11	/1999		
	** FOREIGN APPL EUROPEAN	LICATIONS ***********************	) 98108608.5 05/12/1	998		
	IF REQUIRED, FO GRANTED ** 01/2	DREIGN FILING LICENS	E			
	Foreign Priority claimed 35 USC 119 (a-d) condition met Venfied and Acknowledgaed	Ves D no ons Vyas D no D Met aftr Antiper Signature Inv	BE STATE OR COUNTRY GERMANY	SHEETS DRAWING 1	TOTAL CLAIMS 1	INDEPENDENIT CLAIMS 1
	ADDRESS 20306	r	-			
G- 07 1	TITLE Novel derivatives	of 3,3-diphenylpropylamir	nes			
	FILING FEE FI RECEIVED No 2160 No	EES: Authority has been ( o to charge/c o for followin	given in Paper redit DEPOSIT ACC( g:		l Fees 16 Fees ( Fil 17 Fees ( Pr 18 Fees ( Iss ther redit	ing ) ocessing Ext. of sue )

# 11/15/2000 AGIZAW 00000021 09700094 01 FC:970 860.00

01 FC:970 02 FC:966 03 FC:968 860.00 OP 900.00 OP 270.00 OP palent application serial no. Department of Commerce Patent and Trademark Office Ten record

ź

ĵ.

• •

TRA		EY COMMERCE PATENT	AND TRADEMAI	KOPPICE ATTO	Y'FY'S DOCKET NUMB	ER
Dł	NSMITTAL LETTE	LI. FO THE UNIT	ED STAT	ES ML	•_0-1121	
	ESIGNATED/ELEC	TED OFFICE (D	O/EO/US)	U.S. A	PPLICATION NO. TIP KN	OWN, SEE 37 CFR
CC	NCERNING A FIL	ING UNDER 35	U.S.C. 37	,		· · / T
NTERNATION PC	AL APPLICATION NO. <b>F/EP99/03212</b>	INTERNATIONAL 11 N	FILING DATE <b>Tay 1999</b>	PRIOR	ITY DATE CLAIMED 12 May 19	98
Novel Deriva APPLICANT(S) Claus Meese Bengt Sparf	Itives of 3,3-Diphenylpi FOR DO/EO/US	ropylamines				
Applicant here	with submits to the United	States Designated/Elect	ted Office (D	D/EO/US) the follow	ving items and other info	ormation
: 🖾 Th	us is a FIRST submission	of items concerning a fi	ling under 35	U.S C. 371	-	
2 🖸 Tł	is is a SECOND or SUBS	EQUENT submission	of items conce	erning a filing under	35 U.S.C. 371.	
3 🖾 Th	us is an express request to	begin national examination of the applicable tin	tion procedure ne limit set in	es (35 U.S.C. 371(f) 35 U.S C 371(b) au	) at any time rather than of PCT Articles 22 and 3	delay 39(1).
4 🖾 A	proper Demand for Interna	ational Preliminary Exa	mination was	made by the 19th m	onth from the earliest cl	aimed priority da
5 🖾 A	copy of the International A	Application as filed (35	U.S.C. 371 (c	)(2))		
8	is transmitted herev	with (required only if no	t transmitted	by the International	Bureau).	
b	has been transmitte	d by the International B	ureau.	States Receiving	ffice (RO/US)	
с. 6. 🗆 А	translation of the Internati	onal Application into E	nglish (35 U.S	S.C. 371(c)(2)).		
7. 🖄 A	copy of the International S	Search Report (PCT/ISA	/210).	- <b> / /</b> -		
8. 🖽 A	mendments to the claims o	f the International Appl	ication under	PCT Article 19 (35	U.S.C. 371 (c)(3))	
<b>'a</b>	are transmitted here	ewith (required only if r	tot transmitte	d by the Internations	il Bureau).	
b.	have been transmit	ted by the International e: however, the time line	Burcau.	such amendments	as NOT expired	
d.	have not been mad	e and will not be made.			· · · · ·	
9. 🗆 A	translation of the amendm	ents to the claims under	r PCT Article	19 (35 U.S C. 371 (	:)(3))	
10. 🗋 A	n oath or declaration of the	e inventor(s) (35 U.S.C.	371 (c)(4)).			· .
1'. 🛛 A	copy of the International I	Preliminary Examinatio	n Report (PC	T/IPEA/409).	an DOT, Antinia 26	
14 LI A 15 🖾 A	FIRST preliminary amen	dment.		n compnance with 5	7 CFR 5 26 and 5.51 15	included.
16 🗆 A 17. 🗋 A 18. 🖬 A 19. 🖨 C 20. 🖄 C	A SECOND or SUBSEQU A substitute specification. A change of power of attorn Certificate of Mailing by Ex Other items or information: TO Form 1449 and three Acknowledgement Postcat	ENT preliminary amen ney and/or address letter apress Mail (3) cited references rd	dment.			
16	A SECOND or SUBSEQU A substitute specification. A change of power of attorr Certificate of Mailing by Ep Other items or information: TO Form 1449 and three Acknowledgement Postcat	ENT preliminary amend ney and/or address letter apress Mail (3) cited references rd	dment.			
16	SECOND or SUBSEQU A substitute specification. A change of power of attorr Certificate of Mailing by E- Other items or information: TO Form 1449 and three Acknowledgement Postcal	ENT preliminary amend ney and/or address letter apress Mail e (3) cited references rd	dment.	Page 1 of 2		PCTUS1/R
16	A SECOND or SUBSEQU A substitute specification. A change of power of attorr Certificate of Mailing by Ep Other items or information: TO Form 1449 and three Acknowledgement Postcat	ENT preliminary amen ney and/or address letter apress Mail (3) cited references rd	dment.	Page 1 of 2		PCTUS1/R
16	A SECOND or SUBSEQU A substitute specification. A change of power of attorr Certificate of Mailing by E- Other items or information: TO Form 1449 and three Acknowledgement Postcas	ENT preliminary amend ney and/or address letter apress Mail e (3) cited references rd	dment.	Page 1 of 2		PCTUS1/R
16	A SECOND or SUBSEQU A substitute specification. A change of power of attorr Certificate of Mailing by Ex Other items or information: TO Form 1449 and three Acknowledgement Postcal	ENT preliminary amend ney and/or address letter apress Mail (3) cited references rd	dment.	Page 1 of 2		PCTUS1/R
16	A SECOND or SUBSEQU A substitute specification. A change of power of attorr Certificate of Mailing by Ex Other items or information: TO Form 1449 and three Acknowledgement Postcas	ENT preliminary amend ney and/or address letter apress Mail e (3) cited references rd	dment.	Page 1 of 2		PCTUS1/R
16	A SECOND or SUBSEQU A substitute specification. A change of power of attorr Certificate of Mailing by EP Other items or information: TO Form 1449 and three Acknowledgement Postcal	ENT preliminary amend ney and/or address letter apress Mail (3) cited references rd	dment.	Page 1 of 2		PCTUS1/R
16	A SECOND or SUBSEQU A substitute specification. A change of power of attorr Certificate of Mailing by Ex Other items or information: 'TO Form 1449 and three Acknowledgement Postcas	ENT preliminary amend ney and/or address letter apress Mail e (3) cited references rd	dment.	Page 1 of 2		PCTUSIÆ
16	A SECOND or SUBSEQU A substitute specification. A change of power of attorr Certificate of Mailing by Ep Other items or information: TO Form 1449 and three Acknowledgement Postcal	ENT preliminary amend ney and/or address letter apress Mail (3) cited references rd	dment.	Page 1 of 2		PCTUSI/R
16	A SECOND or SUBSEQU A substitute specification. A change of power of attorr Certificate of Mailing by Ex Other items or information: PTO Form 1449 and three Acknowledgement Postcas	ENT preliminary amend ney and/or address letter opress Mail e (3) cited references rd	dment.	Page 1 of 2		PCTUS1/R
16	A SECOND or SUBSEQU A substitute specification. A change of power of attorr Certificate of Mailing by Ep Other items or information: TO Form 1449 and three Acknowledgement Postcal	ENT preliminary amend ney and/or address letter apress Mail (3) cited references rd	dment.	Page 1 of 2		PCTUS1/R
16	A SECOND or SUBSEQU A substitute specification. A change of power of attorr Certificate of Mailing by Ex Other items or information: PTO Form 1449 and three Acknowledgement Postcas	ENT preliminary amend ney and/or address letter (press Mail e (3) cited references rd	dment.	Page 1 of 2		PCTUS1/R
16	A SECOND or SUBSEQU A substitute specification. A change of power of attorr Certificate of Mailing by Ex Other items or information: PTO Form 1449 and three Acknowledgement Postcal	ENT preliminary amend hey and/or address letter (press Mail e (3) cited references rd	dment.	Page 1 of 2		PCTUSIÆ

ŗ

# 529 Rec'd PCT/PTC 0.8 NOV 2000

ASIC NATIO  ASIC NATIO  Neither in internatio and Intern  Internatio USPTO b  Internatio but intern  Internatio but all ch  Internatio and all ch  CLAIMS  Tocessing fee o nonths from the  ccompanied by  IS A check  Please c A duph	following f NAL FEE International onal search onal prelimi out Internat onal prelimi ational sea onal prelimi ational sea onal prelimi atims did no onal prelimi atims atisfi EN 30.00 for fu carliest cla ims dent Claim 2 for filing l carliest cla f \$130.00 f carliest cla g the enclos an appropr	ees are subm (37 CFR 1. preliminary fee (37 CFR 1. nary examin on Search R nary examin rcch fee (37 C nary examin t satusfy prov nary examin ed provision <b>TER AP</b> mishing the imed priorit? NUMBER 1 70 3 5 (check If a <b>TC</b> by small ent CFR 1.9, 1.	nitted:. 492 (a) (1) - r examination 1.445(a)(2) not prepared hation fee (37) Leport prepared leport	(5)): n fee (37 CFR 1.482) nor paid to USPTO by the EPO or JPO 7 CFR 1.482) not paid to ed by the EPO or JPO 7 CFR 1.482) not paid to USPTO (2)) paid to USPTO (37 CFR 1.48) (2)) paid to USPTO (37 CFR 1.48) (3) (1)-(4) ATE BASIC FEE 4 aration later than FR 1.492 (e)). NUMBER EXTRA 50 0 FABOVE CALCUI able. Verified Small Entity neck if applicable). Stanslation later than (5) (5) (5) (5	SPTO     S8 SPTO     S6 2)     S6 2)     S6 2)     S6 2)     S MOUNT = 20     RAT     X \$18.     X \$80.     E     Z     ATIONS Statement UBTOTAL     20     I NAL FEE nust be licable). ICLOSED	70.00 40.00 90.00 70.00 96.00 = 30 E 00 00 00 = 30 E 00 00 00 = 30 E 00 00 00 =	CALCULATIONS \$860.00 \$0.00 \$900.00 \$900.00 \$270.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00 \$0.00 \$2,030.00 \$0.00	
ASIC NATIO Neither in internation and Internation USPTO to Internation but internation but internation but all children internation and all children CLAIMS	NAL PEE International search national search national search inational search inational search nal preliminational search in preliminational search in prelimination search in statisfi EN 30.00 for fur earliest claumer dent Claumer f \$130.00 f earliest claumer f \$130.00 f f f \$130.00 f f	(37 CFR 1. preliminary fee (37 CFR arch Report i nary examin on Search R nary examin rch fee (37 C nary examin ed provision <b>TER AP</b> rnishing the imed priorit NUMBER 1 70 3 3 (check If a <b>TC</b> by small ent CFR 1.9, 1.	492 (a) (1) - v examination 1.445(a)(2) not prepared hation fee (37) leport preparation fee (37) CFR 1.445(a) hation fee (37) CFR 1.445(a) hation fee pair visions of PCT Ar <b>PROPRI</b> oath or declar y date (37 CFR ity, if applic: 27, 1 28) (cfr g the English y date (37 CFR heet (37 CFR) heet (37 CF	(5)) : n fee (37 CFR 1.482) nor paid to USPTO by the EPO or JPO 7 CFR 1.482) not paid to ed by the EPO or JPO 7 CFR 1.482) not paid to US 7 CFR 1.482 (not SPTO (37 CFR 1.48) 10 CSPTO (37 CFR 1.48)	\$9         \$2)       \$6         2)       \$6         2)       \$6         2)       \$6         2)       \$6         2)       \$6         2)       \$6         2)       \$6         20       \$6         20       \$2         \$2       \$2         \$2       \$2         \$2       \$2         \$2       \$2      \$3       \$3 <t< td=""><td>70.00 40.00 90.00 70.00 96.00 = 30 E 00 00 00 = 30 2 = 30 + = 30 +</td><td>\$860.00 \$0.00 \$900.00 \$900.00 \$270.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00</td><td></td></t<>	70.00 40.00 90.00 70.00 96.00 = 30 E 00 00 00 = 30 2 = 30 + = 30 +	\$860.00 \$0.00 \$900.00 \$900.00 \$270.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00	
Internatic USPTO t Internatic but intern Internatic but all chi Internatic and all cli Internatic and all cli Internatic Internati	onal prelimi but Internat but Internat but Internat but Internat but Internat but Internat but International sea but International but International but International Construction Barborn State Barborn State Barb	nary examin on Search R nary examin rch fee (37 C nary examin t satisfy provision <b>TER AP</b> rmshing the imed provision <b>TER AP</b> rmshing the imed priority NUMBER 1 70 3 5 (check If a <b>TC</b> by small ent CFR 1.9, 1.	ation fee (37 Leport prepar- lation fee (37 CFR 1.445(a) hation fee pai- visions of PCT Ar <b>PROPRI</b> oath or decling y date (37 C FILED - 20 = - 3 = <b>PIICADIE</b> ) <b>DTAL OF</b> ity, if applic: 27, 1 28) (cf g the English y date (37 CFR leet (37 CFR leet (37 CFR	7 CFR 1.482) not paid to         red by the EPO or JPO         7 CFR 1.482) not paid to USPTO         7 CFR 1.482) not paid to USPTO         red to USPTO (37 CFR 1.48:         CT Article 33(1)-(4)         red to USPTO (37 CFR 1.48:         ticle 33(1)-(4)         red to USPTO (37 CFR 1.48:         ticle 33(1)-(4)         ATE BASIC FEE 4         aration later than         FR 1.492 (e)).         NUMBER EXTRA         50         0         F ABOVE CALCUI         able. Verified Small Entity         reck if applicable).         Stranslation later than         F 1.492 (f)).         TOTAL NATIO         1.21(h)). The assignment r         3.28, 3.31) (check if appl         TOTAL FEES EN	\$8         SPTO         2)         2)         2)         2)         20         20         20         20         21         20         21         20         20         20         21         20         21         20         21         22         23         24         25         26         27         28         29         20 <td>40.00 90.00 70.00 96.00 = 30 E 00 00 00 </td> <td>\$860.00 \$0.00 \$900.00 \$270.00 \$270.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00</td> <td></td>	40.00 90.00 70.00 96.00 = 30 E 00 00 00 	\$860.00 \$0.00 \$900.00 \$270.00 \$270.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00	
☐ Internatic but intern ☐ Internatic but all cli ☐ Internatic and all cl ☐ Internatic CLAIMS ☐ CLAIMS ☐ CLA	onal prelimi national sea onal prelimi aims did no onal prelimi aims satisfi EN 30.00 for fu earliest cla dent Claim 2 for filing l ed (Note 37 f \$130.00 fi earliest cla g the enclos an appropr	nary examin rch fee (37 C nary examin t satisfy provision <b>TER AP</b> rnishing the imed priority NUMBER 1 70 3 5 (check If a <b>TC</b> by small ent CFR 1.9, 1.	ation fee (37 CFR 1.445(a) lation fee pai visions of PCT lation fee pai s of PCT Ar <b>PROPRI</b> oath or deck y date (37 CF FILED - 20 = - 3 = <b>pplicable</b> ). <b>DTAL OF</b> ity, if applic: 27, 1 28) (cf g the English y date (37 CFR leet (37 CFR leet (37 CFR	7 CFR 1.482) not paid to US         (2)) paid to USPTO         (2)) paid to USPTO         (3) CFR 1.482         (1) CTAtticle 33(1)-(4)         (1) CTATE BASIC FEE 4         aration later than         (1) FR 1.492 (c)).         NUMBER EXTRA         50         0         6         6         7         ABOVE CALCUI         able. Verified Small Entity         bet translation later than         CFR 1.492 (f)).         TOTAL NATIO         1.21(h)). The assignment r         3.28, 3.31) (check if appl         TOTAL FEES EN	SPTO       \$6         2)       \$6         2)       \$6         2)       \$6         2)       \$6         2)       \$6         2)       \$6         2)       \$6         2)       \$6         2)       \$6         2)       \$6         20       20         RAT       \$18.         x       \$80.         ATIONS       \$5         Statement       \$20         NAL FEE       \$12.0         nust be       \$12.0         ICLOSED       \$12.0	90.00 70.00 96.00 = 30 E 00 00 00 = 30 + = 30 + =	\$860.00 \$0.00 \$900.00 \$270.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00	
Thernatic but all chi internatic and all chi internatic and all chi internatic and all chi internatic and all chi internatic international chi international chi internationa	nal prelimi aims did no onal prelimi aims satisfi EN 30.00 for fu earliest cla dent Claim dent Claim 2 for filing l ed (Note 37 f \$130.00 f earliest cla g the enclos an appropr	nary examin t satisfy provision TER AP rmishing the imed priority NUMBER 70 3 3 (check if a TC by small ent CFR 1.9, 1. or furnishing imed priority	ation fee pai visions of PC visions of PCT Ar <b>PROPRI</b> oath or decli y date (37 C FILED - 20 = - 3 = <b>pplicable</b> ). <b>DTAL OF</b> ity, if applic; 27, 1 28) (cf g the English y date (37 CFR seet (37 CFR seet (37 CFR	id to USPTO (37 CFR 1.48) CT Article 33(1)-(4) id to USPTO (37 CFR 1.48) ticle 33(1)-(4) ATE BASIC FEE 4 aration later than FR 1.492 (c)). NUMBER EXTRA 50 0 7 ABOVE CALCUI able. Verified Small Entity beck if applicable). S translation later than FR 1.492 (f)). TOTAL NATIO 1.21(h)). The assignment r 3.28, 3.31) (check if appl TOTAL FEES EN	2) 2) 56 2) 5 MOUNT = 20 20 20 20 20 20 20 20 20 20 20 20 20	70.00 96.00 = 30 E 00 00 	\$860.00 \$0.00 \$900.00 \$900.00 \$270.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00	
CLAIMS C	onal prelimi aims satisfi EN 30.00 for fu earliest cla ims dent Claim dent Claim 2 for filing I ed (Note 37 f \$130.00 f e earliest cla g the enclos an appropr	nary examin ed provision TER AP rmshing the imed priority NUMBER 1 70 3 (check If a TC by small ent CFR 1.9, 1. or furnishing imed priorit	ation fee pan is of PCT Ar <b>PROPRI</b> oath or declivity oath or declivity (ate (37 C FILED - 20 = - 3 = <b>pplicable</b> ). <b>DTAL OF</b> ity, if applic. 27, 1 28) (cf g the English y date (37 CFR teet (37 CFR teet (37 CFR	ATE BASIC FEE 4 aration later than FR 1.492 (e)). NUMBER EXTRA 50 0 <b>FABOVE CALCUI</b> able. Verified Small Entity neck if applicable). <b>S</b> translation later than FR 1.492 (f)). <b>TOTAL NATIO</b> 1.21(h)). The assignment r 3.28, 3.31) (check if applicable).	2) \$ MOUNT = 20  20  RAT 20  R	96.00 = 30 E 00 00 00 = 30 + = 30 +	\$860.00 \$0.00 \$900.00 \$0.00 \$270.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00	
CLAIMS CL	EIV 30.00 for fu earliest cla ims dent Claim 2 for filing l cd (Note 37 f \$130.00 f earliest cla g the enclos an appropr	rushing the imed priority NUMBER 1 70 3 (check if a TC by small ent CFR 1.9, 1.	oath or decli y date (37 C FILED - 20 = - 3 = pplicable). DTAL OF ity, if applic. 27, 1 28) (cf g the English y date (37 CFR teet (37 CFR	ATE BASIC FEE / aration later than [ FR 1.492 (e)). NUMBER EXTRA 50 0 F ABOVE CALCUI able. Verified Small Entity neck if applicable). S translation later than [ FR 1.492 (f)]. TOTAL NATIO 1.21(h)). The assignment r 3.28, 3.31) (check if applicable).	20       RAT         x       \$18.         X       \$10.         XATIONS       Statement         UBTOTAL       20         1       20         NAL FEE       NAL FEE         nust be       Itable).         ICLOSED       Itable).		\$860.00 \$0.00 \$900.00 \$0.00 \$270.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00	
CLAIMS CLAIMS	dent Claim dent Claim 2 for filing l ed (Note 37 f \$130.00 f e earliest cla g the enclos an appropr	niming the imed priority NUMBER 1 70 3 5 (check if a TC by small ent CFR 1.9, 1. Fr furnishing imed priority ed assignme iate cover sh	y date (37 C FILED - 20 = - 3 = pplicable). DTAL OF ity, if applic; 27, 1 28) (ch g the English y date (37 CFR eet (37 CFR	ABOVE CALCUI         50         0         FABOVE CALCUI         able. Verified Small Entity         beck if applicable).         Stranslation later than         CFR 1.492 (f)).         TOTAL NATIO         1.21(h)). The assignment r         3.28, 3.31) (check if appl         TOTAL FEES EN	RAT         x         <	B 00 00 00 30 + 50 10 10 10 10 10 10 10 10 10 1	\$0.00 \$900.00 \$0.00 \$270.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00	
Control claims  Control claim	dent Claim dent Claim 2 for filing l ed (Note 37 f \$130.00 f earliest cla g the enclos an appropr	70 3 s (check if a TC by small ent CFR 1.9, 1. bor furnishing imed priorit	- 20 = - 3 = pplicable). DTAL OF ity, if applic: 27, 1 28) (cf g the English y date (37 CFR the et (37 CFR the et (37 CFR	50         0         F ABOVE CALCUI         able. Verified Small Entity         able. Verified Small Entity         between the state of the state	x \$18. x \$80. ATIONS Statement UBTOTAL 20 NAL FEE nust be ileable).		\$900.00 \$0.00 \$270.00 \$2,030.00 \$0.00 \$2,030.00 \$2,030.00 \$2,030.00 \$0.00	
A dependent clai A altiple Depen eduction of 1/2 must also be file roccessing fee o months from the eact for recording companied by A check Please c A duple	dent Claim dent Claim 2 for filing l ed (Note 37 f \$130.00 f e earliest cla g the enclos an appropr	3 s (check if a TC by small ent CFR 1.9, 1. or furnishing imed priorit red assignment inter cover sh	- 3 = pplicable). DTAL OF ity, if applic; 27, 1 28) (cf g the English y date (37 CFR teet (37 CFR teet (37 CFR	0         F ABOVE CALCUI         able. Verified Small Entity         peck if applicable).         S         translation later than         FR 1.492 (f).         TOTAL NATIO         1.21(h)). The assignment r         3.28, 3.31) (check if appl         TOTAL FEES EN	x \$80. X \$80. X \$80. X \$80. X \$80. X \$80. Statement X \$80. Statement 2 0 NAL FEE Ilcable). XCLOSED		\$0.00 \$270.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00 \$2,030.00	
A altiple Dependent of 1/2 mist also be file mocessing fee of months from the effor recording companied by A check Please of A duple	dent Claim dent Claim 2 for filing l ed (Note 37 f \$130.00 f e carliest cla g the enclos an appropr	s (check if a TC by small ent CFR 1.9, 1. or furnishing imed priorit ed assignme iate cover sh	pplicable). <b>)TAL OF</b> ity, if applic: 27, 1 28) (cf g the English y date (37 CFR teet (37 CFR teet (37 CFR	F ABOVE CALCUI able. Verified Small Entity neck if applicable). S translation later than FR 1.492 (f)). TOTAL NATIO 1.21(h)). The assignment r 3.28, 3.31) (check if appl TOTAL FEES EN	Xations       Statement       UBTOTAL       20       NAL FEE       nust be       licable).       ICLOSED	30 +	\$270.00 \$2,030.00 \$0.00 \$2,030.00 \$0.00 \$2,030.00 \$2,030.00 \$0.00	
eduction of 1/2 inst also be file foccessing fee o fonths from the ene for recording companied by A check C Please of A duple	f <b>\$130.00</b> f earliest cla g the enclos an appropr	TC by small ent CFR 1.9, 1. or furnishing imed priorit ed assignme iate cover sh	tity, if applic, 27, 1 28) (cf g the English y date (37 CFR teet (37 CFR	F ABOVE CALCUI able. Verified Small Entity neck if applicable). Stranslation later than (FR 1.492 (f)). TOTAL NATIO 1.21(h)). The assignment r 3.28, 3.31) (check if appl TOTAL FEES EN	LATIONS Statement UBTOTAL 20 NAL FEE nust be licable). ICLOSED		\$2,030.00 \$0.00 \$2,030.00 \$0.00 \$2,030.00 \$0.00	
eduction of 1/2 inst also be file forcessing fee o for the form the effort recording companied by A check Please of A duple	f for filing l ed (Note 37 f \$130.00 f e earliest cla g the enclos an appropr	by small ent CFR 1.9, 1. or furnishing imed priorit ed assignme inte cover sh	ity, if applic; 27, 1 28) (cf 3 the English y date (37 C ent (37 CFR seet (37 CFR	able. Verified Small Entity neck if applicable). S translation later than FR 1.492 (f)). TOTAL NATIO 1.21(h)). The assignment r 3.28, 3.31) (check if appl TOTAL FEES EN	Statement UBTOTAL 20 NAL FEE nust be licable). ICLOSED	30 + =	\$0.00 \$2,030.00 \$0.00 \$2,030.00 \$0.00	
Improvessing fee or contrast from the from the for recording companied by         Improvession	f \$130.00 f earliest cla g the enclos an appropr	or furnishing imed priorit ed assignme iate cover sh	g the English y date (37 C ent (37 CFR seet (37 CFR	S translation later than FR 1.492 (f). TOTAL NATIO 1.21(h)). The assignment r 3.28, 3.31) (check if appl TOTAL FEES EN	UBTOTAL 20 NAL FEE nust be licable). ICLOSED	30 +	\$2,030.00 \$0.00 \$2,030.00 \$0.00	
for recording for recording companied by     A check     Decode A duple	f \$130.00 f earliest cla g the enclos an appropr	or furnishing imed priorit ed assignme iate cover sh	g the English y date (37 C ent (37 CFR neet (37 CFR	translation later than FR 1.492 (f)). TOTAL NATIO 1.21(h)). The assignment r 3.28, 3.31) (check if appl TOTAL FEES EN	20 DIAL FEE NAL FEE nust be licable).	30 <sub>+</sub> =	\$0.00 \$0.00 \$2,030.00 \$0.00	
for recording companied by     A     A check     Decode     A duple	g the enclos an appropr	ed assignme iate cover sh	ent (37 CFR leet (37 CJ'R	TOTAL NATIO 1.21(h)). The assignment r 3.28, 3.31) (check if appl TOTAL FEES EN	NAL FEE nust be licable). NCLOSED		\$2,030.00 \$0.00	
for recording companied by     A     A check     A     Please c     A duple	g the enclos an appropr	ed assignme iate cover sh	ent (37 CFR neet (37 CFR	1.21(h)). The assignment r 3.28, 3.31) (check if appl TOTAL FEES EN	nust be licable).		\$0.00	
A check			······································	TOTAL FEES EN	CLOSED	<u> </u>		
A check			· · · · · · · · · · · · · · · · · · ·			-	S2.030.00	
A check							Amount to be:	\$
A check		·					charged	S
	c in the amo charge my I icate copy (	ount of <b>\$2,0</b> Deposit Acco of this sheet	<b>30.00</b> Dunt No. is enclosed.	to cover the above fees in the amo	is enclosed. unt of		to cover the abo	ve fees.
C The Control The	mmissioner osit Accoun	is hereby au No. 1	uthorized to a 3-2490	charge any fees which may A duplicate copy of this sl	be required, or heet is enclosed.	credit a	ny overpayment	
()TE: Where 137(a) or (b))	an approg must be fi	riate time l led and grai	imit under 3 nted to resto	37 CFR 1.494 or 1.495 has ore the application to peac	i not been met, ling status.	a petiti	on to revive (37 CF	R
END ALL CO	RRESPON eenfield	DENCE TO	:		' <u>M</u>	ule	20/ X	Ut
					SIGNA	TURE		
					NAME	el 5. G		
		20	306		37,142			
		PATENT TRA	DEMARK OFFICE	e	REGIS	TRATIC	ON NUMBER	
						141	8-00	
					DATE			
iii								

ł

;



# **09/**700094 9 Rec'd PCT/PTC 0 8 NOV 2000

Descripti

Novel derivatives of 3,3-diphenylpropylamines HI TOWN **111** 751-19103212, Fritt

The present invention relates to novel derivatives of 3,3diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs.

<del>1</del>499.

In man, normal urinary bladder contractions are mediated mainly through cholinergic muscarinic receptor stimulation. There is reason to believe that muscarinic receptors mediate not only normal bladder contractions, but also the main part of the contractions in the overactive bladder resulting in symptoms such as urinary frequency, urgency and urge incontinence. For this reason, antimuscarinic drugs have been proposed for the treatment of bladder overactivity.

Among the antimuscarinic drugs available on the market, oxybutynin is currently regarded as the gold standard for pharmacological treatment of urge incontinence and other symptoms related to bladder overactivity. The effectiveness of oxybutynin has been demonstrated in several clinical studies, but the clinical usefulness of oxybutynin is limited due to antimuscarinic side effects. Dryness of the mouth is the most common experienced side effect which may be severe enough to

result in poor compliance or discontinuation of treatment (Andersson, K.-E., 1988, Current concepts in the treatment of disorders of micturition, Drugs 35, 477-494; Kelleher et al. 1994).

÷\$ Tolterodine is a new, potent and competitive, muscarinic receptor antagonist intended for the treatment of urinary urge incontinence and detrusor hyperactivity. Preclinical pharmacological data show that tolterodine exhibits a favourable tissue selectivity in vivo for the urinary bladder over the effect on the salivation (Nilvebrant et al., 1997, Tolterodine - a new bladder-selective antimuscarinic agent, Eur. J. Pharmacol. 327 (1997), 195-207), whereas oxybutynin exhibits the reversed selectivity. Tolterodine is equipotent to oxybutynin at urinary bladder muscarinic receptors and the favourable tissue selectivity of tolterodine demonstrated in the preclinical studies has been confirmed in clinical studies. Thus a good clinical efficacy has been combined with a very low number of incidences of dry mouth and antimuscarinic side effects.

A major metabolite of tolterodine, the 5-hydroxymethyl derivative is also a potent muscarinic receptor antagonist and the pharmacological in vitro and in vivo profiles of this metabolite are almost identical to those of tolterodine (Nilvebrant et al., 1997, Eur. J. Pharmacol. 327 (1997), 195-207). Combined pharmacological and pharmacokinetic data indicate that it is most likely that the metabolite gives a major contribution to the clinical effect in most patients.

WO 94/11337 proposes the active metabolite of tolterodine as a new drug for urge incontinence. Administration of the active metabolite directly to patients has the advantage com-

#### PCT/EP99/03212

#### WO 99/58478

pared to tolterodine that only one active principle (compound) has to be handled by the patient which normally should result in a lower variation in efficacy and side effects between patients and lower risk of interaction with other drugs.

However, the introduction of an additional hydroxy group in the tolterodine results in an increased hydrophilic property of the new compounds (3,3-diphenylpropylamines) compared to the parent compounds which normally results in a lower absorption/bioavailability, leading to pre-systemic side effects or interactions due to non-absorbed antimuscarinic drug. In a method to circumvent this disadvantage, different prodrugs of the metabolite have been synthesized and tested for their antimuscarinic activity, potential absorption through biological membranes and enzymatic cleavage.

It is an object of the present invention to provide novel derivatives of 3,3-diphenylpropylamines. It is a further object of the present invention to provide new derivatives of 3,3-diphenylpropylamines which will be more useful as prodrugs for treatment of urinary incontinence and other spasmogenic conditions that are caused by muscarinic mechanisms while avoiding the disadvantage of a too low absorption through biological membranes of the drugs or an unfavourable metabolism.

A further object of the invention is to provide novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to present drugs as oxybutynin and tolterodine, methods for preparing thereof, pharmaceutical compositions containing them, a method of using said compounds [N)

PCT/EP99/03212

and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

According to the present invention, novel 3,3-diphenylpropylamines are provided, which are represented by the general formulae I and VII



wherein R and R' are independently selected from

a) hydrogen,  $C_1-C_6$  alkyl,  $C_3-C_{10}$  cycloalkyl, substituted or unsubstituted benzyl, allyl or carbohydrate; or

b) formyl,  $C_1-C_6$  alkylcarbonyl, cycloalkylcarbonyl, substituted or unsubstituted arylcarbonyl, preferably benzoyl; or

c)  $C_1-C_6$  alkoxycarbonyl, substituted or unsubstituted aryloxycarbonyl, benzoylacyl, benzoylglycyl, a substituted or unsubstituted amino acid residue; or

гÌ

PCT/EP99/03212

WO 99/58478

d)

e)

- 6 2

wherein  $R^4$  and  $R^5$  independently

represent hydrogen,  $C_1$ - $C_6$  alkyl, substituted or unsubstituted aryl, preferably substituted or unsubstituted phenyl, benzyl or phenoxyalkyl wherein the alkyl residue has 1 to 4 carbon atoms and wherein  $R^4$  and  $R^5$  may form a ring together with the amine nitrogen; or

R<sup>1</sup> N-SO<sub>T</sub> wherein  ${\tt R}^6$  and  ${\tt R}^7$  independently represent  $C_1-C_6$  alkyl, substituted or unstubstituted aryl,

preferably substituted or unsubstituted phenyl, benzyl or phenoxyalkyl wherein the alkyl residue has 1 to 6 carbon atoms; or

f) an ester moiety of inorganic acids,

 $-SiR_aR_bR_c,$  wherein  $R_a,\ R_b,\ R_c$  are independently selected g) from C1-C4 alkyl or aryl, preferably phenyl,

with the proviso that R'is not hydrogen, methyl or benzyl if R is hydrogen,

X represents a tertiary amino group of formula Ia



PCT/EP99/03212

wherein  $\mathbb{R}^8$  and  $\mathbb{R}^9$  represent non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and wherein  $\mathbb{R}^8$  and  $\mathbb{R}^9$  may form a ring together with the amine nitrogen,

1

Y and Z independently represent a single bond between the  $(CH_2)_n$  group and the carbonyl group, O, S or NH,

A represents hydrogen (<sup>1</sup>H) or deuterium (<sup>2</sup>H),

n is 0 to 12

and

their salts with physiologically acceptable acids, their free bases and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers.

The aforementioned compounds can form salts with physiologically acceptable organic and inorganic acids. Furthermore, the aforementioned compounds comprise the free bases as well as the salts thereof. Examples of such acid addition salts include the hydrochloride, hydrobromide and the like.

When the novel compounds are in the form of optical isomers, the invention comprises the racemic mixture as well as the individual isomers as such.

Preferably each of  $R^8$  and  $R^9$  independently signifies a saturated hydrocarbyl group, especially saturated aliphatic hydrocarbyl groups such as  $C_{1-8}$ -alkyl, especially  $C_{1-6}$ -alkyl, or adamantyl,  $R^8$  and  $R^9$  together comprising at least three, preferably at least four carbon atoms.

PCT/EP99/03212

According to another embodiment of the invention, at least one of  $R^8$  and  $R^9$  comprises a branched carbon chain.

Presently preferred tertiary amino groups X in formula I include the following groups a) to h):









ĊH





H<sub>3</sub>C

h)

,**t)** ;

d)

PCT/EP99/03212

Group a) is particularly preferred.

The aforementioned tertiary amino groups X are described in WO 94/11337 and the compounds according to the present invention can be obtained by using the corresponding starting compounds.

In the compounds according to the present invention, the term "alkyl" preferably represents a straight-chain or branchedchain hydrocarbon group having 1 to 6 carbon atoms. Such hydrocarbon groups may be selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl and hexyl. The term "cycloalkyl" denotes a cyclic hydrocarbon group having 3 to 10 carbon atoms which may be substituted conveniently.

The term "substituted or unsubstituted benzyl" denotes a benyl group  $-CH_2-C_6H_5$  which is optionally substituted by one or more substituents on the phenyl ring. Suitable substituents are selected from alkyl, alkoxy, halogen, nitro and the like. Suitable halogen atoms are fluorine, chlorine and iodine atoms. Preferred substituted benzyl groups are 4-methylbenzyl, 2-methylbenzyl, 4-methoxybenzyl, 2-methoxybenzyl, 4nitrobenzyl, 2-nitrobenzyl, 4-chlorobenzyl and 2-chlorobenzyl.

In the compounds according to the present invention the term  $"C_1-C_6$  alkylcarbonyl" denotes a group R-C(=O) - wherein R is an alkyl group as defined hereinbefore. Preferred  $C_1-C_6$  alk-ylcarbonyl groups are selected from acetyl, propionyl, isobutyryl, butyryl, valeroyl and pivaloyl. The term "cyclo-alkylcarbonyl" denotes a group R-C(=O) - wherein R is a cyclic hydrocarbon group as defined hereinbefore. The same counts to the selected carbonyl groups.

PCT/EP99/03212

The term "aryl" denotes an aromatic hydrocarbon group such as phenyl-  $(C_6H_5-)$ , naphthyl-  $(C_{10}H_7-)$ , anthryl-  $(C_{14}H_9-)$ , etc. Preferred aryl groups according to the present invention are phenyl and naphthyl with phenyl being particularly preferred.

9

The term "benzoyl" denotes an acyl group of the formula  $-CO-C_6H_5$  wherein the phenyl ring may have one or more substituents.

Preferred substituents of the aryl group and in particular of the phenyl group are selected from alkyl, alkoxy, halogen and nitro. As substituted benzoyl groups 4-methylbenzoyl, 2methylbenzoyl, 4-methoxybenzoyl, 2-methoxybenzoyl, 4-chlorobenzoyl, 2-chlorobenzoyl, 4-nitrobenzoyl and 2-nitrobenzoyl may be mentioned.

The term " $C_1-C_6$  alkoxycarbonyl" refers to a group ROC(=0)wherein R is an alkyl group as defined hereinbefore. Preferred  $C_1-C_6$  alkoxycarbonyl groups are selected from  $CH_3OC(=0)-$ ,  $C_2H_5-OC(=0)-$ ,  $C_3H_7OC(=0)-$  and  $(CH_3)_3COC(=0)$ and alicyclic alkyloxycarbonyl.

The term "amino acid residue" denotes the residue of a naturally occurring or synthetic amino acid. Particularly preferred amino acid residues are selected from the group consisting of glycyl, valyl, leucyl, isoleucyl, phenylalanyl, prolyl, seryl, threonyl, methionyl, hydroxyprolyl.

The amino acid residue may be substituted by a suitable group and as substituted amino acid residues, benzoylglycyl and Nacetylglycyl may be mentioned.

- 10 -

The term "carbohydrate" denotes the residue of a polyhydroxy aldehyde or polyhydroxy ketone of the formula  $C_nH_{2n}O_n$  or  $C_n(H_2O)_n$  and correponding carbohydrate groups are, for example, described in Aspinal, The Polysaccharides, New York: Academic Press 1982, 1983. A preferred carbohydrate group in the compounds according to the present invention is a glucuronosyl group, in particular a 1 $\beta$ -D-glucuronosyl group.

The term "LG" as used herein denotes a leaving group selected from halogenides, carboxylates, imidazolides and the like.

The term "Bn" as used herein denotes a benzyl group.

Suitable ester moieties of inorganic acids may be derived from inorganic acids such as sulfuric acid and phosphoric acid.

Preferred compounds according to the present invention are:

A) Phenolic monoesters represented by the general formulae II and II'

ula II



wherein  $R^1$  represents hydrogen,  $C_1-C_6$  alkyl or phenyl.

- 11 -

Particularly preferred phenolic monoesters are listed below:

(±)-formic acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester,

(±)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester,

(±)-propionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-n-butyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-isobutyric acid 2-(3-diisopropylamino-1-phenyl-

propyl)-4-hydroxymethylphenyl ester,

R-(+)-isobutyric acid 2-(3-diisopropylamino-l-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-2,2-dimethylpropionic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-2-acetamidoacetic acid 2-(3-diisopropylamino-1-

phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-cyclopentanecarboxylic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-cyclohexanecarboxylic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-

4-hydroxymethylphenyl ester, apple ap

R-(+)-benzoic acid 2-(3-diisopropylamino-1-phenyl-

propyl)-4-hydroxymethylphenyl ester,

(±)-4-methylbenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-2-methylbenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester;

(±)-2-acetoxybenzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,

. .

(±)-1-naphthoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (±)-2-naphthoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester (±)-4-chlorobenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (±)-4-methoxybenzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester, (±)-2-methoxybenzoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester, (±)-4-nitrobenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (±)-2-nitrobenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (±) -malonic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenyl]ester, (±)-succinic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenyl]ester, (±)-pentanedioic acid bis-[2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethyl-phenyl]ester, (±)-hexanedioic acid bis-[2-(3-diisopropylamino-1-

12 -

phenylpropyl)-4-hydroxymethyl-phenyl]ester.

B)

Identical diesters represented by the general formula III



wherein R<sup>1</sup> is as defined above.

below:

Particularly preferred identical diesters are listed 4 1 1 (±)-formic acid 2-(3-diisopropylamino-1-phenylpropyl)-4formyloxymethylphenyl ester, (±)-acetic acid 4-acetoxy-3-(3-diisopropylamino-1phenylpropyl)-benzyl ester, (±)-propionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-propionyloxymethylphenyl ester,

- 13 -

(±)-n-butyric acid 4-n-butyryloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester,

(±)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-isobutyryloxymethylphenyl ester,

(±)-2,2-dimethylpropionic acid 3-(3-diisopropylamino-1phenylpropyl)-4-(2,2-dimethyl-propionyloxy)-benzyl ester,

(±)-benzoic acid 4-benzoyloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester,

R-(+)-benzoic acid 4-benzoyloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester,

(±)-pent-4-enoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-(pent-4-enoyloxymethyl)-phenyl ester, cyclic oct-4-ene-1,8-dioate of Intermediate B, cyclic octane-1,8-dioate of Intermediate B, poly-co-DL-lactides of Intermediate B.

C)

Mixed diesters represented by the general formula IV



PCT/EP99/03212

wherein R<sup>1</sup> is as defined above

and

 $R^2$  represents hydrogen,  $C_1-C_6$  alkyl or phenyl

with the proviso that  $R^1$  and  $R^2$  are not identical.

Particularly preferred mixed diesters are listed below:

(±)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4formyloxymethylphenyl ester,

(±)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-formyloxymethylphenyl ester,

(±)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-acetoxymethylphenyl ester,

R-(+)-benzoic acid 2-(3-diisopropylamino-1-phenyl-

propyl)-4-acetoxymethylphenyl ester,

(±)-isobutyric acid 4-acetoxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester,

R-(+)-isobutyric acid 4-acetoxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester,

(±)-2,2-dimethylpropionic acid 4-acetoxy-3-(3-diiso-

propylamino-1-phenylpropyl)-benzyl ester,

(±)-2,2-dimethylpropionic acid 4-acetoxymethyl-2-(3diisopropylamino-1-phenylpropyl)-phenyl ester,

(±)-benzoic acid 4-benzyloxy-3-(3-diisopropylamino-1phenylpropyl)-benzyl ester.

D)

Benzylic monoesters represented by the general formula V

PCT/EP99/03212

WO 99/58478



wherein  $R^1$  is as defined above.

Particularly preferred benzylic monoesters are listed below:

(±)-formic acid 3-(3-diisopropylamino-1-phenylpropyl)-4hydroxybenzyl ester,

(±)-acetic acid 3-(3-diisopropylamino-1-phenylpropyl)-4hydroxybenzyl ester,

(±)-propionic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester,

(±)-butyric acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester,

(±)-isobutyric acid 3-(3-diisopropylamino-l-phenylpropyl)-4-hydroxybenzyl ester,

(±)-2,2-dimethylpropionic acid 3-(3-diisopropylamino-1phenylpropyl)-4-hydroxybenzyl ester,

(±)-benzoic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester.

B) Ethers and silyl ethers represented by the general formula VI

PCT/EP99/03212

WO 99/58478



16

wherein at least one of  $R^{10}$  and  $R^{11}$  is selected from  $C_1 - C_6$ alkyl, benzyl or  $-SiR_aR_bR_c$  as defined above and the other one of  $R^{10}$  and  $R^{11}$  may additionally represent hydrogen,  $C_1-C_6$  alkylcarbonyl or benzoyl.

Particularly preferred ethers and silyl ethers are listed below:

(±)-2-(3-diisopropylamino-1-phenylpropyl)-4-methoxymethylphenol,

 $\langle \pm \rangle$  -2-(3-diisopropylamino-1-phenylpropyl)-4-ethoxymethylphenol,

(±)-2-(3-diisopropylamino-1-phenylpropyl)-4-propoxymethylphenol,

(±)-2-(3-diisopropylamino-1-phenylpropyl)-4-isopropoxymethylphenol,

(±)-2-(3-diisopropylamino-1-phenylpropyl)-4-butoxymethylphenol,

(±)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4methoxymethylphenyl ester,

(±)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4ethoxymethylphenyl ester,

(±)-2-(3-diisopropylamino-1-phenylpropyl)-4-trimethylsilanyloxymethylphenol,

(±) -diisopropyl-[3-phenyl-3-(2-trimethylsilanyloxy-5trimethylsilanyloxymethylphenyl)-propyl]-amine, (±)-[3-(3-diisopropylamino-1-phenylpropyl)-4-trimethy]silanyloxyphenyl]-methanol, (±)-diisopropyl-[3-(5-methoxymethyl-2-trimethylsilanyloxyphenyl)-3-phenylpropylamine, (±)-diisopropyl-[3-(5-ethoxymethyl-2-trimethylsilanyloxyphenyl)-3-phenylpropylamine, (±) - [4-(tert.-butyl-dimethylsilanyloxy) -3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-methanol, (±)-acetic acid 4-(tert.-butyl-dimethylsilanyloxy)-3-(3diisopropylamino-1-phenylpropyl)-benzyl ester, (±)-4-(tert.-butyl-dimethylsilanyloxy)-3-(3-diisopropylamino-1-phenylpropyl)-phenol, (±)-acetic acid 4-(tert.-butyl-dimethylsilanyloxy)-2-(3diisopropylamino-1-phenylpropyl)-phenyl ester, (±) -{3-[2-(tert.-butyl-dimethylsilanyloxy)-5-(tert.butyl-dimethylsilanyloxymethyl)-phenyl]-3-phenylpropyl}diisopropylamine, (±)-[4-(tert.-butyl-diphenylsilanyloxy)-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-methanol, (±)-acetic acid 4-(tert.-butyl-diphenylsilanyloxymethyl)-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester, (±)-4-(tert.-butyl-diphenylsilanyloxymethyl)-2-(3-diisopropylamino-1-phenylpropyl)-phenol, (±)-{3-[2-(tert.-butyl-diphenylsilanyloxy)-5-(tert.butyl-diphenylsilanyloxymethyl)-phenyl]-2-phenylpropyl}diisopropylamine, (±)-acetic acid 4-bénzyloxy-3-(3-diisopropylamino-1phenylpropyl)-benzyl ester, (±)-benzoic acid 4-benzyloxy-3-(3-diisopropylamino-1phenylpropyl)-benzyl ester,

17

aid 4-benzylovy-3-(3-diison

(±)-isobutyric acid 4-benzyloxy-3-(3-diisopropylamino-1phenylpropyl)-benzyl ester,

(±)-2-(3-diisopropylamino-1-phenylpropyl)-4-(1 $\beta$ -D-glucuronosyloxymethyl)-phenol.

F)

Carbonates and carbamates represented by the general formulae VII and VIII



wherein Y, Z and n are as defined above and wherein  $R^{12}$ and  $R^{13}$  represent a  $C_1-C_6$  alkoxycarbonyl group or



wherein  $R^4$  and  $R^5$  are as defined above.

Particularly preferred carbonates and carbamates are listed below:

- 19

(±)-N-ethylcarbamic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

 $(\pm)$ -N,N-dimethylcarbamic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,

(t)-N,N-diethylcarbamic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester,

(±) -N-phenyLcarbamic acid 2-(3-diisopropylamino-1phenylpropyl) -4-hydroxymethylphenyl ester,

(±) - [2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenoxycarbonylamino]acetic acid ethyl ester hydrochloride,

(±)-N-ethylcarbamic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-N-ethylcarbamoyloxybenzyl ester,

(±) -N, N-dimethylcarbamic acid 3-(3-diisopropylamino-1phenylpropyl)-4-N, N-dimethylcarbamoyloxybenzyl ester,
(±) -N, N-diethylcarbamic acid 3-(3-diisopropylamino-1phenylpropyl)-4-N, N-diethylcarbamoyloxybenzyl ester,
(±) -N-phenylcarbamic acid 3-(3-diisopropylamino-1phenylpropyl)-4-N-phenylcarbamoyloxybenzyl ester,
(±) -{4-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenoxycarbonylamino]-butyl}-carbamic acid 2-(3diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-carbonic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester ethyl ester,

(±)-carbonic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester phenyl ester,

(±)-carbonic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-ethoxycarbonyloxymethylphenyl ester ethyl ester,

(±)-carbonic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-phenoxycarbonyloxymethylphenyl ester phenyl ester.

#### PCT/EP99/03212

### 20

х -

12

- G) 3,3-Diphenylpropylamines selected from 5
  - (i) compounds of the formulae IX and IX'



wherein o and p are the same or different and represent the number of methylene units  $+ CH_2 +$  and may range from 1 0 to 6,

(ii) (±)-Benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-sulphooxymethyl-phenyl ester

(iii) Poly-co-DL-lactides of 2-(3-diisopropylaminophenylpropyl)-4-hydroxymethyl-phenol

(iv) (±)-2-(3-Diisopropylamino-1-phenylpropyl)-4-(1 $\beta$ -Dglucuronosyloxymethyl)-phenol having the formula





and

their salts with physiologically acceptable acids, their free bases and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers.

3k.

21

The present invention, moreover, relates to processes for the preparation of the aforementioned compounds. In particular, according to the present invention, the following processes are provided:

A process for the production of phenolic monoesters represented by the general formula II



Formula II

as defined above, which comprises treatment of a compound of the formula



PCT/EP99/03212

- 22 -

with an equivalent of an acylating agent selected from

R<sup>1</sup>-C-LG

wherein LG represents a leaving group selected from halogenide, carboxylate and imidazolide and  $R^1$  is as defined above, in an inert solvent in the presence of a condensating agent.

Preferably, the acylating agent is selected from

O II R<sup>1</sup>-C-Hal

atom, and R<sup>1</sup> is as defined above.

wherein Hal represents a halogen atom, preferably a chlorine

or

 $\begin{array}{c} 0 \quad 0 \\ \parallel \quad \parallel \\ R^1 - C - O - C - R^1, \end{array}$ 

A process for the production of phenolic monoesters represented by the general formula II'



• •

as defined above, which comprises treatment of two equivalents of a compound of the formula



with an acylating agent selected from

$$\begin{array}{cccc} & & & & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & &$$

wherein Hal represents a halogen atom, preferably a chlorine atom.

Hence, in these processes, an Intermediate B having the formula



is treated with an equivalent of an acylating agent (e.g. an acyl halogenite or acyl anhydride) in an inert solvent and in the presence of a condensating agent (e.g. amine) to provide phenolic monoesters of formula II or formula II' (wherein n

is 0-12), respectively, if polyfunctional acylating agents (e.g. acid halides, preferably acid chlorides of dicarboxylic acids) are used.

The Intermediate B as used in the processes for the production of the 3,3-diphenylpropylamines according to the present invention can be in the form of a racemic mixture or of optically active compounds in accordance with the formulae shown below:





Intermediate RS

Intermediate R-(+)

Intermediate S-(-)

Alternatively, structures of formula II or II' may be obtained ed by regioselective deprotection of a protected benzylic hydroxy group (chemically or enzymatically: T. W. Greene, P. G. M. Wuts, "Protective Groups in Organic Chemistry", 2nd Ed., J. Wily & Sons, New York 1991).

The identical diesters represented by the general formula III



1

#### PCT/EP99/03212

#### WO 99/58478

as defined above can be prepared by a process which comprises treatment of a compound of the formula



with at least two equivalents of the acylating agent  $R^1-C(=0)$ -LG as defined above.

Thus, the aforementioned di-acyl compounds are readily accessible if an at least two-molar excess of an acylating agent is used in the above-mentioned conversion of Intermediate B or, more general, on treatment of compounds of formula I with acylating agents in the presence of suitable catalysts. In the above process, the following Intermediate A



wherein R' denotes a benzyl group can be used instead of Intermediate B. The Intermediate A can be used in the form of a racemic mixture or of optically active compounds (similar to Intermediate B).

Benzylic monoestes represented by the general formula V
PCT/EP99/03212

WO 99/58478



wherein  $R^1$  is as defined above can be prepared by a process which comprises treatment of a compound of the formula



at room temperature and under anhydrous conditions with activated esters in the presence of enzymes selected from lipases or esterases.

Hence, this process relates to the preparation of phenols with para acyloxymethyl substituents (cf. formula V). These compounds can be prepared in several chemical steps from intermediates such as formula I, where R represents hydrogen and R' is hydrogen or any suitable protective group which can be removed by known methods (T. W. Greene, P.G.M. Wuts, "Protective Groups in Organic Chemistry", 2nd Ed., J. Wily & Sons, New York 1991) in the presence of the newly introduced substituent R<sup>1</sup>CO. It was found, however, that the benzylic substituent R<sup>1</sup>CO can be introduced more conveniently and in only one step if Intermediate B is treated at room temperature and under anhydrous conditions with activated esters (e.g. vinyl acylates, isopropenyl acylates) in the presence of enzymes such as lipases or esterases.

Ľ

The mixed diesters represented by the general formula IV



wherein  $R^1$  and  $R^2$  are as defined above can be prepared by a process which comprises acylation of the above-mentioned benzylic monoester represented by the general formula V



wherein  $R^1$  is as defined above or of a phenolic monoester represented by the general formula II



PCT/EP99/03212

as defined hereinbefore.

In general, mixed diesters of formula IV can be obtained by acylation of compounds of the general formula I wherein R and R' are different substituents selected from the group consisting of hydrogen, acyl residues or protecting groups that are cleavable under the acylation reaction conditions.

Ethers represented by the general formula VI



as defined hereinbefore wherein  $R^{11}$  is hydrogen can be prepared by a process which comprises reacting a compound of the formula



with an alcohol  $R^{10}$ -OH in the presence of an esterification catalyst.

PCT/EP99/03212

WO 99/58478

-- --

A further process for the preparation of ethers represented by the general formula VI

29



wherein  $R^{10}$  and  $R^{11}$  are as defined hereinbefore, comprises acid or base treatment of free benzylic alcohols selected from



and

and



Farmula ()

PCT/EP99/03212

WO 99/58478

or





wherein  $R^{10}$  is hydrogen and  $R^{11}$  is as defined above or



Formula VII

wherein  $R^{12}$  is hydrogen and  $R^{13}$  represents a  $C_1-C_6$  alkoxycarbonyl group or



wherein  $R^4$  and  $R^5$  are as defined above

or of benzylic acylates selected from

PCT/EP99/03212



31

R<sup>1</sup> OH Y OAA Formula V

wherein  $R^1$  and  $R^2$  are as defined hereinbefore in the presence of suitable hydroxy reagents.

Finally, ethers of formula VI can be prepared by a process which comprises treating a compound of the formula



wherein  $R^{10}$  is as defined above with an alkylating agent selected from alkyl halogenides, alkyl sulphates and alkyl triflates, said alkyl group having 1 to 6 carbon atoms.

PCT/EP99/03212

WO 99/58478

In summary, regioselective modification of the benzylic hydroxy groups is achieved either by acid or base treatment of benzylic acylates in the presence of suitable hydroxy reagents (e.g. alcohols) or by catalytic ether formation as described in the literature for other benzylic substrates (J.M. Saa, A. Llobera, A. Garcia-Raso, A. Costa, P.M. Deya; J. Org. Chem. 53: 4263-4273 [1988]). Both free benzylic alcohols such as Intermediates A and B or compounds of formulas II or VI (in which  $R^{10}$  is hydrogen) or formula VII (in which  $R^{12}$  is hydrogen) as well as benzylic acylates such as formulae III, IV, V may serve as starting materials for the preparation of benzylic ethers (B. Loubinoux, J. Miazimbakana, P. Gerardin; Tetrahedron Lett. 30: 1939-1942 [1989]).

Likewise the phenolic hydroxy groups are readily transformed into phenyl ethers (R<sup>11</sup> = alkyl) using alkylating agents such as e.g. alkyl halcgenides, alkyl sulphates, alkyl triflates or employing Mitsunobu type reaction conditions (Synthesis 1981, 1-28). Similarly, both phenolic and alcoholic monosilyl ethers are obtained by regioselective silylation or by desilylation of bis-silyl ethers of Intermediate 3 as described for other compounds in the literature (J. Paladino, C. Guyard, C. Thurieau, J.-L. Fauchere, Helv. Chim. Acta 76: 2465-2472 [1993]; Y. Kawazoe, M. Nomura, Y. Kondo, K. Kohda, Tetrahedron Lett. 26: 4307-4310 [1987]).

Carbonates and carbamates represented by the general formulae VII and VIII

- 33 -



as defined hereinbefore can be prepared by a process which comprises reacting a compound selected from the group consisting of



Formula (I









wherein  $R^1$  is defined as above, n is 0 to 12, Bn is benzyl,  $R^{10}$  or  $R^{11}$  is hydrogen with activated carbonyl compounds or carbonyl precursor reagents selected from haloformates, ketenes, activated esters, mixed anhydrides of organic or inorganic acids, isocyanates and isothiocyanates.

The coupling reactions can be carried out in inert solvents over periods of several hours at temperatures from  $-10 \,^{\circ}$ C to the refluxing temperature of the solvent or reagent used to provide compounds of the general formula VII where  $R^{12}$  represents hydrogen, alkyl, aliphatic or aromatic acyl, or carbamoyl, and  $R^{13}$  represents  $-C(=0)-Y-R^3$ , wherein Y and  $R^3$  represent O, S, NH and alkyl or aryl, respectively. Polyfunctional reagents give the corresponding derivatives. For example, diisocyanates or di-carbonylchlorides provide compounds of formula VIII where X, Y have the meaning of O, S, or NH and n is zero to twelve.

The invention, moreover, relates to pharmaceutical compositions comprising one or more of the aforementioned 3,3-diphenylpropylamines. In other words, the compounds according to the present invention can be used as pharmaceutically active substances, especially as antimuscarinic agents.

35

They can be used for preparing pharmaceutical formulations containing at least one of said compounds.

The compounds according to the present invention in the form of free bases or salts with physiologically acceptable acids, can be brought into suitable galenic forms, such as compositions for oral use, for injection, for nasal spray administration or the like, in accordance with accepted pharmaceutical procedures. Such pharmaceutical compositions according to the invention comprise an effective amount of the compounds of claims 1 to 15 in association with compatible pharmaceutically acceptable carrier materials, or diluents, as is well known in the art. The carriers may be any inert material, organic or inorganic, suitable for enteral, percutaneous or parenteral administration, such as water, gelatine, gum arabicum, lactose, microcrystalline cellulose starch, sodium starch glycolate, calcium hydrogen phosphate, magnesium stearate, talcum, colloidal silicon dioxide, and the like. Such compositions may also contain other pharmaceutically active agents, and conventional additives, such as stabilizers, wetting agents, emulsifiers, flavouring agents, buffers, and the like.

The composition according to the invention can e.g. be made up in solid or liquid form for oral administration, such as tablets, capsules, powders, syrups, elixirs and the like, in

#### PCT/EP99/03212

# - 36 -

the form of sterile solutions, suspensions or emulsions for parenteral administration, and the like.

The compounds according to the invention may be used in a patch formulation. The compounds can be administered transdermally with a reduced incidence of side effects and improved individual compliance.

The compounds and compositions can, as mentioned above, be used for the treatment of urinary incontinence and other spasmogenic conditions that are caused by muscarinic mechanisms. The dosage of the specific compound will vary depending on its potency, the mode of administration, the age and weight of the patient and the severity of the condition to be treated. The daily dosage may, for example, range from about 0.01 mg to about 5 mg, adminstered singly or multiply in doses e.g. from about 0.05 mg to about 50 g each.

The invention will be further illustrated by the following non-limiting examples and pharmacological tests.

#### I. Experimental

1. General

All compounds were fully characterized by <sup>1</sup>H and <sup>13</sup>C NMR spectroscopy (Bruker DPX 200). The chemical shifts reported for <sup>13</sup>C NMR spectra (50 MHz, ppm values given) refer to the solvents CDCl<sub>3</sub> (77.10 ppm), dideuterio dichloromethane (CD<sub>2</sub>Cl<sub>2</sub>, 53.8 ppm), CD<sub>3</sub>OD (49.00 ppm) or hexadeuterio dimethylsulphoxide (DMSO-d<sub>6</sub>, 39.70 ppm), respectively. <sup>1</sup>H NMR data (200 MHz, ppm) refer to internal tetramethylsilane).

## - 37 -

I The Alexander

Thin-layer chromatography (tlc,  $R_f$  values reported) was conducted on precoated 5x10 cm E. Merck silica gel plates (60F254), spots were visualized by fluorescence quenching or spaying with alkaline potassium permanganate solution. Solvent systems: (1), ethyl acetate/n-hexane (30/70, v/v-(3); (2), toluene/acetone/methanol/acetic acid (70/5/20/5, v/v-(3), n-hexane/acetone/diethylamine (70/20/10, v/v-(); (4), n-hexane/acetone/triethylamine (70/20/10, v/v-(); (5), ethyl acetate/n-hexane/2-propanol/triethylamine (60/40/20/1, v/v-(); (6), ethyl acetate/triethylamine (90/10, v/v-(); (7), cyclohexane/acetone/acetic acid (80/20/0.5, v/v-(). Optical rotations were measured at 589.3 nm and room temperature on a Perkin Elmer Polarimeter Type 241. Melting points (mp) reported are uncorrected and were deter-

mined on a Mettler FP 1 instrument.

IR spectra were taken from a Perkin-Elmer FTIR spectrometer Series 1610, resolution  $4 \text{ cm}^{-1}$ .

Gas chromatography-mass spectrometry (GC-MS): spectra (m/z values and relative abundance (%) reported) were recorded on a Finnigan TSQ 700 triple mass spectrometer in the positive (P-CI) or negative (N-CI) chemical ionization mode using methane or ammonia as reactant gas. Hydroxylic compounds were analyzed as their trimethylsilyl ether derivatives. Combined liquid chromatography-mass spectrometry (LC-MS): Waters Integrety System, Thermabeam Mass Detector (EI, 70 eV), m/z values and relative abundance reported.

2. Synthesis of Intermediates A and B

3-Phenylacrylic acid 4-bromophenyl aster An ice-cooled solution of 4-bromophenol (69.2 g) and cinnamoyl chloride (66.8 g) in dichloromethane (150 ml) was treated with triethylamine (40.6 g). After stirring for 18 hrs at - 38 -

room temperature the mixture was washed with water (250 ml), 1 M aqueous HCl, and dried over anhydrous sodium sulphate. Evaporation in vacuum left solid 3-phenylacrylic acid 4-bromophenyl ester (121.0 g, 99.8% yield), m.p. 113.3°C, tlc: (1) 0.83. NMR(CDCl<sub>3</sub>): 116.85, 118.87, 123.49, 128.38, 129.06, 130.90, 132.49, 134.02, 147.07, 149.84, 165.06.

## (±)-6-Bromo-4-phenylchroman-2-one

A portion of the ester (60.0 g) was dissolved in a mixture of acetic acid (60 ml) and concentrated sulphuric acid (18 ml) and refluxed for 2 hrs. After cooling, the reaction mixture was poured into ice water and the product was isolated by extraction with ethylacetate. Evaporation of the solvent and recrystallization of the residue from boiling ethanol (150 ml) yielded 26.3 g (43.8% yield) of pure, crystalline  $(\pm)$ -6-bromo-4-phenylchroman-2-one, m.p. 117.8°C, tlc: (1) 0.67. NMR (CDCl<sub>3</sub>): 36.56, 40.51, 117.29, 118.87, 127.47, 127.89, 128.33, 129.32, 131.07, 131.79, 139.42, 150.76, 166.84.

# $(\pm)$ -3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropionic acid methyl ester

A suspension consisting of  $(\pm)$ -6-bromo-4-phenylchroman-2-one (85.0 g), anhydrous potassium carbonate (46.7 g), sodium iodide (20.5 g) and benzyl chloride (40.6 g) in methanol (350 ml) and acetone (350 ml) was refluxed for 3 hrs. After evaporation of the solvents the residue was extracted with diethyl ether (2 x 300 ml) and the extract was washed with water (2 x 200 ml) and aqueous sodium carbonate. Drying (Na<sub>2</sub>SO<sub>4</sub>) and rotoevaporation left 121.8 g (102.1% crude yield) of ( $\pm$ )-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid methyl ester as a light yellow oil, tlc: (1) 0.77; NMR (CDCl<sub>3</sub>): 39.22, 40.53, 51.63, 70.16, 113.10, 113.77, 126.46,

PCT/EP99/03212

126.92, 127.88, 128.08, 128.34, 128.45, 130.31, 130.55, 134.41, 136.44, 142.37, 154.94, 172.08.

- 39 -

(±)-3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropionic acid A solution of (1)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid methyl ester (0,391 g, 0,92 mmol) in ethanol (5 ml) was treated at 50°C with excess aqueous sodium hydroxide solution until the milky emulsion became clear. The reaction mixture was then acidified (pH 3), evaporated and extracted with dichloromethane. The organic extract was evaporated and the remaining oil was redissolved in a minimum of boiling ethanol. The precipitation formed after 18 hrs at 4°C was filtered off and dried in vacuo to yield 0,27 g (71.4%) of  $(\pm)$ -3-(2-Benzyloxy)-5-bromophenyl)-3-phenylpropionic acid, colourless crystals, m.p. 124.9°C; tlc: (1) 0.15 (starting material methyl ester 0.75); NMR (CDCl<sub>3</sub>): 39.15, 40.26, 70.25, 113.21, 113.90, 126.62, 127.27, 127.98, 128.17, 128.47, 128.54, 130.46, 130.68, 134.34, 136.45, 142.16, 154.95, 177.65. LC-MS: 412/410 (14/11%, M\*), 394/392 (15/13%), 321/319 (17/22%), 304/302 (17/21%), 259 (24%), 194 (22%), 178 (21%), 167 (65%), 152 (49%), 92 (100%). IR (KBr): 3434, 3030, 1708, 1485, 1452, 1403, 1289, 1243, 1126, 1018, 804, 735, 698, 649. Calculated for C<sub>12</sub>H<sub>19</sub>BrO<sub>3</sub> (mol-wgt. 411.30): C 64.25%, H 4.66%, Br 19.43%, O 11.67%; found: C 63.72%, H 4.70%, Br 19.75%; O 11.80%.

Alternatively, the crude reaction mixture from the above described synthesis of  $(\pm)$ -3-(2-benzyloxy-5-bromophenyl)-3phenylpropionic acid methyl ester was evaporated, redissolved in warm ethanol, and treated with excess aqueous potassium hydroxide solution. Acidification to pH 3 (conc. hydrochloric acid) and cooling to 4°C resulted in the formation of a solid, which was filtered off after 18 hrs, washed repeatedly

with water and dried to yield (t)-3-(2-benzyloxy-5-bromo-phenyl)-3-phenylpropionic acid in 82% yield.

40

a) Resolution of 3-(2-benzyloxy-5-bromophenyl)-3phenylpropionic acid

R-(-)-3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropionic acid Warm solutions of (t)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid (815.6 g, 1.85 mol) and 15,2R-(+)-ephedrine hemihydrate (232.1 g, 1.85 mol) in 2000 ml and 700 ml, respectively, of absolute ethanol were combined and then allowed to cool to 0°C. The precipitate formed was collected, washed with cold ethanol and dried in vacuum to give 553.2 g of the ephedrinium salt of the title compound (m.p. 153°C, e.e. 65% as determined by NMR and HPLC). The salt was recrystallized twice from boiling ethanol to give R-(-)-3-(2-)benzyloxy-5-bromophenyl)-3-phenylpropionic acid 1S, 2R-(+)ephedrinium salt in 75% yield, colourless crystalls, m.p. 158.6°C, e.e. 97.6% (HPLC). NMR (CDCl<sub>3</sub>): 9.53, 30.90, 41.54, 42.83, 61.45, 70.15, 70.42, 113.05, 113.68, 125.89, 126.03, 127.33, 127.85, 128.19, 128.28, 128.45, 129.86, 130.70, 135.91, 136.65, 140.40, 144.09, 155.20, 178.94.

1.2 g (2.0 mmol) of the ephedrinium salt were dissolved in a mixture of acetone (5 ml) and ethanol (10 ml). After treatment with water (0.4 ml) and conc. (37%) aqueous hydrochloric acid (0.34 ml), the solution was evaporated in vacuum, and the residue was redissolved in 1M aqueous hydrochloric acid (2 ml) and dichloromethane (10 ml). The organic phase was separated, washed twice with water (2 ml), and evaporated to dryness to give R-(-)-3-(2-Benzyloxy-5-bromophenyl)-3-phenyl-propionic acid as a colourless oil which slowly solidified (0.4 g, 98% yield), m.p. 105.6°C (from ethyl acetate/n-

ί.

4,

heptane); tlc: (7) 0.21;  $[\alpha]_{D}^{20} = -21.1$  (c = 1.0, ethanol), e.e. 99.9% (HPLC). NMR: identical with the racemic acid.

41

S-(+)-3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropionic acid The combined mother liquids from the above resolution and recrystallizations were treated under stirring and cooling (18°C) with excess conc. aqueous hydrochloric acid. The precipitate (ephedrin:um hydrochloride) was filtered off, and the filtrate was evaporated to dryness. The residue was redissolved in dichloromethane (1.5 litre) and then washed with several portions of 1 M aqueous hydrochloric acid followed by water. After drying (Na<sub>2</sub>SO<sub>4</sub>), filtration, and evaporation 479 g of crude S-(+)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid were obtained as a yellow viscous oil. The pure S-(+) enantiomeric acid was converted into the 1R,2S-(-)-ephedrine salt as described above for the R-(-) acid. Two recrystallizations from boiling ethanol provided colourless crystals of S-(+)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid 1R, 2S-(-)-ephedrinium salt in 83% yield, m.p. 158.7°C, e.e. 97.8% (HPLC). NMR (CDCl<sub>3</sub>): 9.47, 30.85, 41.54, 42.92, 61.48, 70.13, 70.30, 113.04, 113.66, 125.89, 126.01, 127.32, 127.84, 128.18, 128.44, 129.83, 130.68, 135.94, 136.63, 140.44, 144.13, 155.19, 178.94.

S-(+)-3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropionic acidwas obtained in quantitative yield from this ephedrinium saltby the method described above for the R-(-) acid, tlc: (7) $0.20, e.e. (NMR) > 99%, mp 105.5°C; <math>[\alpha]_p^{20} = +22.6$  (c = 1.0, ethanol); NMR: identical with the racemic acid.

b) Enantioselective Synthesis of R-(-)- and S-(+)-3-(2benzyloxy-5-bromophenyl)-3-phenylpropionic acid

42



## 2-Benzyloxy-5-bromobenzaldehyde

To a solution of 0.1 mol of 5-bromo-2-benzaldehyde in THF (150 ml) was added 0.1 mol of  $K_2CO_3$  and 0.11 mol of benzyl bromide. The mixture was refluxed for 2 hrs and water (500 ml) was added. After addition of ethyl acetate (400 ml) and stirring the organic layer was washed with water, dried (sodium sulphate) and evaporated to dryness. The resulting slightly yellow solid of pure (tlc) 2-benzyloxy-5-bromobenzaldehyde was used as such in the next step.

## 3-(2-Benzyloxy-5-bromophenyl)-acrylic acid

A mixture of 2-benzyloxy-5-bromobenzaldehyde (0.10 mol), malonic acid (15.0 g), and piperidine (2.0 ml) in 150 ml of pyridine was first heated at 90°C for 90 min and subsequently refluxed for 0.5 hrs. After cooling to room temperature, the reaction was poured on a mixture of ice (1 kg) and concentrated aqueous hydrochloric acid (250 ml). The solid

PCT/EP99/03212

material that precipitated after stirring for 2 frs. was collected by suction and recrystallized from a minimum of boiling methanol.

- .43 -

3-[3-(2-Benzyloxy-5-bromophenyl)-acryloyl]-(4R)-4-phenyloxazolidin-2-one

Pivaloylchloride (7 g) was added dropwise at -30°C to a stirred solution of 3-(2-benzyloxy-5-bromophenyl)-acrylic acid (50.0 mmol) and triethylamine (15.0 ml) in 200 ml of tetrahydrofuran. After an additional hour the temperature was lowered to -50°C and (R)-2-phenyloxazolidin-2-one (9.0 g) and lithium chloride (2.5 g) were added in one portion. The cooling bath was then memoved and stirring was continued over 18 hrs. The reaction was diluted with water and 3-[3-(2-benzyloxy-5-bromophenyl)-acryloyl]-(4R)-4-phenyloxazolidin-2-one was isolated by extraction with ethyl acetate.

# 3-[3-(2-Benzyloxy-5-bromophenyl)-(38)-3-phenylpropionyl]-(4R)-4-phenyloxazolidin-2-one

To a precooled (-30°C) mixture of copper-(I) chloride (21.0 g) and dimethylsulfide (45 ml) in dry tetranydrofuran (150 ml) was added dropwise an ethereal solution of phenylmagnesiumbromide (0.3 mol). The mixture was stirred 20 min at the same temperature and then cooled to -40°C. A solution of 3-[3-(2-Benzyloxy-5-bromophenyl)-acryloyl]-(4R)-4-phenyloxazolidin-2-one (50.0 mmol) in dry tetrahydrofuran (150 ml) was added during 10 min. The cooling bath was removed and stirring was continued for 18 hrs. The mixture was quenched with half-saturated aqueous ammonium chloride solution and the product was isolated by extraction with ethyl acetate.

S- (+) -3- (2-Benzyloxy-5-bromophenyl)-3-phenylpropionic acid A solution of the above described 3-[3-(2-benzyloxy-5-bromophenyl)-(3S)-3-phenylpropionyl]-(4R)-4-phenyloxazolidin-2-one in tetrahydrofuran (300 ml) and water (100 ml) was cooled to 0°C and then treated with 30% aqueous hydrogen peroxide (20 ml) followed by solid lithium hydroxide (4.3 g). Water was added after 2 hrs and the chiral auxiliary was removed by extraction with ethyl acetate. The aqueous phase was acidified with aqueous hydrochloric acid (10%) and crude S-(+)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid was extracted with tert.-butyl-methylether.

HPLC analysis (Chiralpak AD, mobile phase hexane/2-propanol/trifluoro acetic acid [92:8:0.1, vol/vol-%); flow 1.0 ml/min, detection 285 nm) indicated an enantiomeric ratio 93:7 (retention times 14.8 min and 11.5 min, respectively). The e.e. of 86% of the S-(+) enantiomer can be improved to >98.5% by recrystallization of the diastereomeric salts using "nitromix" (Angew. Chem. Int. Ed. Engl. 1998, Vol. 37, p. 2349) or (1R,2S)-(-)-ephedrine hemihydrate as described above. The S-(+)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid was isolated after acidification of aqueous solutions of the diastereomeric salts. It forms colourless crystals which gave an optical rotation of  $[\alpha]_{D}^{22} = +21.6$ (c = 0.5, MeOH).

R-(-)-3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropionic acid Conjugate organocuprate addition of phenylmagnesiumbromide to 3-[3-(2-benzyloxy-5-bromophenyl)-acryloyl]-(45)-4-phenoyloxazolidin-2-one as described above for the S-(+)enantiomer gave crystalline R-(-)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid in an e.e. of 99.6% after two recrystalliza-

PCT/EP99/03212

tions,  $[\alpha]_{p}^{22} = -21.7$  (c = 0.5, MeOH).

c) Synthesis of the R- and S- Enantiomers of Intermediate B

(1) Phenylpropanol Route

(±)-3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropan-1-ol A solution of the methyl( $\pm$ )-propionate (121.0 g) in 350 ml of dry tetrahydrofuran was slowly added under an atmosphere of nitrogen to a suspension of lithium aluminiumhydride (7.9 g) in tetrahydrofuran (350 ml). After stirring at room temperature for 18 hrs, 20% aqueous HCl was added dropwise and the product was isolated by repeated extraction with diethyl ether. The combined extracts were gradually washed with hydrochloric acid, sodium hydroxide solution, distilled water, and then dried  $(Na_2SO_4)$  to give a light yellow viscous oil (108.8 g, 96.3% yield) after evaporation which gradually crystallized, m.p. 73.8°C, tlc: (1) 0.47, (±)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropan-1-ol. NMR (CDCl<sub>3</sub>): 37.52, 39.52, 60.84, 70.54, 113.54, 113.83, 126.29, 127.30, 127.51, 129.99, 128.24, 128.38, 129.99, 130.88, 135.69, 136.40, 143.53, 155.12.

The same product was obtained after reduction of  $(\pm)$ -3-(2benzyloxy-5-bromophenyl)-3-phenylpropionic acid with lithium aluminium hydride in tetrahydrofuran (30 min, 25°C), 31% yield.

(±)-Toluene-4-sulphonic acid 3-(2-benzyloxy-5-bromophenyl)-3phenylpropyl ester

46

A cooled (5°C) solution of  $(\pm)$ -3-(2-benzyloxy-5-bromophenyl)-3-phenylpropan-1-ol (108.0 g) in dichloromethane (300 ml) was treated with pyridine (79.4 ml) and then p-toluenesulphonyl chloride (60.6 g) in dichloromethane (200 ml). After 18 hrs. at room temperature the solvent was removed in vacuum and the residue was extracted with diethyl ether. The extract was washed with hydrochloric acid, water, and dried over anhydrous sodium sulphate to give ( $\pm$ )-toluene-4-sulphonic acid 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl ester as a light yellow oil after concentration under reduced pressure (140.3 g, 93.6% yield), tlc: (1) 0.66. NMR (CDCl<sub>3</sub>): 21.67, 33.67, 39.69, 68.58, 70.28, 113.21, 113.76, 126.47, 127.84, 128.10, 128.25, 128.41, 128.51, 129.81, 130.26, 130.42, 132.91, 134.39, 136.41, 142.16, 155.07.

# (±)-[3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropyl]-diisopropylamine

A solution of the  $(\pm)$ -toluenesulphonate  $((\pm)$ -toluene-4-sulphonic acid 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl ester, 139.3 g) in acetonitrile (230 ml) and N,N-diisopropylamine (256 g) was refluxed for 97 hrs. The reaction mixture was then evaporated to dryness and the residue thus formed was partitioned between diethyl ether (500 ml) and aqueous sodium hydroxide (2 M, 240 ml). The organic phase was washed twice with water (250 ml) and then extracted with 1 M sulphuric acid. The aqueous phase was adjusted to about pH 12-13 and reextracted with ether (500 ml). The organic phase was washed with water, dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated to provide  $(\pm)$ -[3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl]diisopropylamine as a brown and viscous syrup (94.5 g, 77.9\*

PCT/EP99/03212

WO 99/58478

- 47 -

yield), tlc: (2) 0.49. NMR (CDCl<sub>3</sub>): 20.65, 20.70, 36.70, 41.58, 43.78, 48.77, 70.24, 113.52, 126.02, 127.96, 128.20, 128.36, 129.82, 130.69, 136.34, 136.76, 144.20, 155.15.

(ii) Phenylpropionamide Route



# S-(+)-3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropionyl chloride

Thionylchloride (4.5 g, 2.8 ml, 37.8 mmol) and some drops of dimethylformamide were added to a solution of  $S-(+)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid (10.3 g, 25 mmol) in ethyl acetate (60 ml). The mixture was refluxed until tlc control indicated complete consumption of the starting material (2 hrs). Evaporation in vacuum gave the acid chloride as a light yellow liquid in almost quantitative yield (10.7 g). Conversion of an aliquot to the methyl ester showed a single spot in tlc (<math>R_f$  0.54, solvent system (7)).

# S-(+)-N,N-Diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3phenylpropionamide

A solution of S-(+)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionyl chloride (9.6 g, 22.3 mmol) in ethyl acetate (40 ml) was added dropwise to a stirred and cooled (3°C) solution of diisopropylamine (6.4 g, 49.0 mmol) in 60 ml of ethyl acetate. The reaction was stirred for 18 hrs at room temper-

#### PCT/EP99/03212

#### WO 99/58478

ature and then washed with water, aqueous hydrochloric acid (1 M) and half saturated brine. The organic phase was dried (sodium sulphate) and evaporated to dryness. The colourless oily residue (10.7 g, 97% yield) of S-(+)-N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionamide showed a single spot on tlc: ( $R_f$  0.70 (4)). NMR (CDCl<sub>3</sub>): 18.42, 20.46, 20.63, 20.98, 39.51, 41.44, 45.76, 48.63, 70.00, 112.84, 113.64, 126.10, 126.45, 127.34, 127.78, 128.20, 128.36. 129.93, 130.59, 135.18, 136.52, 143.52, 155.17, 169.61.

# (±)-N,N-Diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionamide

The amide was prepared from diisopropylamine and the racemic acid chloride as described above for the S-(+) enantiomer. The viscous colourless oil was dissolved in ethanol and the solution stored at -30°C. From this solution colourless crystals were obtained, m.p. 101.8°C.

# (±)-[3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropyl]-diisopropylamine

To a stirred solution of  $(\pm)$ -N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionamide (11.8 g) in 40 ml of dry tetrahydrofuran was added 1 M lithium aluminium hydride/tetrahydrofuran (36 ml). The reaction was refluxed for 4 hrs and then quenched with the dropwise addition of water. After removal of the precipitate the solvent was evaporated and the oily residue dissolved in diluted sulphuric acid. The aqueous phase was washed several times with diethyl ether, adjusted to pH 10-12 (aqueous NaOH), and extracted with diethyl ether. The extract was dried (sodium sulphate), filtered and evaporated to dryness in vacuum to leave 8.1 g (76.7%) of the title compound as a viscous colourless oil, tlc:(4) 0.86. The NMR spectrum corresponds to the product, obtained from the

#### •

PCT/EP99/03212

#### WO 99/58478

tosylate precursor (see above).

S-(+)-[3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropyl]-diisopropylamine

Repetition of the reaction sequence by using S-(+)-3-(2benzyloxy-5-bromophenyl)-3-phenylpropionic acid as the starting material gave S-(+)-[3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropyl]-diisopropylamine as a viscous colourless oil,  $[\alpha]_{p}^{22} = +18.5$  (c = 10.0, ethanol), e.e. of a representative batch 99.4%

R-(-)-[3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropyl]-diisopropylamine

Repetition of the reaction sequence by using R-(-)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid as the starting material gave <math>R-(-)-[3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropyl]-diisopropylamine as a viscous colourless oil, $<math>[\alpha]_{p}^{22} = -17.3$  (c = 10.0, ethanol), e.e. of a representative batch 98.3%.

The optical purities were determined by chiral HPLC using Chiralpak OD columns.

(±)-4-Benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzoic acid hydrochloride

An ethereal Grignard solution, prepared from the above  $(\pm)$ amine (22.8 g), ethyl bromide (17.4 g) and magnesium (6.1 g) under an atmosphere of nitrogen was diluted with dry tetrahydrofuran (200 ml) and then cooled to -60°C. Powdered solid carbon dioxide (ca. 50 g) was then added in small portions and the green reaction mixture was warmed to room temperature. After the addition of an aqueous solution of ammonium chloride (200 ml, 10%) and adjustment of the aqueous phase to

# - 50 - <sub>18</sub> 19 42

pH 0.95, a white solid was recovered by filtration to provide (±)-4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzoic acid hydrochloride (14.7 g, 64.3% yield), m.p. 140°C (dec.), tlc: (2) 0.33. NMR (CD<sub>3</sub>OD): 17.07, 18.77, 33.55, 43.27, 56.50, 71.50, 112.89, 124.10, 127.94, 129.07, 129.25, 129.34, 129.59, 129.66, 130.18, 131.60, 132.78, 137.60, 143.30, 161.11, 169.70.

(±) - [4-Benzyloxy-3-(3-diisopropylamino-1-phenylpropyl) - phenyl]-methanol

# Intermediate A (n = 1)

The (±)-hydrochloride was converted into its methyl ester (MeOH, trace sulphuric acid, 6h reflux) and the free oily base thus obtained (28 g; tlc (2): R; 0.46) was dissolved in dry diethyl ether (230 ml). This solution was slowly (2h) dropped under a nitrogen atmosphere to a suspension of lithium aluminium hydride (1.8 g) in ether (140 ml). After stirring for 18 hrs, the reaction was quenched by the addition of water (4.7 ml). The organic phase was dried over anhydrous sodium sulphate, filtered and evaporated to dryness to provide (±)-[4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-methanol (26 g, 98.9% yield), as an oil which gradually crystallized, m.p. 86.4°C, tlc: (2) 0.32. NMR (CDCl<sub>3</sub>): 20.53, 20.61, 36.87, 41.65, 44.14, 48.82, 65.12, 70.09, 111.80, 125.77, 125.97, 126.94, 127.55, 128.08, 128.37, 128.44, 133.27, 134.05, 134.27, 137.21, 144.84.



Intermediate A

<u>}.</u>

(±) - [4-Benzyloxy-3-(3-diisopropylamino-1-phenylpropyl) - phenyl] - [C<sup>2</sup>H] methanol

51

Intermediate  $d_2$ -A (n = 2)<sup>7</sup> ···

Repetition of the above described reduction of the methylester of  $\langle \pm \rangle$ -4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzoic acid by the use of lithium aluminium deuteride gave  $\langle \pm \rangle$ -[4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-[C<sup>2</sup>H]methanol, colourless amorphous solid in 77% yield; tlc: (2) 0.33. NMR (CDCl<sub>3</sub>): 20.46, 20.55, 36.77, 41.62, 44.09, 48.77, multiplett centred at 64.96, 70.05, 111.76, 125.72, 127.34, 128.03, 128.32, 128.38, 133.15, 133.99, 137.17, 144.80, 155.52.

(±)-2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol

#### Intermediate B (n = 1)

A solution of Intermediate A (9.1 g) in methanol (100 ml) was hydrogenated over Raneynickel (4.5 g) under ambient conditions. After 5 hrs thin layer chromatography indicated complete hydrogenolysis. The catalyst was filtered off and the solution evaporated to dryness to leave an oil (6.95 g, 96.5% yield) which gradually solidified,  $(\pm)-2-(3-diisopropylamino-$ 1-phenylpropyl)-4-hydroxymethylphenol, m.p. 50°C, tlc: (2)0.15. NMR (CDCl<sub>3</sub>): 19.42, 19.83, 33.22, 39.62, 42.27, 48.27,65.19, 118.32, 126.23, 126.55, 127.47, 128.33, 132.50,144.47, 155.38.

Hydrochloride: colourless crystalls, m.p. 187-190°C (with decomposition)

# 1

PCT/EP99/03212



52

S-(-)-2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol

Hydrogenolysis of  $S - (-) - [4 - benzyloxy - 3 - (3 - diisopropylamino - 1 - phenylpropyl) - phenyl] - methanol (prepared from <math>S - (+) - 3 - (2 - benzyloxy - 5 - bromophenyl) - 3 - phenylpropionic acid as described for the racemic series) gave the title compound in 85% yield, colourless solid; m.p. <math>\geq 50^{\circ}$ C,  $[\alpha]_{p}^{22} = -19.8$  (c = 1.0, ethanol); NMR (CDCl<sub>3</sub>): 19.58, 19.96, 33.30, 39.52, 42.10, 48.00, 65.40, 118.58, 126.31, 126.57, 127.16, 127.54, 128.57, 132.63, 132.83, 144.55, 155.52.

S-(+) hydrochloride: colourless, non-hygroscopic solid, m.p. 186.4°C (dec,); [α]<sub>D</sub><sup>22</sup> = +6.6 (c = 0.5, water). NMR (DMSO-d<sub>6</sub>): 16.58, 18.17, 31.62, 41.37, 45.90, 54.02, 63.07, 115.18, 126.05, 126.37, 128.03, 128.45, 129.04, 133.12, 143.88, 153.77.

R-(+)-2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol

Hydrogenolysis of R-(+)-[4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-methanol (prepared from <math>R-(-)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid as described for the racemic series) gave the title compound in 87% yield,

- 53 -

colourless solid; m.p.  $\geq$  50°C,  $[\alpha]_{D}^{22} = +21.3$  (c = 1.0, ethanol).

R-(-) hydrochloride: colourless, non-hygroscopic solid, m.p. 179.8°C (dec.); [α]<sub>p</sub><sup>22</sup> = -7.2 (c = 0.5, water); NMR (DMSO-d<sub>6</sub>): 16.59, 18.19, 31.64, 41.38, 45.92, 54.07, 63.08, 115.19, 126.07, 126.39, 128.04, 128.46, 129.05, 133.13, 143.89, 153.79.

S-(+)-mandelate: m.p. 139.7°C,  $[\alpha]_{p}^{21} = +38.3$  (c = 1.0, ethanol)

(±)-2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxy-[<sup>2</sup>H<sub>2</sub>]methyl-phenol

Intermediate  $d_2$ -B (n = 2)

A stirred suspension of lithium aluminium deuteride (0.1 g, 2.38 mmol) in 5 ml of dry diethyl ether was treated during 30 min at room temperature under an atmosphere of dry nitrogen with a solution of  $(\pm)$ -4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzoic acid methyl ester (1.0 g, 2.17 mmol) in dry diethyl ether (5 ml). After an additional stirring at room temperature for 18 hrs the reaction was quenched by the dropwise addition of 0.17 ml of  ${}^{2}\text{H}_{2}\text{O}$ . The resultant precipitation was filtered off, washed with small portions of ether, and the combined organic phases were evaporated to dryness in vacuum to leave

(±) - [4-benzyloxy-3- (3-diisopropylamino-1-phenylpropyl) - phenyl] - [<sup>2</sup>H<sub>2</sub>]methanol

as slightly yellow, viscous oil which gradually crystallized, m.p. 84.1°C; tlc: (2) 0.33 (starting material 0.46), 0.725 g, 77.2% yield. NMR (CDCl<sub>3</sub>): 20.46, 20.55, 36.77, 41.62, 44.09, 48.77, multiplett centred at 64.30, 70.05, 111.76, 125.72, 125.94, 126.92, 127.34, 127.71, 128.03, 128.32, 128.38, 133.15, 133.99, 137.17, 144.80, 155.52.

# - 54 -

A solution of the above (±)-[4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-[<sup>2</sup>H<sub>2</sub>]methanol (0.129 g, 0.29 mmol) in a suspension of methanol (5 ml) and wet Raney-Nickel (0.1-0.2 g) was stirred at room temperature under an atmosphere of deuterium gas  $(^{2}H_{2})$ . After 1 hr tlc indicated complete disappearance of the starting material. The mixture was filtered, evaporated and the residue was redissolved in diethyl ether (5 ml). The solution was washed with water (2 x 5 ml), dried over sodium sulphate, filtered and evaporated to dryness to leave a pale yellow oil, 76.3 mg, in 74.6% yield, which gradually solidified to give a colourless solid of a m.p. range of 46-49°C. Tlc:(4) 0.57 (starting material 0.77). NMR (CDCl<sub>3</sub>): 19.57, 19,94, 33.33, 39.56, 42.18, 48.07, 48.43, multiplett centred at 64.61, 118.47, 126.29, 126.58, 127.55, 127.94, 128.38, 132.53, 144.53, 155.37. GC-MS (P-CI, ammonia, TMS derivative): 488.43 (100%), 489.56 (70%), 490.56 (31%), .491.57 (8%).



Intermediate d,-B

n = 2, deuterium

(±)-2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxy-[<sup>2</sup>H<sub>2</sub>]methyl-phenol Intermediate d<sub>2</sub>-B

(111)

Heck-Cuprate-Route to Intermediate B

55



PCT/EP99/03212

## N,N-Diisopropyl-acrylamide

A solution of acroyl chloride (42.2 g, 40.6 ml, 0.467 mol) in 125 ml of dichloromethane was slowly added to a cooled (0-5°C) solution of N,N-diisopropylamine in dichloromethane (500 ml). After 2 hrs the precipitated ammonium salt was filtered off and the filtrate was washed with 1M hydrochloric acid (3 x 100 ml), dried (sodium sulphate), and evaporated to dryness. N,N-diisopropyl-acrylamide was obtained as a slight yellow liquid in 48% yield and ca. 99% purity. NMR (CDCl<sub>3</sub>): 20.54, 21.25, 45.66, 48.10, 125.62, 130.70, 166.17.

(E) -N, N-Diisopropyl-3-(2-methoxy-5-methoxycarbonylphenyl)acrylamide

((E)-3-(2-Diisopropylcarbamoyl-vinyl)-4-methoxybenzoic acid methyl ester)

The reaction was carried out under an atmosphere of dry and oxygen-free nitrogen gas. All solvents and reagents were

dried before use.

A stirred suspension consisting of N,N-dimethylglycine (6.0 mmol), anhydrous sodium acetate (40 mmol), methyl 3-bromo-4methoxybenzoate (20 mmol, 4.90 g), N, N-diisopropylacrylamide (24 mmol, 3.72 g), bis-(benzonitrile)-palladium-II chloride (1.5 mol%), and 20 ml of N-methyl-2-pyrrolidinone was heated at 130°C until no starting material could be detected by tlc (starting material methyl 3-bromo-4-methoxybenzoate: R, 0.73; N,N-diisopropylacrylamide: Rf 0.46; solvent system (1)). After cooling to room temperature 50 ml of an aqueous 2N HCl solution was added. The reaction was diluted with dichloromethane (50 ml) and the precipitated grey palladium metal was filtered off. The organic phase was washed with five portions (50 ml each) of 2N aqueous hydrochloric acid, dried  $(MgSO_4)$ and evaporated to dryness. The remaining off-white solid was recrystallized from ethyl acetate/n-hexane to give 4.40 g (E) -N, N-diisopropyl-3-(2-methoxy-5-methoxycarbonylphenyl) acrylamide in 69% yield, m.p. 139-140°C, tlc: (1) Rf 0.40. NMR (CD<sub>2</sub>Cl<sub>2</sub>): 21.22, 22.10, 46.39, 48.87, 52.59, 56.61, 111.42, 123.39, 123.78, 125.54, 130.32, 132.53, 135.07. MS (EI, DI, 105°C): 319 (M<sup>+.</sup>, 22), 304 (6%), 276 (8%), 219 (100%), 187 (18%), 160 (7%).

56 -

(±)-N,N-Diisopropyl-3-(2-methoxy-5-methoxycarbonylphenyl)-3phenylpropionamide

 $((\pm)-3-(2-Diisopropylcarbamoyl-1-phenylethyl)-4-methoxy$ benzoic acid methyl ester)

The reaction was carried out under an atmosphere of dry and oxygen-free nitrogen gas. All solvents and reagents were dried before use.

A dark green solution of lithium diphenylcuprate was prepared by addition of phenyllithium solution (12 ml, 24 mmol, cyclo-

hexane/diethyl ether) to a cooled (0°C) and stirred suspension of copper-I bromide dimethylsulphide adduct (2.71 g, 13 mmol) in diethyl ether (40 ml). This solution was cooled to -78°C and then subsequently solutions were added of trimethylchlorosilane (1.5 ml, 12 mmol) in diethyl ether (5 ml) followed by the above cinnamide (3.19 g, 10.0 mmol, (E)-N,Ndiisopropyl-3-(2-methoxy-5-methoxycarbonylphenyl)-acrylamide) in 10 ml of tetrahydrofuran. The reaction was stirred for one hour at -78°C, warmed to room temperature and then quenched by the addition of 150 ml of a saturated aqueous solution of ammonium chloride. After 90 min the organic phase was washed with two portions (100 ml) of half saturated aqueous sodium chloride, dried (MgSO<sub>4</sub>) and evaporated to dryness. The yellow oily residue was dissolved in a minimum of ethyl acetate and purified by column chromatography on silica gel (mobile phase (1)). Evaporation of the combined fractions of the title compound gave

- 57 -

(±)-N,N-diisopropy1-3-(2-methoxy-5-methoxycarbonylphenyl)-3phenylpropionamide

as a viscous slightly yellow syrup (1.8 g, 44% yield). NMR (CD<sub>2</sub>Cl<sub>2</sub>): 19.45, 19.56, 19.74, 38.86, 44.87, 47.92, 50.80, 54.76, 109.41, 121.32, 125.53, 128.10, 128.43, 128.78, 132.03, 143.20, 159.95, 165.95, 168.87. MS (EI, DI, 105°C): 397 (M<sup>+</sup>, 41%), 366 (5%), 322 (2%), 269 (3%), 255 (14%), 237 (7%), 165 (5%), 128 (12%), 91 (43%), 58 (100%).

(±)-2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol

A solution of  $(\pm)$ -N,N-diisopropyl-3-(2-methoxy-5-methoxycarbonylphenyl)-3-phenylpropionamide (0.79 g, 2.0 mmol) in 20 ml of tetrahydrofuran was cooled to 5°C and then treated with 2.5 ml of 1M LiAlH<sub>4</sub>/THF. After stirring at room tem-

perature for 18 hrs. finely powdered aluminium chloride (0.3 g) was added and stirring was continued for additional 4 hrs. The reaction was guenched at 5°C by the dropwise addition of water followed by aqueous sodium hydroxide solution. The mixture was diluted with diethyl ether (150 ml) and the organic phase was washed with half saturated brine, dried (sodium sulphate), and evaporated to dryness to give the title compound as a solid off-white foam. Tlc (2) 0.16, m.p. 48-51°C. A portion of the material was converted into the hydrochloride (ethereal hydrochloric acid), m.p. 186-189°C (dec.).

- 58

# Hydrogenolytic Decxygenation of S-(-)-2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol

A mixture of  $S_{-}(-)_{-2} - (3$ -Diisopropylamino-1-phenylpropyl)-4hydroxymethylphenol (683 mg, 2.0 mmol,  $\{\alpha\}_{D}^{22} = -19.8$  (c = 1.0, ethanol)), platinium-on-carbon catalyst (120 mg) and acetic acid (1.0 ml) was diluted with ethyl acetate (50 ml) and then hydrogenated at room temperature under a pressure of 4 bar hydrogen gas for 5 hrs. The catalyst was filtered off and the filtrate was evaporated to leave an oil. The residue was redissolved in dichloromethane (25 ml) and the solution was washed with aqueous sodium hydrogencarbonate solution. The organic phase was concentrated to dryness and the oily residue taken up in ethanol (7 ml). Addition of D-(-)-tartaric acid (300 mg) and storage of the clear solution at -25°C gave colourless crystals (310 mg) of S-(-)-2-(3-diisopropylamino-1-phenylpropyl)-4-methylphenol D-(-) hydrogentartrate

in 33% yield, tlc: (4): 0.66 (starting material 0.31),  $[\alpha]_{D}^{22}$ = -26.7 (c = 1.0, methanol). NMR (CD<sub>3</sub>OD): 17.98, 18.37, 20.69, 33.68, 43.12, 56.33, 74.17, 116.31, 127.51, 129.11, 129.50, 129.70, 129.89, 130.41, 144.57, 153.67, 176.88.

A portion of the tartrate was treated with aqueous sodium hydrogencarbonate solution and the free base was isolated in quantitative yield as a colourless oil by extraction with ethyl acetate and evaporation of the extract.  $[\alpha]_{D}^{22} = -26.3$  (c = 1.0, methanol).

59

Preferred intermediates in the processes for the preparation of the 3,3-diphenylpropylamines according to the present invention are:

 $(\pm)$ -3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropanoic acid and its salts,

R-(-)-(2-Benzyloxy-5-bromophenyl)-3-phenylpropanoic acid and its salts,

S-(+)-(2-Benzyloxy-5-bromophenyl)-3-phenylpropanoic acid and its salts,

(±) -2-(3-Diisopropylamino-1-phenylpropyl) -4-hydroxy-[C<sup>2</sup>H<sub>2</sub>]methyl-phenol,

S-(-)-2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxy-[ $C^{2}H_{2}$ ]methyl-phenol,

R-(+)-2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxy- $[C^{2}H_{2}]$ methyl-phenol and their salts.

# 3. Examples

a) Phenolic monoesters

aa) General procedure

Esters of Carboxylic Acids

A stirred solution of (±)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol (Intermediate B, 1.71 g, 5.01 mmol) and acid chloride (5.00 mmol carboxylic acid monochloride for compounds of formula II, 2.50 mmol for compounds

of formula II') in 60 ml of dichloromethane was cooled to  $0^{\circ}$ C and then triethylamine (0.502 g, 4.96 mmol for compounds of formula II, 1.05 g, 9.92 mmol for compounds of formula II'), dissolved in 10 ml of dichloromethane, was added dropwise during 5-10 min. Stirring was continued for 18 hrs at room temperature, and then the mixture was washed successively with water (25 ml), aqueous sodium hydrogen carbonate (5%, 25 ml), and water (25 ml). The organic phase was then dried (sodium sulphate) and evaporated under reduced pressure and at low temperature. The oily residues thus formed were finally exposed to high vacuum (2-4 hrs.) to remove traces of residual solvents.

60

The esters of formula II or II' were obtained as colourless to light yellow solids or viscous syrups in purities between 90% and 99% (tlc, HPLC, NMR).

 $\hat{p}$ 

# Esters of N-Acylamino Acids

# Phenolic Monoesters

To a solution of the respective amino acid (2.0 mmol) in 0.7 ml to 5 ml of N,N-dimethylformamide and 0.5 ml of triethylamine was added at 5°C in one portion methyl chloroformate (2.0 mmol, 288 mg). After stirring for 2 hrs. at the same temperature the cooling bath was removed and a solution of Intermediate B (2.0 mmol, 682 mg) in 5 ml of dichloromethane and triethylamine (0.5 ml) was added. The reaction was allowed to stir for 2-8 hrs and then diluted with diethyl ether (70 ml). Solid precipitates were filtered off and the mixture was washed with aqueous sodium hydrogen sulphate solution (5%) and water. After drying (sodium sulphate), filtration and evaporation in vacuum the residue was purified by flash chromatography on silica gel (eluent: solvent system (4)). Nacylamino acid esters were obtained as viscous oils or waxy solids in yields between 24% and 73%.

PCT/EP99/03212

#### WO 99/58478

#### bb) Salt formation (Example hydrochloride)

A cooled (0°C) solution of 4.94 mmol amino base in 30 ml of dry diethyl ether was treated under an atmosphere of nitrogen with 4.70 mmol (monoamines of formula II) or 9.4 mmol (diamines of formula II') ethereal (1 M) hydrochloric acid. The oily precipitation was washed repeatedly with dry ether and then evaporated in high vacuum. The residual product solidificated in most cases as an amorphous foam. The highly hygroscopic solids show a wide melting range above 100°C (with decomposition).

61

The following compounds were prepared according to the method described above and their analytical data are listed below:

(±)-Acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester, tlc: R<sub>f</sub> 0.47 (4), NMR (CDCl<sub>3</sub>): 20.36, 20.68, 20.97, 36.59, 42.35, 43.83, 48.76, 64.58, 122.69, 125.61, 126.22, 126.71, 127.96, 128.34, 136.82, 138.97, 143.73, 147.77, 169.24; GC-MS/P-CI (ammonia, trimethylsilyl derivative): 456.8 (100%), 398.4 (4%)

(±) -Propionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester, tlc: R<sub>f</sub> 0.52 (4); NMR (CDCl<sub>3</sub>): 20.44, 20.64, 27.67, 36.67, 42.21, 43.87, 48.78, 64.70, 122.71, 125.62, 126.52, 126.78, 127.97, 128.53, 136.86, 138.82, 143.82, 147.86, 172.68; GC-MS/P-CI (ammonia, trimethylsilyl derivative): 470.38 (100%), 398.4 (4%)

(±)-n-Butyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester, tlc:  $R_f$  0.43 (4); NMR (CDCl<sub>3</sub>): 13.77, 18.40, 20.43, 20.51, 20.59, 36.15, 36.82, 42.16,
#### PCT/EP99/03212

#### - 62 -

43.90, 48.83, 49.20, 64.58, 122.66, 125.98, 126.17, 126.74, 127.33, 127.94, 128.33, 136.79, 138.91, 143.82, 171.88; GC-MS/N-Cl (methane, trimethylsilyl derivative): 482.3 (20%), 412.3 (100%), 340.1 (33%), 298.1 (89%), 234.7 (15%); GC-MS/P-Cl (methane, trimethylsilyl derivative): 484.5 (100%), 468.4 (62%), 394.3 (22%); GC-MS/P-CI (ammonia, trimethylsilyl derivative): 484.4 (100%), 398.4 (3%)

(f)-Isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester, tlc: Rf 0.43 (4); NMR (CDCl<sub>3</sub>): 18.99, 19.11, 20.54, 34.21, 36.88, 41.84, 43.91, 48.78, 64.61, 122.54, 125.57, 126.14, 126.81, 127.94, 128.34, 136.84, 138.84, 143.89, 147.85, 175.36

R-(+)-Isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester

Tlc: R<sub>f</sub> 0.38 (4), starting material: 0.26; colourless oil (yield 95%); NMR (CDCl<sub>3</sub>): 19.02, 19.14, 19.96, 20.61, 34.26, 36.92, 41.87, 43.90, 48.80, 64.84, 122.63, 122.63, 125.64, 126.19, 126.92, 127.98, 128.39, 136.96, 138,76, 143.93, 147.97, 175.39.

Hydrochloride: colourless hygroscopic solid; [α]<sub>p</sub><sup>20</sup> = +5.5 (c = 1.0, chloroform); NMR (CDCl<sub>3</sub>): 17.03, 17.53, 18.30, 18.52, 18.95, 19.12, 31.23, 34.10, 41.69, 45.40, 54.22, 54.47, 64.00, 122.32, 126.62, 126.81, 127.40, 128.06, 128.70, 133.88, 140.64, 142.25, 147.81, 175.89.

(t)-2,2-Dimethylpropionic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester, tlc: R<sub>f</sub> 0.49 (1); NMR (CDCl<sub>3</sub>): 20.45, 20.66, 26.53, 27.34, 37.12, 39.21, 41.46, 43.98, 48.81, 64.65, 122.42, 125.58, 126.16, 126.92, 128.37, 134.27, 136.92, 138.82, 143.97, 148.02, 176.97; GC-MS/P-CI

(ammonia, trimethylsilyl derivative): 498.8 (100%), 482.5 (10%), 398.4 (4%)

- 63 -

(±)-2-Acetamidoacetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester ((±)-2-[Diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-(acetylamino)acetate) NMR (CD<sub>3</sub>OD): 20.33, 20.61, 22.17, 30.54, 42.39, 48.62, 51.04, 64.88, 117.99, 124.73, 125.51, 127.01, 127.75, 129.31, 131.63, 137.33, 146.67, 147.43, 171.47, 173,82

(f)-Cyclopentanecarboxylic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester Tlc: R<sub>f</sub> 0.66 (4), starting material Intermediate B (0.50), colourless oil, yield: 82%. NMR (CDCl<sub>3</sub>): 20.42, 25.87, 30.25, 36.57, 41.89, 43.97, 47.15, 49.02, 64.63, 122.56, 125.60, 126.16, 126.81, 127.60, 127.94, 128.35, 128.77, 136.74, 138.88, 143.85, 147.92, 175.05.

(±)-Cyclohexanecarboxylic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester Tlc: R<sub>f</sub> 0.67 (4), starting material Intermediate B (0.50), colourless oil, yield: 93%. NMR (CDCl<sub>3</sub>): 20.27, 25.40, 25.74, 29.03, 29.16, 36.29, 41.82, 43.31, 44.08, 49.36, 64.62, 122.56, 125.68, 126.22, 126.92, 127.92, 128.38, 136.65,

W R LA P

139.00, 143.72, 147.86, 174.40. (±)-Benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hy-

droxymethylphenyl ester 👘 🗤

Tlc: R<sub>f</sub> 0.31 (4); colourless syrup (99% yield, purity >
95%);gradually crystallized upon refrigeration; NMR (CDCl<sub>3</sub>):
20.41, 20.51, 36.65, 42.42, 43.85, 48.79, 64.70, 122.79,
125.74, 126.17, 126.83, 128.13, 128.28, 128.58, 129.48,
130.25, 133.62, 137.21, 139.10, 143.67, 148.00, 164.99.

PCT/EP99/03212

R-(+)-Benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester tlc R<sub>f</sub> 0.30 (4); colourless syrup

- 64 -

Hydrochloride: colourless amorphous solid;  $[\alpha]_{p}^{20} = +14.9$ (c = 1.0, chloroform); NMR (CDCl<sub>3</sub>): 17.06, 17.53, 18.25, 18.61, 31.23, 42.19, 45.49,

54.26, 54.53, 64.09, 122.55, 126.77, 127.13, 127.58, 128.10, 128.50, 128.72, 128.78, 129.02, 130.17, 133.96, 134.27, 140.81, 142.13, 147.91, 165.40.

(±)-4-Methylbenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester Tlc: R<sub>f</sub> 0.30 (4), starting material Intermediate B: 0.24; yield: quantitative, viscous light yellow oil; NMR (CDCl<sub>3</sub>): 20.32, 20.50, 21.78, 36.13, 42.35, 43.98, 49.29, 64.66, 122.79, 125.81, 126.19, 126.70, 127.04, 128.30, 129.32, 129.76, 130.29, 136.94, 139.20, 143.61, 144.46, 148.04, 165.07. LC-MS: 459 (M<sup>+</sup>, 3.5%), 444 (17%), 223 (2.5%), 195 (2%), 119 (48%), 114 (100%).

(±)-2-Methylbenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester

viscous colourless oil, tlc: (4) 0.64 (starting material  $R_f$  0.51), yield 84%. NMR (CDCl<sub>3</sub>): 20.44, 20.53, 21.86, 22.01, 36.74, 42.36, 43.87, 48.81, 64.76, 122.93, 123.11, 125.71, 126.12, 126.88, 128.10, 128.48, 130.76, 131.26, 131.70, 132.03, 132.79, 137.28, 139.00, 141,73, 143.72, 148.04, 165.25. LC-MS: 459 (M<sup>\*</sup>, 21%), 444 (100%), 326 (1%), 223 (10%), 213 (6%), 195 (9%), 165 (14%), 115 (94%), 91 (99%).

### - 65 -

(±)-2-Acetoxybenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester

colourless syrup, tlc: (4) 0.47 (starting material R<sub>f</sub> 0.51), yield 82%. NMR (CDCl<sub>3</sub>): 20.39, 20.57, 20.96, 36.92, 42.29, 43.88, 48.87, 64.64, 122.39, 122.64, 124.05, 125.80, 126.11, 126.75, 128.09, 128.32, 132.23, 134.66, 137.27, 139.32, 143.64, 147.63, 151.37, 162.72, 169.73. LC-MS: 503 (M\*, 7%), 488 (59%), 446 (6%), 326 (22%), 223 (9%), 213 (9%), 195 (9%), 163 (14%), 121 (100%), 114 (88%).

(±)-1-Naphthoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester

colourless viscous oil, tlc: (4) 0.57 (starting material R<sub>f</sub> 0.51), yield 82%. NMR (CDCl<sub>3</sub>): 20.46, 20.58, 36.82, 42.46, 43.89, 48.76, 64.81, 122.98, 124.51, 125.64, 125.79, 125.98, 126.15, 126.44, 126.94, 128.12, 128.36, 128.65, 131.37, 131.82, 133.98, 134.45, 137.44, 139.08, 143.73, 148.13, 165.49. LC-MS: 495 (M<sup>\*\*</sup>, 8%), 480 (100%), 213 (7%), 165 (8%), 155 (95%), 127 (100%), 114 (90%).

 $(\pm)$ -2-Naphthoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester

colourles's slightly yellow viscous oil, tlc: (4) 0.57 (starting material R<sub>f</sub> 0.51), yield 71%. NMR (CDCl<sub>3</sub>): 20.47, 20.59, 36.71, 42.59, 43.85, 48.81, 64.82, 122.89, 126.89, 127.89, 128.19, 128.41, 128.68, 129.50, 132.03, 132.55, 135.87, 137.22, 139.08, 143.83, 148.20, 165.14. LC-MS: 495 (M<sup>+</sup>, 7%), 480 (98%), 223 (8%), 213 (6%), 195 (6%), 165 (8%), 155 (96%), 127 (100%), 114 (81%).

#### PCT/EP99/03212

#### WO 99/58478

#### - 66 -

(±)-4-Chlorobenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester

Tlc: R<sub>f</sub> 0.54 (4), starting material Intermediate B: 0.44; yield: quantitative, viscous light yellow oil; NMR (CDCl<sub>3</sub>): 20.34, 20.50, 36.41, 42.51, 43.84, 48.93, 64.66, 122.72, 125.82, 126.88, 127.27, 128.06, 128.56, 128.96, 131.60, 133.80, 136.95, 139.30, 140.16, 143.60, 147.87, 164.10. LC-MS: 479 (M<sup>+</sup>, 1.5%), 464 (10%), 223 (2%), 195 (2%), 165 (1.5%), 139 (25%), 114 (100%).

(±)-4-Methoxybenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester

Tlc: R<sub>f</sub> 0.47 (4), starting material Intermediate B: 0.42; yield: 89%, viscous light yellow oil; NMR (CDCl<sub>3</sub>): 20.31, 20.47, 36.43, 42.39, 43.90, 48.97, 55.53, 64.71, 121.79, 122.86, 125.72, 126.14, 126.79, 128.11, 128.27, 131.27, 131.77, 132.36, 132.84, 137.15, 139.01, 143.74, 148.08, 163.92, 164.71. LC-MS: 475 (M<sup>+</sup>, 3.5%), 460 (20%), 223 (2%), 195 (2%), 135 (48%), 114 (100%).

(±)-2-Methoxybenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester

Tlc:  $R_f$  0.40 (4), starting material Intermediate B: 0.42; yield: 98%, viscous light yellow oil; NMR (CDCl<sub>3</sub>): 20.29, 20.42, 36.50, 41.92, 44.02, 49.09, 55.95, 64.72, 119.10, 120.20, 122.86, 125.64, 126.10, 126.82, 128.06, 128.30, 132.38, 134.32, 137.11, 139.01, 143.87, 148.00, 159.82, 164.40. LC-MS: 475 (M<sup>+</sup>, 3.5%), 460 (18%), 223 (1%), 195 (1%), 135 (49%), 114 (100%).

PCT/EP99/03212

(±)-4-Nitrobenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester

- : 67

Tlc: R<sub>f</sub> 0.44 (4), starting material Intermediate B: 0.42; yield: 78%, viscous yellow oil which slowly solidified; m.p. 123.6°C; NMR (CDCl<sub>3</sub>): 20.47, 20.62, 36.52, 42.66, 43.70, 48.75, 64.69, 122.61, 123.72, 125.91, 126.33, 127.04, 128.02, 128.37, 131.32, 134.86, 136.83, 139.55, 143.56, 147.75, 150.93, 163.04. LC-MS: 490 (M<sup>\*</sup>, 1.5%), 475 (15%), 327 (0.8%), 223 (3%), 195 (3%), 150 (15%), 114 (100%).

(±)-2-Nitrobenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester

Tlc: R<sub>f</sub> 0.32 (4), starting material Intermediate B: 0.42; yield: 92%, viscous yellow oil which slowly solidified; NMR (CDCl<sub>3</sub>): 20.39, 20.50, 36.74, 42.14, 43.89, 48.71, 48.92, 64.59, 122.15, 123.95, 124.18, 125.89, 126.25, 127.23, 127.99, 128.39, 129.95, 132.95, 133.08, 136.72, 139.62, 143.64, 147.63, 148.15, 163.90. LC-MS: 490 (M<sup>+</sup>, 1%), 475 (11%), 327 (2.5%), 223 (2.5%), 195 (3%), 165 (3%), 150 (7%), 114 (100%).

(±)-N-Acetylglycine 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester/(±)-2-Acetamidoacetic acid 2-(3diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester ((±)-2-[Diisopropylamino-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-(acetylamino)acetate) NMR (CD<sub>3</sub>OD): 20.33, 20.61, 22.17, 30.54, 42.39, 48.62, 51.04,

64.88, 117.99, 124.73, 125.51, 127.01, 127.75, 129.31, 131.63, 137.33, 146.67, 147.43, 171,47, 173.82.

(±)-Malonic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl]ester, tlc: R<sub>f</sub> 0.38 (4); NMR (CDCl<sub>3</sub>): 20.52, 20.62, 20 69, 36.95, 41.84, 42.82, 43.89, 48.23,

64.83, 123.37, 127.36, 127.97, 128.42, 128.38, 129.06, 131.55, 137.50, 138.90, 148.23, 148.32, 160.54

(±)-Succinic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl]ester, tlc: R<sub>f</sub> 0.40 (4); NMR (CDCl<sub>3</sub>): 20.54, 20.63, 20.73, 30.69, 36.91, 41.80, 43.92, 48.20, 64.81, 122.60, 127.41, 127.93, 128.39, 129.31, 131.80, 136.73, 138.92, 143.82, 148.17, 168.01

- 68 -

(±) -Pentanedioic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl]ester, tlc: R<sub>1</sub> 0.43; NMR (CDCl<sub>3</sub>): 20.47, 20.60, 32.87, 36.93, 41.82, 43.90, 48.22, 64.81, 64.83, 122.85, 127.39, 127.99, 128.35, 129.31, 131.84, 136.98, 138.94, 143.80, 147.40, 169.05

(±)-Hexanedioic acid bis-[2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl]ester, tlc: R<sub>2</sub> 0.43; NMR (CDCl<sub>3</sub>): 20.64, 23.40, 34.37, 36.95, 41.84, 43.88, 48.25, 64.87, 122.88, 127.34, 127.97, 128.39, 129.33, 131.80, 136.99, 138.94, 143.82, 147.65, 168.72

#### b) Identical diesters

 $(\pm)$ -Identical diesters (formula III) were prepared and worked up as described above with the exception that 2.4 mmol of both triethylamine and acyl chloride (R<sup>1</sup>-COCl) were used. The physical properties were similar to the bases and salts described above.

Diesters of N-acylaminoacids were prepared as described for phenolic monoesters with the exception that an additional molar equivalent of acylating agent (mixed acid anhydride) was used.

#### PCT/EP99/03212

#### WO 99/58478

In particular, the following compounds were prepared and their analytical data are given below:

'ş

**\*** 2 7

69

(±)-Formic acid 2-(3-diisopropylamino-1-phenylpropyl)-4formyloxymethylphenyl ester, tlc:  $R_f$  0.65 (4). This diester was prepared from mixed formic acetic anhydride and Intermediate B as described for other substrates previously (F. Reber, A. Lardon, T. Reichstein, Helv. Chim. Acta 37: 45-58 [1954])

(±) -Acetic acid 4-acetoxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester, tlc: Rf 0.76 (4); GC-MS/P-CI (ammonia): 426.3 (100%), 368.3 (22%); GC-MS/P-CI (methane, trimethylsilyl derivative): 426.4 (64%), 410.3 (16%), 366.3 (100%); hydrochloride, NMR (DMSOd<sub>6</sub>) - 16.50, 16.76, 18.05, 20.94, 21.04, 27.02, 31.39, 41.28, 45.26, 53.80, 65.21, 123.39, 126.84, 127.61, 127.85, 128.70, 134.41, 135.49, 142.68, 148.20, 169.32, 170.42

(±)-Propionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4propionyloxymethylphenyl ester, tlc: R: 0.82 (4); NMR (CDCl<sub>3</sub>): 20.53, 20.73, 21.14, 27.66, 36.73, 42.10, 43.68, 48.65, 65.75, 122.65, 126.10, 127.01, 127.70, 128.34, 128.78, 133.73, 136.81, 143.76, 148.45, 172.45, 174.21; GC-MS/P-CI (ammonia): 454.8 (100%), 438.5 (9%), 382.4 (27%)

(±)-n-Butyric acid 4-n-butyryloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester, tlc: R<sub>f</sub> 0.86 (4); NMR (CDCl<sub>3</sub>): 13.70, 13.76, 18.44, 20.53, 20.69, 21.13, 36.14, 36.76, 37.09, 42.08, 43.73, 48.71, 65.64, 122.81, 125.97, 126.97, 127.92, 128.35, 128.77, 133.78, 136.99, 143.76,

...

- 70 - \* \*

148.41, 171.68, 173.40; GC-MS/P-CI (ammonia): 482.8 (100%), 396.4 (67%)

(±)-Isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4isobutyryloxymethylphenyl ester, tlc: R<sub>f</sub> 0.83 (4), NMR (CDCl<sub>3</sub>): 18.97, 19.10, 20.64, 20.67, 34.01, 34.23, 36.98, 41.72, 43.70, 48.65, 65.61, 122.50, 126.18, 126.73, 127.92, 128.13, 128.36, 133.90, 137.01, 143.85, 148.41, 175.17, 176.81; GC-MS/N-CI (methane): 480.3 (15%); GC-MS/P-CI (methane): 482.5 (63%), 466.4 (18%), 394.3 (100%)

(±)-2,2-Dimethylpropionic acid 3-(3-diisopropylamino-1phenylpropyl)-4-(2,2-dimethylpropionyloxy)-benzyl ester, Tlc: R<sub>f</sub> 0.96 (4); NMR (CDCl<sub>3</sub>): 20.44, 20.75, 27.09, 27.24, 37.18, 38.68, 39.15, 41.25, 43.66, 48.20, 65.50, 122.36, 126.32, 127.22, 127.48, 127.83, 128.29, 133.99, 136.98, 143.87, 148.37, 176.70, 178.10; GC-MS/P-CI (methane): 510.5 (76%), 494.5 (21%), 408.4 (100%)

(±)-Benzoic acid 4-benzoyloxymethyl-2-(3-diisopropylamino-1phenylpropyl)-phenyl ester, tlc: R<sub>f</sub> 0.80 (4); NMR (CDCl<sub>3</sub>): 20.62, 36.95, 41.72, 43.89, 48.23, 66.76, 122.22, 125.33, 127.36, 127.62, 127.89, 127.89, 127.97, 128.38, 129.49, 130.52, 130.64, 131.15, 131.22, 131.98, 136.38, 137.66, 143.82, 148.95, 164.77, 166.60

(+)-Benzoic acid 4-benzoyloxymethyl-2-(3-diisopropylamino-1phenylpropyl)-phenyl ester

Hydrochloride: colourless solid; tlc: (4) 0.70, [α]<sub>b</sub><sup>20</sup> = +24.2 (c = 1.0, chloroform). NMR (DMSO-d<sub>6</sub>): 16.52, 17.99, 18.06, 26.99, 31.32, 53.94, 65.98, 123.58, 127.65, 127.98, 128.62, 128.90, 129.02, 129.45, 129.71, 130.10, 133.64, 134.32, 134.55, 135.60, 142.52, 148.37, 164.53, 165.76.

#### c) Mixed diesters

Mixed diesters (formula IV) were prepared by acylation of the respective benzylic or phenolic monoesters. Working up and physical properties corresponded to the bases and salts described above.

In particular, the following compounds were prepared and their analytical data are given below:

(±) -Acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4formyloxymethylphenyl ester, tlc: R<sub>1</sub> 0.76 (4); NMR (CDCl<sub>3</sub>): 20.62, 20.91, 33.25, 42.20, 42.28, 48.23, 70.70, 122.96, 127.36, 127.97, 128.38, 128.73, 132.02, 135.41, 137.11, 143.81, 149.35, 161.34, 168.95

(±)-Benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4formyloxymethylphenyl ester, tlc: R<sub>f</sub> 0.74 (4); NMR (CDCl<sub>3</sub>): 20.60, 36.93, 41.72, 43.89, 48.23, 70.71, 122.50, 125.33, 127.30, 127.89, 127.97, 128.36, 129.57, 130.65, 131.13, 132.05, 135.41, 136.66, 143.80, 149.15, 161.35, 164.78

(t)-Benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4acetoxymethylphenyl ester Viscous colourless oil, tlc:  $R_f$  0.70 (4); NMR (CDCl<sub>3</sub>): identical with R-(+) enantiomer, see below.

R-(+)-Benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4acetoxymethylphenyl ester tlc: R<sub>f</sub> 0.70 (4) Hydrochloride: colourless non-hygroscopic solid  $[\alpha]_p^{20} =$ +27.1 (c = 1.0, chloroform). NMR (CDCl<sub>3</sub>): 17.14, 18.53,

Ľ,

PCT/EP99/03212

21.04, 31.51, 42.25, 46.27, 54.74, 65.58, 123.18, 127.07, 127.55, 127.61, 127.99, 128.80, 130.22, 134.14, 134.81, 135.27, 141.44, 148.54, 165.19, 170.81.

- 72 -

(±)-Isobutyric acid 4-acetoxymethyl-2-(3-diisopropylamino-1phenylpropyl)-phenyl ester, tlc: R<sub>f</sub> 0.77 (4); NMR (CDCl<sub>3</sub>): 18.99, 19.12, 20.65, 21.05, 34.24, 37.02, 41.79, 43.79, 48.72, 65.98, 122.75, 126.76, 127.14, 127.94, 128.39, 128.84, 133.55, 137.04, 143.84, 148.56, 170.84, 175.18

(+)-Isobutyric acid 4-acetoxymethyl-2-(3-diisopropylamino-1phenylpropyl)-phenyl ester colourless oil Hydrochloride: colourless hygroscopic solid;  $[\alpha]_{p}^{20} = +14.6$ (c = 1.0, chloroform); NMR (CDCl<sub>3</sub>): 16.89, 17.04, 18.31, 18.54, 18.92, 19.06, 20.95, 31.49, 34.07, 41.64, 46.17,

54.55, 65.49, 122.91, 126.93, 127.48, 127.83, 128.74, 134.50, 134.88, 141.61, 148.44, 170.67, 175.63.

(±)-2,2-Dimethylpropionic acid 4-acetoxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester, tlc: R<sub>f</sub> 0.80 (4); NMR (CDCl<sub>3</sub>): 20.63, 20.93, 27.19, 33.25, 37.49, 42.21, 42.25, 48.22, 67.37, 123.18, 127.36, 127.84, 128.39, 131.16, 137.34, 143.84, 148.29, 168.93, 178.40

(±)-2,2-Dimethylpropionic acid 4-acetoxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester, tlc: Rf 0.81 (4); NMR (CDCl<sub>3</sub>): 20.60, 20.79, 27.09, 36.93, 37.35, 41.85, 42.29, 48.25, 65.91, 122.36, 127.37, 127.99, 128.39, 129.38, 132.69, 136.00, 136.85, 143.80, 170.45, 176.60

#### PCT/EP99/03212

#### WO 99/58478

#### d) Benzylic monoesters

A mixture consisting of Intermediate B (80 mg, 0.23 mmol), vinyl ester (0.4 ml), tert.-butyl methylether (18 ml), and lipase enzyme (1.0 g) was gently shaken at room temperature. Benzylic formate, acetate, and n-butyrate were prepared from the corresponding vinyl ester donors using SAM I lipase (Amano Pharmaceutical Co.). Benzoylation was achieved with vinyl benzoate in the presence of Lipozym IM 20 (Novo Nordisk), whereas pivalates and isobutyrates were obtained from the corresponding vinyl esters under catalysis of Novozym SP 435 (Novo Nordisk). Tlc analysis indicated after 2 - 24 hrs complete disappearence of the starting material ( $R_f = 0.45$ (3)). The mixture was filtered and then evaporated under high vacuum (< 40°C) to give the carboxylic acid ( $R^1$ -CO<sub>2</sub>H) salts of the respective benzylic monoesters as colourless to light yellow oils.

- 73 -

In particular, the following compounds were prepared and their analytical data are given below:

(±) -Formic acid 3-(3-diisopropylamino-1-phenylpropyl)-4hydroxybenzyl ester, tlc: R<sub>f</sub> 0.25 (2); NMR (CDCl<sub>3</sub>): 19.43, 33.24, 39.61, 42.25, 48.21, 68.44, 118.09, 127.34, 127.66, 128.31, 128.39, 133.97, 144.47, 156.63, 161.32

(±) -Acetic acid 3-(3-diisopropylamino-1-phenylpropyl)-4hydroxybenzyl ester, tlc: R<sub>f</sub> 0.26 (2); NMR (CDCl<sub>3</sub>): 19.45, 20.96, 33.26, 39.63, 42.27, 48.23, 63.59, 118.00, 127.36, 128.33, 128.48, 128.53, 129.13, 131.59, 133.88, 144.49, 155.74, 170.44

PCT/EP99/03212

(±)-Propionic acid 3-(3-diisopropylamino-1-phenylpropyl)-4hydroxybenzyl ester, tlc: R<sub>f</sub> 0.45 (2); NMR (CDCl<sub>3</sub>): 19.02, 19.43, 27.58, 33.20, 39.61, 42.25, 48.21, 64.08, 118.30, 125.30, 127.03, 127.39, 128.31, 130.12, 134.22, 144.51, 155.64, 173.22

(±)-Butyric acid 3-(3-diisopropylamino-1-phenylpropyl)-4hydroxybenzyl ester, tlc: R<sub>f</sub> 0.54 (2); NMR (CDCl<sub>3</sub>): 13.58, 18.40, 19.45, 33.29, 35.88, 39.65, 42.23, 48.25, 63.96, 118.32, 124.55, 126.20, 127.35, 128.32, 129.91, 134.22, 144.50, 155.60, 169.05

(±)-Isobutyric acid 3-(3-diisopropylamino-1-phenylpropyl)-4hydroxybenzyl ester, tlc: R<sub>f</sub> 0.56 (4); NMR (CDCl<sub>3</sub>): 19.09, 19.45, 33.28, 33.59, 39.65, 42.29, 48.25, 64.63, 118.35, 125.35, 127.03, 127.38, 128.35, 128.49, 129.79, 134.22, 144.52, 155.65, 175.48

(±)-2,2-Dimethylpropionic acid 3-(3-diisopropylamino-1phenylpropyl)-4-hydroxybenzyl ester, tlc: Rf 0.61 (4); NMR (CDCl<sub>3</sub>): 19.41, 27.15, 33.24, 37.46, 39.61, 42.25, 48.21, 65.10, 118.30, 125.32, 127.00, 127.34, 128.31, 129.42, 134.18, 144.47, 155.61, 178.39

(±)-Benzoic acid 3-(3-diisopropylamino-1-phenylpropyl)-4hydroxybenzyl ester, tlc: R<sub>f</sub> 0.77 (4); NMR (CDCl<sub>3</sub>): 18.01, 19.40, 33.24, 39.60, 42.40, 48.20, 66.93, 117.13, 127.18, 127.81, 128.33, 129.98, 130.17, 132.96, 133.58, 142.33, 156.95, 166.60

e)

PCT/EP99/03212

# Ethers and silyl ethers

A mixture of Intermediate B (3.4 g, 10 mmol), methanesulphonic acid (2 ml, 31 mmol), and alcohol  $R^{10}$ -OH (50-150 ml) was stirred at room temperature until no starting material was detectable (2-24 hrs). After evaporation to dryness (< 35°C) the residue was redissolved in aqueous sodium hydrogen carbonate solution (100-200 ml, 5%, w/v) and the solution was extracted with ethyl acetate (75 ml). The organic phase was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and evaporated to give bases of formula VI ( $R^{11} = H$ ) as colourless to light yellow oils.

- 75 -

Mixed ester ether derivatives, e.g. of Intermediate A, were prepared by benzylic acylation of phenolic ethers, such as Intermediate A, according to the procedure described for examples of the structure of formula IV.

#### Hydrochlorides:

Molar equivalents of bases of formula VI  $(R^{11} = H)$ , dissolved in tert.-butyl methylether, and ethereal hydrochloric acid were combined at room temperature. Oily precipitates were separated and dried in vacuum, crystalline hydrochlorides were isolated and recrystallized from acetonitrile or acetone to give colourless crystalline material.

In particular, the following compounds were prepared and their analytical data are given below:

i 15

(±)-2-(3-Diisopropylamino-1-phenylpropyl)-4-methoxymethylphenol, tlc: R<sub>f</sub> 0.61 (4); GC-MS/P-CI (methane, trimethylsilyl

т *г* 

# File History Content Report

The following content is missing from the original file history record obtained from the United States Patent and Trademark Office. No additional information is available.

> Document Title: Specification Document Date: 2001-01-02 Page(s): 76

39.60, 42.20, 48.20, 72.45, 117.87, 125.50, 127.29, 128.39, 133.70, 134.30, 144.47, 155.36

(±) -Acetic acid 2- (3-Diisopropylamino-1-phenylpropyl)-4methoxymethylphenyl ester, NMR (CDCl<sub>3</sub>): 19.99, 20.62, 20.90, 33.33, 42.30, 48.21, 58.41, 75.94, 122.92, 127.37, 127.95, 128,35 131.85, 136.99, 138.81, 143.88, 147.88, 168.95

(*i*)-Acetic acid 2-(3-Diisopropylamino-1-phenylpropyl)-4ethoxymethylphenyl ester, NMR (CDCl<sub>3</sub>): 15.49, 19.94, 20.95, 33.23, 42.25, 48.25, 65.70, 73.73, 122.63, 127.46, 127.95, 128.36, 131.65, 136.79, 139.71, 143.80, 147.66, 168.99

(±)-2-(3-Diisopropylamino-1-phenylpropyl)-4-trimethylsilanyloxymethylphenol, NMR (CDCl<sub>3</sub>): 0.10, 19.40, 19.43, 33.25, 39.65, 42.25, 48.20, 64.93, 117.90, 124.90, 126.60, 127.35, 128.35, 128.48, 133.80, 137.15, 144.49, 155.28

(±)-Diisopropyl-[3-phenyl-3-(2-trimethylsilanyloxy-5trimethylsilanyloxymethylphenyl)-propyl]amine, NMR (CDCl<sub>3</sub>): 0.10, 0.29, 19.40, 19.53, 33.28, 41.19, 42.27, 48.25, 66.40, 121.37, 127.36, 128.25, 128.50, 136.42, 144.10, 154.98

(±)-[3-(3-Diisopropylamino-1-phenylpropyl)-4-trimethylsilanyloxyphenyl]methanol, NMR (CDCl<sub>3</sub>): 0.29, 0.33, 19.40, 19.53, 33.27, 41.16, 42.27, 48.23, 65.22, 118.04, 124.99, 126.52, 127.30, 128.25, 134.16, 136.80, 144.14, 155.06

(±)-Diisopropyl-[3-(5-methoxymethyl-2-trimethylsilanyloxyphenyl)-3-phenylpropyl]amine, NMR (CDCl<sub>3</sub>): 0.28, 0.32, 19.39, 19.43, 33.28, 41.22, 42.33, 48.19, 58.40, 75.95, 117.68, 124.92, 126.60, 127.35, 128.25, 128.55, 134.00, 136.47, 144.16, 155.09

(±) -Diisopropyl-[3-(5-ethoxymethyl-2-trimethylsilanyloxyphenyl)-3-phenylpropyl]amine, NMR (CDCl<sub>3</sub>): 0.28, 0.31, 15.50, 19.42, 19.58, 33.29, 41.17, 42.25, 48.20, 65.70, 72.48, 117.50, 124.75, 126.39, 127.39, 128.25, 128.50, 134.99, 136.28, 144.19, 154.28

78

(±) - [4-(tert.-Buty.l-dimethylsilanyloxy) -3-(3-diisopropylamino-1-phenylpropyl)-phenyl]methanol, Rf 0.65 (3)

(±)-Acetic acid 4-(tert.-butyl-dimethylsilanyloxy)-3-(3diisopropylamino-1-phenylpropyl)-benzyl ester, NMR (CDCl<sub>3</sub>): -4.92, -5.00, 19.40, 19.49, 20.40, 20.83, 23.49, 33.25, 41.22, 42.25, 48.25, 72.55, 81.55, 121.24, 124.88, 127.40, 128.26, 128.44, 128.48, 133.37, 135.74, 144.11, 155.20

(±)-4-(tert.-Butyl-dimethylsilanyloxymethyl)-2-(3-diisopropylamino-1-phenylpropyl)-phenol, tlc: R<sub>1</sub> 0.70 (3); GC-MS/N-CI (methane, trimethylsilyl derivative): 526.5 (59%), 454.3 (100%), 412.2 (14%), 340.1 (42%); GC-MS/P-CI (methane, trimethylsilyl derivative): 528.6 (100%), 512.5 (85%), 470.43 (10%), 396.3 (31%)

(±) -Acetic acid 4 - (tert.-butyl-dimethylsilanyloxy) -2 - (3diisopropylamino-l-phenylpropyl) -phenyl ester, NMR (CDCl<sub>3</sub>): -4.77, -4.88, 19.15, 20.65, 20.93, 24.77, 33.25, 42.20, 48.20, 67.90, 122.79, 125.15, 127.44, 127.90, 128.41, 136.99, 140.55, 143.85, 147.86, 168.95

(±) - {3 - [2 - (tert. - Butyl - dimethylsilanyloxy) - 5 - (tert. - butyl - dimethylsilanyloxymethyl) - phenyl] - 3 - phenylpropyl} - diisopropyl amine, tlc: R<sub>f</sub> 0.94 (3); GC-MS/N-CI (methane): 568.6 (62%), 454.3 (100%), 438.2 (10%), 340.2 (58%), 324.8 (16%), 234.7

PCT/EP99/03212

#### - 79 -

(78%); GC-MS/P-CI (methane): 570.6 (70%), 554.5 (52%), 512.5 (18%), 438.4 (24%)

(±) -Acetic acid 4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester, tlc: R<sub>f</sub> 0.56 (5); GC-MS/P-CI (ammonia): 474.4 (100%), 416.4 (54%); NMR (CDCl<sub>3</sub>): 20.44, 20.56, 21.07, 36.73, 41.53, 44.01, 48.79, 66.43, 70.00, 111.61, 125.75, 127.34, 127.55, 127.76, 127.90, 128.03, 128.27, 128.39, 133.98, 136.98, 144.63, 156.05, 170.94

(±)-Benzoic acid 4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester, tlc: R<sub>f</sub> 0.87 (4); NMR (CDCl<sub>3</sub>): 20.54, 20.60, 36.80, 41.51, 43.95, 48.67, 66.83, 70.04, 111.66, 125.76, 127.35, 127.45, 127.78, 128.06, 128.27, 128.30, 128.42, 128.85, 129.66, 130.55, 132.86, 134.05, 137.03, 144.75, 156.08, 166.46; GC-MS/P-CI (ammonia): 536.5 (100%), 416.4 (42%)

(±)-Isobutyric acid 4-benzyloxy-3-(3-diisopropylamino-1phenylpropyl)-benzyl ester, tlc: R<sub>f</sub> 0.77 (4); NMR (CDCl<sub>3</sub>): 19.01, 20.62, 20.65, 34.04, 36.85, 41.54, 43.97, 48.71, 66.15, 70.06, 111.62, 125.79, 125.96, 126.97, 127.24, 127.55, 127.81, 128.08, 128.34, 128.45, 134.05, 137.10, 144.79, 156.00, 177.01; GC-MS/P-CI (ammonia): 502.4 (100%), 416.4 (49%)

#### f) Carbamates and carbonates

#### Mono N-substituted carbamates

A solution of 4.0 mmol of Intermediate B, benzylic ether (formula VI,  $R^{11} = H$ ) or monoester of formula II in dichloromethane (20 ml) was treated at room temperature for 16 hrs with isocyanate (4.8 mmol) or diisocyanate (2.2 mmol). After

washing with 10 ml aqueous sodium hydrogen carbonate (5%, w/v), drying (Na<sub>2</sub>SO<sub>4</sub>) and evaporation oily residues or colourless solids of the free bases were obtained.

80

#### N-disubstituted carbamates

N,N-dialkyl-carbamoylchloride (4.4 mmol) was dissolved in dichloromethane and dropped into a cooled (0°C) and stirred mixture consisting of Intermediate B (4.0 mmol), dichloromethane (30 ml) and triethylamine (7.0 mmol, 0.71 mg, 1 ml). Stirring was continued for 6 hrs. The mixture was then washed with 5 portions (10 ml) of aqueous sodium hydrogen carbonate, dried (sodium sulphate), filtered and evaporated to give the carbamates as colourless oils or solids.

Bis-carbamates were prepared in like manner using Intermediate B and excess isocyanate (4.8 mmol) and toluene as solvent at 65°C over 18 hrs.

Carbonates were prepared and worked-up according to the methods described for the preparation of compounds of formulae II to IV. Alkyl chloroformates were used as acylation reagents.

#### Hydrochlorides:

The oils or solids were redissolved in tetrahydrofuran (10 ml). Addition of ethereal hydrochloric acid and evaporation to dryness in high vacuum gave crystalline or amorphous carbamate hydrochlorides.

In particular, the following compounds were prepared and their analytical data are given below:

(±) -N-Ethylcarbamic acid 2-(3-dilsopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, tlc: R<sub>f</sub> 0.38 (4); GC-MS/P-CI (ammonia, trimethylsilyl derivative): 486.8 (100%), 413.4 (5%), 398.4 (6%); hydrochloride: m.p. 64°C (with decomposition); NMR (DMSO-d<sub>6</sub>): 15.16, 16.68, 18.05, 18.13, 25.33, 31.26, 35.46, 53.94, 62.65, 67.22, 123.04, 125.70, 126.72, 127.86, 128.67, 135.42, 136.02, 140.07, 142.98, 147.53, 154.52

81

(±)-N,N-Dimethylcarbamic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester NMR (CDCl<sub>3</sub>): 20.34, 20.66, 30.51, 36.33, 36.77, 42.00, 48.28, 50.21, 65.65, 119.83, 123.44, 125.19, 126.60, 127.38, 127.54, 129.31, 136.62, 143.33, 150.99, 155.67.

(±)-N,N-Diethylcarbamic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester NMR (CDCl<sub>3</sub>): 20.54, 20.66, 30.49, 35.61, 42.42, 48.31, 50.20, 65.56, 119.43, 123.40, 125.33, 126.66, 126.99, 127.05, 136.30, 143.27, 149.13, 154.97

(±)-N-Phenylcarbamic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester; NMR (CDCl<sub>3</sub>): 20.52, 20.61, 36.91, 39.44, 42.25, 48.22, 62.66, 118.36, 119.46, 123.50, 125.32, 127.11, 127.99, 130.15, 132.63, 139.65, 141.33, 145.16, 152.21, 156.00

(±) - [2-(3-Diisopropylamino-1-phenylpropyl) - 4-hydroxymethylphenoxycarbonylamino]acetic acid ethyl ester hydrochloride Tlc: R<sub>f</sub> 0.14 (4); m.p. colourless crystals (from acetone, 21% yield); NMR (CDCl<sub>3</sub>): 16.76, 16.86, 18.45, 20.96, 31.37, 42.20, 46.13, 54.56, 65.50, 123.10, 126.98, 127.66, 128.72,

PCT/EP99/03212

7 - 82 -

N 6 %

130.14, 134.05, 134.72, 135.22, 141.37, 148.47, 165.12, 170.71

(±)-N-Ethylcarbamic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-N-ethylcarbamoyloxybenzyl ester, tlc: R: 0.36 (3); NMR (CDCl<sub>3</sub>): 15.00, 19.23, 19.40, 33.26, 36.00, 39.62, 42.35, 48.12, 65.95, 118.30, 125.45, 127.08, 128.33, 130.37, 134.24, 144.44, 155.44, 157.74

(±)-N,N-Dimethylcarbamic acid 3-(3-diisopropylamino-1phenylpropyl)-4-N,N-dimethylcarbamoyloxybenzyl ester NMR (CDCl<sub>3</sub>): 20.59, 20.66, 30.59, 35.96, 36.40, 36.74, 36.98, 42.03, 48.26, 50.09, 67.09, 119.04, 123.23, 123.49, 125.01, 126.67, 127.72, 129.33, 133.65, 143.43, 150.99, 155.63.

(±) -N,N-Diethylcarbamic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-N,N-diethylcarbamoyloxybenzyl ester NMR (CDCl<sub>3</sub>): 13.31, 13.64, 13.89, 20.33, 20.71, 31.57, 37.97, 41.55, 42.37, 48.46, 51.00, 67.23, 120.00, 123.39, 124.82, 126.31, 126.95, 127.33, 150.36, 157.18, 158.97.

 $(\pm) - \{4 - [2 - (3 - Diisopropylamino - 1 - phenylpropyl) - 4 - hydroxy$ methyl - phenoxycarbonylamino] - butyl - carbamic acid 2 - (3 diisopropylamino - 1 - phenylpropyl) - 4 - hydroxymethylphenyl ester(formula VII', X = Y = NH, n = 4) tlc: R<sub>f</sub> 0.60 (6);dihydrochloride m.p. 142.5 - 145.6°C

( $\pm$ )-Carbonic acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester ethyl ester, R<sub>f</sub> 0.67 (4)

( $\pm$ )-Carbonic acid 2-(3-diisopropylamino-1-phenylpropyl)-4ethoxycarbonyloxymethylphenyl ester ethyl ester, R<sub>f</sub> 0.87 (4)

PCT/EP99/03212

g) Intramolecular cyclic diesters via Ring Closing
 Metathesis (RCM)

83







#### Example:

(±)-Pent-4-enoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-(pent-4-encyloxymethyl)-phenyl ester (x = y = 2) A cooled (4°C) mixture of pent-4-enoic acid, isobutyl chloroformate, and triethylamine (each 5.84 mmol) in 10 ml of dichloromethane was stirred 5 hrs under an atmosphere of dry nitrogen gas. The cooling bath was then removed and both triethylamine (1.46 mmol) and 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol (1.46 mmol) were added in one portion. After 18 hrs the mixture was diluted with dichloromethane (30 ml), washed several times with water and finally aqueous 5% sodium hydrogen carbonate solution. After drying (sodium sulphate), filtration and evaporation the oily residue was re-dissolved in a small volume of a solvent mixture consisting of ethyl acetate/heptane/triethylamine (65/30/5, vol.-%) and applied on a silica gel flash chromatography column. Elution of the column with the same solvent mixture, collection of the appropriate fractions, and evaporation of the combined fractions gave (1)-pent-4-enoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-(pent-4-enoyloxy-

#### PCT/EP99/03212

#### WO 99/58478

# methyl)-phenyl ester as a pale yellow syrupy oil (50% yield),

tlc: (4) 0.75. NMR (CDCl<sub>3</sub>): 18.95, 20.77, 27.75, 28.87, 33.58, 36.83, 42.13, 43.72, 48.71, 65.85, 70.55, 115.47, 115.99, 122.45, 126.26, 127.08, 127.96, 128.11, 128.83, 133.73, 136.38, 136.79, 137.04, 143.77, 148.46, 171.11, 172.78.

# Intramolecular cyclic diesters of 1,0-dioic acids and Intermediate B

#### <u>Example</u>

Intramolecular cyclic diester of octane-1,8-dioic acid and 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol Grubbs catalyst (benzylidene-bis-(tricyclohexylphosphine)dichlororuthenium, 16 mg, 0.002 mmol, 2 mol-%) was added to a solution of (t)-pent-4-enoic acid 2-(3-diisopropylamino-1phenylpropyl)-4-(pent-4-enoyloxymethyl)-phenyl ester (483 mg, 0.96 mmol) in dichloromethane (150 ml) and the mixture was refluxed for 96 hrs. under an atmosphere of nitrogen gas, after which all of the starting material was consumed as indicated by tlc. The mixture was filtered through a short pad of basic alumina, and the solvent was removed in vacuum. Flash chromatography (solvent system (4)) afforded the intermediate intramolecular cyclic diester of oct-4-ene-1,8dioic acid and 2-(3-diisopropylamino)-1-(phenylpropyl)-4hydroxymethyl-phenol (324 mg) as a colourless syrup (tlc: (4)  $R_f$  0.68) in 71% yield, mixture of two geometrical isomers. NMR (CDCl<sub>3</sub>, major isomer): 19.24, 20.61, 23.11, 25.62, 30.55, 33.53, 35.02, 42.41, 48.29, 50.20, 65.30, 114.46, 124.33, 125.58, 127.15, 128.70, 129.29, 131.10, 132.46, 139.54, 146.76, 147.98, 173.76, 174.39.

A portion of this material (140 mg) was dissolved in ethyl acetate (10 ml) and hydrogenated at room temperature in the

# - 85 -

presence of palladium-on carbon catalyst to afford the intramolecular cyclic diester of octane-1,8-dioic acid and 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol in essentially quantitative yield, 139 mg, colourless oil, tlc: (4) 0.71.

NMR (CDCl<sub>3</sub>): 19.36, 20.73, 24.84, 25.28, 28.90, 29.70, 30.57, 33.72, 34.37, 42.39, 48.26, 50.20, 65.26, 114.45, 124.37, 127.11, 128.67, 129.29, 131.18, 132.45, 139.52, 146.77, 147.69, 173.90, 174.15.

#### Poly-co-DL-Lactides of Intermediate B

All reagents were dried over  $P_2O_5$  in vacuum (< 1 mbar) and at room temperature. The reactions were carried out at room temperature in an atmosphere of dry, oxygen-free nitrogen.

#### Low Molecular Weight Copolymer

A 15% solution of n-butyllithium (0.36 ml) was injected through a rubber septum into a stirred solution of 2-(3diisopropylamino-phenylpropyl)-4-hydroxymethyl-phenol (100 mg, Intermediate B) and DL-dilactide (1.5 g) in 15 ml of dry toluene. The polymerization was allowed to proceed for 4 days at room temperature. Distilled water (10 ml) was then added in order to terminate the polymerization. The organic phase was separated and slowly dropped into 200 ml of methanol. The precipitated colourless oil was treated with water (100 ml) and then dried in high vacuum for 48 hrs.

The copolymer was obtained in 72.7% yield. NMR analysis (see below) indicated an average molecular weight range of  $M_n$ 2000-4000 and a weight content of Intermediate B of about 8.4% (NMR). The analysis showed the absence of monomeric Intermediate B. Gel permeation chromatography (GPC) analysis showed a Mw of 1108 and a Mn of 702.

#### High Molecular Weight Copolymer

The high molecular weight copolymer was prepared as described above with the exception that 3.0 g of DL-dilactide was used. Precipitation by methanol gave a fluffy white solid which was carefully washed with water and then dried as desribed to give the copolymer in 81% yield. NMR analysis (see below) indicated an average molecular weight range of  $M_n$  4000-8000 and a weight content of Intermediate B of about 2.0%. Tlc analysis showed the absence of monomeric Intermediate B. Gel permeation chromatography (GPC) showed a Mw of 9347 and a Mn of 6981. Differential scanning calorimetry (DSC) provided a Tg of 42.5°C.

86

#### NMR Analysis

The <sup>1</sup>H NMR resonance signals of the poly-lactyl chain were clearly separated from the copolymeric part of Intermediate B (solvent CDCl<sub>3</sub>):

CH<sub>3</sub> resonances of the poly-lactyl chain: 1.30-1.60 ppm CH resonances of the poly-lactyl chain: 5.10-5.30 ppm CH resonances of the connecting lactyl units with the two hydroxy groups of Intermediate B: 4.8-5.0 ppm and 5.5-5.7 ppm.

Polymer bound Intermediate B: 1.06-1.11 (CH<sub>3</sub>), 2.20-2.30 (CH<sub>2</sub>CH<sub>2</sub>), 2.40-2.80 (NCH<sub>2</sub>), 3.30-3.50 (NCH), 4.45-4.55 (CHCH<sub>2</sub>), 4.70-4.80 (CH<sub>2</sub>-OCO-lactyl), 6.70-7.30 (aryl CH).

PCT/EP99/03212

#### h) Inorganic ester

#### Example:

(±)-Benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4sulphooxymethyl-phenyl ester Hydrochloride

87

To a stirred solution of chlorosulphonic acid (116 mg, 1.0 mmol) in 5 ml of dry diethyl ether was slowly added at 0°C a solution of  $(\pm)$ -benzoic acid 2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenyl ester (445.6 mg, 1.0 mmol) in 3 ml of dry diethyl ether. The gel formed immediately during the addition was stirred at room temperature until it became a crystalline consistency (ca. 1 hr). The precipitate was washed several times with diethyl ether and then dried in vacuum to give 0.52 g (46% yield) colourless crystals, m.p. 63-65°C. NMR (CDCl<sub>3</sub>): 16.85, 17.03, 18.32, 18.49, 32.01, 42.29, 46.23, 55.23, 55.50, 69.24, 122.52, 126.94, 127.15, 129.04, 129.76, 130.25, 133.89, 134.93, 136.85, 141.87, 147.80, 165.19.

i) Benzylic 1-0-β-D-glucuronide of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol
 ((±)-2-(3-Diisopropylamino-1-phenylpropyl)-4-(1β-D-glucuronosyloxymethyl)-phenol)



PCT/EP99/03212

A solution of methyl 2,3,4-triacetyl-1- $\alpha$ -D-glucuronosylbromide (2.07 g, 4.64 mmol) in 24 ml of dry toluene was cooled to -25°C under an atmosphere of nitrogen and then treated with a solution of  $(\pm)$ -benzoic acid 2-(3-diisopropy)amino-1-phenylpropyl)-4-hydroxymethylphenyl ester in 7 ml of toluene. To this mixture was added dropwise with stirring and under protection from light a solution of silver triflate in 14 ml of toluene (immediate formation of a white precipitate). The cooling bath was removed after 15 min and pyridine (0.38 ml) was added. The mixture was diluted with ethyl acetate (200 ml), filtered and the clear yellow filtrate was washed sequentially with aqueous solutions of sodium thiosulphate (5%), sodium hydrogen carbonate (5%), and sodium chloride (20%). The solution was dried with solid sodium sulphate, treated with charcoal, filtered and evaporated to dryness. The waxy residue was re-dissolved in a small volume of a solvent mixture consisting of ethyl acetate/heptane/triethylamine (65/30/5, vol.-%) and applied on a silica gel flash chromatography column. Elution of the column with the same solvent mixture, collection of the appropriate fractions, and evaporation of the combined fractions gave (±)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4- $(2, 3, 4-triacetyl-1\beta-D-glucuronosyloxymethyl)$ -phenyl ester, colourless syrup, tlc (4) 0.70 (starting amine: 0.31, bromo

88

glycoside: 0.23), yield 14%.

NMR (CDCl<sub>3</sub>, mixture of diastereomers): 20.41, 20.50, 20.60, 20.65, 20.84, 36.49, 42.44, 43.65, 48.73, 52.91, 69.46, 70.43, 71.12, 72.11, 72.60, 73.99, 99.19, 122.91, 126.23, 126.38, 126.54, 127.60, 127.92, 128.06, 128.09, 128.31, 128.59, 129.38, 130.22, 133.67, 134.31, 137.41, 143.52, 148.46, 164.82, 167.26, 169.21, 169.39, 170.07.

A portion (350 mg) of the above described material was dissolved and hydrolyzed in a solvent mixture consisting of tetrahydrofuran/methanol/aqueous potassium hydroxide (excess, 12 hrs, 22°C). The mixture was evaporated, re-dissolved in 5 ml of water and the pH was adjusted to 8.3. This solution was applied to a chromatography column charged with prewashed XAD 2 resin (50 g). The column was washed with water (ca. 250 ml) and then eluted with methanol. Collection of the appropriate methanol fractions, and evaporation of the combined fractions in vacuum gave 111 mg of

-:89 -

(±)-2-(3-diisopropylamino-1-phenylpropyl)-4-(1 $\beta$ -D-glucurono-syloxymethyl)-phenol, sodium salt,

amorphous colourless solid, m.p. ≅ 110-124°C (dec.), tlc (4) 0.12. NMR (CD<sub>3</sub>OD, major isomer): 19.43, 19.67, 33.26, 39.63, 42.27, 48.23, 69.76, 73.55, 74.70, 75.95, 78.03, 107.64, 117.95, 125.51, 127.36, 128.33, 133.83, 134.77, 144.49, 155.36, 176.76.

II. Incubations of different compounds of the invention with human liver S 9-fraction

a) Incubation of unlabelled substrates

A pooled human liver S 9-preparation was used to show the invitro metabolism of different compounds of the invention and to prove the generation of the active metabolite by enzymatic process.

The pooled human liver S 9-preparation was delivered by Gentest, Woburn, MA, USA.

In a routine assay, 25  $\mu$ L of pooled human liver S9 (20 mg protein/mL, H961, Gentest, Woburn, MA, USA) was incubated

# - 90 -

for 2 hrs at 37°C with 40  $\mu$ M substrate in a 0.01 M potassium phosphate buffer in the presence of NADPH (1 mM). The reaction was quenched by the addition of concentrated perchloric acid and precipitating protein was removed by centrifugation. The supernatant was adjusted to pH 3 with concentrated potassium phosphate solution, centrifuged, and injected into the HPLC for analysis of the respective products.

The analysis of the non-deuterated compounds was performed by a routine High Pressure Liquid Chromatography (HPLC) method with UV-detection.

PRETE DESCRIPTION OF THE DRAWING :

The incubation results expressed in (%) of theoretical turnover are presented in Fig. 1.

They ranged from 96 to 63.2%. The formation of the active metabolite is dependent on the substituents both at the benzylic and phenolic side of the respective compounds.

#### Explanation:

The prodrugs introduced in the assay show the following chemical structure:



chemical structure	X-/-Y	
AcO-/-OAc	means	acetate
HO-/-OBut	means	hydroxy and <u>n</u> -butyrate
HO-/-OiBut	means	hydroxy and iso-butyrate

PCT/EP99/03212

	$\tilde{P} = \sqrt{2}$	
iButO-/-OiBut	means	iso-butyrate
ButO-/-OBut	means	<u>n</u> -butyrate
Prop0-/-OProp	means	proprionate
HO-/-OProp	means	hydroxy and proprionate
HO-/-OAC	means	hydroxy and acetate
BzO-/-OBz	means	benzoate and benzoate
AcO-/-OiBut	means	acetate and isobutyrate
AcO-/-OBz	means	acetate and benzoate

91 -

b) Incubation of labelled substrates

The metabolic degradation of the unlabelled hydroxy metabolite (i.e. Intermediate B) and the deuteriated hydroxymetabolite (Intermediate  $d_2B$ ) were compared in vitro. Used were the respective enantiomers and the racemates.

The hydroxy metabolite and the deuteriated hydroxy-metabolite expressed significant differences in the rate to produce the corresponding carboxylic acid.

The measurement was performed with an incubation time of 3 hrs at 37.0°C in a concentration of 40  $\mu$ M. The formation of the carboxylic acid from the deuteriated hydroxy-metabolite showed a significantly decreased velocity of 10%.

These in-vitro experiments indicate a reduced metabolic turnover of the deuteriated compound in vitro, which may result in higher plasma levels.

t .

c) Receptor binding study

WO 94/11337 discloses that the active metabolite has high affinity to muscarinic receptors in the guinea-pig bladder. Different compounds of the present invention were tested in

1....

a well established standardized assay, measuring the binding of [<sup>3</sup>H]-methylscopolamine to recombinant human M3 receptors. BSR-M3H cells transfected with a plasmid encoding the human muscarinic M3 receptor were used to prepare membranes in modified Tris-HCl pH 7.4 buffer using standard techniques. An aliquot of the membrane preparation was incubated with [<sup>3</sup>H]methylscopolamine in the presence or absence of different concentrations of several compounds of the invention for 60 minutes at 25°C. Nonspecific binding was estimated in the presence of 1  $\mu$ M atropine. Membranes were filtered and washed three times and the filters were counted to determine the amount of [<sup>3</sup>H]-methylscopolamine specifically bound. The following table shows the IC<sub>50</sub> values of several compounds of the invention in the M3 receptor binding assay.

92

Prodrug	IC <sub>so</sub> [nM]	¢.
(+) HO-/-OH	8.7	
(-) HO-/-OH	1300	
(+)HO-/-OiBut	159	
(+)HO-/-OBz	172	
BzO-/-OBz	2400	
AcO-/-OiBut	3600	۰.
AcO-/-OBz	5400	

These data clearly showed that derivatization at the phenolic hydroxyl moiety results in an about 20 times less potent binding. If both functionalities are derivatized, the binding is even more dramatically reduced. Furthermore, it is demonstrated that the enantiomers of the active metabolite exhibit a marked difference in the binding characteristics to human M3 receptors.

#### PCT/EP99/03212

#### WO 99/58478

The compounds were tested for their anticholinergic activity in a standard tissue assay, the guinea-pig ileum. A segment of ileum was obtained from Duncan Hartley guinea-pigs which were sacrified by cervical dislocation. The tissue was placed under 1 g tension in a 10 ml bath containing Krebs' solution (pH 7.4, 32°C) and the concentration-dependent ability of different compounds to reduce the methacholine-induced (0.6  $\mu$ M) contractile response was recorded. The IC<sub>50</sub> values for the different substances were calculated and examples are presented in the following table.

Prodrug	IC <sub>so</sub> [nM]
(+) HO-/-OH	20
(-) HO-/-OH	680
(+)HO-/-OiBut	57
(+)HO-/-OBz	180
(+)BzO-/-OBz	220
(+)AcO-/-OiBut	240

Anticholinergic activity in guinea-pig ileum in vitro

: ;

These data confirm the results obtained in the receptor binding assays and demonstrate that the anticholinergic activity of the compounds decreases with increased derivatization.

#### d) Biological membranes

Different compounds of the invention were tested for their ability to penetrate the human skin (200  $\mu$ m thick) in the "Flow through cell" at 32°C according to Tiemessen et al. (Acta Pharm. Technol. 1998; 34:99-101). Phosphate buffer (pH 6.2) was used as the acceptor medium. Samples were drawn at different time points and analysed by RP-HPLC with UV de-

tection (220 nm). Permeation profiles were plotted and mean flux rates of different substances were calculated by linear regression analysis. The data obtained for different compounds of the invention are summarized in the following table.

94

Penetration through human skin

Flux rate [ [µg/cm <sup>2</sup> /24hrs]
3
150
60
70

Disubstitution of the hydroxy group of HO-/-OH leads to a  $\geq$  20-fold increase in skin permeation in relation to the parent HO-/-OH. Suprisingly monosubstitution of the penolic hydroxy group resulted in even higher 50-fold penetration rate through human skin.

Taken together, these biological data clearly demonstrate that the compounds of the invention have a reduced affinity to bind to human muscarinic M3 receptors. They exhibit an increased penetration through biological membranes, e.g. the human skin, and they are rapidly transformed to the active metabolite, once they have entered the systemic circulation as shown by the in vitro metabolism by the human liver S9 preparation.

Thus, the antimuscarinic prodrugs according to this invention showed a profile that defines excellent prodrugs.

a) hydrogen,  $C_1-C_6$  alkyl,  $C_1-C_{10}$  cycloalkyl, substituted or unsubstituted benzyl, allyl or carbohydrate; or

 b) formyl, C<sub>1</sub>-C<sub>6</sub> alkylcarbonyl, cycloalkylcarbonyl, substituted or unsubstituted arylcarbonyl, preferably benzoyl;
 or

c)  $C_1-C_6$  alkoxycarbonyl, substituted or unsubstituted aryloxycarbonyl, benzoylacyl, benzoylglygyl, a substituted or unsubstituted amino acid residue; or

#### PCT/EP99/03212

d)

e)

atoms; or

O- wherein  $R^4$  and  $R^5$  independently

wherein  $R^{\delta}$  and  $R^{7}$  independently

represent hydrogen,  $C_1$ - $C_6$  alkyl, substituted or unsubstituted aryl, preferably substituted or unsubstituted phenyl, benzyl or phenoxyalkyl wherein the alkyl residue has 1 to 4 carbon atoms and wherein  $R^4$  and  $R^5$  may form a ring together with the amine nitrogen; or

represent  $C_1-C_6$  alkyl, substituted or unsubstituted aryl,

or phenoxyalkyl wherein the alkyl residue has 1 to 6 carbon

preferably substituted or unsubstituted phenyl, benzyl

.5

f) an ester moiety of inorganic acids,

g)  $-SiR_aR_bR_c$ , wherein  $R_b$ ,  $R_b$ ,  $R_c$  are independently selected from  $C_1-C_c$  alkyl or aryl, preferably phenyl,

with the proviso that R' is not hydrogen, methyl or benzyl if R is hydrogen, R is not ethyl if R' is hydrogen,

X represents a tertiary amino group of formula Ia

#### - 97 -

wherein  $R^8$  and  $R^9$  represent non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and wherein  $R^8$  and  $R^9$  may form a ring together with the amine nitrogen,

Y and Z independently represent a single bond between the  $(CH_2)_n$  group and the carbonyl group, O, S or NH,

A represents hydrogen  $(^{1}H)$  or deuterium  $(^{2}H)$ ,

n is 0 to 12

and

their salts with physiologically acceptable acids, their free bases and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers.

2. 3,3-Diphenylpropylamines as claimed in claim 1, wherein X is

 $CH(CH_3)_2$ CH(CH<sub>3</sub>)<sub>2</sub>

3. 3,3-Diphenylpropylamines as claimed in claim 2 selected from phenolic monoesters represented by the general formulae II and II'


wherein  $R^2$  represents hydrogen,  $C_1-C_6$  alkyl or phenyl.

4. 3,3-Diphenylpropylamines as claimed in claim 3 selected from:
(+) formin acid 2 (2 diiformenularize 1 should reach a selected from a sele

(±)-formic acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester,

(±)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester,

(±)-propionic acid 2/(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester,

(±)-n-butyric acid/2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester,

(±)-isobutyric adid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester,

R-(+)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-2,2-dimethylpropionic acid 2-(3-diisopropylamino-1phenylpropyl -4-hydroxymethylphenyl ester,

(±)-2-acetamidoacetic acid 2-(3-diisopropylamino-1-

phenylpropy()-4-hydroxymethylphenyl ester,

(±) cyclopentanecarboxylic acid 2-(3-diisopropylamino-1phenxlpropyl)-4-hydroxymethylphenyl ester, (±)-cyclohexanecarboxylic acid 2-(3-diisopropylamino-1phenylphopyl)-4-hydroxymethylphenyl ester, (±)-benzdic acid 2-(3-diisopropylamino-l-phenylpropyl)-4hydroxymethylphenyl ester, R-(+)-benzolc acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester, (±)-4-methylbenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymet:hylphenyl ester, (±)-2-methylbenzdic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymet.hylphenyl ester, (±)-2-acetoxybenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (±)-1-naphthoic acid à-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester, (±)-2-naphthoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester (±)-4-chlorobenzoic acid 2\(3-diisopropylamino-1-phenylpropyl)-4-hydroxymet:hylphen&l ester, (±)-4-methoxybenzoic acid 2- No-diisopropylamino-1-phenylpropyl)-4-hydroxymet:hylphenyl ester, (±)-2-methoxybenzoic acid 2-(3-disopropylamino-1-phenylpropyl)-4-hydroxymet:hylphenyl ester, (±)-4-nitrobenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester (±)-2-nitrobenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (±)-malonic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenyl]ester, (±)-succinic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenyl]ester,

()

#### PCT/EP99/03212

#### - 100 -

(±)-pentanedioic acid bis+[2-(3-diisopropylamino-1-phenylpropyl\_-4-hydroxymethyl-phenyl]ester,

5. 3,3-Diphenylpropylamines as claimed in claim 2 selected from identical diesters represented by the general formula III



wherein R<sup>-</sup> is defined as in claim 3.

3,3-Diphenylpropylamines as claimed in claim 5 selected 6. from: (±)-formic acid 2-(3-disopropylamino-1-phenylpropyl)-4formyloxymethylphenyl ester, (±)-acetic acid 4-acetoxy-3-(3-diisopropylamino-1phenylpropyl) - benzyl ester, (±)-propionic acid 2-(3-d isopropylamino-1-phenylpropyl)-4propionyloxymethylphenyl eter, (±)-n-butyric acid 4-n-buty yloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester, (±)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4isobutyryloxymethylphenyl ester, (±)-2,2-dimethylpropionic acid 3-(3-diisopropylamino-1phenylpropyl) -4- (2,2-dimethyl-phopionyloxy) -benzyl ester, (±)-benzoic acid 4-benzoyloxymethyl-2-(3-diisopropylamino-1phenyipropyl)-phenyl ester,

1. it

3:1

. - 5

#### PCT/EP99/03212

R-(+)-benzoic acid 4-benzoyloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester,

(±)-pent-4-enoic acid 2-(3-dilsopropylamino-1-phenylpropyl)-4-(pent-4-enoyloxymethyl)-phenyl ester,

cyclic oct-4-ene-1,8-dioate of Intermediate B,

cyclic octane-1,8-dioate of Intermediate B,

poly-co-DL lactides of Intermediate B.

7. 3,3-Diphenyipropylamines as claimed in claim 2 selected from mixed diesters represented by the general formula IV

Formula IV

wherein R<sup>2</sup> is defined as in claim 3

and

 $R^2$  represents hydrogen,  $C_1-C_6$  alkyl or phenyl

with the proviso that  $R^1$  and  $R^1$  are not identical.

8. 3,3-Diphenylpropylamines as claimed in claim 7 selected from:

(±)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4formyloxymethylphenyl ester,

(±)-benzcic acid 2-(3-diisopropylam)no-1-phenylpropyl)-4formyloxymethylphenyl ester, Cost

#### PCT/EP99/03212

(±)-benzoic acid 2-(3-diisopropylamino-l-phenylpropyl)-4acetoxymethylphenyl ester,

:102

R-(+)-behzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4acetoxymethylphenyl ester,

(±)-isobutyric acid 4-acetoxymethyl-2-(3-diisopropylamino-1phenylpropyl)-phenyl ester,

R-(+)-isobutvric acid 4-acetoxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester,

(±)-2,2-dimethylpropionic acid 4-acetoxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester,

(±)-2,2-dimethylpropionic acid 4-acetoxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester,

(±)-benzoic acid 4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester.

9. 3,3-Diphenylpropylamines as claimed in claim 2 selected from benzylic monoesters represented by the general formula V



wherein  $R^1$  is defined as in dlaim 3.

10. 3,3-Diphenylpropylamines as claimed in claim 9 selected from:

(±)-formic acid 3-(3-diisopropy amino-1-phenylpropyl)-4hydroxybenzyl ester,

(±)-acetic acid 3-(3-diisopropylanino-1-phenylpropyl)-4hydroxybenzyl ester,

#### PCT/EP99/03212

(±)-propionic acid 3-(3-diisopropylamino-1-phenylpropyl)-4hydroxybenzyl ester,
(±)-butyric acid 3-(3-diisopropylamino-1-phenylpropyl)-4-

103

hydroxybenzyl ester, (±)-isobutyric acid 3-(3-diisopropylamino-1-phenylpropyl)-4hydroxybenzyl ester,

(±)-2,2-dimethylpropionic acid 3-(3-diisopropylamino-1phenylpropyl)-4-hydroxybenzyl ester,

(±)-benzoic acid 3-(3-diisopropylamino-1-phenylpropyl)-4hydroxybenzyl ester.

11. 3,3-Diphenylpropylamines as claimed in claim 2 selected from ethers and silyl ethers represented by the general formula VI



wherein at least one of  $R^{10}$  and  $R^{11}$  is selected from  $C_1-C_6$ alkyl, benzyl or  $-SiR_aR_bR_c$  as defined in claim 1 and the other one of  $R^{10}$  and  $R^{11}$  may additionally represent hydrogen,  $C_1-C_6$  alkylcarbonyl or benzoyl.

12. 3,3-Diphenylpropylamines as claimed in claim 11 selected from:

(±)-2-(3-diisopropylamino-1-phenylpropyl)-4-methoxymethylphenol,

Cint 

 $I_{111}^{\phantom{1}4}$ 

PCT/EP99/03212

- 104 2-(3-diisopropylamino-1-phenylpropyl)-4-ethoxymethyl- $(\pm)$ phend1, (±)-2\(3-diisopropylamino-1-phenylpropyl)-4-propoxymethylphenol (±) -2-(3 diisopropylamino-1-phenylpropyl) -4-isopropoxymethylphenol, (±)-2-(3-d{isopropylamino-1-phenylpropyl)-4-butoxymethylphenol, (±)-acetic adid 2-(3-diisopropylamino-1-phenylpropyl)-4methoxymethylghenyl ester, (±)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4ethoxymethylphenyl ester, (±) -2-(3-diisopropylamino-1-phenylpropyl)-4-trimethylsilanyloxymethylphenol, (±)-diisopropyl-[3\phenyl-3-(2-trimethylsilanyloxy-5-trimethylsilanyloxymethylphenyl)-propyl]-amine, (±) - [3-(3-diisopropylamino-1-phenylpropyl) -4-trimethylsilanyloxyphenyl]-methanol, (±) -diisopropyl - [3-(5 methoxymethyl-2-trimethylsilanyloxyphenyl)-3-phenylpropylamine, (±)-diisopropyl-[3-(5-ethoxymethyl-2-trimethylsilanyloxyphenyl)-3-phenylpropylamine, (±) - [4-(tert.-butyl-dimethylsilanyloxy) -3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-methanol, (±) -acetic acid 4-(tert.-butyl-dimethylsilanyloxy)-3-(3diisopropylamino-l-phenylpropyl)-benzyl ester, (±)-4-(tert.-butyl-dimethylsplanyloxy)-3-(3-diisopropylamino-1-phenylpropyl)-phenol, (±)-acetic acid 4-(tert.-butyl-dimethylsilanyloxy)-2-(3diisopropylamino-1-phenylpropyl)-phenyl ester, (±)-{3-[2-(tert.-butyl-dimethyleilanyloxy)-5-(tert.-butyldimethylsilanyloxymethyl)-phenyl -3-phenylpropyl}diisopropylamine,

-----

(±) {4-(tert.-butyl-diphenylsilanyloxy)-3-(3-diisopropylamino-1-phenylpropyl)-phenyl}-methanol, (±)-acetic acid 4-(tert.-butyl-diphenylsilanyloxymethyl)-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester, (±)-4-(tert.-butyl-diphenylsilanyloxymethyl)-2-(3-diisopropylamino-1-phenylpropyl)-phenol, (±)-{3-(2-(tert.-butyl-diphenylsilanyloxy)-5-(tert.-butyl-diphenylsilanyloxymethyl)-phenyl}-2-phenylpropyl}-diisopropylamine, (±)-acetic acid 4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester,

,105

(±)-benzoic acid 4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester,

(±)-isobutyric acid 4-benzyloxy-3-(3-diisopropylamino-1phenylpropyl)-benzyl ester,

(±)-2-(3-diisopropylamino-1-phenylpropyl)-4-(1β-D-glucuronosyloxymethyl)-phenol.

13. 3,3-Diphenylpropylamines as claimed in <u>claim</u> 2 selected from carbonates and carbamates represented by the general formulae VII and VIII



.....

111.3

#### PCT/EP99/03212

wherein Y, Z and n are as defined in claim 1 and wherein  $R^{12}$ and  $R^{13}$  represent a  $C_1$ - $C_6$  alkoxycarbonyl group or

1-CO-

- 106 -

G'T the second sec

5 wherein  $R^4$  and  $R^5$  are as defined in claim 1. 14. 3,3-Diphenylpropylamines as claimed in claim 13 selected from: (±) -N-ethylcarbamic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydrox methylphenyl ester, (±)-N,N-dimethylcarbamic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hytiroxymethylphenyl ester (±)-N,N-diethylcarhamic acid 2-(3-diisopropylamino-1phenylpropyl)-4-hydroxymethylphenyl ester (±)-N-phenylcarbamic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (±) - [2-(3-Diisopropylamino-1-phenylpropyl) -4-hydroxymethylphenoxycarbonylamino]adetic acid ethyl ester hydrochloride, (±)-N-ethylcarbamic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-N-ethylcarbamoyloxybenzyl ester, (±) -N, N-dimethylcarbamic acid 3-(3-diisopropylamino-1phenylpropyl)-4-N, N-dimethylcarbamoyloxybenzyl ester, (±)-N,N-diethylcarbamic acid 3-(3-diisopropylamino-1phenylpropyl)-4-N, N-diethyldarbamoyloxybenzyl ester, (±)-N-phenylcarbamic acid 3-\$3-diisopropylamino-1phenylpropyl)-4-N-phenylcarbahoyloxybenzyl ester, (±) -{4-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenoxycarbonylamino]-butyl}-carbamic acid 2-(3diisopropylamino-1-phenylpropyl -4-hydroxymethylphenyl ester, (±)-carbonic acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester ethyl dster,

Bed Or

PCT/EP99/03212

- 107 (±)-carbonic acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester phenyl ester,

(±)-carbonic acid 2-(3-diisopropylamino-1-phenylpropyl)-4ethoxyCarbonyloxymethylphenyl ester ethyl ester,
(±)-carbonic acid 2-(3-diisopropylamino-1-phenylpropyl)-4phenoxyCarbonyloxymethylphenyl ester phenyl ester.

## 15. 3,3-Diphenylpropylamines selected from

(i) compounds of the formulae IX and IX'



Formula IX

Formula IX

wherein o and p are the same or different and represent the number of methylene units  $+ CH_2 +$  and may range from 0 to 6,

- (ii) (±)-Benzoic acid 2-(3 diisopropylamino-1-phenylpropyl)-4-sulphooxymethyl-phenyl ester
- (iii) Poly-co-DL-lactides of 2-(3-diisopropylamino-phenylpropyl)-4-hydroxymethyl-phenol
- (iv) (±)-2-(3-Diisopropylamino-1-phenylpropyl)-4-(1β-Dglucuronosyloxymethyl)-phenol having the formula





Conte Secos

and

their salts with physiologically acceptable acids, their free bases and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers.

۲

16. A process for the production of phenolic monoesters represented by the general formula II

÷



as defined in claim 3, which comprises treatment  $o\bar{z}$  a compound of the formula



:

PCT/EP99/03212

Ci-l Suits Q'

with an equivalent of an acylating agent selected from

109

0

∥ R<sup>1</sup>-C-LG

wherein LG represents a leaving group selected from halogenide, carboxylate and imidazolide and  $R^1$  is as defined in claim 3, in an inert solvent in the presence of a condensating agent.

17. A process for the production of phenolic moncesters represented by the general formula II'



as defined in claim 3, which comprises treatment of two equivalents of a compound of the formula



Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0156

PCT/EP99/03212

0

C

 $C-(CH_2)$ 

0

• III

with an acylating agent selected from 0 0 11 h (CH<sub>2</sub>)<sub>n</sub>-C-Hal

wherein Hal represents a halogen atom.

Hal

18. A process for the production of identical diesters represented by the general formula III

- 110 -

or

as defined in claim 5, which comprises treatment of a compound of the formula

HC

with at least two equivalents of the acylating agent as defined in claim 16.

Cont

54) (19

PCT/EP99/03212

19. process for the preparation of benzylic monoesters represented by the general formula V



as defined in claim 9, which comprises treatment cf a compound cf the formula

at room temperature and under anhydrous conditions with activated esters in the presence of enzymes selected from lipases or esterases.

20. A process for the preparation of mixed diesters represented by the general formula IV



Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0158

PCT/EP99/03212

# - 112 -

as defined in claim 7, which comprises acylation of a benzylic monoester represented by the general formula V



as defined in <u>claim</u>9 or of a phenolic monoester represented by the formula II as defined in claim 3.

21. A process for the production of ethers represented by the general formula VI

Ŗ<sup>11</sup>

as defined in claim 11 where  $n R^{11}$  is hydrogen which comprises reacting a compound of the formula



Formula VI

(m)t

with an alcohol  $R^{10}$ -OH in the presence of an esterification catalyst.

22. A process for the preparation of ethers represented by the general formula VI

# R<sup>10-0</sup> A A Formula VI

wherein  $R^{10}$  and  $R^{11}$  are as defined in claim 11, which comprises acid or base treatment of free benzylic alcohols selected from

and



PCT/EP99/03212

#### 

where  $n R^4$  and  $R^5$  are as defined in claim 1 or of benzylic acylates selected from Formula IV Formula 3 R

wherein  $R^1$  and  $R^2$  are as defined in claim 7 in the presence of suitable hydroxy reagents.

23. A process for the preparation of ethers of formula VI as defined in claim 11, which comprises treating a compound of the formula

0 X

a un service of a similar function of the service o

#### PCT/EP99/03212

with an alkylating agent selected from alkyl halcgenides, alkyl sulphates and alkyl triflates, said alkyl group having 1 to 6 carbon atoms.

- 116

24. A process for the préparation of carbonates and carbamates represented by the general formulae VII and VIII

Formula VII



as defined in claim 13, which comprises reacting a compound selected from the group consisting of



wherein  $R^2$  is defined as in claim 3, n is 0 to 12, Bn is benzyl, one of  $R^{10}$  or  $R^{11}$  is hydrogen and the other one is as defined in claim 11 with activated carbonyl compounds or carbonyl precursor reagents selected from haloformates, ketenes, activated esters, mixed anhydrides of organic or inorganic acids, isocyanates and isothiocyanates.

25. 3,3-Diphenylpropriamines as claimed in claims 1 to 15 for use as pharmaceutically active substances, especially as antimuscarinic agents.

PCT/EP99/03212

## - 118 -

26. A pharmaceutical composition comprising a 3,3-diphenylpropylamine as alaimed in claim 1 to 15 and a compatible pharmaceutical cargier

27. Use of a 3,3-diphenylpropylamine as claimed in claims 1 to 15 for preparing an antimuscarinic drug.

Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0165

### TENT COOPERATION TREA.Y

# PCT

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

# (PCT Article 36 and Rule 70)

١.

(

Ċ

Applicant's or agent's file reference	· · · · · · · · · · · · · · · · · · ·	Son Notification of Transmittel at International			
10022/um See Notification of Transmittal of International FOR FURTHER ACTION Preliminary Examination Report (Form PCT/IPEA/416)					
International application No.	International filing date (day/month/)	/ear) Priority data (day/month/year)			
PCT/EP99/03212 11/05/1999 12/05/1998					
International Patent Classification (IPC) or nati CO7C1/00 Applicant	onal classification and IPC				
SCHWARZ PHARMA AG.et.al					
1. This international preliminary examinand is transmitted to the applicant a	nation report has been prepared coording to Article 38.	by this International Preliminary Examining Authority			
2. This REPORT consists of a total of	5 sheets, including this cover sh	eet.			
<ul> <li>This report is also accompanied been amended and are the bas (see Rule 70.16 and Section 60</li> <li>These annexes consist of a total of</li> </ul>	by ANNEXES, i.e. sheets of the is for this report and/or sheets co of the Administrative Instructio of the Administrative Instructio 34 sheets.	e description, claims and/or drawings which have ontaining rectifications made before this Authority ns under the PCT).			
3. This report contains indications rela I 🛛 Basis of the report II 🗋 Priority III 💭 Non-establishment of o	ting to the following items: pinion with regard to novelty, inv	entive step and industrial applicability			
IV LI Lack of unity of invention		·····			
V 🖾 Reasoned statement us citations and explanate	nder Article 35(2) with regard to r ons suporting such statement	welly, inventive step or industrial applicability;			
VI 🗍 Certain documents citr	bed · ·	en and a second s			
VII 🖸 Certain defects in the in	ternational application	· .			
VIII 🛛 Certain observations of	n the international application				
·.	. :				
Dale of submission of the demand	Date of c	completion of this report			
24/06/1999		2 6. 07. 00			
Name and mailing address of the international	Authoriz	ed officer			
preliminary examining authority:					
D-80298 Munich	Gerzal	n.M. (( .))			
Tel. +49 89 2399 - 0 Tx: 52385	8 epmu d	المستحقيل			
Fax: +49 89 2399 - 4465	Telepho	na No. +49 89 2399 2128			
Form PCT/IPEA/409 (cover sheet) (January 19	<b>994)</b>	SR22429, 21.07.2000			

ŗ

#### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP99/03212

#### 1. Basis of the report

ı'

í

1. This report has been drawn on the basis of (substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.):

	Des	cription, pages:		;. :			· · ·			
	1-4, 37-9	7,11-32, 94	as originally filed	· ·	1 1911 -				· .	
	5,6,	8-10,33-36	as received on	, 177	28/04/2	2000	with letter of		28/04/2000	
	Cla	ims, No.:	· · · · ·				· ·			
	1-2	7	as received on	r f	28/04/2	2000	with letter of		28/04/2000	
	Dra	wings, sheets:							r	
	1/1		as originally filed	. (						
						·.	· · ·			
2.	The	e amendments hav	ve resulted in the cance	ellation of:	•		•			
		the description,	pages:		1					
		the claims,	Nos.:						•	
	IJ	the orawings,	SHEELS:	2 E	* .	Υ.				
		• •		t .	. :					
4.	Add	ditional observatio	ins, if necessary:					• .		·
			1	:		Ϋ́ς.	e" y ,			
			<b>`</b>							
				л <sub>201</sub>	•					
			•	•	÷,	.".				
							• • •			
				: .	. •					
Form F	PCTAF	PEA/409 (Boxes I-VIII,	Sheet 1) (January 1994)			•				
			. 1	:	ŕ	-1-				
							•			

#### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

۰.

# V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1.	Statement					·		
	Novelty (N)	Yes: No:	Claims Claims	1-27	1	-2		
	Inventive step (IS)	Yes: No:	Claims Claims	1-27				
	Industrial applicability (IA)	Yes: No:	Claims Claims	1-27				

#### 2. Citations and explanations

#### see separate sheet

í

Form PCT/IPEA/409 (Boxes I-VIII, Sheel 2) (January 1994)

1 - 1 - 1

### Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0168

#### INTERNATIONAL PRELIMINARY Internation EXAMINATION REPORT - SEPARATE SHEET

D1 WO 94 11337

D2 WO 89 06644

D3 L. Nilvebrant et al., European J. of Pharm., vol.327, 195-207 (1997)

#### Item V

(

(

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

÷

All the inconsistencies between the description and claims were corrected (letter of 28/04/00). These amendements do not contravene to Article 34(2)b)PCT and are accordingly allowable.

#### Novelty - Article 33(2) PCT

The Intermediates A (R = H and R' =  $CH_2\phi$ ) and B (R = R' = H) are 3,3-diphenylpropylamines of D1, which are excluded from the present application. They are used as starting materials to synthesize the compounds of the invention.

The 3,3-diphenylpropylamines of D2 do not possess a protected hydroxymethyl group on the 5-position of the 2-hydroxyl-phenyl group.

The antimuscarinic properties of tolterodine (R' = H; Me instead of CA<sub>2</sub>-O-R), oxybutinin and atropine are compared in D3.

The subject-matter of claims 1-15 could therefore be considered as novel in view of D1, D2 or D3. The processes to prepare such novel compounds (claims 16-24), the compositions containing them (claim 26) and their use (claims 25 and 27) could accordingly be considered as novel.

#### inventive step- Article 33(3) PCT

3,3-Diphenylpropylamines of D1 where R = H and R' = H, Me,  $CH_2\phi$  (pages 12-13 and claims 5-6) are excluded from the present demand (claim 1, page 96). The technical problem is to provide other antimuscarinic agents with increased penetrating property through biological membrane. The solution of the applicant are the 3,3-

Form PCT/Separate Sheet/409 (Sheet 1) (EPO-April 1997)

#### INTERNATIONAL PRELIMINARY Inter EXAMINATION REPORT - SEPARATE SHEET

PCT/EP99/03212

diphenylpropylamine derivatives (I) and (VII') (claim 1).

The active metabolite formed from the 3,3-diphenylpropylamines of D1 are used for urge incontinence. The presence of an additional hydroxy group leads to an increased hydrophilic property of these compounds, resulting in a lower absorption. This could be outlined *via* a comparison between the intermediate B (D1) and the derivatives of the invention (page 94, Table). The compounds of the invention have also a reduced affinity to bind to muscarinic receptors (page 92, Table). They are consequently solutions of the present technical problem. Nothing in D1 would have lead the man skilled in the art to derivatize preferentially at the phenolic hydroxyl molety. An inventive step could therefore be acknowledged for claims 1-15.

An inventive step could also be recognized to the processes of making such novel and inventive compounds (claims 16-24), involving the derivatization of the hydroxy phenolic molety, the compositions containing them (claim 26) and their use (claims 25 and 27).

Form PCT/Separate Sheet/409 (Sheet 2) (EPO-April 1997)

. . . . . . . . .

# 09/700094

529 Rec'd PCT/PTC 0 8 NOV 2000

**Group Art Unit: TBA** 

DUPLICATE

- PTO - 1449

Express Mail No. EL602856070US

#### PATENT IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. MBHB00,1121)

In application of:

#### Meese and Sparf

Serial No. U.S. National Phase of PCT/EP99/03212

Filed: October 19, 2000

For: Novel Derivatives of 3,3-Diphenylpropylamines

#### INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

1. International Patent No. WO 94/11337, published May 26, 1994

2. International Patent No. WO 89/06644, published July 27, 1989

3. Nilvebrant et al., (1997) European Journal of Pharmacology, Vol. 327, pp. 195-207

By:

Respectfully submitted, McDonnell Boehnen Hulbert & Berghoff

Date: Noumeber 8, 2000

Michael S. G

Reg. No. 37,142

### 09/700094 Sheet 1 of 1

Dress	Mail No	). EL6028	56070US

Form PTO-1449	U S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Docket No. 529 Rec'd P MBIIB00,1121	CTAPTC 08 NOV 2000 TBA
		Applicant: Meese and Spart Filing Date: October 19, 2000	Group: TBA

#### U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
	 		· · · · · ·			

#### FOREIGN PATENT DOCUMENTS Country Document Number Date Ŀ, <u>Translation</u> Yes No ξ. Class Subclass WO 94/11337 5/26/94 1 PCT WO 89/06644 2 7/27/89 PCT 1

	OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.					
	3	Nilvebrant et al., (1997) European Journal of Pharmacology, Vol. 327, pp. 195-207				
	<u> </u>	. A.17.				
		S NUX				
·	ļ					

Examiner	Date Considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

ĩ

# 09/700094

### 529 Rec'd PCT/PTC 08 NOV 2000 PATENT

**Examiner: TBA** 

Group Art Unit: TBA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 00,1121)

;)

)

)

)

In the Application of:

Meese et al.

Serial No.: U.S. National Phase of PCT/EP99/03212

Filing Date: Int'l Filing Date: May 11, 1999

For: Novel Derivatives of 3,3-diphenylpropylmines

#### PRELIMINARY AMENDENT

Asst. Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Please consider the following amendments and remarks before examination on the merits.

AMENDMENTS

1

In the claims:

Please cancel claim 17, 25, 26, and 27.

Please amend the claims as follows:

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, 32<sup>nd</sup> Floor Chicago, IL 60606 (3) 2)91 3-0001

Serial No. U.S. National Phase of PCTT/EP99/03212 Attorney Docket No. 00,1121



Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0174

CC d)

Cuta GUN SUM wherein  $R^4$  and  $R^5$  independently represent hydrogen,  $C_1$ - $C_6$  alkyl, substituted or unsubstituted aryl, [preferably substituted or unsubstituted phenyl,] benzyl or phenoxyalkyl wherein the alkyl residue has 1 to 4 carbon atoms [and wherein] or  $R^4$  and  $R^5$  [may] form a ring together with the amine nitrogen; or

e)

wherein  $R^6$  and  $R^7$  independently represent  $C_1$ - $C_6$  alkyl, substituted or unsubstituted aryl, [preferably substituted or unsubstituted phenyl,] benzyl or phenoxyalkyl wherein the alkyl residue has 1 to 6 carbon atoms; or

f) an ester moiety of inorganic acids,

SO

g)  $-SiR_{a}R_{b}R_{c}$ , wherein  $R_{a}$ ,  $R_{b}$ ,  $R_{c}$  are independently [selected from]  $C_{1}-C_{4}$  alkyl or aryl, [preferably phenyl,]

with the proviso that R' is not hydrogen, methyl or benzyl [if] when R is hydrogen, and R is not ethyl [if] when R' is hydrogen,

X represents a tertiary amino group of formula Ia

Formula 1a

3

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, 32<sup>nd</sup> Floor Chicago, IL 60606 (312)913 0001 Serial No U.S. National Phase of PCT/EP99/03212 Attorney Docket No, 00,1121 wherein  $\mathbb{R}^8$  and  $\mathbb{R}^9$  represent [non-aromatic hydrocarbyl]  $\underline{C}_1 - \underline{C}_6$  alkyl groups, which may be the same or different and which together contain at least three carbon atoms, [and wherein] or  $\mathbb{R}^8$  and  $\mathbb{R}^9$  may form a ring together with the amine nitrogen,

[Y and Z independently represent a single bond between the  $(CH_2)_n$  group and the carbonyl group, O, S or NH,]

A represents hydrogen ('H) or deuterium ('H)

[n is 0 to 12]

and

2.

their salts with physiologically acceptable acids, their free bases and, when the compounds [can be] <u>are</u> in the form of optical isomers, the racemic mixture and the individual enantiomers.

 $CH(CH_3)_2$ 

CH(CH<sub>3</sub>)<sub>2</sub>

(Amended) The 3,3-Diphenylpropylamine[s] as claimed in claim 1, wherein X is

McDonnell Boehnen Hulbert & Berghoff 30() Sou h Wacker Drive, 32<sup>nd</sup> Floor C'h cago, 1L 60606 (312)91 7-0001

Serial No. U.S. National Phase of PCT/EP99/03212 Autorney Docket No. 00,1121

3. (Amended) <u>The</u> 3,3-Diphenylpropylamine[s] as claimed in claim 2 selected from phenolic monoesters represented by the general formula[e] II [and II']



(±) 2,2-dimethylpropionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-2-acetamidoacetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-cyclopentanecarboxylic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-cyclohexanecarboxylic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

R-(+)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-4-methylbenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-2-methylbenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-2-acetoxybenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-1-naphthoic acid 2-(3-diisopropylamino-1 phenylpropyl)-4-hydroxymethylphenyl ester,
(±)-2-naphthoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
(±)-4-chlorobenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
(±)-4-methoxybenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-2-methoxybenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-4-nitrobenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4 hydroxymethylphenyl ester,

(±)-2-nitrobenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

McDonnel Boehnen Hulbert & Berghoff 6 Serial No. U.S. National Phase of PCT/EP99/03212 300 South Wacker Drive, 32<sup>nd</sup> Floor Atturney Docket No 00,1121 Chicago, IL\_60606 (312)913-0001 (±)-malonic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenyl]ester,
(±)-succinic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenyl]ester,
(±)-pentanedioic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenyl]
ester, and

(±)-hexanedioic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenyl]

5. (Amended) <u>The</u> 3,3-Diphenylpropylamine[s] as claimed in claim 2 [selected from identical diesters] represented by the general formula III



Formula III

wherein  $\mathbb{R}^1$  is [defined as in claim 3] <u>hydrogen,  $\mathbb{C}_1$ - $\mathbb{C}_6$  alkyl or phenyl</u>.

6. (Amended) The 3,3-Diphenylpropylamine[s] as claimed in claim 5 selected from:

(±)-formic acid 2-(3-diisopropylamine-1-phenylpropyl)-4-formyloxymethylphenyl ester,

(±)-acetic acid 4-acetoxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester,

(±)-propionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-propionyloxymethylphenyl ester,

(±)-n-butyric acid 4-n-butyryloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester,

(±)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropy) -4-isobutyryloxymethylphenyl ester,

l McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, 32<sup>nd</sup> Floor Chicago, IL 60606 (3 2)913-0001

ester.

8: Q

Serial No. U.S. National Phase of PCT/EP99/03212 Attorney Docket No 00,1121 (±)-2,2-dimethylpropionic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-(2,2-dimethyl-propionyloxy)-benzyl ester,

(±)-benzoic acid 4-benzoyloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester,

R-(+)-benzoic acid 4-benzoyloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester,

(±)-pent-4-enoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-(pent-4-enoyloxymethyl)-phenyl

ester,

jesh

cyclic oct-4-ene-1,8-dioate of Intermediate B,

cyclic octane-1,8-dioate of Intermediate B, and

poly-co-DL-lactides of Intermediate B, said Intermediate B having the formula



wherein A is hydrogen (<sup>1</sup>H) or deuterium (<sup>2</sup>H).

7. (Amended) <u>The 3,3-Diphenylpropylamine[s] as claimed in claim 2 selected from mixed</u>

diesters represented by the general formula IV



McDonnell Boehnen Hulbert & Berghoff 300 Souta Wacker Drive, 32<sup>ud</sup> Floor Chicago, IL 60606 (312)913-0001 , Formula IV

Serial No U.S. National Phase of PCT/EP99/03212 Attorney Docket No. 00,1121
wherein  $R^1$  is [defined as in claim 3] <u>hydrogen,  $C_1$ -C<sub>6</sub> alkyl or phenyl</u>, and  $R^2$  represents hydrogen,  $C_1$ -C<sub>6</sub> alkyl or phenyl with the proviso that  $R^1$  and  $R^2$  are not identical.

(Amended) <u>The</u> 3,3-Diphenylpropylamine[s] as claimed in claim 7 selected from:
(±)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-formyloxymethylphenyl ester,
(±)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-formyloxymethylphenyl ester,
(±)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-acetoxymethylphenyl ester,
R-(+)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-acetoxymethylphenyl ester,
(±)-isobutyric acid 4-acetoxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester,
R-(+)-isobutyric acid 4-acetoxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester,
(±)-2,2-dimethylpropionic acid 4-acetoxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester,
(±)-2,2-dimethylpropionic acid 4-acetoxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-benzyl ester,

(±)-benzoic acid 4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester.

9. (Amended) The 3,3-Diphenylpropylamine[s] as claimed in claim 2 selected from benzylic monoesters represented by the general formula V



wherein  $R^1$  is [defined as in claim 3] <u>hydrogen,  $C_1$ -C<sub>6</sub> alkyl or phenyl</u>.

10. (Amended) The 3,3-Diphenylpropylamine[s] as claimed in claim 9 selected from:

McDonn(11 Boehnen Hulbert & Berghoff 300 South Wacker Drive, 32 <sup>ad</sup> Floor Chicago, 1L 60606 (512)913 3001	<mark>.9</mark>	Serial No U.S National Phase of Attorney D	PCT/I3P99/03212 ocket No. 00,1121
			•
	ť . . ;		
	е <u>тру</u> ниција 		

(±)-formic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester,

(±)-acetic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester,

(±)-propionic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester,

(±)-butyric acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester,

(±)-isobutyric acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester,

(±)-2,2-dimethylpropionic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester,

(±)-benzoic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester.

11. (Amended) <u>The</u> 3,3-Diphenylpropylamines as claimed in claim 2 selected from ethers and silyl ethers represented by the general formula VI

#### Formula VI

wherein at least one of  $R^{10}$  and  $R^{11}$  is selected from  $C_1$ - $C_6$  alkyl, benzyl [or] and -SiR<sub>a</sub>R<sub>b</sub>R<sub>c</sub> [as defined in claim 1] and the other [one] of  $R^{10}$  and  $R^{11}$  [may additionally] represents hydrogen,  $C_1$ - $C_6$  alkylcarbonyl or benzoyl.

10

OR<sup>11</sup> H<sub>3</sub>C,

 $-CH_3$ 

H<sub>3</sub>C

CH3

12. (Amended) The 3,3-Diphenylpropylamine[s] as claimed in claim 11 selected from:

 $(\pm)$ -2-(3-diisopropylamino-1-phenylpropyl)-4-methoxymethylphenol,

(±)-2-(3-diisopropylamino-1-phenylpropyl)-4-ethoxymethylphenol,

(±)-2-(3-diisopropylamino-1-phenylpropyl)-4-propoxymethylphenol,

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, 32<sup>nd</sup> Floor Chicago, IL 60606 (312)915-0001

and

1

Serial No. U.S. National Phase of PCT/EP99/03212 Attorney Docket No 00,1121 (±)-2-(3-diisopropylamino-1-phenylpropyl)-4-isopropoxymethylphenol,
(±)-2-(3-diisopropylamino-1-phenylpropyl)-4-butoxymethylphenol,
(±)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-methoxymethylphenyl ester,
(±)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-ethoxymethylphenyl ester,
(±)-2-(3-diisopropylamino-1-phenylpropyl)-4-trimethylsilanyloxymethylphenol,
(±)-diisopropyl-[3-phenyl-3-(2-trimethylsilanyloxy-5-trimethylsilanyloxymethylphenyl)-propyl]-

7.1 7.1

amine,

(±)-[3-(3-diisopropylamino 1-phenylpropyl)-4-trimethylsilanyloxyphenyl]-methanol,
(±)-diisopropyl-[3-(5-methoxymethyl-2-trimethylsilanyloxyphenyl)-3-phenylpropylamine,
(±)-diisopropyl-[3-(5-ethoxymethyl-2-trimethylsilanyloxyphenyl)-3-phenylpropylamine,
(±)-[4-(tert.-butyl-dimethylsilanyloxy) (3-diisopropylamino-1-phenylpropyl)-phenyl]-

(±)-acetic acid 4-(tert.-butyl-dimethysilalayloxy)-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester,

(±)-4-(tert.-butyl-dimethylsilanyloxy)-3-(3-diiaopropylamino-1-phenylpropyl)-phenol,

(±)-acetic acid 4-(tert.-butyl-dimethylsilanyloxy)-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester,

(±)-{3-[2-(tert.-butyl-dimethylsilanyloxy)-5-(tert.-butyl-dimethylsilanyloxymethyl)-phenyl]-3-

phenylpropyl}-diisopropylamine,

(±)-[4-(tert.-butyl-diphenylsilanyloxy)-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-

methanol,

(±)-acetic acid 4-(tert.-butyl-diphenylsilanyloxymethyl)-2-(3-diisopropylamino-1-phenylpropyl)-

phenyl ester,

McDonnell Bochnen Hulbert & Berghoff 300 South Wacker Drive, 32<sup>nd</sup> Floor Chicago, IL 60606 (312)913-0001 11

Serial No. U.S National Phase of PCT/EP99/03212 Attorney Docket No. 00,1121 (±)-4-(tert.-butyl-diphenylsilanyloxymethyl)-2-(3-diisopropylamino-1-phenylpropyl)-phenol, (±)-{3-[2-(tert.-butyl-diphenylsilanyloxy)-5-(tert.-butyl-diphenylsilanyloxymethyl)-phenyl]-2phenylpropyl}-diisopropylamine,

(±)-acetic acid 4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester,
 (±)-benzoic acid 4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester,

(±)-isobutyric acid Abenzyloxy-3-(3-diisopropylamino-1-

phenylpropyl)-benzyl ester, and

 $(\pm)$ -2-(3-diisopropylamino- $\lambda$ -phenylpropyl)-4-(1 $\beta$ -D-glucuronosyloxymethyl)-phenol.

13. (Amended) <u>The</u> 3,3-Diphenylpropylamine[s] as claimed in claim 2 selected from carbonates and carbamates represented by the general formula[e] VII [and VIII]



12

#### Formula VII

i....

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, 32<sup>ad</sup> Floor Chicago, IL 60606 (312)913-0001

Serial No U.S National Phase of PCT/EP99/03212 Attorney Docket No. 00,1121 wherein [Y, Z and n are as defined in claim 1 and wherein]  $R^{12}$  and  $R^{13}$  represent a  $C_1$ - $C_6$  alkoxycarbonyl group or

[wherein  $\mathbb{R}^4$  and  $\mathbb{R}^5$  are as defined in claim 1]

14. (Amended) <u>The 3,3-Diphenylpropylamine[s]</u> as claimed in claim 13 selected from:
(±)-N-ethylcarbamic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
(±)-N,N-dimethylcarbamic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester

(±)-N,N-diethylcarbamic acid 2-(3-diise ropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester

(±)-N-phenylcarbamic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-[2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenoxycarbonylamino]acetic acid ethyl ester hydrochloride,

(±)-N-ethylcarbamic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-N-ethylcarbamoyloxybenzyl ester,

(±)-N,N-dimethylcarbamic acid 3-(3-diisopropylamino-1-phenylptopyl)-4-N,N-dimethylcarbam-

oyloxybenzyl ester,

(±)-N,N-diethylcarbamic acid 3-(3-diisopropylamino-1-phenylpropyl)\4-N,N-diethylcarbamoyl-

13

oxybenzyl ester,

McDonnell Boehnen Hulbert & Berghoff 300 Scuth Wacker Drive, 32<sup>sd</sup> Floor Chicago, IL 60606 (312)9 3-0001 Serial No U.S. National Phase of PCT/EP99/03212 Attorney Docket No 00,1121

(±)-N phenylcarbamic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-N-phenylcarbamoyloxybenzyl ester,

(±)-{4-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenoxycarbonylamino]butyl}-carbamic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
(±)-carbonic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester ethyl
ester,

(±)-carbonic acid 2-(3-diisopropyland -phenylpropyl)-4-hydroxymethylphenyl ester phenyl ester,

(±)-carbonic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-ethoxycarbonyloxymethylphenyl ester ethyl ester, and

(±)-carbonic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-phenoxycarbonyloxymethylphenyl ester phenyl ester.

15. (Amended) A 3,3-Diphenylpropylamine[s] selected from

CH<sub>3</sub>

14

(i) compounds of the formulae IX and IX'



Formula IX

CH<sub>3</sub> CH<sub>3</sub> CH<sub>3</sub> H<sub>3</sub>C CH<sub>3</sub> Formula IX'

70

Serial No. U.S. National Phase of PCT/EP99/03212 Attorney Docket No. 00,1121

30C South Wacker Drive, 32<sup>nd</sup> Floor Chicago IL 60606 (312)912.0001

McDonnell Boehnen Hulbert & Berg

wherein 0 and p are the same or different and [represent the number of methylene units -  $CH_2$  - and may] range from 0 to 6,

(ii) (±)-Benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-sulphooxymethyl-phenyl ester

(iii) Poly-co-DL-lactides of 2-(3-diisopropylamino-phenylpropyl)-4-hydroxymethyl-phenol
 (iv) (±)-2-(3-Diisopropylamino-1-phenylpropyl)-4-(1β-D-glucuronosyloxymethyl)-phenol

having the formula



## and

: ng

their salts with physiologically acceptable acids, their free bases and, when the compounds [can be] <u>are</u> in the form of optical isomers, the racemic mixture and the individual enantiomers.

12. K (Amended) A process for the production of phenolic monoesters according to claim 3,

[represented by the general formula II



McDonnell Boehnen Hulbert & Berghoff 30() South Wacker Drive, 32<sup>46</sup> Floor . Ch cago, IL 60606 (312)915-0001

Serial No. U.S. National Phase of PCT/EP99/03212 Attorney Docket No. 00,1121 as defined in claim 3,] which comprises treatment of a compound of the formula



with an equivalent of an acylating agent [selected from] of formula

$$R^{1}$$
  $C$   $LG$ 

wherein LG represents a leaving group selected from [halogenide] <u>halide</u>, carboxylate and imidazolide [and  $R^1$  is as defined in claim 3,] in an inert solvent in the presence of a [condensating] <u>condensing</u> agent.

(Amended) A process for the production of identical diesters according to claim 5,

[represented by the general formula III

Cont. (al

13



as defined in claim 5,] which comprises treatment of a compound of the formula

16

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, 32<sup>nd</sup> Floor Chicage IL 60606 (3 2)91: 0001 rial No. US National Phase of PCT/EP99/03212 Attorney Docket No. 00,1121



at room temperature and under anhydrous conditions with activated esters in the presence of enzymes selected from lipases or esterases.

20. (Amended) A process for the preparation of mixed diesters according to claim 7, [represented by the general formula IV



as defined in claim 7,] which comprises acylation of a benzylic monoester represented by the general formula V



[as defined in claim 9] or of a phenolic monoester represented by the formula II [as defined in claim 3]

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, 32<sup>nd</sup> Floor Chicago, IL 60606 (312)913 (4001

15

八上 - 192

 $\sigma_{\mathcal{F}}$ 

juk

18

Serial No. U S. National Phase of PCT/EP99/03212 Attorney Docket No 00,1121







CH<sub>3</sub>

H<sub>3</sub>C

CH-

Formula II,





[or]  $R^{10} \xrightarrow{O}_{A} \xrightarrow{R^{10} - O}_{A} \xrightarrow{H_3C}_{H_3C} \xrightarrow{CH_3}_{H_3C}$ (d) (d) wherein  $R^{10}$  is hydrogen [and  $R^{11}$  is as defined in claim 11 or],  $R^{12} \xrightarrow{O}_{A} \xrightarrow{V}_{A} \xrightarrow{V}_{CH_3} \xrightarrow{V}_{CH_3}$ 

R

HO

<u>(c)</u>

A

Ω

H<sub>3</sub>C

<u>(e)</u>

Formula VII

wherein  $R^{12}$  is hydrogen and  $R^{13}$  represents a  $C_1$ - $C_6$  alkoxycarbonyl group or

R<sup>4</sup> N--CO-R<sup>5</sup>

21

McDonwell Bochnen Hulbert & Berghoff 300 South Wacker Drive, 32<sup>nd</sup> Floor Chicago, IL 60606 (312)913-0001

Serial No. U.S. National Phase of PCT/EP99/03212 Attorney Docket No. 00,1121 wherein  $R^4$  and  $R^5$  [are as defined in claim 1] independently represent hydrogen,  $C_1$ - $C_6$  alkyl, substituted or unsubstituted aryl, benzyl or phenoxyalkyl wherein the alkyl residue has 1 to 4 carbon atoms or  $R^4$  and  $R^5$  form a ring together with the amine nitrogen, [or of] and

(f) benzylic acylates selected from



[wherein  $R^1$  and  $R^2$  are as defined in claim 7 in the presence of suitable hydroxy reagents.]

wherein  $R^1$  is hydrogen,  $C_1$ - $C_6$  alkyl or phenyl, and  $R^2$  represents hydrogen,  $C_1$ - $C_6$  alkyl or phenyl

22

McDonn (11 Boehnen Hulbert & Berghoff 300 South Wacker Drive, 32<sup>ad</sup> Floor Chicago, L 60606 (312)913 0001

\*\*\*

erial No. U.S. National Phase of PCT/EP99/03212 Attorney Docket No. 00,1121

## with the proviso that $R^1$ and $R^2$ are not identical.

23. (Amended) A process for the preparation of ethers of formula VI [as defined in] according to claim 11, which comprises treating a compound of the formula

OH H<sub>3</sub>C CH3 CH3 R<sup>10</sup> H₃Ć

with an alkylating agent selected from alkyl [halogenides] <u>halides</u>, alkyl sulphates and alkyl triflates, said alkyl group having I to 6 carbon atoms.

24. (Amended) A process for the preparation of carbonates and carbamates according to claim 13 [represented by the general formulae VII and VII]

23

McDonnell Boehnen Hulbert & Berghoff 300 Sou .1 Wacker Drive, 32<sup>nd</sup> Floor (Chicage IL 60606 (312)91: -0001 Serial No. U S National Phase of PCT/EP99/03212 Attorney Docket No. 00,1121

Gode Ad





McDonnell Bochnen Hulbert & Berghoff 300 South Wacker Drive, 32<sup>nd</sup> Floor Chicago, 11, 60606 (312 913-030)

Serial No. U.S National Phase of PCT/EP99/03212 Attorney Docket No. 00,1121

: .



wherein  $R^1$  [is defined as in claim 3] represents hydrogen,  $C_1$ - $C_6$  alkyl or phenyl, n is 0 to 12, Bn is benzyl, one of  $R^{10}$  or  $R^{11}$  is hydrogen and the other one is [as defined in claim 11]  $C_1$ - $C_6$  alkyl, benzyl, -SiR\_8R\_6R\_ hydrogen,  $C_1$ - $C_6$  alkylcarbonyl or benzoyl, wherein  $R_8$ ,  $R_6$ ,  $R_7$  are independently  $C_1$ - $C_4$  alkyl or aryl,

with activated carbonyl compounds or carbonyl precursor reagents selected from haloformates, ketenes, activated esters, mixed anhydrides of organic or inorganic acids, isocyanates and isothiocyanates.

26

Please add the following new claims:

28. A 3,3-Diphenylprop lamine of the general formula VII':

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, 32<sup>ud</sup> Floor Chicago, IL 60606 (312)910-0001 Serial No U.S. National Phase of PCT/EP99/03212 Attorney Docket No. 00,1121

500

ı			
		но	
	$\backslash$		
50h	y	$V$ $O_{2}$ $Z$ $V$ $O_{2}$ $Z$ $V$ $O_{2}$ $V$ $O_{2}$ $V$	
K			
	I		
- 4 #  4 *  - 4 * - 4 * - - - - - - - - - - - - - - - - - -		A Formula VII'	
	wherein P is		
	a) hydrogen CC. a	alkyl CC., cycloalkyl substituted or unsubstituted benzyl allyl or	
	cathohydrate: or		
	b) formyl CC.	alkylcarhonyl cycloallylcarhonyl substituted or unsubstituted	
	arvlcarbonvl: or		
	c) CC. alkoxycarb	onvl substituted or unsubstituted arvloxycarbonyl benzovlacy	
	henzovlelvovl a substitute	ed or unsubstituted amino acid residue: or	
	n4		
	R.		
	d) N-CO	wherein $\mathbb{R}^4$ and $\mathbb{R}^5$ independently	
	R <sup>5</sup>		
<b>McDon</b> 300 Sou Chicago (312)91	nell Boehnen Hulbert & Berghoff ith Viacker Drive, 32 <sup>od</sup> Floor o, IL 50606 3-0001	27 Serial No. U.S. National Phase of PCT/BP99/ Attorney Docket No. 00	)3212 ),1121
(3.2)31			4
	-	· · ·	
		· · · · · ·	

represent hydrogen,  $C_1$ - $C_6$  alkyl, substituted or unsubstituted aryl, benzyl or phenoxyalkyl wherein the alkyl residue has 1 to 4 carbon atoms and wherein  $R^4$  and  $R^5$  may form a ring together with the amine nitrogen; or

e)

R

wherein R<sup>6</sup> and R<sup>7</sup> independently

represent  $C_1$ - $C_6$  alkyl, substituted or unsubstituted aryl, benzyl or phenoxyalkyl wherein the alkyl residue has 1 to 6 carbon atoms; or

f) an ester moiety of inorganic acids,

g)  $-SiR_{a}R_{b}R_{c}$ , wherein  $R_{a}$ ,  $R_{b}$ ,  $R_{c}$  are independently selected from  $C_{1}$ - $C_{4}$  alkyl or aryl, with the proviso that R' is not hydrogen, methyl or benzyl if R is hydrogen, R is not ethyl if R' is hydrogen,

X represents a tertiary amino group of formula Ia

## R<sup>9</sup> Formula Ia

wherein  $R^8$  and  $R^9$  represent non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and wherein  $R^8$  and  $R^9$  may form a ring together with the amine nitrogen,

Y and Z independently represent a single bond between the  $(CH_2)_n$  group and the carbonyl group,

O, S or NH,

A represents hydrogen ('H) or deuterium ('H),

n is 0 to 12, and

McDonnell Boehnen Hulbert & Berghoff 300 South V/acker Drive, 32<sup>nd</sup> Floor Chicago, IL 60606 (312)913-0001 28

Senal No U.S. National Phase of PCT/EP99/03212 Attorney Docket No. 00,1121

X re whe diff

their salts with physiologically acceptable acids, their free bases and, when the compounds are in the form of optical isomers, the racemic mixture and the individual enantiomers.

16 20 The 3,3-Diphenylpropylamines as claimed in claim 28, wherein X is .17 CH(CH<sub>3</sub>)<sub>2</sub> ℃H(CH<sub>3</sub>)<sub>2</sub> ί7 18 The 3,3-Diphenylpropylamine as claimed in claim 29 selected from phenolic monoesters 30. represented by the general formula  $\Pi'$ ĊH3 HC  $CH_{1}$ H<sub>3</sub>C CH<sub>3</sub> (CH<sub>2</sub>)<sub>n</sub> HC Formula II'. į 31. The 3,3-Diphenylpropylautic as claimed in claim 29 selected from carbonates and carbamates represented by the generation f formula VIII McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, 32<sup>nd</sup> Floor Chicage, IL 60606 (312)915-0001 29 Serial No. U.S. National Phase of PCT/EP99/03212 Attorney Docket No 00,1121



with an acylating agent of formula

(ji)

0 || C O Hal  $(CH_2)_{0}$ Hal or

wherein Hal represents a halogen atom.



 $(1 - 1)^{-1} = (1 - 1)^{-1}$ 

•	
•	
	A CH <sub>3</sub>
	HO' $\downarrow$ $\downarrow$ $\downarrow$ $\downarrow$ $CH_3$
	O H <sub>3</sub> C CH <sub>3</sub>
	$O_{\rm S}$ (CH <sub>2</sub> ) <sub>n</sub>
	O H <sub>3</sub> C CH <sub>3</sub>
	HO N CH <sub>3</sub>
	A
11 ( 11 ( 14 1	I Comuna II
/5 /5 /7	wherein n is 0 to 12, with activated carbonyl compounds or carbonyl precursor reagents selected
1 1	from holoformeter letteres estimated esters mined enhutrides of encomis or increasing estimated
	from halotormates, ketenes, activated esters, mixed annydrides of brganic or inorganic acids,
;}  }	isocyanates and isothiocyanates.
	34. A pharmaceutical composition comprising a 3,3-diphenylpropylamine according to any
Sil	one of claims 1-15 and 28-31 and a pharmaceutically acceptable carrier.
C	35. A method of antagonizing a muscarinic receptor, the method comprising contacting the
:	receptor with a compound according to any one of claims 1-15 and 28-31
	1.26 A mothod of tracting a discose in a manual that is amarchic to tractment by
L L.	1.56. A memod of treating a disease in a mammai that is amenable to treatment by
<b>L</b>	antagonizing muscarinic receptors in the mammal, the method comprising administering an 20
	amount of a composition according to claim 94 effective to diminish or eliminate symptoms of
	the disease.
22	22 337. The method according to claim $\frac{36}{56}$ wherein the disease is urinary incontinence.
McDonne 300 South	ell Boehnen Hulbert & Berghoff 32 Serial No U.S. National Phase of PCT/EP99/03212 1 Wacker Drive, 32 <sup>ed</sup> Floor Attorney Docket No. 00,1121
Chicago, (312)913	L 60606 1001
_	

23The method according to claim 27 wherein the mammal is a human.

## REMARKS

÷,

The amendments presented herein bring the claims into conformance with U.S. practice. No new subject matter has been added. If there are any questions or comments regarding this Response or application, the Examiner is encouraged to contact the undersigned attorney as indicated below.

Date: November 8, 2000

Cint

24-38

Michael S. Greenfield Registration No. 37,142

Respectfully submitted,

2. .

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive Chicago, IL 60606

Telephone: 312-913-0001 Facsimile: 312-913-0002

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, 32<sup>nd</sup> Floor Chicago, 'L 60606 (312)913 3001 Serial No. U.S. National Phase of PCT/EP99/03212 Attorney Docket No. 00,1121

33



## PRINT OF DRAWINGS AS ORIGINALLY F

ר

WU 77/30-10...

# 09/700094

PCT/EP99/03212



4

1/1

## , ATENT COOPERATION TREA (Y

	,	From the INTERNATIONAL BUREAU	
РСТ	ł	То:	
NOTIFICATION OF ELECTI	ION	Assistant Commissioner for Patents	
(PCT Rule 61.2)		Office	
	,	Box PCT Washington, D.C. 20231	
		ÉTATS-UNIS D'AMÉRIQUE	
ate of mailing:	00	in its canacity as elected Office	
18 November 1999 (18.11	.99)		
PCT/EP99/03212		Applicant's or agent's tile reference: 10022/um	
ternational filing date:	· · · · · · · · · · · · · · · · · · ·	Priority date:	
11 May 1999 (11.05.99)		12 May 1998 (12.05.98)	
pplicant:		· · · · · · · · · · · · · · · · · · ·	
The designated Office is hereby notified (	of its election mad	le:	
X in the demand filed with the Intern	ational oreliminar	v Examining Authority on	
	24 June 1999	(24.06.99)	
in a notice effecting later election f	filed with the Interi	national Bureau on:	
		· · · · · ·	
The election X was		• •	
was not			•
made before the expiration of 19 months	from the priority	date or, where Rule 32 applies, within the time limit unde	r
Rule 32.2(b).		:	
	: :		
	: 1	1	
	: · ·		
	· ·	а об об •	
<i>.</i>	ی بر ب ب		
	· ·		
The International Bureau of MAR	· · · · · · · · · · · · · · · · · · ·	Authorized officer:	
The International Bureau of WIF 34, chemin des Colombettes 1211 Geneue 20 Swizzeder	PO	Authorized officer:	
The International Bureau of Wif 34, chemin des Colombettes 1211 Geneva 20, Switzerland acsimile No.: (41-22) 740.14.35	PO	Authorized officer: J. Zahra Telephone No. (41-22) 338.83.38	
The International Bureau of Wif 34, chemin des Colombettes 1211 Geneva 20, Switzerland acsimile No.: (41-22) 740.14.35 m PCT/IB/331 (July 1992)	P0	Authorized officer: J. Zahra Telephone No. (41-22) 338.83.38	29468
The International Bureau of WiF 34, chemin des Colombettes 1211 Geneva 20, Switzerland acsimile No.: (41-22) 740.14.35 m PCT/IB/331 (July 1992)	PO	Authorized officer: J. Zahra Telephone No. (41-22) 338.83.38	29468
The International Bureau of Wif 34, chemin des Colombettes 1211 Geneva 20, Switzerland acsimile No.: (41-22) 740.14.35 rm PCT/IB/331 (July 1992)	PO ::	Authorized officer: J. Zahra Telephone No. (41.22) 338.83.38	29468
The International Bureau of Wif 34, chemin des Colombettes 1211 Geneva 20, Switzerland acsimile No.: (41-22) 740.14.35 rm PCT/IB/331 (July 1992)	P0	Authorized officer: J. Zahra Telephone No. (41.22) 338.83.38	29468
The International Bureau of Wif 34, chemin des Colombettes 1211 Geneva 20, Switzerland acsimile No.: (41-22) 740.14.35 rm PCT//B/331 (July 1992)	PO	Authorized officer: J. Zahra Telephone No. (41-22) 338.83.38	29468
The International Bureau of Wif 34, chemin des Colombettes 1211 Geneva 20, Switzerland acsimile No.: (41-22) 740.14.35 rm PCT/IB/331 (July 1992)	PO	Authorized officer: J. Zahra Telephone No. (41.22) 338.83.38	29468
The International Bureau of Wi 34, chemin des Colombettes 1211 Geneva 20, Switzerland acsimile No.: (41-22) 740.14.35 rm PCT/IB/331 (July 1992)	PO ::	Authorized officer: J. Zahra Telephone No. (41-22) 338.83.38	29468
The International Bureau of Wif 34, chemin des Colombettes 1211 Geneva 20, Switzerland acsimile No.: (41-22) 740.14.35 rm PCT/IB/331 (July 1992)	PO ::	Authorized officer: J. Zəhra Telephone No. (41-22) 338.83.38	29468
The International Bureau of Wif 34, chemin des Colombettes 1211 Geneva 20, Switzerland acsimile No.: (41-22) 740.14.35 rm PCT/IB/331 (July 1992)	PO	Authorized officer: J. Zahra Telephone No. (41.22) 338.83.38	29468
The International Bureau of Wi 34, chemin des Colombettes 1211 Geneva 20, Switzerland acsimile No.: (41-22) 740.14.35 rm PCT/IB/331 (July 1992)	PO :	Authorized officer: J. Zahra Telephone No. (41-22) 338.83.38	29468
The International Bureau of Wif 34, chemin des Colombettes 1211 Geneva 20, Switzerland acsimile No.: (41-22) 740.14.35 rm PCT//B/331 (July 1992)	PO	Authorized officer: J. Zehra Telephone No. (41.22) 338.83.38	29468

## 

To: Albrecht, Thomas KRAUS & WEISERT Thomas-Wimmer-Ring 15 80539 München ALLEMAGNE The INTERNATION REP	•
To: Albrecht, Thomas KRAUS & WEISERT Thomas-Wimmer-Ring 15 80539 München ALLEMAGNE	
Albrecht, Thomas (RAUS & WEISERT Thomas-Wimmer-Ring 15 THE INTERNATIONAL PRE ALLEMAGNE	
RRAUS & WEISERT       NOTIFICATION OF TRANS         Thomas-Wimmer-Ring 15       NOTIFICATION OF TRANS         80539 München       THE INTERNATIONAL PRE         ALLEMAGNE       EXAMINATION REP	•
Thomas-wimmer-Ring 15 B0539 München ALLEMAGNE THE INTERNATIONAL PRE EXAMINATION REP	
ALLEMAGNE EXAMINATION REP	LIMINARY
	ORT
(PCT Rule 71.1)	I .
the second of the second s	
Date of mailing 2 6. 07, 00 (day/month/year)	
Applicant's or agent's file reference 10022/um IMPORTANT NOTEFI	CATION
International application No. International filing date (day/month/year) Priority date (day/month/year) Priority date (day/month/year) 12/05/1998	onth/year)
Ann Boost	
SCHWARZ PHARMA AG.et.al	
2. A copy of the report and its annexes, if any, is being transmitted to the International Burea to all the elected Offices.	au for communicatior
3. Where required by any of the elected Offices, the International Bureau will prepare an En report (but not of any annexes) and will transmit such translation to those Offices.	glish translation of th
4. REMINDER	
The applicant must enter the national phase before each elected Office by performing centranslations and paying national fees) within 30 months from the priority date (or later in s	rtain acts (filing some Offices) (Article
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301). Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. It responsibility to prepare and furnish such translation directly to each elected Office conce	, that translation mus I is the applicant's emed.
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301). Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. It responsibility to prepare and furnish such translation directly to each elected Office conce For further details on the applicable time limits and requirements of the elected Offices, se	, that translation mus I is the applicant's emed. se Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301). Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. It responsibility to prepare and furnish such translation directly to each elected Office conce For further details on the applicable time limits and requirements of the elected Offices, so PCT Applicant's Guide.	a, that translation mus I is the applicant's emed. ee Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301). Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. It responsibility to prepare and furnish such translation directly to each elected Office conco For further details on the applicable time limits and requirements of the elected Offices, so PCT Applicant's Guide.	a, that translation mus I is the applicant's emed. se Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301). Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. If responsibility to prepare and furnish such translation directly to each elected Office conce For further details on the applicable time limits and requirements of the elected Offices, so PCT Applicant's Guide.	, that translation mus l is the applicant's emed. ee Volume II of क्षेक
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301). Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. It responsibility to prepare and furnish such translation directly to each elected Office conce For further details on the applicable time limits and requirements of the elected Offices, so PCT Applicant's Guide.	a, that translation mus I is the applicant's amed. se Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301). Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. It responsibility to prepare and furnish such translation directly to each elected Office conce For further details on the applicable time limits and requirements of the elected Offices, so PCT Applicant's Guide.	a, that translation mus I is the applicant's emed. ee Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301). Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. It responsibility to prepare and furnish such translation directly to each elected Office conce For further details on the applicable time limits and requirements of the elected Offices, su PCT Applicant's Guide.	a, that translation mus I is the applicant's emed. ee Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301). Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. It responsibility to prepare and furnish such translation directly to each elected Office conce For further details on the applicable time limits and requirements of the elected Offices, so PCT Applicant's Guide.	e Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301). Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. It responsibility to prepare and furnish such translation directly to each elected Office conce For further details on the applicable time limits and requirements of the elected Offices, so PCT Applicant's Guide.	e, that translation mus I is the applicant's amed. as Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).         Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. It responsibility to prepare and furnish such translation directly to each elected Office concernations of the applicable time limits and requirements of the elected Offices, su PCT Applicant's Guide.         Name and mailing address of the IPEA/       Authorized officer         European Palent Office       Roche, S	e, that translation mus I is the applicant's amed. se Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).         Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. It responsibility to prepare and furnish such translation directly to each elected Office concernation for further details on the applicable time limits and requirements of the elected Offices, su PCT Applicant's Guide.         Name and mailing address of the IPEA/       Authorized officer         European Patent Office       D-B0298 Munich         Tel, +49 89 2399 - 0 Tx; 523656 eomuld       Roche, S	e, that translation must is the applicant's emed. se Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).         Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. It responsibility to prepare and furnish such translation directly to each elected Office concernation of further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior function of a superior function of	e, that translation must lis the applicant's emed. ee Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).         Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. It responsibility to prepare and furnish such translation directly to each elected Office concernation of the applicable time limits and requirements of the elected Offices, supervised officer Applicant's Guide.         Name and mailing address of the IPEA/       Authorized officer         European Patent Office       Roche, S         D-80288 Munich       Tel. +49 89 2399 - 0 Tx; 523658 epmu d         Fax: +49 89 2399 - 4465       Tel.+49 89 2399-8031	e, that translation must lis the applicant's emed. ee Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).         Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. It responsibility to prepare and furnish such translation directly to each elected Office concord.         For further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior Applicant's Guide.         Name and mailing address of the IPEA/       Authorized officer         European Patent Office       Roche, S         D-80298 Munich       Tel. 449 89 2399 - 0 Tx; 523658 epmu d         Fax: +49 89 2399 - 0 Tx; 523658 epmu d       Tel.+49 89 2399-8031         Form PCT/IPEA/416 (July 1992)       SR22429, 21.07.20	e, that translation mus I is the applicant's amed. se Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).         Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. It responsibility to prepare and furnish such translation directly to each elected Office concernation of the international applicable time timits and requirements of the elected Offices, superscripts in the applicable time timits and requirements of the elected Offices, superscripts Guide.         Name and mailing address of the IPEA/       Authorized officer         Burgean Palent Office       Roche, S         D-B0298 Munich       Tel. +49 89 2399 - 0 Tr; 523658 epmu d         Fax: +49 89 2399 - 4465       Tel. +49 89 2399-8031	e, that translation must is the applicant's amed. ee Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT//B/301).         Where a translation of the International application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. It responsibility to prepare and furnish such translation directly to each elected Office concernation of the translation directly to each elected Office concernation of the translation directly to each elected Office concernation of the translation directly to each elected Offices, supervised office and mailing address of the IPEA/         Name and mailing address of the IPEA/       Authorized officer         Buropean Patent Office       P-B0298 Munich         D-B0298 Munich       Tet. +49 89 2399 - 0 Tx; 523658 epmu d         Fax: +49 89 2399 - 0 Tx; 523658 epmu d       Tet. +49 89 2399-8031         Form PCT/IPEA/416 (July 1992)       SR22429, 21.07.20	e, that translation mu l is the applicant's amed. see Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).         Where a translation of the International application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. If responsibility to prepare and furnish such translation directly to each elected Office contained for further details on the applicable time limits and requirements of the elected Offices, super contained for the translation directly to each elected Offices, super contained for the translation directly to each elected Offices, super contained for the translation directly to each elected Offices, super contained for the translation directly to each elected Offices, super contained for the translation directly to each elected Offices, super contained for the translation directly to each elected Offices, super contained for the translation directly to each elected Offices, super contained for the translation directly to each elected Offices, super contained for the translation directly to each elected Offices, super contained for the details on the applicable time limits and requirements of the elected Offices, super contained for the translation directly to each elected Offices, super contained for the details on the applicable time limits and requirements of the elected Offices, super contained for the details on the applicable time limits and requirements of the elected Offices, super contained for the details on the applicable time limits and requirements of the elected Offices, super contained for the details on the applicable time limits and requirements of the elected Office contained for the details on the applicable time limits and requirements of the elected Office for the details of the translation directly applicable time limits and requirements of the elected Office for the details of the translation directly applicable directly applicable titer translation directly applit	, that translation must lis the applicant's emed. ee Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).         Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. If responsibility to prepare and furnish such translation directly to each elected Office contained for further details on the applicable time limits and requirements of the elected Offices, superior for further details on the applicable time limits and requirements of the elected Offices, superior Applicant's Guide.         Name and mailing address of the IPEA/       Authorized officer         European Palent Office       Boche, S         D-80288 Munich       Roche, S         Tel. +49 89 2399 - 0 Tx; 523658 epmu d       Fax; +49 89 2399 - 0 Tx; 523658 epmu d         Fax; +49 89 2399 - 4465       Fel.+49 89 2399-8031	e, that translation must lis the applicant's emed. ee Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).         Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. If responsibility to prepare and furnish such translation directly to each elected Office contained for further details on the applicable time limits and requirements of the elected Office contained for further details on the applicable time limits and requirements of the elected Offices, superior Applicant's Guide.         Name and mailing address of the IPEA/       Authorized officer         Buropean Palent Office       Roche, S         D-80298 Munich       Tel. +49 89 2399 - 0 Tx; 523658 epmu d         Tal: +49 89 2399 - 0 Tx; 523658 epmu d       Tel.+49 89 2399-8031         Form PCT/IPEA/416 (July 1992)       SR22429, 21.07.20	e, that translation mus is the applicant's emed. ee Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).         Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. If responsibility to prepare and furnish such translation directly to each elected Office concernation of further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior function of a superior function of	e Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).         Where a translation of the International application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. If responsibility to prepare and furnish such translation directly to each elected Office concernations of the applicable time limits and requirements of the elected Offices, so PCT Applicant's Guide.         Name and mailing ackress of the IPEA/       Authorized officer         European Patent Office       Roche, S         D-80298 Munich       Tel. 449 89 2399 - 0 Tx; 523658 epmu d         Fax: 449 89 2399 - 4465       Tel. 449 89 2399 - 8031	e, that translation mus I is the applicant's emed. ee Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).         Where a translation of the international application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. If responsibility to prepare and furnish such translation directly to each elected Office contained for further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior function of the IPEA/         Image: Superior function of the IPEA/       Authorized officer         Roche, S       European Patient Office       Roche, S         D-B0298 Munich       Tet. +49 89 2399 - 0 Tx; 523656 epmu d       Fax: +49 89 2399 - 4465         Form PCT/IPEA/416 (July 1992)       SR22429, 21.07 20	e, that translation must lis the applicant's emed. ee Volume II of the
39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).         Where a translation of the internetional application must be furnished to an elected Office contain a translation of any annexes to the international preliminary examination report. It responsibility to prepare and furnish such translation directly to each elected Office concernations of the applicable time limits and requirements of the elected Office concernation of the internetional preliminary examination report. It responsibility to prepare and furnish such translation directly to each elected Office concernations of the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Offices, superior further details on the applicable time limits and requirements of the elected Office on the PCT Applicant's Guide.         Name and mailing address of the IPEA       Authorized officer         European Patent Office       Body and Fax: +49.89 2399 - 0.7x; 523656 epmu d         Fax: +49.89 2399 - 0.7x; 523656 epmu d       Tel.+49.89 2399-8031         Form PCT/IPEA/416 (July 1982)	e, that translation must i is the applicant's emed. ee Volume II of the

1

Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0209

Transaction History Date 2000-12-05 Date information retrieved from USPTO Patent Application Information Retrieval (PAIR) system records at www.uspto.gov

		UNITED STAT Patent and Tra Address: ASSISTA Box PCT Washington D	TES DEPART demark Office NT COMMISSIC	IMENT O	F COMMERCE
	To STATIS OF LEAST			•	
U.S. APPLICATION NO	···	FIRST NAMED	APPLICANT		ATTY. DOCKET NO
09/700094	· ·	MEESE	С	<u></u>	MBHB00-1121
MCDONNELL BOFHNEN HULB	FRT & BERGHOFF		NI IN	FERNATIONAL	APPLICATION NO.
300 SOUTH WACKER DRIVE				PCT/EP	99/03212
CHICAGO, IL 60606			LA Fit	ING DATE	
			11 M		
			DATE MAILED:	A 12 min	
STAT 1. The following items have been su a Designated Office a n Elected Office (3) U.S. Basic National Fee. Copy of the international app a non-English langu K English. Translation of the internation Oath or Declaration of inven Copy of Article 19 amendme Translation of Article 19 ame The International Preliminary Translation of Annexes to the Preliminary amendment(s) fi K Information Disclosure State Assignment document. Power of Attorney and/or Ch	ES DESIGNATED/ ubmitted by the applic (37 CFR 1.494), 7 CFR 1.495): blication in: age. al application into En tors(s) for DO/EO/U nts. endments into English y Examination Report e International Prelim bled <u>8 nov 200</u> ment(s) filed <u>8</u> wange of Address.	ELECTED OFFIC cant or the IB to the nglish. S	E (DO/EO/U United States Annexes, if an Report into E	S) Patent and ny. nglish.	d Trademark Office as
<ul> <li>Verified Statement Claiming</li> <li>Priority Document.</li> <li>Copy of the International Sea</li> <li>Other:</li> <li>The following items MUST be fricceptance under 35 U.S.C. 371:</li> <li>a. Translation of the applicat appropriate 20 or 30 months</li> <li>The current translation.</li> <li>b. Processing fee for providing 30 months from the priority of X c. Oath or declaration of the the International application of the attached PCT</li> <li>d. Surcharge for providing the (37 CFR 1.492(e)).</li> <li>Additional claim fees of \$</li></ul>	Small Entity Status. arch Report <b>1</b> and con- arnished within the pre- tion into English. No from the priority data ation is defective for ing the translation of the late (37 CFR 1.492(1) inventors, in compliant number and internation declaration does not /DO/EO/917, the oath or declaration as a larg	opies of the reference eriod set forth below te a processing fee e. or the reasons ind the application and/o )). note with 37 CFR 1 onal filing date. comply with 37 CFI later than the appro-	es cited there in order to c will be require icated on the or the Annexe .497(a) and (t R 1.497(a) and opriate 20 or 2 tity, including	in. complete th ed if subm a attached s later tha ), identify d (b) for th 30 months ; any requi	e requirements for ttted later than the Notice of Detective in the appropriate 20 or ing the application by the reasons indicated from the priority date ired multiple dependent
aim fee, are required. Applicant n lue. See attached PTO-875.	HIN 2(a)-2(d) AND	onal claim fees or c	ancel the addi	tional clain	ms for which fees are
TROM THE DATE OF THIS NOT THE APPLICATION, WHICHEV ABANDONMENT.	TICE OR BY 21 ER IS LATER. FA	OR 31 MONTH	IS FROM THERLY RESP	IE PRIOI	RITY DATE FOR LL RESULT IN
The time period set above may be ex TFR 1.136(a).	ttended by filing a pe	tition and fee for ex	tension of tim	e under th	e provisions of 37
4. Translation of the Annexes MUS' Note processing fee will be required 5. The Article 19 amendments ar 194(d)) or 30 (37 CFR 1.495(d)) mo	T be submitted no lat if submitted later that e cancelled since a tr mths from the priority	er that the time period in 30 months from t anslation was not pr v date.	od set above he priority da rovided by the	or the annu te. appropria	exes will be cancelled. 1e 20 (37 CFR.
Applicant is reminded that any comm address given in the heading and incl	unication to the Unit ude the U.S. applica	ed States Patent and tion no. shown abov	Trademark ( e. (37 CFR 1	Office mus .5)	t be mailed to the
A copy of this notic	e MUST be r	eturned with	this res	ponse.	, ,
Enclosed: ] PCT/DO/EO/917 ] PTO-875	Notice of Defe	ctive Translation	SHEL	BY VIGI	

·

JCP? "Rec'd PCT/PTO

Group Art Unit: TBA



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 00,1121)

In application of:

## Meese and Sparf

09/700,094 Serial No.

Filed: November 8, 2000

Novel Derivatives of 3,3-Diphenylpropylamines For:

#### TRANSMITTAL LETTER

BOX PCT

÷

210

Asst. Commissioner for Patents Washington, D.C. 20231

01/03/2001 IVERT Sitio00042 09700094 Q12FC:154

1.

In regard to We We we identified application,

We are transmitting herewith the attached:

- copy of Notice to File Missing Requirements; a)
- Response to Notice to File Missing Requirements; b)
- c) Declaration and Power of Attorney; and

d) return receipt postcard.

With respect to fees: 2.

- A check in the amount of \$130.00 is enclosed. a)
- Please charge any underpayment or credit any overpayment our Deposit Account, No. b) 13-2490.

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that 3. this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Asst. Commissioner for Patents, Washington, D.C. 20231 on December 27, 2000.

Date: December 27, 2000

Respectfully submitted, Michael S. Greenb Registration No. 37,142

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive Chicago, 1L 60606 (312)91 3-0001



÷v:

22.

UNIT: ATES DEPAINS MAN. Patent and "Scademark Office Admss: ASISTANT COMMISSIONER POR PATENTS Box PCT Washington, D.C. 20231 ATES DEPARTMENT OF COMMERCE

U.S. APPLICATION N FIRST NAMED APPLICANT ATTY BOCKIT NO. 09/700094 MEESE С MBHB00-1121 INTERNATIONAL APPLICATION NO MCDONNELL BOEHNEN HULBERT & BERGHOFF 300 SOUTH WACKER DRIVE PCT/EP99/03212 CHICAGO, IL 60606 . . PRICILITY DATE I.A. FILING DATE Г 11 MAY 99 12 MAY 98 DATE MAIL In the following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated Office (37 CFR 1.494), an Elected Office (37 CFR 1.495): DOCKETED U.S. Basic National Fee. Copy of the international application in: DEC\_1 8\_2000 1-5-01 ULE DAY I Translation of the international application into English. AB Oath or Declaration of inventors(s) for DO/EO/US. Copy of Article 19 amen ments. Translation of Article 19 amendm ents into English. The International Preliminary Examination Report in English and its Annexes, if any. Translation of Annexes to the International Preliminary Examination Report into English. Information Disclosure Statement(s) filed 8 nov 2000 and
 Information Disclosure Statement(s) filed 8 nov 2000 and \_\_ and Assignment document. Substitute specification filed
Verified Statement Claiming Small Entity Status.

Priority Document. Copy of the International Search Report and copies of the references cited therein. Other: LI Other: 2. The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371: 3. Translation of the application into English. Note a processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date. The current translation is defective for the reasons indicated on the attached Notice of Defective Translation. b. Processing fee for providing the translation of the application and/or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)). SU monute from the priority date (3/ CFR 1.494(1)).
 C. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
 The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917. Surcharge for providing the cash or declaration later than the appropriate 20 or 30 months from the priority date X d (37 CFR 1.492(c)).
 Additional claim fees of \$\_\_\_\_\_\_as a large entity ismall entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due. See attached PTO-875. ALL OF THE FIEMS SET FORTH IN 2(a)-2(d) and 3 above must be submitted within one month prom the date of this notice or by  $\Box$  21 or  $\Box$  31 months from the priority date for the application, whichever is later. Failure to properly respond will result in abandonment. The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a). 4. Translation of the Annexes MUST be submitted no later that the time period set above or the annexes will be cancelled. Note processing fee will be required if submitted later than 30 months from the priority date.
5. The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR. 494(d)) or 30 (37 CFR 1.495(d)) months from the priority date. Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5) A copy of this notice MUST be returned with this response. Enclosed: PCT/DO/E0/917 Notice of Defective Translation SHELBY VIGIL, PARALEGA Telephone: 703-305-3653 FORM PCT/DO/EO/905 (December 1997)

PTO/PCT Rec'd 2 JAN 2001

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 00,1121)

In application of:

Meese and Sparf

Serial No. 09/700,094

Filed: November 8, 2000

Group Art Unit: TBA

For: Novel Derivatives of 3,3-Diphenylpropylamines

## **RESPONSE TO NOTICE OF MISSING REQUIREMENTS**

)

## BOX PCT

Asst. Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In response to the Notice of Missing parts, applicants submit herewith an executed combined Declaration and Power of Attorney. In accordance with the surcharge requirement of 37 CFR 1.492(e), also enclosed is a check in the amount of \$130.00.

Respectfully submitted,

Date: December 27, 2000

Michael S. Gree Registration No. 37,142

McDonnell Boehnen Hulbert & Berghoff 300 South Wacker Drive, 32<sup>nd</sup> Floor Chicago, IL 60606

Telephone: 312-913-0001 Facsimile: 312-913-0002

CERTIFICATE OF MAILING (37 C.F.R. 1.8a) I hereby certify that this correspondence is being deposited with the Unit the Assistant Commissioner for Patents, Washington D C. 20231, on D United Stat

Date December 27, 2000

Case No.: MBHB00,1121

## DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Novel Derivatives of 3.3-diphenylpropylimines

the specification of which is attached hereto unless the following space is checked:

was filed on November 8, 2000 as United States Application Serial Number

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I asknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(a) for patient or inventor's cartificate, or § 365(a) of any PCT international application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's cartificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior	Foreign Application(s)	t		1
	Number	Country	Day/Month/Year Filed	
1.	98108608.5	EPO	12 May 1998	
2.				
I here	by claim the henefit m	der 35 IISC & 119(e)	of any United States provisional and	lication(s) listed helow:
1 0.4	Application Number		late	
,	reputation runto			
1.				

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(2), or § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claums of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the mational or PCT international filing date of this application.

1.	Application Number	Filing Date	Status: patented, pending, abandoned
	PCT/EP99/03212	1 May 1999	Abandoned

VELL BORHNEN T & BERCHORR JTH WACCIE DIR/J' D ILLINDIS SOLOC DNE (312) 113-000'

<u>,</u>]

#### 18/12 '00 MO 10:15 FAX +49 89 29080111

÷

Date: 13 December 2000

I hereby appoint the practitioners associated, with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Tradomark Office connected therewith, and I direct that all coursepondence be addressed to that Customer Number.

j

Customer Number: -020306

Principal attorney or agent: <u>Michael S. Greenfield, Reg. No. 37, 142</u> Telephone number: 312-913-0001

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Table 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: Claus Meese

8 December 2000 Ŀ Vni Date: Inventor's signature: Residence: Germany Civizenship: Germany Post Office Address: Kreuzberger Strasse 50, D-40789 Month

- 2 -

Full name of second joint inventor. Bengt Spart

Inventor's signature: Residence: Sweden Ciazenship: Sweden Post Office Address: Drotningstigen 6, S-142 65 Trangsund

GUTU WAOKER DRIVE NGO. ILLINDIH GOBDA HONE (31 2) 91 3-00(1)

7.

	ANT ANT CON CORRECT	UNITED STATES DEPARTM Patent and Trademark Office	ENT OF COMMERCE
		Address: ASSISTANT COMMISSION	R FOR PATENTS shington, D C. 2023 J
	F 30 974788 08 4084		
US APPLICATION NO		FIRST NAMED APPI ICANT	ATTY DOCKET NO.
09/700094	M	ESE <u>C</u>	MBHB00-1121
CDONNELL BOEHNEN HULB 20 SOUTH WACKER DRIVE	ERT & BERGHOFF		PCT/EP99/03212
UITE 3200 HICAGO, IL 60006	•		C DATE PRIORITY DATI
		11 M/	Y 99 12 MAY 98
NOTIFICATION O	F ACCEPTANCE (	F APPLICATION UND	daye mailed <b>16</b> JAN 2001 ER 35 U.S.C. 371
	AND 37 CFR	1.494 OR 1.495	
The applicant is hereby advised	d that the United State	Patent and Trademark Offic	e in its capacity as 🔲 a
esignated Office (37 CFR 1.494 entified international applicatio itentability examination in the L	b), 🗶 an Elected Offi on has met the requirer United States Patent an	e (37 CFR 1.495), has detern ents of 35 U.S.C. 371, and is I Trademark Office.	nined that the above ACCEPTED for national
The United States Application	n Number assigned to	he application is shown abov	e and the relevant dates are:
2 jan 2001	ť	2 jan 2001	
35 U.S.C. 102(e) DATE	DATE	OF RECEIPT OF	
	35 U.S	C. 371 REQUIREMENTS	
the international application (, nd all correspondence to the Gr	Article 11(3) and 35 L roup Art Unit designal	S.C. 363). Once the Filing R d thereon.	eccipt has been received,
A request for immediate e e application will be examined	examination under 35 in turn.	J.S.C. 371(f) was received on	8 nov 2000 and
		· .	· ·
The following items have been	-		•
The following items have bee	en received:		• •
The following items have been U.S. Basic National Fee.	en received:		
The following items have been U.S. Basic National Fee. Copy of the international a non-English	en received: application in: 1 language.		· · ·
The following items have been U.S. Basic National Fee. Copy of the international a non-English English.	en received: application in: 1 language. tional application into	English	· · ·
The following items have been U.S. Basic National Fee. Copy of the international English Translation of the internation Oath or Declaration of inv	en received: application in: n language. tional application into ventors(s) for DO/EO/	English. JS.	· · · ·
The following items have been U.S. Basic National Fee. Copy of the international English Translation of the internation Oath or Declaration of inv Copy of Article 19 amend	en received: application in: n language. tional application into ventors(s) for DO/EO/ lments.	English. JS. of Article 19 amendments in	to English.
The following items have been U.S. Basic National Fee. Copy of the international English. Translation of the internation Oath or Declaration of inv Copy of Article 19 amend The Article 19 ar	en received: application in: n language. tional application into ventors(s) for DO/EO/ liments Translation mendments . have [	English. JS. of Article 19 amendments in have not been entered.	to English.
The following items have been U.S. Basic National Fee. Copy of the international Fee English. Translation of the internat Oath or Declaration of inv Copy of Article 19 amend The Article 19 ar	en received: application in: n language. tional application into ventors(s) for DO/EO/ lments. Translation mendments have [ nary Examination Rep	English. JS. of Article 19 amendments in have not been entered. ort in English and its Annexe	to English. 5, if any. ED)
The following items have been U.S. Basic National Fee. Copy of the international English. Translation of the internate Oath or Declaration of inv Copy of Article 19 amend The Article 19 ar The International Prelimit Copy of the Annexes to th Translation of the International Prelimit	en received: application in: n language. tional application into ventors(s) for DO/EO/ liments Translation mendments . have . nary Examination Rep ne International Prelim f Annexes to the IEEE	English. JS. of Article 19 amendments in have not been entered. ort in English and its Annexe nary Examination Report (IF	to English. 5, if any. ER).
The following items have been U.S. Basic National Fee. Copy of the international in the international in the international in the internation of the Article 19 amend in the Article 19 are in the International Prelimit Copy of the Annexes to the Translation o The Annexes I in the Annexes I in the International Prelimit Copy of the Annexes I in the Anne	en received: application in: n language. tional application into ventors(s) for DO/EO/ liments. Translation mendments. have [] nary Examination Rep ne International Prelim f Annexes to the IPER have [] have not be	English. JS. of Article 19 amendments in have not been entered. ort in English and its Annexe nary Examination Report (IF into English. on entered.	to English. 5, if any. ER).
The following items have been U.S. Basic National Fee. Copy of the international English. Translation of the internate Oath or Declaration of inv Copy of Article 19 amend The Article 19 ar The International Prelimin Copy of the Annexes to th Translation o The Annexes Preliminary amendment(s	en received: application in: n language. tional application into ventors(s) for DO/EO/ lments Translation mendments . have . nary Examination Rep ne International Prelim f Annexes to the IPEF have . have not be ) filed . 8 nov 200	English. JS. of Article 19 amendments in have not been entered. ort in English and its Annexe nary Examination Report (IF into English. on entered. and	to English. 9, if any. ER).
The following items have been U.S. Basic National Fee. Copy of the international for the international for the international for the internation of the international for the Article 19 are for the Article 19 are for the Annexes to the Translation of the Annexes for the A	en received: application in: n language. tional application into ventors(s) for DO/EO/ liments Translation mendments have [ nary Examination Rep ne International Prelim of Annexes to the IPEF have have not be have not be filed 8 nov 200 matement(s) filed	English. JS. of Article 19 amendments in have not been entered. ort in English and its Annexe nary Examination Report (IF into English. on entered. and nov 2000 and	to English. 5, if any. ER).
The following items have been          Image: Second state of the international image: Second state of the international image: Second state of the international image: Second state of the internation of the international image: Second state of the international image: Second state of the image:	en received: application in: n language. tional application into ventors(s) for DO/EO/ liments	English. JS. of Article 19 amendments in have not been entered. ort in English and its Annexe nary Examination Report (IF into English. on entered. and nov 2000and	to English. 5, if any. ER).
The following items have been U.S. Basic National Fee. Copy of the international Basic National Fee. Copy of the international English. Translation of the internation Oath or Declaration of inv Copy of Article 19 amend The Article 19 are The International Prelimin Copy of the Annexes to th Translation o The Annexes Preliminary amendment(s Frediminary amendment(s Assignment document. Power of Attorney and/or	en received: application in: n language. tional application into ventors(s) for DO/EO/ liments. Translation mendments have [] nary Examination Rep ne International Prelim f Annexes to the IPER have [] have not be blad 8 nov 200 satement(s) filed Change of Address.	English. JS. of Article 19 amendments in have not been entered. ort in English and its Annexe nary Examination Report (IF into English. en entered. and nov 2000 and	to English. s, if any. ER).
The following items have been U.S. Basic National Fee. U.S. Basic National Fee. Copy of the international English. Translation of the internat Oath or Declaration of inv Oath or Declaration of inv Copy of Article 19 amend The Article 19 ar The International Prelimin Copy of the Annexes to th Translation o The Annexes Preliminary amendment(s Preliminary amendment. Power of Attorney and/or Substitute specification fi	en received: application in: n language. tional application into ventors(s) for DO/EO/ liments. Translation mendments. have [ nary Examination Rep ne International Prelim f Annexes to the IPEF have [] have not be ) filed <u>8 nov 200</u> matement(s) filed Change of Address. led	English. JS. of Article 19 amendments in have not been entered. ort in English and its Annexe nary Examination Report (IF into English. on entered. and nov 2000and	to English. s, if any. ER).
The following items have been U.S. Basic National Fee. Copy of the international in a non-English English. Translation of the internation Oath or Declaration of inv Oath or Declaration of inv Copy of Article 19 amend The Article 19 are The International Prelimit Copy of the Annexes to th Translation o The Annexes Preliminary amendment(s Frediminary amendment(s Frediminary and/or Substitute specification fi Verified Statement Claim	en received: application in: n language. tional application into ventors(s) for DO/EO/ liments. Translation mendments have [] nary Examination Rep ne International Prelim of Annexes to the IPEF have [] have not bu billed <u>8 nov 200</u> atement(s) filed Change of Address. led ing Small Entity Statu	English. JS. of Article 19 amendments in have not been entered. ort in English and its Annexes nary Examination Report (IF into English. en entered. and nov 2000 and	to English. 5, if any. ER).
The following items have been U.S. Basic National Fee. Copy of the international English. Copy of the internation of the Article 19 amend The Article 19 amend The Article 19 article 19 article Copy of the Annexes to the Translation on The Annexes Important on Disclosure Statement document. Power of Attorney and/or Substitute specification find Verified Statement Claim Priority Document. Copy of the International	en received: application in: n language. tional application into ventors(s) for DO/EO/ liments	English. JS. of Article 19 amendments in have not been entered. ort in English and its Annexe nary Examination Report (IF into English. on entered. and nov 2000 and	to English. 5, if any. ER).
The following items have been U.S. Basic National Fee. Copy of the international is a non-English English. Translation of the internate Oath or Declaration of inv Copy of Article 19 amend The Article 19 ar The International Prelimit Copy of the Annexes to th Translation o The Annexes Preliminary amendment(s Findematical Statement Claim Priority Document. Copy of the International Other:	en received: application in: n language. tional application into ventors(s) for DO/EO/ liments Translation mendments have [ nary Examination Rep ne International Prelim f Annexes to the IPEF have have not be have c have not be that c have not be have c have not be that c have not be have c have not be change of Address. led Search Report I an	English. JS. of Article 19 amendments in have not been entered. ort in English and its Annexe nary Examination Report (IF into English. en entered. and nov 2000and copies of the references cite	to English. s, if any. ER).
The following items have been U.S. Basic National Fee. Copy of the international in the international in the internation of the Article 19 are the	en received: application in: n language. tional application into ventors(s) for DO/EO/ liments. [] Translation mendments [] have [] nary Examination Rep ne International Prelim f Annexes to the IPEF have [] have not be bar of Address. led ting Small Entity Statu Search Report [] an	English. JS. of Article 19 amendments in have not been entered. ort in English and its Annexe nary Examination Report (IF into English. en entered. and nov 2000 and  copies of the references cite mited States Fatent and Trade	to English. s, if any. ER). d therein. mark Office must be mailed
The following items have been U.S. Basic National Fee. Copy of the international is a non-English English. Translation of the internation of the Article 19 are the Article 19 are to the international Prelimin Copy of the Annexes to the Translation of The Annexes II Information Disclosure Statement document. Power of Attorney and/or Substitute specification fi Verified Statement Claim Priority Document. Copy of the International Other:	en received: application in: n language. tional application into ventors(s) for DO/EO/ liments. Translation mendments have [] nary Examination Rep ne International Prelim of Annexes to the IPEF have [] have not bu b) filed <u>8 nov 200</u> atement(s) filed Change of Address. led Change of Address. led Search Report <b>X</b> an communication to the U	English. JS. of Article 19 amendments in have not been entered. ort in English and its Annexes nary Examination Report (IF into English. en entered. 	to English. s, if any. ER). d therein. mark Office must be mailed (37 CFR 1.5) {}
The following items have been U.S. Basic National Fee. Copy of the international in the international in the internation of the Article 19 are the international Prelimine Copy of the Annexes to the Translation on The Annexes are the Annexes	en received: application in: n language. tional application into ventors(s) for DO/EO/ liments. Translation mendments have [ nary Examination Rep ne International Prelim f Annexes to the IPEF have have not be have have not be the have have not be have have not be the have have not be have have not be the have have not be have have not be a nov 200 tatement(s) filed Change of Address. led ing Small Entity Statu Search Report  an ommunication to the U g and include the U.S	English. JS. of Article 19 amendments in have not been entered. ort in English and its Annexe nary Examination Report (IF into English. en entered. 	to English. s, if any. ER). therein. therein. mark Office must be mailed (37 CFR 1.5)
The following items have been U.S. Basic National Fee. Copy of the international is a non-English English. Translation of the internation Oath or Declaration of inv Copy of Article 19 amend The Article 19 are The International Prelimit Copy of the Annexes to th Translation o The Annexes Preliminary amendment(s Preliminary amendment(s Finformation Disclosure St Assignment document. Power of Attorney and/or Substitute specification fi Verified Statement Claim Priority Document. Copy of the International Other: Delicant is reminded that any cothe address given in the headin DRM PCT/DO/EO/903 (Decem	en received: application in: n language. tional application into ventors(s) for DO/EO/ liments. Translation mendments have [] nary Examination Rep ne International Prelim of Annexes to the IPEF have [] have not bu billed <u>8 nov 200</u> atement(s) filed Change of Address. led Change of Address. led Search Report <b>X</b> an communication to the U ng and include the U.S aber 1997)	English. JS. of Article 19 amendments in have not been entered. ort in English and its Annexes nary Examination Report (IF into English. en entered. and nov 2000 and row 2000 and nov 2000 and Shelby J. Telephone: 703-305-3	to English. a, if any. ER). d therein. mark Office must be mailed (37 CFR 1.5) Vigil
The following items have been U.S. Basic National Fee. Copy of the international is a non-English English. Translation of the internate Oath or Declaration of inv Copy of Article 19 amend The Article 19 ar The International Prelimit Copy of the Annexes to th Translation of Disclosure St Assignment document. Power of Attorney and/or Substitute specification fi Verified Statement Claim Priority Document. Copy of the International Co	en received: application in: n language. tional application into ventors(s) for DO/EO/ liments Translation mendments have [ nary Examination Rep ne International Prelim f Annexes to the IPEF have [ have not be ) filed 8 nov 200 latement(s) filed Change of Address. led ing Small Entity Statu Search Report 🗶 an ommunication to the U spand include the U.S have 1997)	English. JS. of Article 19 amendments in have not been entered. ort in English and its Annexe nary Examination Report (IF into English. en entered. 	to English. s, if any. ER). d therein. mark Office must be mailed (37 CFR 1.5) Vigil
The following items have been U.S. Basic National Fee. Copy of the international is a non-English English. Translation of the internation of the Article 19 are the A	en received: application in: a language. tional application into ventors(s) for DO/EO/ liments. Translation mendments have [] have [] have [] have [] have c] have not be b filed <u>8 nov 200</u> atement(s) filed Change of Address. led Change of Address. led Search Report <b>X</b> an communication to the U ng and include the U.S aber 1997)	English. JS. of Article 19 amendments in have not been entered. ort in English and its Annexes nary Examination Report (IF into English. en entered. and nov 2000 and row 2000 and copies of the references cite hited States 1 stent and Trade application no. shown above Shelby J. Telephone: 703-305-3	to English. a, if any. ER). d therein. mark Office must be mailed (37 CFR 1.5) Vigil

200

лан с. С
IPE б APR 2 4 2001 

#### ber's Docket No. \_\_\_\_\_\_

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

X in re application of: Meese et al.Serial No.: 09 / 700,094Group No.: 1614Filed: January 2, 2001Examiner: Not Yet AssignedFor:NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES

Patent No\*: Basued:

NOTE: insert name(s) of inventor(s) and this also for patent.

#### Assistant Commissioner for Patents Washington, D.C. 20231

#### POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST (REVOCATION OF PRIOR POWERS)

As assignee of record of the entire interest of the above identified

I application,

D patent,

#### REVOCATION OF PRICE BOWERS OF ATCORNEY

all powers of attorney previously given are hereby revoked and

#### NEW POWER OF ATTORNEY

the following attorney(s) and/or agent(s) are hereby appointed to prosecute and transact all business in the Patent and Trademark Office connected therewith.

David G. Conlin George W. Neuner Linda M. Buckley Peter J. Manus Peter F. Corless Cara Z. Lowen William J. Daley, Jr.

wear t	NO. 21	,020
Reg. N	lo. 26	,964
Reg. N	NO. 31	,003
Reg. N	lo. 26	,766
Reg. N	lo. 33	,860
Reg. N	lo. 38	,227
Rea. N	lo. 35	.487

Deg No. 27.026

Christine C. O'Day	Reg. No. 38,256
Robert L. Buchanan	Reg. No. 40,927
David E. Tucker	Reg. No. 27,840
isa Swiszcz Hazzard	Reg. No. 44,368
George W. Hartnell	Reg. No. 42,639
Kathleen Carr	Reg. No. 41,658
Stewart L. Gitler	Reg. No. 31,256

۰.

(check the following item; if applicable)

Attached, as part of this power of attorney, is the authorization of the abovenamed attorney(s) to accept and follow instructions from my representative(s).

(Power of Attorney by Assignee of Entire Interast [12-2]-page 1 of 2)

1P APR 2 4 2001 CADEMARY SEND CORRESPONDENCE DIRECT TELEPHONE CALLS TO: Peter F. Corless Peter F. Corless: (617) 523-3400 EDWARDS & ANGELL, LLP Dike, Bronstein, Roberts & Cushman, IP Group . ÷. . 130 Water Street Boston, MA 02109 Customer No.: Schwarz Pharma AG (type or print identity of easignee of entire interest) Alfred-Nobel-Straße 10 Address Monheim, Germany D-40789 Recorded in PTO on . Reel Frame \*The executed Assignment document was forwarded to the U.S. Patent Office on January 9, 2001 (copy enclosed). Applicant has not yet received the Notice of Recordation. ASSIGNEE STATEMENT Attached to this power is a "STATEMENT UNDER 37 C.F.R. 3.73(b)." Kuf W alaul The Humen is Date March 01, 2001 ppa. Klaus-Dieter Hommerich i.V. Dietrich W. Schacht (type or print name of person authorized to sign on behalf of assignee) Authorized Officer Assistant Manager Title NOTE: The assignee of the entire interest may revoke previous powers and be represented by an attorney of his or her selection. 37 C.F.R. § 1.36. (check the following item, if it forms a part of this power of attorney) Added page-Authorization of attorney(s) to accept and follow instructions from representative. ÷., (Power of Attorney by Assignee of Entire Interest [12-2]-page 2 of 2)

GAU 1614

	THE UNITED STATE	IS PATENT AND TRADEMARK OFFICE	لنحورهم
In re application M	lion of: <u>Meese</u> et al lo:: 09/700,094	1. 약 Group No.: 1614 유 문	REC
Filed: Janu For: NOVEL	BTY 2, 2001 DERIVATIVES OF	Examinar: Not Yet Assigned	H.
Patent*:	ROPYLAMINES		N
Reexaminatik	on No.:	Issue Date:	0
	·	Issue Date:	
•NOTE: Inee	int name(a) of inventor(a) and	tible for patent.	
Assistant Co Washington	, D.C. 20231	nte	
E.	STATEMENT	UNDER 37 C.F.R. § 3.73(b)-	
	STADLISHING AND	II OF ASSIGNEE IO TARE ACTION	
	:		
	CERTIFICATION	UNDER 37 C.F.R. \$\$ 1.8(a) and 1.10*	
	(when using sopress when Express	, the copress Mail lebel number is internetiony; Mail certification is optional.)	
I hereby certify	that, on the data shown be	iow, this correspondence is being: MAILING	
or Patenta,	with the United States Poeta , Washington, D.C. 20231	I Service in an envelope addressed to the Assistant Commissioner	
X with sufficie	37 G.F.R. § 1.8(a) Int postage as first class me	JI. I as "Express Mail Post Office to Addressee" Mailing Label No(manufatory)	
1 transmitted		TRANSMISSION	
	by facamine to the Patent a	Namme M. M. A.	
Date: 4/20	101	Signature	
•		type or print name of person cartilying)	
WARNING: E	Each paper or fee filed by Equipaced thereon prior to mailing	press Mail must have the number of the "Express Mail" mailing label ng. 37 C.F.R. § 1.10(b).	
h /	Since the tiling of correspon a an oversight that can be av equinement will not be grants	Idence under § 1.10 without the Express Mail making label thereon rokled by the exercise of reasonable care, requests for weiver of this ad on petition." Notice of Oct. 24, 1998, 60 Fed. Reg. 56,439, at 56,442.	
	_		
		· ·	
(Statement ur	nder 37 C.F.R. § 3.73(b)	Establishing Right of Assignee to Take Action [18-16]-page 1 of 4)	
(Statement ur	nder 37 C.F.R. § 3.73(b)	Establishing Right of Assignee to Take Abtion [18-16]—page 1 of 4)	
(Statement ur	nder 37 C.F.R. § 3.73(b) i	Establishing Right of Assignee to Take Abtion [18-16]-page 1 of 4)	
(Statement ur	nder 37 C.F.R. § 3.73(b)	Establishing Right of Assignee to Take Abtion [16-16]page 1 of 4)	
(Statement ur	nder 37 C.F.R. § 3.73(b)	Establishing Right of Assignee to Take Astion [18-16]page 1 of 4)	
(Statement ur	nder 37 C.F.R. § 3.73(b)	Establishing Right of Assignee to Take Astion [18-16]page 1 of 4)	
(Statement ur	nder 37 C.F.R. § 3.73(b)	Establishing Right of Assignee to Take Astion [18-16]page 1 of 4)	
(Statement ur	nder 37 C.F.R. § 3.73(b)	Establishing Right of Assignee to Take Astion [18-16]page 1 of 4)	· ·
(Statement ur	nder 37 C.F.R. § 3.73(b)	Establishing Right of Assignee to Take Astion [18-16]page 1 of 4)	
(Statement ur	nder 37 C.F.R. § 3.73(b)	Establishing Right of Assignee to Take Astion [18-16] page 1 of 4)	
(Statement ur	nder 37 C.F.R. § 3.73(b)	Establishing Right of Assignee to Take Astion [18-16]—page 1 of 4)	· ·
(Statement ur	nder 37 C.F.R. § 3.73(b)	Establishing Right of Assignee to Take Astion [18-16] page 1 of 4)	· ·

4

Ϋ.,

· .

- NOTE: 37 CFR 3.73(b) states: "When an assignee seeks to take action in a matter before the Office with respect to a patent application, . . ., patent, registration, or reexamination proceeding, the assignee must establish its ownership of the property to the astisfaction of the Commissioner. Ownership is established by submitting to the Office, in the Office file related to the matter in which action is aought to be taken, documentary evidence of a chain of title from the original owner to the assignee (e.g., copy of an executed assignment submitted for recording) or by specifying (e.g., teel and frame number) where such evidence is recorded in the Office. The submission establishing ownership must be signed by a party authorized to act on behalf of the assignee, Documents submitted to establish ownership may be required to be recorded as a condition to permitting the assignee to take action in a matter pending before the Office."
- NOTE: "Section 3.73(b) is amended to remove the sentence requiring an assignee to specifically state that the evidentiary documents have been reviewed and to cartify that title is in the assignee seeking to take action. The sentence is deemed to be unnecessary in view of the amendment to §§ 1.4(d) and 10.16." Notice of Oct. 10, 1997, 62 Fed. Reg. 53,131, at 53,174.

1. The assignee(s) of the entire right, title and interest hereby seek(s) to take action in the PTO in this matter.

#### IDENTIFICATION OF ASSIGNEE

2. Schwarz Pharma AG

Name of assignee Corporation

Type of assignee, e.g., corporation, partnership, university, government agency, etc.

.

#### PERSON AUTHORIZED TO SIGN

3. <u>ppa. Klaus-Dieter Hommerich</u> i.V. <u>Dietrich W. Schacht</u> (type nume of parson authorized to sign on behalf of assignee)

Authorized Ufficer	Assistant Manager
Title of person authorized to sign	

NOTE: The Notice of April 30, 1993 (1150 O.G. 62-64) points out;

"The statement under 37 (CFR 3.73(b) may be signed on behalf of the assignee in the following two manners if the assignee is an organization (e.g., corporation, partnership, university, government agency, etc.).

"(1) The statement may be signed by a person in the organization having apparent authority to sign on behalf of the organization. An officer (president, vice-president, secretary, or treasurer) is presumed to have authority to sign on behalf of the organization. The signature of the chairman of the board of directors is acceptable, but not the signature of an individual director. A person having a title (manager, director, administrator, general counsel) that does not clearly set forth that person as an officer of the assignee is not presumed to be an officer of the assignee or to have authority to sign the statement on behalf of the assignee. A power of attorney from the inventors in an organization to a practitioner to prosocute a patent application does not make the practitioner an official of an assignee or empower the practitioner to sign the statement on behalf of the assignee.

"(2) The statement may be signed by any person, if the statement includes an averment that the person is empowered to sign the statement on behalf of the assignes and, if not signed by a registered practitioner, the statement must be in oath or declaration form. Where a statement does not include such an averment, and the person signing does not hold a position in the organization that would give rise to a presumption that the person is empowered to sign the statement on behalf of the assignee, evidence of the person's authority to sign will be required."

[Author's Note: The requirement for an outh or declaration for this statement by a person not a registered practitioner was rescinded by the rules effective December 1, 1997.]

#### (complete the following, if applicable)

☑ I, the person signing below, state that I am empowered to sign this statement on behalf of the assignee.

(Statement under 37 C.F.R. § 3.73(b) - Establishing Right of Assignee to Take Action [16-18]-page 2 of 4)

t al

	BASIS	OF ASSIGNE	E'S INTEREST		
Ownership by	the assignee is	s established as	follows:	· · · · · · · · · · · · · · · · · · · ·	
A.		•	· · · ·	e de la companya de la compa	
1. 🗋 An as recor	ssignment from ded in the PTO	the inventor(s) of at	of the matter ide	ntified above, which was	
	Reel	Fran	ne		
2. 🛛 Ana	ssignment (doci	ument) separately	/ being submitte	d for recordal herewith.	
		AND/O	R	• 	
R. 🕅 A chain	of title from the	inventor(s) to th	a current ession	a a chown halmur	
			o currant Beargin		
1. F	mm: Claus M	EESE and Beng	t SPARF		`
		Name of invento	x(8)	-	• .
r	o: <u>Schwarz</u>	Pharma AG		_ ·	
			· ·	Recorded in PTO: Reel	
		۰. <u>۴</u>	X X		
2. <del>f</del>	From:			<u>.</u>	·
	INEL/1	na or inventor(a) or			
	ſo:		<u></u>	<b>_</b> · ·	
		<u> </u>		Recorded in PTO: Reel	
3 6	From <sup>.</sup>		· .		•
0. 1	Nar	ne of Inventor(s) or	assignee	-	
٦	Го:	4	* <u>* </u> * .		
			·	Recorded in PTO: Real	
				, Frame	
	(check iten	below. and add	i details, if applic	able)	
		- 1- the chets of t			
L Addi Shee	njonal document at.	s in the chain of t		te attached oupplementa	
		•			
	COPIES OF	DOCUMENTS	IN CHAIN OF	TITLE	
				, ,	
	(complet	e this item. If co	oles are being si	anti	
_					
BLI COD	ies of the assign clicws:	ment(s) or other d	iocument(s) in the		1
			9		
<b></b>		<b>х</b> и.,1 Ц	ة لل <sub>م</sub> ع		A
(Statement under	37 C.F.A. § 3.73(b	) Establishing Rigi	ht of Assignee to Ta	ke Action [16-16]page 3 of 4	9
		•		•• : •	
				•	
			. •		

۰.

:

Wichard

ppa. Klaus-Dieter Hommerich <u>Dietrich W, S</u>chacht i.V. (type or print name of authorized person)

Authorized Officer Assistant Manager Title of authorized person

Reg. No.:

33,860

 $\mathcal{I}_{1}$ 

Tel. No.: (617) 523-3400

Customer No.:

(type or print mane of practitioner) EDWARDS & ANGELL, LLP P.O. Address

SIGNATURE OF PRACTITIONER

Peter F. Corless

P.O. BOX 9169

Boston, Massachusetts 02209

(Statement under 37 C.F.R. # 3.73(b) va Right of – Estab

Page 1 of 1

Hrg8

UNITED STATES I	ATENT AND TRAD	EMARK OFFICE United St	Commissioner for Patents ates Patent and Trademark Office Washington, D.C. 20231 www.usplo.gov
APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO/TITLE
09/700,094	01/02/2001	Claus Meese	MBHB00-1121
PETER F. CORLESS EDWARDS & ANGELL, LLP 330 WATER STREET EOSTON, MA 02109	• . •	*OC0000 •OC0000000	CONFIRMATION NO. 1408 000006234276* 234276*
			Date Mailed: 06/27/2001

#### NOTICE REGARDING POWER OF ATTORNEY

 $\mathcal{A}_{i}^{\mathbf{q}}$ 

:.

This is in response to the Power of Attorney filed 04/24/2001.

BATLAT LOD BALL

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

Ï,

1

Customer Service Center Initial Patent Examination Division (703) 308-1202

OFFICE COPY

UNITED STATES	Patent and Tradema	<u>RK OFFICE</u> United S	Commissioner for Patents fates Patent and Trademark Office Washington, D.C. 2023 www.uspto.gov
APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY DOCKET NO /ITTLE
09/700,094	01/02/2001	Claus Meese	MBHB00-1121
20306 MCDONNELL BOEHNEN HU 300 SOUTH WACKER DRIVE SUITE 3200	LBERT & BERGHOFF	*OCD0000000	CONFIRMATION NO. 1408
CHICAGO, IL 60606	•		,
	· .		Date Mailed: 06/27/2001

#### NOTICE REGARDING POWER OF ATTORNEY

This is in response to the Power of Attorney filed 04/24/2001.

• The Power of Attorney to you in this application has been revoked by the assignee who has intervened as provided by 37 CFR 3.71. Future correspondence will be mailed to the new address of record(37 CFR 1.33).

**OFFICE COPY** 

ì

÷.

Customer Service Center Initial Patent Examination Division (703) 308-1202

Docket No. 55647 (451

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	C. Meese et al.	·		8	.4
Serial No.:	09/700,094	it is a second sec	GROUP:	1614	H C
Filed:	January 2, 2001		EXAMINER:	Not Yet Assigned	M
For:	NOVEL DERIVATIVES	OF 3,3-DIPHEN	YLPROPYLAMI	NES	

Assistant Commissioner for Patents Washington, D.C. 20231

\*\*\*\*\*\*\*\*\*\*

#### CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Date 8-13-01

TRADE

By: <u>Christine C. O'Day</u>

Sir:

#### INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached form PTO-1449, for consideration by the Examiner in connection with the examination of the above-identified patent application.

#### REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being

filed:

(1) within three (3) months of the Filing Date or before the mailing
 date of the First Office Action on the merits; or

(2) within three months of the mailing date of the Written Opposition issued by the: \_\_\_\_\_Patent Office (dated \_\_\_\_\_); or

after the period defined in (1) but before the mailing date of a
 Final Rejection or Notice of Allowance, and the requisite

C. Meese et al. U.S.S.N. 09/700,094 Page 2

Certification or fee under Rule 1.17(p), namely \$240.00, is included herein; or

 (4) after the mailing date of a Final Rejection or Notice of Allowance but before the payment of the Issue Fee, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached form(s) PTO-1449 be made of record in this application. Copies of these documents (CHECK ONE):

Х

are enclosed herewith; or

have been cited in the parent application, and are thus not being resubmitted herein.

Early examination and allowance of the present application are respectfully solicited.

#### FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 04-1105. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,

C.n la

Christine C. O'Day (Reg. 38,256) DIKE, BRONSTEIN, ROBERTS & CUSHMAN Intellectual Property Practice Group Edwards & Angell, LLP PO Box 9169 Boston, MA 02209 (617) 439-4444

Date: August 13, 2001



AUG 1 5 2001 E		FECH CENT	דבטה טבווד		T] at f of 1
FORM PTO-1449	DOCKET NO.: 55647	SERIAL NO.: 09/700,094			1
INFORMATION DISCLOSURE STATEMENT	APPLICANT(S): C. Meese et al.			200 F	5
	FILING DATE: January 2, 2001	GROUP NO .: 4814 162	Į.		7
	······································	Z	5		

#### UNITED STATES PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
				Ale to		
			л. — <u>Р</u>			

#### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
ZT.	AA	WO 89/06644	7/27/89	WIPO	·	~	
21	AB	WO 94/11337	5/26/94	WIPO		-	
			1				
					· ·		
			1	<u> </u>	]		
				r a			
	····	OTHER DOCU	MENTS (IN	CLUDING AUTHOR, TITLE, DATE, PI	ERTINENT	PAGES, ETC.)	

21-	AC	C Nilvebrant et al., European Journal of Pharmacology, 327(1997) pp. 195-207.						
.  .		,	:					
			<u> </u>					
·							· _	
Examiner:	·	Zalah		. X	Date:	28 JANVAR	17 2003	

# BEST COPY

Transaction History Date 2001-09-07 Date information retrieved from USPTO Patent Application Information Retrieval (PAIR) system records at www.uspto.gov



#### UNITED STATE JEPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

		: , ·····		12
NO.	FILING DATE	FIRST NAMED INVENTOR	¥	ATTORNEY DOCKET NO.
		• <b>1</b> .	• •	l ta print i si s
				EXAMINER
	• •			
				PAPER NUMBER
•	··· · ·		•	0
			DATE MAILE	<b>D:</b> P <sup>1</sup> [23, 41, 114]

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

PTCI-90C (Rev 11/00)

1- File Copy

		Application No		Applicant(s)	··· <u>··································</u>
		09/700,094		MEESE ET AL.	
Office Action Summary	Y	Examiner		Art Unit	·····
	_	Zachary C. Tud	er	1623	
The MAILING DATE of this com	munication a	opears on the cove	r sheet with th	e correspondence ad	dross
Period for Reply         A. SHORTENED STATUTORY PERIOD         THE MAILING DATE OF THIS COMM         Extensions of time may be available under the provaties SIX (6) MONTHS from the mailing date of this         If the pend for reply specified above is less than the         If the pend for reply is specified above, the maxim         Failure to reply within the set or extended period for         Any reply received by the Office later than three mode amed patent term adjustment. See 37 CFR 1.704         Status         1) Responsive to communication(         2a) This action is FINAL.         3) Since this application is in conductored in accordance with the point of Claims         4) Claim(s) <u>1-16, 18-24 and 28-38</u> 4a) Of the above claim(s)	D FOR REP IUNICATION Asions of 37 CFR to communication individual and the statu- num statutory peno r reply will, by statu- num statutory peno r reply will, by statu- num statutory peno r reply will, by statu- ion, and the statu (b). (s) filed on <u>15</u> 2b)[2] T diftion for allow practice under is/are pendir is/are withdr to.	LY IS SET TO EX 198(a) In no event, how ply within the statutory m d will apply and will explor the, cause the application ing date of this communic <u>5 August 2001</u> This action is non- wance except for f er <i>Ex parte Quayle</i> ng in the application awn from conside	PIRE <u>1</u> MONT rever, may a reply b nimum of thirty (30) SIX (6) MONTHS f to become ABANDC ation, evan if timely final. ormal matters , 1935 C.D. 1 n. ration.	H(S) FROM a timely filed days will be considered timely rom the mailing date of this co wED (35 U.S.C. § 133). filed, may reduce any , prosecution as to th ), 453 O.G. 213.	e merits is
8) Claim(s) <u>1-16, 18-24, and 28-38</u>	are subject	to restriction and/	or election req	uirement	
Application Papers	•	· .			
9) The specification is objected to t	by the Exami	ner.			
10) The drawing(s) filed on is	/are: a)∏ aco	epted or b) 🗌 obje	ted to by the E	xaminer.	
Applicant may not request that an	ny objection to	the drawing(s) be h	eld in abeyance	. See 37 CFR 1.85(a).	
11) The proposed drawing correction	n filed on	is: a) approv	ved b) 🗌 disap	proved by the Examin	er.
If approved, corrected drawings a	ne required in	reply to this Office a	ction.		
(z) ine call of declaration is objection of the state $(z)$	ed to by the l	zxaminer.			
Torny under 35 U.S.C. §§ 119 and 120	J ninini fan faard				
	ciaim tor tore	ign priority under (	io U.S.Ç. § 11	ਤ(8)-(0) OF (1).	
a, <u>a</u> , <u>a</u> , <u>b</u>	ority docume	nts have been red	eived		
2 Certified copies of the pri	ionity docume	nts have been red	eived in Appli	cation No	
2. Use times copies of the pri	nies of the c	ins nave ueen rec	oweu in Appli	Bived in this National	Stane
application from the l * See the attached detailed Office	nternational l action for a li	Bureau (PCT Rule	ave been rec 17.2(a)). copies not rece	eived in uns mational Bived.	วเอยูะ
14)[]] Acknowledgment is made of a cl	aim for dome	stic priority under	35 U.S.C. § 1	19(e) (to a provisiona	l application).
a) The translation of the foreig	n lanouade i	provisional applice	tion has been	received.	, e
15) Acknowledgment is made of a cl	aim for dome	estic priority under	35 U.S.C. §§	120 and/or 121.	
Attachment(s)					
1) Notice of References Cited (PTO-892)	10W (DTO 040)	4) [ 5) [	Interview Sum	mary (PTO-413) Paper No	<b>)(8)</b>
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Rev</li> <li>In formation Disclosure Statement(s) (PTO-14</li> </ol>	ılaw (F <sup>.</sup> TO-948) 449) Paper No(s	4) [ 5) [ )6] [	Interview Sum Notice of Infor Other:	mary (PTO-413) Paper No nal Patent Application (P1	9(8) 'O-152)
1) Notice of References Cited (PTO-892) 2)  Notice of Draftsperson's Patent Drawing Rev 3)  In formation Disclosure Statement(s) (PTO-14 5 Patent and Trademark Office TO-326 (Pay: 04.01)	vlaw (PTO-948) 449) Paper No(s	4) [ 5) [ )6) [	Interview Sum Notice of Inforn Other:	mary (PTO-413) Paper No nal Patent Application (P1	(6) O-152)
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Rev 3) In formation Disclosure Statement(s) (PTO-14 5 Patent and Trademark Office TO-326 (Rev. 04-01)	lew (PTO-948) 449) Paper No(s Office	4) [ 5) [ ) 6) [ Action Summary	Interview Sum Notice of Inforn Other:	mary (PTO-413) Paper No nal Patent Application (P1 Part o	(s) 'O-152) ' Paper No. 10
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Rev</li> <li>In formation Disclosure Statement(s) (PTO-14</li> <li>Patent and Trademark Office</li> <li>TO-326 (Rev. 04-01)</li> </ol>	ilew (PTO-948) 449) Paper No(s Office	4) [ 5) [ ) 6) [ Action Summary	] Interview Sum ] Notice of Infor ] Other:	mary (PTO-413) Paper No nal Patent Application (P1 Part o	(s) O-152) / Paper No. 10
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Rev</li> <li>In formation Disclosure Statement(s) (PTO-14</li> <li>Patent and Trademark Office</li> <li>TO-326 (Rev. 04-01)</li> </ol>	ilew (PTO-948) 449) Paper No(s Office	4) [ 5) [ ) 6) [ Action Summary	Interview Sum Notice of Infor Other:	mary (PTO-413) Paper No nal Patent Application (PT Part o	(8) O-152) Paper No. 10
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Rev</li> <li>In formation Disclosure Statement(s) (PTO-14</li> <li>Pelent and Trademark Office</li> <li>TO-326 (Rev. 04-01)</li> </ol>	ilew (PTO-948) 449) Paper No(s Office	4) [ 5) [ )6) [ Action Summary	Interview Sum Notice of Infor Other:	mary (PTO-413) Paper No nal Patent Application (P1 Part o	(s) O-152) / Paper No. 10
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Rev</li> <li>In formation Disclosure Statement(s) (PTO-14</li> <li>Petent and Trademark Office</li> <li>rO-326 (Rev. 04-01)</li> </ol>	ilew (PTO-948) 449) Paper No(s ————————————————————————————————————	4) [ 5) [ ) 6) [ Action Summary	Interview Sum Notice of Infor Other:	mary (PTO-413) Paper No nal Patent Application (P1 Part o	(8) O-152) / Paper No. 10
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Rev</li> <li>In formation Disclosure Statement(s) (PTO-14 Patent and Trademark Office TO-326 (Rev. 04-01)</li> </ol>	ilew (PTO-948) 449) Paper No(s Office	4) [ 5) [ 6) [ Action Summary	] Interview Sum ] Notice of Infor ] Other:	mary (PTO-413) Paper No nal Patent Application (P) Part o	(s) (O-152) 7 Paper No. 10
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Rev</li> <li>In formation Disclosure Statement(s) (PTO-1/ 5 Patent and Trademark Office TO-326 (Rev. 04-01)</li> </ol>	ilew (PTO-948) 449) Paper No(s Office	4) [ 5) [ )6) [ Action Summary	Interview Sum Notice of Infor Other:	mary (PTO-413) Paper No nal Patent Application (PT Part o	v(s) 'O-152) ' Paper No. 10
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Rev</li> <li>In formation Disclosure Statement(s) (PTO-1- Felent and Trademark Office     </li> <li>TO-326 (Rev. 04-01)</li> </ol>	ilew (PTO-948) 449) Paper No(s Office	4) [ 5) [ 6) [ Action Summary	Interview Sum Notice of Infor	mary (PTO-413) Paper No nal Patent Application (P) Part o	(\$) (O-152) 7 Paper No. 10
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Rev</li> <li>In formation Disclosure Statement(s) (PTO-1/ Patent and Trademark Office TO-326 (Rev. 04-01)</li> </ol>	ilew (PTO-948) 449) Paper No(s Office	4) [ 5) [ )6) [ Action Summary	] Interview Sum ] Notice of Infor ] Other:	mary (PTO-413) Paper No nal Patent Application (PT Part o	(8) O-152) Paper No. 10
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Rev</li> <li>In formation Disclosure Statement(s) (PTO-1- i Patent and Trademark Office TO-326 (Rev. 04-01)</li> </ol>	ilew (PTO-948) 449) Paper No(s Office	4) [ 5) [ 6) [ Action Summary	Interview Sum Notice of Infor	mary (PTO-413) Paper No nal Patent Application (P) Part o	(\$) (O-152) ( Paper No. 10
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Rev</li> <li>In formation Disclosure Statement(s) (PTO-1- 5 Patent and Trademark Office TO-326 (Rev. 04-01)</li> </ol>	ilew (PTO-948) 449) Paper No(s Office	4) [ 5) [ )6) [ Action Summary	Interview Sum Notice of Infor	mary (PTO-413) Paper No nal Patent Application (PT Part o	v(s) O-152) Paper No. 10

Ì.,

Application/Control Number: 09/700,094 Art Unit: 1623

#### DETAILED ACTION

#### Lack of Unity of Invention

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted. Group 1, claim 1 in part (wherein R and R' are b), 2-10, and 16, 18, 19 and 20, drawn to ester derivatives of the diphenylpropylamine compound of formula I and processes for the preparation thereof.

Group 2, claim 1 in part (wherein R and R' are a or g), 2, 11, 12, and 21-23, drawn to ethers and silyl ether derivatives of the diphenylpropylamine compound of formula I and processes for the preparation thereof.

Group 3, claim 1 in part (wherein R and R' are c and d), 2, 13, 14 and 24 and 33, drawn to carbonate and carbamate derivatives of the diphenylpropylamine compound of formula I and processes for the preparation thereof.

Group 4, claim 1 in part, (wherein R and R' are e), and 2, drawn to sulfamate derivatives of the diphenylpropylamine compound of formula I.

Application/Control Number: 09/700,094 Art Unit: 1623

Group 5, claim 1 in part, (wherein R and R' are f), and 2, drawn to inorganic ester derivatives of the diphenylpropylamine compound of formula I.

Group 6, claim 15, drawn to (i) cyclic diesters of formulae IX and IX', (ii) a benzoic acid ester of the diphenylpropylamine compound of formula I, (iii) poly-co-DL-lactides of the diphenylpropylamine compound of formula I and (iv) a  $1\beta$ -D-glucuronosyloxymethyl derivative of the diphenylpropylamine compound of formula I.

Group 7, claim 28 in part (wherein R is a or g) and 29, drawn to ether and silvl ether derivatives of the compound of formula VII'.

Group 8, claim 28 in part (wherein R is b), 29, 30, and 32, drawn to ester derivatives of the compound of formula VII' and a process for preparing the phenolic monoester derivative.

Group 9, claim 28 in part (wherein R is c or d), 29, 31 and 33, drawn to carbonate and carbamate derivatives of the compound of formula VII' and a process for the preparation lhereof.

Group 10, claim 28 in part (wherein R is e or f), and 29, drawn to sulfamate and inorganic ester derivatives of the compound of formula VII'.

Application/Control Number: 09/700,094 Art Unit: 1623

The composition and method of use claims will be examined along with the elected inventions and commensurate in scope therewith if dependent thereupon.

The special technical feature in common to groups 1-10 is a structural moiety which was known in the art at the time the inventions were made (WO 94/11337 see first page), and as such does not represent a contribution over the prior art, therefore groups 1-10 represent different inventions pursuant to 37 CFR 1.475 (a).

#### Conclusion

Any inquiry concerning this communication should be directed to Zachary Tucker whose telephone number is (703) 305-2050 and facsimile telephone number is (703) 746-3176. The examiner can normally be reached Monday-Friday from 8:00am to 4:00pm. If Attempts to reach the examiner are unsuccessful, the examiner's supervisor, Gary Geist, can be reached at (703) 308-1701. The fax number for the organization where this application or proceeding is assigned is (703) 308-4556 for regular communications and (703) 308-4242 for after-final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

SUPERVISOR TENT EXAMINER TECH CENTER 1600

		Notice of Deferre		Application/ 09/700,094	Control No.	Applicant(s)/Pa Reexamination MEESE ET AL.	tent Under
		NOTICE OF REFERENCE	s Ched	Examiner		Art Unit	Designation
	·	L.,		Zachary C.	Zachary C. Tucker 1623 Page 1 of 1		
	·	Degument Number	Data	U.S. PATENT DOCUM	ENTS		
*		Country Code-Number-Kind Code	MM-YYYY	<u> </u>	Name		Classification
	A	US-					
	В.	US		······································			
	С	US-			N V al		
	D	US			· · · · · · · · · · · · · · · · · · ·		
	E	US			·		
	F	US-		·	·		
	G	US					
	н	US					
	1	US-			÷		
	J	US-			N 2 2		
	к	US-					
	L	US-					
	м	US-		r i i	1		
	······	······································		FOREIGN PATENT DO	CUMENTS		
*	ĺ	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name		Classification
*	N	WO 94/11337	05-1994	PCT	Johansson et al (P	UPLICATE CTTA	4700N)
	0				1		
	P	1					
	Q	l		· · · · · · · · · · · · · · · · · · ·			
	R	I '		!			
	s	· · · · · · · · · · · · · · · · · · ·					
	Т						
	4			NON-PATENT DOCU	MENTS		· · · · · · · · · · · · · · · · · · ·
*	ļ	Inclu	de as applicabl	e: Author, Title Date, Pub	lisher, Edition or Volume	a, Pertinent Pages)	·
	υ			· .			
	┼						
	· v				•		
	w			<u></u>			· / / · · · · · · · · · · · · · · · · ·
<u> </u>		_					
	x						
*A ca Date	py of the	his reference is not being furnished with A YYYY format are publication dates. Cir	this Office action.	(See MPEP § 707 05(a).) Se US or foreign.			·····
u s PTC	Patent a D-892 (	n: Trademark Office (f?ev. 01-2001)	, <b></b> , <b></b> , <b></b> , <b></b> _, <b></b> , <b></b> _, <b></b> , <b>_</b>	Notice of References (	Cited	Part	of Paper No. 10 .
				4	X = C = C		•
					· .		

:

			UNITED STATES DEFABTA United States Patent and T Address COMMISSIONER OF P. Weshington, D.C 20231 www.uspto gov	IENT OF COMMERCE rademark Office Atents and Trademark
APPLICATION NO	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/700,094	01/02/2001	Claus Mccso	MBHB00-1121	1408
75	0 04/10/2002	•		
PETER F. CO	RLESS		EXAM	INER
EDWARDS & A 130 WATER ST	NGELL, LLP REET	ſ	TUCKER, Z	ACHARY C
BOSTON, MA	02109	· · · ·	ART UNIT	PAPER NUMBER
			1624	11
		, ₹ 7	DATE MAILED: 04/10/2002	2

ŝ,

I'lease find below and/or attached an Office communication concerning this application or proceeding. ŗ

4

Ì

.

PTO-90C (Rev. 07-01)

		Application No.	A	pplicant(s)	
		00/700 004			
Notice of Abandonment		Examiner		IEESE ET AL. rt Unit	<u> </u>
	· •	Zochany C. Tucker		804	
The MAILING DATE of this communic	ation app	aars on the cover sheet w	th the corr	espondence a	ddress-
s application is abandoned in view of:		<u>!</u>			
<ul> <li>Applicant's failure to timely file a proper reply to a)</li></ul>	the Offic ilicate of f of time of out it does	e letter mailed on <u>07 Septem</u> Malling or Transmission date month(s)) which expl not constitute a proper reply	b <u>er 2001</u> . d ), v red on under 37 C	vhich is after the  FR 1.113 (a) to	e expiration of the
(A proper reply under 37 CFR 1.113 to a fin application in condition for allowance; (2) a Continued Examination (RCE) in complianc	al rejectio timely file a with 37	n consists only of: (1) a time d Notice of Appeal (with app CFR 1.114).	ly filed ame bal fee); or (	ndment which p (3) a timely filed	laces the Request for
(c) A reply was received on but it does r linal rejection. See 37 CFR 1.85(e) and 1.1	not constit 11. (See	ute a proper reply, or a bona explanation in box 7 below).	fide attemp	ot at a proper re	ply, to the non-
(d) 🔀 No reply has been received.		· ,			
Applicant's failure to timely pay the required iss from the mailing date of the Notice of Allowanc	sue fee an e (PTOL-I	nd publication fee, if applicab 85).	e, within th	e statutory perio	od of three month
(a) The issue fee and publication fee, if appliance, if appliance, if appliance (PTOL-85).	cable, wa statutory p	is received on (with a ) with a geniod for payment of the issue	a Certificate	of Mailing or T publication fee)	Fransmission dat set in the Notice
(b) 🔲 The submitted fee of \$ is insufficient.	A balanc	e of \$ is due.	• 1		
The issue fee required by 37 CFR 1.18 is (c) The issue fee and publication fee, if applica	i\$ Ible, has r	The publication fee, if requir not been received.	ed by 37 Ci	FR 1.18(d), is \$_	<b>-</b> •
Applicant's failure to timely file corrected drawin	ngs as req	uired by, and within the three	e-month per	iod set in, the N	lotice of
<ul> <li>(a)          Froposed corrected drawings were received after the expiration of the period for reply.     </li> </ul>	d on	_ (with a Certificate of Mailin	g or Transr	nission dated _	), which is
b) [] No corrected drawings have been received	•				
		1	· ·		
1.34 (a)) upon the tiling of a continuing applicat	uçın.				
<ul> <li>The decision by the Board of Patent Appeals a of the decision has expired and there are no al</li> <li>The reason(s) below:</li> </ul>	and Interfe Nowed cla	erence rendered on ar lms.	d because	the period for s	eeking court revi
<ul> <li>The decision by the Board of Patent Appeals a of the decision has expired and there are no al</li> <li>The reason(s) below:</li> </ul>	and Interfe llowed cla	erence rendered on ar lms.	d because	the period for s	eeking court revi
<ul> <li>The decision by the Board of Patent Appeals a of the decision has expired and there are no al</li> <li>The reason(s) below:</li> </ul>	and Interfe lkowed cla	erence rendered on ar lims.	d because	the period for s the period for s up 1. Killos ARY EXAMINES	eeking court revi
<ul> <li>The decision by the Board of Patent Appeals a of the decision has expired and there are no al</li> <li>The reason(s) below:</li> </ul>	and Interfe Nowed cla	prence rendered on ar	ed because	the period for so the period for so up 1. Killos ARY EXAMINED U. 16.2	eeking court revi
☐ The decision by the Board of Patent Appeals a of the decision has expired and there are no al ☐ The reason(s) below:	and Interfe Nowed cla	arence rendered on ar	d because	the period for s the period f	eeking court rev
<ul> <li>The decision by the Board of Patent Appeals a of the decision has expired and there are no al</li> <li>The reason(s) below:</li> <li>the reason(s) The reason spectrum of the patent below:</li> </ul>	and Interfe llowed cla sts to withd	prence rendered on ar lims. raw the holding of abandonmen	ad because	the period for st the period f	eeking court rev
<ul> <li>The decision by the Board of Patent Appeals a of the decision has expired and there are no al</li> <li>The reason(s) below:</li> <li>titions to revive under 37 CFR 1.137(a) or (b), or request nimize any negative effects on patent term.</li> </ul>	and Interfe llowed cla sts to withd	arence rendered on ar lims. raw the holding of abandonmen	d because	the period for st the period fo	eeking court revi
<ul> <li>The decision by the Board of Patent Appeals a of the decision has expired and there are no al</li> <li>The reason(s) below:</li> <li>The reason(s) below:</li> <li>titions to revive under 37 CFR 1.137(a) or (b), or request nimize any negative effects on patent term.</li> <li>Patent and Tradement Office</li> <li>1432 (Rev. 04-01)</li> </ul>	and Interfe llowed cla ste to withd Notic	raw the holding of abandonmen	t under 37 Cl	the period for se where the period for set where t	eeking court rev
<ul> <li>The decision by the Board of Patent Appeals a of the decision has expired and there are no al</li> <li>The reason(s) below:</li> <li>The reason(s) below:</li> <li>titlions t: revive under 37 CFR 1.137(a) or (b), or request nimize any negative effects on patent term.</li> <li>Patent and Trademerk Office</li> <li>1432 (Rev. 04-01)</li> </ul>	and Interfe llowed cla ste to withd Notic	arence rendered on ar lims. raw the holding of abandonmen	ad because	the period for st the period fo	eeking court revi
<ul> <li>The decision by the Board of Patent Appeals a of the decision has expired and there are no al</li> <li>The reason(s) below:</li> <li>The reason(s) below:</li> <li>attitions to revive under 37 CFR 1.137(a) or (b), or request nimize any negative effects on patent term.</li> <li>Patent and Trademerk Office</li> <li>1432 (Rev. 04-01)</li> </ul>	and Interfe llowed cla sts to withd Notic	raw the holding of abandonmen	t under 37 Cl	the period for so the period for so uL J. KilLOS ARY, EXAMINED C. 16 2. R 1.181, should Part of Pape	eeking court revi
The decision by the Board of Patent Appeals a of the decision has expired and there are no al The reason(s) below: Sultions to revive under 37 CFR 1.137(a) or (b), or requese nimize any negative effects on patent term. Patent and Trademark Office D-1432 (Nev. 04-01)	and Interfe llowed cla ste to withd Notic	rence rendered on ar lims. raw the holding of abandonmen	ad because	the period for st UL J. KILLOS ARY EXAMINED TR 1.181, should Part of Pape	eeking court revi
<ul> <li>The decision by the Board of Patent Appeals a of the decision has expired and there are no al</li> <li>The reason(s) below:</li> <li>attitions to revive under 37 CFR 1.137(a) or (b), or request nimize any negative effects on patent term.</li> <li>Patent and Trademerk Office D-1432 (Rev. 04-01)</li> </ul>	and Interfe llowed cla ste to withd Notic	raw the holding of abandonmen	t under 37 Cl	the period for st where the period for st wh	eeking court revi
The decision by the Board of Patent Appeals a of the decision has expired and there are no al The reason(s) below: additions to revive under 37 CFR 1.137(a) or (b), or requese inimize any negative effects on patent term. Patent and Trademark Office D-1432 (Rev. 04-01)	ste to withd	arence rendered on ar lims. raw the holding of abandonmen	ad because	the period for st UL J. KILLOS ARY EXAMINED T. 1.181, should Part of Pape	eeking court revi
The decision by the Board of Patent Appeals a of the decision has expired and there are no al The reason(s) below: additions to revive under 37 CFR 1.137(a) or (b), or reques <u>nimize any negative effects on patent term.</u> Patent and Trademerk Office D-1432 (Rev. 04-01)	ste to withd	erence rendered on ar lims. raw the holding of abandonmen te of Abandonment	t under 37 Cl	the period for st UL J. KILLOS ARY, EXAMINEL C. 16 2 R 1.181, should Part of Papa	eeking court revi
The decision by the Board of Patent Appeals a of the decision has expired and there are no al. The reason(s) below: atilions t: revive under 37 CFR 1.137(a) or (b), or request inimize any negative effects on patent term. Patent and Trademark Office D-1432 (Rev. 04-01)	and Interfe llowed cla ste to withd Notic	arence rendered on ar lims. raw the holding of abandonmen te of Abandonment	t under 37 Cl	the period for su UL J. KILLOS ARY EXAMINE U. 16 2 R 1.181, should Part of Papa	eeking court revi
The decision by the Board of Patent Appeals a of the decision has expired and there are no al The reason(s) below: atilions to revive under 37 CFR 1.137(a) or (b), or request inimize any negative effects on patent term. Patent and Trademerk Office D-1432 (Rev. 04-01)	and Interfe llowed cla sts to withd Notic	arence rendered on ar lims. raw the holding of abandonmen se of Abandonment	t under 37 Cl	the period for st when the pe	eeking court revi
The decision by the Board of Patent Appeals a of the decision has expired and there are no al The reason(s) below:  Attraction of the reason	ste to withd	arence rendered on ar lims. raw the holding of abandonmen te of Abandonment	t under 37 Cl	the period for so UL J. KILLOS ARY EXAMINED C. 16 2 TR 1.181, should Part of Papa	eeking court revi
The decision by the Board of Patent Appeals a of the decision has expired and there are no al The reason(s) below: additions to revive under 37 CFR 1.137(a) or (b), or request inimize any negative effects on patent term. Patent and Trademerk Office 2-1432 (Rev. 04-01)	and Interfe llowed cla sts to withd Notic	arence rendered on ar lims. raw the holding of abandonmen se of Abandonment	t under 37 Cl	the period for so www. UL J. KILLOS ARY EXAMINED U. 16 2. R 1.181, should Part of Pape	eeking court revi
The decision by the Board of Patent Appeals a of the decision has expired and there are no al The reason(s) below: titions t: revive under 37 CFR 1.137(a) or (b), or reques <u>nimize any negative effects on patent term.</u> 2etent and Trademark Office 1432 (Rev. 04-01)	ste to withd	arence rendered on ar lims. raw the holding of abandonmen te of Abandonment	t under 37 Cl	the period for se the period for se UL J. KILLOS ARY EXAMINED T. 1.181, should Part of Pape	eeking court rev

Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0235

200/160 Docket No. CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8) Applicant(s): C. Meese et al. 55647 (45107) Serial No. Filing Date Examiner Group Art Unit 09/700,094 January 2, 2001 Z. Tucker 1624 Invention: Novel Derivatives of 3,3-Diphenylpropylamines 3 1 2002 BADEMAN I hereby certify that this Petition to Withdraw a Holding of Abandonment Pursuant to 37 CFR 1.181 (Identify type of correspondence). is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on May 21, 2002 (Date) t vi Susan M. Dillon (Typed or Printed Name of Person Malling Correspondence) Jusan M Dillon (Signature of Person Mailing Correspondence) Note: Each paper must have its own certificate of mailing. POTA/REV03



Docket No. 55647 (45107)

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	C. Meèse et al.	
SERIAL NO.:	09/700,094	GROUP: 1624
FILED:	January 2, 2001	EXAMINER: Z. Tucker
FOR:	NOVEL DERIVATIVES (	)F 3,3-DIPHENYLPROPYLAMINES

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

### PETITION TO WITHDRAW A HOLDING OF ABANDONMENT PURSUANT TO 37 C.F.R. §1.181

Pursuant to 37 C.F.R. §1.181, Applicants respectfully petition for withdrawal of the holding of abandonment for the above-referenced patent application, which, as indicated in a Notice of Abandonment mailed by the Patent Office on April 10, 2002, was deemed to be abandoned for Applicants' alleged failure to properly respond to an Office letter mailed on September 7, 2001.

#### **STATEMENT OF FACTS**

The Attorneys of Record for Applicants confirm receipt of the Office letter of September 7, 2001, which Office letter indicated that claims 1-16, 18-24, and 28-38 were subject to a Restriction Requirement.

On November 29, 2001, the Attorneys of Record for Applicants sent via first-class mail, a complete and timely response to the Office letter of September 7, 2001. In particular, Applicants sent a response to the Assistant Commissioner for Patents, Washington, D.C. 20231, which contained the following materials, copies of which are enclosed herein:

C. Meese, et al. SERIAL NO.: 09/700,094 Page -2-

(1) An amendment transmittal including (i) a duly executed certificate of mailing bearing the date of November 29, 2001, and (ii) a petition for a two-month extension of time;

(2) An amendment and response to the Restriction Requirement;

(3) A copy of the International Preliminary Examination Report for the corresponding international application, provided in support of a traverse to the Restriction Requirement;

(4) A check for \$400.00 representing the extension fee; and

(5) A return receipt postcard.

As indicated in (1) above, the amendment transmittal included a duly executed certificate of mailing (pursuant to 37 C.F.R. §1.8). The certificate of mailing properly certified that the correspondence was deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C., on November 29, 2001.

The Attorneys of Record for the subject application received a Notice of Abandonment (mail date: April 10, 2002) for the above-referenced application on April 17, 2002, for Applicants' alleged failure to submit a proper response to the Office letter of September 7, 2001.

#### **RELIEF REQUESTED**

Applicants respectfully request that the Commissioner, based on the following arguments, withdraw the erroneous holding of abandonment and enter the enclosed response into the record for the subject application.

#### ARGUMENT

The within petition and the related enclosures are being filed within two (2) months of the mail date of the Notice of Abandonment. Accordingly, the within petition is considered to be timely filed [37 C.F.R. 1.181(f)].

Real States

MPEP 711.04(c) provides that a petition to withdraw the holding of abandonment may be adequate relief when a response with a certificate of mailing has been filed by an applicant but was not received. The MPEP also suggests that a Petition to revive is not required in these C. Meese, et al. SERIAL NO.: 09/700,094 Page -3-

circumstances. The foregoing is believed to be applicable to the facts relating to the abandonment of the subject application.

In the instant case, Applicants filed a timely and complete response to the Office letter mailed on September 7, 2001, as evidenced by the enclosed materials. Thus, the abandonment of the subject application is wholly unintentional and erroneous.

#### **CONCLUSION**

In view of the foregoing, Applicants submit that the holding of abandonment be withdrawn. As evidenced by the enclosed materials, Applicants provided a timely and complete reply to the Office letter of September 7, 2001.

Accordingly, Applicants respectfully request withdrawal of the holding of abandonment of the above-referenced patent application, and entry of the enclosed response to the Office letter of September 7, 2001.

No fee is believed to be due in connection with the filing or consideration of this petition. In the event any fee(s) is/are due, however, please charge such fee(s) to Deposit Account No. 04-1105.

By:

Respectfully submitted,

5-21-02 Date:

Christine C. O'Day (Reg. No. 38,256) EDWARDS & ANGELL, LLP P.O. Box 9169 Boston, MA 02209 Tel. No. (617) 439-4444

BOS2\_301878.1



Practitioner's Docket No. <u>55647</u>

#### PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re applicat	ion of: C. Meese et al.			
Serial No.:	09/700,094		Group No.:	1623
Filed:	January 2, 2001		Examiner:	Z. Tucker
For:	NOVEL DERIVATIVES	OF 3 3-DIPHENVI PR	OPYLAMINES	

**Assistant Commissioner for Patents** Washington, D.C. 20231

#### AMENDMENT TRANSMITTAL

Transmitted herewith is an amendment for this application. 1.

#### **STATUS**

2. Applicant is

[] a small entity. A statement:

is attached.

[] [] was already filed.

- **[X]** other than a small entity.

#### **EXTENSION OF TERM**

NOTE: "Extension of Time in Patent Cases (Supplement Amendments) - If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

#### CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. 1.8(a))

I hereby certify that, on the date shown below, this correspondence is being:

#### MAILING

deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant [X] Commissioner for Patents, Washington, D.C. 20231.

FACSIMILE transmitted by facsimile to the Patent and

æ Signature

Date: 11 29/01

Deanna M. Rivernider (type or print name of person certifying)

Trademark Office.

(Amendment Transmittal-page 1 of 4)

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of December 10, 1985 (1061 O.G. 34-35).

NOTE: See 37 C.F.R. 1.645 for extensions of time in interference proceedings, and 37 C F.R. 1.550(c) for extensions of time in reexamination proceedings.

3. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply.

(complete (a) or (b), as applicable)

(a)

[X] Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(4)) for the total number of months checked below:

	Extension	Fee for other than	Fee for
	(months)	small entity	small entity
[]	one month	\$110.00	\$55.00
[X]	two months	\$400.00	\$190.00
ĨĨ	three months	\$870.00	\$435.00
[]	four months	\$1360.00	\$680.00
• •		and the second	a de la companya de l La companya de la comp
		Fee: \$ 400.00	

If an additional extension of time is required, please consider this a petition therefor.

#### (check and complete the next item, if applicable)

[] An extension for \_\_\_\_\_months has already been secured. The fee paid therefor of \$\_\_\_\_\_ is deducted from the total fee due for the total months of extension now requested.

Extension fee due with this request \$\_\_\_\_\_400.00

 $\mathbf{r}$ 

Į

#### OR

(b)

[]

Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition for extension of time.

#### (Amendment Transmittal—page 2 of 4)

#### FEE FOR CLAIMS

						4	OTHER 1	HAN A	
	(Col.1)	)	(Col. 2	!) (Col. 3) SN	ALL ENT	TTY	SMALL I	ENTITY	
	Cla Rem A: Amer	iims aining fter idment		Highest No. Previously Paid For	Present Extra	Rate	Addit. Fee OR	Rate	Addit. Fee
otal		* N	finus	**		x \$9 =	\$	x \$18 =	\$
idep.		* M	linus	***	= 0	x \$39 =	\$	x \$78 =	\$0
] Fir	st Prese	ntation	of Multi	ple Depende	ent Claim	+ \$130 =	= \$	+ \$260 =	\$0
						Total Addit, Fee	OR \$	Total Addit. Fee	\$
, " • •	If the en If the "I If the "I The "H a prior a	ntry in Col Highest No Highest No. ighest No. mendment	l. 1 is less o. Previou o. Previou . Previous t or the nu	than the entry Isly Paid For" I Isly Paid For" I Iy Paid For" (T Imber of claims	in Col. 2, wri N THIS SPA N THIS SPA otal or Indep originally fi	te "0" in Col. 3, CE is less than CE is less than .) is the highest led.	20, enter "20". 3, enter "3". number found in the	appropriate bo	κ in Col. 1
ARNI	NG:	"After j require	linal rejec ment of fa	tion or action ( orm which has a	(§ 1 113) ame been made." .	ndments may b 37 C.F.R. 1.116	e made canceling clo (a) (emphasis addeo	aims or complyii  ).	ng with an
				(compl	ete (c) or (	d), as applica	able)		
	(c)	<b>[X]</b>	No ad	ditional fee	for claims	is required.			
					ťO	D	·		
					U	N	.:	, .	
	(d)	[]	Total	additional f	ee for clain	ns required \$	4		
				,	FEE PA	YMENT	N j s j		
i.	[ <b>X]</b> []	Attacl Charg A dur	hed is a ge Accou olicate o	check in the unt No f this transm	sum of \$the that is atta	<u>400.00</u> . sum of <b>\$</b> ched.	•	· ·	·
					,				
					FEE DEF	ICIENCY			
NOTE:	if there the add before to chai to app should	e is a fee d ditional tir the deficie rge is inch ly these ch be checke	eficiency ne consun ency is no uded, prov uarges pri ed. See thu	and there is no ned in making s ted and correct cessing delays or to action on e Notice of Apr	authorizatio up the origina ted, the appli are encounter the cases. Au il 7, 1986, (10	n to charge an o al deficiency. If cation is held al red in returning uthorization to c 065 O.G. 31-33,	account, additional j the maximum, six-m bandoned. In those i the papers to the P' harge the deposit ac ).	fees are necessai onth period has nstances where TO Finance Bran count for any fe	ry to cover expired authorizatu nch in ordu e deficienc
					•		(Amendm	ent Transmittal-	—page 3 o
				,		•	r		
									,
					•				
					,				
					· · ·				

[X] If any additional extension and/or fee is required, charge Account No. <u>04-1105.</u>

#### AND/OR

.

6.

[X] If any additional fee for claims is required, charge Account No. \_\_\_\_\_04-1105.

SIGNATURE OF PR CTITIONER

Reg. No. 33,860

Tel. No. (617) 523-3400

Peter F. Corless (type or print name of practitioner) EDWARDS & ANGELL, LLP Dike, Bronstein, Roberts & Cushman, IP Group P.O. Box 9169 P.O. Address

Boston, Massachusetts 02209

(Amendment Transmittal-page 4 of 4)



Docket No. 55647

HIZKB

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	C. Meese et al.			
SERIAL NO.:	09/700,094	'n	GROUP:	1623
FILED:	January 2, 2001	1 TH	EXAMINER:	Z. Tucker
FOR:	NOVEL DERIVATI	ES OF 3,3-DI	PHENYLPROP	YLAMINES

THE HONORABLE COMMISSIONER OF PATENTS AND TRADEMARKS WASHINGTON, DC 20231

SIR:

G

#### AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Applicants are in receipt of the Office Action dated September 7, 2001. Please amend the above-identified application as follows.

#### **IN THE CLAIMS**

Please add the following new claim 39.

39. A pharmaceutical composition of claim 26 wherein the composition is a patch formulation.

#### REMARKS

Claim 39 has been added. No new matter has been added by virtue of that amendment. For instance, support for the new claim appears e.g. at page 36, lines 3-4 of the application.

Applicants respectfully request reconsideration of the Restriction Requirement.

A unity objection was not raised in the corresponding International Application (the present case was filed under 35 U.S.C. 371). A copy of the International Preliminary Examination Report is enclosed, which shows the application claims satisfied novelty and inventive step requirements.

C. Meese et al. U.S.S.N. 09/700,094 Page 2

Additionally, it is believed the searches of multiple Groups identified in the Restriction will be overlapping and, therefore, examination of multiple Groups would not cause undue burden. Indeed, significant expense and time would be required if divisional applications to each of the <u>ten</u> Groups identified in the Restriction must be separately prosecuted.

It is thus requested that all the presented subject matter be considered at this time. See, again, the International Preliminary Examination Report, copy enclosed. As an alternative, it is requested that at least Groups I through 5 be examined together at this time.

To be fully responsive to the Restriction, Applicants elect Group 1, as that Group is defined in the Office Action.

Respectfully, Applicants strongly disagree with statements on page 4 of the Office Action regarding what was known in the art. As discussed above, the International Preliminary Examination Report states the claims satisfy novelty and inventive step requirements.

Early consideration and allowance of the application are earnestly solicited.

Respectfully submitted,

Peter F -Corless (Reg. 33,860) EDWARDS & ANGELL, LLP Dike, Bronstein, Roberts & Cushman IP Group P.O. Box 9169 Boston, MA 02209 (617) 523-3400

OPE	10.35
( MIN 3'	The second
SALENT&T	RADENIE

Mailing Date. <b>Novemb</b> e Client: <b>Kraus &amp; Wed</b> Inventors: <b>C. Me</b> ese	er 29, 2001 lsert (45107) et al.	Allomey/Sec PFC/dmr Docket No 55647	
Senal No.: 09/700,09 Filing Dale: January	94 2, 2001	Patent No Grant Date	
The dating stamp of the Pa	itent and Trademark Office he	reon will be taken as the date of t	hling of the later
Amendment Tra	nsmittal; Respons	e to Restriction	
Requirement;	and check in the	amount of \$400.00.	i
	$\sum_{i=1}^{n} \sum_{j=1}^{n} \sum_{i=1}^{n} \sum_{i=1}^{n} \sum_{i=1}^{n} \sum_{j=1}^{n} \sum_{i=1}^{n} \sum_{i$		
		: ; ,	<b>)</b>
		· · ·	i .
	,	· · · · · ·	i
Due Date <sup>.</sup> December	7, 2001		i
			·
		•	
	, , , , , , , , , , , , , , , , , , ,	:	•
	· ,	-, · · ·	• •
	EXPLAN	ATION AMOUNT	57-1/115
COUNSELLORS AT LAW	Code: 116		1665
since 1899 28 Lord Russd Suite 230 Mariburn JAA 01752			1000
Rour Bundrod Dollars and 00	/100		
TO THE OPPER OF	100	DESCRIPTION	CHECK AMOUNT
	(45)0	7) 55647	1665 \$ 400 00
nor winn tor raten LS	1	VOIDIEIS	
		VOLD A 16	V DA 15 OR OLDAR
	· · · ·	(	
· · · · · · · · · · · · · · · · · · ·	· · ·		
<i>O</i> Fleet www.fleet.com	······································	Draus	Purchan
		Draus	Purchan
	15000101: 931	Dans 955 76629"	Purchan
	15000 10 <b>1</b> : 931	Daux 955 76629"	Purchen
Fleet         www.fleet.com           II*0036651I*         II*01	15000101: 93	Dans 955 7662911	Purcher
() Fleet www.fleet.com	. 1 5000 10: 93	Dans 955 76629"	Pivine_
€ Fleet www.fleet.com	5000 ioi: 93	Daux 955 76629"	Purchen
	. 1 5000 10: 93	Dans 955 76629"	Pivice
€ Fleet www.fleet.com II®OO ℃665II® ICO №	• • • • • • • • • • • • • • • • • • •	Dava 955 76629"	Pivine_
€ Fleet www.fleet.com II®OOЪББ5II® ICO♪	• <b>1</b> 5000 <b>1</b> 0 <b>1</b> 9 3 9	Daus 955 76629"	Purier_
€ Fleet www.fleet.com II®OOЪББ5II® ICO♪	• <b>1</b> 5000 <b>1</b> 0 <b>:</b> 93	Dans 955 76629"	Purcies_
Fleet www.fleet.com	<b>,                                    </b>	Daux 955 76629"	Purier_
€ Fleet www.fleet.com II"OO LEE 5II" ICO L	• <b>1</b> 5000 <b>1</b> 0 <b>1</b> : 93	Daus 955 76629"	Pivinen_
Fleet www.fleet.com	• • • • • • • • • • • • • • • • • • •	Dava 955 76629"	Purier_
Fleet www.fleet.com	• <b>1</b> 5000 <b>1</b> 0 <b>1</b> : 93	Daus 955 76629"	Purier_
Fleet www.fleet.com	• • • • • • • • • • • • • • • • • • •	Jaua 955 76629"	Purier_
Fleet www.fleet.com	• • • • • • • • • • • • • • • • • • •	Daus 755 76629"	Twie
Fleet www.fleet.com	• • • • • • • • • • • • • • • • • • •	Jaua 955 76629	Pivinen_
Fleet www.fleet.com	<b>,                                    </b>	Daua 755 76629"	Twie
€ Fleet www.fleet.com I"OO LEE 5II" ::O L	• • • • • • • • • • • • • • • • • • •	Daus 155 76629"	Pivier_
€ Fleet www.fleet.com I™OO LEE 5II* I;O L	• • • • • • • • • • • • • • • • • • •	Jaua 755 76629"	Twie

ŗ,

Transaction History Date \_\_\_\_\_\_ Date information retrieved from USPTO Patent Application Information Retrieval (PAIR) system records at www.uspto.gov



JAN 17 2002

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 2023I WWW.USPTO GOV

PETER F. CORLESS EDWARDS & ANGELL, LLP 130 WATER STREET BOSTON MA 02109

United States

**RADEMARK OFFICE** 

Patent and

In re Application of Claus Meese et al Serial No.: 09/700,094 Filed: January 2, 2001 Attorney Docket No.: 55647(45107)

**PETITION DECISION** 

This is in response to applicants' petition under 37 CFR 1.181, filed May 21, 2002 (duplicate filed November 19, 2002), requesting revival of the above-identified application based on a timely response to the last Office action. The delay in acting on this petition is regretted, however it was not forwarded for decision until recently.

A review of the file history indicates the examiner mailed an Office action to applicants on September 7, 2001, setting a one month shortened statutory period for reply. Upon failure to receive a reply, the application was held abandoned by Notice of Abandonment mailed April 10, 2002. Applicants states that a reply to the Office action was filed on November 29, 2001, accompanied by a request and fee for a two month extension of time. It appears that the reply was never received by the Office, possibly due to US Postal Service irregularities at the time. The copy of the reply which accompanied the petition has now been placed in the file in lieu of the original. In view applicants timely reply, the Notice of Abandonment was mailed in error and is withdrawn and the application is restored to a pending status with the mailing of this decision.

Applicant's petition is **GRANTED**.

The application will be forwarded to the examiner for further consideration.

Should there be any questions with respect to this decision, please contact William R. Dixon, Jr., by mail addressed to Director, Technology Center 1600, Washington, D.C. 20231, or by telephone at (703) 308-3824 or by facsimile transmission at (703) 305-7230.

Bruce M. Kisliuk Director, Technology Center 1600

UNITED STAT PATENT AND **** TRADEMARK	res Office	,	
JAN 1 7 5002	UNDER SECRE	TARY OF COMMERCE FOR R OF THE UNITED STATES PA	INTELLECTUAL PROPERTY TENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 WWW.USPTO.GOV
PETER F. CORLESS		· .	RECEIVED
EDWARDS & ANGELL, LLP	e e e e e e e e e e e e e e e e e e e		FEB 0 3 2003
130 WATER STREET	· ,		
BOSTON MA 02109			TECH CENTER 1000/2300
In re Application of	1. e <b>i</b>		
Claus Meese et al			HECEWER
Serial No.: 09/700,094	:PI	ETITION DECISION	N N N N N N N N N N N N N N N N N N N
Filed: January 2, 2001	:	1	MAY 1 5 2002
Attorney Docket No.: 55647(45107)		• • •	
	•	.Ÿ	TECH CENTER 1000/00
			1000/29

This is in response to applicants' petition under 37 CFR 1.181, filed May 21, 2002 (duplicate filed November 19, 2002), requesting revival of the above-identified application based on a timely response to the last Office action. The delay in acting on this petition is regretted, however it was not forwarded for decision until recently.

A review of the file history indicates the examiner mailed an Office action to applicants on September 7, 2001, setting a one-month shortened statutory period for reply. Upon failure to receive a reply, the application was held abandoned by Notice of Abandonment mailed April 10, 2002. Applicants states that a reply to the Office action was filed on November 29, 2001, accompanied by a request and fee for a two month extension of time. It appears that the reply was never received by the Office, possibly due to US Postal Service irregularities at the time. The copy of the reply which accompanied the petition has now been placed in the file in lieu of the original. In view applicants timely reply, the Notice of Abandonment was mailed in error and is withdrawn and the application is restored to a pending status with the mailing of this decision.

Applicant's petition is **GRANTED**.

The application will be forwarded to the examiner for further consideration.

Should there be any questions with respect to this decision, please contact William R. Dixon, Jr., by mail addressed to Director, Technology Center 1600, Washington, D.C. 20231, or by telephone at (703) 308-3824 or by lacsimile transmission at (703) 305-7230.

Bruce M. Kisliuk Director, Technology Center 1600 · 6. 14

11 1 1

1. 1. 14

sa toar Siringear

#### JAN-28-2003 TUE 10:37 AM EDWARDS & ANGELL

P. 02

#14

Docket No. 55647 (45107)

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	C. Meese et al.	•	· .	
SERIAL NO .:	09/700 <b>,094</b>		GROUP:	1624
FILED:	January 2, 2001	· ·	EXAMINER:	Z, Tucker

FOR: NOVEL DERIVATIES OF 3,3-DIPHENYLPROPYLAMINES

ľ

Commissioner for Patents and Trademarks Washington, D.C. 20231

SIR:

#### CHANGE OF ATTORNEY'S ADDRESS IN APPLICATION

NOTE: Section 601.03 (Change of Correspondence Address), M.P.E.P., 7th Edition states:

"Where an ulturney or agent of record (or applicant, if he or she is prosecuting the application pro se) changes his or her correspondence address, he or she is responsible for promptly notifying the Patent and Trademark Office of the new correspondence address (including ZIP code number). The notification should also include his or her telephone number A change of correspondence address may not be signed by an attorney or agent not of record (see MPEP Section 403).

"Unless the correspondence address is designated as the address associated with a Customer Number, a separate natification must be filed in each application for which a person is intended to receive communitations from the Office. See MPEP Section 403 for Customer Number Practice. In these instances where a change in the correspondence address of a registered attorney or agent is necessary in a plurality of applications, the notification filed in each

÷.,

[X]

(ERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. Section 1.8(a))

I hereby certify that, on the date shown below, this correspondence is being:

#### MAILING

 deposited with the United States Postal Service with sufficient postage as first class multiman envelope addressed to the Commissioner for Patonis and Trademarks, Washington, D.C. 20231. transmitted by facsimile to the Patent and Trademark Office (703) .746-3176.

FACSIMILE

in C.N

<u>Ch</u>. Signature

Date: 1-28-03

Christine C. O'Day. (type or print name of person certifying)

(Change of Attorney's Address in Application-page 1 of 2)

#### Received from < 617 439 4170 > at 1/28/03 10:34:39 AM [Eastern Standard Time]

#### JAN-28-2003 TUE 10:37 AM EDWARDS & ANGELL

# FAX NO. 617 4 J9 4170

application may be a reproduction of a properly executed, original notification. The original notice may either be sent to the Office of Enrallment and Discipline as notification to the Attornay's Roster of the change of address, or may be filed in one of the applications affected, provided that the notice includes an authorization for the public to inspect and copy the original notice in the event one of the applications containing a copy mutures into a patent and the application containing the original paper is either pending or has become abundoned. Alternatively, the paper containing the original signature may be retained by applicant. See MPEP Section 502.02. The copies submitted in each affected application must identify where the original paper is located.

"Special care should be taken in continuation or divisional applications to ensure that any change of correspondence address in a prior application is reflected in the continuation or divisional application. For example, where a copy of the oath or declaration from the prior application is submitted for a continuation or divisional application filed under 37 CFR 1.53(b) and the copy of the oath or declaration from the prior application designates an old correspondence address, the Office may not recognize, in the continuation or divisional application, the change of correspondence address made during the prosecution of the prior application. Applicant is required to identify the change of correspondence address in the continuation or divisional application to unsure that communications from the Office are mailed to the current correspondence address. 37 CFR 1.63(d)(4).

"Nee MPEP Section 711.03(c) for treatment of petitions to revive applications abandoned as a consequence of failure to timely receive an Office action addressed to the old correspondence address.

"The required notification of change of correspondence address need take no particular form. However, it should be provided in a manner calling attention to the fact that a change of address is being made. Thus, the mere inclusion, in a paper being filed for another purpose, of an address which is different from the previously provided correspondence address, without mention of the fact that an address change is being made would not ordinarily be recognized or devened as instructions to change the correspondence address on the file record."

Please send all correspondence for this application as follows:

Peter F. Corless IDWARDS & ANGELL, LLP P.O. Box 9169 Boston, MA 02209

Please direct telephone calls to:

Peter F. Corless or Christine C. O'Day Tel: (617) 439-4444 Fax: (617) 439-4170

TC.a m SIGNATURE OF PRACTITIONER

Reg. No. 38,256

Christing C. O'Day

(upo or print name of practitioner) Edwards & Angell, LLP

Boston, Massachusetts 02209

P.O. Rox 9169 P.O. Address

Customer No. 21874

Tel. No. (617) 439-4444

(Change of Attorney's Address in Application -- page 2 of 2)

Received from < 617 439 4170 > at 1/28/03 10:34:39 AM [Eastern Standard Time]

P. 03

				UNITED STATES DEPARTM United States Patent and Ti Address COMMISSIONER OF P Washington, D.G. 20231 www.usptc.gov	ient of commerce radgedste Office NTENTS and TRADEMARK
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	11 × 1	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/700,094	01/02/2001	Claus Meese		MBHB00-1121	1408
21874 75	90 02/06/2003	•	•	•	
EDWARDS &	ANGELL, LLP			EXAM	NER
P.O. BOX 9169 BOSTON, MA 02209			*	TUCKER, Z/	ACHARY C
		· ·	. '	ART UNIT	PAPER NUMBER
		$\left[ F_{1} \right] = \left[ \left[ \left[ F_{1} \right] \right] \right]$		1624 DATE MAILED: 02/06/2003	15

Please find below and/or attached an Office communication concerning this application or proceeding.

P'I'O-90C (Rev 07-01)

	· · ·	· ·
	Application No.	Applicant(s)
	09/700.094	MEESE ET AL.
Office Action Summary	Examiner	Art Unit
· · · · · · · · · · · · · · · · · · ·	Zachary C. Tucker	1624
The MAILING DATE of this communication ap	opears on the cover sheet with the	correspondence address
		NS) FROM
<ul> <li>A SHOKTENED STATUTORY PERIOD FOR ACTION</li> <li>Fixtensions of time may be available under the provisions of 37 CFR 1 after SiX (6) MONTHS from the mailing date of this communication.</li> <li>If the period for reply specified above is less than thirty (30) days, a re</li> <li>If NO period for reply is specified above, the maximum statutory period</li> <li>Failure to reply within the set or extended period for reply will, by statu</li> <li>Any reply received by the Office later than three months after the mailing parmed patent term adjustment. See 37 CFR 1 704(b).</li> </ul>	138(a) In no event, however, may a reply be to ply within the statutory minimum of thirty (30) di d will apply and will expire SIX (6) MONTHS fro rise, cause the application to become ABANDON ing date of this communication, even if timely file	imely filed ays will be considered timely. m the mailing date of this communication. IED (36 U.S.C. § 133). ed, may reduce any
1)[X] Responsive to communication(s) filed on 31	May 2002 .	
(2a) This action is <b>FINAL</b> . $(2b)$	This action is non-final.	
3)[	wance except for formal matters, er <i>Ex par</i> te <i>Quayl</i> e, 1935 C.D. 11,	prosecution as to the merits is , 453 O.G. 213.
4) ⊠ Claim(s) <u>1-16,19-24 and 28-39</u> is/are pendir	ng in the application.	<b>.</b>
4a) Of the above claim(s) <u>11-14,21-24,31 and</u>	d 33 is/are withdrawn from consid	ieration.
5) Claim(s) is/are allowed.	; , <u>.</u>	
6) Claim(s) is/are rejected.	( 20 jelone objected to	•
7) X Claim(s) <u>1-10,15,16,18-20,28-30,32 and 34</u>	1-39 is/are objected to.	
8) Claim(s) are subject to restriction and Application Papers		
9) The specification is objected to by the Exami	ner.	
10) The drawing(s) filed on <u>02 January 2001</u> is/a	re: a) accepted or b) 🛛 objected t	to by the Examiner.
Applicant may not request that any objection to	the drawing(s) be held in abeyance.	See 37 CFR 1.85(a).
11) The proposed drawing correction filed on	is: a) approved b) disap	proved by the Examiner.
If approved, corrected drawings are required in	reply to this Office action.	
12) The oath or declaration is objected to by the	Examiner.	
Priority under 35 U.S.C. §§ 119 and 120	i i sveni me	
13) Acknowledgment is made of a claim for fore	ign priority under 35 U.S.C. § 11	9(a)-(d) or (f).
a) 🖾 All b) 🔲 Some * c) 🛄 None of:		
1. Certified copies of the priority docume	ents have been received.	notion No
2. Certified copies of the priority docume	ents have been received in Applic	allon ND
3.⊠ Copies of the certified copies of the p application from the International * See the attached detailed Office action for a	Bureau (PCT Rule 17.2(a)). list of the certified copies not rece	sived in this National Stage
14) Acknowledgment is made of a claim for dom	estic priority under 35 U.S.C. § 11	9(e) (to a provisional application).
a) 🔲 The translation of the foreign language	provisional application has been	received.
15} Acknowledgment is made of a claim for dom	estic priority under 35 U.S.C. §§	120 and/or 121.
Attachment(s) 1) X Notice of References Cited (PTO-892) 2) X Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) X Information Disclosure Statement(s) (PTO-1449) Paper No(	4)  Interview Sumi 5)  Notice of Infor (s) 2. 6)  Other:	mary (PTO-413) Paper No <b>(s).</b> nal Patent Application (PTO-152)
U.S. Peteril and Tredemark Office	e Action Summary	Part of Paper No. 14
		,
		. *
	j. 	
	•	
1		
	, <b>`</b>	
· · · · · · · · · · · · · · · · · · ·		

, N
# DETAILED ACTION

# **Election/Restrictions**

Applicant's election with traverse of the invention of Group 1 in Paper No. 11 is acknowledged. The traversal is on the ground(s) that the European Patent Office did not find Unity of Invention to be lacking, and that examination of the subject matter of all of the inventions would not place an undue burden on the examiner. These arguments are not found persuasive because the USPTO is not beholden to any decisions made by a foreign patent office concerning unity of invention, nor is search burden a factor taken into consideration when a determination of Lack of Unity of Invention is made.

As stated in the Requirement for Election of Invention, the tolterodine skeleton, common to all of the claimed compounds, is a significant structural element shared by all of the alternatives. This structural element was known at the time the invention was made, and as such is not a special technical feature.

That the claimed compounds do not posses unity of invention for the reasons that when considered as a whole, there is no special technical feature common to all of the claimed compounds is further demonstrated hereinbelow:

The reference cited in the requirement for Election of Invention, mailed 7 September 2001, WO 94/11337 (Johansson et al), discloses at least two of the instantly claimed compounds.

Page 1 of the Johansson et al publication depicts a compound of formula I, wherein R<sup>1</sup> is methyl (2-methoxy), and on page 2, Johansson et al states that the --CH<sub>2</sub>OH group is preferably at the 5- position, corresponding to compounds of instant

claim 1 wherein R' is  $C_1$ - $C_6$  alkyl. Pages 12 and 13 disclose the 2-benzyloxy derivative, corresponding to compounds of instant claim 1 wherein R' is substituted or unsubstituted benzyl.

Compound (iv) in instant claim 15 was known at the time the invention was made, and is disclosed in Brynne et al, "Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity" J. Clin. Pharm. Ther. vol. 35(7), pages 287-295 (1997).

Figure 2 on page 291 of Brynne et al disclosses a series of metabolites of tolterodine, one of which is "IIa," the 5-hydroxymethyl metabolite. The caption of figure 2 and the second full paragraph on page 291 state that all metabolites were also identified as glucuronides, which means the 5-hydroxymethyl glucuronide of tolterodine was identified by Brynne et al.

Applicant is reminded that the determination whether a group of inventions is so linked as to form a single general inventive concept is be made without regard to whether the inventions are claimed in separate claims or as alternatives within a single claim.

The requirement for Election of Invention is hereby modified so as to include phenolic monoesters, benzylic monoesters, wherein R and R' are hydrogen, with the proviso that R and R' are not both hydrogen, and the "bis" dicarboxylic esters, such as the last 4 compounds specified in claim 4, and in claim 28, wherein R is hydrogen or alternative "b."

Claims 11-14,21-24,31 and 33 are withdrawn from consideration as being drawn

to nonelected inventions.

The requirement is still deemed proper and is therefore repeated and

maintalned.

# Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 4 recites the following four compounds:

(±)-malonic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-

phenyl]ester,

(±)-succinic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-

phenyl]ester,

(±)-pentanedioic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-

hydroxymethyl-phenyl]ester, and

(±)-hexanedioic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-

hydroxymethyl-phenyl]ester

as the last four compounds in the claim.

There is insufficient antecedent basis for this limitation in claim 4, as claim 4

depends ultimately from claim 1, wherein an alkylcarbonyl-2-(3-dialkylamino)-1-

phenylpropyl-1-(4-hydroxymethyl)phenyl ester group is not one of the possible identities

for R'. Claim 4 is rejected under 35 U.S.C. 112, second paragraph.

## Drawing

The Drawing is objected to for reasons given on the enclosed PTO-948 form.

## Specification

The Specification is objected to for lack of a Brief Description of the Drawing.

## Claim Objections/Allowable Subject Matter

Claims 1-10,15,16,18-20,28- 30,32 and 34-39 are objected to, as they contain nonelected subject matter, but would be allowable upon cancellation of nonelected subject matter.

Compounds of the elected invention are deemed allowable. The elected invention includes phenolic monoesters, benzylic monoesters, identical diesters, mixed diesters, "bis" dicarboxylic esters (last four compounds of instant claim 4 and compounds of formula VII' –claim 28-, wherein R is hydrogen or identity "b").

Claims directed to a pharmaceutical composition comprising compounds of the elected invention, method of antagonizing muscarinic receptors comprising contacting the receptor with a compound according to the elected invention, and a method of treating a disease in a mammal by antagonizing muscarinic receptors in the mammal comprising administering an amount of a composition according to the elected invention effective to diminish or eliminate symptoms of the disease will be allowed forthwith upon cancellation of nonelected subject matter.

# Conclusion

Any inquiry concerning this communication should be directed to Zachary Tucker whose telephone number is (703) 305-2050. The examiner can normally be reached Monday-Friday from 7:00am to 3:30pm. If Attempts to reach the examiner are unsuccessful, the examiner's supervisor, Mukund Shah, can be reached at (703) 308-

Page 6

4716. The fax number for the organization where this application or proceeding is assigned is (703) 308-4556 for regular communications and (703) 308-4242 for after-final communications.

Any inquiry of a general nature or relating to the status of this application or

proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

zt Zeh

Art Unit 1624

Line         Examiner Sector         At Unit Te24         Page 1 of 1           -         U.S. PATENT DOCUMENTS         -			Notice of Reference		Application/ 09/700,094	Control No.	Applicant( Reexamin MEESE E	s)/Patent Under ation T AL.
Landray G. Tucker         1624         Page 1 of 1			WORLS OF VEIGLENCE	s Ciled	Examiner	· · · · · ·	Art Unit	······································
U.S. PATENT DOCUMENTS         Dataset           0         Decument Number Confry CodeNumber Number Set         Dataset         Dataset         Dataset           0         U.S.         Dataset         Dataset         Dataset         Dataset           0         U.S.         Dataset         Dataset         Dataset         Dataset         Dataset           0         U.S.         Dataset         Data					Zachary C.	Tucker	1624	Page 1 of 1
Constitution of All States A	<b>-</b>	r	1		U.S. PATENT DOCUN	IENTS		
A       US-	*		Document Number	Date MM-YYYY	$E = \sum_{i=1}^{n} e_i$	Name		Classification
s     US-     US-       c     US-     US-       c     US-     US-       c     US-     US-       c     US-     US-       d     US-     US-       i     Debrained warrise Color     Dath Yry       i     Debrained warrise Color     Dath Yry       i     Debrained warrise Color     MAYry       i     Debrained warrise Color     Marrise Color       i     Debraine Color     Marr		A	, US-				· · · · · · · · · · · · · · · · · · ·	
C         US-		в	US-			•		
b     US     US       E     US       A     US       H     US       J     US       L     US       V     Document Number       Document Number     Document Number       R     Coupling One Number Coupling       Q     Coupling One Numate Social Coupling       V		С	US-		· · ·		<i></i>	
E     US-     US-       G     US-     US-       I     US-     US-       I     US-     US-       I     US-     US-       K     US-     US-       M     US-     US-       V     Document Number     Document Number       Q     US-     US-       Q     US- <td></td> <td>D</td> <td>US-</td> <td></td> <td></td> <td></td> <td></td> <td>·</td>		D	US-					·
r       US       US         ii       US       US         ii       US       US         ji       US       US         ji       US       US         ji       US       US         iiii       US       US         iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii		Е	US-					
S       US.         I       US.         J       US.         K       US.         L       US.         K       US.         K       US.         M       US.         Control Number       Decoment Number         Control CodeNumeer/Name Code Mathematic Code       MALYYY         Control CodeNumeer/Name Code Mathematic Code       MALYYY         Control CodeNumeer/Name Code Mathematic Code       MALYYY         Q		F	US-			· · ·		
Image: state of the state o		G	US-	<u> </u>				
I       US-		н	US-		· · · · · ·	· · · · · · · · · · · · · · · · · · ·		
J     US-       K     US-       L     US-       M     US-       POREION PATENT DOCUMENTS         *     Contry Code Number Kind Code       M     Document Number       O     Date       P     Contry Code Number Kind Code       N     Document Number       Q     Date       P     Contry Code Number Kind Code       N     Date       Q     Date       Q     Date       Q     Date       Q     Date       R     Date       S     Date       Y     Non-Pattent CodUMENTS       Non-Pattent CodUMENTS       Non-Pattent CodUMENTS       Non-Pattent CodUMENTS       V     Non-Pattent CodUMENTS       V     Non-Pattent CodUMENTS       V     Non-Pattent CodUMENTS       V     Non-Patent CodUMENTS       V     Non-Pattent CodUMENTS       V     Non-Patte			US.	<u> </u>		·		
N       US-	••••••		118-					
Non-       Non-         I       US-         IV       POREION PATENT DOCUMENTS         Country Code Number-Kont Code       MMA YYYY       Country         N       Document Number         Q       Document Number         R       Document Number         Y       Document Number         W       Non-PATENT DOCUMENTS         Molder Backback Aubor, Title Dake, Publisher, Editorior Volume, Pertinent Pages)         W       Document Status         U       Brynne Status         Brynne Status       Pharma Theor. vol. 35(7), pages 287-295 (1997).         V       V         W       X         Actory of Nummer Regression Market with The Ofice action, (See MEPE § 707 05(b).)         Monter Inference is not being humabled with The Ofice ac					· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·		
N     US-       *     Document Number County Cook-Numer-Kind Colo MAYYYY     County     Name     Classification       *     County Cook-Numer-Kind Colo MAYYYY     County     Name     Classification       0     -     -     -     -       0     -     -     -     -       0     -     -     -     -       1     -     -     -     -       2     -     -     -     -       3     -     -     -     -       7     -     -     -     -       8     -     -     -     -       9     -     -     -     -       10     -     -     -     -       10     -     -     -     -       10     -     -     -     -       10     -     -     -     -       10     -     -     -     -       10     -     -     -     -     -       11     -     -     -     -     -       11     -     -     -     -     -       12     -     -     -     -     - <t< td=""><td></td><td><u> </u></td><td></td><td><u> </u></td><td></td><td></td><td></td><td>· · · · · · · · · · · · · · · · · · ·</td></t<>		<u> </u>		<u> </u>				· · · · · · · · · · · · · · · · · · ·
M     US-       POREIGN PATENT DOCUMENTS       Country Code-Number-Kind Code       N       O       O       P       Country Code-Number-Kind Code       MMA-YYYY       Country Code-Number-Kind Code       MMA-YYYY       Country Code-Number-Kind Code       MAN-YYY       Q       Q       Q       Q       Q       Q       Q       Y       Noth-PATENT DOCUMENTS       *       Include as applicable. Author, Title Date, Publisher, Edition or Volume, Partment Pages)       Y       Brynne et al., "Pharmacolynamics of totbrooline in man: a new drug for the treatment of urinary bladder overactivity" J. Clin. Pharm. Ther. vol. 35(7), pages 257:296 (1997).       V       W       X   Antervision is not being functified with this Office action. (Sas MPEP § 707:05(1)) TO-F692 (Fibry, 01-2001) Notice of References Cited Part of Paper No. 14							······	
POREIGN PATENT DOCUMENTS           Document Number         Document Number           N         Country         Name         Classification           N         O         Country         Name         Classification           P         Country         Name         Classification           Q         Q         Country         Name         Classification           R         Q         Q         Q         Q         Q           R         Q         Q         Q         Q         Q           T         Q         Q         Q         Q         Q           T         Q         Q         Q         Q         Q           T         Q </td <td>]</td> <td>м</td> <td>US</td> <td></td> <td><u>r</u></td> <td></td> <td><u> </u></td> <td></td>	]	м	US		<u>r</u>		<u> </u>	
County Code-Number-Kind Code         Mat/VYYY         County         Name         Classification           N		<u> </u>	Document Number	FO	REIGN PATENT DOC			
N		<b></b> ,	Country Code-Number-Kind Code	MM-YYYY	Country	. Nam	B	Classification
0		N	• <b></b> ,		·		· · · · · · · · · · · · · · ·	
P		0			· · · ·			
Q	_	<u>р</u>	•					
R       NON-PATENT DOCUMENTS         *       Include as applicable: Author, Tillo Date, Publisher, Edition or Volume, Pertinent Pages)         Brynne et al, "Pharmacokinetics and pharmacodynamics of bullsmodine in man: a new drug for the treatment of urinary bladder overactivity" J. Clin. Pharm. Ther. vol. 35(7), pages 287-295 (1997).         V		Q						
S		R			<u>!</u>			
Y         NON-PATENT DOCUMENTS           Include as applicable: Author, Title Date, Publisher, Edition or Volume, Partnent Pages)         Brynne et al. "Pharmacokinetics and pharmacodynamics of tolerodine in man: a new drug for the treatment of urinary bladder overactivity" J. Clin. Pharm. Ther. vol. 35(7), pages 287-285 (1997).           V         V           X           Acopy of thur reference is not being furnished with this Office action. (See MPEP § 707 05(a).)           X           Acopy of thur reference is not being furnished with this Office action. (See MPEP § 707 05(a).)           XBR in MM-YVTO met are publication dates. Classifications may be US or foreign.)           XB-Platest and Trademark Ottop           TTO-692 (Flow. 01-2001)   Notice of References Cited Part of Paper No. 14		S			· · · · · · · · · · · · · · · · · · ·			
NON-PATENT DOCUMENTS           Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)           U         Brynne et al, "Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity" J. Clin. Pharm. Ther. vol. 35(7), pages 287-285 (1997).           V         V           Acopy of this reference is not being fumibhed with this Office action. (See MPEP § 707 05(6).)           Materia In Mir/YY format are publication dates. Classificationa may be 13 or foreign.           IS-Petint and Treference Ditor           IS-Petint and Treference Ditor           Materia In Mir/YY format are publication dates. Classificationa may be 13 or foreign.           IS-Petint and Treference Ditor           IS-Petint and Treference Ditor           Notice of References Cited           Part of Paper No. 14		Т						
*       Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)         U       Brynne et al, "Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity" J. Clin. Pharm. Ther. vol. 35(7), pages 267-295 (1997).         V		<b></b>		1	NON-PATENT DOCUM	AENTS		
u       Brynne et al, "Pharmacokinetics and pharmacodynamics of tollarodine in man: a new drug for the treatment of urinary bladder overactivity" J. Clin. Pharm. Ther. vol. 35(7), pages 297-295 (1997).         v	*		Inclue	de as applicable: A	uthor, Title Date, Publi	sher, Edition or Volum	e, Pertinent Pag	68)
V         A copy of this reference is not being furnished with this Offica action. (See MPEP § 707 05(a).)         bates in NM-YYYY formal are publication dates. Classifications may be US or foreign.         S. Peters darf Trademark Offica         YTO-492 (Rev. 01-2001)         Notice of References Cited         Part of Paper No. 14		U	Brynne et al, "Pharmacokineti overactivity" J. Clin. Pharm. T	cs and pharmact her. vol. 35(7), p	odynamics of toltero ages 287-295 (1997	dine in man: a new c ).	Irug for the tre	atment of urinary bladder
A copy of thur reference is not being furnished with this Office action. (See MPEP § 707 05(a).) takes in MA-YYYY formal are publication dates. Cleasifications may be US or forsign. Is Peterland Trademark Otico TO-492 (Rev. 01-2001) Notice of References Cited Part of Paper No. 14		v						
A copy of this reference is not being furnished with this Office action. (See MPEP § 707 05(a).) Safes in MA-YYYY format ere publication dates. Classifications may be US or foreign. US. Patent and Trademark Office 7TO-492 (Rev. 01-2001) Notice of References Clied Part of Paper No. 14					•			
A copy of thus reference is not being furnished with this Office action. (See MPEP § 707 05(s).) Tates in MM-YYY format are publication dates. Classifications may be US or toreign. IS Patter lan Trademark Otice YTO-F92 (Rev. 01-2001) Notice of References Cited Part of Paper No. 14		w						
A copy of this reference is not being furnished with this Office action. (See MPEP § 707 05(a).) Jates in MM-/YYY format are publication dates. Classifications may be US or toreign. IS. Patent and Trademark Office YTO-R92 (Fiev. 01-2001) Notice of References Cited Paper No. 14		x						
A COPY of Initi reference is not being furnished with the Unice action. (See MP2P § 707 06(a).) Takes in MM-YVY formal exp publication dates. Classifications may be US or foreign. I.S. Patent and Trademark Office TO-692 (Nev. 01-2001) Notice of References Cited Part of Paper No. 14				1.0.0				
13. Palini and Trademark Office TO-692 (Rev. 01-2001) Part of Paper No. 14	Dates	in MM	In reference is not being furnished with the YYYY format are publication dates. Claim YYYY format are publication dates.	his Office action. (See salfications may be U	a MPEP § 707 05(a).) S or foreign.			,
	U.S. P	etent en -892 (l	d Trademark Office Rev. 01-2001)	No	tica of References C	ited	·	Part of Paper No. 14
						· ·		•
						•		
						. • * *		
					: . · ·			
						· ·		
						· · · · · · · · · · · · · · · · · · ·		
				1		· •		
· · · · · · · · · · · · · · · · · · ·	,							· · ·
•						• •		
					,			

ł.

U.S. DEPARTMENT OF COMMERCE - Patent and Trademark Office

<u>9/700,09</u>4 Application No.

## NOTICE OF DRAFTSPERSON'S PATENT DRAWING REVIEW

The drawing(s) tiled (insert date) 1- 2.01 are:

Form PTO 948 (Rev. 03/01)

A. hpproved by the Draftsperson under 37 CFR 1.84 or 1.152 B. objected to by the Draftsperson under 37 CFR 1.84 or 1.152 for the reasons indicated below. The Examiner will require submission of new, corrected drawings when necessary. Corrected drawing must be sumitted according to the instructions on the back of this notice.

1 DRAWINGS 37 CFR 1 84(a): Acceptable categories of drawings: 8. ARRANGEMENT OF VIEWS. 37 CFR 1.84(i) Black ink Color Words do not appear on a horizontal, left-to-right fashion when page is either upright or turned so that the top Color drawings are not acceptable until petiton is granted. becomes the right side, except for graphs. Fig(s) 9. SCALE. 37 CFR I 84(k) Fig(s) Pencil and non black ink not permitted Fig(s) \_ 2 PHOTOGRAPHS. 37 CFR 1.84(b) Scale not large enough to show mechanism without I lull-tone set is required. Fig(s) crowding when drawing is reduced in size to two-thirds in Photographs may not be mounted 37 CFR | 84(e) Poor quality (half-tone) Fig(s) reproduction. Fig(s) 3 THPE OF PAPER. 37 CFR 1.84(e) 10. CHARACTER OF LINES, NUMBERS, & LETTERS. 37 CFR 1.84(i) Paper not flexible, strong, white, and durable Fig(s)\_ Lines, numbers & letters not uniformly thick and well Erasures, alterations, overwritings, interlineations, defined, clean, durable, and black (poor line quality). Fig(s)\_\_\_\_\_ folds, copy machine marks not accepted Fig(s)\_ Mylar, velum paper is not acceptable (too thin). Fig(s) \_\_\_\_\_\_\_ S ZE OF PAPER. 37 CFR 1.84(f): Acceptable sizes. \_ Solid black areas pale. Fig(s) \_ 21.0 cm by 29.7 cm (DIN size A4) \_ 21.6 cm by 27.9 cm (8 1/2 x 11 inches) 12. NUMBERS, LETTERS, & REFERENCE CHARACTERS All drawing sheets not the same size. 37 CER 1.84(p) Sheet(s)\_\_\_\_\_\_Drawings sheets not an acceptable size. Fig(s)\_\_\_\_\_\_ 5. NARGINS. 37 CFR 1.84(g): Acceptable margins: Numbers and reference characters not plain and legible. Fig(s) The 2.5 cm Left 2.5 cm Right 1.5 cm Bottom 1.0 cm SIZE: A4 Size same direction as the view. 37 CFR 1.84(p)(1) Fig(s) Tup 2.5 cm Left 2.5 cm Right 1.5 cm Boltom 1.0 em SIZE: 8 1/2 x 11 English alphabet not used. 37'CFR 1.84(p)(2) Figs Numbers, letters and reference characters must be at least 32 cm (1/8 inch) in height 37 CFR I 84(p)(3) Margins not acceptable. Fig(s)\_ Top (T) \_\_\_\_\_\_Right (R) V-EWS. 37 CFR 1.84(h) Lefi (L) Bottom (B) Fig(s) 13. LEAD LINES. 37 CFR 1.84(q) 6 Lead lines cross each other. Fig(s) \_\_\_\_\_ Lead lines missing. Fig(s) \_\_\_\_\_ REMINDER: Specification may require revision to correspond to drawing changes Partial views. 37 CFR 1.84(h)(2) 14 NUMBERING OF SHEETS OF DRAWINGS. 37 CFR 1 84(1) Sheets not numbered consecutively, and in Arabic numerals Brackets needed to show figure as one entity. beginning with number 1. Sheet(s)\_\_\_\_\_\_ 15. NUMBERING OF VIEWS. 37 CFR 1.84(u) Fig(s) Views not labeled separately or properly \_ Views not numbered consecutively, and in Arabic numerals, Fig(s)\_ Enlarged view not labeled separetely or property. beginning with number 1. Fig(s). 16. CORRECTIONS. 37 CFR 1 84(w) Fig(s) Corrections not made from prior PTO-948 dated 7. SECTIONAL VIEWS. 37 CFR 1.84 (b)(3) 17. DESIGN DRAWINGS 37 CFR 1 152 Hatching not indicated for sectional portions of an object Surface shading shown not appropriate. Fig(s) Fig(s) Sectional designation should be noted with Atabic or Roman numbers. Fig(s) Solid black shading not used for color contrast. Fig(s) А COMMENTS 9.4.01 TELEPHONE NO. 7033058430 REVIEWER DATE\_ ATTACHMENT TO PAPER NO.

# Attachment for PTO-948 (Rev. 03/01, or earlier) 6/18/01

The below text replaces the pre-printed text under the heading, "Imformation on How to Effect Drawing Changes," on the back of the PTO-948 (Rev. 03/01, or earlier) form.

## INFORMATION ON HOW TO EFFECT DRAWING CHANGES

## 1. Correction of Informalities -- 37 CFR 1.85

New corrected drawings must be filed with the changes incorporated therein. Identifying indicia, if provided, should include the title of the invention, inventor's name, and application number, or docket number (if any) if an application number has not been assigned to the application. If this information is provided, it must be placed on the front of each sheet and centered within the top margin. If corrected drawings are required in a Notice of Allowability (PTOL-37), the new drawings **MUST** be filed within the **THREE MONTH** shortened statutory period set for reply in the Notice of Allowability Extensions of time may NOT be obtained under the provisions of 37 CFR 1 136(a) or (b) for filing the corrected drawings after the mailing of a Notice of Allowability. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftsperson.

2. Corrections other than Informalities Noted by Draftsperson on form PTO-948.

All changes to the drawings, other than informalities noted by the Draftsperson, MUST be made in the same manner as above except that, normally, a highlighted (preferably red ink) sketch of the changes to be incorporated into the new drawings MUST be approved by the examiner before the application will be allowed No changes will be permitted to be made, other than correction of informalities, unless the examiner has approved the proposed changes

### **Timing of Corrections**

Applicant is required to submit the drawing corrections within the <u>time period set in the attached Office communication</u> See 37 CFR 1.85(a).

Failure to take corrective action within the set period will result in **ABANDONMENT** of the application.

06/01/01

#	16	Ć
	ŀ	os

Docket No. 55647 (45107)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	C. Meese, ct al.			
SERIAL NO .:	09/700,094		GROUP:	1624
FILED:	January 2, 2001	· · · ·	BXAMINER:	Z. Tucker
FOR:	NOVEL DERIVATIVE	25 OF 3,3-D	PHENYLPRO	PYLAMINES

THE HONORABLE COMMISSIONER OF PATENTS AND TRADEMARKS WASHINGTON, DC 20231

Sir:

### AMENDMENT

Applicants are in receipt of the Office Action dated February 6, 2003. Kindly amend the above-identified application as follows.

# IN THE SPECIFICATION

Kindly insert the following section header following the title on page 1:

ET	BACKGROUND OF THE INVENTION	
•	Kindly insert the following section header on page 3, at line 16:	
R2	SUMMARY OF THE INVENTION	
	Kindly insert the following section headers and text beginning at page 4, line 4:	
<b>B</b> <sup>3</sup>	BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows the formation of the active metabolite from different prodrugs by human liver S 9 (%) in 1 hour.	

FIG. 1 shows the formation of the active metabolite from different prodrugs by human liver S 9 (%) in 1 hour.

DETAILED DESCRIPTION OF THE INVENTION

## IN THE CLAIMS

Please cancel non-elected claims 11-14, 21-24, 31 and 33, without prejudice or disclaimer.

i

1010000

MON 16:59 [TX/RX NO 9123] 2006 04/14/03

C. Meese, et al. USSN 09/700,094 Page -2-

# EDWARDS ANGELL

Please amend claims 1, 4, 6, 15, 28, 34, 35 and 39 such that they read as follows:



Ż

## Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0262

008

C. Meese, et al. USSN 09/700,094 Page -3-

wherein  $\mathbb{R}^8$  and  $\mathbb{R}^9$  represent  $C_1 \cdot C_6$  alkyl groups, which may be the same or different and which together contain at least three carbon atoms, or  $\mathbb{R}^8$  and  $\mathbb{R}^9$  may form a ring together with the amine nitrogen,

A represents hydrogen (<sup>1</sup>H) or deuterium (<sup>2</sup>H),

and

64

their salts with physiologically acceptable acids, their free bases and, when the compounds are in the form of optical isomers, the racemic mixture and the individual enantiomers.

4. The 3,3-Diphenylpropylamine as claimed in claim 2 selected from:
(±)-formic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
(±)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
(±)-propionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
(±)-n-butyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
(±)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
(±)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
(±)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-2,2-dimethylpropionic acid 2-(3-diisopropylamino-l-phenylpropyl)-4hydroxymethylphenyl ester,

(±)-cyclopentanecarboxylic acid 2-(3-diisopropylamino-l-phenylpropyl)-4hydroxymethylphenyl ester,

(±)-cyclohexanecarboxylic acid 2-(3-diisopropylamino-l-phenylpropyl)-4-

hydroxymethylphenyl ester,

(±)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

R-(+)-benzoic acid 2-(3-diisopropylamino-l-phenylpropyl)-4-hydroxymethylphenyl ester,

1

(±)-4-methylbenzoic acid 2-(3-diisopropylamino-l-phenylpropyl)-4-

hydroxymethylphenyl ester,

C. Meese, et al. USSN 09/700,094 Page -4-

(±)-2-methylbenzoic acid 2-(3-diisopropylamino-l-phenylpropyl)-

hydroxymethylphenyl ester,

(±)-2-acetoxybenzoic acid 2-(3-diisopropylamino-l-phenylpropyl)-4hydroxymethylphenyl ester,

(±)-1-naphthoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester.

(±)-2-naphthoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-4-chlorobenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-

hydroxymethylphenyl ester,

(±)-4-mothoxybenzoic acid 2-(3-diisopropylamino-l-phenylpropyl)-4hydroxymethylphenyl ester,

(±)-2-methoxybenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-

hydroxymethylphenyl ester,

(±)-4-nitrobenzoic acid 2-(3-diisopropylamino-l-phenylpropyl)-4-hydroxymethylphenyl ester, and

(±)-2-nitrobenzoic acid 2-(3-diisopropylamino-l-phenylpropyl)-4-hydroxymethylphenyl ester.

6. The 3,3-Diphenylpropylamine as claimed in claim 5 selected from:

(±)-formic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-formyloxymethylphenyl ester, (±)-acetic acid 4-acetoxy-3-(3-diisopropylamino-l-phenylpropyl)-benzyl ester, (±)-propionic acid 2-(3-diisopropylamino-l-phenylpropyl)-4-propionyloxymethylphenyl

(±)-n-butyric acid 4-n-butyryloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl

(±)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-isobutyryloxymethylphenyl

(±)-2,2-dimethylpropionic acid 3-(3-diisopropylamino-l-phenylpropyl)-4-(2,2-dimethyl-

03

6k

ester,

ester,

ester,

propionyloxy)-benzyl ester,

Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0264

MON 16:59 [TX/RX NO 9123] 2009

Bl

## EDWARDS ANGELL

C. Meese, et al. USSN 09/700,094 Page -5-

(±)-benzoic acid 4-benzoyloxymethyl-2-(3-diisopropylamino-l-phenylpropyl)-phenyl ester,

R-(+)-benzoic acid 4-benzoyloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester,

(±)-pent-4-enoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-(pent-4-

encyloxymethyl)-phenyl ester,

cyclic oct-4-ene-1,8-dioste of Intermediate B,

cyclic octane-1,8-dioate of Intermediate B, and

poly-co-DL-lactides of Intermediate B, said Intermediate B having the formula



and

#### EDWARDS ANGELL

C. Meese, et al. USSN 09/700,094 Page -6-

(ii) Poly-co-DL-lactides of 2-(3-diisopropylamino-phenylpropyl)-4-hydroxymethylphenol

E?

B

their salts with physiologically acceptable acids, their free bases and, when the compounds are in the form of optical isomers, the racemic mixture and the individual enantiomers.

 $j \not \bigcirc$  A 3,3-Diphenylpropylamine of the general formula VII':



C. Mecse, et al. USSN 09/700,094 Page -7-

wherein R is

a) hydrogen; or

b) formyl,  $C_1$ - $C_6$  alkylcarbonyl, cycloalkylcarbonyl, substituted or unsubstituted arylcarbonyl;

X represents a tertiary amino group of formula la

R<sup>9</sup> Formula Ia

wherein  $\mathbb{R}^8$  and  $\mathbb{R}^9$  represent non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and wherein  $\mathbb{R}^8$ and  $\mathbb{R}^9$  may form a ring together with the amine nitrogen,

Y and Z independently represent a single bond between the  $(CH_2)_n$  group and the carbonyl group, O, S or NH,

A represents hydrogen (<sup>1</sup>H) or deuterium (<sup>2</sup>H),

n is 0 to 12, and

patch formulation.

their salts with physiologically acceptable acids, their free bases and, when the

compounds are in the form of optical isomers, the racemic mixture and the individual enantiomers.

20-34. A pharmaceutical composition comprising a 3,3-diphenylpropylamine i ( /6 ~12 according to any one of claims 1-10, 15 and <del>28-30</del> and a pharmaceutically acceptable carrier.

21 95. A method of antagonizing a muscarinic receptor, the method comprising contacting the receptor with a compound according to any one of claims 1-10, 12 and 28-



+12<sup>3</sup>

39. A pharmaceutical composition of claim 34 wherein the composition is a

#### 04/14/2003 17:01 FAX 6174394170

1

6!

EDWARDS ANGELL

C. Meese, et al. USSN 09/700,094 Page -8-

## -Kindly add the following new claims:

25,40. (new) A 3,3-Diphenylpropylamine selected from:

(±)-malonic acid bis-[2-(3-diisopropylamino-l-phenylpropyl) 4-hydroxymethylphenyl] ester,

(±)-succinic acid bis-[2-(3-diisopropylamino-l-phenylpropyl)-4-hydroxymethyl-phenyl] ester,

(±)-pentanedioic acid bis-[2-(3-diisopropylamino-l-phenylpropyl)-4-hydroxymethylphenyl] ester, and

(±)-hexanedioic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-

hydroxymethylphcnyl] ester.

26 44. (new) The 3,3-Diphenylpropylamine of claim 2, wherein the 3,3-Diphenylpropylamine is R-(+)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester or a pharmaceutically acceptable salt thereof.

## REMARKS

Claims 11-14, 21-24, 31 and 33 have been cancelled without prejudice or disclaimer, as being drawn to a non-elected invention. Claims 1, 4, 6, 15, 28, 34, 35 and 39 have been amended, merely to cancel non-elected subject matter and to address minor informalities. Claims 40-41 have been added. The specification has been amended to provide several section headings as well as a "Brief Description of the Drawings" section.

No new matter has been added by virtue of these amendments. Support therefore can be found throughout the specification and in the original claims of the application. In particular, with respect to new claim 40, support can be found in original claim 4; support for new claim 41 also can be found in original claim 4 and at pages 11 and 62 of the specification.

Applicants appreciate the indication of allowable subject matter, i.e., that claims

C. Meese, et al. USSN 09/700,094 Page -9-

1-10, 15, 16, 18-20, 28-30, 32 and 34-39 are merely objected to as containing non-elected subject matter, but would be allowable upon cancellation of that non-elected subject matter.

The Office Action further indicates that claims directed to a pharmaceutical composition comprising compounds of the elected invention, a method of antagonizing muscarinic receptors comprising contacting the receptor with a compound according to the elected invention, and a method of treating a disease in a mammal by antagonizing muscarinic receptors in the mammal comprising administering an amount of a composition according to the elected invention effective to diminish or eliminate symptoms of the disease also will be allowed upon cancellation of that non-elected subject matter.

Accordingly, Applicants submit the within amendment merely to cancel the nonelected subject matter from the claims and place those claims in condition for immediate allowance.

Additionally, claim 4 was rejected under 35 USC §112, second paragraph. As the rejection is understood, it is alleged that there is insufficient antecedent basis for the last four compounds in the claim. As grounds for the rejection, it is asserted that claim 1 (from which claim 4 depends) does not recite an alkylcarbonyl-2-(3-dialkylamino)-1-phenylpropyl-1-(4-hydroxymethyl)phenyl ester group as a possible  $\mathbb{R}^1$  identity.

Applicants submit that the within amendments obviate the §112, second paragraph, rejection. In particular, the last 4 compounds of claim 4 are presented as new independent claim 40. Thus, withdrawal of the rejection is requested.

The drawing was objected to for various informalities. Applicants will submit a replacement sheet for Figure 1 under separate cover, in order to correct those informalities.

# Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0269

015

C. Meese, et al. USSN 09/700,094 Page -10-

The specification was objected to for lacking a section entitled "Brief Description of the Drawings". Applicants have amended the specification to add that section which includes a description of Figure 1 of the application. Additionally, the specification was further amended to recite other section headers, where appropriate, to conform to U.S. patent practice.

In view thereof, withdrawal of the objection to the specification is requested.

It is believed that the application is in condition for immediate allowance, which action is earnestly solicited.

Respectfully submitted,

h

c C.n Christine C. O'Day (Reg. 38,256) John B. Alexander, Ph.D. (Reg. 48,399) EDWARDS & ANGELL, LLP P.O. Box 9169 Boston, MA 02209 (617) 439-4444

04/14/03 MON 16:59

[TX/RX NO 9123] 2015

# File History Content Report

The following content is missing from the original file history record obtained from the United States Patent and Trademark Office. No additional information is available.

Document Title: An Document Date: 200 Page(s): 11

Amendment/Req. Reconsideration After Non-Final Rejection 2003-04-14

C. Meese, et al. USSN 09/700,094 Page -12-

R

a) hydrogen[,  $C_1$ - $C_6$  alky],  $C_3$ - $C_{10}$  cycloalky], substituted or unsubstituted benzy], allyl or carbohydrate]; <u>or</u>

b) formyl,  $C_1$ - $C_6$  alkylcarbonyl, cycloalkylcarbonyl, substituted or unsubstituted arylcarbonyl;

[c)  $C_1$ - $C_6$  alkoxycarbonyl, substituted or unsubstituted aryloxycarbonyl, benzoylacyl, benzoylglycyl, a substituted or unsubstituted amino acid residue; or

d)  $R^5$  wherein  $R^4$  and  $R^5$  independently represent hydrogen,  $C_1$ - $C_6$ alkyl, substituted or unsubstituted aryl, benzyl or phenoxyalkyl wherein the alkyl residue has 1 to 4 carbon atoms or  $R^4$  and  $R^5$  form a ring together with the amine nitrogen; or

e)  $R^7$  wherein  $R^6$  and  $R^7$  independently represent  $C_1$ - $C_6$  alkyl, substituted or unsubstituted aryl, benzyl or phenoxyalkyl wherein the alkyl residue has 1 to 6 carbon atoms; or

f) an ester moiety of inorganic acids,

-00-

g)  $-SiR_{a}R_{b}R_{c}$ , wherein  $R_{a}$ ,  $R_{b}$ ,  $R_{c}$  are independently  $C_{1}$ - $C_{4}$  alkyl or aryl,]

with the provise that R' is not hydrogen, methyl or benzyl when R is hydrogen, and R is not ethyl when R' is hydrogen,

X represents a tortiary amino group of formula Ia

C. Meese, et al. USSN 09/700,094 Page -13-

Formula ja

wherein  $\mathbb{R}^8$  and  $\mathbb{R}^9$  represent C<sub>1</sub>.C<sub>6</sub> alkyl groups, which may be the same or different and which together contain at least three carbon atoms, or  $\mathbb{R}^8$  and  $\mathbb{R}^9$  may form a ring together with the amine nitrogen,

A represents hydrogen (<sup>1</sup>H) or deuterium (<sup>2</sup>H),

and

their salts with physiologically acceptable acids, their free bases and, when the compounds are in the form of optical isomers, the racemic mixture and the individual enantiomers.

4. The 3,3-Diphenylpropylamine as claimed in claim 2 selected from:
(±)-formic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
(±)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
(±)-propionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
(±)-n-butyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
(±)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
(±)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,
(±)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-2,2-dimethylpropionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester,

[(±)-2-acetamidoacetic acid 2-(3-diisopropylamino-l-phenylpropyl)-4hydroxymethylphenyl ester,]

đ

÷

C. Mccsc, ct al. USSN 09/700.094 Page -14-(±)-cyclopentanecarboxylic acid 2-(3-diisopropylamino-l-phenylpropyl)-4hydroxymethylphenyl ester, (±)-cyclohexanecarboxylic acid 2-(3-diisopropylamino-l-phenylpropyl)-4hydroxymethylphenyl ester, (±)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, R-(+)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-4-methylbenzoic acid 2-(3-diisopropylamino-l-phenylpropyl)-4hydroxymethylphenyl ester,

(±)-2-methylbenzoic acid 2-(3-diisopropylamino-l-phenylpropyl)-4-

hydroxymethylphenyl ester,

(±)-2-acetoxybenzoic acid 2-(3-diisopropylamino-l-phenylpropyl)-4-

hydroxymethylphenyl ester,

(±)-1-naphthoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester,

(±)-2-naphthoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester. 4

(±)-4-chlorobenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-

hydroxymethylphenyl ester,

(±)-4-methoxybenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-

hydroxymethylphenyl ester,

(±)-2-methoxybenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-

hydroxymethylphenyl ester,

(±)-4-nitrobenzoic acid 2-(3-diisopropylamino-l-phenylpropyl)-4-hydroxymethylphenyl ester, and

(±)-2-nitrobenzoic acid 2-(3-diisopropylamino-l-phenylpropyl)-4-hydroxymethylphenyl ester[,

(±)-malonic acid bis-[2-(3-diisopropylamino-l-phenylpropyl)-4-hydroxymethylphenyl] ester, 1 5 

(±)-succinic acid bis-[2-(3-diisopropylamino-l-phonylpropyl)-4-hydroxymethyl-phonyl] ester,

> MON 16:59 04/14/03 [TX/RX NO 9123] 2019

C. Meese, et al. USSN 09/700,094 Page -15-

6.

(±)-pentanedioic acid bis-[2-(3-diisopropylamino-l-phenylpropyl)-4-hydroxymethylphenyl] ester,

(±)-hexanedioic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl] ester].

The 3,3-Diphenylpropylamine as claimed in claim 5 selected from:

(±)-formic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-formyloxymethylphenyl ester,
 (±)-acetic acid 4-acetoxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester,

(±)-propionic acid 2-(3-diisopropylamino-l-phenylpropyl)-4-propionyloxymethylphenyl ester,

(±)-n-butyric acid 4-n-butyryloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester,

(±)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-isobutyryloxymethylphenyl ester,

(±)-2,2-dimethylpropionic acid 3-(3-diisopropylamino-l-phenylpropyl)-4-(2,2-dimethylpropionyloxy)-benzyl ester,

(±)-benzoic acid 4-benzoyloxymethyl-2-(3-diisopropylamino-l-phenylpropyl)-phenyl ester,

R-(+)-benzoic acid 4-benzoyloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester,

(±)-pent-4-enoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-(pent-4enoyloxymethyl)-phenyl ester,

cyclic oct-4-one-l,8-dioate of Intermediate B,

cyclic octanc-1,8-dioate of Intermediate B, and

poly-co-DL-lactides of Intermediate B, said Intermediate B having the formula

#### 04/14/03 MON 16:59 [TX/RX NO 9123] 2020

## Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0275

C. Meese, et al. USSN 09/700,094 Page -16-



[wherein A is hydrogen (<sup>1</sup>H) or deuterium (<sup>2</sup>H)].

15. The 3,3-Diphenylpropylamine selected from;(i) compounds of the formulae IX and IX'



Formula IX

Formula DC<sup>4</sup>

wherein o and p are the same or different and range from 0 to 6,

(ii) [(±)-Benzoic acid 2-(3-diisopropylamino-l-phenylpropyl)-4-sulphooxymethylphenyl ester

(iii)] Poly-co-DL-lactides of 2-(3-diisopropylamino-phenylpropyl)-4-hydroxymethylphenol

7

C. Meese, et al. USSN 09/700,094 Page -17-

 $|(iv) (\pm) -2- (3-Diisopropylamino-1-phenylpropyl) -4- (1\beta-D-glucuronosyloxymethyl)-phenol having the formula$ 



and

their salts with physiologically acceptable acids, their free bases and, when the compounds are in the form of optical isomers, the racemic mixture and the individual cnantiomers.

04/14/03

MON 16:59

28. A 3,3-Diphenylpropylamine of the general formula VII:

[TX/RX NO 9123] 2022

EUTARUS ANGELL

C. Meese, et al. USSN 09/700,094 Page -18-



# wherein R is

a) hydrogen (,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl, substituted or unsubstituted benzyl, allyl or carbohydrate]; or

b) formyl,  $C_1$ - $C_6$  alkylcarbonyl, cycloalkylcarbonyl, substituted or unsubstituted arylcarbonyl; [or

c)  $C_1$ - $C_6$  alkoxycarbonyl, substituted or unsubstituted aryloxycarbonyl, benzoylacyl, benzoylglycyl, a substituted or unsubstituted amino acid residue; or

## 04/14/03 MON 16:59 [TX/RX NO 9123] 2023



12023

EUNARUS ANGEL

C. Meese, et al. USSN 09/700,094 Page -19-

d) R<sup>4</sup> N-CO-

## wherein $\mathbb{R}^4$ and $\mathbb{R}^5$ independently

represent hydrogen, C,-C<sub>6</sub> alkyl, substituted or unsubstituted aryl, benzyl or phenoxyalkyl wherein the alkyl residue has 1 to 4 carbon atoms and wherein  $R^4$ and  $R^5$  may form a ring together with the amine nitrogen; or

e) R<sup>6</sup>

wherein  $\mathbb{R}^{4}$  and  $\mathbb{R}^{7}$  independently

represent  $C_1$ - $C_6$  alkyl, substituted or unsubstituted aryl, benzyl or phenoxyalkyl wherein the alkyl residue has 1 to 6 carbon atoms; or

f) an ester moiety of inorganic acids,

g)  $-SiR_{a}R_{b}R_{C}$ , wherein  $R_{a}$ ,  $R_{b}$ ,  $R_{c}$ , are independently selected from  $C_{1}-C_{4}$  alkyl or aryl,

with the proviso that R' is not hydrogen, methyl or benzyl if R is hydrogen, R is not ethyl if R' is hydrogen,]

X represents a tertiary amino group of formula la

## R' Formula Is

wherein R<sup>8</sup> and R<sup>9</sup> represent non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and wherein R<sup>8</sup> and R<sup>9</sup> may form a ring together with the amine nitrogen,

## 04/14/03 MON 16:59 [TX/RX NO 9123] 20024

024

Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0279

C. Meese, et al. USSN 09/700,094 Page -20-

Y and Z independently represent a single bond between the  $(CH_2)_n$  group and the carbonyl group, O, S or NH,

A represents hydrogen (<sup>1</sup>H) or deuterium (<sup>2</sup>H),

n is 0 to 12, and

their salts with physiologically acceptable acids, their free bases and, when the compounds are in the form of optical isomers, the racemic mixture and the individual enantiomers.

34. A pharmaceutical composition comprising a 3,3-diphonylpropylamine according to any one of claims 1-<u>10</u>, 15 and 28-<u>30</u> [31] and a pharmaceutically acceptable carrier.

35. A method of antagonizing a muscarinic receptor, the method comprising contacting the receptor with a compound according to any one of claims 1-<u>10.</u> 15 and 28-<u>30</u> [31].

39. A pharmaceutical composition of claim [26] <u>34</u> wherein the composition is a patch formulation.

The following new claims were added:

40. (new) A 3,3-Diphenylpropylamine selected from: (±)-malonic acid bis-[2-(3-diisopropylamino-l-phenylpropyl)<sup>4</sup>-hydroxymethylphenyl] ester,

(±)-succinic acid bis-[2-(3-diisopropylamino-l-phenylpropyl)-4-hydroxymethyl-phenyl] ester,

(±)-pentanedioic acid bis-[2-(3-diisopropylamino-l-phenylpropyl)-4-hydroxymethylphenyl] ester, and

(±)-hexanedioic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl] ester.

C. Meesc, ct al. USSN 09/700,094 Page -21-

-----

41. (new) The 3,3-Diphenylpropylamine of claim 2, wherein the 3,3-Diphenylpropylamine is R-(+)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4hydroxymethylphenyl ester or a pharmaceutically acceptable salt thereof.

ł.





# Docket No. 5564MAR75101) 2003 TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	C. Meese, et al.	<u>,</u> ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
SERIAL NO.:	09/700,094	GROUP: 1624
FILED:	January 2, 2001	EXAMINER: Z. Tucker
FOR:	NOVEL DERIVATIVES OF	3,3-DIPHENYLPROPYLAMINES

THE HONORABLE COMMISSIONER OF PATENTS AND TRADEMARKS WASHINGTON, DC 20231

Sir:

## SUPPLEMENTAL AMENDMENT

Applicants are in receipt of the Office Action dated February 6, 2003. Kindly amend the above-identified application as follows.

# IN THE DRAWINGS:



Kindly enter the enclosed replacement drawing sheet for Figure 1 (sheet 1/1).

## REMARKS

The within Supplemental Amendment is submitted merely to provide a suitable formal drawing for the application. No new matter is presented by virtue of the within amendment.

By way of history, the Office Action mailed on February 6, 2003, indicated that the drawing (Figure 1) was objected to with reference to the PTO-948 form. Applicants filed a timely response to that Office Action on April 14, 2003, and addressed each of the rejections and objections of record. In Applicants' response, it was indicated that a suitable formal drawing would be provided under separate cover. Accordingly, Applicants herewith provide such drawing, thus obviating the objection. C. Meese, et al. USSN 09/700,094 Page -2-

It is believed the application is in condition for immediate allowance, which action is earnestly solicited.

Respectfully submitted,

Chi r.C.n

Christine C. O'Day (Reg. 38,256) EDWARDS & ANGELL, LLP P.O. Box 9169 Boston, MA 02209 Tel. (617) 439-4444 C. Meese, et al. USSN 09/700,094 Page -3-

# VERSION WITH MARKINGS TO SHOW CHANGES

÷

# **IN THE DRAWINGS:**

A replacement drawing sheet for Figure 1 (sheet 1/1) was submitted to replace the earlier filed drawing.



Transaction History Date 2003 - 05 - 16 Date information retrieved from USPTO Patent

Application Information Retrieval (PAIR) system records at www.uspto.gov

	Applicat	tion No.	Applicant(s	)
Notice of Allowshills	09/700,0	94 - ta and ta an	MEESE ET	AL.
Notice of Anowability	Examine	ər	Art Unit	
	Zachary	C. Tucker	1624	
<ul> <li>All claims being allowable, PROSECUTION ON THE MERIT herewith (or previously mailed), a Notice of Allowance (PTO) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATER of the Office or upon petition by the applicant. See 37 CFR</li> <li>1. X This communication is responsive to <u>14 April 2003</u>.</li> <li>2. X The allowed claim(s) is/are <u>1-10,15,16,18-20,28-30,3</u></li> <li>3. X The drawings filed on <u>28 April 2003</u> are accepted by 1.</li> <li>4. X Acknowledgment is made of a claim for foreign priorit a) X All b) □ Some* c) □ None of the:</li> </ul>	IS IS (OR REM L-85) or other a <b>NT RIGHTS</b> . TI 1.313 and MPE <u>2.34-38,40 and</u> the Examiner. Iy under 35 U.S	AINS) CLOSED in th ppropriate communi- his application is sub P 1308. <u>41</u> . .C. § 119(a)-(d) or (f	is application. If no cation will be mailed ject to withdrawal fi	t included f in due course. THIS om issue at the initiative
<ul> <li>2 Certified copies of the priority documents</li> <li>3. O Copies of the certified copies of the priori</li> </ul>	have been rec ity documents h	eived in Application I ave been received in	No n this national stage	application from the
International Bureau (PCT Rule 17.2(a * Certified conjes not received:	a)).	•		
5. Acknowledgment is made of a claim for domestic prio	rity under 35 U.	.S.C. § 119(e) (to a p	rovisional application	
(a) The translation of the foreign language provision 6. Acknowledgment is made of a claim for domestic pro-	onal application	has been received.	121	
Applicant has THREE MONTHS FROM THE "MAILING DAT below. Failure to timely comply will result in ABANDONNES	FE" of this com	nunication to file a re	ply complying with	the requirements noted
7. A SUBSTITUTE OATH OR DECLARATION must be INFORMAL PATENT APPLICATION (PTO-152) which gives	submitted. Notes	ation. This This The ettached EXAM	INER'S AMENDM	ENT or NOTICE OF
<ol> <li>hereto or 2) to Paper No</li> <li>(b) [] including changes required by the proposed draw (c) [] including changes required by the attached Examinentifying indicia such as the application number (see 37 Cleach sheet.</li> <li>9. [] DEPOSIT OF and/or INFORMATION about the clattached Examiner's comment regarding REQUIREMENT For attached Examiner's comment regarding REQUIREMENT For a stached Examiner's stached Examiner'</li></ol>	wing correction miner's Amendr CFR 1.84(c)) sho CFR 1.84(c)) sho OR THE DEPO	filled, which i nent / Comment or in uld be written on the LOGICAL MATER SIT OF BIOLOGICA	has been approved the Office action o drawings in the from IAL must be subn L MATERIAL.	by the Examiner. f Paper No (not the back) of nitted. Note the
Attachment(s)				
1⊠ Notice of References Cited (PTO-892) 3□ Notice of Draftperson's Patent Drawing Review (PTC-94 5□ Information Disclosure Statements (PTO-1449), Paper M	48) No	2 Notice of Ir 4 Interview S 6 Examiner's	nformal Patent Appl Summary (PTO-413) Amendment/Comm	cation (PTO-152) ), Paper No nent
of Biological Material	sit	8X Examiner's 91 Other	Statement of Reas	ons for Allowance
				m
U.S. Patent and Tilldamark Office PTO-37 (Rev. 04-03)	Notice of Alic	wability		Part of Paper No. 10
	:		•.	
· ·		· .		. ·
	t s.		·	• • •
				<i>.</i> .
	ŗ	· · ·		
		•	1970 - A.	
			:	

*!* ,

## **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Christine C. O'Day on 28 April 2003. E \$1:103

D

IN THE CLAIMS -

Claim 39 has been cancelled.

## Page 3

## Response to Amendment

The amendments to the specification have been entered. The amendments to claims 1,4, 6, 15, 28, 34 and 35 have been entered. Claims 40 and 41 have been added. Claims 11-14, 21-24, 31 and 33, directed to non-elected subject matter, have been cancelled. Claim 39 has been cancelled by Examiner's Amendment, authorized by applicant.

## Allowable Subject Matter

Claims 1-10,15,16,18-20,28-30, 32, 34-38, 40 and 41 are allowed.

The following is an examiner's statement of reasons for allowance:

Applicant has cancelled all non-elected subject matter.

The compounds of claims 1-10, 15, 28-30, 40 and 41 are not disclosed in the prior art, nor is there any express suggestion in the prior art that would render said compounds obvious to make. Therefore, a process for preparing compounds of the invention, compositions comprising said compounds, a method of antagonizing a muscarinic receptor with, and a method of treating a muscarinic receptor mediated condition with these compounds are novel and unobvious.

The compounds of the invention are novel derivatives of tolterodine, a known compound. The state of the art as it pertains to tolterodine derivatives is exemplified by the following four references:

Nilvebrant et al, "Antimuscarinic Potency and Bladder Selectivity of PNU-200577, a Major Metabolite of Tolterodine" Pharmacology and Toxicology, vol. 81, pages 169-172 (1997).

Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0288
# Application/Control Number: 09/700,094

Nilvebrant et al, "Tolterodine - A New Bladder Selective Muscarinic Receptor Antagonist: Preclinical Pharmacological and Clinical Data" Life Sciences, vol. 60(13/14), pages 1129-1136 (1997).

Postlind et al, "Tolterodine, A New Muscarinic Receptor Antagonist, is Metabolized by Cytochromes P450 and 3A in Human Liver Microsomes" Drug Metabolism and Disposition, vol. 26(4), pages 289-293 (1998).

Andersson et al, "Biotransformation of Tolterodine, A New Muscarinic Receptor Antagonist, in Mice, Rats, and Dogs" Drug Metabolism and Disposition, vol. 26(6), pages 528-535 (1998).

The two Nilvebrant et al references disclose that the 5-hydroxymethyl metabolite of tolterodine contributes significantly to the therapeutic efficacy of tolterodine.

The Postlind et al reference explores the effects of concomitantly administered drugs on the metabolism of tolterodine in human liver microsomes.

The Andersson et al reference describes several distinct tolterodine derivatives formed in the metabolism of that compound by mice, rats and dogs.

None of the aformentioned references disclose an ester derivative of tolterodine, or that an ester derivative of tolterodine would be an effective therapeutic agent.

With regard to the method of claim 36, the instant specification, on page 36, states that diseases amenable to treatment by antagonizing muscarinic receptors in a mammal refers to spasmogenic conditions that are caused by muscarinic mechanisms.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance." Application/Control Number: 09/700,094 Art Unit: 1624

#### Conclusion

All Post-Allowance Correspondence concerning this application must be mailed

#### to:

BOX ISSUE FEE COMMISSIONER FOR PATENTS 2 WASHINGTON, DC 20231

Or you can fax them to the Office of Patent Publications at 703-308-5083, in order to expedite the handling of such correspondence as amendments under 37 CFR 1.312; information disclosure statements, and formal drawings. Sending Post-Allowance papers to Technology Center 1600 will only cause delays in matching papers with the case.

For information concerning status of correspondence sent after receipt of the Notice of Allowance, please contact the Correspondence Branch at (703) 305-8027. The Notice of Allowance also has an insert containing contact information on other items, including Issue Fees, receipt of formal drawings and the status of the application.

Murkend J. Shil

Mukund Shah Supervisory Patent Examiner Art Unit 1624

	Notice of Reference	Application/Co 09/700,094	ntrol No.	Applicant(s)/Pa Reexamination MEESE ET AL	alent Under 1				
			Examiner	X 2 2	Art Unit				
		·····	Zachary C. Tuo	cker	1624	Page 1 of 1			
·r	Dogument Number		U.S. PATENT DOCUMEN	ITS					
1	Country Code-Number-Kind Code	MM-YYYY		Name		Classification			
A.	US-		E A V						
8	US-								
c	US-			• •					
D	US-			¢					
E.	US-		· · · · · · · · · · · · · · · · · · ·			· ·			
F	US-			· · · · · · · · · · · · · · · · · · ·					
0	US-								
н	US-		·····						
1	US-					······································			
	US-	<b> </b>							
ĸ	US-			\$					
ι	US-	1	· · · · · · · · · · · · · · · · · · ·	· · ·					
м	US-	<u> </u> +							
		FC	REIGN PATENT DOCUM	AENTS	i				
	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	3	Classification			
N									
0		-							
P		┟────┤							
Q				• .					
R				·					
S			r						
т									
			NON-PATENT DOCUME	NTS					
<u> </u>	Indu	de as applicable /	Author, Title Date, Publish	er, Edition or Volume	e, Pertinent Pages)	·			
U	Nilvebrant et al, "Antimuscari Pharmacology and Toxicolog	nic Potency and y, vol. 81, pages	Bladder Selectivity of P 3 169-172 (1997).	NU-200577, a Ma	jor Metabolite of T	"olterodine"			
	Nilvebrant et al, "Tolterodine Clinical Data" Life Sciences,	- A New Bladder vol. 60(13/14), p	r Selective Muscarinic R ages 1129-1136 (1997)	Receptor Antagonia	st: Preclinical Pha	rmacological and			
\	Postilind et al, "Tolterodine, A New Muscarinic Receptor Antagonist, is Metabolized by Cytochromes P450 and 3A in Human Liver Microsomes" Drug Metabolism and Disposition, vol. 26(4), pages 289-293 (1998).								
- v	, Postlind et al. "Tolterodine, A Liver Microsomes" Drug Meta	New Muscarinic ibolism and Disp	position, vol. 26(4), page	85 208-285 (1880)	Andersson et al, "Biotransformation of Tollerodine, A New Muscarinic Receptor Antagonist, in Mice, Rats, and Dogs" Drug				
v w	, Postlind et al, "Tolterodine, A Liver Microsomes" Drug Meta Andersson et al, "Biotransford Metabolism and Disposition,	New Muscarinic abolism and Disp mation of Tollerc vol. 26(6), pages	oosition, vol. 26(4), page odine, A New Muscarink s 528-535 (1998).	c Receptor Antago	pnist, in Mice, Rats	s, and Dogs" Drug			
W X x x x x x x x x x x x x x x x x x x	Postlind et al, "Tolterodine, A Liver Microsomes" Drug Meta Andersson et al, "Biotransform Metabolism and Disposition, this reference is not being furnished with M-Y'YY formal are publication dates. Cit	New Muscarinic abolism and Disp mation of Tollero vol. 28(6), pages his Office action (Se issefications may be l	bosition, vol. 28(4), page bdine, A New Muscarink a 528-535 (1998). se MPEP § 707.05(a).) US or foreign	c Receptor Antago	onist, in Mice, Rats	s, and Dogs" Drug			

,				
	ŕ		·	
	· · · ·	i Line in design	<b>ه</b> المحافظ المحافظ المحافظ	
				4
	× 1	Ϋ́,	5	·
			· ·	
	•		2017 - N. 19	
		- * · · ·		•
	••			
		• •		
	-14 -	T. W. L. W.		
		·		
			. `	
(CONTED STATES PATENT	AND TRADEMARK O	FPICE	ED STATES DEPARTMENT OF CO	MMERCE
		Unite	d States Patent and Trademark C COMMISSIONER OF PATENTS AND TR	Mine Ademarks
			Alexandria, Vincase 22313-1450 www.uspto.gov	
		4 M		
NOT	FICE OF ALLOWA	NCE AND FEE	C(S) DUE	
218''4 7590 05/16/2003				
EDWARDS & ANGELL, LLP			EXAMI	NER
P.O. BOX 9169 BOSTON, MA 02209	!	· ·	TUCKER, 2/	CHARY C
		•	ART UNIT	CLASS-SUBCLASS
			1624	514-175000
			DATE MAILED: 05/16/2003	
APPLICATION NO. FILING DATE	FIRST NAME	DINVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO
09/700,094 01/02/2001	Claus	Meese	MBHB00-1121	1408
TITLE OF INVENTION NOVEL DERIVATIVES OF :	3,3-DIPHEN YLPROPYLAMII	NES		ч. Т
APPLN, TYPE SMALL ENTITY	185UE FEE	PUBLICATION FEE	TOTAL FEE(\$) DUE	DATE DUE
APPLN. TYPE     SMALL ENTITY       nonprovisional     NO       THE APPLICATION IDENTIFIED ABOVE	3,3-DIPHENYLPROPYLAMII 19SUE FEE \$1300 VE HAS BEEN FYAMI	PUBLICATION FEE \$0	TOTAL FEE(\$) DUE \$1300	DATE DUE ' 08/18/2003
APPLN. TYPE SMALL ENTITY nonprovisional NO THE APPLICATION IDENTIFIED ABOY PROSECUTION ON THE MERITS IS CI THIS APPLICATION IS SUBJECT TO W PETITION BY THE APPLICANT. SEE 3	193.3-DIPHENYLPROPYLAMII 19SUE FEE \$1300 VE HAS BEEN EXAMI <u>OSED.</u> THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE	PUBLICATION FEE \$0 NED AND IS ALL OF ALLOWANC ISSUE AT THE IJ P 1308.	TOTAL FEE(5) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON
APPL.N. TYPE       SMALL ENTITY         nonprovisional       NO         THE APPLICATION IDENTIFIED ABOY         PROSEC: UTION ON THE MERITS IS CI         THIS APPLICATION IS SUBJECT TO W         PETITION BY THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION F	ISSUE FEE ISSUE FEE \$1300 VE HAS BEEN EXAMI <u>OSED.</u> THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M	PUBLICATION FEE 50 NED AND IS ALL OF ALLOWANC ISSUE AT THE II P 1308. UST BE PAID WI	TOTAL FEE(S) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN THREE MONTHS	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE
APPLN. TYPE SMALL ENTITY nonprovisional NO THE APPLICATION IDENTIFIED ABOY PROSECUTION ON THE MERITS IS CI THIS APPLICATION IS SUBJECT TO W PETITION BY THE APPLICANT. SEE 3 THE ISSUE FEE AND PUBLICATION F MAILING DATE OF THIS NOTICE OR DEDUCT OF DUCTOR	1950E FEE 1950E FEE \$1300 VE HAS BEEN EXAMI <u>OSED.</u> THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION S	PUBLICATION FEE \$0 NED AND IS ALL OF ALLOWANC ISSUE AT THE IJ P 1308. UST BE PAID WIT SHALL BE REGA	TOTAL FEE(3) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN <u>THREE MONTHS</u> RDED AS ABANDONED	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY
TITLE OF INVENTION NOVEL DERIVATIVES OF :         APPL.N. TYPE         MALL ENTITY         nonprovisional         NO         THE APPLICATION IDENTIFIED ABOY         PROSEC: UTION ON THE MERITS IS CI         THE APPLICATION IS SUBJECT TO W         PETITION BY THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION F         MAILING DATE OF THIS NOTICE OR         PERIOD CANNOT BE EXTENDED. SEE         FOR AN Y PREVIOUSLY PAID ISSUE F	ISSUE FEE ISSUE FEE	PUBLICATION FEE SO INED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T	TOTAL FEE(S) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI HE PTOL-85B (OR AN	DATE DUE OB/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE A THIS STATUTORY JECTS A CREDIT EQUIVALENT)
APPL.N. TYPE       SMALL ENTITY         nonprovisional       NO         THE APPLICATION IDENTIFIED ABOY       PROSEC: UTION ON THE MERITS IS CI         THIS AP PLICATION IS SUBJECT TO W       PETITION BY THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION F       MAILING DATE OF THIS NOTICE OR         PERIOD CANNOT BE EXTENDED. SEE       FOR ANY PREVIOUSLY PAID ISSUE FI         MUST BE RETURNED WITHIN THIS PI	ISSUE FEE ISSUE FEE \$1300 VE HAS BEEN EXAMI <u>OSED</u> , THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION 35 U.S.C. 151. THE IS EE APPLIED IN THIS ERIOD EVEN IF NO F	PUBLICATION FEE \$0 NED AND IS ALL OF ALLOWANC ISSUE AT THE II P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH	TOTAL FEE(S) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF INTIATIVE OF THE OF FHIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI HE PTOL-85B (OR AN IE APPLICATION WILL	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY JECTS A CREDIT EQUIVALENT) BE REGARDED AS
APPLN. TYPE       SMALL ENTITY         nonprovisional       NO         THE APPLICATION IDENTIFIED ABOY       PROSEC. UTION ON THE MERITS IS CI         THIS APPLICATION IDENTIFIED ABOY       PROSEC. UTION ON THE MERITS IS CI         THIS APPLICATION IS SUBJECT TO W       PETITION BY THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION F       MAILING DATE OF THIS NOTICE OR OF         PERIOD CANNOT BE EXTENDED. SEE       FOR ANY PREVIOUSLY PAID ISSUE FI         MUST BE RETURNED WITHIN THIS PI         ABANDONED.         HOW TO BEPLY TO THIS NOTICE.	19SUE FEE \$1300 VE HAS BEEN EXAMI <u>OSED.</u> THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION S 35 U.S.C. 151. THE IS EE APPLIED IN THIS ERIOD EVEN IF NO F	PUBLICATION FEE SO INED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH	TOTAL FEE(S) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI HE PTOL-85B (OR AN IE APPLICATION WILL	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY JECTS A CREDIT EQUIVALENT) L BE REGARDED AS
APPLN. TYPE SMALL ENTITY nonprovisional NO THE APPLICATION IDENTIFIED ABOY PROSECUTION ON THE MERITS IS CI THIS APPLICATION IS SUBJECT TO W PETITION BY THE APPLICANT. SEE 3 THE ISSUE FEE AND PUBLICATION FI MAILING DATE OF THIS NOTICE OR PERIOD CANNOT BE EXTENDED. SEE FOR ANY PREVIOUSLY PAID ISSUE FI MUST BE RETURNED WITHIN THIS PI ABANDONED. HOW TO REPLY TO THIS NOTICE: I. Review the SMALL ENTITY status shown	ISSUE FEE ISSUE FEE \$1300 VE HAS BEEN EXAMI <u>OSED</u> , THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION S 35 U.S.C. 151. THE ISS EE APPLIED IN THIS ERIOD EVEN IF NO F 1 above.	PUBLICATION FEE 50 INED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH	TOTAL FEE(S) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF ITHIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI HE PTOL-85B (OR AN IE APPLICATION WILL	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY JECTS A CREDIT EQUIVALENT) J BE REGARDED AS
TITLE OF INVENTION NOVEL DERIVATIVES OF :         APPL.N. TYPE         MALL ENTITY         nonprovisional         NO         THE APPLICATION IDENTIFIED ABOY         PROSE(::UTION ON THE MERITS IS CI         THE APPLICATION IDENTIFIED ABOY         PROSE(::UTION ON THE MERITS IS CI         THE APPLICATION IS SUBJECT TO W         PETITION BY THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION F         MAILING DATE OF THIS NOTICE OR 'PERIOD CANNOT BE EXTENDED. SEE         FOR ANY PREVIOUSLY PAID ISSUE FI         MUST BE RETURNED WITHIN THIS PI         ABANDONED.         HOW TO REPLY TO THIS NOTICE:         I. REVIEW the SMALL ENTITY status shown         If the SMALL ENTITY is shown as YES, ve:	19SUE FEE 19SUE FEE \$1300 VE HAS BEEN EXAMI <u>OSED.</u> THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION S 35 U.S.C. 151. THE IS EE APPLIED IN THIS ERIOD EVEN IF NO F 1 above. rify your current	PUBLICATION FEE \$0 INED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH I fine SMALL E	TOTAL FEE(S) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI HE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO:	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY JECTS A CREDIT EQUIVALENT) L BE REGARDED AS
APPL.N. TYPE       SMALL ENTITY         nonprovisional       NO         THE APPLICATION IDENTIFIED ABOY       PROSECUTION ON THE MERITS IS CI         THIS APPLICATION IDENTIFIED ABOY       PROSECUTION ON THE MERITS IS CI         THIS APPLICATION IS SUBJECT TO W       PETITION BY THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION F       MAILING DATE OF THIS NOTICE OR         PERIOD CANNOT BE EXTENDED. SEE       FOR ANY PREVIOUSLY PAID ISSUE F         MUST BE RETURNED WITHIN THIS P         ABANDONED.         HOW TO REPLY TO THIS NOTICE:         I. Review the SMALL ENTITY is shown as YES, ver         SMALL ENTITY status:         A If the ubtus is the same may the TOTAL E	ISSUE FEE SI 300 VE HAS BEEN EXAMI OSED. THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION S EE APPLIED IN THIS ERIOD EVEN IF NO F above. rify your current SEE(S) DI IE shown	PUBLICATION FEE 50 INED AND IS ALL OF ALLOWANC ISSUE AT THE IJ P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH If the SMALL EI A Pay TOTAL I	TOTAL FEE(S) DUE S1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI THE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: (CEF(S) DUE shown as NO:	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY JECTS A CREDIT EQUIVALENT) . BE REGARDED AS
APPLN. TYPE       SMALL ENTITY         nonprovisional       NO         THE APPLICATION IDENTIFIED ABOY       PROSEC: UTION ON THE MERITS IS CI         THIS APPLICATION IDENTIFIED ABOY       PROSEC: UTION ON THE MERITS IS CI         THIS APPLICATION IS SUBJECT TO W       PETITION BY THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION F       MAILING DATE OF THIS NOTICE OR OF         PERIOD CANNOT BE EXTENDED. SEE       FOR ANY PREVIOUSLY PAID ISSUE FI         MUST BE RETURNED WITHIN THIS PAANDONED.       HOW TO REPLY TO THIS NOTICE:         I. Review the SMALL ENTITY is shown as YES, versional SMALL ENTITY status:       A. If the status is the same, pay the TOTAL Fabove.	19SUE FEE \$1300 VE HAS BEEN EXAMI <u>JOSED.</u> THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION S 35 U.S.C. 151. THE IS EE APPLIED IN THIS ERIOD EVEN IF NO F above. rify your current FEE(S) DUE shown	PUBLICATION FEE \$0 INED AND IS ALL OF ALLOWANC ISSUE AT THE II P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH If the SMALL EI A. Pay TOTAL I	TOTAL FEE(S) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI HE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: TEE(S) DUE shown above,	DATE DUE OB/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY JECTS A CREDIT EQUIVALENT) L BE REGARDED AS
APPLN. TYPE       SMALL ENTITY         nonprovisional       NO         THE APPLICATION IDENTIFIED ABOY       PROSECUTION ON THE MERITS IS CI         THIS APPLICATION IDENTIFIED ABOY       PROSECUTION ON THE MERITS IS CI         THIS APPLICATION IS SUBJECT TO W       PETITION BY THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION F       MAILING DATE OF THIS NOTICE OR         PERIOD CANNOT BE EXTENDED. SEE       FOR ANY PREVIOUSLY PAID ISSUE FI         MUST BE RETURNED WITHIN THIS PI         ABANDONED.         HOW TO REPLY TO THIS NOTICE:         I. Review the SMALL ENTITY status shown         If the SMALL ENTITY is shown as YES, ver         SMALL ENTITY status:         A. If the status is the same, pay the TOTAL F         above.         B. If the status is changed, pay the PUBLICA	ISSUE FEE \$1300 VE HAS BEEN EXAMI OSED. THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION S EE APPLIED IN THIS EE APPLIED IN THIS ERIOD EVEN IF NO F above. rify your current FEE(S) DUE shown TION FEE (if required) un above and notify the	PUBLICATION FEE 50 INED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH If the SMALL ED A. Pay TOTAL I B. If applicant cl chiming SMALL	TOTAL FEE(S) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI THE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: TEE(S) DUE shown above, aimed SMALL ENTITY st EDITITY when shows the	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY JECTS A CREDIT EQUIVALENT) . BE REGARDED AS OF atus before, or is now
TITLE OF INVENTION NOVEL DERIVATIVES OF :         APPLIN, TYPE         MALL ENTITY         nonprovisional         NO         THE APPLICATION IDENTIFIED ABOY         PROSEC: UTION ON THE MERITS IS CI         THE APPLICATION IDENTIFIED ABOY         PROSEC: UTION ON THE MERITS IS CI         THE APPLICATION IS SUBJECT TO W         PETITION BY THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION FI         MAILING DATE OF THIS NOTICE OR         PERIOD CANNOT BE EXTENDED. SEE         FOR ANY PREVIOUSLY PAID ISSUE FI         MUST BE RETURNED WITHIN THIS PLABANDONED.         HOW TO REPLY TO THIS NOTICE:         I. Review the SMALL ENTITY is shown as YES, ver         SMALL ENTITY is shown as YES, ver         SMALL ENTITY status:         A. If the status is the same, pay the TOTAL F         above.         B. If the status is changed, pay the PUBLICA         and twice the amount of the ISSUE FEE show         United States Patent and Trademark Office of	ISSUE FEE ISSUE FEE \$1300 VE HAS BEEN EXAMI OSED, THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION S 35 U.S.C. 151. THE IS EE APPLIED IN THIS ERIOD EVEN IF NO F above. rify your current FEE(S) DUE shown ATION FEE (if required) wn above and notify the f the change in status, or	PUBLICATION FEE \$0 INED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH If the SMALL ED A. Pay TOTAL H B. If applicant cl claiming SMALI the PUBLICATION	TOTAL FEE(S) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF ITHIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI HE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: YEE(S) DUE shown above, aimed SMALL ENTITY status, check the ON FEE and 1/2 the ISSUE	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY ECTS A CREDIT EQUIVALENT) L BE REGARDED AS or atus before, or is now box below and enclose 2 FEE shown above.
TITLE OF INVENTION NOVEL DERIVATIVES OF INTERIOR OF INVENTION NOVEL DERIVATIVES OF INTERIOR OF THE APPLICATION IDENTIFIED ABOY         APPLICATION IDENTIFIED ABOY         THE APPLICATION IDENTIFIED ABOY         PROSECUTION ON THE MERITS IS CL         THE APPLICATION IDENTIFIED ABOY         PROSECUTION ON THE MERITS IS CL         THE APPLICATION IS SUBJECT TO W         PERION ON THE MERITS IS CL         THE ISSUE FEE AND PUBLICATION F         MAILING DATE OF THIS NOTICE OR         PERIOD CANNOT BE EXTENDED. SEE         FOR ANY PREVIOUSLY PAID ISSUE FI         MUST BE RETURNED WITHIN THIS PLABANDONED.         HOW TO REPLY TO THIS NOTICE:         I. REVIEW the SMALL ENTITY status shown         If the Status is the same, pay the TOTAL F         above.         B. If the status is changed, pay the PUBLICA         and twice the amount of the ISSUE FEE show         UNITEd States Patent and Trademark Office of	ISSUE FEE \$1300 VE HAS BEEN EXAMI OSED. THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION S EE APPLIED IN THIS EE APPLIED IN THIS ERIOD EVEN IF NO F 1 above. rify your current FEE(S) DUE shown ATION FEE (if required) wn above and notify the f the change in status, or	PUBLICATION FEE 50 NED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH B. If applicant cl. claiming SMALI the PUBLICATION Claiming CALL	TOTAL FEE(S) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI HE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: YEE(S) DUE shown above, aimed SMALL ENTITY status, check the ON FEE and 1/2 the ISSUE aims SMALL ENTITY status	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY JECTS A CREDIT EQUIVALENT) BE REGARDED AS OF atus before, or is now box below and enclose 2 FEE shown above. tus.
TITLE OF INVENTION NOVEL DERIVATIVES OF :         APPL.N. TYPE         MALL ENTITY         nonprovisional         NO         THE APPLICATION IDENTIFIED ABOY         PROSECUTION ON THE MERITS IS CI         THE APPLICATION IS SUBJECT TO W         PROSECUTION ON THE MERITS IS CI         THE APPLICATION IS SUBJECT TO W         PROSECUTION ON THE MERITS IS CI         THIS APPLICATION IS SUBJECT TO W         PERITION BY THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICANT. SEE 3         THE ISSUE FEE AND PUBLICA ISSUE FE         MANUE PAREVIOUSLY PAID ISSUE FE         MUST BE RETURNED WITHIN THIS PI         ABANDONED.         HOW TO REPLY TO THIS NOTICE:         I. Review the SMALL ENTITY is shown as YES, ver         SMALL ENTITY is shown as YES, ver         SMALL ENTITY is shown as YES, ver	ISSUE FEE \$1300 VE HAS BEEN EXAMI <u>OSED.</u> THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION S 2 35 U.S.C. 151. THE ISS EE APPLIED IN THIS ERIOD EVEN IF NO F 1 above. rify your current FEE(S) DUE shown TTION FEE (if required) wn above and notify the f the change in status, or	PUBLICATION FEE 30 INED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH B. If applicant cl claiming SMALI the PUBLICATION I Applicant cl See 37 CFR	TOTAL FEE(S) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI THE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: YEE(S) DUE shown above, aimed SMALL ENTITY status, check the ON FEE and 1/2 the ISSUE aims SMALL ENTITY status, 1.27.	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY ECTS A CREDIT EQUIVALENT) L BE REGARDED AS OF atus before, or is now box below and enclose 2 FEE shown above. tus.
APPLN. TYPE       SMALL ENTITY         nonprovisional       NO         THE APPLICATION IDENTIFIED ABOY       PROSEC. UTION ON THE MERITS IS CI         THIS APPLICATION IDENTIFIED ABOY       PROSEC. UTION ON THE MERITS IS CI         THIS APPLICATION IN SUBJECT TO W       PETITION BY THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION F       MAILING DATE OF THIS NOTICE OR         PERIOD CANNOT BE EXTENDED. SEE       FOR ANY PREVIOUSLY PAID ISSUE FI         MUST BE RETURNED WITHIN THIS PI         ABANDONED.         HOW TO REPLY TO THIS NOTICE:         I. Review the SMALL ENTITY status shown         If the status is the same, pay the TOTAL F         above.         B. If the status is changed, pay the PUBLICA         and twice the amount of the ISSUE FEE show         United States Patent and Trademark Office of         II. PART B - FEE(S) TRANSMITTAL show	ISSUE FEE \$1300 VE HAS BEEN EXAMI OSED. THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION S 2 35 U.S.C. 151. THE IS EE APPLIED IN THIS ERIOD EVEN IF NO F above. rify your current FEE(S) DUE shown ATION FEE (if required) wn above and notify the f the change in status, or abd be completed and retuil	PUBLICATION FEE SO NED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH B. If applicant cl. claiming SMALI the PUBLICATION Claiming SMALI Claiming SMALI See 37 CFR med to the United S	TOTAL FEE(S) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI THE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: YEE(S) DUE shown above, aimed SMALL ENTITY sta _ ENTITY status, check the ON FEE and 1/2 the ISSUE aims SMALL ENTITY sta 1.27.	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY JECTS A CREDIT EQUIVALENT) BE REGARDED AS OF atus before, or is now box below and enclose 2 FEE shown above. tus. Office (USPTO) with
APPL.N. TYPE       SMALL ENTITY         nonprovisional       NO         THE APPLICATION IDENTIFIED ABOY       PROSECUTION ON THE MERITS IS CI         THIS APPLICATION IDENTIFIED ABOY       PROSECUTION ON THE MERITS IS CI         THIS APPLICATION IS SUBJECT TO W         PETITION BY THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION F         MAILING DATE OF THIS NOTICE OR         PERIOD CANNOT BE EXTENDED. SEE         FOR ANY PREVIOUSLY PAID ISSUE F         MUST BE RETURNED WITHIN THIS P         ABANDONED.         HOW TO REPLY TO THIS NOTICE:         I. Review the SMALL ENTITY is shown as YES, ver         MALL ENTITY is shown as YES, ver         SMALL ENTITY is shown as YES, ver         MALL ENTITY is Shown as YES, ver	ISSUE FEE \$1300 VE HAS BEEN EXAMI <u>OSED.</u> THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION S EE APPLIED IN THIS ERIOD EVEN IF NO F above. rify your current FEE(S) DUE shown TION FEE (if required) wn above and notify the f the change in status, or lid be completed and retur if required). Even if the f he fee(s) to your deposit	PUBLICATION FEE 30 NED AND IS ALL OF ALLOWANC ISSUE AT THE IJ P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH B. If applicant cl. claiming SMALI the PUBLICATION D. Applicant cl. See 37 CFR med to the United S ce(s) have already b account. section "44	TOTAL FEE(S) DUE S1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI THE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: TEE(S) DUE shown above, aimed SMALL ENTITY sta LENTITY status, check the ON FEE and 1/2 the ISSUE aims SMALL ENTITY sta 1.27. Inters Patent and Trademark een paid, Part B - Fee(s) Transm	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY ECTS A CREDIT EQUIVALENT) L BE REGARDED AS or atus before, or is now box below and enclose 2 FEE shown above. tus. Office (USPTO) with ransmittal should be pittal should be
TITLE OF INVENTION NOVEL DERIVATIVES OF :         APPLICATION NOVEL DERIVATIVES OF :         NO         THE APPLICATION IDENTIFIED ABOY         PROSEC: UTION ON THE MERITS IS CI         THE APPLICATION IDENTIFIED ABOY         PROSEC: UTION ON THE MERITS IS CI         THE APPLICATION IS SUBJECT TO W         PERION ON THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION F         MAILING DATE OF THIS NOTICE OR         PERIOD CANNOT BE EXTENDED. SEE         FOR ANY PREVIOUSLY PAID ISSUE FI         MUST BE RETURNED WITHIN THIS PI         ABANDONED.         HOW TO REPLY TO THIS NOTICE:         I. REVIEW the SMALL ENTITY status shown         If the Status is the same, pay the TOTAL F         above.         B. If the status is changed, pay the PUBLICA         II. PART B - FEE(S) TRANSMITTAL show         your ISSUE FEE and PUBLICATION FEE (         Completed and returned. If you are charging to completed and an extra copy of the form show	ISSUE FEE \$1300 VE HAS BEEN EXAMI <u>JOSED.</u> THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION 5 235 U.S.C. 151. THE IS EE APPLIED IN THIS ERIOD EVEN IF NO F above. rify your current FEE(S) DUE shown ATION FEE (if required) wn above and notify the f the change in status, or ald be completed and retuing if required). Even if the f he fee(s) to your deposition and be submitted.	PUBLICATION FEE \$0 NED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH B. If applicant cl claiming SMALI the PUBLICATION D. Applicant cl See 37 CFR med to the United S ee(s) have already b account, section "4b	TOTAL FEE(S) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI THE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: FEE(S) DUE shown above, aimed SMALL ENTITY sta . ENTITY status, check the ON FEE and 1/2 the ISSUE aims SMALL ENTITY sta 1.27. tates Patent and Trademark een paid, Part B - Fee(s) Transn	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY JECTS A CREDIT EQUIVALENT) L BE REGARDED AS OF atus before, or is now box below and enclose 2 FEE shown above. tus. Office (USPTO) with ransmittal should be
TITLE OF INVENTION NOVEL DERIVATIVES OF :         APPL.N. TYPE         MALL ENTITY         nonprovisional         NO         THE APPLICATION IDENTIFIED ABOY         PROSEC: UTION ON THE MERITS IS CL         THE APPLICATION IDENTIFIED ABOY         PROSEC: UTION ON THE MERITS IS CL         THE APPLICATION IS SUBJECT TO W         PETITION BY THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION F         MAILENTITY SUBJECT TO W         PETITION BY THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION F         MAILING DATE OF THIS NOTICE OR         PERIOD CANNOT BE EXTENDED. SEE         FOR ANY PREVIOUSLY PAID ISSUE FI         MUST BE RETURNED WITHIN THIS PL         ABANDONED.         HOW TO REPLY TO THIS NOTICE:         I. Review the SMALL ENTITY is shown as YES, ver         SMALL ENTITY status:         A. If the status is changed, pay the TOTAL F         above.         B. If the status is changed, pay the PUBLICA         II. PART B - FEE(S) TRANSMITTAL shou <td< th=""><th>ISSUE FEE \$1300 VE HAS BEEN EXAMI <u>OSED.</u> THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION S EE APPLIED IN THIS ERIOD EVEN IF NO F above. rify your current FEE(S) DUE shown TION FEE (if required) wn above and notify the f the change in status, or hd be completed and retur if required). Even if the f he fee(s) to your deposit ald be submitted. ation must give the application</th><th>PUBLICATION FEE 50 INED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH B. If applicant cl claiming SMALL He PUBLICATION D. Applicant cl claiming SMALI the PUBLICATION Complete the United S ce(s) have already b account, section "4b cation number. Please</th><th>TOTAL FEE(S) DUE S1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI THE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: TEE(S) DUE shown above, aimed SMALL ENTITY sta . ENTITY status, check the ON FEE and 1/2 the ISSUE aims SMALL ENTITY sta 1.27. tates Patent and Trademark een paid, Part B - Fee(S) Transn se direct all communication</th><th>DATE DUE O&amp;/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY JECTS A CREDIT EQUIVALENT) L BE REGARDED AS OF atus before, or is now to box below and enclose 2 FEE shown above. tus. Office (USPTO) with ransmittal should be itual should be s prior to issuance to</th></td<>	ISSUE FEE \$1300 VE HAS BEEN EXAMI <u>OSED.</u> THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION S EE APPLIED IN THIS ERIOD EVEN IF NO F above. rify your current FEE(S) DUE shown TION FEE (if required) wn above and notify the f the change in status, or hd be completed and retur if required). Even if the f he fee(s) to your deposit ald be submitted. ation must give the application	PUBLICATION FEE 50 INED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH B. If applicant cl claiming SMALL He PUBLICATION D. Applicant cl claiming SMALI the PUBLICATION Complete the United S ce(s) have already b account, section "4b cation number. Please	TOTAL FEE(S) DUE S1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI THE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: TEE(S) DUE shown above, aimed SMALL ENTITY sta . ENTITY status, check the ON FEE and 1/2 the ISSUE aims SMALL ENTITY sta 1.27. tates Patent and Trademark een paid, Part B - Fee(S) Transn se direct all communication	DATE DUE O&/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY JECTS A CREDIT EQUIVALENT) L BE REGARDED AS OF atus before, or is now to box below and enclose 2 FEE shown above. tus. Office (USPTO) with ransmittal should be itual should be s prior to issuance to
TITLE OF INVENTION NOVEL DERIVATIVES OF :         APPL.N. TYPE         SMALL ENTITY         nonprovisional         NO         THE APPLICATION IDENTIFIED ABOY         PROSECUTION ON THE MERITS IS CI         THE APPLICATION IS SUBJECT TO W         PROSECUTION ON THE MERITS IS CI         THE APPLICATION IS SUBJECT TO W         PERION BY THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION FI         MAILING DATE OF THIS NOTICE OR         PERIOD CANNOT BE EXTENDED. SEE         FOR ANY PREVIOUSLY PAID ISSUE FI         MUST BE RETURNED WITHIN THIS PLABANDONED.         HOW TO REPLY TO THIS NOTICE:         I. REVIEW the SMALL ENTITY is shown as YES, veries         SMALL ENTITY status:         A. If the status is changed, pay the TOTAL F         B. If the status is changed, pay the PUBLICA         MUST B - FEE(S) TRANSMITTAL show         VINTE FEE and PUBLICATION FEE (         Completed and returned. If you are charging to completed and an extra copy of the form show         III. PART B - FEE(S) TRANSMITTAL show         YOUNICATION FEE ( <th>ISSUE FEE \$1300 VE HAS BEEN EXAMI <u>OSED</u>, THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION 5 CARPLIED IN THIS ERIOD EVEN IF NO F 1 above. rify your current FEE(S) DUE shown ATION FEE (if required) wn above and notify the f the change in status, or If required). Even if the f he fee(s) to your deposit ald be submitted. ration must give the applia ry.</th> <th>PUBLICATION FEE SO INED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH B. If applicant cl claiming SMALI the PUBLICATION D. Applicant cl Claiming SMALI the PUBLICATION See 37 CFR med to the United S te(s) have already b account, section "4b cation number. Please</th> <th>TOTAL FEE(S) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF ITHIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI THE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: EE(S) DUE shown above, aimed SMALL ENTITY sta LENTITY status, check the ON FEE and 1/2 the ISSUE aims SMALL ENTITY sta 1.27. Tates Patent and Trademark ten paid, Part B - Fee(s) Transn are direct all communication</th> <th>DATE DUE OB/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY JECTS A CREDIT EQUIVALENT) L BE REGARDED AS OF atus before, or is now box below and enclose 2 FEE shown above. tus. Office (USPTO) with ransmittal should be hittal should be s prior to issuance to</th>	ISSUE FEE \$1300 VE HAS BEEN EXAMI <u>OSED</u> , THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION 5 CARPLIED IN THIS ERIOD EVEN IF NO F 1 above. rify your current FEE(S) DUE shown ATION FEE (if required) wn above and notify the f the change in status, or If required). Even if the f he fee(s) to your deposit ald be submitted. ration must give the applia ry.	PUBLICATION FEE SO INED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH B. If applicant cl claiming SMALI the PUBLICATION D. Applicant cl Claiming SMALI the PUBLICATION See 37 CFR med to the United S te(s) have already b account, section "4b cation number. Please	TOTAL FEE(S) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF ITHIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI THE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: EE(S) DUE shown above, aimed SMALL ENTITY sta LENTITY status, check the ON FEE and 1/2 the ISSUE aims SMALL ENTITY sta 1.27. Tates Patent and Trademark ten paid, Part B - Fee(s) Transn are direct all communication	DATE DUE OB/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY JECTS A CREDIT EQUIVALENT) L BE REGARDED AS OF atus before, or is now box below and enclose 2 FEE shown above. tus. Office (USPTO) with ransmittal should be hittal should be s prior to issuance to
TITLE OF INVENTION NOVEL DERIVATIVES OF :         APPLICATION NOVEL DERIVATIVES OF :         NO         THE APPLICATION IDENTIFIED ABOY         PROSEC: UTION ON THE MERITS IS CL         THE APPLICATION IDENTIFIED ABOY         PROSEC: UTION ON THE MERITS IS CL         THE APPLICATION IS SUBJECT TO W         PERIOD ON THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION F         MAIL INC DATE OF THIS NOTICE OR 1         PERIOD CANNOT BE EXTENDED. SEE         FOR ANY PREVIOUSLY PAID ISSUE FI         MUST BE RETURNED WITHIN THIS PLABANDONED.         HOW TO REPLY TO THIS NOTICE:         I. Review the SMALL ENTITY status shown         If the Status is the same, pay the TOTAL F         Above.         B. If the status is changed, pay the PUBLICA and twice the amount of the ISSUE FEE show         United States Patent and Trademark Office of         II. PART B - FEE(S) TRANSMITTAL show         your ISSUE FEE and PUBLICATION FEE (         Completed and returned. If you are charging to completed and returned. If you are charging to completed and an extra copy of the form show         III. All communications regarding	ISSUE FEE \$1300 VE HAS BEEN EXAMI <u>JOSED.</u> THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION 5 2 35 U.S.C. 151. THE IS EE APPLIED IN THIS ERIOD EVEN IF NO F above. rify your current FEE(S) DUE shown ATION FEE (if required) wn above and notify the f the change in status, or above in status, or above in status, or above in the fill of the fill of the fee(s) to your deposit ation must give the application polity to ensure timely particular of the fill of	PUBLICATION FEE SO INED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH B. If applicant cl claiming SMALI the PUBLICATION D. Applicant cl See 37 CFR med to the United S secount, section "4b cation number. Please s filed on or after I syment of maintene	TOTAL FEE(S) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI HE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: YEE(S) DUE shown above, aimed SMALL ENTITY sta . ENTITY status, check the ON FEE and 1/2 the ISSUE aims SMALL ENTITY sta 1.27. Hates Patent and Trademark een paid, Part B - Fee(s) Transm are direct all communication Dec. 12, 1980 may require unce fees when due.	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY JECTS A CREDIT EQUIVALENT) L BE REGARDED AS OF atus before, or is now box below and enclose 2 FEE shown above. tus. Office (USPTO) with ransmittal should be itual should be s prior to issuance to payment of
TITLE OF INVENTION NOVEL DERIVATIVES OF 1         APPL.N. TYPE         MALL ENTITY         nonprovisional         NO         THE APPLICATION IDENTIFIED ABOY         PROSECUTION ON THE MERITS IS CL         THE APPLICATION IS SUBJECT TO W         PROSECUTION ON THE MERITS IS CL         THE APPLICATION IS SUBJECT TO W         PERIOD ON THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION F         MAIL INC DATE OF THIS NOTICE OR         PERIOD CANNOT BE EXTENDED. SEE         FOR ANY PREVIOUSLY PAID ISSUE F         MUST BE RETURNED WITHIN THIS PLABANDONED.         HOW TO REPLY TO THIS NOTICE:         I. Review the SMALL ENTITY status shown         If the Status is the same, pay the TOTAL F         ABANDONED.         HOW TO REPLY TO THIS NOTICE:         I. Review the SMALL ENTITY status shown         If the Status is changed, pay the TOTAL F         above.         B. If the status is changed, pay the PUBLICA         and twice the amount of the ISSUE FEE show         United States Patent and Trademar	ISSUE FEE \$1300 VE HAS BEEN EXAMI <u>OSED.</u> THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION S EE APPLIED IN THIS ERIOD EVEN IF NO F above. rify your current FEE(S) DUE shown TION FEE (if required) wn above and notify the f the change in status, or lid be completed and return if required). Even if the f he fee(s) to your deposit ald be submitted. ation must give the application pility to ensure timely particular to show the submitted. TION FEE (10 PAC) TO PEE (10 PAC) TO	PUBLICATION FEE 50 INED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH B. If applicant cl claiming SMALL the PUBLICATION D. Applicant cl See 37 CFR med to the United S sec(s) have already b account, section "4b cation number. Please s filed on or after I	TOTAL FEE(S) DUE S1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI THE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: TEE(S) DUE shown above, aimed SMALL ENTITY sta LENTITY status, check the ON FEE and 1/2 the ISSUE aims SMALL ENTITY sta 1.27. Iates Patent and Trademark een paid, Part B - Fee(s) Transn se direct all communication Dec. 12, 1980 may require ince fees when due.	DATE DUE O&/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY ECTS A CREDIT EQUIVALENT) BE REGARDED AS OF atus before, or is now box below and enclose 2 FEE shown above. tus. Office (USPTO) with ransmittal should be s prior to issuance to payment of
TITLE OF INVENTION NOVEL DERIVATIVES OF 1         APPLICATION NOVEL DERIVATIVES OF 1         APPLICATION IDENTIFIED ABOY         NO         THE APPLICATION IDENTIFIED ABOY         PROSEC: UTION ON THE MERITS IS CL         THE APPLICATION IS SUBJECT TO W         PERIOD ON THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION F         MAIL INCIDE OF THIS NOTICE OR 1         PERIOD CANNOT BE EXTENDED. SEE FOR ANY PREVIOUSLY PAID ISSUE FI         MUST BE RETURNED WITHIN THIS PLABANDONED.         HOW TO REPLY TO THIS NOTICE:         I. REVIEW the SMALL ENTITY status shown         If the Status is the same, pay the TOTAL F         Above.         B. If the status is changed, pay the PUBLICA and twice the amount of the ISSUE FEE show         United States Patent and Trademark Office of         II. PART B - FEE(S) TRANSMITTAL show         your ISSUE FEE and PUBLICATION FEE (         Completed and returned. If you are charging to completed and an extra copy of the form show         III. PART B - FEE(S) TRANSMITTAL show         YOUR ISSUE FEE unless advised to the contrain the status of the form show         III. PAR	ISSUE FEE \$1300 VE HAS BEEN EXAMI <u>OSED</u> , THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION 5 35 U.S.C. 151. THE IS EE APPLIED IN THIS ERIOD EVEN IF NO F above. rify your current FEE(S) DUE shown ATION FEE (if required) wn above and notify the f the change in status, or A above and notify the f the change in status, or ald be completed and return if required). Even if the f he fee(s) to your deposit ald be submitted. ation must give the application polity to ensure timely pa Page 10/2004.	PUBLICATION FEE SO INED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH B. If applicant cl. claiming SMALI the PUBLICATION I Applicant cl. claiming SMALI the PUBLICATION Cation number. Please account, section "4b cation number. Please s filed on or after I byment of mainteners 1 of 4	TOTAL FEE(S) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF ITHIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI HE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: YEE(S) DUE shown above, aimed SMALL ENTITY sta . ENTITY status, check the ON FEE and 1/2 the ISSUE aims SMALL ENTITY sta 1.27. Inters Patent and Trademark ten paid, Part B - Fee(s) Transm are direct all communication Dec. 12, 1980 may require ince fees when due.	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY JECTS A CREDIT EQUIVALENT) L BE REGARDED AS OF atus before, or is now box below and enclose 2 FEE shown above. tus. Office (USPTO) with ransmittal should be itual should be s prior to issuance to payment of
TITLE OF INVENTION NOVEL DERIVATIVES OF 1         APPL.N. TYPE         MALL ENTITY         nonprovisional         NO         THE APPLICATION IDENTIFIED ABOY         PROSECUTION ON THE MERITS IS CL         THE APPLICATION IS SUBJECT TO W         PROSECUTION ON THE MERITS IS CL         THE APPLICATION BY THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION F         MAIL ING DATE OF THIS NOTICE OR         PERIOD CANNOT BE EXTENDED. SEE         FOR ANY PREVIOUSLY PAID ISSUE FI         MUST BE RETURNED WITHIN THIS PLABANDONED.         HOW TO REPLY TO THIS NOTICE:         I. Review the SMALL ENTITY is shown as YES, veries         SMALL ENTITY is shown as YES, veries         MALL ENTITY is shown as YES, veries         SMALL ENTITY status:         A. If the status is changed, pay the PUBLICA F         above.         II he status is changed, pay the PUBLICA F         above.         II. PART B - FEE(S) TRANSMITTAL shou         YOUR ISSUE FEE and PUBLICATION FEE (         Completed and returned. If you a	ISSUE FEE \$1300 VE HAS BEEN EXAMI <u>OSED.</u> THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION S 2 35 U.S.C. 151. THE IS EE APPLIED IN THIS ERIOD EVEN IF NO F a above. rify your current FEE(S) DUE shown TION FEE (if required) wn above and notify the f the change in status, or ald be completed and return if required). Even if the f he fee(s) to your deposit ald be submitted. ation must give the application polity to ensure timely page 10/2004.	PUBLICATION FEE 50 INED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH B. If applicant cl claiming SMALI the PUBLICATION I Applicant cl claiming SMALI the PUBLICATION California Strain See 37 CFR med to the United S sec(s) have already b account, section "4b cation number. Please s filed on or after I syment of mainteners 1 of 4	TOTAL FEE(S) DUE S1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI THE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: TEE(S) DUE shown above, aimed SMALL ENTITY sta . ENTITY status, check the ON FEE and 1/2 the ISSUE aims SMALL ENTITY sta 1.27. Iates Patent and Trademark een paid, Part B - Fee(S) Transn are direct all communication Dec. 12, 1980 may require ince fees when due.	DATE DUE O&/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY ECTS A CREDIT EQUIVALENT) L BE REGARDED AS OF atus before, or is now box below and enclose 2 FEE shown above. tus. Office (USPTO) with ransmittal should be itual should be s prior to issuance to payment of
APPL.N. TYPE       SMALL ENTITY         nonppovisional       NO         THE APPLICATION IDENTIFIED ABOY       PROSECUTION ON THE MERITS IS CI         THIS APPLICATION IDENTIFIED ABOY       PROSECUTION ON THE MERITS IS CI         THIS APPLICATION IS SUBJECT TO W       PETITION BY THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION FI       MAILING DATE OF THIS NOTICE OR         PERIOD CANNOT BE EXTENDED. SEE       FOR ANY PREVIOUSLY PAID ISSUE FI         MUST BE RETURNED WITHIN THIS PLABANDONED.       HOW TO REPLY TO THIS NOTICE:         I. Review the SMALL ENTITY is shown as YES, version ALL ENTITY status:       A. If the Status is the same, pay the TOTAL Fabove.         B. If the status is changed, pay the PUBLICA and twice the amount of the ISSUE FEE show       United States Patent and Trademark Office of         II. PART B - FEE(S) TRANSMITTAL show       your ISSUE FEE and PUBLICATION FEE (completed and returned. If you are charging to completed and an extra copy of the form show         III. All communications regarding this applic Box ISSUE FEE unless advised to the contrait         IMPORTANT REMINDER: Utility patent         maintenance fees, It is patentee's responsite	ISSUE FEE \$1300 VE HAS BEEN EXAMI <u>OSED</u> , THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION 5 35 U.S.C. 151. THE IS EE APPLIED IN THIS ERIOD EVEN IF NO F above. rify your current FEE(S) DUE shown ATION FEE (if required) wn above and notify the f the change in status, or Id be completed and return if required). Even if the f he fee(s) to your deposit ald be submitted. ration must give the application polity to ensure timely pa Page 10/2004.	PUBLICATION FEE 50 INED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH A. Pay TOTAL H B. If applicant cl claiming SMALI the PUBLICATION Claiming SMALI the PUBLICATION Claiming SMALI the PUBLICATION See 37 CFR med to the United S Sec(s) have already b account, section "4b cation number. Please s filed on or after I syment of maintent 1 of 4	TOTAL FEE(S) DUE \$1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF ITHIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI HE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: EE(S) DUE shown above, aimed SMALL ENTITY sta LENTITY status, check the ON FEE and 1/2 the ISSUE aims SMALL ENTITY sta 1.27. Tates Patent and Trademark cen paid, Part B - Fee(s) Transn se direct all communication Dec. 12, 1980 may require ince fees when due.	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY ECTS A CREDIT EQUIVALENT) BE REGARDED AS OF atus before, or is now box below and enclose 2 FEE shown above. tus. Office (USPTO) with ransmittal should be itual should be s prior to issuance to payment of
APPLN, TYPE       SMALL ENTITY         nonprovisional       NO         THE APPLICATION IDENTIFIED ABOY       PROSEC: UTION ON THE MERITS IS CI         THE APPLICATION IDENTIFIED ABOY       PROSEC: UTION ON THE MERITS IS CI         THIS APPLICATION IN SUBJECT TO W       PETITION BY THE APPLICANT. SEE 3         THE ISSUE FEE AND PUBLICATION FI       MAILING DATE OF THIS NOTICE OR         PERIOD CANNOT BE EXTENDED. SEE       FOR ANY PREVIOUSLY PAID ISSUE FI         MUST BE RETURNED WITHIN THIS PI       ABANDONED.         HOW TO REPLY TO THIS NOTICE:       I. Review the SMALL ENTITY is shown as YES, veries         SMALL ENTITY status:       A. If the status is the same, pay the TOTAL F         above.       B. If the status is changed, pay the PUBLICA and twice the amount of the ISSUE FEE show         United States Patent and Trademark Office of       II. PART B - FEE(S) TRANSMITTAL shou         Your ISSUE FEE and PUBLICATION FEE (completed and returned. If you are charging to completed and an extra copy of the form show         III. All communications regarding this applic Box ISSUE FEE unless advised to the contrainabilitenance fees. It is patentee's responsite         PTOL-85 (%EV. 05-03) Approved for use through 04/3	ISSUE FEE \$1300 VE HAS BEEN EXAMI OSED. THIS NOTICE VITHDRAWAL FROM 7 CFR 1.313 AND MPE EE (IF REQUIRED) M THIS APPLICATION S 35 U.S.C. 151. THE ISS EE APPLIED IN THIS ERIOD EVEN IF NO F above. rify your current FEE(S) DUE shown TION FEE (if required) wn above and notify the f the change in status, or Id be completed and retuin if required). Even if the f he fee(s) to your deposition all be submitted. ation must give the application offiction of the completed in the submitted. The s	PUBLICATION FEE 50 INED AND IS ALL OF ALLOWANC ISSUE AT THE ID P 1308. UST BE PAID WIT SHALL BE REGA SUE FEE DUE INI APPLICATION. T EE IS DUE OR TH B. If applicant cl: claiming SMALI the PUBLICATION I Applicant cl: claiming SMALI the PUBLICATION Carrier SMALL EN A. Pay TOTAL H B. If applicant cl: claiming SMALI the PUBLICATION See 37 CFR med to the United S ce(s) have already b account, section "4b cation number. Please s filed on or after I syment of mainteners 1 of 4	TOTAL FEE(S) DUE S1300 OWED FOR ISSUANCE E IS NOT A GRANT OF NITIATIVE OF THE OF THIN THREE MONTHS RDED AS ABANDONED DICATED ABOVE REFI THE PTOL-85B (OR AN IE APPLICATION WILL NTITY is shown as NO: TEE(S) DUE shown above, aimed SMALL ENTITY sta . ENTITY status, check the ON FEE and 1/2 the ISSUE aims SMALL ENTITY sta 1.27. tates Patent and Trademark een paid, Part B - Fee(S) T " of Part B - Fee(S) Transn se direct all communication Dec. 12, 1980 may require ince fees when due.	DATE DUE 08/18/2003 AS A PATENT. PATENT RIGHTS. FICE OR UPON FROM THE THIS STATUTORY JECTS A CREDIT EQUIVALENT) BE REGARDED AS OF atus before, or is now box below and enclose PEE shown above. tus. Office (USPTO) with ransmittal should be nittal should be s prior to issuance to payment of

### PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to:	Mail	Mail Stop ISSUE FEE
	•	Commissioner for Patents
	-	Alexandria, Virginia 22313-1450

Ϋ́, · · · ·

NSTRUCTIONS: This form a propriate, All further corresp idicated unless corrected belo	should be used for tran ondence including the w or directed otherwise	smitting the ISSUE F Patent, advance orders in Block I, by (a) and	EE and PUBLIC and notification	ATION FEE (if of maintenance fe	required) Blocks   through 4 ics will be mailed to the current ress; and/or (b) indicating a se	should be completed where a correspondence address as parate "FRE ADDRESS" for	
maintenance fee notifications. UNREENT UNRESPONDENCE ADDRESS (Note: Legebly mank-up with any torice idea of due Block 1) 21874 7590 05/16/2003 EDWARDS & ANGELL, LLP P O. HOX 9169 BOST(DN, MA 02209			Act 1)	Note: A certificate of mailing can only be used for domestic mailings of the Pee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. Certificate of Mailing or Transmission I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Roy Issue Fee address above or being feering in			
				transmitted to th	e USPTO, on the date indicated	(Depositor's name)	
		i	1			(Signatuie)	
		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	· · · · · · · · · · · · · · · · · · ·			(Date)	
09/7/00,094	FILING DATE 01/02/2001	FIRS	Claus Meese	TOR	MBHB00-1121	CONFIRMATION NO.	
'LE OF INVENTION: NOV	EL DERIVATIVES OF	3,3-DIPHENYLPROP	YLAMINES /	• •	• •		
APPLN. TYPE	SMALL ENTITY	ISSUR FRE	PUBL	ICATION FEE	TOTAL FEE(S) DUB	DATE DUE	
nonprovisional	NO	\$1300		\$0	\$1300	08/18/2003	
EXAMINER		ART UNIT	CLASS-SUBC	LASS			
Change of correspondence : R (155) D Change of correspondence Address form PTO/SB/122) D "Fee Address" indication TO/SB/47; Rev 03-02 or n Number is required.	address or indication of e address (or Change of attached. (or "Pee Address" Indic: nore recent) attached. Un	"Fee Address" (37 Coπespondence ation form se of a Customer	2. For printing the names of u or agents OR, single firm (h attorney or ag registered pate is listed, no nar	on the patent fro pt to 3 registered alternatively, (2) aving as a ment ent) and the nan nt attorneys or age ne will be printed.	nt page, list (1) patent attorneys the name of a ber a registered nes of up to 2 ints. If no name 3		
JEASE NOTE. Unless an a m previously submitted to 1 () NAME ()F ASSIGNEE ase check the appropriate as	ssignee is identified bel the USPTO or is being s signee category or categ	ow, no assigner: data w ubmitted under separate (B) RE ories (will not be printe	ill appear on the cover. Complete SIDENCE: (CIT d on the patent)	patent. Inclusion o on of this form is t Y and STATE OR	f assignce data is only approprion NOT a substitute for filing an as COUNTRY) O corporation or other private	ate when an assignment has signment. group entity O government	
The following fec(s) are end	losed.	4b Pay	yment of Fee(s): beck in the amou	nt of the fee(s) is e	aciosed.		
Dissue Fee			ment by credit ca	rd. Form PTO-203	B is attached.		
Advance Order - # of Copi	cs	Depos	Commissioner in it Account Numb	er	by charge the required fee(s), c (enclose an extra copy of th	r credit any overpayment, to is form).	
immissioner for Patents is rea	quested to apply the Issu	e Fee and Publication F	ree (if any) or to I	c-apply any previo	ously paid issue fee to the applic	ation identified above.	
uthorized Signature)		(Date)			- <u></u>		
VOTE: The Issue Fee and F ther than the applicant; a i nterest as shown by the recor- bition or recam a benefit by pplication. Confidentiality is simated to take 12 minutes completed application form ase: Any comments on the aggestions for reducing this fatent and frademark Off PEND TO: Commissioner for Under the Properwork Redu	Aublication Fee (if required attorney or a ds of the United States I n is required by 37 CF the public which is to governed by 35 U.S.C. to complete, including to the USPTO. Time wour burden, should be sen fince, U.S. Department ND FEES OR COMPL Patents, Alexandria, Vi ction Act of 1995, no sei it displays a valid ON	ired) will not be accep gent; or the assignce of Patent and Trademark O R 1.311. The information file (and by the USPT 122 and 37 CFR 1.14. 122 and 37 CFR 1.14. require to complete it to the Chief Information of Commerce, Alex OF Commerce, Alex LETED FORMS TO T irguina 22313-14:10. persons are required AB control number.	ted from anyone or other party in fifte on is required to O to process) an This collection is a submitting the on the individual this form and/or ion Officer, U.S. andria, Virgina HIS ADDRESS. to respond to a				
		TRANSMIT TH	HIS FORM WITH	H FEE(S)			
OL 83 (RE.9. 03-03) Appr	oved for use through 04	30/2004 (JMID 0031-0	033 0.5		Derk Omos, U.S. DEFARIME	NI OF COMMERCE	
				•			
		,	Į	·;			
•				· · ·	· · · ·		
·				· .			
			t i	· .			
				•			
			į	÷.	e a c		
			•				
· · · · · · · · · · · · · · · · · · ·			<u> </u>		· · · · · · · · · · · · · · · · · · ·		
			t ;	· · ·			

UNITED STATES PATENT AND TRADEMARK OFFICE

		· · · · · · · · · · · · · · · · · · ·	United Address. (	States Patent and Trademark O DOMMISSIONER OF PATENTS AND TRJ O Boz 1450 Waraning, Vagina 22313-1450 Www.uspin.gov	ADBMARKS
APPLICATION NO.	FILINO DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.	CONFIRMATION NO.
03/700,094	01/02/2001	Claus Meese		MBHB00-1121	1408
. 21 874 75	0 05/16/2003			EXAMI	NER
EDWARDS & Al	NGELL, LLP	$k_{\rm eff} = k_{\rm eff} + k_{\rm eff}$	ï.	TUCKER, ZA	CHARY C
BOSTON, MA 022	09		۰	ART UNIT	PAPER NUMBER
UNITED STATES		<i></i>		1624	
			۰,	DATE MAILED: 05/16/2003	

#### Determination of Patent Term Extension under 35 U.S.C. 154 (b) (application filed after June 7, 1995 but prior to May 29, 2000)

The patent term extension is 0 days. Any patent to issue from the above identified application will include an indication of the 0 day extension on the front page.

If a continued prosecution application (CPA) was filed in the above-identified application, the filing date that determines patent term extension is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) system. (http://pair.uspto.gov)

Any questions regarding the patent term extension or adjustment determination should be directed to the Office of Patent Legal Administration at (703)305-1383.

Page 3 of 4

PTO1\_85 (REV. 05-03) Approved for use through 04/30/2004.

Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0294

		UNITED United 8 Addres CO Au	BTATES DEPARTMENT OF COA tates Patont and Trademark OII MultsiONER OF PATENTS AND TRAD Ber 1450 undruk Vigton 22313-1450 w inpto gov	IMERCE Too BMARKS
PPLICA TION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/700,094	01/02/2001	Claus Meese	MBHB00-1121	1408
21874 759	0 05/16/2003		EXAMIN	ER
EDWARDS & AN	IGELL, LLP		TUCKER, ZAC	HARY C
OSTON, MA 0220	)9		ARTUNIT	PAPER NUMBER
INITED STATES		· · · · · · · · · · · · · · · · · · ·	1624	

#### Notice of Fee Increase on January 1, 2003

If a reply to a "Notice of Allowance and Fee(s) Due" is filed in the Office on or after January 1, 2003, then the amount due will be higher than that set forth in the "Notice of Allowance and Fee(s) Due" since there will be an increase in fees effective on January 1, 2003. See Revision of Patent and Trademark Fees for Fiscal Year 2003: Final Rule, 67 Fed. Reg. 70847, 70849 (November 27, 2002).

The current fee schedule is accessible from: http://www.uspto.gov/main/howtofees.htm.

If the issue fee paid is the amount shown on the "Notice of Allowance and Fee(s) Due," but not the correct amount in view of the fee increase, a "Notice to Pay Balance of Issue Fee," will be mailed to applicant. In order to avoid processing delays associated with mailing of a "Notice to Pay Balance of Issue Fee," if the response to the Notice of Allowance and Fee(s) due form is to be filed on or after January 1, 2003 (or mailed with a certificate of mailing on or after January 1, 2003), the issue fee paid should be the fee that is required at the time the fee is paid. If the issue fee was previously paid, and the response to the "Notice of Allowance and Fee(s) Due" includes a request to apply a previously paid issue fee to the issue fee now due, then the difference between the issue fee amount at the time the response is filed and the previously paid issue fee should be paid. See Manual of Patent Examining Procedure, Section 1308.01 (Eighth Edition, August 2001).

Page 4 of 4

Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (703) 305-8283.

PTOL-85 (REV. 05-03) Approved for use through 04/30/2004.

-----

			•	<b>र</b>		a relution	-20
	·				· i	LUI 60	149103
A FIGURATION OF A CONTROL O	SIPE	"Cractiti ner's Doc	ket No55647 (45	i <b>107)</b>	PATI	ENT ; A	type
<form></form>	18 1 82	Ø <sup>₩</sup> ₩	THE UNITED STAT	ES PATENT AND TRADEM	IARK OFFICE		۰ ۱
Support     Application     C. Meese, et al.       SERUAL NO:     09750,094     GROUP:     1524       FILED:     Jammy 2, 2001     EXAMPLER: Z. Tusker       FOR:     NOVEL DERIVATIVES OF 33-DIPPENVLPROPYLAMINES     RECEIVED       Commissioner for Parma     Match and Return     RECEIVED       Commissioner for Parma     Match and Return     Auf 5 2 0 2003       P.O. Soci 1450     Match and Return     Auf 5 2 0 2003       Commissioner for Parma     Match and Return     Auf 5 2 0 2003       P.O. Soci 1450     Match and Return     Auf 5 2 0 2003       P.O. Soci 1450     Match and Return     Auf 5 2 0 2003       Commissioner for Parma     Match and Return     Auf 5 2 0 2003       I. Second Hand Shore Vide 20150     CERTER Ho002500     TECH CENTER Ho002500       I. Second Hand Shore Vide 20150     CERTERCHONO NODER 7 CFR SECOND Light And 13 07 CFR Second Hand Y 100 (Second Hand Y	-	A.S.					• · ·
SERIAL NG:     99700,094     GROUP:     124       FUED:     Jamary 2, 2001     EXAMINER:     Z. Darket       FOR:     NOVEL DERIVATIVES OF 3,3_DIPHENVER/OPVLAMINES     MAG 2 0, 2003       Commissioner for Memmi Rousedia, VA. 2313-1450     AUG 2 0, 2003       Commissioner for Memmi Rousedia, VA. 2313-1450     AUG 2 0, 2003       Commissioner for Memmi Rousedia, VA. 2313-1450     AUG 2 0, 2003       Commissioner for Memmi Rousedia, VA. 2313-1450     AUG 2 0, 2003       Commissioner for Memmi Rousedia, VA. 2313-1450     CERUEST FOR CONTINUES PERAMINATION (RCE) (PC CFR. 1.116)       Commissioner for Memory Rouse is the formation of the adverse infering designed is the formation of the adverse infering designed is the formation of the adverse infering of the adverse infe	CANDER	APPLICANT:	C. Meese, et al.		an a	U	
<form><form><form><form><form><form><form><form><form><form><form><form></form></form></form></form></form></form></form></form></form></form></form></form>		SERIAL NO .:	09/700,094	GROUP	: 1624		
<text><text><text><text><text></text></text></text></text></text>		FILED:	January 2, 2001	EXAMI	NER: Z. Tucker		
<section-header></section-header>		FOR:	NOVEL DERIVA	TTVES OF 3,3-DIPHENYLPR	OPYLAMINES		
				$(1, 1, \dots, N)$	RE	CEIVED	
P.O. Box 1439 Alexandria, VA 2313-1450  EXCURSION CONTINUED EXAMINATION (RCE) (J.C.F.R. L114)		Mail Stop: <u>RCE</u> Commissioner for 1	Patents M	latch and Retu	AU AU	G 2 0 2003	
EXAMPLES FOR CONTINUED EXAMPLATION (RCE) (J7 CFR. L114)  1. Applicate hereby requests continued examination, in accordance with 37 CFR. Section 1.114. for the above identified application CERTFFCATION UNDER 37 CFR. SECTIONS LED (APD 130 (Mar with Express Mich above intermediate intermediate) CERTFFCATION UNDER 37 CFR. Section CERTFFCATION CERTFFC		P.O. Box 1450 Alexandria, VA 22	2313-1450		TFCH C	ENTER 1600/2900	·
(3) CFER 1.114     (1.14, for the Application thereby requests a continued examination, in accordance with 37 CF.R. Soction     (1.14, for the above identified application.     CARTERCATION (NORR 97 CF.R. 2.0C/TONE 1.50) 1.0     (Martine Control Conterect Control Control Control Control Control C			REQUEST FOR (	YONTINUED BY AMINATIO			
1.114. Applicant hereby registes continued examination, in secondance with 37 C.F.R. Soction 1.114. for the above identified application.         CENTRECTION IONESE 77 C.F.R. SICTIONS I.LED (NE 1.16)         (Phone table 2 pares to led tradit halo mankare); Express Mail Pare (March 1.10)         (Phone table 2 pares to led tradit halo mankare); Express Mail Pare (March 1.10)         (Phone table 2 pares to led to regional)         Intrets out to the data from below, this compositions is high Sing RCE, Commissions for Paces, P.O. Box 1.93         (Phone table 2 pares to the set out to the man enclope addresset is Mail Sing RCE, Commissions for Paces, P.O. Box 1.93         (Phone table 2 pares to the set out to the man enclope addresset is Mail Pare Office to Addresset" Mail Pare Office to Addresset addr				(37 C.F.R. 1.114)	AT (ACL)		
EXATURACION UNDER 27 C.7.2. SECTIONS 1.4(a) AND 1.10 (Mara stage depress Mark halo masker is manufactor.  EXATURACION UNDER 27 C.7.2. SECTIONS 1.4(a) AND 1.10 (Mara stage depress Mark halo masker is manufactor.  Express Mark and process is large MALIFIC  (A dependent with the flower balow from the component is baloge (A dependent with the flower balow from the component is baloge (A dependent with the flower balow from the component is baloge (A dependent with the flower balow from the component is baloge (A dependent with the flower balow from the component is baloge (A dependent with the flower balow from the component is baloge (A dependent with the flower balow from the component is baloge (A dependent with the flower balow from the component is baloge (A dependent with the flower balow from the component is baloge (A dependent with the flower balow from the component is baloged (A dependent with the flower balow from the component is baloged (A dependent with the flower balow from the component is baloged (A dependent with the flower balow from the component is baloged (A dependent with the component is baloged (A depen	•,	1. Ap	plicant hereby requests	continued examination, in acco	ordance with 37 C.F.F	L Section	
Contraining of Contractions of Contractions and Contracti					· · · · · · · · · · · · · · · · · · ·		
Interby certify that, on the data shown hadrow, this correspondences is being:         (X)       depasted with the United States Frontal Service in an envelope addressed to Mail Stop RCE, Commissioner for Panents, P.O. Box 1430, Alexandrin, VA 22313-1439.         (X)       depasted with the United States Frontal Service in an envelope addressed to Mail Stop RCE, Commissioner for Panents, P.O. Box 1430, Alexandrin, VA 22313-1439.         (X)       write sufficient portage as first chase mail.       If I			CERTIFICATION ( (When using Express I	UNDER 37 C.F.R. SECTIONS 1.8(8) AN Val., the Express Matt Label number is ma	nd 1.10 mdatory;		
Address of the data inform percent and information addressed in Security  (2) deposited with the United Stores Potent Service is an envelope addressed to Mail Storp RCE, Comministorer for Penner, P.O. Box (3) Advessed in VA 22313-1450.  T C.F.B. Section 1.16  (2) with sufficient potentiate of the near and (1) as "Express Mail Paul Office in Addresses" (anadatary)  TEANENMISSION  (1) factionals tormeristica to the Paunt and Trademate Office (700)  (2) factionals tormeristica to the Paunt and Trademate Office (700)  (3) Section 1.10  (3) Section 1.10  (3) Section 1.10  (3) Section 1.10  (2) with sufficient potentiate of Trademate Office (700)  (3) Section 1.10  (3) Secti		the sector contraction and the	Equi	sis Mail certification is optional.)			
(X) deputited with the United Status Postal Service in an envelope addressed to Mail Stop RCE, Commissioner for Panets, P.O. Box 140, Alexandrik, VA 2213-1450.       S7 C.F.B. Section 1.4(a)     37 C.F.B. Section 1.40       S7 C.F.B. Section 1.4(a)     37 C.F.B. Section 1.40       S8 Section 1.40     1       S8 Section 1.40     1       S8 Section 1.40     37 C.F.B. Section 1.40       S8 Section 1.40     1       S8 Section		I hereby centry that, on the	t date shown delow, this opticsp	MAILENG			· .
37 C.F.B. Section 1.4(c)       37 C.F.B. Section 1.10         [X]       with molfactar postage as first class mail.       []       Billing 1.461 Million Office to Addressee"         [X]       with molfactar postage as first class mail.       []       Million Office to Addressee"         []       finational communities to the Planet and Trademark Office (100)		[X] deposited with	the United States Postal Service	in an envelope addressed to Mail Stop RC	E, Commissioner for Patents,	P.O. Box	
(c)     with participat portage as first class mail.     []     as "Express Mail Post Offices to Addresses" (mandetstry)       TEANSMUSSION       []     faising Lei Mail     []     as "Express Mail Post Offices to Addresses" (mandetstry)       Date:		1430, Alexandi	18, VA 22313-1450.	e e e e e e e e e e e e e e e e e e e			
(A) Vita humanez pologie is into data sour. () B () Copyers Mail Polarization ((candition)) Halling Labol No. ((candition)) TRANSMISSION () Eximals committed to the Preside and Trademark Office (703) Date: AllARI Od/19/2003 HEIZURES 60000044 09700094 () Stream M. Dillon. () Severa M. Dillon. () Seve		37	P.K. Secnos (.J(a)		/ C.P.R. Scenos I.IV	_	
TRANSMISSION  TRANSMISSION  TRANSMISSION  TRANSMISSION  Date:	•	(X) with sumplicity	postage as first cause mail.	[] as Express Mailing Lak	Mail Post Ottice to Addresse wi No.	5	
Increases         Image: Increas	A			TO A VICE IS STORE	,		
Image: Linking outdation is to be a ream and interaction to inter (int)       Date:			mittend on she December and Was down				
Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature				Lunan m Qill	5m		
OB/19/2003 HEIZURES 00000048 09700094       (pps or prion mass of perion cortificing)         01 FC:1801       750.00 09         (Request for Continued Examination (RCE))page 1 of 6)				Signature			
08/19/2001 #21/UK2'S GOVERN TO TO TO TO TO THE ALMAN OF PART ALMAN OF PA			9708094	Suse M Dillon		<b>_</b>	
	03/19/2 01 FC11	801 801	750.00 OP	(type or print accession of p			
	•••			(Keybest for Contin	ideo Exaministian (RCE)/~	γρα <u>β</u> αιοιο)	
				• • • • • • • • •			
					· ·		••
				r			
				· · · · ·	. ·		•
				. ·			
				• • • • • • • • •			
				10			
				$t \sim 10^{-10}$	<b>x</b>		
						•	
				· ·			
		,		· · · · · · · · · · · · · · · · · · ·	· · ·		

,

35 U.S.C. 132(b) and Section 1.114 provide for the or WARNING: n of an aol n of a ntinuing opplication). Accordingly, the Office will not permit an applicant to of ain a basis of claims that are independent and distinct from the claims previously claimed and exomined. Notice of March 10, 2000, 65 Fed Reg 14865, at 14868.

A continued examination request connot be made if at locat one affice action under 35 U.S.C. 132 or a notice of allowance under 35 U.S.C. 161 has not been mailed. The provisions of 37 C.F.R. 1.114 also do not apply (1) to a provisional application, an application for a utility or plant patent filed under 35 U.S.C. 111(a); (2) an international application filed under 35 U.S.C. 363 before June 8, 1995; (3) a patent under recommentation; or (4) an application for a WARNING: design patent. 37 C.F.R. Secsion 1.114(d).

There is no limit to the number of times the fee for continued exa NOTE: m may be submitted. Notice of March 10, 2000, 65 Fed Reg . ĩ 14865, at 14868. 7

Unlike a conti ation request can utilize the mailing procedure of 37 C.F.R. 1.8, See 37 NOTE: tion appl d exc C.F.R. Section J.8(a)(2)(1)(A).

TIME REQUEST IS BEING MADE

- This request is being submitted (check appropriate item(s) below): 2.
- Prior to abandonment of the application i. [X]
- ii. In lieu of payment of the issue fee [X]
  - Prior to payment of issue fee [X]
    - [] Issue fee has been paid but a petition under Section 1.313 has been filed herewith
- iii. Prior to a decision on appeal to the Board of Patent Appeals & Interferences [] A notice is being separately sent to the Board of Patent Appeals & Interferences that this Request for Continued Examination is being filed.

If such a notice is not sent to the Board, they may refuse to vacate a decision rendered after the filing of the RCE but before recognition by the Office of the RCE request under Section 1.114. NOTE:

Appeal to the U.S. Court of Appeals of the Federal Circuit under 35 U.S.C. 145 iv. []

- or [ ]Commencement of a civil action under 35 U.S.C. 146
  - Prior to the filing of such appeal or commencement of civil action

[] [] Such appeal or commencement of civil action has been terminated

**ENCLOSURES** 

3. Enclosed herewith is/are:

WARNING:

If reply to a final or non-final Office action under 35 U.S.C. 132 is on nding, the submission must meet the reply requirements of Section 1.111. 37 C.F.R. Section 1.114(b).

**[X]** An information disclosure (37 C.F.R. Section 1.98) Form PTO-1449 (PTO/SB/08A and 08B) [X]

(Request for Continued Examination (RCE))--page 2 of 6)

- [] [] A Response
- New arguments . . . . .
- [] New evidence in support of patentability 10

. : : . .

[] Other:

#### FEE FOR REQUEST (37 C.F.R. Section 1.17(e)).

\$ 375.00

\$750.00

4. This application is on behalf of:

[] Small entity (and status is still as small entity)

Other than a small entity [X] .

#### Continued Prosecution Request Fee

\$\_\_\_\_750.00

#### FEE FOR CLAIMS

MITE: "The fee for conti nation under Section 1.114 (Section 1.17(e)) does not include additional claims fee (cf. 1.53 wed exan (4)(3)(11)." See Notice of March 10, 2000, 65 Fed Reg 14865, at 14868.

37 C.F.R. 1.53(d)(3): "The filing fee for a continued prosecution application filed under this paragraph is:

(i) The basic filing fee as set forth in Section 1.16; and

(1) Any additional Section 1.16 fee due based on the number of claims reuning in the a amendment accompanying the request for an application under this paragraph and entry of any an nte s Section 1.116 unentered in the prior application which applicant has requested to be entered in the conti secution application.\* DP

5. The fee for claims (37 C.F.R. Section 1.16(b)-(d)) has been calculated as shown below:

	(Col.1)	(Col. 2)	(Col. 3) S	MALL ENTTY		SMALL ENT	IER 11 ITY		
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	_ Rate _	Addit.	OR	Rate	Addit. Fee
Total	•	Minus			x \$9 =	_\$		x \$18 -	5
Indep.	•	Minus	644	-0	x \$39 =	\$		x \$84 =	\$0
[] First	Presentation of	Multiple Dep	endent Clain	0	+ \$130 -	- 5		+ \$280 =	\$0
					Total Addit. Fee	s	OR	Total Addit. Fee	\$

If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3, 58

...

If the "Highest No. Previously Paid For" IN THIS SPACE is less than 20, enter "20". If the "Highest No. Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest No. Previously Paid For" (Total or Indep.) is the highest number found in the appropriate box in Col. 1 of a prior amendment or the number of claims originally filed.

(Request for Continued Examination (RCE))-page 3 of 6)

See 37 C.F.R. Section 1.116.

WARNING:

#### : (complete (c) or (d), as applicable)

No additional fee is required. (c) [X]

OR

۰<u>،</u>

ł

(d) [] Total additional fee required is \$

#### **EXTENSION OF TIME**

#### (If an extension of time is appropriate complete (a) or (b), as applied ble

6. The proceedings herein are for a patent application, and the provisions of 37 C.F.R. Section 1.136(a) apply.

#### Applicant petitions for an extension of time, the fees for which are set out in 37 C.F.R. Section 1.17(a)(1)-(4), for the total number of months checked below: **(a)** []

Extension for (months)	Fee for other thansmall entity	Fee for small entity
[] one month	\$110.00	\$ 55.00
[] two months	\$410.00	\$205.00
[] three months	\$930.00	\$465.00
[] four months	\$1,450.00	\$725.00
[] five months	\$1,970.00	\$985.00
		Fee \$

If an additional extension of time is required, please consider this a petition therefor.

(check and complete the next tiem, if applicable)

[] An extension for \_\_\_\_ \_ months has already been secured, and the fee paid therefor of \$ . is deducted from the total fee due for the total months of extension now requested.

> Extension fee due with this request · S.

#### OR

**(b)** 

[X]

Applicant believes that no extension of time is required. However, this is a conditional petition and authorization to pay the necessary fees to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

(Request for Continued Examination (RCE))-page 4 of 6)

	IUIAL FEE(3) DUE	-	
NG:	The fee for continued examination under Section 1.114 may not be deferre	ed. 37 C.F.R. Section 1.5	30.
7.	The total fee(s) due is/are:		
Con	tinued Prosecution Fee (Section 1.17(e))	S	250.00
Fee( Exte	(s) for additional claims (if any) (Section 1.16(b)-(d)) ension of time fee (if any) (Section 1.17(a)(1)-(4))	\$ \$	
	Total Fee(s)	Due: \$	750.00
	$e^{-i\omega t} = E^{-i\omega t} e^{-i\omega t}$	, V	
	PAYMENT OF FEE(S) DUE		

PAT EPP/Q) DITE

. : : : .

#### •

8. Please pay the fee(s) for this continued examination application as follows:

[X]	Check are attached for the sum of	\$750.00
[]	Charge Account the sum of	\$
[]	Charge Credit Card the sum of (Credit Card Payment Form (PTO-2038) attached.)	<b>\$</b>

Please charge any required additional fcc(s) for Section 1.17(e), Section 1.16(b)-(d) and/or Section 1.17(a)(1)-(4) to

[X] Account \_\_\_\_04-1105\_\_\_\_\_

WARNI

[] Credit Card (Credit Card Payment Form (PTO-2038) attached.)

#### INVENTORSHIP

NOTE: Any change of inventors must be via the procedure set forth in 37 C.F.R. Section 1.48. See Notice of March 10, 2000, 65 Fed Reg. 14865, at 14868.

9. This application as amended names as inventors:

[] the same inventors as previously designated for the claims.

[] fewer than the inventors previously designated and a statement accompanies this request for the deletion of the name or names of the person or persons who are not inventors of the invention now being claimed.

ŗ

(Request for Continued Examination (RCB))-page 5 of 6)

۲.

#### Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0300

a person not named previously as an inventor and a petition under 37 C.F.R. Section 1.48 is/has separately: [] being filed [] been filed

ï

ŀ :

(Req

pest for Continued Ex

tination (RCE))-page 6 of 6)

Reg. No.: 38,256

[]

Tel. No.: (617) 439-4444

C. N SIGNATURE OF PRACTITIONER

Christine C. O'Day (type or print name of practitioner)

Edwards & Angell, LLP P.O. Box 9169, Boston, MA 02209 P.O. Address

Customer No.: 21874

6	TPE
R N	6 1 8 2003 B
HAR &	BACIERAE
	Applicants:

•	$h_{\rm eff} = \frac{1}{2} \left[ \frac{1}{2} - \frac{1}{2} \right] \left[ \frac{1}{2} + \frac{1}{2} \right] \left[ \frac{1}{$	#21
		10/29/03
	Docket No. 55647 (45107)	C. Stepler
IN THE UNITED ST.	ATES PATENT AND TRADEMARK OFFICE	5
C. Meese et al.	TECH AUG 20	VED .
09/700,094	GROUP: 1624	03
January 2, 2001	BXAMINER: Z. Tucker	2900

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

For:

Filed:

Serial No .:

Mail Stop: <u>RCE</u>

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES

Date	8/14/03	By: lunar m Dillon
		Susan M. Dillon
******	*********************	***************************************

Sir.

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached form PTO-1449, for consideration by the Examiner in connection with the examination of the above-identified patent application.

#### REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

<u>X</u>

 within three (3) months of the Filing Date or before the mailing date of the First Office Action on the merits; or

(2)

within three months of the mailing date of the Written Opposition issued by the: \_\_\_\_\_\_Patent Office (dated \_\_\_\_\_); or C. Meese et al. U.S.S.N. 09/700,094 Page 2

: : .

(3) after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and the requisite Certification or fee under Rule 1.17(p), namely \$180.00, is included herein; or

(4)

after the mailing date of a Final Rejection or Notice of Allowance but before the payment of the Issue Fee, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached form(s) PTO-1449 be made of record in this application. Copies of these documents (CHECK ONE):

<u>X</u>

are enclosed herewith; or

have been cited in the parent application, and are thus not being resubmitted herein.

Early examination and allowance of the present application are respectfully solicited.

#### FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 04-1105. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,

T.C.M Ch

Christine C. O'Day (Reg. 38,256) Edwards & Angell, LLP PO Box 9169 Boston, MA 02209 (617) 439-4444

Dale: August <u>14</u>, 2003

## TECH CENTER 1600/2900

.

MIG ,							Sheet 1 of
Servero.	100	·····		DOCKET NO.: 55647	SERIAL N	0.: 09/700,094	<del></del>
NFORMATI	- On dis	CLOSURE STATE	MENT	APPLICANT(S): C. Mees. et al.			······································
		t.		FILING DATE: January 2, 2001	GROUP N	O.; 1624	
			U	NITED STATES PATENT DOCUME	INTS		,
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
225	AA	6,313,132 B1	11/8/01	R. Johansson, et al.	514	277	
ور المحمولين المحمولين المحمولين.	$\left\{ - \right\}$						
سىلى () ئالىرىنىڭ ھال جىر	<u> </u>		L	FOREIGN PATENT DOCUMENT	B	<b></b>	L
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YESMO
	┝─┤		╂			{	
				· · · · · · · · · · · · · · · · · · ·			
	┼╌┥		╉			<u>}</u>	
	I	·····		L,		<u>.</u>	L
		OTHER DOCU	Ments (in	CLUDING AUTHOR, TITLE, DATE,	PERTINENT	PAGES, ETC.)	
					: 		
	$\left  - \right $				·	·	
Fyaminer	Ļ	(1)			Date:		
	Ch	the her			2	7 04086	< 2003
ور استگاه میچنین بارد			· ·				
				· · · · · · · · · · · · · · · · · · ·	ar i i	7	
					'		
					· .	· .	
				· · · · · · · · · · · · · · · · · · ·			
		•					
				÷	iv <sub>a</sub> ≞	2	
						х .	
				)			
					,		
•							
						$X_{ij} = 0$	
					• **		

Transaction History Date 2003 - 11 - 04 Date Information retrieved from USPTO Patent Application Information Retrieval (PAIR) system records at www.uspto.gov

		1 244				
			7700 004		MEEGE CT	
Notice o	f Allowabllity	Ex	aminer		Art Unit	
		7-	chary C. Tucker		1624	{
The MAILING     ims being allowable, P     ith (or previously malle     CE OF ALLOWABILIT     Office or upon petition     This communication is     The allowed claim(s)     The allowed claim(s)     The drawings filed on     Acknowledgment is m     a)    All b)    S     1. □ Certified     3. ⊠ Copies of     Intern * Certified copies not     Acknowledgment is m	DATE of this communication ROSECUTION ON THE MERD od), a Notice of Allowance (PTO Y IS NOT A GRANT OF PATE by the applicant. See 37 CFR a responsive to <u>18 August 2003</u> islare <u>1-10,15,16,18-20,28-30.3</u> <u>28 April 2003</u> are accepted by nade of a claim for foreign priori ome* c) $\Box$ None of the: copies of the priority documents (the certified copies of the priori ational Bureau (PCT Rule 17.2) received:	TS IS (OR TS IS (OR DL-85) or o I.313 and 32.34-38.4 The Exam ity under 3 s have be s have be rity docum (a)).	on the cover she REMAINS) CLOS other appropriate c <b>TS.</b> This application of MPEP 1308. <u>40 and 41</u> . siner. 35 U.S.C. § 119(a) an received. en received in App pents have been re	et with the co ED in this app ommunication on is subject to -(d) or (f). lication No ceived in this	prrespondence e blication. If not inc will be mailed in withdrawal from national stage app ional application)	ddress cluded due course. THIS issue at the initiative
a)  The translation Acknowledgment is m	of the foreign language provisi nade of a claim for domestic pro	ional appli ority unde	cation has been re r 35 U.S.C. §§ 120	and/or 121.	,	
cant has THREE MONT v. Failure to timely com	THS FROM THE "MAILING DA Iply will result in ABANDONME	TE" of this	application. THIS	o file a reply c S THREE-MO	omplying with the NTH PERIOD IS I	requirements noted NOT EXTENDABLE
) A SUBSTITUTE OAT IRMAL PATENT APPLI	H OR DECLARATION must be CATION (PTO-152) which give	e submitte es reason(	d. Note the attaches) why the oath or	ed EXAMINER declaration is	R'S AMENDMENT deficient.	or NOTICE OF
				1		
<ul> <li>(b) ] Including change</li> <li>(c) ] including change</li> <li>(c) ] including change</li> <li>(c) ] including change</li> <li>(c) I including c</li></ul>	es required by the proposed dra es required by the attached Exa s the application number (see 37 or INFORMATION about the ent regarding REQUIREMENT F lited (PTO-892) Patent Drawing Review (PTO-8 Statements (PTO-1449), Paper Regarding Requirement for Dep	awing corr aminer's A CFR 1.84( CGFR 1.84( F()R THE F()R THE P48) No. <u>21</u> . osit	ection filed mendment / Comr c)) should be writte of BIOLOGICAL DEPOSIT OF BIC 2[] No 4[] In 6[] E2 8[] E3 9[] O	, which has b nent or in the n on the drawi MATERIAL DLOGICAL MA DLOGICAL MA	een approved by Office action of Pa ngs in the front (no must be submitte TERIAL. al Patent Applicat pary (PTO-413), P endment/Commen ement of Reasons	the Examiner. aper No of the back) of ed. Note the don (PTO-152) aper No it s for Allowance
<ul> <li>(b) [] Including change</li> <li>(c) [] Including change</li> <li>tentifying Indicia such as ach sheet.</li> <li>] DEPOSIT OF and/c hed Examiner's comment (s)</li> <li>Notice of References C Notice of Draitperson's Information Disclosure is Examiner's Comment R of Biological Material</li> </ul>	es required by the proposed dra as required by the attached Exa a the application number (see 37 or INFORMATION about the ant regarding REQUIREMENT f lited (PTO-892) Patent Drawing Review (PTO-8 Statements (PTO-1449), Paper Regarding Requirement for Dep	awing corr aminer's A GFR 1.84( Geposit F()R THE P48) No. <u>21</u> . osit	ection filed mendment / Comr c)) should be writte of BIOLOGICAL DEPOSIT OF BIC 2[] No 4[] In 6[] E: 8[] E: 9[] O	, which has b nent or in the n on the drawi MATERIAL i bLOGICAL MA bLOGICAL MA bLOGICAL MA blogical market blogical inform caminer's Ame caminer's Stat ther	een approved by Office action of Pa ngs in the front (no must be submitte TERIAL. al Patent Applicate hary (PTO-413), P endment/Commen ement of Reasons	the Examiner. aper No of the back) of ed. Note the don (PTO-152) aper No it s for Allowance
b) [] Including change ic) [] Including change sentifying Indicia such as ach sheet. ] DEPOSIT OF and/o hed Examiner's comme chment(s) Notice of References C Notice of Drattperson's Information Disclosure is Examiner's Comment R of Biological Material	es required by the proposed dra as required by the attached Exa a the application number (see 37 or INFORMATION about the ont regarding REQUIREMENT f lited (PTO-892) Patent Drawing Review (PTO-8 Statements (PTO-1449), Paper Regarding Requirement for Dep	awing corr aminer's A GFR 1.84( Geposit F()R THE P48) No. <u>21</u> . osit	ection filed mendment / Comr c)) should be writte of BIOLOGICAL DEPOSIT OF BIC 2[] No 4[] In 6[] Es 8[] Es 9[] O	, which has b nent or in the n on the drawi MATERIAL i DLOGICAL MA DUCGICAL MA	een approved by Office action of Pa ngs in the front (no must be submitte TERIAL. al Patent Applicate hary (PTO-413), P endment/Commen ement of Reasons	the Examiner. aper No of the back) of ed. Note the tion (PTO-152) aper No it is for Allowance
(b) ] Including change (c) ] Including change dentifying Indicia such at ach sheet. ] DEPOSIT OF and/c hed Examiner's comme chment(s) Notice of References C Notice of References C Notice of Draitperson's Information Disclosure 3 Examiner's Comment R of Biological Material	es required by the proposed dra as required by the attached Exa as the application number (see 37 or INFORMATION about the ent regarding REQUIREMENT F lited (PTO-892) Patent Drawing Review (PTO-8 Statements (PTO-1449), Paper tegarding Requirement for Dep	awing corr aminer's A GFR 1.84( Geposit FOR THE 948) No. <u>21</u> . osit	ection filed mendment / Comr c)) should be writte of BIOLOGICAL DEPOSIT OF BIC 2[] Ni 4[] In 6[] Es 8[] Es 9[] O	, which has b nent or in the n on the drawi MATERIAL DUOGICAL MA DUOGICAL MA	een approved by Office action of Pa ngs in the front (no must be submitte TERIAL. al Patent Applicat hary (PTO-413), P andment/Commen ement of Reasons	the Examiner. aper No bt the back) of ed. Note the tion (PTO-152) aper No it is for Allowance Part of Paper No. 2
b) including change c) including change entifying Indicia such an ach sheet. ] DEPOSIT OF and/c hed Examinen's comme chment(s) Notice of References C Notice C Notice Of References C Notice C Notice Of References C Notice C Notic	es required by the proposed dra as required by the attached Exa as the application number (see 37 or INFORMATION about the ant regarding REQUIREMENT f lited (PTO-892) Patent Drawing Review (PTO-8 Statements (PTO-1449), Paper Regarding Requirement for Dep	awing corr aminer's A GFR 1.84( Geposit F()R THE P48) No. <u>21</u> . osit	ection filed mendment / Comr c)) should be writte of BIOLOGICAL DEPOSIT OF BIC 2[] No 4[] In 6[] Es 8[] Es 9[] O	, which has b nent or in the n on the drawi MATERIAL in DEOGICAL MA DEOGICAL MA	een approved by Office action of Pa ngs in the front (no must be submitte ATERIAL. al Patent Applicate hary (PTO-413), P andment/Commen ement of Reasons	the Examiner. aper No bt the back) of ed. Note the dion (PTO-152) aper No t s for Allowance Part of Paper No. 2
b)	es required by the proposed dra as required by the attached Exa as the application number (see 37 or INFORMATION about the ent regarding REQUIREMENT f lited (PTO-892) Patent Drawing Review (PTO-8 Statements (PTO-1449), Paper legarding Requirement for Dep	awing corr aminer's A CFR 1.84( CFR 1.84( F()R THE 948) No. <u>21</u> . osit	ection filed mendment / Comr c)) should be writte of BIOLOGICAL DEPOSIT OF BIC 2[] Na 4[] In 6[] E3 8[] E3 9[] O	, which has b ment or in the mon the drawi MATERIAL DUOGICAL MA DUCGICAL MA DUCGICAL MA DUCGICAL MA DUCGICAL MA DUCGICAL MA DUCGICAL MA DUCGICAL MA	een approved by Office action of Pa ngs in the front (no must be submitte TERIAL. al Patent Applicat hary (PTO-413), P andment/Commen ement of Reasons	the Examiner. aper No bt the back) of ed. Note the tion (PTO-152) aper No at s for Allowance Part of Paper No. 2
including change inclu	es required by the proposed dra as required by the attached Exa as the application number (see 37 or INFORMATION about the ent regarding REQUIREMENT F lited (PTO-892) Patent Drawing Review (PTO-8 Statements (PTO-1449), Paper tegarding Requirement for Dep	awing corr aminer's A GFR 1.84( Geposit FOR THE 948) No. <u>21</u> . osit	ection filed mendment / Comr c)) should be writte of BIOLOGICAL DEPOSIT OF BIC 2[] Ni 4[] In 6[] E3 8[] E3 9[] O	, which has b nent or in the n on the drawi MATERIAL DUOGICAL MA DUOGICAL MA DUCGICAL MA D	een approved by Office action of Pa ngs in the front (no must be submitte TERIAL. al Patent Applicat hary (PTO-413), P andment/Commen ement of Reasons	the Examiner. aper No bt the back) of ed. Note the tion (PTO-152) aper No it is for Allowance Part of Paper No. 2
including change including change entifying Indicia such an ch sheet. DEPOSIT OF and/c led Examiner's comment hment(s) Iotice of References C lotice of Draitperson's nformation Disclosure is isominer's Comment R f Biological Material stent and Trademark Office 37 (Rev 04-0:3)	es required by the proposed dra as required by the attached Exa as the application number (see 37 or INFORMATION about the ant regarding REQUIREMENT F lited (PTO-892) Patent Drawing Review (PTO-8 Statements (PTO-1449), Paper Regarding Requirement for Dep	awing corr aminer's A CFR 1.84( CGFR 1.84( F()R THE P48) No. <u>21</u> . osit	ection filed mendment / Comr c)) should be writte of BIOLOGICAL DEPOSIT OF BIC 2[] No 4[] In 6[] E3 8[] E3 9[] O	, which has b nent or in the n on the drawi MATERIAL MA DECOGICAL MA	een approved by Office action of Pa ngs in the front (no must be submitte ATERIAL. al Patent Applicate hary (PTO-413), P endment/Commen ement of Reasons	the Examiner. aper No bt the back) of ed. Note the tion (PTO-152) aper No it is for Allowance Part of Paper No. 2
including change including change including change antifying Indicia such an ch sheet. DEPOSIT OF and/c led Examiner's comment hment(s) Intice of Refurences C into of Draitperson's information Disclosure is information Disclosure is examiner's Comment R f Biological Material Jenti and Trademark Office 37 (Rev 04-4):3	es required by the proposed dra as required by the attached Exa as the application number (see 37 or INFORMATION about the ant regarding REQUIREMENT f lited (PTO-892) Patent Drawing Review (PTO-8 Statements (PTO-1449), Paper legarding Requirement for Dep	awing corr aminer's A CFR 1.84( CFR 1.84( FOR THE 948) No. <u>21</u> . osit	ection filed mendment / Comr c)) should be writte of BIOLOGICAL DEPOSIT OF BIC 2[] Na 4[] In 6[] Es 9[] O	, which has b ment or in the mon the drawi MATERIAL DUOGICAL MA DUCGICAL MA DUCGICAL MA DUCGICAL MA DUCGICAL MA DUCGICAL MA DUCGICAL MA DUCGICAL MA DUCGICAL MA	een approved by Office action of Pa ngs in the front (no must be submitte TERIAL. al Patent Applicate hary (PTO-413), P andment/Commen ement of Reasons	the Examiner. aper No bt the back) of ed. Note the tion (PTO-152) aper No t s for Allowance Part of Paper No. 2
b) hincluiding change incluiding change entifying indicia such au- ich sheet. DEPOSIT OF and/c ned Examiner's comme thment(s) Notice of References C Notice of Draitperson's information Disclosure is Examiner's Comment R if Biological Material alent and Tredemark Office L-37 (Rev. 04-03)	es required by the proposed dra as required by the attached Exa as the application number (see 37 or INFORMATION about the ent regarding REQUIREMENT F lited (PTO-892) Patent Drawing Review (PTO-8 Statements (PTO-1449), Paper tegarding Requirement for Dep	awing com aminer's A GFR 1.84( Geposit FOR THE 948) No. <u>21</u> . osit	ection filed mendment / Comr c)) should be writte of BIOLOGICAL DEPOSIT OF BIC 2[] Na 4[] In 6[] Es 8] Es 9[] O	, which has b nent or in the n on the drawi MATERIAL DUOGICAL MA DUOGICAL MA D	een approved by Office action of Pa ngs in the front (no must be submitte TERIAL. al Patent Applicate bary (PTO-413), P andment/Comment ement of Reasons	the Examiner. aper No bt the back) of ed. Note the tion (PTO-152) aper No it is for Allowance Part of Paper No. 2
b)   Including change including change includi	es required by the proposed dra es required by the attached Exa is the application number (see 37 or INFORMATION about the ent regarding REQUIREMENT F lited (PTO-892) Patent Drawing Review (PTO-8 Statements (PTO-1449), Paper Regarding Requirement for Dep	awing corr aminer's A CFR 1.84( CGFR 1.84( F()R THE P48) No. <u>21</u> . osit	ection filed mendment / Comr c)) should be writte of BIOLOGICAL DEPOSIT OF BIC 2[] No 4[] In 6[] E2 8[] E3 9[] O	, which has b nent or in the n on the drawi MATERIAL I DEOGICAL MA Detice of Inform terview Summ caminer's Ame caminer's State ther	een approved by Office action of Pa ngs in the front (no must be submitte ATERIAL. al Patent Applicate hary (PTO-413), P endment/Commen ement of Reasons	the Examiner. aper No bt the back) of ed. Note the tion (PTO-152) aper No it is for Allowance Part of Paper No. 2
b) including change c) including change lentifying Indicia such an ach sheet. ] DEPOSIT OF and/c hed Examiner's comme chment(s) Notice of References C Notice of Draitperson's Information Disclosure : Examiner's Comment R of Biological Material	es required by the proposed dra as required by the attached Exa as the application number (see 37 or INFORMATION about the ent regarding REQUIREMENT F lited (PTO-892) Patent Drawing Review (PTO-8 Statements (PTO-1449), Paper legarding Requirement for Dep	awing corr aminer's A GFR 1.84( FOR THE 948) No. <u>21</u> . osit	ection filed mendment / Comr c)) should be writte of BIOLOGICAL DEPOSIT OF BIC 2[] Na 4[] In 6[] E5 9[] O e of Allowability	, which has b ment or in the mon the drawi MATERIAL DUOGICAL MA DUCGICAL MA DU	een approved by Office action of Pa ngs in the front (no must be submitte TERIAL. al Patent Applicat hary (PTO-413), P andment/Commen ement of Reasons	the Examiner. aper No bt the back) of ed. Note the tion (PTO-152) aper No at s for Allowance Part of Paper No. 2
b) including change c) including change lentifying Indicia such an ach sheet. ] DEPOSIT OF and/c hed Examinen's comment chment(s) Notice of References C Notice of References C Notice of Drattperson's Information Disclosure Examiner's Comment R of Biological Material	es required by the proposed dra as required by the attached Exa as the application number (see 37 or INFORMATION about the ent regarding REQUIREMENT F lited (PTO-892) Patent Drawing Review (PTO-8 Statements (PTO-1449), Paper tegarding Requirement for Dep	awing com aminer's A GFR 1.84( GER 1.84( FOR THE 948) No. <u>21</u> . osit	ection filed mendment / Comr c)) should be writte of BIOLOGICAL DEPOSIT OF BIC 2[] Na 4[] In 6[] Es 8] Es 9[] O	, which has b nent or in the n on the drawi MATERIAL DUOGICAL MA DUOGICAL MA D	een approved by Office action of Pa ngs in the front (no must be submitte ATERIAL. al Patent Applicate hary (PTO-413), P andment/Commen ement of Reasons	the Examiner. aper No bt the back) of ed. Note the tion (PTO-152) aper No it is for Allowance Part of Paper No. 2
b)   including change including change including change including change including change including change including change ach sheet. ] DEPOSIT OF and/c index comment's comment chment(s) Notice of References C Notice O Notice O N	es required by the proposed dra as required by the attached Exa as the application number (see 37 or INFORMATION about the ent regarding REQUIREMENT F lited (PTO-892) Patent Drawing Review (PTO-8 Statements (PTO-1449), Paper Regarding Requirement for Dep	awing com aminer's A CFR 1.84( FOR 1.84( FOR THE 948) No. <u>21</u> . osit	ection filed mendment / Comr c)) should be writte of BIOLOGICAL DEPOSIT OF BIC 2[] Na 4[] In 6[] E3 9[] O	, which has b nent or in the n on the drawi MATERIAL I DLOGICAL MA DUCGICAL MA DUCGICAL MA DUCGICAL MA DUCGICAL MA DUCGICAL MA DUCGICAL MA DUCGICAL MA	een approved by Office action of Pa ngs in the front (no must be submitte TERIAL. al Patent Applicate hary (PTO-413), P endment/Commen ement of Reasons	the Examiner. aper No bt the back) of ad. Note the tion (PTO-152) aper No at s for Allowance Part of Paper No. 2
b)   including change including change lentifying Indicia such and ach sheet. DEPOSIT OF and/c hed Examiner's comment imment(s) Notice of References C Notice of Draitperson's nformation Disclosure is Examiner's Comment R of Biological Material bient and Tredemark Office L-37 (Rev. 04-03)	es required by the proposed dra as required by the attached Exa as the application number (see 37 or INFORMATION about the ant regarding REQUIREMENT F lited (PTO-892) Patent Drawing Review (PTO-8 Statements (PTO-1449), Paper tegarding Requirement for Dep	awing com aminer's A GFR 1.84( FOR THE 948) No. <u>21</u> . osit	ection filed mendment / Comr c)) should be writte of BIOLOGICAL DEPOSIT OF BIC 2 Na 4 In 6 Es 8 Es 9 O	, which has b nent or in the n on the drawi MATERIAL DUOGICAL MA DUOGICAL MA DUCGICAL MA D	een approved by Office action of Pa ngs in the front (no must be submitte ATERIAL. al Patent Applicate hary (PTO-413), P andment/Commen ement of Reasons	the Examiner. aper No bt the back) of ed. Note the tion (PTO-152) aper No it is for Allowance Part of Paper No. 2
b) including change including change entifying Indicia such an ich sheet. DEPOSIT OF and/c ned Examinen's comme ihment(s) lotice of References C lotice of Draitperson's information Disclosure i Examiner's Comment R if Biological Material elemented Tredement Office L-37 (Rev. 04-03)	es required by the proposed dra es required by the attached Exa a the application number (see 37 or INFORMATION about the ent regarding REQUIREMENT F lited (PTO-892) Patent Drawing Review (PTO-8 Statements (PTO-1449), Paper Regarding Requirement for Dep	awing corr aminer's A CFR 1.84( FOR THE 948) No. <u>21</u> . osit	ection filed mendment / Comr c)) should be writte of BIOLOGICAL DEPOSIT OF BIC 2[] Na 4[] In 6[] E3 8[] E3 9[] O	, which has b nent or in the n on the drawi MATERIAL I DLOGICAL MA DUCE of Inform terview Summ caminer's Stat ther	een approved by Office action of Pa ngs in the front (no must be submitte ATERIAL. al Patent Applicate hary (PTO-413), P endment/Commen ement of Reasons	the Examiner. aper No bt the back) of ad. Note the tion (PTO-152) aper No at s for Allowance Part of Paper No. 2
b)   including change including change including change including change including change ach sheet. ] DEPOSIT OF and/c hed Examiner's comment shment(s) Notice of References C Notice of Draitperson's nformation Disclosure Examiner's Comment R of Biological Material bient and Trademark Office L-37 (Rev. 04-03)	es required by the proposed dra as required by the attached Exa as the application number (see 37 or INFORMATION about the ant regarding REQUIREMENT F lited (PTO-892) Patent Drawing Review (PTO-8 Statements (PTO-1449), Paper tegarding Requirement for Dep	awing com aminer's A GFR 1.84( GER 1.84( FOR THE 948) No. <u>21</u> . osit	ection filed mendment / Comr c)) should be writte of BIOLOGICAL DEPOSIT OF BIC 2 Na 4 In 6 Ex 8 E 9 0 0	, which has b nent or in the n on the drawi MATERIAL DUOGICAL MA DUCGICAL MA D	een approved by Office action of Pa ngs in the front (no must be submitte ATERIAL. al Patent Applicate hary (PTO-413), P andment/Commen ement of Reasons	the Examiner. aper No bt the back} of ed. Note the tion (PTO-152) aper No it is for Allowance Part of Paper No. 2

Ŷ

÷

А.

Application/Control Number: 09/700,094 Art Unit: 1624

#### Response to Request for Continued Examination

The claims have not been amended. A supplemental Information Disclosure Statement has been submitted, citing one reference, US 6,313,132 B1 (Johannson et al).

This reference does not anticipate nor render obvious any of the instantly

claimed compounds, compositions, or method. Compounds of instant claim 1 cannot be constructed from the genus in the section headed "Summary of the Invention" in

Johannson et al. The cyclic diesters of the instant application and the dimeric

compounds claimed herein are not touched upon by Johansson et al either.

Claims 1-10,15,16,18-20,28-30,32,34-38,40 and 41 are allowed.

Conclusion

All Post-Allowance Correspondence concerning this application must be mailed

to:

Mail Stop Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Or you can fax them to the Office of Patent Publications at 703-308-5083, in order to expedite the handling of such correspondence as amendments under 37 CFR 1.312; information disclosure statements, and formal drawings. Sending Post-Allowance papers to Technology Center 1600 will only cause delays in matching papers with the case.

For information concerning status of correspondence sent after receipt of the Notice of Allowance, please contact the Correspondence Branch at (703) 305-8027. The Notice of Allowance also has an insert containing contact information on other items, including Issue Fees, receipt of formal drawings and the status of the application.

Mukund Shah Supervisory Patent Examiner Art Unit 1624

JOHN M. FORD PRIMARY EXAMINER GROUP - ART UNIT

	ted States Pate	nt and Trademark Office	UNITED STATES DEPARTMENT OF COMMERCE United States Potent and Trademark Office Address COMMISSIONER FOR PATENTS F O Box 1450
			Alculadra, Vingelis 22313-1450 www.uspio gov
•	NOTIC	E OF ALLOWANCE AND FEE(	S) DUE
2: 874 7:	i90 l 1/04/2003		EXAMINER
EDWARDS & A	NGELL, LLP	a na sa	TUCKER. ZACHARY C
BOSTON, MA 02:	209		ART UNIT PAPER NUMBER
		ал на селото на селот	1624
			DATE MAILED: 11/04/2003
			· · ·
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.   CONFIRMATION NO.

الأحب منبا له خف مسل عط

TITLE OF INVENTION NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES

01/02/2001

APP).N TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1330	\$0	\$1330	02/04/2004

Claus Mo

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSE(:UTION ON THE MERITS IS CLOSED</u>. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. <u>THIS</u> <u>STATUTORY PERIOD CANNOT BE EXTENDED</u>. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE RECARDED AS ABANDONED.

HOW TO REPLY TO THIS NOTICE:

09/700,094

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and 1/2 the ISSUE FEE shown above.

MBHB00-1121

1408

Applicant claims SMALL ENTITY status. Sec 37 CFR 1.27.

A. Pay TOTAL FEE(S) DUE shown above, or

If the SMALL ENTITY is shown as NO:

II. PART B - FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISS(JE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

Page 1 of 4

PTCL-85 (Rev. 10/03) Approved for use through 04/30/2004.

### PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail

	Mail Stop ISSUE FEE
	Commissioner for Patents
	P.O. Box 1450
	Alexandria Virginia 22313-1
~	"Lessenmental" + of Printie day 12-1.

		• •	or P	Alexandria, Vir ax (703) 746-4000	ginia 22313-1450	•
INSTRUCTIONS: This fa appropriate. All further co indicated unless corrected	orm should be used for tran prespondence including the l below or directed otherwise	smitting the ISSUE Patent, advance ord in Block I, by (a)	FEE and F ers and notif specifying a	UBLICATION FEE (if requires the correspondence address	ired). Blocks I through 4 s will be mailed to the current ; and/or (b) indicating a sep	hould be completed where correspondence address as arate "FEE ADDRESS" for
CURRENT CORRESPONDEN 2' 6.74 EDWARDS & A	nns. ICG ADDRESS (Note: Legibly mark-uj 7590 I 1/04/2003 ANGELL, LLP	p with any corrections or u	se Block 1)	Note: A certificate of Fee(9) Transmittal. Th papers, Each addition have its own certificat	f mailing can only be used f tis certificate cannot be used al paper, such as an assignm te of mailing or transmission.	or domestic mailings of the for any other accompanying ent or formal drawing, must
P.O. BOX 9169 BOSTON, MA 02	209			I hereby certify that it States Postal Service addressed to the Ma transmitted to the USI	his Fee(s) Transmittal is bein with sufficient postage for fin il Stop ISSUE FEE address PTO, on the date indicated be	g deposited with the United rst class mail in an envelope above, or being facsimile low.
				i v .		(Depositor's name)
					·	(Signature) (Date)
APPLICATION NO.	FILING DATE	F	IRST NAMED	INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
05?700,094 TITLE OF INVENTION: 1	01/02/2001 NOVEL DERIVATIVES OF	3,3-DIPHENYLPR	Claus I OPYLAMIN	Meese ES	MBHB00-1121	1408
APPLN. TYPE	SMALL ENTITY	ISSUE FE	B	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1330	······	\$0	\$1330	02/04/2004
EXA	MINER	ARTUNI	T T	CLASS-SUBCLASS	<b>-</b>	
TUCKER,	ZACHARYC	1624	ا م	514-175000	<b>.</b>	
I. Change of corresponder CFR 1.363)	ace address or Indication of "F	ec Address" (37	2 For prin names of agents OR	nting on the patent front page up to 3 registered patent t, alternatively, (2) the name	attorncys or }	······································
Address form PTO/SB/ "Fee Address" indice PTO/SII/47; Rev 03-02 Number is consulted	122) attached ation (or "Fee Address" Indica or more recent) attached. Us	ation form se of a Customer	firm (havi agont) and attorneys will be pri	ng as a member a registered the names of up to 2 regis or agents, If no name is liste nted.	attorney or 2 stered patent ed, no name 3	
PLEASI: NOTE Unle been previously submit (A) NAME OF ASSIG	ss en assignee is identified be ted to the USPTO or is being NEE	elow, no assignee da submitted under sep (B)	ta will apper arate cover. RESIDENC	ar on the patent. Inclusion of Completion of this form is NC 2: (CITY and STATE OR CC	assignee data is only appropr IT a substitute for filmg an as DUNTRY)	iate when an assignment has signment.
Please check the appropris	to assignce category or catego	ories (will not be pri	nted on the p	atent); : Oindividual O	corporation of other private j	group entity D government
4a. The following fee(s) as	re enclosed:	4b.	Payment of	Fcc(s):	nolored	
D Publication Fee			O Payment I	by credit card. Form PTO-203	8 is attached	· .
🗅 Advance Order - # d	of Copies		O The Dire	ctor is hereby authorized by o	charge the required fec(s), or (enclose an extra	r credit any overpayment, to copy of this form).
Director for Patents is requ	uested to apply the Issue Fee a	and Publication Fee	(if any) or to	re-apply any previously paid	issue fee to the application id	entified above.
(Authorized Signature)		(Date)				
NOTE: The Issue Fee a other than the applican interest as shown by the	and Publication Fee (if requi t; a registered attorney or a records of the United States F	red) will not be acc gent; or the assigne atent and Trademar	cepted from te or other p k Office.	anyone party in		
This collection of inform obtain or retain a benef application. Confidentia estimated to take 12 min completed application f case: Any comments o suggestions for reducing Patent and Trademark 22313-1430. DO NOT SEND TC: Commission	mation is required by 37 CFI it by the public which is to liny is governed by 35 U.S.C. nutes to complete, including ( orm to the USPTO. Time on the amount of time you g this burden, should be sen Office, U.S. Department SEND FRES OR COMPL er for Patents, Alexandria, Vi	R 1.311. The inform file (and by the US 122 and 37 CPR 1.1 gethering, preparing require to complet t to the Chief Inform of Commetce, A ETED FORMS TO Griginia 22313-1450;	nation is requ PTO to proce (4. This colled , and submitti upon the ind te this form nation Offici lexandria, N ) THIS ADI	aired to zes) an cition is ing the invidual and/or cr. U.S. Virgina DRESS.	й. 	
Under the Paperwork I collection of information	Reduction Act of 1995, no o unless at displays a valid OM	persons are requir AB control number.	ed to respon	nd to a		
PTOL-85 (Rev 10/03) A	pproved for use through 04/3	TRANS 0/2004.	MIT THIS F OMB 06	ORM WITH PEE(S) 51-0033 U.S. Patent and T	rademark Office, U.S. DEPA	RTMENT OF COMMERCE
	·				d.	
				•· · ·		
					•	
			<i>!</i> ;			
				•		
			•	2 <sup>2</sup> A 2		
			• • •	· .	• .	
•			t x			•

x e

			•	UNITED STATES DEPART United States Fairal and T Address: COMMISSIONER F( P.O Box 1450 Ale sendrie, Vergette 223 www.upto gov	IMENT OF COMMERCI Frademark Office DR PATENTS 13-1450
APPLICATION NO	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.	CONFIRMATION NO.
0%/700,094	01/02/2001	Claus Meese	. *.	MBHB00-1121	1408
21.374 75	90 11/04/2003			EXAM	INER
EDWARDS & A	NGELL, LLP			TUCKER, Z	ACHARYC
BOSTON, MA 022	09		: 1	· ART UNIT	PAPER NUMBER
,				1624	
				DATE MAILED: 11/04/200	3

#### Determination of Patent Term Extension under 35 U.S.C. 154 (b) (application filed after June 7, 1995 but prior to May 29, 2000)

The Patent Term Extension is 0 day(s). Any patent to issue from the above-identified application will include an indication of the 0 day extension on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Extension is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) system (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (703) 305-1383. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (703) 305-8283.

Page 3 of 4

PTOL 85 (Rev. 10/03) Approved for use through 04/30/2004.

-----

#### United States Patent and Trademark Office

			United States Patent and Address COMMISSIONER F P.O. Box 1450 Alexandria, Virginia 22: www.tapto.gov	Tredemerk Office OR PATENTS 113-1450
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO.
09/100,094	01/02/2001	Claus Moose	МВНВ00-1121	1408
2181-1	7590 11/04/2003		EXAN	INER
EDWARDS &	ANGELL, LLP		TUCKER, 2	ACHARY C
P.O. BOX 9169 BOSTON, MA 0	2209		ARTUNIT	PAPER NUMBER
			1624	
			DATE MAILED: 11/04/200	3

UNITED STATES DEPARTMENT OF COMMERCE

#### Notice of Fee Increase on October 1, 2003

a reply to a "Notice of Allowance and Fee(s) Due" is filed in the Office on or after October 1, 2003, then the count due will be higher than that set forth in the "Notice of Allowance and Fee(s) Due" since there will be an rease in fees effective on October 1, 2003. See Revision of Patent Fees for Fiscal Year 2004; Final Rule, 68 Fed. g. 41532, 41533, 41534 (July 14, 2003).

e current fee schedule is accessible from (http://www.uspto.gov/main/howtofees.htm).

the fee paid is the amount shown on the "Notice of Allowance and Fee(s) Due" but not the correct amount in view the fee increase, a "Notice of Pay Balance of Issue Fee" will be mailed to applicant. In order to avoid processing lays associated with mailing of a "Notice of Pay Balance of Issue Fee," if the response to the Notice of Allowance to be filed on or after October 1, 2003 (or mailed with a certificate of mailing on or after October 1, 2003), the ue fee paid should be the fee that is required at the time the fee is paid. If the issue fee was previously paid, and the ponse to the "Notice of Allowance and Fee(s) Due" includes a request to apply a previously-paid issue fee to the ue fee now due, then the difference between the issue fee amount at the time the response is filed and the eviously-paid issue fee should be paid. See Manual of Patent Examining Procedure, Section 1308.01 (Eighth ition, August 2001).

fective October 1, 2003, 37 CFR 1.18 is amended by revising paragraphs (a) through (c) to read as set forth below.

ction 1.18 Patent post allowance (including issue) fees.

Issue fee for issuing each original or reissue patent, ept a design or plant patent: By a small entity (Sec. 1.27(a)).......\$665.00 By other than a small entity......\$1,330.00 Issue fee for issuing a design patent: By a small entity (Sec. 1.27(a))......\$240.00 By other than a small entity......\$480.00 ssue fee for issuing a plant patent: Iy a small entity (Sec. 1.27(a)).......\$320.00 y other than a small entity......\$320.00 y other than a small entity......\$320.00

tions relating to issue and publication fee payments should be directed to the Customer Service Center of the e of Patent Publication at (703) 305-8283.

Page 4 of 4

(Rev. 10/03) Approved for use through 04/30/2004.

						B1#
81q		in the second				
Proctitioner's Docke	t No. <u>55647 (45107)</u>			the second	PATENT	
in el					·	
	THE UNITED STATES PAT	ENT AND TRAD	EMARK	OFFICE	· .	
in re application of:	Claus Meese	· , '				
Application No.:	09/700,094 Tuby 2: 2001	Grou	p No.:	1624 Tucker	Zaabam C	
1. 11001	<i>vuy 2, 2001</i>		illingi.	I ULKEI,	Zaciary C.	
For: NOV	EL DERIVATIVES OF 3,3	-DIPHENYLPRO	PYLAM	INES		
Commissioner for P	atents	· · ·		. ' '		
				•		
IP.O. Box 1450		1. I'				
P.O. Box 1450 Alexandria, Virginis MAIL STOP ISSUE	22313-1450 Fee		1			,
IP.O. Box 1450 Alexandria, Virginis MAIL STOP ISSUE TRANSI	22313-1450 Fee Atttal of payment of	ISSUE FEE (37 C	.F.R. SEC	CTION 1.	.311)	
P.O. Box 1450 Alexandria, Virginis MAIL STOP ISSUE TRANS! 1. Applicant hereby	a 22313-1450 FEE ATTTAL OF PAYMENT OF pays the issue fee for the attac	ISSUE FEE (37 C bed Issue Fee Trans	.F.R. SEC mittal PTC	CTION 1. OL-85.	311)	
P.O. Box 1450 Alexandria, Virginis MAIL STOP ISSUE TRANSM 1. Applicant hereby 2. Fee (37 C.F.R. se	a 22313-1450 FEE ATTTAL OF PAYMENT OF pays the issue fee for the attac ction 1.18(a) and (b)):	ISSUE FEE (37 C hed Issue Fee Trans	c.F.R. SEC smittal PTC	CTION 1. OL-85.	311)	
P.O. Box 1450 Alexandria, Virginis MAIL STOP ISSUE TRANSM 1. Applicant hereby 2. Fee (37 C.F.R. se Application statu	a 22313-1450 FEE AITTAL OF PAYMENT OF pays the issue fee for the attac ction 1.18(a) and (b)): s is:	ISSUE FEE (37 C hed Issue Fee Trans Regular	<b>C.F.R. SEC</b> mittal PTC	CTION 1. OL-85. Design	311)	
P.O. Box 1450 Alexandria, Virginis MAIL STOP ISSUE TRANSM 1. Applicant hereby 2. Fee (37 C.F.R. se Application statu [] small busined	a 22313-1450 FEE ATTTAL OF PAYMENT OF pays the issue fee for the attact ction 1.18(a) and (b)): s is: s entity fee	ISSUE FEE (37 C hed Issue Fee Trans Regular [ ] \$ 665.0	C.F.R. SEC mittal PTV	CTION 1. OL-85. Design ] \$240.00	311) )	·
<ul> <li>IP.O. Box 1450 Alexandria, Virginis MAIL STOP ISSUE TRANSM</li> <li>1. Applicant hereby</li> <li>2. Fee (37 C.F.R. se Application status [ ] small business</li> <li>[X] other than a</li> </ul>	a 22313-1450 FFEE ATTTAL OF PAYMENT OF pays the issue fee for the attact ction 1.18(a) and (b)): s is: ss entity foc small entity fee	ISSUE FEE (37 C hed Issue Fee Trans Regular [ ] \$ 665.0 [X ]\$1,330.0	2.F.R. SEC mittal PT 0 [ ]	CTION 1. OL-85. Design ] \$240.00 ] \$480.00	311) )	
<ul> <li>P.O. Box 1450 Alexandria, Virginis MAIL STOP ISSUE TRANSN </li> <li>1. Applicant hereby</li> <li>2. Fee (37 C.F.R. se Application status <ul> <li>[] small busines</li> <li>[X] other than a</li> </ul> 3. Publication fee</li></ul>	a 22313-1450 FEE ATTTAL OF PAYMENT OF pays the issue fee for the attact action 1.18(a) and (b)): s is: s entity foc small entity fee	ISSUE FEE (37 C hed Issue Fee Trans Regular [ ] \$ 665.0 [X ]\$1,330.0 [ ] \$ 300.00	2. <b>F.R. SE</b> ( mittal PT) 0 [ ]	CTION 1. OL-85. Design ] \$240.00 ] \$480.00	311) )	
<ul> <li>IP.O. Box 1450 Alexandria, Virginis IMAIL STOP ISSUE TRANSN <ol> <li>Applicant hereby</li> <li>Fee (37 C.F.R. se</li> <li>Application status</li> <li>small busines</li> <li>other than a</li> <li>Publication fee</li> </ol> </li> <li>Advanced order of</li> </ul>	A 22313-1450 FEE ATTTAL OF PAYMENT OF pays the issue fee for the attact ction 1.18(a) and (b)): s is: as entity fee small entity fee	ISSUE FEE (37 C hed Issue Fee Trans Regular [] \$ 665.0 [X] \$ 300.00 [X] \$ 30.00	C.F.R. SEC mittal PTV 0 [ ]	CTION 1. OL-85. Design ] \$240.00 ] \$480.00	<b>311</b> ) )	
<ul> <li>P.O. Box 1450</li> <li>Alexandria, Virginis</li> <li>MAIL STOP ISSUE</li> <li>TRANSI</li> <li>1. Applicant hereby</li> <li>2. Fee (37 C.F.R. se Application status</li> <li>[ ] small busines</li> <li>[X] other than a</li> <li>3. Publication fee</li> <li>4. Advanced order of</li> </ul>	A 22313-1450 FEE ATTTAL OF PAYMENT OF pays the issue fee for the attact ction 1.18(a) and (b)): s is: is entity fee small entity fee	ISSUE FEE (37 C hed Issue Fee Trans Regular [] \$ 665.0 [X] \$1,330.0 [] \$ 300.00 [X] \$ 30.00 [X] \$ 30.00	C.F.R. SEC smittal PTC 0 [ ] 0 [ ]	CTION 1. OL-85. Design ] \$240.00 ] \$480.00	.311) ) )	
<ul> <li>IP.O. Box 1450 Alexandria, Virginis IMAIL STOP ISSUE TRANSN <ol> <li>Applicant hereby</li> <li>Fee (37 C.F.R. se</li> <li>Application statu</li> <li>small busines</li> <li>other than a</li> <li>Publication fee</li> <li>Advanced order of</li> </ol></li></ul>	A 22313-1450 FFEE ATTTAL OF PAYMENT OF pays the issue fee for the attact ction 1.18(a) and (b)): s is: ss entity fee small entity fee	ISSUE FEE (37 C         hed Issue Fee Trans         Regular         [] \$ 665.0         [X] \$ 300.00         [X] \$ 30.00         Total Fee Enclose	2.F.R. SEC mittal PT 0 [ ] 0 [ ] 1 3 4 1	CTION 1. OL-85. Design ] \$240.00 ] \$480.00	.311) ) )	·

ŀ

ŀ

MAILING

deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, MAIL STOP ISSUE FEE. ж

FACSIMILE

transmitted by facsimile to the Patent and Trademark Office. ۵

U а. j) Signature

Date: \_\_\_\_lanuary 26, 2004

.

Elena Misi (type or print name of person certifying)

(Transmittal of Payment of Issue Fee-page 1 of 2)

z,

.

#### 5. Payment of fee:

[X] Enclosed please find a check in the amount of 5\_1,360.00\_\_\_\_

[X] Charge Account \_\_\_\_\_04-1105\_\_\_\_\_ for any fee deficiency.

[] Charge Account \_\_\_\_\_\_ the sum of \$\_\_\_\_\_

A duplicate of this request is attached,

.c.h Ch SIGNATURE OF PRACTITIONER

Reg. No. 38,256

•

Tel. No. (617) 439-4444

Customer No. 21874

Christine C. O'Day (type or print name of practitioner)

EDWARDS & ANGELL, LLP P.O. Box 55874 P.O. Address

Boston, Massachusetts 02205

-page 2 of 2)

PART B - FEE(S) TRANSMITTAL         appletu and send this form, together with applicable fee(s), to: Mail       Mail Stop ISSUE FEE C munical mer f P Istants         P.O. B 21 1450       Atsandirts, Virginia 22313-1459         PART B - FEE(S) TRANSMITTAL       FEE C munical mer f P Istants         P.O. B 20 1450       Atsandirts, Virginia 22313-1459         P.O. B 20 1450       C (703) 746-4000         RUMCTIONS, The form should be used for meaning the form formating the form of the first of the stand otherwise in Block 1, by (a) specifying a more consequences and/or (b) inducting a maximum for and/or form of the stand otherwise in Block 1, by (a) specifying a more consequences and/or (b) inducting a maximum for and/or form of the stand otherwise in Block 1, by (a) specifying a more consequences and/or form of the stand otherwise in Block 1, by (a) specifying a more consequences and/or form of the stand otherwise in Block 1, by (a) specifying a more consequences and/or form of the stand otherwise in Block 1, by (a) specifying a more consequences and/or form of the stand otherwise in Block 1, by (b) specifying a more consequences and/or form of the stand otherwise in Block 1, by (a) specifying a more consequences and/or form of the stand otherwise in Block 1, by (b) specifying a more consequences and block 1, by (b) indication barry constrained otherwise and barry constrained	be completed where monitories address as "FEE ADDRESS" for inscript shallings of face to other accompanying "formal drawing, musi- motion with the United as mail is as gevelope w, or being faceimate (Commert amer) (Commert amer) (Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert Commert
PART B - FEE(S) TRANSMITTAL Mail Step ISSUE FEE C mmissi nor f / Patants F.O. B z 1450 Abstanding, Virginia 22313-1459 F.O. B z 1450 Abstanding, Virginia 22313-1459 FEQCTIONS: The form should be used for transmitting the ISSUE FEE and FURICATION FEE (dress of the should be about a second for transmitting the ISSUE FEE and FURICATION FEE (dress of the should be about a second for transmitting the ISSUE FEE and FURICATION FEE (dress of the should be about a second for transmitting the ISSUE FEE and FURICATION FEE (dress of the should be about a second for transmitting the ISSUE FEE and FURICATION FEE (dress of the should be about a second for the should be about a second for the should be about a second for the should be about a second	be completed where monitors address as FEE ADDRESS for metic mailings of fac y other accompanying formal drawing, musi- man control with the United as mailing as asymptote (Dapaster's ame) (Dapaster's
C an mission and the series of Palenets C. B. 21459 C. B. 2145 C. B. 2145 C. C. B. 2145 C. C. B. 2145	be completed where mendance address as "FEE ADDRESS" for metric analities of fue y other scompanying "formal drawing, musi mained with the United as wall in as gevelope w, or being factories (Commer amer) (Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer Commer
RECENTIONS: The form should be used for transmitting the ISSUE FEE and FUELCATION FEE (// mealer.), Blocks 1 through 4 should be used for transmitting the ISSUE FEE and FUELCATION FEE (// mealer.), Blocks 1 through 4 should be used for the process as monitored below or dimeted on the process as monitored below.         REFERENCE       FILE CATEON FEE (// mealer.), Blocks 1 through 4 should be used for the process as monitored below.         REFERENCE       FILE CATEON FEE (// mealer.), Blocks 1 through 4 should be used for the process as monitored below.         REFERENCE       FILE CATEON FEE (// mealer.), Blocks 1 through 4 should be used for the process as monitored below.         REFERENCE       FILE CATEON FEE (// mealer.), Blocks 1 through 4 should be used for the process as monitored below.         REFERENCE       FILE CATEON FEE (// meaning) are transmitted to a standard below.         REFERENCE       FILE CATEON FEE (// meaning) are transmitted to a standard below.         REFERENCE       FILE CATEON FEE (// meaning) are transmitted to a standard below.         REFERENCE       FILE CATEON FEE (// meaning) are transmitted to a standard below.         REFERENCE       FILE CATEON FEE (// meaning) are transmitted to a standard below.         REFERENCE       FILE CATEON FEE (// meaning) are transmitted to a standard below.         REFERENCE       FILE CATEON FEE (// meaning) are transmitted to a standard below.         REFERENCE       FILE CATEON FEE (// meaning) are transmitted to a standard below.         REFERENCE       FILE CA	be completed where mendence address as FEE ADDRESS' for metic malines of fac ty other accompanying formal drawing, musi an menden mendence (Computer's anew) (Computer's anew)
RUCTIONS: The form about to used for presenting the ISSUE FEE and PUBLICATION FEE (# mainted). Block 1 through 4 should be used for an enternance for additioned of the former of the should be used for an enternance for additioned of the former of the should be used for a single former of the should be used for a single former of the should be used for a single former of the should be used for a single former of the should be used for a single former of the should be used for a single former of the should be used for a single former of the should be used for a single former of the should be used for a single former of the should be used for a single former of the should be	be completed where semandance address as FEE ADDRESS" for mestic mailings of flo ty other accompanying Permal drawing, must imm oriend with the United en mail in a sevelope we, or bring facimite (Depender's new) (Dipender's new) (Dipe
APPLIA. TYPE SMALL ENTITY ESUE FEE MULLCATION FEE TOTAL FEE(S) DUR APPLIA. TYPE SMALL ENTITY ESUE FEE MULLCATION FEE TOTAL FEE(S) DUR APPLIA. TYPE SMALL ENTITY ESUE FEE MULLCATION FEE TOTAL FEE(S) DUR APPLIA. TYPE SMALL ENTITY ESUE FEE MULLCATION FEE TOTAL FEE(S) DUR APPLIA. TYPE SMALL ENTITY ESUE FEE MULLCATION FEE TOTAL FEE(S) DUR APPLIA. TYPE SMALL ENTITY ESUE FEE MULLCATION FEE TOTAL FEE(S) DUR APPLIA. TYPE SMALL ENTITY ESUE FEE MULLCATION FEE TOTAL FEE(S) DUR APPLIA. TYPE SMALL ENTITY ESUE FEE MULLCATION FEE TOTAL FEE(S) DUR APPLIA. TYPE SMALL ENTITY ESUE FEE MULLCATION FEE TOTAL FEE(S) DUR SIGN OF TRANSMENT OF THE ADDRESS OF CORRESPONDENCE TUCKER, ZACHARY C 1624 S14-175000 SIGN OF TOTAL FEE(S) DUR SIGN OF THE ADDRESS OF CORRESPONDENCE OF THE ADDRESS OF TOTAL FEE(S) DUR SIGN OF THE ADDRESS OF INSTEADOR. TO BE FRINTED ON THE PATENTY (when or type)	Instic mailings of flo ty other accompanying Formal drawing, must imported with the United so mail in an eavelope w, or being faceimile (Depender's amo) (Depender's am
2111/4       7560       1100/2000         DW ARDS & ANGELL, LLP       DW ARDS & ANGELL, LLP       DW ARDS & ANGELL, LLP         D. BOX 9169       DSTIDN, MA 02209       DW 2 8 20% model         DW ARDS & ANGELL, LLP       DW 2 8 20% model       Certificate of Mailing or Treasmission.         DW ARDS & ANGELL, LLP       DW 2 8 20% model       Certificate of Mailing or Treasmission.         DSTIDN, MA 02209       DW 2 8 20% model       Certificate of Mailing or Treasmission.         PLIC/, TION NO.       FULINO DATE       FUEST NAMED DIVENTOR.       ATTORNEY DOCKST NO.       C         PRUS, TION NO.       FUENO DATE       FUEST NAMED DIVENTOR.       ATTORNEY DOCKST NO.       C         OF 11/2 LOOY       FUENO DATE       FUEST NAMED DIVENTOR.       ATTORNEY DOCKST NO.       C         OF 11/2 LOOY       0.002/2001       Claus Moree       MBHB00-1121       C         OF 11/VENTION: NOVEL DERIVATIVES OF 3.3-DIPHENYLPROPYLAMINES       TOTAL FEE(s) DUR       MBHB00-1121         APPLUS, TYPE       SMALL ENTITY       ISSUE FEE       MIBLCATION FEE       TOTAL FEE(s) DUR         APPLUS, TYPE       SMALL ENTITY       ISSUE FEE       MIBLCATION FEE       TOTAL FEE(s) DUR         APPLUS, TYPE       SMALL ENTITY       ISSUE FEE       MIBLCATION FEE       TOTAL FEE(s) DUR	Permai drawing, musi les opined with the United as mail in as gevelope (Commert amer) (Commert amer) (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert (Commert
DWARDS & ANGELL, LLP       O. BOX 9169         O. BOX 9169       O. BOX 9169         OSTIDN, MA 02209       WILL 2 8 20%         WILL 2 8 20%       Image: State Fortal Enviro. with site Feel Presents of first of State Sta	Consisted with the United an anall in an envelope we, or being decimils (Consister amor) (Consister (Consister amor) (Consister (Consister amor) (Consister (Consister amor) (Consister amor) (Consiste
OSTIDN, MA 02209       IM 7 6 624       edimend to the Med Scop HSUE FEE edimend below.         Eleman Mislasse K.       Eleman Mislasse K.         ILC.TION NO.       FILMO DATE       FILM NAMED DIVENTOR         MALECATION NO.       FILMO DATE       FILM NAMED DIVENTOR         MALECATION NO.       FILMO DATE       FILM NAMED DIVENTOR         MALECATION NO.       FILMO DATE       FILM NAMED DIVENTOR         09/700,094       01/02/2001       Claus Messe         09/700,094       01/02/2001       Claus Messe         APPRINT TYPE       SMALL ENTERY       ISSUE FEE         EXAMINER       ART UNIT       CLASS-SUBCLASS         TUCKER, ZACHARY C       IG24       SI4-175000         Insoli       ISSUE FEE of Address (or Change of Correspondence dates form (Dates Istormy or ageas) and the ases of a poits astormy or ageas) and the a	Companies score) (Companies sco
PELCATION NO.       FILENO DATE       FIRST NAMED DIVENTOR       ATTORNEY DOCKST NO.       C         09/700,094       01/02/2001       Claus Mosse       MBHB00-1121         000 F11/VENTION: NOVEL DERIVATIVES OF 3.3-DIPHENYLPROPYLAMINES       TOTAL FEE(8) DUR       APPLIA. TYPE         APPLIA. TYPE       SMALL ENTITY       ESSUE FEE       PUBLICATION FEE       TOTAL FEE(8) DUR         APPLIA. TYPE       SMALL ENTITY       ESSUE FEE       PUBLICATION FEE       TOTAL FEE(8) DUR         APPLIA. TYPE       SMALL ENTITY       ESSUE FEE       PUBLICATION FEE       TOTAL FEE(8) DUR         APPLIA. TYPE       SMALL ENTITY       ESSUE FEE       PUBLICATION FEE       TOTAL FEE(8) DUR         APPLIA. TYPE       SMALL ENTITY       ESSUE FEE       PUBLICATION FEE       TOTAL FEE(8) DUR         APPLIA. TYPE       SIGNOR       SIGNOR       SIGNOR       SIGNOR       SIGNOR       SIGNOR         Charge of correspondence address or indication of "Fee Address" (37 (350)       SIGNOR       SIGNOR       SIGNOR       SIGNOR       SIGNOR       SI	CRUMENT CDure DATE DURE 02/04/2004 & Angell, LLP
I do 0 01         PLICATION NO.       FILENG DATE       FIRST NAMED DIVENTOR       ATTORNEY DOCKET NO.       C         09/700,094       01/02/2001       Claus Moose       MBHB00-1121         OF 11/VENTION: NOVEL DERIVATIVES OF 3,3-DIPHENYL/PROPYLAMINES       MUBLICATION FEB       TOTAL FEE(5) DUR         AFFUNT. TYPE       SMALL ENTITY       ISSUE FEB       MUBLICATION FEB       TOTAL FEE(5) DUR         Despirovisional       NO       \$1330       S0       \$1330         EXAMINER       ART UNIT       CLASS-SUBCLASS       100         TUCKER, ZACHARY C       1624       \$14-175000       1         TUCKER, ZACHARY C       1624       \$14-175000       1         TRE of Correspondence address or indication of "Fee Address" (37 NSI/17, Rev 01-02 er enory escent) stitched.       2. For printing ce de patent front page, list (1) the armes of up to 3 registered patent atorneys or agents atorneys or agents of up to 2 registered patent atorneys or agents different will be printed.       1         YELY 7, Rev 01-02 er enory encently stitched.       Use of a Customerr will be printed.       1       Chr1st1         YELY 7, Rev 01-02 er enory encently stitched.       Use of a Customerr will be printed.       1       Chr1st1         YELY 1, Rev 01-02 er enory encently stitched.       Use of a Customerr will be printed.       1       Chr1st1	DATE DUE 02/04/2004
09/700,094       01/02/2001       Claus Mosee       MBHB00-1121         OF INVENTION: NOVEL DERIVATIVES OF 3.3-DIPHENYLPROPYLAMINES       MBHB00-1121         APPLIN. TYPE       SMALL ENTITY       ISSUE FEE       MUBL/CATION FEE       TOTAL FEE(S) DUR         APPLIN. TYPE       SMALL ENTITY       ISSUE FEE       MUBL/CATION FEE       TOTAL FEE(S) DUR         Deenprovisional       NO       \$1130       SO       \$1330         EXAMINER       ART UNIT       CLASS-SUBCLASS       TUCKER, ZACHARY C       1624       \$14-175000         TUCKER, ZACHARY C       1624       \$14-175000       Image of correspondence address or indication of "Fee Address" (37       2. For printing on the partest front page, list (1) the names of up to 3 registered patters attorneys or a gents of up to 3 registered patters attorneys or a gents of up to 3 registered patters attorneys or a gents of up to 2 registered patters attorneys or a gents of up to 2 registered patters attorneys or agents of up to 2 registered patters attorneys or agents, lif no name is listed, in any of Christ 1         YELOY T Stard 7. Kar 00-002       The and include of Correspondence address" Indication form MEE of the partest of up to 2 registered patters attorney or agents of up to 2 registered patters       1         PET OF Address" Indication form MEE of the partest of up to 2 registered patters       1       Christ 1         YELOY T Boo address attracted to a gents of up to 2 registered patters       1       Christ 1	1408 DATE DUE 02/04/2004 & Angell, LLP
OF INVENTION: NOVEL DERIVATIVES OF 3.3-DIPHENYLPROPYLAMINES         AFFILM: TYPE       SMALL ENTITY       ISSUE FEE       MUBLICATION FEE       TOTAL FEE(5) DUR         Image of correspondence address or indication of "Fee Address" (37       CLASS-SUBCLASS       S1330       S0       S1330         EXAMINER       ART UNIT       CLASS-SUBCLASS       S14-175000         gen of correspondence address or indication of "Fee Address" (37       2. For printing on the passes front page, list (1) the names of up to 3 traphtered passes anormays or agents of up to 3 traphtered passes anormays or agents of up to 3 traphtered passes anormays or agents of up to 3 traphtered passes anormays or agents of up to 3 traphtered passes anormays or agents of up to 3 traphtered passes anormays or agents of up to 3 traphtered passes anormays or agents of up to 3 traphtered passes anormays or agents of up to 3 traphtered passes anormays or agents of up to 3 traphtered passes anormays or agents of up to 2 registered passes anormays or agents of up to 2 registered passes anormays or agents of up to 2 registered passes anormays or agents of up to 2 registered passes anormays or agents of up to 2 registered passes anormays or agents of up to 2 registered passes (or Change of Correspondence of up to 3 traphtered passes anormays or agents of up to 2 registered passes (or Change of Correspondence of up to 3 traphtered passes anormays or agents of up to 2 registered passes (or Change of Correspondence of up to 3 traphtered passes (or Change of Correspondence of up to 3 traphtered passes (or Change of Correspondence of up to 3 traphtered passes (or the passes of up to 2 registered passes (or the passes of up to 2 registered passes (or the passes) (or the passes of up to 2 registered passes)       1 <td>DATE DUE 12/04/2004 &amp; Angell, LLP</td>	DATE DUE 12/04/2004 & Angell, LLP
APPLIA. TYPE       SMALL ENTITY       ISSUE FEE       PUBLICATION FEB       TOTAL FEE(s) DUR         nemp(syvisional       NO       \$1330       SO       \$1330         EXAMENER       ART UNIT       CLASS-SUBCLASS         TUCKER, ZACHARY C       1624       \$14-175000         ge of correspondence address or indication of "Fee Address" ()?       2. For priming on the passes front page, list (1) the names of up to 3 registered passes acomeys or agents. OR, absensatively, (2) the same of a single form PTOSEN122) attached.       1         Fee Address" indication form NEH' IS registered.       gents coll on the sames of up to 2 registered passes acomeys or agents, lif no same is listed, to same is listed, to same will be privide.       1         IGNIIE NAME AND RESIDENCE DATA TO BE FRINTED ON THE FATENT (print or type)       1       Chr 1 St 1	DATE DUE 12/04/2094 & Angell, LLP
Contract of the second seco	02/04/2004
EXAMINER     ART UNIT     CLASS-SUBCLASS       TUCKER, ZACHARY C     1624     \$14-175000       Age of correspondence address or indication of "Fee Address" (37 (363).     2. For printing on the patent front page, list (1) the names of up to 3 registered patent and the sames of up to 3 registered stormy or agents OK, abernatively, (2) the same of single from (daving as a member a registered stormy or agent) and the sames of up to 2 registered patent atorneys or agents. If no name is listed, to name will be printed.     1     Edwards       URNIER     Intervent     Intervent     1     Edwards       The same of up to 3 registered patent and agents OK, abernatively, (2) the same of single from (baving us a member a registered stormy or agent) and the sames of up to 2 registered patent atorneys or agents. If no name is listed, to name will be printed.     1       IGNIE NAME AND RESIDENCE DATA TO BE PRINTED ON THE FATENT (print or type)	& Angell, LLP
Index       Index <td< td=""><td>&amp; Angell, LLP</td></td<>	& Angell, LLP
sample of correspondence address (or Change of Correspondence trans form FTO/SB/122) attached.       names of up to 3 registered patent anormeys or agents OR, abrassively, (2) the same of a single firm (baving as a member a registered stormey or agent) and the sames of up to 2 registered patent atomneys or agents. If no same is listed, to same will be printed.       1 EdWaTda         Splits       2 Peter I (norm storm stormey member)       2 Peter I (norm stormey stormey member)         Splits       Rev 0.902       registered patent atomneys or agents. If no same is listed, to same will be printed.         IGNIE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)	a WIRETT TTL
en Address' indication (or IFec Address' Indication form SEL47, Rev 03-02 er unory recent) stached. Use of a Cestomer ther is required. GNIE NAME AND RESIDENCE DATA TO BE FRINTED ON THE FATENT (print or type)	. Corless
ber is required. will us primus. 3NILE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (prim or type)	ne C. O'Day
anne i an anna anna anna bainn ta an cumuna du cum cumun finana. Abh	
r for Patrins is requested to apply the lasue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application Identify (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date) (Date	icd above. 0094 1338, 00 199 30, 00 199
t aud Trademati Office, U.S. Department of Commerce. Alexandrin, Virginia 3-14:00 NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. DTC: Commissioner for Parana, Alexandria, Virginia 22313-1430.	
the: Paperwork Reduction Act of 1995, no persons are required to respond to a tion of information unless it displays a valid OMB control number.	
TRANSMIT THIS FORM WITH FEE(S) 5 (Rev. 10/03) Approved for use through 04/20/2004. OMB 0651-0033 U.S. Primt and Trademark Office; U.S. DEPARTI	IENT OF COMMERCE
	•
	•
	•

ŀ

•			Fije
	OIP.		И., (
(	· · · · · · · · · · · · · · · · · · ·	Docket No. 55647 (45107)	FAY
IN TH	E UNEFERSITATES PA	TENT AND TRADEMARK OFFICE	Ch
APPLICANT:	C. Meese et al.		2-1804
SERIAL NO.:	09/700.094	GROIP: 1624	
FILED:	January 2, 2001	EXAMINER: Z. Tucker	
FOR:	NOVEL DERIVATIV	ES OF 3.3-DIPHENYLPROPYLAMINES	
Commissioner for )	Patents and Trademarks		
Washington, D.C. 2	0231	•	
SIR:	•		
	CHANGE OF ATTORNE	Y'S ADDRESS IN APPLICATION	
VOTE: Section 601.	03 (Change of Correspondence Ada	iress ), M.P.E.P., 7th Edition states:	
*Where an c	uttorney or agent of record (or app	licant, if he or she is prosecuting the application pro se) changes his or	
her correspo corresponde	mdence address, he or she is respon ince address (including ZiP cod	usible for promptly notifying the Patent and Trademark Office of the new ie number). The notification should also include his or her telephone	
number. A ( Section 405)	thange of correspondence address	may not be signed by an attorney or agent not of record (see MPEP	
"Unless the	correspondence address is design	rated as the address associated with a Customer Number, a separate	
notification	must be filed in each application fa Section 401 for Customer Number	r which a person is intended to receive communications from the Office.	
address of	a registered attorney or agent is	necessary in a plurality of applications, the notification filed in each	
· · · · · · · · · · · · · · · · · · ·	CERTIFICATE OF MAILING	FRANSMISSION (37 C.F.R. Section 1.4(a))	
hereby certify that, on t	he date shown below, this correspo	ondence is being:	
;	MAILING	FACSIMILE	
X] deposited with	the United States Postal Service	() transmitted by facsimile to the Patent and Trad-much Office (702), 746 3176	
cavelope addr	cost to the Commissioner for		
20231.	sociality, wasnington, D.C.	Elson Minister	
		Signature	, · ·
Date:1/26/04		Eiraa Miniaazek	
		(type or print name of person certifying)	
		Comingo or unouted a Vooress in ubburenon-befort of sh	
		· ·	
		, ,	
	-	· ·	
		2 <sup>.</sup>	

£ .

 $\{ \ldots \}_{i \in \mathbb{N}}$ 

Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0314

application may be a reproduction of a property executed, original notification. The original notice may either be sent to the Office of Enrollment and Discipline as notification to the Attorney's Roster of the change of address, or may be filed in one of the applications affected, provided that the notice buckdes an authorization for the public to inspect and copy the original notice in the event one of the applications containing a copy matures into a patent and the application containing the original paper is either pending or has become abandoned. Alternatively, the paper containing the original signature may be retained by applicant. See MPEP Section 502.02. The copies submitted in each affected application must identify where the original paper is located.

"Special care should be taken in continuation or divisional applications to ensure that any change of correspondence address in a prior application is reflected in the continuation or divisional application. For example, where a copy of the oath or declaration from the prior application is submitted for a continuation or divisional application filed under 37 CFR 1.53(b) and the copy of the oath or declaration from the prior application designates an old correspondence address, the Office may not recognize, in the continuation or divisional application, the change of correspondence address made during the prosecution of the prior application. Applicant is required to identify the change of correspondence address in the continuation or divisional application to ensure that communications from the Office are mailed to the current correspondence caddress, 37 CFR 1.63(d)(4).

"See MPEP Section 711.03(c) for presentent of petitions to revive applications abandoned as a consequence of failure to timely receive an Office action addressed to the old correspondence address.

"The required natification of change of correspondence address need take no particular form. However, it should be provided in a manner calling attention to the fact that a change of address is being made. Thus, the mere inclusion, in a paper being filed for another purpose, of an address which is different from the previously provided carrespondence address, without mention of the fact that an address change is being made would not ordinarily be recognized or deemed as instructions to change the correspondence address on the file record."

Please send all correspondence for this application as follows:

Peter F. Corless EDWARDS & ANGELL, LLP P.O. Box 55874 Boston, MA 02205

Please direct telephone calls to:

 Peter F. Corless or Christine C. O'Day

 Tel:
 (617) 439-4444

 Fax:
 (617) 439-4170

SIGNATURE OF PRACTITIONER

Reg. No. 38,256

Tel. No. (617) 439-4444

Customer No. 21874

Christing C. O'Day (type or print name of practilioner)

Edwards & Angell, LLP P.O. Box 55874 P.O. Address

Boston Massachusetts 02205

(Change of Attorney's Address in Application-page 2 of 2)

Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0315

OIPE 6	5713'64		i
(SEP 0 1 2005 8	COM	PLETESS	
A MADEMATH OF	U.S. DEPARTMENT C PATENT AND TRADE	OF COMMERCE EMARK OFFICE	
TRANSMITTAL LE	TTER	Docket Number: MBHB00-1121 (New Atty. Docket No.:	12961/46101)
Application Number 09/700,094	Filing Date January 02, 2001	Examiner Zachary C. TUCKER	Art Umt 1624
Patent Number 6,713,464	Issue Date March 30, 2004		
Invention Title NOVEL DERIVATIVI 3,3-DIPHENYLPROP	ES OF YLAMINES	Inventor(s) Claus MEESE et al.	
Address to:	,	I hereby certify that this correspondence is being	deposited with the

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

United States Postal Service with sufficient in an envelope addressed to. Commissioner as first class mail ssioner for Patents, P.O. Box 1450, dria, VA 22313-1450 or Alexan 2005 AU GUST 29

Sir:

Transmitted herewith for filing in the above-identified patent application is a Power of Attorney by Assignee of Entire Interest (Revocation of Prior Powers and Appointment of New Power) and 3.73(b) statement. Please note that two (2) copies are being submitted, each signed by separate authorized representatives of the assignee.

Please record the Power and change of address in the above application.

In addition, please change the Attorney Docket Number for the above-identified patent application from "MBHB00-1121" to -- 12961/46101 --.

By:

Dated: AVGUST 29,2005

Compla

Joseph A. Coppola (Reg. No. 38,413)

KENYON & KENYON One Broadway New York, N.Y. 10004 (212) 425-7200 (telephone) (212) 425-5288 (facsimile) Customer No. 26646

NY01 1036084 v1

SEP 01	2005 8			
	k.	U.S. DEPARTMENT OF	COMMERCE	,
A There a	A C	PATENT AND TRADEN	ARK OFFICE	
TADEM	<b>REVOCATION O</b>	F PRIOR POWER	Docket Number:	
	OF ATTORNEY	and APPOINTMENT	12961/46101	
	ASSIGNEE and 3.	.73(b) STATEMENT		
	Application Number:	Filing Date:		
	09/700,094	January 02, 2001		
	Patent Number:	Issue Date:	·	
	6,713,464	March 30, 2004		
	Invention Title: NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES		Inventor(s):	
			Claus MEESE et al.	

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

SIR:

OIP

SEP

SCHWARZ PHARMA AG, as assignee of the entire interest of the above-identified patent by virtue of executed assignments as indicated below, hereby revokes all powers of attorney previously given and appoints Bradford Paul Schmidt, Reg. No. 42,128, and the practitioners associated with Kenyon & Kenyon's customer number:

#### 26646

to prosecute and transact all business in the Patent and Trademark Office connected therewith.

SCHWARZ PHARMA AG, is the assignee of the entire right, title and interest in U.S. Patent Application Serial No. 09/700,094 filed on January 02, 2001, now U.S. Patent No. 6,713,464 issued on March 30, 2004 by virtue of the following assignment of title from the inventor(s) to the current assignee as shown below:

1. From: Claus Meese, and

From: Bengt Sparf

To: Schwarz Pharma AG

The document was recorded on January 11, 2001 in the United States Patent and Trademark Office at Reel 011443, Frame 0478.

NYO1 1030397 v1

Please send all correspondence and direct telephone calls to:

į.

Jeffrey Ginsberg, Esq.

Kenyon & Kenyon One Broadway New York, NY 10004 Customer No: 26646

By:

Name:

Title:

2

The undersigned are authorized to act on behalf of the assignee:

Į

Date: August 22, 2005

Date:

SCHWARZ PHARMA AG By:

Name: Klaus Veitinger, MD

Title: Executive Board Member, Schwarz Pharma AG

SCHWARZ PHARMA AG

5	
X	

ų				
Å	U.S. DEPARTMENT OF COMMERCE			
7		PATENT AND TRADEN	AARK OFFICE	
REVOCATION		F PRIOR POWER	Docket Number: 12961/46101	
	OF ATTORNEY and APPOINTMENT OF NEW POWER OF ATTORNEY BY			
	<b>ASSIGNEE</b> and 3.	.73(b) STATEMENT	ν	
ſ	Application Number:	Filing Date:		
	09/700,094	January 02, 2001		
Ī	Patent Number:	Issue Date:		
Ì	6,713,464	March 30, 2004		
ł	Invention Title:	······································	Inventor(s):	
ļ	NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES		Claus MEESE et al.	

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

SIR:

SCHWARZ PHARMA AG, as assignee of the entire interest of the above-identified patent by virtue of executed assignments as indicated below, hereby revokes all powers of attorney previously given and appoints Bradford Paul Schmidt, Reg. No. 42,128, and the practitioners associated with Kenyon & Kenyon's customer number:

#### 26646

to prosecute and transact all business in the Patent and Trademark Office connected therewith.

Ľ

SCHWARZ PHARMA AG, is the assignce of the entire right, title and interest in U.S. Patent Application Serial No. 09/700,094 filed on January 02, 2001, now U.S. Patent No. 6,713,464 issued on March 30, 2004 by virtue of the following assignment of title from the inventor(s) to the current assignce as shown below:

1. From: <u>Claus Meese</u>, and

From: Bengt Sparf

To: <u>Schwarz Pharma AG</u>

The document was recorded on January 11, 2001 in the United States Patent and Trademark Office at Reel 011443, Frame 0478.

NYO1 1030397 v1

Please send all correspondence and direct telephone calls to:

Jeffrey Ginsberg, Esq.

Kenyon & Kenyon One Broadway New York, NY 10004 Customer No: 26646

The undersigned are authorized to act on behalf of the assignee:

Ţ

Date: August 22, 2005

SCHWARZ PHARMA AG

By:

Name: Klaus Veitinger, MD

Title: Executive Board Member, Schwarz Pharma AG

Date: August 2, 2005

SCHWARZ PHARMA AG By:

Name: Detlef Thielgen

Title: CFO and Member of the Executive Board, Schwarz Pharma AG

#### Page 1 of 1



NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 09/01/2005.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

TIMOTHY M WILLIAMS OIPE (703) 308-9010

OFFICE COPY

Page 1 of 1

		UNITED STATES DEPARTMENT OF COMME United States Patent and Trademark Office Addess COMMISSIONER FOR PATENTS PO Box 1430 Advandra, Vigna 22313-1450 www.neps	
APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTY DOCKET NO /TITLE
09/700,094	01/02/2001	Claus Meese	12961/46101
21874 EDWARDS & ANGELL, LLP P.O. BOX 55874 BOSTON, MA 02205		-00000000	CONFIRMATION NO. 140

### NOTICE REGARDING CHANGE OF POWER OF ATTORNEY

, v

i a

This is in response to the Power of Attorney filed 09/01/2005.

• The Power of Attorney to you in this application has been revoked by the assignee who has intervened as provided by 37 CFR 3.71. Future correspondence will be mailed to the new address of record(37 CFR 1.33).

ŗ

TIMOTHY M WILLIAMS OIPE (703) 308-9010

OFFICE COPY

# Thomson Innovation Patent Export, 2013-09-17 14:58:06 -0500

### Table of Contents

1. US6713464B1 Derivatives of 3,3-diphenylpropylamines

L

# Family 1/1 71 record(s) per family, collapsed by 45 record(s)

**Record 1/45** EP957073A1 Novel derivatives of 3,3-diphenylpropylamines | 3,3-Diphenylpropylaminderivate | Dérivés de 3,3-diphénylpropylamines

Title: Novel derivatives of 3,3-diphenylpropylamines | 3,3-Diphenylpropylaminderivate | Dérivés de

3,3-diphénylpropylamines

**Title - DWPI:** New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome

Priority Number: EP1998108608A

Priority Date: 1998-05-12

Application Number: EP1998108608A

Application Date: 1998-05-12

Publication Date: 1999-11-17

IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	А	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
------------	---	-----	------	----------	------------
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	с	C07	C07C	C07C0219	C07C021900
C07C027100	с	C07	C07C	C07C0271	C07C027100
C07C030700	с	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	A	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216

A61K003122	A	A61	A61K	A61K0031	A61K003122
A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	А	A61	A61K	A61K0031	A61K0031235
A61K003124	А	A61	A61K	A61K0031	A61K003124
A61K0031315	А	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	А	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	А	A61	A61K	A61K0031	A61K00317034
A61K000970	А	A61	A61K	A61K0009	A61K000970
A61P000100	А	A61	A61P	A61P0001	A61P000100
A61P000104	А	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	А	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	А	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	А	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762

C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: SCHWARZ PHARMA AG,40789 Monheim, DE,01049371

JP F Terms:

JP FI Codes:

Assignee - Original: SCHWARZ PHARMA AG

Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP
Current	C07C 307/02		20130101	CF

ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly the invention concerns to provide novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to present drugs as oxybutynin and tolterodine, methods for preparing thereof, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly the invention concerns to provide novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to present drugs as oxybutynin and tolterodine, methods for preparing thereof, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions. <IMAGE>

5

Language of Publication: EN

INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact			
2000-07-26	AXX	+			
Description: PAYMENT OF EXTENS	ION FEES SI PAYMENT 19980512				
2000-07-26	AKX	+			
Description: PAYMENT OF DESIGNA	ATION FEES AT BE CH CY DE DK ES FI	FR GB GR IE IT LI LU MC NL PT			
2000-06-21	18W	-			
Description: WITHDRAWN					
1999-11-17	AX	+			
Description: EXTENSION OR VALID/ 19980512	ATION OF THE EUROPEAN PATENT TO	AL; LT; LV; MK; RO; SI PAYMENT			
1999-11-17	AK	+			
Description: DESIGNATED CONTRACTING STATES: EP 0957073 A1 AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT					
1999-11-17	17P	+			
Description: REQUEST FOR EXAMINATION FILED 1998-05-12					

Post-Issuance (US):

Reassignment (US) Table:

Maintenance Status (US):

Litigation (US):

Opposition (EP):

License (EP):

**EPO Procedural Status:** RJ-WDRAW 2000-04-17 2000 Withdrawal | EX-RQ 1998-05-12 1998 Request for examination

Front Page Drawing:



## Record 2/45 WO1999058478A1 NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | NOUVEAUX DERIVES DE 3,3-DIPHENYLPROPYLAMINES

**Title:** NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | NOUVEAUX DERIVES DE 3,3-DIPHENYLPROPYLAMINES

**Title - DWPI:** New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome

Priority Number: EP1998108608A

Priority Date: 1998-05-12

Application Number: WO1999EP3212A

Application Date: 1999-05-11

Publication Date: 1999-11-18

IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144

C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	A	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	A	A61	A61K	A61K0031	A61K003122
A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	А	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235

A61K003124	A	A61	A61K	A61K0031	A61K003124
A61K0031315	А	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61K000970	Α	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	С07В	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900

C07C023347	С	C07	C07C	C07C0233	C07C023347
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	с	C07	C07C	C07C0069	C07C006922
C07C006934	с	C07	C07C	C07C0069	C07C006934
C07C006976	с	C07	C07C	C07C0069	C07C006976
C07C006978	с	C07	C07C	C07C0069	C07C006978
C07D020706	с	C07	C07D	C07D0207	C07D020706
C07D029506	с	C07	C07D	C07D0295	C07D029506
C07D032100	с	C07	C07D	C07D0321	C07D032100
C07D032110	с	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	с	C07	C07H	C07H0015	C07H001518
C12P001300	с	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	с	C07	C07C	C07C0217	C07C021754
C07C022902	с	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: SCHWARZ PHARMA AG,DE JP F Terms:

JP FI Codes: Assignee - Original: SCHWARZ PHARMA AG Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

# **ECLA:** C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

### Abstract:

The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compouds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

L'invention concerne de nouveaux dérivés de 3,3-diphénylpropylamines, des procédés permettant de les préparer, des compositions pharmaceutiques contenant ces nouveaux composés et l'utilisation de ces composés pour la préparation de médicaments. L'invention concerne plus particulièrement de nouveaux précurseurs d'agents anti-muscariniques qui ont des propriétés pharmacocinétiques supérieures à celles des médicaments existants tels que l'oxybutynine et la toltérodine, un procédé de préparation de ces précurseurs, des compositions pharmaceutiques les contenant et un procédé d'utilisation de ces composés, ainsi que des compositions destinées au traitement de l'incontinence urinaire, de l'hyperactivité gastro-intestinale (syndrome du côlon irritable) et d'autres pathologies affectant la contractilité des muscles lisses.

### Language of Publication: EN

#### INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact				
2006-04-12	WWG	+				
Description: WIPO INFORMATION: GRANT IN NATIONAL OFFICE CZ PV2000-3774						
	1					
2006-04-04	WWG	+				
Description: WIPO INFORMATION: C	GRANT IN NATIONAL OFFICE KR 1020	007012653				
2006-01-16	WWE	+				
Description: WIPO INFORMATION: ENTRY INTO NATIONAL PHASE CZ PV2006-29						
2002-09-12	WWG	+				

Description: WIPO INFORMATION: GRANT IN NATIONAL OFFICE AU 41412/99							
2002-07-03	WWG	+					
Description: WIPO INFORMATION: GRANT IN NATIONAL OFFICE EP 1999924929							
2001-11-12	NENP	-					
Description: NON-ENTRY INTO TH	E NATIONAL PHASE IN: CA						
2001-08-30		+					
Description: WIPO INFORMATION:	PUBLISHED IN NATIONAL OFFICE KR	1020007012653					
• • • • • • • • • • • • • • • • • • •							
2001-03-15	REG	-					
Description: REFERENCE TO NAT ENT. GERMAN PHASE	IONAL CODE DE 8642 IMPACT ABOLIS	SHED FOR DE - I.E. PCT APPL. NOT					
2001-03-14	WWP	+					
Description: WIPO INFORMATION:	PUBLISHED IN NATIONAL OFFICE CZ	PV2000-3774					
2001-02-28	WWP	+					
Description: WIPO INFORMATION:	PUBLISHED IN NATIONAL OFFICE EP	1999924929					
2001-01-02	WWE	+					
Description: WIPO INFORMATION:	ENTRY INTO NATIONAL PHASE US 09	700094					
2000-11-11	WWE	+					
Description: WIPO INFORMATION:	ENTRY INTO NATIONAL PHASE KR 10	20007012653					
2000-11-10	WWE	+					
Description: WIPO INFORMATION:	ENTRY INTO NATIONAL PHASE MX PA	A/a/2000/011096					
2000-11-03	WWE	+					
Description: WIPO INFORMATION:	ENTRY INTO NATIONAL PHASE AU 41	412/99					
2000-10-19	WWE	+					
Description: WIPO INFORMATION:	ENTRY INTO NATIONAL PHASE EP 19	99924929					
2000-10-18	WWE	+					

Description: WIPO INFORMATION: ENTRY INTO NATIONAL PHASE IL 139110								
2000-10-17	ENP	-						
Description: ENTRY INTO THE NAT	Description: ENTRY INTO THE NATIONAL PHASE IN: CA 2328920 A							
2000-10-17	ENP	-						
Description: ENTRY INTO THE NAT	Description: ENTRY INTO THE NATIONAL PHASE IN: CA 2328920							
2000-10-13	WWE	+						
Description: WIPO INFORMATION: I	ENTRY INTO NATIONAL PHASE SK 15	472000						
2000-10-13	ENP	-						
Description: ENTRY INTO THE NAT	IONAL PHASE IN: SK 15472000 A							
2000-10-12	WWE	+						
Description: WIPO INFORMATION: I	ENTRY INTO NATIONAL PHASE NZ 50	7487						
2000-10-11	WWE	+						
Description: WIPO INFORMATION: I	ENTRY INTO NATIONAL PHASE CZ PV	/2000-3774						
2000-01-12	121	-						
Description: EP: THE EPO HAS BEE	IN INFORMED BY WIPO THAT EP WAS D	DESIGNATED IN THIS APPLICATION						
1999-12-16	DFPE	-						
Description: REQUEST FOR PRELIM PRIORITY DATE (PCT APPLICATION FI	/INARY EXAMINATION FILED PRIOR TO LED BEFORE 20040101)	EXPIRATION OF 19TH MONTH FROM						
1999-11-18	AL	+						
Description: DESIGNATED COUNTRIES FOR REGIONAL PATENTS WO 9958478 A1 GH; GM; KE; LS; MW; SD; SL; SZ; UG; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG								
1999-11-18	AK	+						
<b>Description:</b> DESIGNATED STATES WO 9958478 A1 AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZA; ZW								

Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



Record 3/45 AU199941412A Novel derivatives of 3,3-diphenylpropylamines

Title: Novel derivatives of 3,3-diphenylpropylamines Title - DWPI: New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: AU199941412D Application Date: 1999-05-11 Publication Date: 1999-11-29 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	А	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152

C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	A	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	A	A61	A61K	A61K0031	A61K003122
A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	А	A61	A61K	A61K0031	A61K0031235
A61K003124	A	A61	A61K	A61K0031	A61K003124

A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	А	A61	A61K	A61K0031	A61K00317034
A61K000970	А	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	А	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347

C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	А	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office

Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

Language of Publication: EN INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



Record 4/45 BR199910406A Derivados de 3,3-difenilpropilaminas

Title: Derivados de 3,3-difenilpropilaminas Title - DWPI: New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: BR199910406A Application Date: 1999-05-11 Publication Date: 2001-01-09 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	с	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	с	C07	C07C	C07C0213	C07C021306
C07C021748	с	C07	C07C	C07C0217	C07C021748
C07C021762	с	C07	C07C	C07C0217	C07C021762
C07C021922	с	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152

C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	А	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	А	A61	A61K	A61K0031	A61K003122
A61K0031221	А	A61	A61K	A61K0031	A61K0031221
A61K0031222	А	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K003124	А	A61	A61K	A61K0031	A61K003124

A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	А	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347

C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	А	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office

Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

# **ECLA:** C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

Language of Publication: PT
INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact					
2012-08-28	B07D	-					
Description: TECHNICAL EXAMINAT	Description: TECHNICAL EXAMINATION (OPINION) RELATED TO ARTICLE 229 OF INDUSTRIAL PROPERTY LAW						
2011-05-17	B15K	-					
<b>Description:</b> OTHERS CONCERNING APPLICATIONS: ALTERATION OF CLASSIFICATION PARA:INT.CI.C07C 1/00, C07C 217/62, C07C 217/48, C07C 219/28, C07C 219/22, C07D 207/06, C07D 295/06, C07C 271/08, C07F 7/18, C07C 307/02, A61K 31/135, A61K 31/325, A61K 31/40, A61K 31/435, A61P 13/00.							
2011-05-17	B06A	-					
Description: NOTIFICATION TO APP INADEQUACY OF THE APPLCATION AC	LICANT TO REPLY TO THE REPORT FO CORDING ART. 36 INDUSTRIAL PATEN	R NON-PATENTIABILITY OR I LAW					
2008-10-28	B06G	-					
Description: TECHNICAL AND FORMAL REQUIREMENTS: OTHER REQUIREMENTS ATRAVES DA PETICAO NO 043712 DE 06/09/2001, O REQUERENTE SOLOCITOU O EXAME DO PRESENTE E EFETUOU ARETRIBUICAO EQUIVALENTE A 27 REIVINDICACOES. NO ENTANTO, EM PETICAO NO 042028 DE 29/08/2001 FOI APRESENTADO UM NOVO QUADRO REIVINDICATORIO CONSTANDO 28 REIVINDICACOES. DESSE MODO, A FIM DE DAR CONTINUIDADE AO AXAME DO PEDIDO O REQUERENTE DEVERA COMPLEMENTAR A RETRIBUICAO AQUIVALENTE A 1 REIVINDICACAO EXEDENTE.							

Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



Record 5/45 ZA200005728A Novel derivatives of 3,3-diphenylpropylamines.

**Title:** Novel derivatives of 3,3-diphenylpropylamines.

Title - DWPI: New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome Priority Number: EP1998108608A Priority Date: 1998-05-12 Application Number: ZA20005728A Application Date: 2000-10-17 Publication Date: 2001-03-05 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	с	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	А	A61	A61K	A61K0031	A61K0031325
A61K0031357	А	A61	A61K	A61K0031	A61K0031357
A61K0031365	А	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	с	C07	C07C	C07C0213	C07C021306
C07C021748	с	C07	C07C	C07C0217	C07C021748
C07C021762	с	C07	C07C	C07C0217	C07C021762
C07C021922	с	C07	C07C	C07C0219	C07C021922
C07C021928	с	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152

C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	А	A61	A61K	A61K0031	A61K0031215
A61K0031216	А	A61	A61K	A61K0031	A61K0031216
A61K003122	А	A61	A61K	A61K0031	A61K003122
A61K0031221	А	A61	A61K	A61K0031	A61K0031221
A61K0031222	А	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K003124	А	A61	A61K	A61K0031	A61K003124

A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	А	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	А	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347

C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	А	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office

Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

Language of Publication: EN INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



Title: NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES Title - DWPI: Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: IL139110A Application Date: 1999-05-11 Publication Date: 2001-11-25 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	А	A61	A61K	A61K0031	A61K0031325
A61K0031357	А	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702

C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	С07Н	C07H0015	C07H001518

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH
JP F Terms:
JP FI Codes:
Assignee - Original:
Any CPC Table:
ECLA:
Abstract:
Language of Publication: EN
INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact						
2013-05-30	КВ	+						
Description: PATENTS RENEWED								
	-							
2010-12-30	EXTF	+						
Description: APPLICATION FOR PA	TENT EXTENSION FILED							
	-							
2009-11-18	КВ	+						
Description: PATENTS RENEWED								
	-							
2009-07-20	EXTF	+						
Description: APPLICATION FOR PA	TENT EXTENSION FILED							
2005-09-25	КВ	+						
Description: PATENTS RENEWED								
2005-07-25	FF	+						
Description: PATENTS GRANTED								

Post-Issuance (US):

Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



Record 7/45 TR200003319T2 3,3-Difenilpropilaminlerin yeni türevleri

Title: 3,3-Difenilpropilaminlerin yeni türevleri Title - DWPI: Priority Number: EP1998108608A Priority Date: 1998-05-12 Application Number: TR20003319T Application Date: 1999-05-11 Publication Date: 2001-12-21 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702

C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	С07Н	C07H0015	C07H001518

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

**ECLA**: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

Language of Publication: TR INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:

(No drawing/image available)

Record 8/45 AU748057B2 Novel derivatives of 3,3-diphenylpropylamines

Title: Novel derivatives of 3,3-diphenylpropylamines Title - DWPI: New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: AU199941412A Application Date: 1999-05-11 Publication Date: 2002-05-30 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	А	A61	A61K	A61K0031	A61K003140
A61K0031435	А	A61	A61K	A61K0031	A61K0031435
A61K00317028	А	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	А	A61	A61P	A61P0013	A61P001300
A61P001310	А	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
------------	---	-----	------	----------	------------
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	А	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	А	A61	A61K	A61K0031	A61K003122
A61K0031221	А	A61	A61K	A61K0031	A61K0031221
A61K0031222	А	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K003124	А	A61	A61K	A61K0031	A61K003124

## Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0361

A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	А	A61	A61K	A61K0031	A61K0031357
A61K0031365	А	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347

## Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0362

C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	А	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office

Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

## **ECLA**: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

### Abstract: Language of Publication: EN INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact				
2002-09-26	FGA	+				
Description: LETTERS PATENT SEALED OR GRANTED (STANDARD PATENT)						

Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



**Record 9/45** MX2000PA011096A NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES. | NUEVOS DERIVADOS DE 3,3 -DIFENILPROPILAMINAS.

**Title:** NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES. | NUEVOS DERIVADOS DE 3,3 -DIFENILPROPILAMINAS.

Title - DWPI:

Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: MX2000PA11096A Application Date: 2000-11-10 Publication Date: 2002-06-04 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152

C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table: ECLA: C07C021748 | C07C021762 | C07C021928 | C07C027144 | C07C027152 | C07C030702 Abstract:

The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compouds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

Language of Publication: ES INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:

(No drawing/image available)

**Record 10/45** EP1077912B1 NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | 3,3-DIPHENYLPROPYLAMINDERIVATE | NOUVEAUX DERIVES DE 3,3-DIPHENYLPROPYLAMINES

Title: NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | 3,3-DIPHENYLPROPYLAMINDERIVATE | NOUVEAUX DERIVES DE 3,3-DIPHENYLPROPYLAMINES Title - DWPI: New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: EP1999924929A Application Date: 1999-05-11 Publication Date: 2002-07-03 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	с	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	с	C07	C07C	C07C0213	C07C021306
C07C021748	с	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108

C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	A	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	A	A61	A61K	A61K0031	A61K003122
A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225

A61K0031235	А	A61	A61K	A61K0031	A61K0031235
A61K003124	А	A61	A61K	A61K0031	A61K003124
A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	А	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	А	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	А	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930

## Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0369

C07C022900	с	C07	C07C	C07C0229	C07C022900
C07C023347	с	C07	C07C	C07C0233	C07C023347
C07C027108	с	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	с	C07	C07F	C07F0007	C07F000718
C07H001518	с	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: SCHWARZ PHARMA AG,D 40789 Monheim/Rhld.,DE,01049370 JP F Terms: JP FI Codes: Assignee - Original: SCHWARZ PHARMA AG Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

# ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

### Abstract:

The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compouds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

L'invention concerne de nouveaux dérivés de 3,3-diphénylpropylamines, des procédés permettant de les préparer, des compositions pharmaceutiques contenant ces nouveaux composés et l'utilisation de ces composés pour la préparation de médicaments. L'invention concerne plus particulièrement de nouveaux précurseurs d'agents anti-muscariniques qui ont des propriétés pharmacocinétiques supérieures à celles des médicaments existants tels que l'oxybutynine et la toltérodine, un procédé de préparation de ces précurseurs, des compositions pharmaceutiques les contenant et un procédé d'utilisation de ces composés, ainsi que des compositions destinées au traitement de l'incontinence urinaire, de l'hyperactivité gastro-intestinale (syndrome du côlon irritable) et d'autres pathologies affectant la contractilité des muscles lisses.

#### Language of Publication: EN

#### INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact		
2013-08-30	PGFP	+		
Description: POSTGRANT: ANNUAL	Description: POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE FI			
2013-08-30	PGFP	+		
Description: POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE BE				
2013-08-30	PGFP	+		
Description: POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE NL				

2013-08-30	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE GF	2
2013-08-30	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE PT	
2013-08-30	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE FR	
2013-08-30	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE IT	
	2052	
2013-07-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE CY	
2013-07-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE CH	
2013-07-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE LU	
2013-07-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE DK	
2013-07-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE DE	
2013-07-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE IE	
2013-07-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE SE	
2013-07-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE GE	·
	1	

2013-04-30	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE MC	
2013-03-29	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE AT	
2013-01-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE PT	
2012-12-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE ES	
2012-09-28	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE CY	
2012.00.28	DCED	
Description: POSTGRANT: ANNUAL		·
2012-08-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE FI	
2012-08-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE GR	
2012-08-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE GB	
2012-08-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE BE	
	2052	
		+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE FR	
2012-08-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE SE	

2012-07-31	PGFP	+		
Description: POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE NL				
2012-07-31	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE MC			
2012-07-31	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE IE			
2012-07-31	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE CH			
2012 07 21	DCED	4		
2012-07-31	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE LU			
2012-07-31	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE DK			
2012-07-31	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE DE			
2011-12-30	REG	-		
Description: REFERENCE TO A NAT GRANTED PRODUCT NAME: FESOTE	IONAL CODE CH SPCG SUPPLEMEN RODIN; REGISTRATION NUMBER/DATE:	ITARY PROTECTION CERTIFICATE SWISSMEDIC 58743 18.12.2008		
2011-11-30	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE CY			
2011-11-15	REG	-		
Description: REFERENCE TO A NATIONAL CODE CH PFA NAME/FIRM CHANGED UCB PHARMA GMBH SCHWARZ PHARMA AG#ALFRED-NOBEL-STRASSE 10#D-40789 MONHEIM/RHLD. (DE) -TRANSFER TO- UCB PHARMA GMBH#ALFRED-NOBEL-STRASSE 10#40789 MONHEIM (DE)				
2011-11-15	REG	-		
Description: REFERENCE TO A NATIONAL CODE CH SPCF SUPPLEMENTARY PROTECTION CERTIFICATE FILED PRODUCT NAME: FESOTERODIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58743 18.12.2008				
2011-10-31	REG	-		

Description: REFERENCE TO A NATIONAL CODE CH PK CORRECTION GESTUETZT AUF DAS AM 23.04.2010 EINGEREICHTE WIEDEREINSETZUNGSGESUCH AUF GRUND VON ART. 47 PATG, IST AM 25.10.2011 DIE WIEDEREINSETZUNG IN DIE ESZ-FRIS			
2011-09-30	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE DE		
2011-09-30	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE IT		
2011-08-31	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE FI		
2011-08-31	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE NL		
2011-08-31	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE BE		
2011-08-31	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE AT		
2011-08-31	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE DK		
2011-08-31	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE GB		
2011-07-29	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE FR		
2011-07-29	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE ES		
2011-07-29	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE CH		
	· · · · · · · · · · · · · · · · · · ·		

2011-07-29	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE LU	
2011-07-29	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE GR	
2011-07-29	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE MC	
2011-07-29	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE SE	
2011-07-29	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE PT	
2011-07-29	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE IE	
2011-05-27	REG	_
Description: REFERENCE TO A NAT	IONAL CODE FI SPCG SUPPLEMENT	TARY PROTECTION CERTIFICATE SPC
GRANTED		
2010-12-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE GR	
2010-11-30	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE CY	
2010-11-30	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE SE	
2010-10-29	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE CH	
2010-10-29	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE BE	

2010-08-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE AT	
2010-08-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE DE	
2010-08-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE NL	
2010-08-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE IT	
2010-07-30	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE PT	
2010-07-30	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE MC	;
2010-07-30	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE LU	
2010-07-30	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE IE	
2010-07-30	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE FR	
2010-07-30	DGED	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE FI	
	PGFP	+
	FEES PAID TO NATIONAL OFFICE DK	
2010-07-30	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE ES	

2010-06-30	PGFP	+		
Description: POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE GB				
2010-02-10	REG	-		
<b>Description:</b> REFERENCE TO A NATIONAL CODE GB CTFG CERTIFICATE GRANTED PRODUCT NAME: FESOTERODINE AND ITS SALTS WITH PHYSIOLOGICALLY ACCEPTABLE ACIDS, INCLUDING FUMARIC ACID; REGISTERED: UK EU/1/07/386/001 20070420; UK EU/1/07/386/002 20070420; UK EU/1/07/386/003 20070420; UK EU/1/07/386/004 20070420; UK EU/1/07/386/005 20070420; UK EU/1/07/386/006 20070420; UK EU/1/07/386/007 20070420; UK EU/1/07/386/008 20070420; UK EU/1/07/386/009 20070420; UK EU/1/07/386/010 20070420 2010-01-14				
2009-12-31	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE CY			
2009-11-30	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE GR			
2009-11-30	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE GB			
2009-10-30	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE CH			
2009-09-30	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE BE			
2009-08-31	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE AT			
2009-08-31	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE SE			
2009-08-31	PGFP	+		
Description: POSTGRANT: ANNUAL FEES PAID TO NATIONAL OFFICE PT				
2009-08-31	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE LU			
2009-08-31	PGFP	+		

Description:	POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE	IT	
2009-08-31		PGFP		+
Description:	POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE	FR	
2009-08-31		PGEP		+
Description:	POSTGRANT: ANNUAL		FI	·
2009-08-31		PGFP		+
Description:	POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE	DE	
2009-07-31		PGFP		+
Description:	POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE	DK	
2009-07-31		PGFP		+
Description:	POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE	ES	
2009-07-31		PGFP		+
Description:	POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE	IE	
2009-07-31		PGFP		+
Description:	POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE	MC	
2009-07-31		PGFP		+
Description:	POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE	NL	
2009-05-29		PGFP		+
Description:	POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE	GR	
2009-03-31		PGFP		+
Description:	POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE	BE	
2008-12-31		PGFP		+
Description:	POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE	GB	
2008-10-31		PGFP		+

Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE	:	
2008-10-31	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE		
2008.10.31	PCEP		
Description: POSTGRANT ANNUAL		·	
2008-09-30	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE	2	
2008-09-30	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE	,	
2008-09-30	PGEP	+	
Description: POSTGRANT: ANNUAL			
2008-09-30	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE		
2008-09-30	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE		
2008-08-29	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE		
2008-07-31	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE	ł	
2008-07-31	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE		
2008-07-31	PGFP	+	
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE	(	
2008-07-31	PGFP	+	

Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE DE			
2008-07-31	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE ES			
2008-06-11	REG	-		
Description: REFERENCE TO A NAT GRANTED SPC037/2007: 20080507, E	TIONAL CODE IE SPCG SUPPLEMEN XPIRES: 20220419	TARY PROTECTION CERTIFICATE		
2008-05-30	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE GR			
2008-05-09	REG	-		
Description: REFERENCE TO A NATIONAL CODE FR CY SUPPLEMENTARY CERTIFICATE OF PROTECTION GRANTED (EEC REGULATION OF 18 JUNE 1992) PRODUCT NAME: FESOTERODINE ET SES SELS AVEC DES ACIDES PHYSIOLOGIQUEMENT ACCEPTABLES NOTAMMENT L ACIDE FUMARIQUE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/386/001 DU 20070420; REGISTRATION NO/DATE AT EEC: EU/1/07/386/001 DU 20070420				
2008-04-30	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE FR			
2008-03-18	REG	-		
Description: REFERENCE TO A NATIONAL CERTIFICATE 0790047-5	TIONAL CODE SE SPCG GRANTED S	UPPLEMENTARY PROTECTION		
2008-03-18	REG	-		
Description: REFERENCE TO A NATION CERTIFICATE	TIONAL CODE SE SPCG GRANTED S	UPPLEMENTARY PROTECTION		
2008-02-15	REG	-		
Description: REFERENCE TO A NATIONAL CODE CH PFA NAME/FIRM CHANGED SCHWARZ PHARMA AG SCHWARZ PHARMA AG#ALFRED-NOBEL-STRASSE 10#D-40789 MONHEIM/RHLD. (DE) -TRANSFER TO- SCHWARZ PHARMA AG#ALFRED-NOBEL-STRASSE 10#D-40789 MONHEIM/RHLD. (DE)				
2008-01-31	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE BE			
2008-01-11	REG	-		
Description: REFERENCE TO A NAT	TIONAL CODE FR CP SUPPLEMENTA	RY CERTIFICATE OF PROTECTION		

FILED				
2008-01-02	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE IT			
2007-11-24	PGFP	+		
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE GB			
	1			
2007-11-16	REG	-		
Description: REFERENCE TO A NAT LAID OPEN TO THE PUBLIC (EEC REG AVEC DES ACIDES PHYSIOLOGIQUEM NO/DATE IN FRANCE: EU/1/07/386/001	TIONAL CODE FR CR SUPPLEMENTA ULATION OF 18 JUNE 1992) PRODUCT IENT ACCEPTABLES NOTAMMENT L ACI DU 20070420; REGISTRATION NO/DATE	ARY CERTIFICATE OF PROTECTION NAME: FESOTERODINE ET SES SELS IDE FUMARIQUE; REGISTRATION AT EEC: EU/1/07/386/001 DU 20070420		
2007-11-14	REG	-		
91365, EXPIRES: 20220420	TIONAL CODE LU CCP SUPPLEMENT	ARY PROTECTION CERTIFICATE		
2007-11-12	REG	-		
Description: REFERENCE TO A NAT	TIONAL CODE DK CTFF SUPPLEMEN	TARY PROTECTION CERTIFICATE		
2007-11-06	REG	-		
Description: REFERENCE TO A NAT PROTECTION CERTIFICATE PRODUC GODTAGBARA SYROR,; NAT REG. NO, 20070420	FIONAL CODE SE SPCF APPLICATION T NAME: FESOTERODIN OCH DESS SAI /DATE: EG EU/1/07/386/001 20070420; FIF	N FOR SUPPLEMENTARY LTER MED FYSIKALISKT RST REG.: EG EU/1/07/386/001		
2007-11-06	REG	-		
Description: REFERENCE TO A NATIONAL CODE SE SPCF APPLICATION FOR SUPPLEMENTARY PROTECTION CERTIFICATE PRODUCT NAME; FESOTERODIN OCH DESS SALTER MED FYSIKALISKT GODTAGBARA SYROR, INKLUDERANDE FUMARSYRA REGISTRATION NO/DATE: EU/1/07/386/001 / 20071106				
2007-11-06	REG	-		
Description: REFERENCE TO A NATIONAL CODE SE SPCF APPLICATION FOR SUPPLEMENTARY PROTECTION CERTIFICATE 0790047-5, 20070420				
2007-11-01	REG	-		
Description: REFERENCE TO A NAT PROTECTION CERTIFICATE	FIONAL CODE NL AC1 APPLICATION	FOR A SUPPLEMENTARY		

2007-10-31	REG	-
Description: REFERENCE TO A NAT	IONAL CODE GB CTFF CERTIFICATE	E FILED SPC/GB07/053: 20071003
0007 40 40	550	
2007-10-18	REG	-
Description: REFERENCE TO A NAT APPLICATION FILED	TONAL CODE FI SPCF SUPPLEMENT	ARY PROTECTION CERTIFICATE
2007-10-17	REG	-
Description: REFERENCE TO A NAT PROTECTION CERTIFICATE SPC037/2	TONAL CODE IE SPCF REQUEST FO 2007: 20070914	R GRANT OF SUPPLEMENTARY
2007-06-21	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE ES	
2007-05-24	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE LU	
2007-05-16	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE CH	
2007-05-15	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE DK	
2007-05-14	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE FI	
	1	
2007-05-14	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE IE	
2007.05.11	DCED	
2007-05-11	PGrP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE AT	
2007-05-09	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE PT	
2007-05-08	PGFP	+

Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE SE	
2007-05-03	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE NL	-
0007.05.00	DOED	
2007-05-03		
Description. Postgrant: Annual	FEES PAID TO NATIONAL OFFICE DE	-
2007-04-26	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE MO	2
2007-04-19	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE CY	,
2006-07-12	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE BE	
2006-05-31	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE IT	
2006-05-15	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE FF	
2006-05-10	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE GE	3
2006-04-13	PGFP	+
Description: POSTGRANT: ANNUAL	FEES PAID TO NATIONAL OFFICE G	2
2003-06-25	26N	+
Description: NO OPPOSITION FILE	D 2003-04-04	
2003-02-16	REG	-
Description: REFERENCE TO A NAT	FIONAL CODE ES FG2A DEFINITIVE	PROTECTION
2002-12-30	LTIE	-

Description: LT: INVALIDATION OF EUROPEAN PATENT OR PATENT EXTENSION 2002-07-03				
2002-12-06	ET	+		
Description: FR: TRANSLATION FILE	ED			
2002-11-29	REG	-		
Description: REFERENCE TO A NAT NATIONAL TRANSLATION 2002-10-02	TIONAL CODE PT SC4A TRANSLATIO	N IS AVAILABLE AVAILABILITY OF		
2002-10-28	REG	-		
Description: REFERENCE TO A NAT	TIONAL CODE DK T3 TRANSLATION (	OF EP PATENT		
2002-10-15	REG	-		
Description: REFERENCE TO A NAT	TIONAL CODE CH NV NEW AGENT			
2002-08-08	REF	-		
Description: CORRESPONDS TO: 1	DE 69902037			
2002-07-24	REG	-		
Description: REFERENCE TO A NAT	FIONAL CODE IE FG4D EUROPEAN P	ATENTS GRANTED DESIGNATING		
2002 07 45				
Description. Reference to a nat	IONAL CODE CH EP ENTRY IN THE	NATIONAL PHASE		
2002-07-03	REF	-		
Description: CORRESPONDS TO:	AT 220056 T			
2002.07.03	٨٧			
Description: EXTENSION OR VALIDATION OF THE EUROPEAN PATENT TO AL PAYMENT 20001019; LT PAYMENT 20001019; LV PAYMENT 20001019; MK PAYMENT 20001019; RO PAYMENT 20001019; SI PAYMENT 20001019				
2002-07-03	AK	+		
Description: DESIGNATED CONTRACTING STATES: EP 1077912 B1 AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE				
2002-01-16	17Q	+		
Description: FIRST EXAMINATION REPORT 2001-12-04				

2001-02-28	AX	+		
Description: EXTENSION OR VALIDATION OF THE EUROPEAN PATENT TO AL PAYMENT 20001019; LT PAYMENT 20001019; LV PAYMENT 20001019; MK PAYMENT 20001019; RO PAYMENT 20001019; SI PAYMENT 20001019				
2001-02-28	AK	+		
Description: DESIGNATED CONTRACTING STATES: EP 1077912 A1 AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE				
	1	1		
2001-02-28	17P	+		
Description: REQUEST FOR EXAMINATION FILED 2000-10-19				

Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: EX-RQ 2000-10-19 2000 Request for examination | EX-REPORT 2001-

12-04 2001 Dispatch of 1st examination report





Title: 3,3-DIPHENYLPROPYLAMINDERIVATE Title - DWPI: Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: AT1999924929T Application Date: 1999-05-11 Publication Date: 2002-07-15 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702

C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

## **ECLA**: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

Language of Publication: XX INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact			
2008-05-15	EEZF	+			
Description: GRANT FOR A CERTIFICATE OF PROTECTION (E-SERIES) SZ 47/2007, 20071005, EXPIRES:20220420					
2008-01-15	ESZA	+			
Description: APPLICATION FILED FOR	OR A CERTIFICATE OF PROTECTION (E-	SERIES) SZ 47/2007, 20071005			
2002-12-15	UEP	+			
Description: PUBLICATION OF TRANSLATION OF EUROPEAN PATENT SPECIFICATION					

Post-Issuance (US):

Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:

(No drawing/image available)

Record 12/45 DK1077912T3 Hidtil ukendte derivater af 3,3-diphenylpropylaminer

Title: Hidtil ukendte derivater af 3,3-diphenylpropylaminer Title - DWPI: Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: DK1999924929T Application Date: 1999-05-11 Publication Date: 2002-10-28 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702

C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

**ECLA**: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

Language of Publication: DA INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:

(No drawing/image available)

**Record 13/45** EP1254890A1 Derivatives of 3,3-diphenylpropylamines | 3,3-Diphenylpropylaminderivate | Dérivés de 3,3-diphénylpropylamines

**Title:** Derivatives of 3,3-diphenylpropylamines | 3,3-Diphenylpropylaminderivate | Dérivés de 3,3-diphénylpropylamines

**Title - DWPI:** New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome

Priority Number: EP1998108608A | EP1999924929A

Priority Date: 1998-05-12 | 1999-05-11

Application Number: EP200213481A

Application Date: 1999-05-11

Publication Date: 2002-11-06

IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144

C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	А	A01	A01N	A01N0037	A01N003710
A01N003712	А	A01	A01N	A01N0037	A01N003712
A01N003744	А	A01	A01N	A01N0037	A01N003744
A61K0031135	А	A61	A61K	A61K0031	A61K0031135
A61K0031137	А	A61	A61K	A61K0031	A61K0031137
A61K003121	А	A61	A61K	A61K0031	A61K003121
A61K0031215	А	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	A	A61	A61K	A61K0031	A61K003122
A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222
A61K0031225	А	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235

A61K003124	A	A61	A61K	A61K0031	A61K003124
A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	А	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	А	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	А	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900

## Patent Owner, UCB Pharma GmbH – Exhibit 2010 - 0394

C07C023347	С	C07	C07C	C07C0233	C07C023347
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	с	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	с	C07	C07C	C07C0069	C07C006922
C07C006934	с	C07	C07C	C07C0069	C07C006934
C07C006976	с	C07	C07C	C07C0069	C07C006976
C07C006978	с	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	с	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	с	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	с	C07	C07H	C07H0015	C07H001518
C12P001300	с	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	с	C07	C07C	C07C0217	C07C021754
C07C022902	с	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: SCHWARZ PHARMA AG,D 40789 Monheim/Rhld.,DE,01049370 JP F Terms: JP FI Codes:

Assignee - Original: SCHWARZ PHARMA AG Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	_	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

## **ECLA:** C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

### Abstract:

The invention concerns novel derivatives of 3,3- diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

## Language of Publication: EN INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact			
2004-03-31	18D	-			
Description: DEEMED TO BE WITHD	DRAWN 2003-05-07				
	-				
2003-08-28	REG	-			
Description: REFERENCE TO A NAT	IONAL CODE DE 8566 DESIGNATED	COUNTRY DE NOT LONGER VALID			
2003-07-23	AKX	+			
Description: PAYMENT OF DESIGNA	ATION FEES				
2002-11-06	AX	+			
Description: EXTENSION OR VALID	ATION OF THE EUROPEAN PATENT TO	AL; LT; LV; MK; RO; SI			
2002-11-06	AK	+			
Description: DESIGNATED CONTRACTING STATES: EP 1254890 A1 AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE					
2002-11-06	AC	-			
Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: RJ-DWDRAW 2003-05-07 2003 Deemed to be withdrawn Front Page Drawing:



Record 14/45 NZ507487A 3,3-Diphenylpropylamine derivatives useful as anti muscarinic agents

Title: 3,3-Diphenylpropylamine derivatives useful as anti muscarinic agents Title - DWPI: New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: NZ507487A Application Date: 1999-05-11 Publication Date: 2002-11-26 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	с	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	Α	A61	A61K	A61K0031	A61K0031325
A61K0031357	А	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	с	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	с	C07	C07C	C07C0217	C07C021762
C07C021922	с	C07	C07C	C07C0219	C07C021922
C07C021928	с	C07	C07C	C07C0219	C07C021928
C07C027108	с	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152

C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	А	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	А	A61	A61K	A61K0031	A61K003122
A61K0031221	А	A61	A61K	A61K0031	A61K0031221
A61K0031222	А	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K003124	А	A61	A61K	A61K0031	A61K003124

A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	А	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	А	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	А	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347

C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office

Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

# **ECLA**: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

3,3-diphenylpropylamines of formulae I and VII' (as described in the specification) and their derivatives, methods for their preparation, pharmaceutical compositions containing 3,3-diphenylpropylamines. These 3,3-diphenylpropylamines can be used for preparing drugs such as antimuscarinic agents for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

#### Language of Publication: EN

#### INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact						
2012-05-25	RENW	+						
Description: RENEWAL (RENEWAL	Description: RENEWAL (RENEWAL FEES ACCEPTED)							
2009-05-29	RENW	+						
Description: RENEWAL (RENEWAL	FEES ACCEPTED)							
2006-05-26	RENW	+						
Description: RENEWAL (RENEWAL	FEES ACCEPTED)							
2003-10-31	RENW	+						
Description: RENEWAL (RENEWAL FEES ACCEPTED)								
2003-03-28	PSEA	+						
Description: PATENT SEALED								

Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status:

# Front Page Drawing:



#### Record 15/45 PT1077912E NOVOS DERIVADOS DE 3,3-DIFENILPROPILAMINAS

Title: NOVOS DERIVADOS DE 3,3-DIFENILPROPILAMINAS Title - DWPI: Priority Number: EP1998108608A Priority Date: 1998-05-12 Application Number: PT924929T Application Date: 1999-05-11 Publication Date: 2002-11-29 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702

C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

**ECLA**: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

Language of Publication: PT INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:

(No drawing/image available)

Title: 3,3-DIPHENYLPROPYLAMINDERIVATE Title - DWPI: Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: DE69902037A Application Date: 1999-05-11 Publication Date: 2003-02-06 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	с	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	с	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702

C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

Assignee/Applicant: Schwarz Pharma AG JP F Terms: JP FI Codes: Assignee - Original: Schwarz Pharma AG Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

# ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compouds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

L'invention concerne de nouveaux dérivés de 3,3-diphénylpropylamines, des procédés permettant de les préparer, des compositions pharmaceutiques contenant ces nouveaux composés et l'utilisation de ces composés pour la préparation de médicaments. L'invention concerne plus particulièrement de nouveaux précurseurs d'agents anti-muscariniques qui ont des propriétés pharmacocinétiques supérieures à celles des médicaments existants tels que l'oxybutynine et la toltérodine, un procédé de préparation de ces composés, ainsi que des compositions destinées au traitement de l'incontinence urinaire, de l'hyperactivité gastro-intestinale (syndrome du côlon irritable) et d'autres pathologies affectant la contractilité des muscles lisses.

INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



Record 17/45 ES2181443T3 NUEVOS DERIVADOS DE 3,3-DIFENILPROPILAMINAS.

Title: NUEVOS DERIVADOS DE 3,3-DIFENILPROPILAMINAS.

Title - DWPI: New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome Priority Number: EP1998108608A Priority Date: 1998-05-12 Application Number: ES1999924929T Application Date: 1999-05-11 Publication Date: 2003-02-16 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	с	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	А	A61	A61K	A61K0031	A61K0031235
A61K0031325	А	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	А	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	А	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	А	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	с	C07	C07C	C07C0217	C07C021748
C07C021762	с	C07	C07C	C07C0217	C07C021762
C07C021922	с	C07	C07C	C07C0219	C07C021922
C07C021928	с	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152

C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	А	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	А	A61	A61K	A61K0031	A61K003122
A61K0031221	А	A61	A61K	A61K0031	A61K0031221
A61K0031222	А	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K003124	А	A61	A61K	A61K0031	A61K003124

A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	А	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	А	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347

C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office

Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

Language of Publication: ES INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



**Record 18/45** RU2199525C2 NOVEL DERIVATIVES OF 3,3-DIPHENYLROPYLAMINES, METHODS OF THEIR SYNTHESIS (VERSIONS) AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF

Title: NOVEL DERIVATIVES OF 3,3-DIPHENYLROPYLAMINES, METHODS OF THEIR SYNTHESIS (VERSIONS) AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF Title - DWPI: New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome Priority Number: EP1998108608A Priority Date: 1998-05-12 Application Number: RU2000125813A Application Date: 1999-05-11 Publication Date: 2003-02-27 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	А	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108

C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	А	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	А	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	A	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	A	A61	A61K	A61K0031	A61K003122
A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225

A61K0031235	А	A61	A61K	A61K0031	A61K0031235
A61K003124	А	A61	A61K	A61K0031	A61K003124
A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	А	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	А	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	А	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930

C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes:

Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

# ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

FIELD: organic chemistry, chemical technology, pharmacy. SUBSTANCE: invention describes derivatives of 3,3-diphenylpropyl-amines of the general formula (I) and where R and R1 are taken independently among hydrogen atom, C1-C6-alkyl, C3-C10-cycloalkyl, C1-C6-alkylcarbonyl, C1-C6-alkoxycarbonyl, substituted or unsubstituted benzene and others; X means tertiary aminogroup; Y and Z mean independently a single bond between (CH2)n-group and carbonyl group, O, S or NH; A means hydrogen atom (1H) or deuterium (2H); n is a number from 0 to 12, and their salts with physiologically acceptable acids, their free bases. Invention relates also to methods of their synthesis, pharmaceutical compositions comprising these compounds and the use of these compounds for antimuscarine drug preparing. Invention provides preparing novel prodrugs of antimuscarine agents with good pharmacokinetic properties as compared with existing drugs, for example, oxybutynin and tolterodine. The synthesized compounds and pharmaceutical compositions comprising thereof are used for treatment of enuresis and other contractile states of smooth muscles. EFFECT: improved methods of synthesis, valuable medicinal properties of agents and composition. 30 cl, 2 dwg, 5 tbl

# Language of Publication: RU INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact		
2013-08-20	PD4A	-		
Description: CORRECTION OF NAME OF PATENT OWNER				

Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



Record 19/45 US6713464B1 Derivatives of 3,3-diphenylpropylamines

Title: Derivatives of 3,3-diphenylpropylamines Title - DWPI: New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: US2000700094A Application Date: 2001-01-02 Publication Date: 2004-03-30 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	с	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	с	C07	C07C	C07C0213	C07C021306
C07C021748	с	C07	C07C	C07C0217	C07C021748
C07C021762	с	C07	C07C	C07C0217	C07C021762
C07C021922	с	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152

C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	А	A61	A61K	A61K0031	A61K0031215
A61K0031216	А	A61	A61K	A61K0031	A61K0031216
A61K003122	А	A61	A61K	A61K0031	A61K003122
A61K0031221	А	A61	A61K	A61K0031	A61K0031221
A61K0031222	А	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K003124	А	A61	A61K	A61K0031	A61K003124

A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	А	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	А	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	А	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61K000970	А	A61	A61K	A61K0009	A61K000970
A61P000100	А	A61	A61P	A61P0001	A61P000100
A61P000104	А	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	А	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	А	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347

C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: Schwarz Pharma AG,Monheim,DE JP F Terms: JP FI Codes: Assignee - Original: Schwarz Pharma AG Any CPC Table:

Туре	Invention	Additional	Version	Office

Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

# ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

# Language of Publication: EN INPADOC Legal Status Table:

	Code	INPADOC Legal Status Impact				
1-08-31 F	FPAY	+				
Description: FEE PAYMENT						
0-05-24	AS	-				
Description: ASSIGNMENT UCB PHARMA GMBH, GERMANY CHANGE OF NAME; ASSIGNOR:SCHWARZ PHARMA AG; REEL/FRAME:024424/0724 2010-01-20						
7-09-07 F	FPAY	+				
7-02-20	AS	-				
Description: ASSIGNMENT PFIZER INC., NEW YORK CONFIRMATION OF EXCLUSIVE PATENT LICENSE; ASSIGNORS: SCHWARZ PHARMA AG; SCHWARZ PHARMA LIMITED; REEL/FRAME:018942/0916 2006-04-12						
scription: FEE PAYMENT 0-05-24 A scription: ASSIGNMENT UCB PHA NRMA AG; REEL/FRAME:024424/0724 7-09-07 F scription: FEE PAYMENT 7-02-20 Scription: ASSIGNMENT PFIZER I SIGNORS:SCHWARZ PHARMA AG; SC	AS ARMA GMBH, GERMANY CHANGE OF 2010-01-20 FPAY AS INC.,NEW YORK CONFIRMATION OF E CHWARZ PHARMA LIMITED; REEL/FRAI	- NAME; ASSIGNOR:SCHWARZ + - XCLUSIVE PATENT LICENSE; ME:018942/0916 2006-04-12				

# **Post-Issuance (US):** CORR-CERT Certificate of Correction 2005-05-31 2005 2005-06-21 2005 a Certificate of Correction was issued for this patent **Reassignment (US) Table:**

Assignee	Assignor	Date Signed	Reel/Frame	Date

PFIZER INC.,NEW	SCHWARZ PHARMA AG	2006-04-12	018942/0916	2007-02-20			
YORK,NY,US	SCHWARZ PHARMA LIMITED	2006-04-12					
Conveyance: CONFIRMATION OF EXCLUSIVE PATENT LICENSE							
Corresponent: CARL J. GODDARD PFIZER INC., PATENT DEPT. EASTERN POINT RD. GROTON, CT 06340							
SCHWARZ PHARMA	MEESE, CLAUS	2000-12-13	011443/0478	2001-01-11			
AG,MONHEIM,DE	SPARF, BENGT	2000-12-13					
Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).							
Corresponent: MCDONNELL BOEHNEN, HULBERT & BERGHOFF MICHAEL S. GREENFIELD 300 SOUTH WACKER DRIVE, SUITE 3200 CHICAGO, IL 60606							

Maintenance Status (US): CC Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



**Record 20/45** CN1207268C Novel derivatives of 3-3-diphenylpropylamines | 3, 3-diphenyl-propyl amine derivant

Title: Novel derivatives of 3-3-diphenylpropylamines | 3, 3-diphenyl-propyl amine derivant Title - DWPI: New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome Priority Number: EP1998108608A Priority Date: 1998-05-12 Application Number: CN1999806038A Application Date: 1999-05-11 Publication Date: 2005-06-22 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	А	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	А	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	А	A61	A61K	A61K0031	A61K00317028
A61P000100	А	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	А	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152

C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	А	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	А	A61	A61K	A61K0031	A61K003122
A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	Α	A61	A61K	A61K0031	A61K0031235
A61K003124	А	A61	A61K	A61K0031	A61K003124

A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	А	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	А	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347

C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: SCHWARZ PHARMA AG,US JP F Terms: JP FI Codes: Assignee - Original: SCHWARZ PHARMA AG Any CPC Table:

Туре	Invention	Additional	Version	Office

Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

# ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compouds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

This invention relates to the 3, 3-diphenyl-propyl amine of formula I and VII and with a physiologically acceptable acid salt, free base and/or racemic mixture and enantiomer. Definition of each group and symbol specification. They are applied to the muscarinic medicine in the active substance.

L'invention concerne de nouveaux dérivés de 3,3-diphénylpropylamines, des procédés permettant de les préparer, des compositions pharmaceutiques contenant ces nouveaux composés et l'utilisation de ces composés pour la préparation de médicaments. L'invention concerne plus particulièrement de nouveaux précurseurs d'agents anti-muscariniques qui ont des propriétés pharmacocinétiques supérieures à celles des médicaments existants tels que l'oxybutynine et la toltérodine, un procédé de préparation de ces précurseurs, des compositions pharmaceutiques les contenant et un procédé d'utilisation de ces composés, ainsi que des compositions destinées au traitement de l'incontinence urinaire, de l'hyperactivité gastro-intestinale (syndrome du côlon irritable) et d'autres pathologies affectant la contractilité des muscles lisses.

# Language of Publication: ZH

#### INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact			
2011-05-18	C56	-			
Description: CHANGE IN THE NAME OR ADDRESS OF THE PATENTEE UCB PHARMA INC. FORMER NAME: SCHWARZ PHARMA AG					
2011.05.18	056				

2005-06-22	C14	+					
Description: GRANTED							
2002-06-19	C06	+					
Description: PUBLICATION							
2002-06-05	C10	-					
Description: REQUEST OF EXAMINATION AS TO SUBSTANCE							

Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



Record 21/45 IS2044B Nyjar afleithur af 3,3-dífenylpropylamínum

Title: Nyjar afleithur af 3,3-dífenylpropylamínum Title - DWPI: Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: IS5670A Application Date: 2000-10-17 Publication Date: 2005-09-15 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	с	C07	C07C	C07C0219	C07C021922
C07C021928	с	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
------------	---	-----	------	----------	------------
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

**ECLA**: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

### Abstract:

Language of Publication: IS INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:

(No drawing/image available)

Record 22/45 HK1046269A1 Derivatives of 3,3-diphenylpropylamines.

Title: Derivatives of 3,3-diphenylpropylamines. Title - DWPI: Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: HK2002107859A Application Date: 2002-10-30 Publication Date: 2005-09-23 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	с	C07	C07C	C07C0219	C07C021922
C07C021928	с	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702

C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

**ECLA**: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

### Abstract:

Language of Publication: ZH INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:

(No drawing/image available)

**Record 23/45** CZ296605B6 3,3-Diphenylpropylamines, pharmaceutical compositions, process of their preparation and use

**Title:** 3,3-Diphenylpropylamines, pharmaceutical compositions, process of their preparation and use

**Title - DWPI:** New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome

Priority Number: EP1998108608A Priority Date: 1998-05-12 Application Number: CZ20003774A Application Date: 1999-05-11 Publication Date: 2006-04-12 IPC Class Table:

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 <td< th=""><th>IPC</th><th>Section</th><th>Class</th><th>Subclass</th><th>Class Group</th><th>Subgroup</th></td<>	IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300CC12C12PC12P0013C12P001300A61K0031135AA61A61KA61K0031A61K0031135A61K0031235AA61A61KA61K0031A61K0031235A61K0031325AA61A61KA61K0031A61K0031325A61K0031325AA61A61KA61K0031A61K0031325A61K0031357AA61A61KA61K0031A61K0031357A61K0031455AA61A61KA61K0031A61K003140A61K003140AA61A61KA61K0031A61K003140A61K0031405AA61A61KA61K0031A61K003140A61K0031405AA61A61KA61K0031A61K003140A61K0031406AA61A61KA61K0031A61K0031405A61K0031405AA61A61KA61K0031A61K0031405A61K00317028AA61A61FA61K0031A61P00100A61P001300AA61A61PA61P00130A61P001300A61P004300AA61A61PA61P00130A61P001300A61P004300AA61A61PA61P00130A61P004300C07C021306CCCCCCC07C021748CCCCCCC07C021922CCCCCCCC07C021924CCCCCCCC07C021925CCCC <td>C07C021928</td> <td>С</td> <td>C07</td> <td>C07C</td> <td>C07C0219</td> <td>C07C021928</td>	C07C021928	С	C07	C07C	C07C0219	C07C021928
A61K0031135AA61A61KA61K0031135A61K0031135A61K0031255AA61A61KA61K0031A61K0031325A61K0031327AA61A61KA61K0031A61K0031327A61K0031357AA61A61KA61K0031A61K0031357A61K0031357AA61A61KA61K0031A61K0031357A61K0031355AA61A61KA61K0031A61K0031355A61K003140AA61A61KA61K0031A61K0031405A61K0031435AA61A61KA61K0031A61K0031405A61K00317028AA61A61KA61K0031A61K0031405A61P00100AA61A61P0A61P00130A61P00130A61P00130A61P001300AA61A61P0A61P00130A61P00130A61P00130A61P001300AA61A61P0A61P00130A61P00130A61P00130A61P001300AA61A61P0A61P00130A61P00130A61P00130A61P001300AA61A61P0A61P00130A61P00130A61P00130A61P001300AAA61A61P00130A61P00130A61P00130A61P001300AAA61A61P00130A61P00130A61P00130A61P001300AAA61A61P00130A61P00130A61P00130A61P001300AAA61A61P00130A61P00130A61P00130A61P001300AAAAAA <td>C12P001300</td> <td>С</td> <td>C12</td> <td>C12P</td> <td>C12P0013</td> <td>C12P001300</td>	C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031235AA61A61KA61K0031A61K0031325A61K0031325AA61A61KA61K0031A61K0031325A61K0031357AA61A61KA61K0031A61K0031357A61K0031357AA61A61KA61K0031A61K0031357A61K0031357AA61A61KA61K0031A61K0031357A61K003140AA61A61KA61K0031A61K003140A61K003140AA61A61KA61K0031A61K003140A61K003140AA61A61KA61K0031A61K00317028A61K00317028AA61A61KA61K0031A61K00317028A61P00100AA61A61P0A61P00130A61P00130A61P00130A61P001300AA61A61P0A61P00130A61P00130A61P00130A61P001300AA61A61P0A61P00130A61P00130A61P00130A61P001300AA61A61P0A61P00130A61P00130A61P00130A61P001300AA61A61P0A61P00130A61P00130A61P00130A61P001300AA61A61P0A61P00130A61P00130A61P00130A61P001300AA61A61P0A61P00130A61P00130A61P00130A61P001300AAA61P00130A61P00130A61P00130A61P00130A61P001300AAA61P00130A61P00130A61P00130A61P00130A61P001300AAAA <td< td=""><td>A61K0031135</td><td>A</td><td>A61</td><td>A61K</td><td>A61K0031</td><td>A61K0031135</td></td<>	A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031325AA61A61KA61K0031325A61K0031325A61K0031357AA61A61K0A61K0031357A61K0031357A61K0031365AA61A61K0A61K0031A61K0031365A61K003140AA61A61K0A61K003140A61K003140A61K0031435AA61A61K0A61K003140A61K0031435A61K00317028AA61A61KA61K0031A61K00317028A61P00100AA61A61P0A61P00130A61P00130A61A61P001300AA61A61P0A61P00130A61P00130A61P00130A61P001300AA61A61P0A61P00130A61P00130A61900130A61P001300AA61A61P0A61P00130A61P00130A61900130A61P001300AA61A61P0A61P00130A61P00130A61900130A61P001300AA61A61P0A61P00130A61P00130A61P00130A61P001300AA61A61P0A61P00130A61P00130A61P00130A61P001300AA61A61P00130A61P00130A61P00130A61P00130A61P001300AA61A61P00130A61P00130A61P00130A61P00130A61P001300AAA61A61P00130A61P00130A61P00130A61P00130A61P001300AAA61A61P00130A61P00130A61P00130A61P00130A61P00130A61P001300AAAAA61P00	A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031357AA61A61KA61K0031A61K0031357A61K0031365AA61A61K0A61K0031A61K0031365A61K003140AA61A61KA61K0031A61K003140A61K0031435AA61A61KA61K0031A61K0031435A61K00317028AA61A61KA61K0031A61K00317028A61K00317028AA61A61P001A61P00130A61P00130A61AA61P001300AA61A61P0A61P00130A61P00130A61P00130A61P004300AA61A61P0A61P00130A61P00130A61P00130A61P004300AA61A61P0A61P00130A61P00130A61P00130A61P004300AA61A61P0A61P00130A61P00130A61P00130A61P004300AA61A61P0A61P00130A61P00130A61P00130A61P004300AA61A61P0A61P00130A61P00130A61P00130A61P004300AA61A61P0A61P00130A61P00130A61P00130A61P004300AA61A61P0A61P00130A61P00130A61P00130A61P004300AA61A61P00130A61P00130A61P00130A61P00130A61P004300AA61P00130A61P00130A61P00130A61P00130A61P00130A61P004300AAA61P00130A61P00130A61P00130A61P00130A61P004300AAAAAAAA <td>A61K0031325</td> <td>A</td> <td>A61</td> <td>A61K</td> <td>A61K0031</td> <td>A61K0031325</td>	A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031365AA61A61KA61K003140A61K0031365A61K003140AA61A61KA61K003140A61K003140A61K0031435AA61A61KA61K003140A61K0031435A61K00317028AA61A61KA61K00317028A61K00317028A61P00100AA61A61P0A61P00100A61P00100A61P00100AA61A61P0A61P00100A61P00100A61P001300AA61A61P0A61P00130A61P00130A61P001310AA61A61P0A61P00130A61P001300A61P001300AA61A61P0A61P00130A61P001300A61P001300AA61A61P0A61P00130A61P001300A61P001300AA61A61P0A61P00130A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AAA61P0A61P001300A61P001300 <t< td=""><td>A61K0031357</td><td>A</td><td>A61</td><td>A61K</td><td>A61K0031</td><td>A61K0031357</td></t<>	A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K003140AA61A61KA61K003140A61K003140A61K0031435AA61A61KA61K0031A61K0031435A61K00317028AA61A61KA61K0031A61K00317028A61P00100AA61A61PA61P00130A61P001300A61P001300AA61A61PA61P00130A61P001300A61P001300AA61A61PA61P00130A61P001300A61P001300AA61A61PA61P00130A61P001300A61P001300AA61A61PA61P001300A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AA61A61P0A61P001300A61P001300A61P001300AA61P0A61P001300A61P001300A61P001300 <t< td=""><td>A61K0031365</td><td>A</td><td>A61</td><td>A61K</td><td>A61K0031</td><td>A61K0031365</td></t<>	A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K0031435AA61A61KA61K0031435A61K0031435A61K00317028AA61A61KA61K0031A61K00317028A61P00100AA61A61PA61P0010A61P00100A61P001300AA61A61PA61P00130A61P001300A61P001310AA61A61PA61P00130A61P001300A61P001300AA61A61PA61P00130A61P001300A61P001300AA61A61PA61P00130A61P001300A61P001300AA61A61PA61P00130A61P001300A61P001300AA61A61PA61P00130A61P001300A61P001300AA61A61PA61P00130A61P001300A61P001300AA61A61P00A61P00130A61P001300A61P001300AA61A61P00A61P00130A61P001300A61P001300AA61A61P00A61P00130A61P001300A61P001300AA61A61P00A61P00130A61P001300A61P001300AA61A61P00A61P00130A61P001300A61P001300AA61A61P00A61P00130A61P001300C07C021306CCCCCC07C021702CCCCCC07C021703CCCCCC07C021704AAAAAAAAAAAAAAC07	A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K00317028AA61A61KA61K0031A61K00317028A61P00100AA61A61PA61P0010A61P00100A61P001300AA61A61PA61P0013A61P001300A61P001310AA61A61PA61P0013A61P001310A61P004300AA61A61PA61P0043A61P004300A61P004300AA61A61PA61P0043A61P004300C07C021306CC07C07C0213C07C021306C07C021306C07C021762CC07C07C0217C07C021762C07C021762C07C021922CC07C07C0210C07C02108C07C02108C07C021108CC07C07C02108C07C02108C07C02108	A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61P000100AA61A61PA61P001100A61P00100100A61P001300AA61A61PA61P00130A61P001300A61P001310AA61A61PA61P00130A61P001310A61P004300AA61A61PA61P00430A61P004300A61P004300AA61A61P0A61P004300A61P004300C07C021306CC07C07C021306C07C021306C07C021306C07C021748CC07C07C02170C07C021748C07C02172C07C021922CC07C07C0219C07C02192C07C02108C07C021108CC07C07C02110C07C02108C07C021108CC07C07C02110C07C02108	A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P001300AA61A61PA61P0013A61P001300A61P001310AA61A61PA61P0013A61P001310A61P004300AA61A61PA61P0043A61P00430C07C021306CC07C07C0213C07C021306C07C021306C07C021748CC07C07C0217C07C021748C07C021748C07C021762CC07C07C0217C07C021762C07C021762C07C021922CC07C07C02192C07C02192C07C02108C07C02108CC07C07C02108C07C02108C07C02108C07C02108CC07C07C02108C07C02108C07C02108	A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001310AA61A61PA61P0013A61P001310A61P004300AA61A61PA61P0043A61P004300C07C021306CC07C07C0213C07C021306C07C021306C07C021748CC07C07C0217C07C021748C07C021748C07C021762CC07C07C0217C07C021762C07C021762C07C021922CC07C07C0210C07C02108C07C02108C07C02108CC07C07C02108C07C02108C07C02108	A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P004300 A A61 A61P A61P00430 A61P004300   C07C021306 C C07 C07C021306 C07C021306 C07C021306   C07C021748 C C07 C07C021748 C07C021748 C07C021748 C07C021748   C07C021762 C C07 C07C021762 C07 C07C021762 C07C021762   C07C021922 C C07 C07C02 C07C02192 C07 C07C02   C07C027108 C C07 C07C02 C07 C07C02 C07 C07C02	A61P001310	A	A61	A61P	A61P0013	A61P001310
C07C021306 C C07 C07C0213 C07C021306   C07C021748 C C07 C07C0217 C07C021748   C07C021762 C C07 C07C0217 C07C021762   C07C021922 C C07 C07C02 C07C02192 C07 C07C02192   C07C027108 C C07 C07C02 C07C027108 C07C027108 C07C027108 C07C027108	A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021748   C   C07   C07C02176   C07C021748     C07C021762   C   C07   C07C0217   C07C021762     C07C021922   C   C07   C07C02   C07C021922     C07C027108   C   C07   C07C02   C07C027108     C07C027108   C   C07   C07C02   C07C027108	C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021762 C C07 C07C02172 C07C021762   C07C021922 C C07 C07C0219 C07C021922   C07C027108 C C07 C07C027108 C07C027108   C07C027108 C C07 C07C027108 C07C027108	C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021922   C   C07   C07C   C07C0219   C07C021922     C07C027108   C   C07   C07C   C07C0271   C07C027108     C07C027108   C   C07   C07C   C07C0271   C07C027108	C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C027108   C   C07   C07C0   C07C027108   C07C027108	C07C021922	С	C07	C07C	C07C0219	C07C021922
	C07C027108	С	C07	C07C	C07C0271	C07C027108
CU/CU2/144 C CU/CU2/144 C C0/C C0/C02/1 C07C027144	C07C027144	С	C07	C07C	C07C0271	C07C027144

C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	А	A01	A01N	A01N0037	A01N003710
A01N003712	А	A01	A01N	A01N0037	A01N003712
A01N003744	А	A01	A01N	A01N0037	A01N003744
A61K0031135	А	A61	A61K	A61K0031	A61K0031135
A61K0031137	А	A61	A61K	A61K0031	A61K0031137
A61K003121	А	A61	A61K	A61K0031	A61K003121
A61K0031215	А	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	A	A61	A61K	A61K0031	A61K003122
A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222
A61K0031225	А	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235

A61K003124	A	A61	A61K	A61K0031	A61K003124
A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	С07В	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900

C07C023347	С	C07	C07C	C07C0233	C07C023347
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	с	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	с	C07	C07D	C07D0321	C07D032110
C07F000718	с	C07	C07F	C07F0007	C07F000718
C07H001518	с	C07	C07H	C07H0015	C07H001518
C12P001300	с	C12	C12P	C12P0013	C12P001300
C07C021546	с	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	с	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

### Abstract:

In the present invention, there are disclosed novel derivatives of 3,3-diphenylpropylamines, processes for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing medicaments. More particularly, the invention relates to novel prodrugs of anti-muscarine agents with superior pharmacokinetic properties, processes for their preparation, pharmaceutical compositions containing them, a method of using said compounds and pharmaceutical compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

Language of Publication: CS INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



Record 24/45 US7230030B2 Derivatives of 3,3-diphenylpropylamines

Title: Derivatives of 3,3-diphenylpropylamines Title - DWPI: New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome Priority Number: EP1998108608A | WO1999EP3212A | US2001700094A Priority Date: 1998-05-12 | 1999-05-11 | 2001-01-02 Application Number: US2004766263A Application Date: 2004-01-27 Publication Date: 2007-06-12 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
A01N003702	A	A01	A01N	A01N0037	A01N003702
C12P001300	С	C12	C12P	C12P0013	C12P001300
A01N003706	A	A01	A01N	A01N0037	A01N003706
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762

C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	с	C07	C07C	C07C0271	C07C027100
C07C030700	с	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	А	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	A	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	A	A61	A61K	A61K0031	A61K003122

A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K003124	A	A61	A61K	A61K0031	A61K003124
A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	А	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	А	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	А	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	А	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922

C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: Schwarz Pharma AG,Monheim,DE JP F Terms: JP FI Codes: Assignee - Original: Schwarz Pharma AG Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

**ECLA**: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

### Abstract:

The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

## Language of Publication: EN INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact				
2010-11-10	FPAY +					
Description: FEE PAYMENT						
2010-05-24	AS	-				
Description: ASSIGNMENT UCB PHARMA GMBH, GERMANY CHANGE OF NAME; ASSIGNOR:SCHWARZ PHARMA AG; REEL/FRAME:024424/0724 2010-01-20						

### Post-Issuance (US): Reassignment (US) Table:

Assignee	Assignor	Date Signed	Reel/Frame	Date
UCB PHARMA GMBH,MONHEIM,DE	SCHWARZ PHARMA AG	2010-01-20	024424/0724	2010-05-24

 $\label{eq:conveyance: change of name (see document for details).$ 

Corresponent: JEFFREY GINSBERG ONE BROADWAY KENYON & KENYON LLP NEW YORK, NY 10004

Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



Record 25/45 JP03929702B2 The novel derivative of a 3, 3- diphenyl propyl amine

Title: The novel derivative of a 3, 3- diphenyl propyl amine Title - DWPI: New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: JP2000548284A Application Date: 1999-05-11 Publication Date: 2007-06-13 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C07C021762	С	C07	C07C	C07C0217	C07C021762
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	А	A61	A61K	A61K0031	A61K0031235
A61K0031325	А	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	А	A61	A61K	A61K0031	A61K0031365
A61K003140	А	A61	A61K	A61K0031	A61K003140
A61K0031435	А	A61	A61K	A61K0031	A61K0031435
A61K00317028	А	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	А	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152

C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	А	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	A	A61	A61K	A61K0031	A61K003122
A61K0031221	А	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222
A61K0031225	Α	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K003124	A	A61	A61K	A61K0031	A61K003124

A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	А	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	А	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347

C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

### Assignee/Applicant: SCHWARZ PHARM AG

JP F Terms: | 4B064AE01 | 4B064CA21 | 4B064CB25 | 4B064CC03 | 4B064CD12 | 4B064DA01 | 4C022MA02 | 4C057AA18 | 4C057BB02 | 4C057DD01 | 4C057JJ20 | 4C086AA01 | 4C086AA02 | 4C086AA03 | 4C086AA04 | 4C086CA03 | 4C086EA07 | 4C086MA01 | 4C086MA02 | 4C086MA04 | 4C086MA05 | 4C086NA06 | 4C086NA11 | 4C086NA14 | 4C086NA15 | 4C086ZA66 | 4C086ZA84 | 4C086ZA94 | 4C086ZC42 | 4C201 | 4C206AA01 | 4C206AA02 | 4C206AA03 | 4C206AA04 | 4C206DB04 | 4C206DB11 | 4C206DB15 | 4C206DB16 | 4C206DB18 | 4C206DB29 | 4C206DB57 | 4C206FA51 | 4C206GA13 | 4C206GA22 | 4C206HA24 | 4C206MA01 | 4C206MA02 | 4C206MA04 | 4C206MA05 | 4C206NA06 | 4C206NA11 | 4C206NA14 | 4C206NA15 | 4C206ZA66 | 4C206ZA84 | 4C206ZA94 | 4C206ZC42 | 4H006AA01 | 4H006AA02 | 4H006AA03 | 4H006AB20 | 4H006AC13 | 4H006AC48 | 4H006AC52 | 4H006AC56 | 4H006BJ50 | 4H006BN10 **JP FI Codes:** | A61K0031235 | A61K0031325 | A61K0031357 | A61K0031365 | A61K00317028 | A61P000100 | A61P001300 | A61P004300-111 | C07C021306 | C07C021762 | C07C021928 | C07C027108 | C07C030702 | C07D032100 | C07H001518 | C12P001300 **Assignee - Original:** SCHWARZ PHARM AG

Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

# ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

### Abstract:

The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compouds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

L'invention concerne de nouveaux dérivés de 3,3-diphénylpropylamines, des procédés permettant de les préparer, des compositions pharmaceutiques contenant ces nouveaux composés et l'utilisation de ces composés pour la préparation de médicaments. L'invention concerne plus particulièrement de nouveaux précurseurs d'agents anti-muscariniques qui ont des propriétés pharmacocinétiques supérieures à celles des médicaments existants tels que l'oxybutynine et la toltérodine, un procédé de préparation de ces précurseurs, des compositions pharmaceutiques les contenant et un procédé d'utilisation de ces composés, ainsi que des compositions destinées au traitement de l'incontinence urinaire, de l'hyperactivité gastro-intestinale (syndrome du côlon irritable) et d'autres pathologies affectant la contractilité des muscles lisses.

### Language of Publication: JA

### INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact			
2013-06-19	R153	+			
Description: GRANT OF PATENT TERM EXTENSION JAPANESE INTERMEDIATE CODE: R153					

2013-04-03	FPAY	+			
Description: RENEWAL FEE PAYMENT (PRS DATE IS RENEWAL DATE OF DATABASE) PAYMENT UNTIL: 20140316					
2013-03-05	FPAY	+			
Description: RENEWAL FEE PAYMENT (PRS DATE IS RENEWAL DATE OF DATABASE) PAYMENT UNTIL: 20140316					
2013-02-28	FPAY	+			
Description: RENEWAL FEE PAYME 20130316	ENT (PRS DATE IS RENEWAL DATE OF D	ATABASE) PAYMENT UNTIL:			
2012-03-06	FPAY	+			
Description: RENEWAL FEE PAYME 20130316	NT (PRS DATE IS RENEWAL DATE OF D	ATABASE) PAYMENT UNTIL:			
2012-03-01	FPAY	+			
Description: RENEWAL FEE PAYME 20120316	ENT (PRS DATE IS RENEWAL DATE OF D	ATABASE) PAYMENT UNTIL:			
2011-04-27	R350	-			
Description: WRITTEN NOTIFICATIO	ON OF REGISTRATION OF TRANSFER	IAPANESE INTERMEDIATE CODE:			
2011-04-27	FPAY	+			
Description: RENEWAL FEE PAYME 20120316	ENT (PRS DATE IS RENEWAL DATE OF D	ATABASE) PAYMENT UNTIL:			
2011-04-19	S201	_			
Description: REQUEST FOR REGIST R314201	TRATION OF EXCLUSIVE LICENCE JAP	ANESE INTERMEDIATE CODE:			
2011-04-13	RD04	-			
<b>Description</b> : NOTIFICATION OF RESIGNATION OF POWER OF ATTORNEY JAPANESE INTERMEDIATE CODE: R3D04					
2011-04-13	FPAY	+			
Description: RENEWAL FEE PAYME 20120316	ENT (PRS DATE IS RENEWAL DATE OF D	ATABASE) PAYMENT UNTIL:			
	-				

2011-03-28	RD02	-
Description: NOTIFICATION OF ACC R3D02	CEPTANCE OF POWER OF ATTORNEY	JAPANESE INTERMEDIATE CODE:
2011-03-03	FPAY	+
Description: RENEWAL FEE PAYME 20110316	ENT (PRS DATE IS RENEWAL DATE OF D	DATABASE) PAYMENT UNTIL:
2011-02-10	R350	_
Description: WRITTEN NOTIFICATIO	DN OF REGISTRATION OF TRANSFER	JAPANESE INTERMEDIATE CODE:
2011-02-10	FPAY	+
Description: RENEWAL FEE PAYME 20110316	ENT (PRS DATE IS RENEWAL DATE OF D	DATABASE) PAYMENT UNTIL:
2011-02-02	S533	-
Description: WRITTEN REQUEST FOR R313533	OR REGISTRATION OF CHANGE OF NAM	/E JAPANESE INTERMEDIATE CODE:
2011-02-02	FPAY	+
Description: RENEWAL FEE PAYME 20110316	ENT (PRS DATE IS RENEWAL DATE OF D	DATABASE) PAYMENT UNTIL:
2010-03-09	FPAY	+
Description: RENEWAL FEE PAYME 20110316	ENT (PRS DATE IS RENEWAL DATE OF D	DATABASE) PAYMENT UNTIL:
2007-03-16	R150	+
Description: CERTIFICATE OF PATE INTERMEDIATE CODE: R150	ENT (=GRANT) OR REGISTRATION OF U	TILITY MODEL JAPANESE
2007-03-15	A61	+
Description: FIRST PAYMENT OF AN CODE: A61 2007-03-07	NNUAL FEES (DURING GRANT PROCED	URE) JAPANESE INTERMEDIATE
2007-02-27	A01	+
Description: WRITTEN DECISION TO JAPANESE INTERMEDIATE CODE: A01	O GRANT A PATENT OR TO GRANT A RE 2007-02-26	EGISTRATION (UTILITY MODEL)

2007-02-21	TRDD	+			
Description: DECISION OF GRANT OR REJECTION WRITTEN					
2007-01-19	A521	-			
Description: WRITTEN AMENDMEN	Description: WRITTEN AMENDMENT JAPANESE INTERMEDIATE CODE: A523 2007-01-18				
2006-12-05	A131	-			
Description: NOTIFICATION OF REA	ASONS FOR REFUSAL JAPANESE INTE	RMEDIATE CODE: A131 2006-12-04			
2006-10-19	A521	-			
Description: WRITTEN AMENDMENT JAPANESE INTERMEDIATE CODE: A523 2006-10-18					

Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



Title: NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES Title - DWPI: Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: PL347823A Application Date: 1999-05-11 Publication Date: 2007-10-31 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C07C021928	С	C07	C07C	C07C0219	C07C021928
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702

C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

**ECLA**: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

Language of Publication: PL INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:

(No drawing/image available)

**Record 27/45** LU91365I2 Fésotérodine et ses sels avec des acides physiologiquement acceptables, y compris l'acide fumarique (TOVIAZ)

**Title:** Fésotérodine et ses sels avec des acides physiologiquement acceptables, y compris l'acide fumarique (TOVIAZ) **Title - DWPI:** 

Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: LU200791365C Application Date: 2007-09-14 Publication Date: 2007-11-14 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152

C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC Class Table - DWPI: Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702 Abstract: Language of Publication: FR INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:

(No drawing/image available)

**Record 28/45** SK286052B6 3,3-Diphenylpropylamines, pharmaceutical compositions, method for the preparation thereof and use

**Title:** 3,3-Diphenylpropylamines, pharmaceutical compositions, method for the preparation thereof and use

**Title - DWPI:** New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome

Priority Number: EP1998108608A | WO1999EP3212A

Priority Date: 1998-05-12 | 1999-05-11

Application Number: SK20001547A

Application Date: 1999-05-11

Publication Date: 2008-02-05

IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762

C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	с	C07	C07C	C07C0271	C07C027100
C07C030700	с	C07	C07C	C07C0307	C07C030700
A01N003702	А	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	А	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	А	A01	A01N	A01N0037	A01N003744
A61K0031135	А	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	А	A61	A61K	A61K0031	A61K0031215
A61K0031216	Α	A61	A61K	A61K0031	A61K0031216
A61K003122	A	A61	A61K	A61K0031	A61K003122

A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K003124	A	A61	A61K	A61K0031	A61K003124
A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	А	A61	A61K	A61K0031	A61K0031325
A61K0031357	А	A61	A61K	A61K0031	A61K0031357
A61K0031365	А	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922

C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

### Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

**ECLA**: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

### Abstract:

Described are compounds of the formula (I) and (VII'), wherein the meaning of the substituents is described in description. Besides the method of the preparation of 3,3-diphenylpropylamines the pharmaceutical composition containing thereof is also described, that is active at treatment of urinary incontinence, gastrointestinal hyperactivity and other smooth muscle contractile conditions. **Language of Publication:** SK

INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



Record 29/45 NL300293I2 Nieuwe derivaten van 3,3-difenylpropylaminen

Title: Nieuwe derivaten van 3,3-difenylpropylaminen Title - DWPI: Priority Number: EP1998108608A | WO1999EP3212A | EP1999924929A Priority Date: 1998-05-12 | 1999-05-11 | 1999-05-11 Application Number: NL300293C Application Date: 2007-09-13 Publication Date: 2008-03-03 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	с	C07	C07C	C07C0219	C07C021922
C07C021928	с	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702

C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

**ECLA**: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

### Abstract:

Language of Publication: NL INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:

(No drawing/image available)

# **Record 30/45** CA2328920C NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | NOUVEAUX DERIVES DE 3,3-DIPHENYLPROPYLAMINES

**Title:** NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | NOUVEAUX DERIVES DE 3,3-DIPHENYLPROPYLAMINES

**Title - DWPI:** New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome

**Priority Number:** EP1998108608A | WO1999EP3212A

Priority Date: 1998-05-12 | 1999-05-11

Application Number: CA2328920A

Application Date: 1999-05-11

Publication Date: 2008-04-15

IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K0031215	A	A61	A61K	A61K0031	A61K0031215
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	А	A61	A61P	A61P0021	A61P002100
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306

C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	с	C07	C07C	C07C0271	C07C027100
C07C030700	с	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	А	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	А	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	A	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216

A61K003122	A	A61	A61K	A61K0031	A61K003122
A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K003124	A	A61	A61K	A61K0031	A61K003124
A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
-------------	---	-----	------	----------	-------------
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	А	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: SCHWARZ PHARMA AG,MONHEIM,DE JP F Terms: JP FI Codes: Assignee - Original: SCHWARZ PHARMA AG Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

# **ECLA**: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

### Abstract:

The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compouds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

L'invention concerne de nouveaux dérivés de 3,3-diphénylpropylamines, des procédés permettant de les préparer, des compositions pharmaceutiques contenant ces nouveaux composés et l'utilisation de ces composés pour la préparation de médicaments. L'invention concerne plus particulièrement de nouveaux précurseurs d'agents anti-muscariniques qui ont des propriétés pharmacocinétiques supérieures à celles des médicaments existants tels que l'oxybutynine et la toltérodine, un procédé de préparation de ces précurseurs, des compositions pharmaceutiques les contenant et un procédé d'utilisation de ces composés, ainsi que des compositions destinées au traitement de l'incontinence urinaire, de l'hyperactivité gastro-intestinale (syndrome du côlon irritable) et d'autres pathologies affectant la contractilité des muscles lisses.

# Language of Publication: EN INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact		
2002-11-19	EEER	+		
Description: EXAMINATION REQUEST				

Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: EX-RQ 2002-11-19 2002 Request for examination Front Page Drawing:



Record 31/45 US7384980B2 Derivatives of 3,3-diphenylpropylamines

Title: Derivatives of 3,3-diphenylpropylamines

Title - DWPI: New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome Priority Number: EP1998108608A | WO1999EP3212A | US2001700094A | US2004766263A Priority Date: 1998-05-12 | 1999-05-11 | 2001-01-02 | 2004-01-27 Application Number: US2005201756A Application Date: 2005-08-10 Publication Date: 2008-06-10 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
A01N003712	A	A01	A01N	A01N0037	A01N003712
C12P001300	с	C12	C12P	C12P0013	C12P001300
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K003122	A	A61	A61K	A61K0031	A61K003122
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	с	C07	C07C	C07C0213	C07C021306
C07C021748	с	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928

C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

## IPC Class Table - DWPI:

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	с	C07	C07C	C07C0217	C07C021700
C07C021900	с	C07	C07C	C07C0219	C07C021900
C07C027100	с	C07	C07C	C07C0271	C07C027100
C07C030700	с	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	A	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	A	A61	A61K	A61K0031	A61K003122
A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222

A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K003124	A	A61	A61K	A61K0031	A61K003124
A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928

C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	с	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	с	C07	C07C	C07C0069	C07C0069017
C07C006922	с	C07	C07C	C07C0069	C07C006922
C07C006934	с	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: Schwarz Pharma AG,Monheim,DE JP F Terms: JP FI Codes: Assignee - Original: Schwarz Pharma AG

## Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

# ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

### Abstract:

The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

# Language of Publication: EN INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact			
2011-09-19	FPAY	+			
Description: FEE PAYMENT					
2010-05-24	AS	-			
Description: ASSIGNMENT UCB PHARMA GMBH, GERMANY CHANGE OF NAME; ASSIGNOR:SCHWARZ PHARMA AG; REEL/FRAME:024424/0724 2010-01-20					

## Post-Issuance (US): Reassignment (US) Table:

Assignee	Assignor	Date Signed	Reel/Frame	Date		
UCB PHARMA GMBH,MONHEIM,DE	SCHWARZ PHARMA AG	2010-01-20	024424/0724	2010-05-24		
Conveyance: CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).						
Corresponent: JEFFREY GINSBERG ONE BROADWAY KENYON & KENYON LLP NEW YORK, NY 10004						

## Maintenance Status (US):

Litigation (US): 2013-06-21 2013 Pfizer Inc. UCB Pharma Gmbh Alkem Laboratories Ltd. Delaware 1:13cv01110 | 2013-06-21 2013 Pfizer Inc. UCB Pharma Gmbh Sandoz Inc. Delaware 1:13cv01111 | 2013-06-24 2013 Inc Pfizer UCB Pharma Gmbh Alkem Laboratories, Ltd. N.D. Illinois 1:13cv04628 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Accord Healthcare Inc., USA Delaware 1:13cv01155 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Amerigen Pharmaceuticals Inc. Amerigen Pharmaceuticals Ltd Delaware 1:13cv01156 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Amneal Pharmaceuticals LLC Delaware 1:13cv01157 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Impax Laboratories Inc. Delaware 1:13cv01158 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Lupin Ltd. Delaware 1:13cv01153 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Zydus Pharmaceuticals (USA) Inc. Delaware 1:13cv01154 | 2013-08-02 2013 Pfizer Inc. UCB Pharma Gmbh Wockhardt Bio AG Wockhardt USA LLC Delaware 1:13cv01387

Opposition (EP):

License (EP):

**EPO Procedural Status:** 

Front Page Drawing:



### Record 32/45 GEP20084461B NEW DERIVATIVE OF 3,3- DIPHENYL-PROPYLAMINE

Title: NEW DERIVATIVE OF 3,3- DIPHENYL-PROPYLAMINE Title - DWPI: Priority Number: EP1998108608A Priority Date: 1998-05-12 Application Number: GE2007AP10260A Application Date: 2007-09-10 Publication Date: 2008-08-25 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C07C000100	С	C07	C07C	C07C0001	C07C000100
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152

C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC Class Table - DWPI: Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

## Abstract:

The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their pre¬para¬tion, pharmaceutical compositions containing them, and the use of the compounds for preparing antimuscarinic agents.

Language of Publication: EN INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:

(No drawing/image available)

Record 33/45 CZ299721B6 Medicament for treating urinary incontinence

Title: Medicament for treating urinary incontinence Title - DWPI: New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome Priority Number: EP1998108608A Priority Date: 1998-05-12 Application Number: CZ200629A Application Date: 1999-05-11 Publication Date: 2008-10-29 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C07C021928	с	C07	C07C	C07C0219	C07C021928
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	А	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	А	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	с	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152

C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

## IPC Class Table - DWPI:

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	A	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	А	A61	A61K	A61K0031	A61K003122
A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	Α	A61	A61K	A61K0031	A61K0031235
A61K003124	A	A61	A61K	A61K0031	A61K003124

A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	А	A61	A61K	A61K0031	A61K0031357
A61K0031365	А	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	А	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347

C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office

Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

## Abstract:

In the present invention, there is disclosed the use of (.+-.)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester, R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-

hydroxymethylphenylisobutyrate ester or salt thereof with physiologically acceptable acids for the preparation of a medicament intended for the treatment of urinary incontinence.

Language of Publication: CS

INPADOC Legal Status Table:

Post-Issuance (US):

Reassignment (US) Table:

Maintenance Status (US):

Litigation (US):

Opposition (EP):

License (EP):

**EPO Procedural Status:** 

Front Page Drawing:



**Record 34/45** HU226490B1 NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES, PROCESS FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF USE THEM

**Title:** NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES, PROCESS FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF USE THEM

**Title - DWPI:** New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome

Priority Number: EP1998108608A | WO1999EP3212A

Priority Date: 1998-05-12 | 1999-05-11

Application Number: HU2001779A

Application Date: 1999-05-11

Publication Date: 2009-03-02

**IPC Class Table:** 

IPC	Section	Class	Subclass	Class Group	Subgroup
C07C000100	С	C07	C07C	C07C0001	C07C000100
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021900	С	C07	C07C	C07C0219	C07C021900

C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

# IPC Class Table - DWPI:

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	А	A01	A01N	A01N0037	A01N003710
A01N003712	А	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	А	A61	A61K	A61K0031	A61K0031135
A61K0031137	А	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	A	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216

A61K003122	A	A61	A61K	A61K0031	A61K003122
A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K003124	A	A61	A61K	A61K0031	A61K003124
A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762

C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

## Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

# **ECLA**: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

# Language of Publication: HU INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact			
2010-12-28	FG4S	+			
<b>Description:</b> GRANT OF SUPPLEMENTARY PROTECTION CERTIFICATE PRODUCT NAME: FESOTERODINE OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTINCLUDING FU ; REG. NO/DATE: EU/1/07/386/001-010 20070420					
2009-06-29	AA1S	+			
<b>Description:</b> INFORMATION ON APPLICATION FOR A SUPPLEMENTARY PROTECTION CERTIFICATE PRODUCT NAME: FESOTERODINE OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTINCLUDING FU ; REG. NO/DATE: EU/1/07/386/001-010 20070420					

Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



**Record 35/45** NO326872B1 Nye derivater av 3,3-difenylpropylaminer, farmasoytisk preparat inneholdende disse, samt fremgangsmater for fremstilling derav

Title: Nye derivater av 3,3-difenylpropylaminer, farmasoytisk preparat inneholdende disse, samt fremgangsmater for fremstilling derav Title - DWPI: Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: NO20005669A Application Date: 2000-11-10 Publication Date: 2009-03-09 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C07C021748	с	C07	C07C	C07C0217	C07C021748
C12P001300	с	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	с	C07	C07C	C07C0213	C07C021306
C07C021762	с	C07	C07C	C07C0217	C07C021762
C07C021922	с	C07	C07C	C07C0219	C07C021922
C07C021928	с	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152

C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

## IPC Class Table - DWPI: Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

# **ECLA:** C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

### Abstract:

Language of Publication: NO INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact			
2012-11-12	SPCG	+			
Description: GRANTED SUPPLEMENTARY PROTECTION CERTIFICATE PRODUCT NAME: TOVIAZ; NAT. REG. NO/DATE: EU107386001/NO-010/NO 20070531; FIRST REG. NO/DATE: EU107386001-010 20070420					

Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status:

# Front Page Drawing:

(No drawing/image available)

Record 36/45 CN100491336C Novel derivatives of 3,3-diphenylpropylamines

Title: Novel derivatives of 3,3-diphenylpropylamines Title - DWPI: New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome Priority Number: EP1998108608A Priority Date: 1998-05-12 Application Number: CN200510070299A Application Date: 1999-05-11 Publication Date: 2009-05-27 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C07C021928	с	C07	C07C	C07C0219	C07C021928
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	А	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	А	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	А	A61	A61P	A61P0001	A61P000100
A61P001300	А	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	с	C07	C07C	C07C0213	C07C021306
C07C021748	с	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144

C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

## IPC Class Table - DWPI:

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	А	A01	A01N	A01N0037	A01N003710
A01N003712	А	A01	A01N	A01N0037	A01N003712
A01N003744	А	A01	A01N	A01N0037	A01N003744
A61K0031135	А	A61	A61K	A61K0031	A61K0031135
A61K0031137	А	A61	A61K	A61K0031	A61K0031137
A61K003121	А	A61	A61K	A61K0031	A61K003121
A61K0031215	А	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	A	A61	A61K	A61K0031	A61K003122
A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222
A61K0031225	А	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235

A61K003124	A	A61	A61K	A61K0031	A61K003124
A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	А	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	А	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900

C07C023347	С	C07	C07C	C07C0233	C07C023347
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	с	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	с	C07	C07D	C07D0321	C07D032110
C07F000718	с	C07	C07F	C07F0007	C07F000718
C07H001518	с	C07	C07H	C07H0015	C07H001518
C12P001300	с	C12	C12P	C12P0013	C12P001300
C07C021546	с	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	с	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702 Abstract: Language of Publication: EN

INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact					
2011-05-18	C56	-					
Description: CHANGE IN THE NAME OR ADDRESS OF THE PATENTEE UCB PHARMA INC. FORMER NAME: SCHWARZ PHARMA AG							
2011-05-18	C56	_					
Description: CHANGE IN THE NAME	OR ADDRESS OF THE PATENTEE						
2009-05-27	C14	+					
Description: GRANTED							
2006-07-21	REG	-					
Description: REFERENCE TO A NAT HONG KONG	TONAL CODE HK HK 1084099 DE F	REQUESTS TO DESIGNATE PATENT IN					
2005-12-28	C10	-					
Description: REQUEST OF EXAMINATION AS TO SUBSTANCE							
2005-11-02	C06	+					
Description: PUBLICATION							

Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US):

## Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



**Record 37/45** PL202489B1 Derivatives of 3,3-diphenylopropyloamines, their production methods, pharmaceutical composition and applications

Title: Derivatives of 3,3-diphenylopropyloamines, their production methods, pharmaceutical composition and applications Title - DWPI: Priority Number: EP1998108608A Priority Date: 1998-05-12 Application Number: PL380081A Application Date: 1999-05-11 Publication Date: 2009-06-30

IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C07C021762	С	C07	C07C	C07C0217	C07C021762
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	А	A61	A61K	A61K0031	A61K0031135
A61K0031235	А	A61	A61K	A61K0031	A61K0031235
A61K0031325	А	A61	A61K	A61K0031	A61K0031325
A61K0031357	А	A61	A61K	A61K0031	A61K0031357
A61K0031365	А	A61	A61K	A61K0031	A61K0031365
A61K003140	А	A61	A61K	A61K0031	A61K003140
A61K0031435	А	A61	A61K	A61K0031	A61K0031435
A61K00317028	А	A61	A61K	A61K0031	A61K00317028
A61P000100	А	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	А	A61	A61P	A61P0013	A61P001310
A61P004300	А	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152

C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC Class Table - DWPI: Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

**ECLA**: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

Abstract:

Language of Publication: PL INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:

(No drawing/image available)

Record 38/45 HK1084099A1 DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES 3,3-

Title: DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES 3,3-Title - DWPI: Priority Number: EP1998108608A Priority Date: 1998-05-12 Application Number: HK2006104367A Application Date: 2006-04-11 Publication Date: 2009-11-20 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	с	C07	C07C	C07C0213	C07C021306
C07C021748	с	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	с	C07	C07C	C07C0219	C07C021928
C07C027108	с	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702

C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

#### IPC Class Table - DWPI:

Assignee/Applicant: SANOL ARZNEI SCHWARZ GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		2013010120130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02			EP

**ECLA**: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

### Abstract:

Language of Publication: ZH INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:

(No drawing/image available)

Title: 3,3-DIPHENYLPROPYLAMINDERIVATE Title - DWPI: Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: DE122007000065C Application Date: 1999-05-11 Publication Date: 2010-03-25 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C07C000100	с	C07	C07C	C07C0001	C07C000100
C12P001300	с	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	с	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
------------	---	-----	------	----------	------------
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC Class Table - DWPI: Assignee/Applicant: SCHWARZ PHARMA AG ALFRED NOBEL JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702 Abstract: Language of Publication: DE INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:

(No drawing/image available)

Record 40/45 US7855230B2 Derivatives of 3,3-diphenylpropylamines

**Title:** Derivatives of 3,3-diphenylpropylamines

**Title - DWPI:** New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome

Priority Number: EP1998108608A | WO1999EP3212A | US2001700094A | US2004766263A | US2005201756A

Priority Date: 1998-05-12 | 1999-05-11 | 2001-01-02 | 2004-01-27 | 2005-08-10

Application Number: US2008105016A

Application Date: 2008-04-17

Publication Date: 2010-12-21

IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
A61K003124	A	A61	A61K	A61K0031	A61K003124
C12P001300	С	C12	C12P	C12P0013	C12P001300
A01N003710	A	A01	A01N	A01N0037	A01N003710
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928

C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

### IPC Class Table - DWPI:

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	С	C07	C07C	C07C0271	C07C027100
C07C030700	с	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	A	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	A	A61	A61K	A61K0031	A61K003122
A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222

A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K003124	A	A61	A61K	A61K0031	A61K003124
A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928

C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	с	C07	C07C	C07C0271	C07C027152
C07C030702	с	C07	C07C	C07C0307	C07C030702
C07C0069017	с	C07	C07C	C07C0069	C07C0069017
C07C006922	с	C07	C07C	C07C0069	C07C006922
C07C006934	с	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: UCB Pharma GmbH,Monheim,DE JP F Terms: JP FI Codes: Assignee - Original: UCB Pharma GmbH

## Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

# ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

# Language of Publication: EN INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact			
2010-05-18	AS	-			
Description: ASSIGNMENT UCB PHARMA GMBH, GERMANY CHANGE OF NAME; ASSIGNOR:SCHWARZ					

#### Post-Issuance (US): Reassignment (US) Table:

Assignee	Assignor	Date Signed	Reel/Frame	Date		
UCB PHARMA GMBH,MONHEIM,DE	SCHWARZ PHARMA AG	2010-01-20	024400/0191	2010-05-18		
Conveyance: CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).						
Corresponent: JEFFREY GINSBERG ONE BROADWAY KENYON & KENYON LLP NEW YORK, NY 10004						

### Maintenance Status (US):

Litigation (US): 2013-06-21 2013 Pfizer Inc. UCB Pharma Gmbh Alkem Laboratories Ltd. Delaware 1:13cv01110 | 2013-06-21 2013 Pfizer Inc. UCB Pharma Gmbh Sandoz Inc. Delaware

1:13cv01111 | 2013-06-24 2013 Inc Pfizer UCB Pharma Gmbh Alkem Laboratories, Ltd. N.D. Illinois 1:13cv04628 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Accord Healthcare Inc., USA Delaware 1:13cv01155 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Amerigen Pharmaceuticals Inc. Amerigen Pharmaceuticals Ltd Delaware 1:13cv01156 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Amneal Pharmaceuticals LLC Delaware 1:13cv01157 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Impax Laboratories Inc. Delaware 1:13cv01158 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Lupin Ltd. Delaware 1:13cv01153 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Zydus Pharmaceuticals (USA) Inc. Delaware 1:13cv01154 | 2013-08-02 2013 Pfizer Inc. UCB Pharma Gmbh Wockhardt Bio AG Wockhardt USA LLC Delaware 1:13cv01387

Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



Record 41/45 JP04658895B2 The novel derivative of 3, 3- diphenylpropylamine

Title: The novel derivative of 3, 3- diphenylpropylamine

Title - DWPI: New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome Priority Number: EP1998108608A Priority Date: 1998-05-12 Application Number: JP2006283861A Application Date: 2006-10-18 Publication Date: 2011-03-23 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C07C021748	с	C07	C07C	C07C0217	C07C021748
C12P001300	с	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031222	А	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	А	A61	A61K	A61K0031	A61K0031435
A61K00317028	А	A61	A61K	A61K0031	A61K00317028
A61K00317034	А	A61	A61K	A61K0031	A61K00317034
A61P000100	А	A61	A61P	A61P0001	A61P000100
A61P000104	А	A61	A61P	A61P0001	A61P000104
A61P001300	А	A61	A61P	A61P0013	A61P001300
A61P001302	А	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	Α	A61	A61P	A61P0021	A61P002100
A61P004300	Α	A61	A61P	A61P0043	A61P004300
C07C021300	С	C07	C07C	C07C0213	C07C021300

C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

## IPC Class Table - DWPI:

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	с	C07	C07C	C07C0219	C07C021900
C07C027100	с	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	A	A61	A61K	A61K0031	A61K0031215

A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	A	A61	A61K	A61K0031	A61K003122
A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K003124	A	A61	A61K	A61K0031	A61K003124
A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	Α	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748

C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516

C07F000708	С	C07	C07F	C07F0007	C07F000708

#### Assignee/Applicant: SCHWARZ PHARMA AG, JP

JP F Terms: |4B064AE01 |4B064CA21 |4B064DA01 |4C022MA02 |4C057BB02 |4C057CC01 |4C057DD02 |4C057JJ20 |4C086AA01 |4C086AA02 |4C086AA03 |4C086BA17 |4C086EA07 | 4C086MA01 |4C086MA04 |4C086MA09 |4C086NA14 |4C086ZA68 |4C086ZA84 |4C086ZA94 | 4C086ZC42 |4C201 |4C206AA01 |4C206AA02 |4C206AA03 |4C206DB03 |4C206DB04 | 4C206DB16 |4C206DB29 |4C206DB57 |4C206JA06 |4C206MA01 |4C206MA16 |4C206MA28 |4C206NA14 |4C206ZA68 |4C206ZA84 |4C206ZA94 |4C206ZC42 |4H006AA01 |4H006AA02 | 4H006AA03 |4H006AB20 |4H006AB26 |4H006AB84 |4H006AC43 |4H006AC48 |4H006BB12 | 4H006BB15 |4H006BB20 |4H006BB31 |4H006BB61 |4H006BJ50 |4H006BN30 |4H006BP10 | 4H006BP30 |4H006BT12 |4H006BT16 |4H006BU36

JP FI Codes: | A61K0031222 | A61K0031225 | A61K0031235 | A61K0031365 | A61K00317034 | A61P000104 | A61P001302 | A61P002100 | A61P004300-111 | C07B005300-G | C07C021300 | C07C021306 | C07C021748 | C07C021922 | C07C021928 | C07D032100 | C07H001518 | C12P001300

#### Assignee - Original: SCHWARZ PHARMA AG

#### Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

## ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

## Language of Publication: JA INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact			
2011-04-13	RD04	-			
<b>Description:</b> NOTIFICATION OF RESIGNATION OF POWER OF ATTORNEY JAPANESE INTERMEDIATE CODE: R3D04					
2011-04-13	<b>ΓΡ</b> ΔΥ	+			
Description: RENEWAL FEE PAYMENT (PRS DATE IS RENEWAL DATE OF DATABASE) PAYMENT UNTIL:   20140107					
2011-03-28	RD02	-			

Description: NOTIFICATION OF ACC R3D02	EPTANCE OF POWER OF ATTORNEY	JAPANESE INTERMEDIATE CODE:				
2011-02-10	R350	-				
Description: WRITTEN NOTIFICATION OF REGISTRATION OF TRANSFER JAPANESE INTERMEDIATE CODE: R350						
2011-02-10	FPAY	+				
Description: RENEWAL FEE PAYME 20140107	NT (PRS DATE IS RENEWAL DATE OF D	ATABASE) PAYMENT UNTIL:				
2011-02-02	S533	-				
Description: WRITTEN REQUEST FOR R313533	OR REGISTRATION OF CHANGE OF NAM	IE JAPANESE INTERMEDIATE CODE:				
2011-02-02	FPAY	+				
Description: RENEWAL FEE PAYME 20140107	NT (PRS DATE IS RENEWAL DATE OF D	ATABASE) PAYMENT UNTIL:				
2011-01-07	R150	+				
Description: CERTIFICATE OF PATE INTERMEDIATE CODE: R150	NT (=GRANT) OR REGISTRATION OF U	TILITY MODEL JAPANESE				
2011-01-07	FPAY	+				
Description: RENEWAL FEE PAYME 20140107	NT (PRS DATE IS RENEWAL DATE OF D	ATABASE) PAYMENT UNTIL:				
2011-01-06	A61	+				
Description: FIRST PAYMENT OF ANNUAL FEES (DURING GRANT PROCEDURE) JAPANESE INTERMEDIATE   CODE: A61 2010-12-24						
2010-12-16	A01	+				
Description: WRITTEN DECISION TO GRANT A PATENT OR TO GRANT A REGISTRATION (UTILITY MODEL) JAPANESE INTERMEDIATE CODE: A01						
2010-12-09	A01	+				
Description:   WRITTEN DECISION TO GRANT A PATENT OR TO GRANT A REGISTRATION (UTILITY MODEL)     JAPANESE INTERMEDIATE CODE: A01   2010-12-08						
2010-12-01	TRDD	+				

Description: DECISION OF GRANT OR REJECTION WRITTEN				
2010-11-18	A521	-		
Description: WRITTEN AMENDMEN	T JAPANESE INTERMEDIATE CODE: AS	523 2010-11-17		
2010-10-15	A602	-		
Description: WRITTEN PERMISSION	N OF EXTENSION OF TIME JAPANESE I	NTERMEDIATE CODE: A602 2010-10-		
2010-10-09	A601	-		
Description: WRITTEN REQUEST FO	OR EXTENSION OF TIME JAPANESE IN	TERMEDIATE CODE: A601 2010-10-08		
2010-09-27	A602	-		
Description: WRITTEN PERMISSION	N OF EXTENSION OF TIME JAPANESE I	NTERMEDIATE CODE: A602 2010-09-		
2010-09-18	A601	-		
Description: WRITTEN REQUEST FO	OR EXTENSION OF TIME JAPANESE IN	TERMEDIATE CODE: A601 2010-09-17		
2010-08-19	A602	-		
Description: WRITTEN PERMISSION	N OF EXTENSION OF TIME JAPANESE I	NTERMEDIATE CODE: A602 2010-08-		
2010-08-14	A601	-		
Description: WRITTEN REQUEST FO	OR EXTENSION OF TIME JAPANESE IN	TERMEDIATE CODE: A601 2010-08-13		
2010-05-20	A131	-		
Description: NOTIFICATION OF REA	ASONS FOR REFUSAL JAPANESE INTE	RMEDIATE CODE: A131 2010-05-19		
2007-02-28	A521	-		
Description: WRITTEN AMENDMEN	T JAPANESE INTERMEDIATE CODE: A	523 2007-02-27		
2006-12-27	A521	-		
Description: WRITTEN AMENDMEN	T JAPANESE INTERMEDIATE CODE: A	523 2006-11-30		

Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



Record 42/45 US7985772B2 Derivatives of 3,3-diphenylpropylamines

**Title:** Derivatives of 3,3-diphenylpropylamines

**Title - DWPI:** New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome

Priority Number: EP1998108608A | WO1999EP3212A | US2001700094A | US2004766263A | US2005201756A | US2008105016A

**Priority Date:** 1998-05-12 | 1999-05-11 | 2001-01-02 | 2004-01-27 | 2005-08-10 | 2008-04-17 **Application Number:** US2010814982A

Application Date: 2010-06-14

Publication Date: 2011-07-26

IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
A61K003121	A	A61	A61K	A61K0031	A61K003121
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031215	A	A61	A61K	A61K0031	A61K0031215
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762

C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

## IPC Class Table - DWPI:

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	с	C07	C07C	C07C0219	C07C021900
C07C027100	с	C07	C07C	C07C0271	C07C027100
C07C030700	с	C07	C07C	C07C0307	C07C030700
A01N003702	А	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	А	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	А	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	А	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	А	A61	A61K	A61K0031	A61K0031215
A61K0031216	Α	A61	A61K	A61K0031	A61K0031216
A61K003122	A	A61	A61K	A61K0031	A61K003122

A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K003124	A	A61	A61K	A61K0031	A61K003124
A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	А	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	А	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	А	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	А	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922

C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: UCB Pharma GmbH,Monheim,DE JP F Terms: JP FI Codes: Assignee - Original: UCB Pharma GmbH Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

**ECLA**: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

Language of Publication: EN

INPADOC Legal Status Table:

Post-Issuance (US):

Reassignment (US) Table:

Maintenance Status (US):

Litigation (US): 2013-06-21 2013 Pfizer Inc. UCB Pharma Gmbh Alkem Laboratories Ltd. Delaware 1:13cv01110 | 2013-06-21 2013 Pfizer Inc. UCB Pharma Gmbh Sandoz Inc. Delaware 1:13cv01111 | 2013-06-24 2013 Inc Pfizer UCB Pharma Gmbh Alkem Laboratories, Ltd. N.D. Illinois 1:13cv04628 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Accord Healthcare Inc., USA Delaware 1:13cv01155 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Amerigen Pharmaceuticals Inc. Amerigen Pharmaceuticals Ltd Delaware 1:13cv01156 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Amneal Pharmaceuticals LLC Delaware 1:13cv01157 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Impax Laboratories Inc. Delaware 1:13cv01158 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Lupin Ltd. Delaware 1:13cv01153 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Zydus Pharmaceuticals (USA) Inc. Delaware 1:13cv01154 | 2013-08-02 2013 Pfizer Inc. UCB Pharma Gmbh Wockhardt Bio AG Wockhardt USA LLC Delaware 1:13cv01387 **Opposition (EP):** License (EP): **EPO Procedural Status:** Front Page Drawing:



Record 43/45 JP04833884B2 The novel derivative|guide\_body of 3, 3- diphenylpropylamine

Title: The novel derivative|guide\_body of 3, 3- diphenylpropylamine Title - DWPI: New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome Priority Number: EP1998108608A Priority Date: 1998-05-12 Application Number: JP200739857A Application Date: 2007-02-20 Publication Date: 2011-12-07 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C07C021930	С	C07	C07C	C07C0219	C07C021930
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	с	C07	C07C	C07C0213	C07C021306
C07C021748	с	C07	C07C	C07C0217	C07C021748
C07C021762	с	C07	C07C	C07C0217	C07C021762
C07C021922	с	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C023347	С	C07	C07C	C07C0233	C07C023347
C07C027108	С	C07	C07C	C07C0271	C07C027108

C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
A61K0031215	A	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61P001302	А	A61	A61P	A61P0013	A61P001302
A61P002502	А	A61	A61P	A61P0025	A61P002502

## IPC Class Table - DWPI:

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	С	C07	C07C	C07C0217	C07C021700
C07C021900	с	C07	C07C	C07C0219	C07C021900
C07C027100	с	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	A	A61	A61K	A61K0031	A61K0031215

A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	A	A61	A61K	A61K0031	A61K003122
A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	А	A61	A61K	A61K0031	A61K0031222
A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K003124	A	A61	A61K	A61K0031	A61K003124
A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	Α	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	С07В	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748

C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07C0069017	С	C07	C07C	C07C0069	C07C0069017
C07C006922	С	C07	C07C	C07C0069	C07C006922
C07C006934	С	C07	C07C	C07C0069	C07C006934
C07C006976	С	C07	C07C	C07C0069	C07C006976
C07C006978	С	C07	C07C	C07C0069	C07C006978
C07D020706	С	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516

C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: UCB PHARMA GMBH, JP

JP F Terms: |4C201 |4C206AA01 |4C206AA02 |4C206AA03 |4C206AA04 |4C206FA11 | 4C206GA02 |4C206GA28 |4C206MA01 |4C206MA04 |4C206NA14 |4C206ZA24 |4C206ZA66 |4C206ZA81 |4C206ZA84 |4H006AA01 |4H006AA02 |4H006AA03 |4H006AB20 |4H006BJ50 | 4H006BN10 |4H006BT16 |4H006BU32

JP FI Codes: | A61K0031215 | A61K0031216 | A61K0031221 | A61K0031325 | A61P000100 | A61P001302 | A61P002502-103 | C07C021306 | C07C021930 | C07C023347 | C07C027144 Assignee - Original: UCB PHARMA GMBH

#### Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

# **ECLA**: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

Language of Publication: JA INPADOC Legal Status Table:

Gazette Date	Code	INPADOC Legal Status Impact		
2011-10-03	FPAY	+		
Description: RENEWAL FEE PAYMENT (PRS DATE IS RENEWAL DATE OF DATABASE) PAYMENT UNTIL: 20140930				
2011-09-30	R150	+		
Description: CERTIFICATE OF PATE INTERMEDIATE CODE: R150	ENT (=GRANT) OR REGISTRATION OF U	TILITY MODEL JAPANESE		
2011-09-29	A61	+		
Description: FIRST PAYMENT OF ANNUAL FEES (DURING GRANT PROCEDURE) JAPANESE INTERMEDIATE CODE: A61 2011-09-22				
2011-09-08	A01	+		
Description: WRITTEN DECISION TO GRANT A PATENT OR TO GRANT A REGISTRATION (UTILITY MODEL) JAPANESE INTERMEDIATE CODE: A01				

	1			
2011-09-05	A01	+		
Description: WRITTEN DECISION TO GRANT A PATENT OR TO GRANT A REGISTRATION (UTILITY MODEL) JAPANESE INTERMEDIATE CODE: A01 2011-09-02				
2011-08-31	TRDD	+		
Description: DECISION OF GRANT	DR REJECTION WRITTEN			
2011-04-23	A521	-		
Description: WRITTEN AMENDMEN	T JAPANESE INTERMEDIATE CODE: A5	523 2011-04-22		
2011-04-09	RD04	-		
Description: NOTIFICATION OF RES	SIGNATION OF POWER OF ATTORNEY	JAPANESE INTERMEDIATE CODE:		
2011-03-28	A602	-		
Description: WRITTEN PERMISSION	N OF EXTENSION OF TIME JAPANESE I	NTERMEDIATE CODE: A602 2011-03-		
2011-03-23	A601	-		
Description: WRITTEN REQUEST FO	DR EXTENSION OF TIME JAPANESE IN	TERMEDIATE CODE: A601 2011-03-22		
2011-02-16	RD02	-		
Description: NOTIFICATION OF ACC A7422 2011-01-27	CEPTANCE OF POWER OF ATTORNEY	JAPANESE INTERMEDIATE CODE:		
2010-12-24	Δ131	_		
Description: NOTIFICATION OF REA	SONS FOR REFUSAL JAPANESE INTE	RMEDIATE CODE: A131 2010-12-22		
2010-12-03	A521	-		
Description: WRITTEN AMENDMEN	T JAPANESE INTERMEDIATE CODE: AS	523 2010-12-02		
2010-11-18	A521	-		
Description: WRITTEN AMENDMEN	T JAPANESE INTERMEDIATE CODE: AS	523 2010-11-17		
2010-10-15	A602	-		
Description: WRITTEN PERMISSION	I OF EXTENSION OF TIME JAPANESE I	NTERMEDIATE CODE: A602 2010-10-		

2010-10-09	A601	-		
Description: WRITTEN REQUEST FOR EXTENSION OF TIME JAPANESE INTERMEDIATE CODE: A601 2010-10-08				
2010-09-27	A602	-		
Description: WRITTEN PERMISSION	NOF EXTENSION OF TIME JAPANESE I	NTERMEDIATE CODE: A602 2010-09-		
2010-09-18	A601	-		
Description: WRITTEN REQUEST FO	OR EXTENSION OF TIME JAPANESE IN	TERMEDIATE CODE: A601 2010-09-17		
2010-08-18	A602	-		
Description: WRITTEN PERMISSION OF EXTENSION OF TIME JAPANESE INTERMEDIATE CODE: A602 2010-08-17				
2010-08-13	A601	-		
Description: WRITTEN REQUEST FOR EXTENSION OF TIME JAPANESE INTERMEDIATE CODE: A601 2010-08-12				
2010-05-20	A131	-		
Description: NOTIFICATION OF REASONS FOR REFUSAL JAPANESE INTERMEDIATE CODE: A131 2010-05-19				

Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:



**Record 44/45** NO2009015I2 Fesoterodine, eventuelt i form av et fysiologisk akseptabelt salt, inkludert hydrogenfumaratsaltet

Title: Fesoterodine, eventuelt i form av et fysiologisk akseptabelt salt, inkludert hydrogenfumaratsaltet Title - DWPI: Priority Number: EP1998108608A | WO1999EP3212A Priority Date: 1998-05-12 | 1999-05-11 Application Number: NO200915C Application Date: 2009-07-17 Publication Date: 2012-11-12 IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
C12P001300	с	C12	C12P	C12P0013	C12P001300
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	А	A61	A61K	A61K0031	A61K0031365
A61K003140	А	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	с	C07	C07C	C07C0213	C07C021306
C07C021748	с	C07	C07C	C07C0217	C07C021748
C07C021762	с	C07	C07C	C07C0217	C07C021762
C07C021922	с	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152

C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

IPC Class Table - DWPI: Assignee/Applicant: UCB PHARMA GMBH JP F Terms: JP FI Codes: Assignee - Original: Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702 Abstract: Language of Publication: NO INPADOC Legal Status Table: Post-Issuance (US): Reassignment (US) Table: Maintenance Status (US): Litigation (US): Opposition (EP): License (EP): EPO Procedural Status: Front Page Drawing:

(No drawing/image available)

Record 45/45 US8338478B2 Derivatives of 3,3-diphenylpropylamines

**Title:** Derivatives of 3,3-diphenylpropylamines

**Title - DWPI:** New diphenyl-propylamine derivatives useful as antimuscarinic agents for treatment of e.g. urinary incontinence and irritable bowel syndrome

Priority Number: EP1998108608A | WO1999EP3212A | US2001700094A | US2004766263A | US2005201756A | US2008105016A | US2010814982A

**Priority Date:** 1998-05-12 | 1999-05-11 | 2001-01-02 | 2004-01-27 | 2005-08-10 | 2008-04-17 | 2010-06-14

Application Number: US13161049A Application Date: 2011-06-15 Publication Date: 2012-12-25

IPC Class Table:

IPC	Section	Class	Subclass	Class Group	Subgroup
A61K003121	A	A61	A61K	A61K0031	A61K003121
C12P001300	С	C12	C12P	C12P0013	C12P001300
A61K0031135	А	A61	A61K	A61K0031	A61K0031135
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	A	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61P000100	A	A61	A61P	A61P0001	A61P000100
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001310	A	A61	A61P	A61P0013	A61P001310
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07C021306	с	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021928	С	C07	C07C	C07C0219	C07C021928
C07C022900	С	C07	C07C	C07C0229	C07C022900

C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	С	C07	C07C	C07C0271	C07C027152
C07C030702	С	C07	C07C	C07C0307	C07C030702
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	С	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518

### IPC Class Table - DWPI:

IPC - DWPI	Section - DWPI	Class - DWPI	Subclass - DWPI	Class Group - DWPI	Subgroup - DWPI
C07C021700	с	C07	C07C	C07C0217	C07C021700
C07C021900	С	C07	C07C	C07C0219	C07C021900
C07C027100	с	C07	C07C	C07C0271	C07C027100
C07C030700	С	C07	C07C	C07C0307	C07C030700
A01N003702	A	A01	A01N	A01N0037	A01N003702
A01N003706	A	A01	A01N	A01N0037	A01N003706
A01N003710	A	A01	A01N	A01N0037	A01N003710
A01N003712	A	A01	A01N	A01N0037	A01N003712
A01N003744	A	A01	A01N	A01N0037	A01N003744
A61K0031135	A	A61	A61K	A61K0031	A61K0031135
A61K0031137	A	A61	A61K	A61K0031	A61K0031137
A61K003121	A	A61	A61K	A61K0031	A61K003121
A61K0031215	A	A61	A61K	A61K0031	A61K0031215
A61K0031216	A	A61	A61K	A61K0031	A61K0031216
A61K003122	A	A61	A61K	A61K0031	A61K003122
A61K0031221	A	A61	A61K	A61K0031	A61K0031221
A61K0031222	A	A61	A61K	A61K0031	A61K0031222

A61K0031225	A	A61	A61K	A61K0031	A61K0031225
A61K0031235	A	A61	A61K	A61K0031	A61K0031235
A61K003124	A	A61	A61K	A61K0031	A61K003124
A61K0031315	A	A61	A61K	A61K0031	A61K0031315
A61K0031325	A	A61	A61K	A61K0031	A61K0031325
A61K0031357	A	A61	A61K	A61K0031	A61K0031357
A61K0031365	А	A61	A61K	A61K0031	A61K0031365
A61K003140	A	A61	A61K	A61K0031	A61K003140
A61K0031435	A	A61	A61K	A61K0031	A61K0031435
A61K00317028	A	A61	A61K	A61K0031	A61K00317028
A61K00317034	A	A61	A61K	A61K0031	A61K00317034
A61K000970	A	A61	A61K	A61K0009	A61K000970
A61P000100	А	A61	A61P	A61P0001	A61P000100
A61P000104	A	A61	A61P	A61P0001	A61P000104
A61P001300	A	A61	A61P	A61P0013	A61P001300
A61P001302	A	A61	A61P	A61P0013	A61P001302
A61P001310	А	A61	A61P	A61P0013	A61P001310
A61P002100	A	A61	A61P	A61P0021	A61P002100
A61P002502	A	A61	A61P	A61P0025	A61P002502
A61P004300	A	A61	A61P	A61P0043	A61P004300
C07B005300	С	C07	C07B	C07B0053	C07B005300
C07C000100	С	C07	C07C	C07C0001	C07C000100
C07C021100	С	C07	C07C	C07C0211	C07C021100
C07C021300	С	C07	C07C	C07C0213	C07C021300
C07C021306	С	C07	C07C	C07C0213	C07C021306
C07C021748	С	C07	C07C	C07C0217	C07C021748
C07C021762	С	C07	C07C	C07C0217	C07C021762
C07C021922	С	C07	C07C	C07C0219	C07C021922
C07C021926	С	C07	C07C	C07C0219	C07C021926
C07C021928	С	C07	C07C	C07C0219	C07C021928

C07C021930	С	C07	C07C	C07C0219	C07C021930
C07C022900	С	C07	C07C	C07C0229	C07C022900
C07C023347	С	C07	C07C	C07C0233	C07C023347
C07C027108	С	C07	C07C	C07C0271	C07C027108
C07C027144	С	C07	C07C	C07C0271	C07C027144
C07C027152	с	C07	C07C	C07C0271	C07C027152
C07C030702	с	C07	C07C	C07C0307	C07C030702
C07C0069017	с	C07	C07C	C07C0069	C07C0069017
C07C006922	с	C07	C07C	C07C0069	C07C006922
C07C006934	с	C07	C07C	C07C0069	C07C006934
C07C006976	с	C07	C07C	C07C0069	C07C006976
C07C006978	с	C07	C07C	C07C0069	C07C006978
C07D020706	с	C07	C07D	C07D0207	C07D020706
C07D029506	С	C07	C07D	C07D0295	C07D029506
C07D032100	С	C07	C07D	C07D0321	C07D032100
C07D032110	с	C07	C07D	C07D0321	C07D032110
C07F000718	С	C07	C07F	C07F0007	C07F000718
C07H001518	С	C07	C07H	C07H0015	C07H001518
C12P001300	С	C12	C12P	C12P0013	C12P001300
C07C021546	С	C07	C07C	C07C0215	C07C021546
A61K0031395	A	A61	A61K	A61K0031	A61K0031395
C07C021754	С	C07	C07C	C07C0217	C07C021754
C07C022902	С	C07	C07C	C07C0229	C07C022902
C07C027140	С	C07	C07C	C07C0271	C07C027140
C07C030704	С	C07	C07C	C07C0307	C07C030704
C07D029516	С	C07	C07D	C07D0295	C07D029516
C07F000708	С	C07	C07F	C07F0007	C07F000708

Assignee/Applicant: UCB Pharma GmbH,Monheim,DE JP F Terms: JP FI Codes: Assignee - Original: UCB Pharma GmbH

## Any CPC Table:

Туре	Invention	Additional	Version	Office
Current	C07C 217/48	-	20130101	EP
Current	C07C 217/62		20130101	EP
Current	C07C 219/28		20130101	EP
Current	C07C 229/34		20130101	EP
Current	C07C 271/44		20130101	EP
Current	C07C 271/52		20130101	EP
Current	C07C 307/02		20130101	EP

# ECLA: C07C021748 | C07C021762 | C07C021928 | C07C022934 | C07C027144 | C07C027152 | C07C030702

#### Abstract:

The invention concerns novel derivatives of 3,3-diphenyl-propylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

Language of Publication: EN

INPADOC Legal Status Table:

Post-Issuance (US):

Reassignment (US) Table:

#### Maintenance Status (US):

Litigation (US): 2013-06-21 2013 Pfizer Inc. UCB Pharma Gmbh Alkem Laboratories Ltd. Delaware 1:13cv01110 | 2013-06-21 2013 Pfizer Inc. UCB Pharma Gmbh Sandoz Inc. Delaware 1:13cv01111 | 2013-06-24 2013 Inc Pfizer UCB Pharma Gmbh Alkem Laboratories, Ltd. N.D. Illinois 1:13cv04628 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Accord Healthcare Inc., USA Delaware 1:13cv01155 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Amerigen Pharmaceuticals Inc. Amerigen Pharmaceuticals Ltd Delaware 1:13cv01156 35 USC 271 Patent Infringement ::: ## | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Amneal Pharmaceuticals LLC Delaware 1:13cv01157 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Impax Laboratories Inc. Delaware 1:13cv01158 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Lupin Ltd. Delaware 1:13cv01153 | 2013-06-28 2013 Pfizer, Inc. UCB Pharma Gmbh Zydus Pharmaceuticals (USA) Inc. Delaware 1:13cv01154 | 2013-08-02 2013 Pfizer Inc. UCB Pharma Gmbh Wockhardt Bio AG Wockhardt USA LLC Delaware 1:13cv01387 **Opposition (EP):** License (EP): **EPO Procedural Status:** Front Page Drawing:





Copyright 2007-2013 THOMSON REUTERS
## **USPTO Maintenance Report**

Patent Bibliographic Data			09/17/2013 03:56 PM		
Patent Number:	6713464		Application Number:	09700094	
Issue Date:	03/30/2004		Filing Date:	01/02/2001	
Title:	NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES				
Status:	12th year fee win	ndow opens: 03/3	80/2015	Entity:	LARGE
Window Opens:	N/A	Surcharge Date:	N/A	Expiration:	N/A
Fee Amt Due:	Window not open	Surchg Amt Due:	Window not open	Total Amt Due:	Window not open
Fee Code:					
Surcharge Fee Code:					
Most recent events (up to 7):	08/31/2011 09/07/2007	Payment of Maintenance Fee, 8th Year, Large Entity. Payment of Maintenance Fee, 4th Year, Large Entity. End of Maintenance History			
Address for fee purposes:	EDWARDS WILDMAN PALMER LLP P.O. BOX 55874 BOSTON MA 02205				